PT J
AU Bredenoord, AL
   Dondorp, W
   Pennings, G
   De Die-Smulders, CEM
   De Wert, G
AF Bredenoord, A. L.
   Dondorp, W.
   Pennings, G.
   De Die-Smulders, C. E. M.
   De Wert, G.
TI PGD to reduce reproductive risk: the case of mitochondrial DNA disorders
SO HUMAN REPRODUCTION
LA English
DT Article
DE PGD; mitochondrial DNA; reproductive risk; ethics; genetic disorders
ID preimplantation genetic diagnosis; hereditary optic neuropathy; adult-onset conditions; prenatal-diagnosis; nucleotide 8993; young-people; transmission; mutations; children; ethics
AB This paper discusses the pros and cons of introducing PGD for mitochondrial DNA (mtDNA) disorders such as NARP (Neurogenic muscle weakness, Ataxia, Retinis Pigmentosa)/Leigh, MELAS (Mitochondrial myopathy, Encephalopathy, Lactic acidosis, and Stroke-like episodes), private mtDNA mutations and LHON (Leber Hereditary Optic Neuropathy). Although there is little experience with PGD for mtDNA disorders, it is reasonable to assume that in many cases, the best one can achieve is the selection of the 'least' affected embryos for transfer. So instead of 'promising' parents a healthy child, PGD in these cases can only aim at reducing reproductive risk. From an ethical point of view, this raises challenging questions about parental and medical responsibilities. The main argument in favour of PGD is that it offers couples at risk the opportunity of reducing their chances of having a severely affected child. Potential objections are manifold, but we conclude that none of them supplies convincing moral arguments to regard risk-reducing PGD as unacceptable. Nevertheless, introducing this new application of PGD in clinical practice will raise further complex issues of determining conditions for its responsible use.
C1 [Bredenoord, A. L.; Dondorp, W.; De Wert, G.] Maastricht Univ, Hlth Eth & Soc & Res Inst GROW, Maastricht, Netherlands.
   [Pennings, G.] Univ Ghent, Bioeth Inst Ghent, B-9000 Ghent, Belgium.
   [De Die-Smulders, C. E. M.] Univ Hosp Maastricht Clin Genet, Maastricht, Netherlands.
C3 Maastricht University; Ghent University; Maastricht University; Maastricht University Medical Centre (MUMC)
RP Bredenoord, AL (corresponding author), Maastricht Univ, Hlth Eth & Soc & Res Inst GROW, Maastricht, Netherlands.
EM a.bredenoord@zw.unimaas.nl
FU European Union [005260]
CR Amor DJ, 2008, HUM REPROD, V23, P729, DOI 10.1093/humrep/dem433
   [Anonymous], 1998, GENETIC TESTING CHIL, V0, P0
   [Anonymous], 2006, PUBL HLTH COUNC NETH, V0, P0
   [Anonymous], 2007, ENHANCING EVOLUTION, V0, P0
   ARRAS JD, 1990, MILBANK Q, V68, P353, DOI 10.2307/3350110
   Benatar D, 2006, HUM REPROD, V21, P2491, DOI 10.1093/humrep/del209
   Bickerstaff H, 2001, HUM FERTIL (CAMB), V4, P24, DOI 10.1080/1464727012000199221
   Boivin J, 2005, ARCH DIS CHILD, V90, P784, DOI 10.1136/adc.2004.064485
   Borry P, 2006, CLIN GENET, V70, P374, DOI 10.1111/j.1399-0004.2006.00692.x
   Bredenoord AL, 2008, HUM REPROD UPDATE, V14, P83, DOI 10.1093/humupd/dmm037
   Brown DT, 2006, LANCET, V368, P87, DOI 10.1016/S0140-6736(06)68972-1
   Buchanan A, 2000, CHANCE CHOICE GENETI, V0, P0
   BURGESS JA, 1993, J MED ETHICS, V19, P169, DOI 10.1136/jme.19.3.169
   CAVAGHAN C, 2007, DEFENDING GENETIC SU, V0, P0
   Chinnery P, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004426.pub2
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   Chinnery PF, 2002, MITOCHONDRION, V2, P149, DOI 10.1016/S1567-7249(02)00046-6
   Chinnery PF, 2001, AM J MED GENET, V106, P94, DOI 10.1002/ajmg.1426
   CIAFALONI E, 1993, J PEDIATR-US, V122, P419, DOI 10.1016/S0022-3476(05)83431-6
   Dahl H H, 2000, HUM REPROD, V15 Suppl 2, P246
   Dahl HHM, 2001, AM J MED GENET, V106, P1, DOI 10.1002/ajmg.1427
   de Wert G, 2005, HUM REPROD, V20, P3261, DOI 10.1093/humrep/dei222
   de Wert GMWR, 1998, HUM REPROD, V13, P219, DOI 10.1093/humrep/13.suppl_1.219
   de Wert G, 2007, STEM CELLS, V25, P2167, DOI 10.1634/stemcells.2006-0625
   DEWERT G, 1999, THESIS AMSTERDAM, V0, P0
   Duncan RE, 2006, CLIN GENET, V69, P8, DOI 10.1111/j.1399-0004.2005.00505.x
   Duncan RE, 2007, AM J MED GENET A, V143A, P1984, DOI 10.1002/ajmg.a.31720
   Dworkin Ronald, 1993, LIFES DOMINION: AN ARGUMENT ABOUT ABORTION AND EUTHANASIA, V0, P0
   EVERSKIEBOOM G, 2006, TIJDSCHR GENEESKUNDE, V62, P463
   Glover Jonathan, 2006, CHOOSING CHILDREN: GENES, V0, P0
   Graff C, 2000, PRENATAL DIAG, V20, P426, DOI 10.1002/(SICI)1097-0223(200005)20:5<426::AID-PD845>3.3.CO;2-B
   Harris J, 2000, HEALTH CARE ANAL, V8, P27, DOI 10.1023/A:1009430326447
   Hudson G, 2007, AM J HUM GENET, V81, P228, DOI 10.1086/519394
   Huoponen K, 2002, ACTA OPHTHALMOL SCAN, V80, P38, DOI 10.1034/j.1600-0420.2002.800108.x
   Jacobs LJAM, 2005, MOL HUM REPROD, V11, P223, DOI 10.1093/molehr/gah152
   LAMB D, 1988, DOWN THE SLIPPERY SLOPE, V0, P0
   Laurie Graeme T, 1999, EUR J HEALTH LAW, V6, P119, DOI 10.1163/15718099920522730
   Man PYW, 2002, J MED GENET, V39, P162, DOI 10.1136/jmg.39.3.162
   McGleenan T, 1995, J MED ETHICS, V21, P350, DOI 10.1136/jme.21.6.350
   Parfit D, 1984, REASONS PERSONS, V0, P0
   Parker Michael, 2005, HUM FERTIL (CAMB), V8, P13, DOI 10.1080/14647270500050371
   Parker M, 2007, J MED ETHICS, V33, P279, DOI 10.1136/jme.2006.018176
   Pennings G, 1999, HUM REPROD, V14, P1146, DOI 10.1093/humrep/14.5.1146
   Pennings G, 2003, J MED ETHICS, V29, P321, DOI 10.1136/jme.29.6.321
   Pennycook A, 2003, J SOCIOLING, V7, P513, DOI 10.1111/j.1467-9841.2003.00240.x
   Poulton J, 2000, NEUROMUSCULAR DISORD, V10, P484, DOI 10.1016/S0960-8966(00)00130-9
   Rhodes R, 2006, MT SINAI J MED, V73, P609
   Robertson John, 1994, CHILDREN OF CHOICE: FREEDOM AND THE NEW REPRODUCTIVE TECHNOLOGIES, V0, P0
   Robertson S, 2001, BIOETHICS, V15, P26, DOI 10.1111/1467-8519.00210
   Savulescu J, 1999, J MED ETHICS, V25, P121, DOI 10.1136/jme.25.2.121
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Schwartz B, 2004, PARADOX CHOICE WHY M, V0, P0
   Spikings EC, 2006, HUM REPROD UPDATE, V12, P401, DOI 10.1093/humupd/dml011
   SPRUIJT L, 2007, ENCY LIFE SCI, V0, P0, DOI DOI 10.1002/9780470015902.A0005541
   Steffann J, 2007, J MED GENET, V44, P664, DOI 10.1136/jmg.2006.048553
   Steffann J, 2006, J MED GENET, V43, P244, DOI 10.1136/jmg.2005.032326
   STEINBOCK B, 1994, HASTINGS CENT REP, V24, P15
   Steinbock B, 2007, REPROD BIOMED ONLINE, V15, P38, DOI 10.1016/S1472-6483(10)60548-2
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Thorburn DR, 2004, J INHERIT METAB DIS, V27, P349, DOI 10.1023/B:BOLI.0000031098.41409.55
   Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380
   van der Burg W, 1992, J CLIN ETHICS, V3, P256
   White SL, 1999, PRENATAL DIAG, V19, P1165, DOI 10.1002/(SICI)1097-0223(199912)19:12<1165::AID-PD719>3.3.CO;2-4
   White SL, 1999, AM J HUM GENET, V65, P474, DOI 10.1086/302488
   White SL, 1999, J INHERIT METAB DIS, V22, P899, DOI 10.1023/A:1005639407166
NR 68
TC 32
Z9 33
U1 0
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
EI 1460-2350
J9 HUM REPROD
JI Hum. Reprod.
PD NOV 15
PY 2008
VL 23
IS 11
BP 2392
EP 2401
DI 10.1093/humrep/den290
PG 10
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 361QT
UT WOS:000260142900001
PM 18664474
DA 2024-11-01
ER

PT J
AU Kiyomoto, BH
   Tengan, CH
   Godinho, RO
AF Kiyomoto, Beatriz H.
   Tengan, Celia H.
   Godinho, Rosely O.
TI Effects of short-term zidovudine exposure on mitochondrial DNA content and succinate dehydrogenase activity of rat skeletal muscle cells
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE zidovudine; skeletal muscle; mitochondria; succinate dehydrogenase; mitochondrial DNA
ID ultrastructural-changes; induced destruction; didanosine ddi; human myotubes; l-carnitine; toxicity; azt; myopathy; therapy; aids
AB Long-term use of zidovudine (AZT) may cause mitochondrial abnormalities in various tissues, including a toxic myopathy in AIDS patients associated with mitochondrial DNA (mtDNA) depletion. In the present study, we examine the short-term (48 h) effect of AZT (10, 30 and 100 mu g/ml) on the mitochondrial succinate dehydrogenase (SDH) and mtDNA content of rat cultured skeletal muscle. The effect of AZT on cytochrome c oxidase (COX) enzyme was also analyzed. The histochemical quantitative analysis of SDH showed that AZT 10, 30 and 100 mu g/ml increased by 7%, 9% and 13% the mitochondrial content. Conversely, treatment of rat cultures with 10 to 100 mu g/ml AZT reduced the mtDNA content by 23% to 66%, when compared to control values. The spontaneous contraction and the COX activity were not modified by up to 100 mu g/ml AZT. Taken together, these results show that short-term treatment with AZT can induce severe myotoxicity that involves mitochondrial proliferation and mtDNA depletion in the rat cultured myotubes. Our results also indicate that rat cultured skeletal muscle might be a valuable in vitro assay to evaluate the effect of drugs on mitochondria to predict their potential to induce mitochondrial toxicity. (C) 2007 Elsevier B.V. All rights reserved.
C1 [Godinho, Rosely O.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Pharmacol INFAR, BR-04044020 Sao Paulo, Brazil.
   [Kiyomoto, Beatriz H.; Tengan, Celia H.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Neurol & Neurosurg, BR-04039032 Sao Paulo, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP)
RP Godinho, RO (corresponding author), Univ Fed Sao Paulo, Escola Paulista Med, Dept Pharmacol INFAR, Rua 03 Maio 100, BR-04044020 Sao Paulo, Brazil.
EM godinho@farm.epm.br
CR AMAUDO E, 2001, LANCET, V337, P508
   [Anonymous], 1983, J IMMUNOL METH, V0, P0
   [Anonymous], 2006, ANT THER HIV INF AD, V0, P0
   Benbrik E, 1997, J NEUROL SCI, V149, P19, DOI 10.1016/S0022-510X(97)05376-8
   Birkus G, 2002, ANTIMICROB AGENTS CH, V46, P716, DOI 10.1128/AAC.46.3.716-723.2002
   Casademont J, 1996, BRAIN, V119, P1357, DOI 10.1093/brain/119.4.1357
   Cazzalini O, 2001, BIOCHEM PHARMACOL, V62, P893, DOI 10.1016/S0006-2952(01)00713-4
   CHEN CH, 1989, J BIOL CHEM, V264, P11934
   CHEN CH, 1991, MOL PHARMACOL, V39, P625
   Clumeck N, 2000, BIOMED PHARMACOTHER, V54, P7, DOI 10.1016/S0753-3322(00)88634-5
   CUPLER EJ, 1995, ACTA NEUROPATHOL, V90, P1
   Dalakas MC, 2001, LAB INVEST, V81, P1537, DOI 10.1038/labinvest.3780367
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   DAMATI G, 1994, LAB INVEST, V71, P879
   de la Asunción JG, 1998, J CLIN INVEST, V102, P4, DOI 10.1172/JCI1418
   de Mendoza C, 2004, AIDS REV, V6, P169
   Godinho RO, 2003, BRIT J PHARMACOL, V138, P995, DOI 10.1038/sj.bjp.0705130
   HERZBERG NH, 1992, MUSCLE NERVE, V15, P706, DOI 10.1002/mus.880150613
   Höschele D, 2006, TOXICOL IN VITRO, V20, P535, DOI 10.1016/j.tiv.2005.11.007
   LAMPERTH L, 1991, LAB INVEST, V65, P742
   LEWIS LD, 1992, ANTIMICROB AGENTS CH, V36, P2061, DOI 10.1128/AAC.36.9.2061
   LEWIS W, 1991, LAB INVEST, V65, P228
   LEWIS W, 1992, J CLIN INVEST, V89, P1354, DOI 10.1172/JCI115722
   LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417
   Masini A, 1999, J NEUROL SCI, V166, P131, DOI 10.1016/S0022-510X(99)00126-4
   MEDINA DJ, 1994, ANTIMICROB AGENTS CH, V38, P1824, DOI 10.1128/AAC.38.8.1824
   Moraes Carlos T, 1993, P97, V0, P0
   Pedrol E, 1996, J NEUROL SCI, V138, P42, DOI 10.1016/0022-510X(96)00009-3
   PETERS BS, 1993, Q J MED, V86, P5
   Poot M, 1996, J HISTOCHEM CYTOCHEM, V44, P1363, DOI 10.1177/44.12.8985128
   Schroder JM, 1996, ACTA NEUROPATHOL, V92, P138, DOI 10.1007/s004010050501
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   SELIGMAN AM, 1951, SCIENCE, V113, P317, DOI 10.1126/science.113.2934.317-a
   SEMINOMORA MC, 1994, LAB INVEST, V71, P773
   SEMINOMORA MC, 1994, LAB INVEST, V71, P102
   SIMPSON MV, 1989, BIOCHEM PHARMACOL, V38, P1033, DOI 10.1016/0006-2952(89)90245-1
   Srivastava S, 2001, HUM MOL GENET, V10, P3093, DOI 10.1093/hmg/10.26.3093
   Tanji K, 2001, METHOD CELL BIOL, V65, P311, DOI 10.1016/S0091-679X(01)65019-2
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   YARCHOAN R, 1986, LANCET, V1, P575
NR 41
TC 7
Z9 7
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD MAY 15
PY 2008
VL 268
IS 1-2
BP 33
EP 39
DI 10.1016/j.jns.2007.10.026
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 292JH
UT WOS:000255261800006
PM 18045616
DA 2024-11-01
ER

PT J
AU Cízková, A
   Stránecky, V
   Ivánek, R
   Hartmannová, H
   Nosková, L
   Piherová, L
   Tesarová, M
   Hansíková, H
   Honzík, T
   Zeman, J
   Divina, P
   Potocká, A
   Paul, J
   Sperl, W
   Mayr, JA
   Seneca, S
   Houstek, J
   Kmoch, S
AF Cizkova, Alena
   Stranecky, Viktor
   Ivanek, Robert
   Hartmannova, Hana
   Noskova, Lenka
   Piherova, Lenka
   Tesarova, Marketa
   Hansikova, Hana
   Honzik, Tomas
   Zeman, Jiri
   Divina, Petr
   Potocka, Andrea
   Paul, Jan
   Sperl, Wolfgang
   Mayr, Johannes A.
   Seneca, Sara
   Houstek, Josef
   Kmoch, Stanislav
TI Development of a human mitochondrial oligonucleotide microarray (h-MitoArray) and gene expression analysis of fibroblast cell lines from 13 patients with isolated F<sub>I</sub>F<sub>o</sub> ATP synthase deficiency
SO BMC GENOMICS
LA English
DT Article
ID activated protein-kinase; focused cdna microarray; cytochrome-c-oxidase; complex-i deficiency; oxidative-phosphorylation; replicative senescence; integrative genomics; binding protein; skeletal-muscle; disease
AB Background: To strengthen research and differential diagnostics of mitochondrial disorders, we constructed and validated an oligonucleotide microarray (h-MitoArray) allowing expression analysis of 1632 human genes involved in mitochondrial biology, cell cycle regulation, signal transduction and apoptosis. Using h-MitoArray we analyzed gene expression profiles in 9 control and 13 fibroblast cell lines from patients with FIFo ATP synthase deficiency consisting of 2 patients with mt9205 Delta TA microdeletion and a genetically heterogeneous group of 11 patients with not yet characterized nuclear defects. Analysing gene expression profiles, we attempted to classify patients into expected defect specific subgroups, and subsequently reveal group specific compensatory changes, identify potential phenotype causing pathways and define candidate disease causing genes. Results: Molecular studies, in combination with unsupervised clustering methods, defined three subgroups of patient cell lines - M group with mtDNA mutation and N1 and N2 groups with nuclear defect. Comparison of expression profiles and functional annotation, gene enrichment and pathway analyses of differentially expressed genes revealed in the M group a transcription profile suggestive of synchronized suppression of mitochondrial biogenesis and GI/S arrest. The N1 group showed elevated expression of complex I and reduced expression of complexes III, V, and V-type ATP synthase subunit genes, reduced expression of genes involved in phosphorylation dependent signaling along MAPK, Jak-STAT, JNK, and p38 MAP kinase pathways, signs of activated apoptosis and oxidative stress resembling phenotype of premature senescent fibroblasts. No specific functionally meaningful changes, except of signs of activated apoptosis, were detected in the N2 group. Evaluation of individual gene expression profiles confirmed already known ATP6/ATP8 defect in patients from the M group and indicated several candidate disease causing genes for nuclear defects. Conclusion: Our analysis showed that deficiency in the ATP synthase protein complex amount is generally accompanied by only minor changes in expression of ATP synthase related genes. It also suggested that the site (mtDNA vs nuclear DNA) and the severity (ATP synthase content) of the underlying defect have diverse effects on cellular gene expression phenotypes, which warrants further investigation of cell cycle regulatory and signal transduction pathways in other OXPHOS disorders and related pharmacological models.
C1 [Cizkova, Alena; Stranecky, Viktor; Ivanek, Robert; Hartmannova, Hana; Piherova, Lenka; Tesarova, Marketa; Hansikova, Hana; Zeman, Jiri; Potocka, Andrea; Paul, Jan; Houstek, Josef; Kmoch, Stanislav] Charles Univ Prague, Fac Med 1, Ctr Appl Genom, Prague, Czech Republic.
   [Cizkova, Alena; Stranecky, Viktor; Ivanek, Robert; Hartmannova, Hana; Noskova, Lenka; Piherova, Lenka; Kmoch, Stanislav] Charles Univ Prague, Fac Med 1, Inst Inherited Metabol Disorders, Prague, Czech Republic.
   [Tesarova, Marketa; Hansikova, Hana; Honzik, Tomas; Zeman, Jiri] Charles Univ Prague, Fac Med 1, Dept Pediat, Prague, Czech Republic.
   [Ivanek, Robert; Divina, Petr] Acad Sci Czech Republic, Inst Mol Genet, Prague, Czech Republic.
   [Cizkova, Alena; Potocka, Andrea; Paul, Jan; Houstek, Josef] Acad Sci Czech Republic, Inst Physiol, Dept Bioenerget, Prague, Czech Republic.
   [Sperl, Wolfgang; Mayr, Johannes A.] Paracelsus Med Univ, Dept Pediat, Salzburg, Austria.
   [Seneca, Sara] Free Univ Brussels, Ctr Med Genet, Brussels, Belgium.
C3 Charles University Prague; Charles University Prague; Charles University Prague; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Paracelsus Private Medical University; Universite Libre de Bruxelles
RP Kmoch, S (corresponding author), Charles Univ Prague, Fac Med 1, Ctr Appl Genom, Prague, Czech Republic.
EM acizk@LF1.cuni.cz; vstra@LF1.cuni.cz; ivanek@img.cas.cz; hhart@LF1.cuni.cz; lnosk@LF1.cuni.cz; Lenka.Piherova@LF1.cuni.cz; Marketa.Tesarova@LF1.cuni.cz; HHansikova@seznam.cz; HonzikT@seznam.cz; jzem@LF1.cuni.cz; divina@img.cas.cz; potockaa@biomed.cas.cz; paulj@biomed.cas.cz; w.sperl@salk.at; h.mayr@salk.at; sara.seneca@az.vub.ac.be; houstek@biomed.cas.cz; skmoch@LF1.cuni.cz
FU NINR NIH HHS [F31 NR008069] Funding Source: Medline
CR Alesci S, 2006, PHARMACOGENOMICS J, V6, P333, DOI 10.1038/sj.tpj.6500377
   Bai XY, 2007, BIOTECHNIQUES, V42, P365, DOI 10.2144/000112388
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Boneh A, 2006, CELL MOL LIFE SCI, V63, P1236, DOI 10.1007/s00018-005-5585-2
   Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365
   Calvo S, 2006, NAT GENET, V38, P576, DOI 10.1038/ng1776
   Chalmers CJ, 2007, CELL SIGNAL, V19, P695, DOI 10.1016/j.cellsig.2006.09.001
   Chen HH, 2007, BIOCHEM BIOPH RES CO, V357, P56, DOI 10.1016/j.bbrc.2007.03.113
   Chen JJ, 2007, PHARMACOGENOMICS, V8, P473, DOI 10.2217/14622416.8.5.473
   Chinnery PF, 2003, TRENDS GENET, V19, P60, DOI 10.1016/S0168-9525(02)00030-6
   Chrzanowska-Lightowlers ZMA, 2004, BIOCHEM J, V377, P725, DOI 10.1042/bj20031556
   Cristofalo VJ, 2004, MECH AGEING DEV, V125, P827, DOI 10.1016/j.mad.2004.07.010
   Cuervo Ana Maria, 1998, FRONTIERS IN BIOSCIENCE, V3, P0
   De Meirleir L, 2004, J MED GENET, V41, P120, DOI 10.1136/jmg.2003.012047
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 2007, BIOSCIENCE REP, V27, P5, DOI 10.1007/s10540-007-9032-5
   Gajewski CD, 2003, MOL BIOL CELL, V14, P3628, DOI 10.1091/mbc.E02-12-0796
   Gemin A, 2005, BIOCHEM BIOPH RES CO, V332, P1122, DOI 10.1016/j.bbrc.2005.05.061
   Halgren RG, 2001, NUCLEIC ACIDS RES, V29, P582, DOI 10.1093/nar/29.2.582
   Hardie DG, 2006, J PHYSIOL-LONDON, V574, P7, DOI 10.1113/jphysiol.2006.108944
   Holloway AJ, 2002, NAT GENET, V32, P481, DOI 10.1038/ng1030
   Houstek J, 1999, HUM MOL GENET, V8, P1967
   Houstek J, 2006, BBA-BIOENERGETICS, V1757, P1400, DOI 10.1016/j.bbabio.2006.04.006
   Hrebícek M, 2006, AM J HUM GENET, V79, P807, DOI 10.1086/508294
   HU CM, 2007, J BIOMED SCI, V0, P0
   Iakova P, 2004, EMBO J, V23, P406, DOI 10.1038/sj.emboj.7600052
   Ijlst L, 2002, AM J HUM GENET, V71, P1463, DOI 10.1086/344712
   Jesina P, 2004, BIOCHEM J, V383, P561, DOI 10.1042/BJ20040407
   Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027
   Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604
   Kerstann KW, 2000, AM J HUM GENET, V67, P271
   Kirby DM, 2004, J CLIN INVEST, V114, P837, DOI 10.1172/JCI200420683
   KLEMENT P, 1995, ANAL BIOCHEM, V231, P218, DOI 10.1006/abio.1995.1523
   Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722
   Liao TSV, 2006, GENETICS, V174, P525, DOI 10.1534/genetics.106.061705
   Limatola C, 1999, J BIOL CHEM, V274, P36537, DOI 10.1074/jbc.274.51.36537
   Mandal S, 2005, DEV CELL, V9, P843, DOI 10.1016/j.devcel.2005.11.006
   Martínez-Diez M, 2006, PLOS ONE, V1, P0, DOI 10.1371/journal.pone.0000107
   Mayr JA, 2004, PEDIATR RES, V55, P988, DOI 10.1203/01.pdr.0000127016.67809.6b
   McFarland R, 2007, CURR TOP DEV BIOL, V77, P113, DOI 10.1016/S0070-2153(06)77005-3
   Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699
   MOOTHA VK, 2003, P NATL ACAD SCI US, V0, P0
   NAKAGAWA J, 1995, P NATL ACAD SCI USA, V92, P2051, DOI 10.1073/pnas.92.6.2051
   Park WY, 2000, J BIOL CHEM, V275, P20847, DOI 10.1074/jbc.M908162199
   Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01
   Scarpulla RC, 2006, J CELL BIOCHEM, V97, P673, DOI 10.1002/jcb.20743
   Seneca S, 1996, J INHERIT METAB DIS, V19, P115, DOI 10.1007/BF01799407
   SENECHAL M, 1993, READ RES QUART, V28, P361
   SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680
   Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5
   Shepherd RK, 2006, J INHERIT METAB DIS, V29, P86, DOI 10.1007/s10545-006-0148-8
   Shoubridge EA, 2001, SEMIN NEUROL, V21, P261, DOI 10.1055/s-2001-17943
   Slomovic S, 2005, MOL CELL BIOL, V25, P6427, DOI 10.1128/MCB.25.15.6427-6435.2005
   Slonim DK, 2002, NAT GENET, V32, P502, DOI 10.1038/ng1033
   Smyth G, 2005, LIMMA LINEAR MODELS, V0, P0
   Sperl W, 2006, NEUROMUSCULAR DISORD, V16, P821, DOI 10.1016/j.nmd.2006.08.008
   Stöckl P, 2006, EXP GERONTOL, V41, P674, DOI 10.1016/j.exger.2006.04.009
   THORBURN DR, 2004, BIOCH BIOPHYS ACTA, V0, P0
   Timchenko LT, 2006, J BIOL CHEM, V281, P32806, DOI 10.1074/jbc.M605701200
   van der Westhuizen FH, 2003, NEUROPEDIATRICS, V34, P14, DOI 10.1055/s-2003-38618
   Wang CG, 2006, P NATL ACAD SCI USA, V103, P11567, DOI 10.1073/pnas.0603363103
   Wang W, 2002, MOL CELL BIOL, V22, P3425, DOI 10.1128/MCB.22.10.3425-3436.2002
   Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000
   Wang WG, 2003, J BIOL CHEM, V278, P27016, DOI 10.1074/jbc.M300318200
   Wang WG, 2001, MOL CELL BIOL, V21, P5889, DOI 10.1128/MCB.21.17.5889-5898.2001
   Whitmarsh AJ, 2000, CELL MOL LIFE SCI, V57, P1172, DOI 10.1007/PL00000757
   Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599
NR 67
TC 23
Z9 24
U1 1
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2164
EI 
J9 BMC GENOMICS
JI BMC Genomics
PD JAN 25
PY 2008
VL 9
IS 
BP 
EP 
DI 10.1186/1471-2164-9-38
PG 18
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 274FP
UT WOS:000253987500001
PM 18221507
DA 2024-11-01
ER

PT J
AU Kornblum, C
   Zsurka, G
   Wiesner, RJ
   Schröder, R
   Kunz, WS
AF Kornblum, Cornelia
   Zsurka, Gabor
   Wiesner, Rudolf J.
   Schroeder, Rolf
   Kunz, Wolfram S.
TI Concerted action of two novel tRNA mtDNA point mutations in chronic progressive external ophthalmoplegia
SO BIOSCIENCE REPORTS
LA English
DT Article
DE chronic progressive external ophthalmoplegia (CPEO); mitochondrial DNA (mtDNA); mitochondrial DNA disease; mitochondrial tRNA; oxidative phosphorylation
ID mitochondrial transfer-rna; reference sequence; skeletal-muscle; dna; gene; heteroplasmy; diseases
AB CPEO (chronic progressive external ophthalmoplegia) is a common mitochondrial disease phenotype in adults which is due to mtDNA (mitochondrial DNA) point mutations in a subset of patients. Attributing pathogenicity to novel tRNA mtDNA mutations still poses a challenge, particularly when several mtDNA sequence variants are present. In the present study we report a CPEO patient for whom sequencing of the mitochondrial genome revealed three novel tRNA mtDNA mutations: G5835A, del4315A, T1658C in tRNA(Tyr), tRNA(lle) and tRNA(val) genes. In skeletal muscle, the tRNA(val) and tRNA(lle) mutations were homoplasmic, whereas the tRNA(Tyr) mutation was heteroplasmic. To address the pathogenic relevance, we performed two types of functional tests: (i) single skeletal muscle fibre analysis comparing G5835A mutation loads and biochemical phenotypes of corresponding fibres, and (ii) Northern-blot analyses of mitochondrial tRNA(Tyr), tRNA(lle) and tRNA(val). We demonstrated that both the G5835A tRNA(Tyr) and de14315A tRNA(lle) mutation have serious functional consequences. Single-fibre analyses displayed a high threshold of the tRNATyr mutation load for biochemical phenotypic expression at the single-cell level, indicating a rather mild pathogenic effect. In contrast, skeletal muscle tissue showed a severe decrease in respiratory-chain activities, a reduced overall COX (cytochrome c oxidase) staining intensity and abundant COX-negative fibres. Northern-blot analyses showed a dramatic reduction of tRNA(Tyr) and tRNA(lle) levels in muscle, with impaired charging of tRNA(lle), whereas tRNA(val) levels were only slightly decreased, with amino-acylation unaffected. Our findings suggest that the heteroplasmic tRNA(Tyr) and homoplasmic tRNA(lle) mutation act together, resulting in a concerted effect on the biochemical and histological phenotype. Thus homoplasmic mutations may influence the functional consequences of pathogenic heteroplasmic mtDNA mutations.
C1 [Zsurka, Gabor; Kunz, Wolfram S.] Univ Bonn, Med Ctr, Dept Epileptol, D-53105 Bonn, Germany.
   [Kornblum, Cornelia] Univ Bonn, Med Ctr, Dept Neurol, D-53105 Bonn, Germany.
   [Zsurka, Gabor; Kunz, Wolfram S.] Platform NeuroCognit Life & Brain Ctr, D-53105 Bonn, Germany.
   [Wiesner, Rudolf J.] Univ Cologne, Fac Med, Inst Vegetat Physiol, D-50931 Cologne, Germany.
   [Wiesner, Rudolf J.] Univ Cologne, CMMC, D-50931 Cologne, Germany.
   [Schroeder, Rolf] Univ Erlangen Nurnberg, Dept Neuropathol, D-91054 Erlangen, Germany.
   [Schroeder, Rolf] Univ Erlangen Nurnberg, Dept Neurol, D-91054 Erlangen, Germany.
C3 University of Bonn; University of Bonn; University of Cologne; University of Cologne; University of Erlangen Nuremberg; University of Erlangen Nuremberg
RP Kunz, WS (corresponding author), Univ Bonn, Med Ctr, Dept Epileptol, D-53105 Bonn, Germany.
EM wolfram.kunz@ukb.uni-bonn.de
CR Achilli A, 2004, AM J HUM GENET, V75, P910, DOI 10.1086/425590
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Biousse V, 2003, CURR OPIN NEUROL, V16, P35, DOI 10.1097/00019052-200302000-00005
   Cardaioli E, 2005, BIOCHEM BIOPH RES CO, V327, P675, DOI 10.1016/j.bbrc.2004.11.170
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Dubowitz V, 2006, MUSCLE BIOPSY PRACTI, V0, P0
   Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   Limongelli A, 2004, J MED GENET, V41, P342, DOI 10.1136/jmg.2003.016048
   Mancuso M, 2007, BIOSCIENCE REP, V27, P31, DOI 10.1007/s10540-007-9035-2
   Maniura-Weber K, 2006, NUCLEIC ACIDS RES, V34, P6404, DOI 10.1093/nar/gkl727
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   PETRUZZELLA V, 1994, HUM MOL GENET, V3, P449, DOI 10.1093/hmg/3.3.449
   Pruitt KD, 2005, NUCLEIC ACIDS RES, V33, PD501, DOI 10.1093/nar/gki025
   Scuderi C, 2007, NEUROMUSCULAR DISORD, V17, P258, DOI 10.1016/j.nmd.2006.11.006
   Siciliano G, 2007, BIOSCIENCE REP, V27, P53, DOI 10.1007/s10540-007-9037-0
   Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Tully LA, 2000, AM J HUM GENET, V67, P432, DOI 10.1086/302996
   Varlamov DA, 2002, HUM MOL GENET, V11, P1797, DOI 10.1093/hmg/11.16.1797
   Wiedemann FR, 2000, ANAL BIOCHEM, V279, P55, DOI 10.1006/abio.1999.4434
   Wittenhagen LM, 2002, NAT STRUCT BIOL, V9, P586, DOI 10.1038/nsb820
   Yasukawa T, 2000, NUCLEIC ACIDS RES, V28, P3779, DOI 10.1093/nar/28.19.3779
   Zsurka G, 2004, J MED GENET, V41, P0, DOI 10.1136/jmg.2004.022566
   Zsurka G, 2005, NAT GENET, V37, P873, DOI 10.1038/ng1606
NR 28
TC 8
Z9 8
U1 0
U2 0
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0144-8463
EI 
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD APR 15
PY 2008
VL 28
IS 2
BP 89
EP 96
DI 10.1042/BSR20080004
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 317KS
UT WOS:000257019700004
PM 18384291
DA 2024-11-01
ER

PT J
AU Brieba, LG
AF Brieba, Luis G.
TI Template Dependent Human DNA Polymerases
SO CURRENT TOPICS IN MEDICINAL CHEMISTRY
LA English
DT Review
DE DNA polymerases; structure-function
ID progressive external ophthalmoplegia; base-excision-repair; pigmentosum-variant patients; purified human proteins; unique error signature; thymine-thymine dimer; p55 accessory subunit; mitochondrial-dna; polg mutations; xeroderma-pigmentosum
AB The genetic material in humans contains approximately 6 billion base pairs in the nuclear genome and 16,569 base pairs in the mitochondrial genome [1-3]. In some cases the difference between a healthy and a sick individual consists in only one nucleotide. Thus, it is evident that the pristine replication of the genome is a key event in the avoidance of mutations and therefore diseases. Although it is generally believed that DNA is an inert molecule, it contains reactive groups that are exposed to a multitude of chemical agents like Reactive Oxidative Species (ROS), xenobiotic compounds, and UV light which can react with DNA to form adducts that compromise its coding potential. For instance, it is estimated that a mammalian genome suffers close to 100,000 abasic sites per day [4, 5]. In general, replicative DNA polymerases are responsible for maintaining the integrity of the genome during it replication, family X polymerases are important in DNA repair mechanisms, and Translesion Synthesis DNA polymerases ensure the faithful replication across from DNA lesions. This revision attempts to briefly summarize the role of human template dependent DNA polymerases involved in replication, DNA repair, and lesion bypass.
RP Brieba, LG (corresponding author), CINVESTAV IPN, Campus Guanajuato,Km 9-6 Libramiento Norte,Carret, Guanajuato 36500, Mexico.
EM lgbrieba@ira.cinvestav.mx
FU Howard Hughes Medical Institute International Program; CONACYT-Mexico [J48770-Q]
CR Acharya N, 2005, MOL CELL BIOL, V25, P9734, DOI 10.1128/MCB.25.21.9734-9740.2005
   Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Aknin-Seifer IE, 2005, HUM REPROD, V20, P736, DOI 10.1093/humrep/deh666
   ALLEN D, 2008, BIOL REPROD, V0, P0
   Alt A, 2007, SCIENCE, V318, P967, DOI 10.1126/science.1148242
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   ARANA ME, 2008, NUCL ACIDS RES, V0, P0
   Arana ME, 2007, DNA REPAIR, V6, P213, DOI 10.1016/j.dnarep.2006.09.012
   Asturias FJ, 2006, NAT STRUCT MOL BIOL, V13, P35, DOI 10.1038/nsmb1040
   Batra VK, 2008, MOL CELL, V30, P315, DOI 10.1016/j.molcel.2008.02.025
   Bavoux C, 2005, CANCER RES, V65, P325
   Beard WA, 2006, CHEM REV, V106, P361, DOI 10.1021/cr0404904
   Bebenek K, 2003, J BIOL CHEM, V278, P34685, DOI 10.1074/jbc.M305705200
   Bebenek K, 2001, SCIENCE, V291, P2156, DOI 10.1126/science.1058386
   BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987
   Bemark M, 2000, CURR BIOL, V10, P1213, DOI 10.1016/S0960-9822(00)00724-7
   Berman AJ, 2007, EMBO J, V26, P3494, DOI 10.1038/sj.emboj.7601780
   Bertocci B, 2003, IMMUNITY, V19, P203, DOI 10.1016/S1074-7613(03)00203-6
   Bertocci B, 2002, J IMMUNOL, V168, P3702, DOI 10.4049/jimmunol.168.8.3702
   Bertocci B, 2006, IMMUNITY, V25, P31, DOI 10.1016/j.immuni.2006.04.013
   BOLLUM FJ, 1958, J BIOL CHEM, V233, P478
   Braithwaite EK, 2005, J BIOL CHEM, V280, P31641, DOI 10.1074/jbc.C500256200
   BRONDELLO JM, 2008, ONCOGENE, V0, P0
   Broughton BC, 2002, P NATL ACAD SCI USA, V99, P815, DOI 10.1073/pnas.022473899
   BYRNES JJ, 1976, BIOCHEMISTRY-US, V15, P2817, DOI 10.1021/bi00658a018
   Capp JP, 2007, NUCLEIC ACIDS RES, V35, P3551, DOI 10.1093/nar/gkm243
   Carrodeguas JA, 2001, MOL CELL, V7, P43, DOI 10.1016/S1097-2765(01)00153-8
   CHOI JY, 2008, J BIOL CHEM, V0, P0
   Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682
   COPELAND WC, 1993, J BIOL CHEM, V268, P11041
   COPELAND WC, 1993, J BIOL CHEM, V268, P26179
   DSouza S, 2008, DNA REPAIR, V7, P1455, DOI 10.1016/j.dnarep.2008.05.009
   DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10
   Dalal S, 2008, NUCLEIC ACIDS RES, V36, P411, DOI 10.1093/nar/gkm1053
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Davis BJ, 2008, NUCLEIC ACIDS RES, V36, P3085, DOI 10.1093/nar/gkn164
   Del Bo R, 2003, NEUROLOGY, V61, P903, DOI 10.1212/01.WNL.0000092303.13864.BE
   DeRose EF, 2007, BIOCHEMISTRY-US, V46, P12100, DOI 10.1021/bi7007728
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Diaz M, 2003, MOL CANCER RES, V1, P836
   Doublié S, 1998, NATURE, V391, P251, DOI 10.1038/34593
   Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283
   Dumstorf CA, 2006, P NATL ACAD SCI USA, V103, P18083, DOI 10.1073/pnas.0605247103
   Engelsen BA, 2008, BRAIN, V131, P818, DOI 10.1093/brain/awn007
   Esposito G, 2000, CURR BIOL, V10, P1221, DOI 10.1016/S0960-9822(00)00726-0
   Fan W, 2004, BIOCHEM BIOPH RES CO, V323, P1328, DOI 10.1016/j.bbrc.2004.09.002
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Ferraris S, 2008, ARCH NEUROL-CHICAGO, V65, P125, DOI 10.1001/archneurol.2007.9
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Fischhaber PL, 2002, J BIOL CHEM, V277, P37604, DOI 10.1074/jbc.M206027200
   Flohr T, 1999, INT J CANCER, V80, P919, DOI 10.1002/(SICI)1097-0215(19990315)80:6<919::AID-IJC19>3.0.CO;2-U
   FLOY KM, 1990, AM J MED GENET, V35, P301, DOI 10.1002/ajmg.1320350302
   Fortune JM, 2005, J BIOL CHEM, V280, P29980, DOI 10.1074/jbc.M505236200
   Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1
   Frick DN, 2001, ANNU REV BIOCHEM, V70, P39, DOI 10.1146/annurev.biochem.70.1.39
   Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236
   Gago MF, 2006, NEUROMUSCULAR DISORD, V16, P507, DOI 10.1016/j.nmd.2006.05.016
   Garcia-Diaz M, 2004, MOL CELL, V13, P561, DOI 10.1016/S1097-2765(04)00061-9
   García-Díaz M, 2001, J BIOL CHEM, V276, P34659, DOI 10.1074/jbc.M106336200
   García-Díaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005
   Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876
   Goldsby RE, 2002, P NATL ACAD SCI USA, V99, P15560, DOI 10.1073/pnas.232340999
   González-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107
   Graziewicz MA, 2007, HUM MOL GENET, V16, P2729, DOI 10.1093/hmg/ddm227
   GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642
   Guo CX, 2003, EMBO J, V22, P6621, DOI 10.1093/emboj/cdg626
   He XH, 2008, EUR J EPIDEMIOL, V23, P403, DOI 10.1007/s10654-008-9251-5
   HOLMES AM, 1985, J BIOL CHEM, V260, P840
   HOLMES AM, 1976, EUR J BIOCHEM, V62, P229, DOI 10.1111/j.1432-1033.1976.tb10152.x
   Hübscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041
   Hudson G, 2007, ARCH NEUROL-CHICAGO, V64, P553, DOI 10.1001/archneur.64.4.553
   Hudson G, 2006, HUM MOL GENET, V15, PR244, DOI 10.1093/hmg/ddl233
   Inui H, 2008, J INVEST DERMATOL, V128, P2055, DOI 10.1038/jid.2008.48
   Invernizzi F, 2008, NEUROMUSCULAR DISORD, V18, P460, DOI 10.1016/j.nmd.2008.04.005
   ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045
   Jensen M, 2004, HUM REPROD, V19, P65, DOI 10.1093/humrep/deh038
   JENSEN MB, 2008, ANN ONCOL, V0, P0
   Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030
   Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001
   Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263
   Johnson RE, 2006, MOL CELL BIOL, V26, P6435, DOI 10.1128/MCB.00851-06
   Juárez R, 2006, NUCLEIC ACIDS RES, V34, P4572, DOI 10.1093/nar/gkl457
   KAGUNI LS, 1983, P NATL ACAD SCI-BIOL, V80, P2221, DOI 10.1073/pnas.80.8.2221
   Kiechl S, 2004, J NEUROL NEUROSUR PS, V75, P1125, DOI 10.1136/jnnp.2003.025890
   Klingbeil MM, 2002, MOL CELL, V10, P175, DOI 10.1016/S1097-2765(02)00571-3
   Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341
   Kobayashi Y, 2002, MOL CELL BIOL, V22, P2769, DOI 10.1128/MCB.22.8.2769-2776.2002
   Krahn JM, 2003, STRUCTURE, V11, P121, DOI 10.1016/S0969-2126(02)00930-9
   Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   KUNKEL TA, 1989, MOL CELL BIOL, V9, P4447, DOI 10.1128/MCB.9.10.4447
   Lamantea E, 2004, ANN NEUROL, V56, P454, DOI 10.1002/ana.20219
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101
   Lee JW, 2004, J BIOL CHEM, V279, P805, DOI 10.1074/jbc.M307913200
   LEHMAN IR, 1958, P NATL ACAD SCI USA, V44, P1191, DOI 10.1073/pnas.44.12.1191
   Lemée F, 2007, ONCOGENE, V26, P3387, DOI 10.1038/sj.onc.1210116
   Li Y, 2000, J BIOL CHEM, V275, P23247, DOI 10.1074/jbc.M002548200
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Lin QC, 2006, CANCER RES, V66, P87, DOI 10.1158/0008-5472.CAN-05-1862
   Lin WS, 1999, MUTAT RES-DNA REPAIR, V433, P89, DOI 10.1016/S0921-8777(98)00065-2
   LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018
   Liu L, 2000, J BIOL CHEM, V275, P18739, DOI 10.1074/jbc.M001217200
   Lone S, 2007, MOL CELL, V25, P601, DOI 10.1016/j.molcel.2007.01.018
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2007, NEUROLOGY, V69, P1152, DOI 10.1212/01.wnl.0000276955.23735.eb
   Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002
   Maloisel L, 2008, MOL CELL BIOL, V28, P1373, DOI 10.1128/MCB.01651-07
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Marini F, 2003, J BIOL CHEM, V278, P32014, DOI 10.1074/jbc.M305646200
   MARMOTO SA, 2008, DNA REPAIR IN PRESS, V0, P0
   Masuda K, 2005, P NATL ACAD SCI USA, V102, P13986, DOI 10.1073/pnas.0505636102
   Masuda K, 2007, J BIOL CHEM, V282, P17387, DOI 10.1074/jbc.M611849200
   Masuda K, 2006, DNA REPAIR, V5, P1384, DOI 10.1016/j.dnarep.2006.06.006
   Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447
   McCulloch SD, 2004, NATURE, V428, P97, DOI 10.1038/nature02352
   McDonald JP, 2003, J EXP MED, V198, P635, DOI 10.1084/jem.20030767
   McElhinny SAN, 2005, MOL CELL, V19, P357, DOI 10.1016/j.molcel.2005.06.012
   McElhinny SAN, 2008, MOL CELL, V30, P137, DOI 10.1016/j.molcel.2008.02.022
   Milone M, 2008, NEUROMUSCULAR DISORD, V18, P626, DOI 10.1016/j.nmd.2008.05.009
   Moon AF, 2007, NAT STRUCT MOL BIOL, V14, P45, DOI 10.1038/nsmb1180
   Nair DT, 2008, STRUCTURE, V16, P239, DOI 10.1016/j.str.2007.12.009
   Nair DT, 2006, STRUCTURE, V14, P749, DOI 10.1016/j.str.2006.01.010
   Nair DT, 2005, SCIENCE, V309, P2219, DOI 10.1126/science.1116336
   Nair DT, 2004, NATURE, V430, P377, DOI 10.1038/nature02692
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0
   Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Ogi T, 2002, P NATL ACAD SCI USA, V99, P15548, DOI 10.1073/pnas.222377899
   Ogi T, 2006, NAT CELL BIOL, V8, P640, DOI 10.1038/ncb1417
   Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200
   Ohkumo T, 2006, MOL CELL BIOL, V26, P7696, DOI 10.1128/MCB.01076-06
   Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7
   Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642
   Ott RD, 2002, MOL CELL BIOL, V22, P5669, DOI 10.1128/MCB.22.16.5669-5678.2002
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Pagnamenta AT, 2006, HUM REPROD, V21, P2467, DOI 10.1093/humrep/del076
   Parsons JL, 2007, NUCLEIC ACIDS RES, V35, P1054, DOI 10.1093/nar/gkl1115
   Pascucci B, 1999, J BIOL CHEM, V274, P33696, DOI 10.1074/jbc.274.47.33696
   Pavlov YI, 2001, GENETICS, V159, P47
   Pavlov YI, 2006, CURR BIOL, V16, P202, DOI 10.1016/j.cub.2005.12.002
   Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d
   Picher AJ, 2007, DNA REPAIR, V6, P1749, DOI 10.1016/j.dnarep.2007.06.007
   Picher AJ, 2006, NUCLEIC ACIDS RES, V34, P3259, DOI 10.1093/nar/gkl377
   PLEVANI P, 1988, BIOCHIM BIOPHYS ACTA, V951, P268, DOI 10.1016/0167-4781(88)90096-6
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Popanda O, 1999, J CANCER RES CLIN, V125, P598, DOI 10.1007/s004320050322
   Prasad R, 2003, J BIOL CHEM, V278, P29649, DOI 10.1074/jbc.M305399200
   Pursell ZF, 2007, SCIENCE, V317, P127, DOI 10.1126/science.1144067
   REMES AM, 2008, PARKINSONISM RELAT D, V0, P0
   Roettger MP, 2004, BIOCHEMISTRY-US, V43, P13827, DOI 10.1021/bi048782m
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Santoro L, 2006, J NEUROL, V253, P869, DOI 10.1007/s00415-006-0082-6
   Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812
   Seki M, 2004, EMBO J, V23, P4484, DOI 10.1038/sj.emboj.7600424
   Seki M, 2003, NUCLEIC ACIDS RES, V31, P6117, DOI 10.1093/nar/gkg814
   Seki M, 2008, DNA REPAIR, V7, P119, DOI 10.1016/j.dnarep.2007.08.005
   SELAK N, 2008, NUCL ACIDS RES, V0, P0
   Shcherbakova PV, 2003, J BIOL CHEM, V278, P43770, DOI 10.1074/jbc.M306893200
   Shimizu T, 2003, IMMUNOL LETT, V86, P265, DOI 10.1016/S0165-2478(03)00046-4
   SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012
   Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0
   STADLBAUER F, 1994, EUR J BIOCHEM, V222, P781, DOI 10.1111/j.1432-1033.1994.tb18925.x
   Starcevic D, 2004, CELL CYCLE, V3, P998
   Stuart JA, 2004, NUCLEIC ACIDS RES, V32, P2181, DOI 10.1093/nar/gkh533
   Sugo N, 2000, EMBO J, V19, P1397, DOI 10.1093/emboj/19.6.1397
   SZCZESNY B, 2008, J BIOL CHEM, V0, P0
   Takata K, 2006, J BIOL CHEM, V281, P23445, DOI 10.1074/jbc.M604317200
   Tanioka M, 2007, J INVEST DERMATOL, V127, P1745, DOI 10.1038/sj.jid.5700759
   Tano K, 2007, DNA REPAIR, V6, P869, DOI 10.1016/j.dnarep.2007.01.011
   Tissier A, 2000, GENE DEV, V14, P1642
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9
   Uusimaa J, 2008, EPILEPSIA, V49, P1038, DOI 10.1111/j.1528-1167.2008.01544.x
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Venkatesan RN, 2007, MOL CELL BIOL, V27, P7669, DOI 10.1128/MCB.00002-07
   Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040
   Vermeulen C, 2007, RADIAT RES, V168, P683, DOI 10.1667/RR1057R.1
   Vermulst M, 2008, NAT GENET, V40, P392, DOI 10.1038/ng.95
   Vermulst M, 2007, NAT GENET, V39, P540, DOI 10.1038/ng1988
   WANG TSF, 1989, FASEB J, V3, P14, DOI 10.1096/fasebj.3.1.2642867
   Wang Y, 2007, CANCER RES, V67, P3018, DOI 10.1158/0008-5472.CAN-06-3073
   Washington MT, 2004, MOL CELL BIOL, V24, P6900, DOI 10.1128/MCB.24.16.6900-6906.2004
   Washington MT, 2003, MOL CELL BIOL, V23, P8316, DOI 10.1128/MCB.23.22.8316-8322.2003
   Washington MT, 2003, MOL CELL BIOL, V23, P5107, DOI 10.1128/MCB.23.14.5107-5112.2003
   WEISER T, 1991, J BIOL CHEM, V266, P10420
   WEISSBACH A, 1975, SCIENCE, V190, P401, DOI 10.1126/science.1179222
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wittschieben J, 2000, CURR BIOL, V10, P1217, DOI 10.1016/S0960-9822(00)00725-9
   Wittschieben JP, 2006, CANCER RES, V66, P134, DOI 10.1158/0008-5472.CAN-05-2982
   Wolfle WT, 2005, MOL CELL BIOL, V25, P7137, DOI 10.1128/MCB.25.16.7137-7143.2005
   Wong LJ, 2008, HUM MUTAT, V0, P0
   WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x
   Yakubovskaya E, 2007, EMBO J, V26, P4283, DOI 10.1038/sj.emboj.7601843
   YANG CL, 1992, NUCLEIC ACIDS RES, V20, P735, DOI 10.1093/nar/20.4.735
   YONEDA M, 1965, J BIOL CHEM, V240, P3385
   Yoshimura M, 2006, MOL CELL, V24, P115, DOI 10.1016/j.molcel.2006.07.032
   Zan H, 2005, EMBO J, V24, P3757, DOI 10.1038/sj.emboj.7600833
   Zander L, 2004, DNA REPAIR, V3, P743, DOI 10.1016/j.dnarep.2004.03.031
   Zhang DK, 2000, GENOMICS, V69, P151, DOI 10.1006/geno.2000.6333
   Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138
   Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4147, DOI 10.1093/nar/28.21.4147
   Zhang YB, 2000, MOL CELL BIOL, V20, P7099, DOI 10.1128/MCB.20.19.7099-7108.2000
   Zhang YB, 2002, J BIOL CHEM, V277, P44582, DOI 10.1074/jbc.M207297200
   Zhang YB, 2001, MOL CELL BIOL, V21, P7995, DOI 10.1128/MCB.21.23.7995-8006.2001
   Zhong XJ, 2006, NUCLEIC ACIDS RES, V34, P4731, DOI 10.1093/nar/gkl465
   2002, 1900, V293, V0, P1132
NR 216
TC 4
Z9 6
U1 1
U2 11
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES
SN 1568-0266
EI 1873-5294
J9 CURR TOP MED CHEM
JI Curr. Top. Med. Chem.
PD OCT 15
PY 2008
VL 8
IS 15
BP 1312
EP 1326
DI 10.2174/156802608786141098
PG 15
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 386YB
UT WOS:000261917400002
PM 18991720
DA 2024-11-01
ER

PT J
AU Milone, M
   Brunetti-Pierri, N
   Tang, LY
   Kumar, N
   Mezei, MM
   Josephs, K
   Powell, S
   Simpson, E
   Wong, LJC
AF Milone, Margherita
   Brunetti-Pierri, Nicola
   Tang, Lin-Ya
   Kumar, Neeraj
   Mezei, Michelle M.
   Josephs, Keith
   Powell, Suzanne
   Simpson, Ericka
   Wong, Lee-Jun C.
TI Sensory ataxic neuropathy with ophthalmoparesis caused by <i>POLG</i> mutations
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE DNA polymerase gamma; POLG mutations; SANDO; arPEO; mtDNA multiple deletions; sensory ataxia
ID mitochondrial-dna polymerase; progressive external ophthalmoplegia; diffuse cerebral degeneration; gamma; depletion; spectrum; a467t; gene
AB Mutations in POLG gene are responsible for a wide spectrum of clinical disorders with altered mitochondrial DNA (mtDNA) integrity, including mtDNA multiple deletions and depletion. Sensory ataxic neuropathy with ophthalmoparesis (SANDO) caused by mutations in POLG gene, fulfilling the clinical triad of sensory ataxic neuropathy, dysarthria and/or dysphagia and ophthalmoparesis, has described in a few reports. Here we described five cases of adult onset autosomal recessive sensory ataxic neuropathy with ophthalmoplegia. All patients had ataxia, neuropathy, myopathy, and progressive external ophthalmoplegia (PEO). The muscle pathology revealed ragged-red and cytochrome c oxidase (COX) negative fibers in three patients. However, deficiencies in the activities of mitochondrial respiratory chain enzyme complexes were not detected in any of the patients' muscle samples. Multiple deletions of mtDNA were detected in blood and muscle specimens but mtDNA depletion was not found. Due to these diagnostic difficulties, POLG-related syndromes are definitively diagnosed based on the presence of deleterious mutations in the POLG gene. (C) 2008 Published by Elsevier B.V.
C1 [Brunetti-Pierri, Nicola; Tang, Lin-Ya; Wong, Lee-Jun C.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Milone, Margherita; Kumar, Neeraj; Josephs, Keith] Mayo Clin, Dept Neurol, Rochester, MN USA.
   [Powell, Suzanne; Simpson, Ericka] Methodist Hosp, Dept Neurol, Houston, TX 77030 USA.
   [Mezei, Michelle M.] Univ British Columbia, Div Neurol, Vancouver, BC V5Z 1M9, Canada.
C3 Baylor College of Medicine; Mayo Clinic; Houston Methodist Hospital; University of British Columbia
RP Wong, LJC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza,NAB2015, Houston, TX 77030 USA.
EM ljwong@bcm.edu
CR Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8
   BLACKWOOD W, 1963, ARCH DIS CHILD, V38, P193, DOI 10.1136/adc.38.199.193
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Gago MF, 2006, NEUROMUSCULAR DISORD, V16, P507, DOI 10.1016/j.nmd.2006.05.016
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Hudson G, 2007, ARCH NEUROL-CHICAGO, V64, P553, DOI 10.1001/archneur.64.4.553
   Hudson G, 2006, HUM MOL GENET, V15, PR244, DOI 10.1093/hmg/ddl233
   HUTTENLOCHER PR, 1976, ARCH NEUROL-CHICAGO, V33, P186, DOI 10.1001/archneur.1976.00500030042009
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lecrenier N, 1997, GENE, V185, P147, DOI 10.1016/S0378-1119(96)00663-4
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   Naïmi M, 2006, EUR J HUM GENET, V14, P917, DOI 10.1038/sj.ejhg.5201627
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wong LJC, 2007, HEPATOLOGY, V46, P1218, DOI 10.1002/hep.21799
   Wong LJC, 1997, CLIN CHEM, V43, P1857
   Wong LJC, 2005, CLIN CHIM ACTA, V354, P1, DOI 10.1016/j.cccn.2004.11.003
   Wong LJC, 2003, J MED GENET, V40, P0
NR 27
TC 55
Z9 58
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD AUG 15
PY 2008
VL 18
IS 8
BP 626
EP 632
DI 10.1016/j.nmd.2008.05.009
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 353UM
UT WOS:000259594000005
PM 18585914
DA 2024-11-01
ER

PT J
AU Bao, XH
   Wu, Y
   Wong, LJC
   Zhang, YH
   Xiong, H
   Chou, PC
   Truong, CK
   Jiang, YW
   Qin, J
   Yuan, Y
   Lin, Q
   Wu, XR
AF Bao, Xinhua
   Wu, Ye
   Wong, Lee-Jun C.
   Zhang, Yuehua
   Xiong, Hui
   Chou, Ping-Chieh
   Truong, Cavatina K.
   Jiang, Yuwu
   Qin, Jiong
   Yuan, Yun
   Lin, Qing
   Wu, Xiru
TI Alpers syndrome with prominent white matter changes
SO BRAIN & DEVELOPMENT
LA English
DT Article
DE Alpers syndrome; POLGI mutations; leukoencephalopathy
ID dna-polymerase-gamma; progressive neuronal degeneration; mitochondrial-dna; polg mutations; liver-disease; external ophthalmoplegia; childhood; depletion; spectrum; a467t
AB Alpers syndrome is a fatal neurogenetic disorder caused by the mutations in POLG1 gene encoding the mitochondrial DNA polymerase gamma (pol gamma). Two missense variants, c.248T > C (p.L83P), c.2662G >A (p.G888S) in POLG1 were detected in a 10-year-old Chinese girl with refractory seizures, acute liver failure after exposure to valproic acid, cortical blindness, and psychomotor regression. The pathology of left occipital lobe showed neuronal loss, spongiform degeneration, astrocytosis, and demyelination. In addition, there were prominent white matter changes in a series of brain magnetic resonance imaging (MRI) and increased immunological factors in CSF. (c) 2007 Elsevier B.V. All rights reserved.
C1 [Bao, Xinhua; Wu, Ye; Zhang, Yuehua; Xiong, Hui; Jiang, Yuwu; Qin, Jiong; Lin, Qing; Wu, Xiru] Peking Univ, Hosp 1, Dept Pediat, Beijing 100034, Peoples R China.
   [Wong, Lee-Jun C.; Chou, Ping-Chieh; Truong, Cavatina K.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Yuan, Yun] Peking Univ, Hosp 1, Dept Neurol, Beijing 100034, Peoples R China.
C3 Peking University; Baylor College of Medicine; Peking University
RP Bao, XH (corresponding author), Peking Univ, Hosp 1, Dept Pediat, Beijing 100034, Peoples R China.
EM zwhang@pku.edu.cn
CR Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   DEVRIES MC, 2006, EUR J PEDIAT 0907, V0, P0
   DiMauro S, 2006, BRAIN, V129, P1637, DOI 10.1093/brain/awl169
   DIMMOCK DP, 2007, ACMG 2007 ANN M ABST, V0, P0
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   HARDING BN, 1995, J NEUROL NEUROSUR PS, V58, P320, DOI 10.1136/jnnp.58.3.320
   HARDING BN, 1990, J CHILD NEUROL, V5, P273, DOI 10.1177/088307389000500402
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   HUTTENLOCHER PR, 1976, ARCH NEUROL-CHICAGO, V33, P186, DOI 10.1001/archneur.1976.00500030042009
   KENDALL BE, 1987, NEURORADIOLOGY, V29, P174, DOI 10.1007/BF00327545
   Kollberg G, 2006, J NEUROPATH EXP NEUR, V65, P758, DOI 10.1097/01.jnen.0000229987.17548.6e
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Simonati A, 2003, J NEUROL, V250, P702, DOI 10.1007/s00415-003-1065-5
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   WATERS P, 2006, ACMG 2006 ANN M ABST, V0, P0
   Wong LJC, 1997, CLIN CHEM, V43, P1857
   WONG LJC, 2007, HEPATOLOGY 0810, V0, P0
NR 27
TC 12
Z9 15
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0387-7604
EI 1872-7131
J9 BRAIN DEV-JPN
JI Brain Dev.
PD APR 15
PY 2008
VL 30
IS 4
BP 295
EP 300
DI 10.1016/j.braindev.2007.08.009
PG 6
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 283ZL
UT WOS:000254674900010
PM 17923349
DA 2024-11-01
ER

PT J
AU Spinazzi, M
   Cazzola, S
   Bortolozzi, M
   Baracca, A
   Loro, E
   Casarin, A
   Solaini, G
   Sgarbi, G
   Casalena, G
   Cenacchi, G
   Malena, A
   Frezza, C
   Carrara, F
   Angelini, C
   Scorrano, L
   Salviati, L
   Vergani, L
AF Spinazzi, Marco
   Cazzola, Silvia
   Bortolozzi, Mario
   Baracca, Alessandra
   Loro, Emanuele
   Casarin, Alberto
   Solaini, Giancarlo
   Sgarbi, Gianluca
   Casalena, Gabriella
   Cenacchi, Giovanna
   Malena, Adriana
   Frezza, Christian
   Carrara, Franco
   Angelini, Corrado
   Scorrano, Luca
   Salviati, Leonardo
   Vergani, Lodovica
TI A novel deletion in the GTPase domain of <i>OPA1</i> causes defects in mitochondrial morphology and distribution, but not in function
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID dominant optic atrophy; dynamin-related protein; complex-i-deficiency; proteolytic cleavage; mtdna maintenance; cultured muscle; mutations; fusion; apoptosis; dysfunction
AB Autosomal dominant optic atrophy (ADOA), the commonest cause of inherited optic atrophy, is caused by mutations in the ubiquitously expressed gene optic atrophy 1 (OPA1), involved in fusion and biogenesis of the inner membrane of mitochondria. Bioenergetic failure, mitochondrial network abnormalities and increased apoptosis have all been proposed as possible causal factors. However, their relative contribution to pathogenesis as well as the prominent susceptibility of the retinal ganglion cell (RGC) in this disease remains uncertain. Here we identify a novel deletion of OPA1 gene in the GTPase domain in three patients affected by ADOA. Muscle biopsy of the patients showed neurogenic atrophy and abnormal morphology and distribution of mitochondria. Confocal microscopy revealed increased mitochondrial fragmentation in fibroblasts as well as in myotubes, where mitochondria were also unevenly distributed, with clustered organelles alternating with areas where mitochondria were sparse. These abnormalities were not associated with altered bioenergetics or increased susceptibility to pro-apoptotic stimuli. Therefore, changes in mitochondrial shape and distribution can be independent of other reported effects of OPA1 mutations, and therefore may be the primary cause of the disease. The arrangement of mitochondria in RGCs, which degenerate in ADOA, may be exquisitely sensitive to disturbance, and this may lead to bioenergetic crisis and/or induction of apoptosis. Our results highlight the importance of mitochondrial dynamics in the disease per se, and point to the loss of the fine positioning of mitochondria in the axons of RGCs as a possible explanation for their predominant degeneration in ADOA.
C1 [Spinazzi, Marco; Cazzola, Silvia; Loro, Emanuele; Malena, Adriana; Angelini, Corrado; Vergani, Lodovica] Univ Padua, Dept Neurosci, I-35100 Padua, Italy.
   [Bortolozzi, Mario; Frezza, Christian; Scorrano, Luca] Venetian Inst Mol Med, Dulbecco Telethon Inst, Padua, Italy.
   [Baracca, Alessandra; Solaini, Giancarlo; Sgarbi, Gianluca; Casalena, Gabriella] Univ Bologna, Dept Biochem, I-40126 Bologna, Italy.
   [Casarin, Alberto; Salviati, Leonardo] Univ Padua, Dept Pediat, Padua, Italy.
   [Cenacchi, Giovanna] Univ Bologna, Dept Radiol & Histocytopathol Sci, Bologna, Italy.
   [Carrara, Franco] Ist Neurol C Besta, Milan, Italy.
C3 University of Padua; Veneto Institute Molecular Medicine; Fondazione Telethon; Dulbecco Telethon Institute (DTI); University of Bologna; University of Padua; University of Bologna; Fondazione IRCCS Istituto Neurologico Carlo Besta
RP Spinazzi, M (corresponding author), Neurol Clin 2, Via Facciolati 71, I-35100 Padua, Italy.
EM marco.spinazzi@unipd.it
FU Association Francaise Contre le Myopathies [11032]; Telethon Bank [GTB07001]; Eurobiobank [QLRT 2001-027769]; Telethon Italy [TELU02016]
CR Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Amati-Bonneau P, 2005, ANN NEUROL, V58, P958, DOI 10.1002/ana.20681
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Bach D, 2003, J BIOL CHEM, V278, P17190, DOI 10.1074/jbc.M212754200
   Baloh RH, 2007, J NEUROSCI, V27, P422, DOI 10.1523/JNEUROSCI.4798-06.2007
   Baracca A, 2005, ARCH NEUROL-CHICAGO, V62, P730, DOI 10.1001/archneur.62.5.730
   Baracca A, 2007, BBA-BIOENERGETICS, V1767, P913, DOI 10.1016/j.bbabio.2007.05.005
   Barron MJ, 2004, BRIT J OPHTHALMOL, V88, P286, DOI 10.1136/bjo.2003.027664
   Bénit P, 2001, AM J HUM GENET, V68, P1344, DOI 10.1086/320603
   Bette S, 2005, ACTA NEUROPATHOL, V109, P393, DOI 10.1007/s00401-004-0970-8
   Biousse V, 2003, CURR OPIN NEUROL, V16, P35, DOI 10.1097/00019052-200302000-00005
   Campello S, 2006, J EXP MED, V203, P2879, DOI 10.1084/jem.20061877
   Carelli V, 2004, BBA-BIOENERGETICS, V1658, P172, DOI 10.1016/j.bbabio.2004.05.009
   Carelli V, 2002, NEUROCHEM INT, V40, P573, DOI 10.1016/S0197-0186(01)00129-2
   Cenacchi G, 2005, J CLIN PATHOL, V58, P190, DOI 10.1136/jcp.2004.018978
   Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010
   Chen HC, 2006, CURR OPIN CELL BIOL, V18, P453, DOI 10.1016/j.ceb.2006.06.004
   Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   Ferré M, 2005, HUM MUTAT, V25, P423, DOI 10.1002/humu.20161
   Frezza C, 2006, CELL, V126, P177, DOI 10.1016/j.cell.2006.06.025
   Griparic L, 2007, J CELL BIOL, V178, P757, DOI 10.1083/jcb.200704112
   Huang P, 2007, EUR J CELL BIOL, V86, P289, DOI 10.1016/j.ejcb.2007.04.002
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Irwin WA, 2003, NAT GENET, V35, P367, DOI 10.1038/ng1270
   Ishihara N, 2006, EMBO J, V25, P2966, DOI 10.1038/sj.emboj.7601184
   Kamei S, 2005, INVEST OPHTH VIS SCI, V46, P4288, DOI 10.1167/iovs.03-1407
   Kjer B, 1996, ACTA OPHTHALMOL SCAN, V74, P3
   Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793
   Lenaz G, 2004, BBA-BIOENERGETICS, V1658, P89, DOI 10.1016/j.bbabio.2004.03.013
   Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003
   Man CYYW, 2005, MED HYPOTHESES, V65, P1038, DOI 10.1016/j.mehy.2004.10.021
   Martín MA, 2005, ARCH NEUROL-CHICAGO, V62, P659, DOI 10.1001/archneur.62.4.659
   MARTINUZZI A, 1991, BIOCHIM BIOPHYS ACTA, V1095, P217, DOI 10.1016/0167-4889(91)90102-4
   Misaka T, 2002, J BIOL CHEM, V277, P15834, DOI 10.1074/jbc.M109260200
   Olichon A, 2007, CELL DEATH DIFFER, V14, P682, DOI 10.1038/sj.cdd.4402048
   Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200
   Olichon A, 2002, FEBS LETT, V523, P171, DOI 10.1016/S0014-5793(02)02985-X
   Olichow A, 2007, J CELL PHYSIOL, V211, P423, DOI 10.1002/jcp.20950
   Payne M, 2004, AM J OPHTHALMOL, V138, P749, DOI 10.1016/j.ajo.2004.06.011
   Pesch UEA, 2001, HUM MOL GENET, V10, P1359, DOI 10.1093/hmg/10.13.1359
   Pletjushkina OY, 2006, BBA-BIOENERGETICS, V1757, P518, DOI 10.1016/j.bbabio.2006.03.018
   Robinson KM, 2008, NAT PROTOC, V3, P941, DOI 10.1038/nprot.2008.56
   Russell AP, 2003, J CLIN ENDOCR METAB, V88, P5921, DOI 10.1210/jc.2003-030885
   Sgarbi G, 2006, BIOCHEM J, V395, P493, DOI 10.1042/BJ20051748
   Solaini G, 2007, BIOSCIENCE REP, V27, P11, DOI 10.1007/s10540-007-9033-4
   Toomes C, 2001, HUM MOL GENET, V10, P1369, DOI 10.1093/hmg/10.13.1369
   Trounce I A, 1996, METHODS ENZYMOL, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Vergani L, 2007, BRAIN, V130, P2715, DOI 10.1093/brain/awm151
   Verhoeven K, 2006, BRAIN, V129, P2093, DOI 10.1093/brain/awl126
   Wang AG, 2006, EXP EYE RES, V83, P1171, DOI 10.1016/j.exer.2006.06.004
   Zanna C, 2008, BRAIN, V131, P352, DOI 10.1093/brain/awm335
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   Züchner S, 2006, ANN NEUROL, V59, P276, DOI 10.1002/ana.20797
NR 55
TC 80
Z9 92
U1 0
U2 15
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD NOV 1
PY 2008
VL 17
IS 21
BP 3291
EP 3302
DI 10.1093/hmg/ddn225
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 359GI
UT WOS:000259974000004
PM 18678599
DA 2024-11-01
ER

PT J
AU Fan, WW
   Waymire, KG
   Narula, N
   Li, P
   Rocher, C
   Coskun, PE
   Vannan, MA
   Narula, J
   MacGregor, GR
   Wallace, DC
AF Fan, Weiwei
   Waymire, Katrina G.
   Narula, Navneet
   Li, Peng
   Rocher, Christophe
   Coskun, Pinar E.
   Vannan, Mani A.
   Narula, Jagat
   MacGregor, Grant R.
   Wallace, Douglas C.
TI A mouse model of mitochondrial disease reveals germline selection against severe mtDNA mutations
SO SCIENCE
LA English
DT Article
ID follicle-stimulating-hormone; adaptive selection; apoptosis; gene; dna
AB The majority of mitochondrial DNA ( mtDNA) mutations that cause human disease are mild to moderately deleterious, yet many random mtDNA mutations would be expected to be severe. To determine the fate of the more severe mtDNA mutations, we introduced mtDNAs containing two mutations that affect oxidative phosphorylation into the female mouse germ line. The severe ND6 mutation was selectively eliminated during oogenesis within four generations, whereas the milder COI mutation was retained throughout multiple generations even though the offspring consistently developed mitochondrial myopathy and cardiomyopathy. Thus, severe mtDNA mutations appear to be selectively eliminated from the female germ line, thereby minimizing their impact on population fitness.
C1 [Fan, Weiwei; Waymire, Katrina G.; Rocher, Christophe; Coskun, Pinar E.; MacGregor, Grant R.; Wallace, Douglas C.] Univ Calif Irvine, Ctr Mol & Mitochondrial Med & Genet, Irvine, CA 92697 USA.
   [Fan, Weiwei; Waymire, Katrina G.; Rocher, Christophe; Coskun, Pinar E.; Wallace, Douglas C.] Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA.
   [Narula, Navneet] Univ Calif Irvine, Dept Pathol, Irvine, CA 92697 USA.
   [Li, Peng; Vannan, Mani A.; Narula, Jagat] Univ Calif Irvine, Div Cardiol, Dept Med, Irvine, CA 92697 USA.
   [MacGregor, Grant R.] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA.
   [MacGregor, Grant R.] Univ Calif Irvine, Ctr Dev Biol, Irvine, CA 92697 USA.
   [Wallace, Douglas C.] Univ Calif Irvine, Dept Ecol & Evolut Biol, Irvine, CA 92697 USA.
   [Wallace, Douglas C.] Univ Calif Irvine, Dept Pediat, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine
RP Wallace, DC (corresponding author), Univ Calif Irvine, Ctr Mol & Mitochondrial Med & Genet, Irvine, CA 92697 USA.
EM dwallace@uci.edu
FU NIA NIH HHS [AG24373, AG13154, AG16573] Funding Source: Medline; NICHD NIH HHS [U01 HD045913-03, U01 HD045913-02, HD45913, U01 HD045913-01, U01 HD045913-04] Funding Source: Medline; NIDDK NIH HHS [DK73691] Funding Source: Medline; NINDS NIH HHS [NS21328] Funding Source: Medline
CR Acín-Pérez R, 2003, HUM MOL GENET, V12, P329, DOI 10.1093/hmg/ddg021
   Bai YD, 1998, EMBO J, V17, P4848, DOI 10.1093/emboj/17.16.4848
   Hussein MR, 2005, HUM REPROD UPDATE, V11, P162, DOI 10.1093/humupd/dmi001
   Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146
   Kasahara A, 2006, HUM MOL GENET, V15, P871, DOI 10.1093/hmg/ddl005
   Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229
   Levy SE, 1999, TRANSGENIC RES, V8, P137, DOI 10.1023/A:1008967412955
   MacGregor GR, 2006, EMBRYONIC STEM CELLS, V0, P72
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   Ruiz-Pesini E, 2006, HUM MUTAT, V27, P1072, DOI 10.1002/humu.20378
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Sligh JE, 2000, P NATL ACAD SCI USA, V97, P14461, DOI 10.1073/pnas.250491597
   TILLY JL, 1995, ENDOCRINOLOGY, V136, P242, DOI 10.1210/en.136.1.242
   Trounce I, 1996, SOMAT CELL MOLEC GEN, V22, P81, DOI 10.1007/BF02374379
   Tsai-Turton M, 2006, ENDOCRINOLOGY, V147, P1224, DOI 10.1210/en.2005-1281
   Wallace DC, 2007, EMERY AND RIMOINS PRINCIPLES AND PRACTICE OF MEDICAL GENETICS, V5th, P194
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wallace DC, 2007, ANNU REV BIOCHEM, V76, P781, DOI 10.1146/annurev.biochem.76.081205.150955
NR 19
TC 343
Z9 389
U1 1
U2 24
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD FEB 15
PY 2008
VL 319
IS 5865
BP 958
EP 962
DI 10.1126/science.1147786
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 262RM
UT WOS:000253165700048
PM 18276892
DA 2024-11-01
ER

PT J
AU Chiyonobu, T
   Noda, R
   Yoshida, M
   Fujiki, A
   Ishii, R
   Nukina, S
   Fujita, K
   Goto, YI
   Morimoto, M
AF Chiyonobu, Tomohiro
   Noda, Rei
   Yoshida, Michiko
   Fujiki, Atsushi
   Ishii, Rumiko
   Nukina, Sadayuki
   Fujita, Kinya
   Goto, Yu-ichi
   Morimoto, Masafumi
TI Intestinal pseudo-obstruction in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) associated with phenytoin therapy
SO BRAIN & DEVELOPMENT
LA English
DT Article
DE MELAS; intestinal pseudo-obstruction; phenytoin
ID encephalomyopathy; features
AB Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) is most commonly associated with a mitochondrial DNA A to G point mutation at nucleotide 3243 (A3243G) and individuals with the disorder present a wide range of multisystemic symptoms. Seizures in MELAS patients are often intractable and require multiple antiepileptic drugs. Here we report a MELAS patient who presented with acute intestinal pseudo-obstruction following the administration of phenytoin (PHT) as an antiepileptic treatment. She presented with the first stroke-like episode at the age of 6 years and mitochondrial DNA analysis revealed A3243G with 94% mutation load in skeletal muscle. Despite treatment with phenobarbital and clobazam at the age of 16 years, she developed status epilepticus which ceased following PHT infusion. Thereafter, she was started on PHT treatment. One month later, however, she was readmitted because of remarkable abdominal distention. Although abdominal CT showed acute ileus with hepatic portal venous gas mimicking surgical emergency, the abdominal distention gradually recovered over several days following the discontinuation of PHT. Our clinical observations suggest the possibility that intestinal pseudo-obstruction in this patient related to PHT therapy. Careful clinical observation including gastrointestinal symptoms is required in the management of epilepsy in MELAS patients. (C) 2007 Elsevier B.V. All rights reserved.
C1 [Chiyonobu, Tomohiro; Noda, Rei; Yoshida, Michiko; Fujiki, Atsushi; Ishii, Rumiko; Nukina, Sadayuki] Akashi Municipal Hosp, Dept Pediat, Akashi, Hyogo 6738501, Japan.
   [Fujita, Kinya] Akashi Municipal Hosp, Dept Gastroenterol, Akashi, Hyogo, Japan.
   [Goto, Yu-ichi] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Kodaira, Tokyo 1870031, Japan.
   [Morimoto, Masafumi] Kyoto Prefectural Univ Med, Dept Pediat, Kyoto 602, Japan.
C3 National Center for Neurology & Psychiatry - Japan; Kyoto Prefectural University of Medicine
RP Chiyonobu, T (corresponding author), Akashi Municipal Hosp, Dept Pediat, 1-33 Takasho Machi, Akashi, Hyogo 6738501, Japan.
EM chiyonobu@kobe.zaq.jp
CR Chang TM, 2004, PEDIATR NEUROL, V31, P374, DOI 10.1016/j.pediatrneurol.2004.05.009
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   ISOJARVI JIT, 1992, EPILEPSIA, V33, P142, DOI 10.1111/j.1528-1157.1992.tb02297.x
   Krähenbühl S, 2000, LIVER, V20, P346, DOI 10.1034/j.1600-0676.2000.020004346.x
   Lyford GL, 2003, CURR OPIN PHARMACOL, V3, P583, DOI 10.1016/j.coph.2003.06.010
   Mori O, 2000, ACTA NEUROPATHOL, V100, P712, DOI 10.1007/s004010000209
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   SHAFER RB, 1984, GASTROENTEROLOGY, V86, P852
   Shimotake T, 1998, J PEDIATR SURG, V33, P1837, DOI 10.1016/S0022-3468(98)90301-3
NR 10
TC 25
Z9 26
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0387-7604
EI 1872-7131
J9 BRAIN DEV-JPN
JI Brain Dev.
PD JUN 15
PY 2008
VL 30
IS 6
BP 430
EP 433
DI 10.1016/j.braindev.2007.12.006
PG 4
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 303UH
UT WOS:000256065900010
PM 18226864
DA 2024-11-01
ER

PT J
AU Downham, E
   Winterthun, S
   Nakkestad, HL
   Hirth, A
   Halvorsen, T
   Taylor, RW
   Bindoff, LA
AF Downham, Esther
   Winterthun, Synnove
   Nakkestad, Hanne Linda
   Hirth, Asle
   Halvorsen, Thomas
   Taylor, Robert W.
   Bindoff, Laurence A.
TI A novel mitochondrial ND5 (<i>MTND5</i>) gene mutation giving. isolated exercise intolerance
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE miochondrial DNA; exercise intolerance; muscle disease; MTND5
ID respiratory-chain; dna; subunit; dehydrogenase; myopathy; disease
AB We describe a patient with isolated exercise intolerance caused by a new, maternally inherited mutation in mitochondrial DNA. The heteroplasmic T>C transition at position 13271 in MTND5 affects a highly conserved base and segregates with the disease, being present at highest levels in skeletal muscle fibres showing abnormal mitochondrial accumulation. This is the 15th mutation affecting the MTND5 subunit of respiratory chain complex I and confirms this protein as an important site for disease with phenotypes ranging from MELAS and infantile encephalopathies to isolated syndromes affecting a single tissue such as Leber hereditary optic neuropathy and now skeletal muscle. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Downham, Esther; Winterthun, Synnove; Nakkestad, Hanne Linda; Hirth, Asle; Bindoff, Laurence A.] Univ Bergen, Heukeland Univ Hosp, Dept Clin Med, N-5021 Bergen, Norway.
   [Hirth, Asle] Haukeland Hosp, Dept Heart Dis, Bergen, Norway.
   [Halvorsen, Thomas] Haukeland Hosp, Dept Paediat, Bergen, Norway.
   [Taylor, Robert W.] Univ Newcastle, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne, Tyne & Wear, England.
   [Taylor, Robert W.] Univ Newcastle, Inst Human Genet, Newcastle Upon Tyne, Tyne & Wear, England.
   [Bindoff, Laurence A.] Haukeland Hosp, Dept Neurol, Bergen, Norway.
C3 University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; Newcastle University - UK; Newcastle University - UK; University of Bergen; Haukeland University Hospital
RP Bindoff, LA (corresponding author), Univ Bergen, Heukeland Univ Hosp, Dept Clin Med, N-5021 Bergen, Norway.
EM laurence.bindoff@nevro.uib.no
FU Wellcome Trust Funding Source: Medline; Department of Health Funding Source: Medline
CR Andreu AL, 1999, ANN NEUROL, V45, P820, DOI 10.1002/1531-8249(199906)45:6<820::AID-ANA22>3.0.CO;2-W
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Bai YD, 2000, MOL CELL BIOL, V20, P805, DOI 10.1128/MCB.20.3.805-815.2000
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   DiMauro S, 1999, ITAL J NEUROL SCI, V20, P387
   Ingman M, 2006, NUCLEIC ACIDS RES, V34, PD749, DOI 10.1093/nar/gkj010
   Kirby DM, 2007, METHOD CELL BIOL, V80, P93, DOI 10.1016/S0091-679X(06)80004-X
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   McFarland R, 2004, NEUROMUSCULAR DISORD, V14, P162, DOI 10.1016/j.nmd.2003.10.011
   *MITOMAP, 2007, HUM MIT GEN DAT PROG, V0, P0
   Nakamaru-Ogiso E, 2003, BIOCHEMISTRY-US, V42, P746, DOI 10.1021/bi0269660
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   Pulkes T, 2005, NEUROLOGY, V64, P1091, DOI 10.1212/01.WNL.0000154471.33156.55
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, PD823, DOI 10.1093/nar/gkl927
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   Taivassalo T, 2004, BBA-BIOENERGETICS, V1659, P221, DOI 10.1016/j.bbabio.2004.09.007
   Vissing J, 2001, ANN NEUROL, V49, P672, DOI 10.1002/ana.1026
NR 19
TC 18
Z9 21
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD APR 15
PY 2008
VL 18
IS 4
BP 310
EP 314
DI 10.1016/j.nmd.2008.01.003
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 304PS
UT WOS:000256122000006
PM 18396045
DA 2024-11-01
ER

PT J
AU La Morgia, C
   Achilli, A
   Iommarini, L
   Barboni, P
   Pala, M
   Olivieri, A
   Zanna, C
   Vidoni, S
   Tonon, C
   Lodi, R
   Vetrugno, R
   Mostacci, B
   Liguori, R
   Carroccia, R
   Montagna, P
   Rugolo, M
   Torroni, A
   Carelli, V
AF La Morgia, C.
   Achilli, A.
   Iommarini, L.
   Barboni, P.
   Pala, M.
   Olivieri, A.
   Zanna, C.
   Vidoni, S.
   Tonon, C.
   Lodi, R.
   Vetrugno, R.
   Mostacci, B.
   Liguori, R.
   Carroccia, R.
   Montagna, P.
   Rugolo, M.
   Torroni, A.
   Carelli, V.
TI Rare mtDNA variants in Leber hereditary optic neuropathy families with recurrence of myoclonus
SO NEUROLOGY
LA English
DT Article
ID mitochondrial-dna mutation; complex-i deficiency; missense mutation; gene; dystonia; disease; muscle; melas; manifestation; involvement
AB Objective: To investigate the mechanisms underlying myoclonus in Leber hereditary optic neuropathy (LHON). Methods: Five patients and one unaffected carrier from two Italian families bearing the homoplasmic 11778/ND4 and 3460/ND1 mutations underwent a uniform investigation including neurophysiologic studies, muscle biopsy, serum lactic acid after exercise, and muscle (P-31) and cerebral (H-1) magnetic resonance spectroscopy (MRS). Biochemical investigations on fibroblasts and complete mitochondrial DNA (mtDNA) sequences of both families were also performed. Results: All six individuals had myoclonus. In spite of a normal EEG background and the absence of giant SEPs and C reflex, EEG-EMG back-averaging showed a preceding jerk-locked EEG potential, consistent with a cortical generator of the myoclonus. Specific comorbidities in the 11778/ND4 family included muscular cramps and psychiatric disorders, whereas features common to both families were migraine and cardiologic abnormalities. Signs of mitochondrial proliferation were seen in muscle biopsies and lactic acid elevation was observed in four of six patients. P-31-MRS was abnormal in five of six patients and H-1-MRS showed ventricular accumulation of lactic acid in three of six patients. Fibroblast ATP depletion was evident at 48 hours incubation with galactose in LHON/myoclonus patients. Sequence analysis revealed haplogroup T2 (11778/ND4 family) and U4a (3460/ND1 family) mtDNAs. A functional role for the non-synonymous 4136A>G/ND1, 9139G>A/ATPase6, and 15773G>A/cyt b variants was supported by amino acid conservation analysis. Conclusions: Myoclonus and other comorbidities characterized our Leber hereditary optic neuropathy (LHON) families. Functional investigations disclosed a bioenergetic impairment in all individuals. Our sequence analysis suggests that the LHON plus phenotype in our cases may relate to the synergic role of mtDNA variants.
C1 [La Morgia, C.; Iommarini, L.; Vetrugno, R.; Mostacci, B.; Liguori, R.; Montagna, P.; Carelli, V.] Univ Bologna, Dipartimento Sci Neurol, I-40123 Bologna, Italy.
   [Zanna, C.; Vidoni, S.; Rugolo, M.] Univ Bologna, Dipartimento Biol Evoluz Sperimentale, I-40123 Bologna, Italy.
   [Tonon, C.; Lodi, R.] Univ Bologna, Dipartimento Med Clin & Biotecnol Appl, I-40123 Bologna, Italy.
   [Zanna, C.; Vidoni, S.; Rugolo, M.] Univ Pavia, Dipartimento Genet & Microbiol, Bologna, Italy.
   [Achilli, A.; Pala, M.; Olivieri, A.; Torroni, A.] Ctr Oftalmol Salus, Bologna, Italy.
C3 University of Bologna; University of Bologna; University of Bologna; University of Pavia
RP La Morgia, C (corresponding author), Univ Bologna, Dipartimento Sci Neurol, Via Ugo Foscolo 7, I-40123 Bologna, Italy.
EM valerio.carelli@unibo.it
FU Telethon [GGP06233] Funding Source: Medline
CR Achilli A, 2004, AM J HUM GENET, V75, P910, DOI 10.1086/425590
   Achilli A, 2005, AM J HUM GENET, V76, P883, DOI 10.1086/430073
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Brown P, 2000, PROG NEUROBIOL, V60, P97, DOI 10.1016/S0301-0082(99)00029-5
   Brown P, 1999, BRAIN, V122, P461, DOI 10.1093/brain/122.3.461
   Carelli V, 2006, AM J HUM GENET, V78, P564, DOI 10.1086/501236
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Carelli V, 2001, J NEUROL NEUROSUR PS, V71, P813, DOI 10.1136/jnnp.71.6.813
   Crimi M, 2003, NEUROLOGY, V60, P1857, DOI 10.1212/01.WNL.0000066048.72780.69
   Cupini LM, 2003, NEUROLOGY, V60, P717, DOI 10.1212/01.WNL.0000048662.77572.FB
   DeVries DD, 1996, AM J HUM GENET, V58, P703
   DIEHL GE, 1990, LARYNGO RHINO OTOL, V69, P369, DOI 10.1055/s-2007-998210
   DiMauro S, 1998, BBA-BIOENERGETICS, V1366, P199, DOI 10.1016/S0005-2728(98)00113-3
   Esteitie N, 2005, ANN NEUROL, V58, P544, DOI 10.1002/ana.20570
   FUNAKAWA I, 1995, J NEUROL, V242, P75, DOI 10.1007/BF00887819
   Funalot B, 2002, ANN NEUROL, V52, P374, DOI 10.1002/ana.10299
   GHELLI A, 1994, THESIS U BOLOGNA, V0, P0
   Giordano C, 2006, GASTROENTEROLOGY, V130, P893, DOI 10.1053/j.gastro.2006.01.004
   Gropman A, 2004, AM J MED GENET A, V124A, P377, DOI 10.1002/ajmg.a.20456
   HARDING AE, 1992, BRAIN, V115, P979, DOI 10.1093/brain/115.4.979
   Howell N, 2002, J NEURO-OPHTHALMOL, V22, P262, DOI 10.1097/00041327-200212000-00002
   HOWELL N, 1991, AM J HUM GENET, V48, P935
   JUN AS, 1994, P NATL ACAD SCI USA, V91, P6206, DOI 10.1073/pnas.91.13.6206
   Kaufmann P, 2004, NEUROLOGY, V62, P1297, DOI 10.1212/01.WNL.0000120557.83907.A8
   Kirby DM, 2000, ANN NEUROL, V48, P102, DOI 10.1002/1531-8249(200007)48:1<102::AID-ANA15>3.3.CO;2-D
   Kirby DM, 2004, J MED GENET, V41, P784, DOI 10.1136/jmg.2004.020537
   Kivisild T, 2006, GENETICS, V172, P373, DOI 10.1534/genetics.105.043901
   LARSSON NG, 1991, ANN NEUROL, V30, P701, DOI 10.1002/ana.410300511
   Lodi R, 2002, J NEUROL NEUROSUR PS, V72, P805, DOI 10.1136/jnnp.72.6.805
   NEWMAN NJ, 2005, HOYTS CLIN NEURO OPH, V0, P466
   NIKOSKELAINEN E, 1985, LANCET, V1, P696
   NIKOSKELAINEN EK, 1995, J NEUROL NEUROSUR PS, V59, P160, DOI 10.1136/jnnp.59.2.160
   NOVOTNY EJ, 1986, NEUROLOGY, V36, P1053, DOI 10.1212/WNL.36.8.1053
   PAULUS W, 1993, J NEUROL, V240, P251, DOI 10.1007/BF00818714
   Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493
   Shibasaki H, 2000, MUSCLE NERVE, V23, P321, DOI 10.1002/(SICI)1097-4598(200003)23:3<321::AID-MUS3>3.3.CO;2-V
   Simon DK, 1999, NEUROLOGY, V53, P1787, DOI 10.1212/WNL.53.8.1787
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Torroni A, 1997, AM J HUM GENET, V60, P1107
   Torroni A, 2001, AM J HUM GENET, V69, P1348, DOI 10.1086/324511
   Ugalde C, 2003, ANN NEUROL, V54, P665, DOI 10.1002/ana.10734
   WALLACE DC, 1970, BRAIN, V93, P121, DOI 10.1093/brain/93.1.121
   Zanna C, 2005, APOPTOSIS, V10, P997, DOI 10.1007/s10495-005-0742-5
NR 44
TC 56
Z9 60
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD MAR 4
PY 2008
VL 70
IS 10
BP 762
EP 770
DI 
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA 271GE
UT WOS:000253776100005
PM 18216301
DA 2024-11-01
ER

PT J
AU Crispim, D
   Estivalet, AAF
   Roisenberg, I
   Gross, JL
   Canani, LH
AF Crispim, Daisy
   Estivalet, Aline A. F.
   Roisenberg, Israel
   Gross, Jorge L.
   Canani, Luis H.
TI Prevalence of 15 Mitochondrial DNA Mutations Among Type 2 Diabetic Patients with or without Clinical Characteristics of Maternally Inherited Diabetes and Deafness
SO ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA
LA English
DT Article
DE Type 2 diabetes; Mitochondrial DNA mutations; Mitochondrial diabetes; MIDD; A3243G tRNA(Leu(UUR)) mutation
ID mtdna mutations; gene; mellitus; japanese; association; expression; myopathy; sequence; defects
AB The aim of the present study is to investigate the prevalence of ten described mitochondrial DNA (mtDNA) mutations in patients with type 2 diabetes, and search for new mutations in four mtDNA genes in a subgroup of patients with characteristics of maternally inherited diabetes and deafness (MIDD). These mutations were investigated in 407 type 2 diabetic patients without characteristics of mitochondrial diabetes ("classical" type 2 diabetes group) and in 38 type 2 diabetic patients with characteristics suggestive of MIDD. Through sequencing of four mtDNA genes in MIDD patients, we selected five others potentially pathogenic mutations that were also screened in the remaining patients. Overall, the frequency of the fifteen analyzed mutations was 36.84% in the MIDD group and 2.45% in the "classical" type 2 diabetes group (p < 0.001). In conclusion, our study reinforces the importance of mtDNA mutations in the pathogenesis of MIDD. (Arq Bras Endocrinol Metab 2008; 52/8:1228-1235)
C1 [Crispim, Daisy] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Div Endocrinol, Serv Endocrinol, BR-90035003 Porto Alegre, RS, Brazil.
   [Roisenberg, Israel] Univ Fed Rio Grande do Sul, Dept Genet, BR-90035003 Porto Alegre, RS, Brazil.
C3 Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul
RP Crispim, D (corresponding author), Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Div Endocrinol, Serv Endocrinol, Rua Ramiro Barcelos 2350,Predio 12,4 Andar, BR-90035003 Porto Alegre, RS, Brazil.
EM daisy_crispim@hotmail.com
CR Alcolado JC, 2002, DIABETIC MED, V19, P89, DOI 10.1046/j.1464-5491.2002.00675.x
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Brown MD, 2001, HUM GENET, V109, P33, DOI 10.1007/s004390100538
   Carelli V, 2003, TRENDS GENET, V19, P257, DOI 10.1016/S0168-9525(03)00072-6
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   Choo-Kang ATW, 2002, DIABETES, V51, P2317, DOI 10.2337/diabetes.51.7.2317
   Crispim D, 2002, CLIN ENDOCRINOL, V57, P141, DOI 10.1046/j.1365-2265.2002.01569_1.x
   Crispim Daisy, 2006, ARQ BRAS ENDOCRINOL METAB, V50, P862, DOI 10.1590/S0004-27302006000500006
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Fukuda M, 1999, J DIABETES COMPLICAT, V13, P277, DOI 10.1016/S1056-8727(99)00060-4
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HANNA MG, 1995, AM J HUM GENET, V56, P1026
   HAO HL, 1995, AM J HUM GENET, V56, P1017
   Hirai M, 1996, BIOCHEM BIOPH RES CO, V219, P951, DOI 10.1006/bbrc.1996.0324
   IKEBE S, 1995, MOL BRAIN RES, V28, P281, DOI 10.1016/0169-328X(94)00209-W
   Ingman M, 2006, NUCLEIC ACIDS RES, V34, PD749, DOI 10.1093/nar/gkj010
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   LAM CW, 2001, J MED GENET, V0, P38
   Lamson Davis W, 2002, ALTERN MED REV, V7, P94
   Lehtonen MS, 2003, HUM GENET, V113, P220, DOI 10.1007/s00439-003-0966-9
   Liu SM, 2007, DIABETES RES CLIN PR, V76, P425, DOI 10.1016/j.diabres.2006.09.032
   Maassen JA, 2006, ENDOCRIN METAB CLIN, V35, P385, DOI 10.1016/j.ecl.2006.02.014
   Maassen JA, 2004, DIABETES, V53, PS103, DOI 10.2337/diabetes.53.2007.S103
   *MITOMAP, 2008, MITOMAP HUM MIT GEN, V0, P0
   Murphy R, 2008, DIABETIC MED, V25, P383, DOI 10.1111/j.1464-5491.2008.02359.x
   NAKAGAWA Y, 1995, BIOCHEM BIOPH RES CO, V209, P664, DOI 10.1006/bbrc.1995.1550
   Ohkubo K, 2001, CLIN CHEM, V47, P1641
   Perucca-Lostanlen D, 2000, BIOCHEM BIOPH RES CO, V277, P771, DOI 10.1006/bbrc.2000.3751
   Povalko N, 2005, MITOCHONDRION, V5, P194, DOI 10.1016/j.mito.2005.03.003
   Suzuki S, 2003, DIABETES RES CLIN PR, V59, P207, DOI 10.1016/S0168-8227(02)00246-2
   Tang DL, 2006, DIABETES RES CLIN PR, V73, P77, DOI 10.1016/j.diabres.2005.12.001
   Tawata M, 1998, DIABETES, V47, P276, DOI 10.2337/diab.47.2.276
   Tawata M, 2000, DIABETES, V49, P1269, DOI 10.2337/diabetes.49.7.1269
   Terasaki F, 2001, JPN CIRC J, V65, P691, DOI 10.1253/jcj.65.691
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Vialettes BH, 1997, DIABETES CARE, V20, P1731, DOI 10.2337/diacare.20.11.1731
   *WHO STUD GROUP, 1985, TECHN REP SER, V727, P0
   Yu P, 2004, CHINESE MED J-PEKING, V117, P985
NR 38
TC 18
Z9 18
U1 0
U2 5
PU SBEM-SOC BRASIL ENDOCRINOLOGIA & METABOLOGIA
PI RIO DE JANEIRO, RJ
PA RUA HUMAITA, 85 CJ 501, RIO DE JANEIRO, RJ, 22261-000, BRAZIL
SN 0004-2730
EI 1677-9487
J9 ARQ BRAS ENDOCRINOL
JI Arq. Bras. Endocrinol. Metabol.
PD NOV 15
PY 2008
VL 52
IS 8
BP 1228
EP 1235
DI 10.1590/S0004-27302008000800005
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 392PB
UT WOS:000262313500005
PM 19169474
DA 2024-11-01
ER

PT J
AU Brown, KH
AF Brown, K. H.
TI Fish mitochondrial genomics: sequence, inheritance and functional variation
SO JOURNAL OF FISH BIOLOGY
LA English
DT Review
DE coadaptation; coevolution; functional variation; maternal inheritance; metabolism; mtDNA
ID trout oncorhynchus-mykiss; cytochrome-c-oxidase; complete nucleotide-sequence; japanese black cattle; dna control region; rainbow-trout; drosophila-subobscura; experimental populations; tigriopus-californicus; muscle mitochondria
AB Mitochondrial genomic research currently primarily focuses on the analysis and understanding of how mitochondrial mutations produce detrimental phenotypes in humans. Reasons for this focus on negative impacts include the large number of human diseases that are known to result from specific mitochondrial genomes, and the long held belief that mitochondria change only through the accumulation of mutations due to its clonal, maternal inheritance. Recent studies are beginning to challenge these preconceptions and have shown that mitochondrial genomes can have significant positive impacts. Although the number of studies using fishes as models in mitochondrial research is limited, many fish model species provide excellent opportunity for furthering the understanding of mitochondrial genomes, their interactions with the nuclear genome, the potential for understanding the mechanisms of how functional variation effects organisms and how selection for positive functional variation effects population variation. (C) 2008 The Author Journal compilation (C) 2008 The Fisheries Society of the British Isles.
C1 Univ Idaho, Dept Biol Sci, Moscow, ID 83843 USA.
   Univ Idaho, Ctr Reprod Biol, Moscow, ID 83843 USA.
C3 University of Idaho; University of Idaho
RP Brown, KH (corresponding author), Univ Idaho, Dept Biol Sci, POB 443051, Moscow, ID 83843 USA.
EM khbrown@uidaho.edu
CR Abbott CL, 2005, MOL ECOL, V14, P3605, DOI 10.1111/j.1365-294X.2005.02672.x
   Amer SAM, 2005, GENE, V346, P249, DOI 10.1016/j.gene.2004.11.014
   Andersson SGE, 2003, PHILOS T R SOC B, V358, P165, DOI 10.1098/rstb.2002.1193
   Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094
   ATTARDI G, 1985, INT REV CYTOL, V93, P93, DOI 10.1016/S0074-7696(08)61373-X
   AVISE JC, 1991, ANNU REV GENET, V25, P45, DOI 10.1146/annurev.ge.25.120191.000401
   AVISE JC, 1987, ANNU REV ECOL SYST, V18, P489, DOI 10.1146/annurev.es.18.110187.002421
   BALLARD JWO, 1994, GENETICS, V138, P757
   BARRELL BG, 1979, NATURE, V282, P189, DOI 10.1038/282189a0
   Bayona-Bafaluy MP, 2005, MOL BIOL EVOL, V22, P716, DOI 10.1093/molbev/msi059
   BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303
   Birkedal R, 2004, J COMP PHYSIOL B, V174, P255, DOI 10.1007/s00360-003-0410-4
   Birkedal R, 2006, BBA-BIOENERGETICS, V1757, P764, DOI 10.1016/j.bbabio.2006.04.022
   Birky CW, 2001, ANNU REV GENET, V35, P125, DOI 10.1146/annurev.genet.35.102401.090231
   Blier PU, 2001, J COMP PHYSIOL B, V171, P247, DOI 10.1007/s003600000169
   Boettcher PJ, 1996, J DAIRY SCI, V79, P655, DOI 10.3168/jds.S0022-0302(96)76411-1
   Bogenhagen DF, 1999, AM J HUM GENET, V64, P1276, DOI 10.1086/302392
   Bouchard P, 2003, J EXP BIOL, V206, P3455, DOI 10.1242/jeb.00578
   Bowen BW, 2006, MAR BIOL, V149, P899, DOI 10.1007/s00227-006-0252-1
   Brown KH, 2006, COMP BIOCHEM PHYS B, V143, P415, DOI 10.1016/j.cbpb.2005.12.015
   Brown KH, 2006, COMP BIOCHEM PHYS D, V1, P219, DOI 10.1016/j.cbd.2005.11.004
   Burton RS, 1999, AM ZOOL, V39, P451
   Burzynski A, 2003, MOL BIOL EVOL, V20, P388, DOI 10.1093/molbev/msg058
   Chan DC, 2006, ANNU REV CELL DEV BI, V22, P79, DOI 10.1146/annurev.cellbio.22.010305.104638
   CHOMYN A, 1985, NATURE, V314, P592, DOI 10.1038/314592a0
   Christie JS, 2004, HEREDITY, V93, P371, DOI 10.1038/sj.hdy.6800513
   Dalziel AC, 2006, J MOL EVOL, V62, P319, DOI 10.1007/s00239-005-0110-7
   Das J, 2006, BIOESSAYS, V28, P890, DOI 10.1002/bies.20463
   delaBastide PY, 1997, APPL ENVIRON MICROB, V63, P3426, DOI 10.1128/AEM.63.9.3426-3431.1997
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Dyall SD, 2004, SCIENCE, V304, P253, DOI 10.1126/science.1094884
   Edmands S, 1999, EVOLUTION, V53, P1972, DOI 10.1111/j.1558-5646.1999.tb04578.x
   Edwards SV, 2005, P ROY SOC B-BIOL SCI, V272, P979, DOI 10.1098/rspb.2004.3035
   Ellison CK, 2006, EVOLUTION, V60, P1382, DOI 10.1554/06-210.1
   FELSENSTEIN J, 1974, GENETICS, V78, P737
   FOS M, 1990, P NATL ACAD SCI USA, V87, P4198, DOI 10.1073/pnas.87.11.4198
   Futuyma DJ, 1998, EVOL BIOL, V0, P0
   Gabaldón T, 2003, SCIENCE, V301, P609, DOI 10.1126/science.1085463
   García-Martínez J, 1998, GENETICS, V149, P1377
   Gemmell NJ, 2004, TRENDS ECOL EVOL, V19, P238, DOI 10.1016/j.tree.2004.02.002
   Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476
   Guderley H, 1996, J EXP BIOL, V199, P1311
   Guderley H, 2002, J EXP BIOL, V205, P2237
   Guderley H, 2004, COMP BIOCHEM PHYS B, V139, P371, DOI 10.1016/j.cbpc.2004.04.001
   Guderley H, 1999, J COMP PHYSIOL B, V169, P474, DOI 10.1007/s003600050244
   Guderley H, 1997, FISH PHYSIOL BIOCHEM, V16, P531, DOI 10.1023/A:1007708826437
   Guo XH, 2006, GENETICS, V172, P1745, DOI 10.1534/genetics.105.049841
   GYLLENSTEN U, 1991, NATURE, V352, P255, DOI 10.1038/352255a0
   HARMAN D, 1992, MUTAT RES, V275, P257, DOI 10.1016/0921-8734(92)90030-S
   Harrison JS, 2006, MOL BIOL EVOL, V23, P559, DOI 10.1093/molbev/msj058
   HECHT NB, 1984, DEV BIOL, V102, P452, DOI 10.1016/0012-1606(84)90210-0
   Hoarau G, 2002, MOL BIOL EVOL, V19, P2261, DOI 10.1093/oxfordjournals.molbev.a004049
   Hurst CD, 1999, GENE, V239, P237, DOI 10.1016/S0378-1119(99)00425-4
   HUTTER CM, 1995, GENETICS, V140, P537
   Ikeguchi K, 2006, MAR BIOTECHNOL, V8, P178, DOI 10.1007/s10126-005-5110-5
   Itoi S, 2001, FISHERIES SCI, V67, P191, DOI 10.1046/j.1444-2906.2001.00222.x
   Jacobs HT, 2000, BIOESSAYS, V22, P564, DOI 10.1002/(SICI)1521-1878(200006)22:6<564::AID-BIES9>3.0.CO;2-4
   Jansen RPS, 1998, MOL CELL ENDOCRINOL, V145, P81, DOI 10.1016/S0303-7207(98)00173-7
   Johnston IA, 1998, J EXP BIOL, V201, P1
   Kim BC, 2006, DNA SEQUENCE, V17, P181, DOI 10.1080/10425170600806928
   KIMURA M, 1968, NATURE, V217, P624, DOI 10.1038/217624a0
   KONDO R, 1990, GENETICS, V126, P657
   Kraytsberg Y, 2004, SCIENCE, V304, P981, DOI 10.1126/science.1096342
   Kurland CG, 2000, MICROBIOL MOL BIOL R, V64, P786, DOI 10.1128/MMBR.64.4.786-820.2000
   Kvist L, 2003, MOL BIOL EVOL, V20, P243, DOI 10.1093/molbev/msg025
   Ladoukakis ED, 2001, MOL BIOL EVOL, V18, P1168, DOI 10.1093/oxfordjournals.molbev.a003904
   Lannig G, 2003, MAR BIOL, V142, P589, DOI 10.1007/s00227-002-0967-6
   LATORRE A, 1992, HEREDITY, V68, P15, DOI 10.1038/hdy.1992.2
   Li S, 1998, J HERED, V89, P222, DOI 10.1093/jhered/89.3.222
   Lunt DH, 1997, NATURE, V387, P247, DOI 10.1038/387247a0
   Lynch M, 1997, MOL BIOL EVOL, V14, P914, DOI 10.1093/oxfordjournals.molbev.a025834
   Lynch M, 1996, MOL BIOL EVOL, V13, P209, DOI 10.1093/oxfordjournals.molbev.a025557
   MAGOULAS A, 1993, MOL BIOL EVOL, V10, P319
   Mannen H, 2003, J ANIM SCI, V81, P68
   Mannen H, 1998, J ANIM SCI, V76, P36
   Martin W, 2001, BIOL CHEM, V382, P1521, DOI 10.1515/BC.2001.187
   McFarland R, 2007, CURR TOP DEV BIOL, V77, P113, DOI 10.1016/S0070-2153(06)77005-3
   Miya M, 2005, BIOL J LINN SOC, V85, P289, DOI 10.1111/j.1095-8312.2005.00483.x
   MORITZ C, 1987, ANNU REV ECOL SYST, V18, P269, DOI 10.1146/annurev.ecolsys.18.1.269
   MOYA A, 1993, GENOME, V36, P890, DOI 10.1139/g93-117
   MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8
   Nachman MW, 1998, GENETICA, V102-3, P61, DOI 10.1023/A:1017030708374
   Nishida M, 2005, ZOOL SCI, V22, P1394
   Nishimura Y, 2006, P NATL ACAD SCI USA, V103, P1382, DOI 10.1073/pnas.0506911103
   Oliver P, 2005, GENOME, V48, P1010, DOI 10.1139/G05-077
   Pakkasmaa S, 2006, J COMP PHYSIOL B, V176, P387, DOI 10.1007/s00360-005-0057-4
   Parsons TJ, 1997, NAT GENET, V15, P363, DOI 10.1038/ng0497-363
   Patterson DA, 2004, CAN J FISH AQUAT SCI, V61, P1225, DOI 10.1139/F04-076
   Pelster B, 2003, AM J PHYSIOL-REG I, V285, PR339, DOI 10.1152/ajpregu.00110.2003
   Rand DM, 2004, TRENDS ECOL EVOL, V19, P645, DOI 10.1016/j.tree.2004.10.003
   Rand DM, 2006, GENETICS, V172, P329, DOI 10.1534/genetics.105.046698
   Rand DM, 1998, GENETICA, V102-3, P393, DOI 10.1023/A:1017006118852
   RAND DM, 1994, TRENDS ECOL EVOL, V9, P125, DOI 10.1016/0169-5347(94)90176-7
   Rawson PD, 2006, J MOL EVOL, V62, P753, DOI 10.1007/s00239-005-0074-7
   RENNIE CM, 1979, CLIN CHIM ACTA, V98, P119, DOI 10.1016/0009-8981(79)90172-4
   Roger AJ, 1999, AM NAT, V154, PS146, DOI 10.1086/303290
   Saitoh K, 2006, J MOL EVOL, V63, P826, DOI 10.1007/s00239-005-0293-y
   SCHUTZ MM, 1994, LIVEST PROD SCI, V37, P283, DOI 10.1016/0301-6226(94)90123-6
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Shigenobu Y, 2005, GENES GENET SYST, V80, P297, DOI 10.1266/ggs.80.297
   SKIBINSKI DOF, 1994, NATURE, V368, P817, DOI 10.1038/368817b0
   Slate J, 2004, TRENDS ECOL EVOL, V19, P561, DOI 10.1016/j.tree.2004.09.001
   Stärner H, 2004, BEHAVIOUR, V141, P1357, DOI 10.1163/1568539042948114
   STPIERRE J, 1998, J EXPT ZOOLOGY, V258, P277
   Sutovsky P, 1999, NATURE, V402, P371, DOI 10.1038/46466
   Tatarenkov A, 2007, P R SOC B, V274, P1795, DOI 10.1098/rspb.2007.0169
   Thyagarajan B, 1996, J BIOL CHEM, V271, P27536, DOI 10.1074/jbc.271.44.27536
   Tiano L, 2003, MITOCHONDRION, V2, P428, DOI 10.1016/S1567-7249(03)00032-1
   Timmis JN, 2004, NAT REV GENET, V5, P123, DOI 10.1038/nrg1271
   VANDENTHILLART G, 1978, BIOCHIM BIOPHYS ACTA, V510, P38, DOI 10.1016/0005-2736(78)90128-1
   Wilhelm D, 2007, FRONT BIOSCI-LANDMRK, V12, P1229
   Willett CS, 2001, EVOLUTION, V55, P1592
   Yamanoue Y, 2004, ICHTHYOL RES, V51, P269, DOI 10.1007/s10228-004-0218-6
   Yue GH, 2006, DNA SEQUENCE, V17, P115, DOI 10.1080/10425170600700378
   Zardoya R, 1995, J MOL EVOL, V41, P942, DOI 10.1007/BF00173174
   Zeh JA, 2005, TRENDS GENET, V21, P281, DOI 10.1016/j.tig.2005.03.006
   Zeviani M, 2003, CURR OPIN GENET DEV, V13, P262, DOI 10.1016/S0959-437X(03)00052-2
   Zeyl C, 2005, EVOLUTION, V59, P910
NR 118
TC 46
Z9 49
U1 2
U2 27
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-1112
EI 1095-8649
J9 J FISH BIOL
JI J. Fish Biol.
PD FEB 15
PY 2008
VL 72
IS 2
BP 355
EP 374
DI 10.1111/j.1095-8649.2007.01690.x
PG 20
WC Fisheries; Marine & Freshwater Biology
SC Fisheries; Marine & Freshwater Biology
GA 272IF
UT WOS:000253852400002
DA 2024-11-01
ER

PT J
AU Ashley, N
   O'Rourke, A
   Smith, C
   Adams, S
   Gowda, V
   Zeviani, M
   Brown, GK
   Fratter, C
   Poulton, J
AF Ashley, Neil
   O'Rourke, Anthony
   Smith, Conrad
   Adams, Susan
   Gowda, Vasantha
   Zeviani, Massimo
   Brown, Garry K.
   Fratter, Carl
   Poulton, Joanna
TI Depletion of mitochondrial DNA in fibroblast cultures from patients with POLG1 mutations is a consequence of catalytic mutations
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID progressive external ophthalmoplegia; polymerase-gamma; mtdna depletion; saccharomyces-cerevisiae; alpers-syndrome; w748s mutation; tk2 deficiency; human-cells; disease; expression
AB We investigated clinical and cellular phenotypes of 24 children with mutations in the catalytic (alpha) subunit of the mitochondrial DNA (mtDNA) gamma polymerase (POLG1). Twenty-one had Alpers syndrome, the commonest severe POLG1 autosomal recessive phenotype, comprising hepatoencephalopathy and often mtDNA depletion. The cellular mtDNA content reflected the genotype more closely than did clinical features. Patients with tissue depletion of mtDNA all had at least one allele with either a missense mutation in a catalytic domain or a nonsense mutation. Four out of 12 patients exhibited a progressive, mosaic pattern of mtDNA depletion in cultured fibroblasts. All these patients had mutations in a catalytic domain in both POLG1 alleles, in either the polymerase or exonuclease domain or both. The tissue mtDNA content of patients who had two linker mutations was normal, and their phenotypes the mildest. Epilepsy and/or movement disorder were major features in all 21. Previous studies have implicated replication stalling as a mechanism for mtDNA depletion. The mosaic cellular depletion that we have demonstrated in cell cultures may be a manifestation of severe replication stalling. One patient with a severe cellular and clinical phenotype was a compound heterozygote with POLG1 mutations in the polymerase and exonuclease domain in trans. This suggests that POLG1 requires both polymerase and 3'-5' exonuclease activity in the same molecule. This is consistent with current functional models for eukaryotic DNA polymerases, which alternate between polymerizing and editing modes, as determined by competition between these two active sites for the 3' end of the DNA.
C1 [Ashley, Neil; Gowda, Vasantha; Poulton, Joanna] Univ Oxford, Nuffield Dept Obstet & Gynaecol, Womens Ctr, John Radcliffe Hosp, Oxford OX3 9DU, England.
   [O'Rourke, Anthony; Smith, Conrad; Adams, Susan; Fratter, Carl] Churchill Hosp, Oxford Med Genet Lab, Oxford OX3 7LJ, England.
   [Zeviani, Massimo] Natl Neurol Inst C Besta, Div Mol Neurogenet, I-20126 Milan, Italy.
   [Brown, Garry K.] Univ Oxford, Dept Biochem, Oxford OX3 9DU, England.
C3 University of Oxford; University of Oxford; Fondazione IRCCS Istituto Neurologico Carlo Besta; University of Oxford
RP Poulton, J (corresponding author), Univ Oxford, Nuffield Dept Obstet & Gynaecol, Womens Ctr, John Radcliffe Hosp, Oxford OX3 9DU, England.
EM joanna.poulton@obs-gyn.ox.ac.uk
FU MRC [G0500695] Funding Source: UKRI; Medical Research Council [G0500695] Funding Source: Medline; Wellcome Trust Funding Source: Medline
CR Alberio S, 2007, MITOCHONDRION, V7, P6, DOI 10.1016/j.mito.2006.11.010
   Ashley N, 2005, EXP CELL RES, V303, P432, DOI 10.1016/j.yexcr.2004.10.013
   Ashley N, 2007, HUM MOL GENET, V16, P1400, DOI 10.1093/hmg/ddm090
   Barthélémy C, 2002, HUM GENET, V110, P479, DOI 10.1007/s00439-002-0708-4
   Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   Baruffini E, 2006, HUM MOL GENET, V15, P2846, DOI 10.1093/hmg/ddl219
   Blake JC, 1999, AM J PATHOL, V155, P67, DOI 10.1016/S0002-9440(10)65100-0
   BODNAR AG, 1993, AM J HUM GENET, V53, P663
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Chan SSL, 2006, HUM MOL GENET, V15, P3473, DOI 10.1093/hmg/ddl424
   Chan SSL, 2005, DNA REPAIR, V4, P1381, DOI 10.1016/j.dnarep.2005.08.010
   CHINNERY PF, 2007, NEUROMUSCULAR DISORD, V18, P259
   Ducluzeau PH, 2002, J HEPATOL, V36, P698, DOI 10.1016/S0168-8278(02)00021-1
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Elson JL, 2002, NEUROMUSCULAR DISORD, V12, P858, DOI 10.1016/S0960-8966(02)00047-0
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   González-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107
   Graziewicz MA, 2007, HUM MOL GENET, V16, P2729, DOI 10.1093/hmg/ddm227
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   HARDING BN, 1995, J NEUROL NEUROSUR PS, V58, P320, DOI 10.1136/jnnp.58.3.320
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2006, HUM MOL GENET, V15, PR244, DOI 10.1093/hmg/ddl233
   LEWIN B, 2004, GENES, V8, P387
   Magnusson J, 2003, EXP CELL RES, V289, P133, DOI 10.1016/S0014-4827(03)00249-0
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Moraes Carlos T, 1993, P97, V0, P0
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   MORTEN KJ, 2007, MITOCHONDRION, V16, P1400
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Stuart GR, 2006, HUM MOL GENET, V15, P363, DOI 10.1093/hmg/ddi454
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Taanman JW, 1997, HUM MOL GENET, V6, P935, DOI 10.1093/hmg/6.6.935
   Taanman JW, 2003, HUM MOL GENET, V12, P1839, DOI 10.1093/hmg/ddg192
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Wanrooij S, 2007, NUCLEIC ACIDS RES, V35, P3238, DOI 10.1093/nar/gkm215
NR 45
TC 47
Z9 50
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 15
PY 2008
VL 17
IS 16
BP 2496
EP 2506
DI 10.1093/hmg/ddn150
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 330SL
UT WOS:000257963000009
PM 18487244
DA 2024-11-01
ER

PT J
AU Yerdelen, D
   Koc, F
   Koc, Z
AF Yerdelen, Deniz
   Koc, Filiz
   Koc, Zafer
TI Delayed diagnosis of kearns-sayre syndrome in a 38-year-old male patient: A case report
SO INTERNATIONAL JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE clinical; laboratory; and histopathologic findings; Kearns-Sayre syndrome
ID mitochondrial-dna; involvement; deletion; disease; block
AB Kearns-Sayre syndrome is a rare disorder caused by mitochondrial deoxyribonucleic acid deletion. It is characterized by a triad of progressive external ophthalmoplegia, initial symptoms that develop before the age of 20 years, and pigmentary retinopathy. Multisystem involvement is frequently associated with those features. Ragged red fibers can be identified during histopathologic examination and confirmed by electron microscopy. In this article, the case of a 38-year-old mail with Keams-Sayre syndrome in whom diagnosis was delayed despite abundant clinical evidence is presented. A brief review of clinical and laboratory findings in patients with that disorder is also provided.
C1 [Koc, Filiz] Cukurova Univ, Dept Neurol, Med Sch Adana, TR-01330 Adana, Turkey.
   [Yerdelen, Deniz] Baskent Univ, Sch Med, Dept Neurol, Adana, Turkey.
   [Koc, Zafer] Baskent Univ, Sch Med, Dept Radiol, Adana, Turkey.
C3 Cukurova University; Baskent University; Baskent University; Cukurova University
RP Koc, F (corresponding author), Cukurova Univ, Dept Neurol, Med Sch Adana, TR-01330 Adana, Turkey.
EM koc.filiz@gmail.com
CR ANAN R, 1995, CIRCULATION, V91, P955, DOI 10.1161/01.CIR.91.4.955
   Artuch R, 1998, HORM RES, V50, P99, DOI 10.1159/000023243
   Boles RG, 1998, EUR J PEDIATR, V157, P643, DOI 10.1007/s004310050902
   Chinnery PF, 2000, MOL MED TODAY, V6, P425, DOI 10.1016/S1357-4310(00)01805-0
   Chu BC, 1999, NEURORADIOLOGY, V41, P759, DOI 10.1007/s002340050838
   EVIATAR L, 1990, NEUROLOGY, V40, P1761, DOI 10.1212/WNL.40.11.1761
   Gross-Jendroska M, 1992, EUR J OPHTHALMOL, V2, P15
   HARVEY JN, 1992, CLIN ENDOCRINOL, V37, P97, DOI 10.1111/j.1365-2265.1992.tb02289.x
   Karanikis P, 2005, INT J CARDIOL, V101, P147, DOI 10.1016/j.ijcard.2004.01.027
   Katsanos KH, 2002, INT J CARDIOL, V83, P179, DOI 10.1016/S0167-5273(02)00040-2
   KOC F, 2003, MARMARA MED J, V16, P116
   KOSINSKI C, 1995, STROKE, V26, P1950, DOI 10.1161/01.STR.26.10.1950
   LOWES M, 1975, ACTA OPHTHALMOL, V53, P610
   Marie SKN, 1999, ARQ NEURO-PSIQUIAT, V57, P1017, DOI 10.1590/S0004-282X1999000600020
   POULTON J, 1995, DIABETOLOGIA, V38, P868, DOI 10.1007/s001250050366
   RAJAKANNAN G, 2000, INDIAN J OPHTHALMOLO, V48, P54
   Reichmann H, 1996, EUR NEUROL, V36, P98, DOI 10.1159/000117217
   SCHNITZLER ER, 1979, NEUROLOGY, V29, P1172, DOI 10.1212/WNL.29.8.1172
   Wilichowski E, 1997, PEDIATR RES, V41, P193, DOI 10.1203/00006450-199702000-00007
   Zanssen S, 1998, CLIN NEUROPATHOL, V17, P291
NR 20
TC 1
Z9 2
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0020-7454
EI 
J9 INT J NEUROSCI
JI Int. J. Neurosci.
PD FEB 15
PY 2008
VL 118
IS 2
BP 267
EP 275
DI 10.1080/00207450701242669
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 253LO
UT WOS:000252519900006
PM 18205082
DA 2024-11-01
ER

PT J
AU Lehnhardt, FG
   Horvath, R
   Ullrich, R
   Kracht, L
   Sobesky, J
   Möller-Hartmann, W
   Jacobs, AH
   Haupt, WF
AF Lehnhardt, Fritz-Georg
   Horvath, Rita
   Ullrich, Roland
   Kracht, Lutz
   Sobesky, Jan
   Moeller-Hartmann, Walter
   Jacobs, Andreas H.
   Haupt, Walter F.
TI Altered cerebral glucose metabolism in a family with clinical features resembling mitochondrial neurogastrointestinal encephalomyopathy syndrome in association with multiple mitochondrial DNA deletions
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID progressive external ophthalmoplegia; paralytic ileus; proton mrs; mngie; melas; tomography; mutations; children
AB Objective: To determine the involvement of cerebral metabolism in 2 siblings with mitochondrial neurogastrointestinal encephalomyopathy syndrome (MNGIE)-like disease with multiple mitochondrial DNA(mtDNA) deletions. Design: Case report. Setting: Department of Neurology at a university medical center. Patients: Two siblings with MNGIE-like disease with multiple mtDNA deletions. Main Outcome Measures: Clinical, biochemical, genetic, and imaging findings, including cerebral magnetic resonance imaging, proton magnetic resonance spectroscopy, and positron emission tomography with fluorine 18-labeled deoxyglucose (FDG-PET). Results: Genetic analysis of muscle DNA revealed multiple mtDNA deletions, while no mutations were detected in ECGF1, POLG1, ANT1, or Twinkle. Cerebral magnetic resonance imaging and proton magnetic resonance spectroscopy findings were unremarkable. Reduced regional glucose metabolism was found in a patchy and asymmetrical pattern predominantly in the frontotemporal region in both siblings by means of FDG-PET. Conclusions: The discrepancy between absence of clinical signs of cerebral involvement and the substantial impairment of glucose metabolism reflects a chronic subclinical encephalopathy. To our knowledge, the predominantly frontotemporal distribution has not been described previously in mitochondrial disorders.
C1 [Lehnhardt, Fritz-Georg; Sobesky, Jan; Jacobs, Andreas H.; Haupt, Walter F.] Univ Cologne, Dept Neurol, D-50931 Cologne, Germany.
   [Moeller-Hartmann, Walter] Univ Cologne, Dept Radiol, D-50931 Cologne, Germany.
   [Ullrich, Roland; Kracht, Lutz] Max Planck Inst Neurol Res, Cologne, Germany.
   [Horvath, Rita] Univ Munich, Dept Neurol, Friedrich Baur Inst, D-8000 Munich, Germany.
   [Horvath, Rita] Med Genet Ctr Munich, Munich, Germany.
C3 University of Cologne; University of Cologne; Max Planck Society; University of Munich
RP Haupt, WF (corresponding author), Univ Cologne, Dept Neurol, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.
EM walter.haupt@uk-koeln.de
CR BERKOVIC SF, 1989, BRAIN, V112, P1231, DOI 10.1093/brain/112.5.1231
   Chang TM, 2004, PEDIATR NEUROL, V31, P374, DOI 10.1016/j.pediatrneurol.2004.05.009
   Damian MS, 1998, EUR NEUROL, V39, P9, DOI 10.1159/000007892
   Dinopoulos A, 2005, NEUROPEDIATRICS, V36, P290, DOI 10.1055/s-2005-872807
   DUNCAN DB, 1995, ANN NEUROL, V37, P351, DOI 10.1002/ana.410370311
   FISCHER JC, 1986, EUR J PEDIATR, V144, P441, DOI 10.1007/BF00441735
   FRACKOWIAK RSJ, 1988, BRAIN, V111, P1009, DOI 10.1093/brain/111.5.1009
   Gamez J, 2005, PEDIATR NEUROL, V33, P151, DOI 10.1016/j.pediatrneurol.2005.05.023
   Herholz K, 2002, NEUROIMAGE, V17, P302, DOI 10.1006/nimg.2002.1208
   MATTHEWS PM, 1993, NEUROLOGY, V43, P2484, DOI 10.1212/WNL.43.12.2484
   Molnár MJ, 2000, NEUROLOGY, V55, P544, DOI 10.1212/WNL.55.4.544
   Nishino I, 2000, ANN NEUROL, V47, P792
   Salvan AM, 1998, EUR NEUROL, V40, P46, DOI 10.1159/000007955
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Vissing J, 2002, NEUROLOGY, V59, P926, DOI 10.1212/WNL.59.6.926
NR 15
TC 13
Z9 13
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9942
EI 1538-3687
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD MAR 15
PY 2008
VL 65
IS 3
BP 407
EP 411
DI 10.1001/archneur.65.3.407
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA 272TD
UT WOS:000253881900018
PM 18332256
DA 2024-11-01
ER

PT J
AU Götz, A
   Isohanni, P
   Pihko, H
   Paetau, A
   Herva, R
   Saarenpää-Heikkilä, O
   Valanne, L
   Marjavaara, S
   Suomalainen, A
AF Gotz, Alexandra
   Isohanni, Pirjo
   Pihko, Helena
   Paetau, Anders
   Herva, Riitta
   Saarenpaa-Heikkila, Outi
   Valanne, Leena
   Marjavaara, Sanna
   Suomalainen, Anu
TI Thymidine kinase 2 defects can cause multi-tissue mtDNA depletion syndrome
SO BRAIN
LA English
DT Article
ID mitochondrial-dna depletion; respiratory-chain; polg mutations; gene; deficiency; myopathy; expression; patient; pcr
AB Mitochondrial DNA depletion syndrome (MDS) is a severe recessively inherited disease of childhood. It manifests most often in infancy, is rapidly progressive and leads to early death. MDS is caused by an increasing number of nuclear genes leading to multisystemic or tissue-specific decrease in mitochondrial DNA (mtDNA) copy number. Thymidine kinase 2 (TK2) has been reported to cause a myopathic form of MDS. We report here the clinical, autopsy and molecular genetic findings of rapidly progressive fatal infantile mitochondrial syndrome. All of our seven patients had rapidly progressive myopathy/encephalomyopathy, leading to respiratory failure within the first 3 years of life, with high creatine kinase values and dystrophic changes in the muscle with cytochrome c oxidase-negative fibres. In addition, two patients also had terminal-phase seizures, one had epilepsia partialis continua and one had cortical laminar necrosis. We identified two different homozygous or compound heterozygous mutations in the TK2 gene in all the patients: c.739 C s T and c.898 C T, leading to p.R172W and p.R225W changes at conserved protein sites. R172W mutation led to myopathy or encephalomyopathy with the onset during the first months of life, and was associated with severe mtDNA depletion in the muscle, brain and liver. Homozygosity for R225W mutation manifested during the second year of life as a myopathy, and showed muscle-specific mtDNA depletion. Both mutations originated from single ancient founders, with Finnish origin and enrichment for the new R172W mutation, and possibly Scandinavian ancestral origin for the R225W. We conclude that TK2 mutations may manifest as infantile-onset fatal myopathy with dystrophic features, but should be considered also in infantile progressive encephalomyopathy with wide-spread mtDNA depletion.
C1 [Gotz, Alexandra; Isohanni, Pirjo; Marjavaara, Sanna; Suomalainen, Anu] Univ Helsinki, Res Programme Mol Neurol Biomed Helsinki, FIN-00290 Helsinki, Finland.
   [Isohanni, Pirjo; Pihko, Helena; Paetau, Anders] Univ Helsinki, Cent Hosp, Hosp Children & Adolescents, Dept Paediat Neurol, Helsinki, Finland.
   [Paetau, Anders] Univ Helsinki, Dept Pathol, Helsinki, Finland.
   [Herva, Riitta] Oulu Univ Hosp, Dept Pathol, Oulu, Finland.
   [Saarenpaa-Heikkila, Outi] Tampere Univ Hosp, Paediat Clin, Tampere, Finland.
   [Valanne, Leena] Univ Helsinki, Helsinki Med Imaging Ctr, Helsinki, Finland.
   [Suomalainen, Anu] Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki, Finland.
C3 University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Oulu; Tampere University; Tampere University Hospital; University of Helsinki; University of Helsinki; Helsinki University Central Hospital
RP Suomalainen, A (corresponding author), Univ Helsinki, Res Programme Mol Neurol Biomed Helsinki, Room C523A,Haartmaninkatu 8, FIN-00290 Helsinki, Finland.
EM anu.wartiovaara@helsinki.fi
FU Academy of Finland; Helsinki University; Sigrid Juselius Foundation; Graduate School of Biotechnology and Molecular Biology; Foundation for Paediatric Research and Helsinki University Central Hospital EVO; Human Frontier Science Program [LT00341/2001-M]
CR Akman HO, 2008, HUM MOL GENET, V17, P2433, DOI 10.1093/hmg/ddn143
   Alberio S, 2007, MITOCHONDRION, V7, P6, DOI 10.1016/j.mito.2006.11.010
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Carrozzo R, 2003, HUM MUTAT, V21, P0, DOI 10.1002/humu.9135
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MAJANDER A, 1995, J NEUROL SCI, V134, P95, DOI 10.1016/0022-510X(95)00225-5
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Norio R, 2003, HUM GENET, V112, P470, DOI 10.1007/s00439-002-0877-1
   Norio R, 2003, HUM GENET, V112, P441, DOI 10.1007/s00439-002-0875-3
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Pietiläinen KH, 2008, PLOS MED, V5, P0, DOI 10.1371/journal.pmed.0050051
   PIHKO H, 1992, NEUROPEDIATRICS, V23, P116, DOI 10.1055/s-2008-1071325
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Suomalainen A, 2000, MOL BIOTECHNOL, V15, P123, DOI 10.1385/MB:15:2:123
   Tulinius M, 2005, NEUROMUSCULAR DISORD, V15, P412, DOI 10.1016/j.nmd.2005.03.010
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Vilá MR, 2008, J NEUROL SCI, V267, P137, DOI 10.1016/j.jns.2007.10.019
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Vu TH, 1998, NEUROLOGY, V51, P1190, DOI 10.1212/WNL.51.4.1190
NR 31
TC 69
Z9 77
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD NOV 15
PY 2008
VL 131
IS 
BP 2841
EP 2850
DI 10.1093/brain/awn236
PG 10
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 373MQ
UT WOS:000260976400006
PM 18819985
DA 2024-11-01
ER

PT J
AU Li, J
   Zhou, K
   Meng, X
   Wu, Q
   Li, S
   Liu, Y
   Wang, J
AF Li, J.
   Zhou, K.
   Meng, X.
   Wu, Q.
   Li, S.
   Liu, Y.
   Wang, J.
TI Increased ROS generation and SOD activity in heteroplasmic tissues of transmitochondrial mice with A3243G mitochondrial DNA mutation
SO GENETICS AND MOLECULAR RESEARCH
LA English
DT Article
DE Mitochondria; Mitochondrial DNA; A3243G mutation; Mitochondrial disorders; Transmitochondrial mice; Transmitochondrial
ID complex-i; myopathy; disease; mtdna; melas; acid; gene
AB The mitochondrial A3243G tRNALeu(UUR) mutation associated with a variety of mitochondrial disorders results in a severe respiratory deficiency, an increase in reactive oxygen species (ROS) production and activities of anti-oxidative enzyme in vitro. However, the phenotypic implications of this mutation have not been described in vivo. Here, mitochondria carrying A3243G transition from the peripheral blood of diabetes mellitus patients were microinjected into zygotes. Influence of this mutation on mitochondrial respiratory enzyme activities, ROS generation, and antioxidative enzyme activities in the heteroplasmic tissues of transmitochondrial mice was evaluated. The chimeric mice exhibited a subtle impaired oxidative phosphorylation, reduced activity of complex I/IV, increased activity of superoxide dismutase, and in turn, enhanced ROS generation. Our results suggest that mitochondrial A3243G mutation may be responsible for the high ROS production in vivo. Increased generation of ROS caused by mtDNA mutation may also play a role in the pathogenesis of the A3243G mutationassociated diseases.
C1 [Li, J.; Meng, X.; Wu, Q.; Li, S.; Wang, J.] Capital Med Univ, Dept Lab Anim Sci, Beijing, Peoples R China.
   [Zhou, K.; Li, S.] Guangdong Med Coll, Dept Biochem, Dongguan, Peoples R China.
C3 Capital Medical University; Guangdong Medical University
RP Wang, J (corresponding author), Capital Med Univ, Dept Lab Anim Sci, Beijing, Peoples R China.
EM wangju53@263.net
FU Beijing science and technology
CR Beretta S, 2006, NEUROBIOL DIS, V24, P308, DOI 10.1016/j.nbd.2006.07.016
   Bonora E, 2006, CANCER RES, V66, P6087, DOI 10.1158/0008-5472.CAN-06-0171
   Carelli V, 2007, BIOSCIENCE REP, V27, P173, DOI 10.1007/s10540-007-9045-0
   Gardner JL, 2007, BIOSCIENCE REP, V27, P139, DOI 10.1007/s10540-007-9042-3
   Hervouet E, 2007, BIOCHIMIE, V89, P1080, DOI 10.1016/j.biochi.2007.03.010
   Ishikawa K, 2005, CIRC J, V 69, P617, DOI 10.1253/circj.69.617
   Janssen RJRJ, 2006, J INHERIT METAB DIS, V29, P499, DOI 10.1007/s10545-006-0362-4
   KASRAIE S, 2008, CELL MOL NEUROBIOL, V0, P0
   Lionetti L, 2004, CELL MOL LIFE SCI, V61, P1366, DOI 10.1007/s00018-004-4073-4
   Long JG, 2007, BIOGERONTOLOGY, V8, P373, DOI 10.1007/s10522-007-9081-y
   Maechler P, 2006, BIOCHEM SOC T, V34, P824, DOI 10.1042/BST0340824
   McKenzie M, 2004, NEUROCHEM RES, V29, P589, DOI 10.1023/B:NERE.0000014829.42364.dd
   McKenzie M, 2007, J BIOL CHEM, V282, P36845, DOI 10.1074/jbc.M704158200
   Meany DL, 2006, FREE RADICAL BIO MED, V41, P950, DOI 10.1016/j.freeradbiomed.2006.06.003
   Meissner C, 2007, Z GERONTOL GERIATR, V40, P325, DOI 10.1007/s00391-007-0481-z
   Meulemans A, 2006, ARCH NEUROL-CHICAGO, V63, P1194, DOI 10.1001/archneur.63.8.1194
   Mkaouar-Rebai E, 2007, BIOCHEM BIOPH RES CO, V355, P1031, DOI 10.1016/j.bbrc.2007.02.083
   Panov AV, 2005, MOL CELL BIOCHEM, V269, P143, DOI 10.1007/s11010-005-3454-9
   Petrozzi L, 2007, BIOSCIENCE REP, V27, P87, DOI 10.1007/s10540-007-9038-z
   Pinkert CA, 1997, TRANSGENIC RES, V6, P379, DOI 10.1023/A:1018431316831
   Rusanen H, 2000, BBA-MOL BASIS DIS, V1500, P10, DOI 10.1016/S0925-4439(99)00081-2
   Sandhu JK, 2005, BIOCHEM J, V391, P191, DOI 10.1042/BJ20050272
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Urata M, 1998, CLIN CHEM, V44, P2088
   Vergani L, 2007, BRAIN, V130, P2715, DOI 10.1093/brain/awm151
   Vives-Bauza C, 2006, NEUROSCI LETT, V391, P136, DOI 10.1016/j.neulet.2005.08.049
   Wang ZX, 2002, CHINESE MED J-PEKING, V115, P995
   Zhang Ying, 2005, ZHONGGUO YI XUE KE XUE YUAN XUE BAO, V27, P77
NR 29
TC 17
Z9 18
U1 1
U2 5
PU FUNPEC-EDITORA
PI RIBEIRAO PRETO
PA RUA FLORIANO PEIXOTO 2444, ALTO DA BOA VISTA, RIBEIRAO PRETO, SP 00000, BRAZIL
SN 1676-5680
EI 
J9 GENET MOL RES
JI Genet. Mol. Res.
PD JUN 15
PY 2008
VL 7
IS 4
BP 1054
EP 1062
DI 10.4238/vol7-4gmr480
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 362WF
UT WOS:000260227200008
PM 19048484
DA 2024-11-01
ER

PT J
AU Invernizzi, F
   Varanese, S
   Thomas, A
   Carrara, F
   Onofrj, M
   Zeviani, M
AF Invernizzi, Federica
   Varanese, Sara
   Thomas, Astrid
   Carrara, Franco
   Onofrj, Marco
   Zeviani, Massimo
TI Two novel <i>POLG1</i> mutations in a patient with progressive external ophthalmoplegia, levodopa-responsive pseudo-orthostatic tremor and parkinsonism
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE progressive external ophthalmoplegia; parkinsonism; polymerase gamma; mitochondrial DNA; multiple mtDNA deletions
ID dna-polymerase-gamma; familial parkinsonism; autosomal-dominant; disease; deletions; neuropathy; region
AB Different mutations, or combinations of mutations, in POLG1, the gene encoding pol gamma A, the catalytic subunit of mitochondrial DNA polymerase, are associated with a spectrum of clinical presentations including autosomal dominant or recessive progressive external ophthalmoplegia (PEO), juvenile-onset ataxia and epilepsy, and Alpers-Huttenlocher syndrome. Parkinsonian features have been reported as a late complication of POLG1-associated dominant PEO. Good response to levodopa or dopamine agonists, reduced dopamine uptake in the corpus striatum and neuronal loss of the Substantia Nigra pars compacta have been documented in a few cases. Here we report two novel mutations in POLG1 in a compound heterozygous patient with autosomal recessive PEO, followed by pseudo-orthostatic tremor evolving into levodopa-responsive parkinsonism. These observations support the hypothesis that mtDNA dysfunction is engaged in the pathogenesis of idiopathic Parkinson's disease. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Invernizzi, Federica; Carrara, Franco; Zeviani, Massimo] IRCCS, C Besta Neurol Inst Fdn, Unit Mol Neurogenet Pierfranco, Milan, Italy.
   [Invernizzi, Federica; Carrara, Franco; Zeviani, Massimo] IRCCS, C Besta Neurol Inst Fdn, Luisa Mariani Ctr Study Childrens Mitochondrial D, Milan, Italy.
   [Varanese, Sara; Thomas, Astrid; Onofrj, Marco] Univ G DAnnunzio, Dept Oncol Neurosci & Neurophysiopathol, Chieti, Italy.
   [Varanese, Sara; Thomas, Astrid; Onofrj, Marco] CeSI G DAnnunzio Univ Fdn, Aging Res Ctr, Chieti, Italy.
C3 G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara
RP Zeviani, M (corresponding author), IRCCS, C Besta Neurol Inst Fdn, Unit Mol Neurogenet Pierfranco, Milan, Italy.
EM zeviani@istituto-besta.it
FU Telethon [GGP07019] Funding Source: Medline
CR Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   Graziewicz MA, 2007, HUM MOL GENET, V16, P2729, DOI 10.1093/hmg/ddm227
   Horvath R, 2007, NEUROLOGY, V68, P56, DOI 10.1212/01.wnl.0000250334.48038.7a
   Hudson G, 2007, ARCH NEUROL-CHICAGO, V64, P553, DOI 10.1001/archneur.64.4.553
   Hudson G, 2006, HUM MOL GENET, V15, PR244, DOI 10.1093/hmg/ddl233
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2007, NEUROLOGY, V69, P1152, DOI 10.1212/01.wnl.0000276955.23735.eb
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Stopinska K, 2006, ACTA BIOCHIM POL, V53, P591
   Thomas A, 2007, MOVEMENT DISORD, V22, P1652, DOI 10.1002/mds.21621
   Tiangyou W, 2006, NEUROLOGY, V67, P1698, DOI 10.1212/01.wnl.0000238963.07425.d5
   Wilcox RA, 2007, MOVEMENT DISORD, V22, P1020, DOI 10.1002/mds.21416
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 18
TC 41
Z9 42
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD JUN 15
PY 2008
VL 18
IS 6
BP 460
EP 464
DI 10.1016/j.nmd.2008.04.005
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 331PB
UT WOS:000258023000005
PM 18502641
DA 2024-11-01
ER

PT J
AU Liu, ZR
   Ding, Y
   Du, AL
   Zhang, BR
   Zhao, GH
   Ding, MP
AF Liu, Zhirong
   Ding, Yao
   Du, Ailian
   Zhang, Baorong
   Zhao, Guohua
   Ding, Meiping
TI A novel Twinkle (<i>PEO1</i>) gene mutation in a Chinese family with adPEO
SO MOLECULAR VISION
LA English
DT Article
ID progressive external ophthalmoplegia; autosomal-dominant; polymerase-gamma; mtdna deletions; dna helicase; region; depletion; disorder; polg
AB Purpose: Autosomal dominant progressive external ophthalmoplegia (adPEO) is a genetically heterogeneous, adult-onset disease. Thus far, disease loci have been identified on four different nuclear genes. The purpose of this study is to identify the gene responsible for causing adPEO in a Chinese family. Methods: Clinical data and genomic DNA of a Chinese adPEO family were collected following informed consent. Gene scan by two-point linkage analysis was performed for four genes, and mutation screening was conducted in the Twinkle (PEO1) gene by direct sequencing. Results: A maximum two-point LOD score of 2.8 at theta=0.00 was obtained with marker D10S192 in close proximity to PEO1. A novel missense mutation (c. 1423G>A, p.475A>T) was identified. Conclusions: This study widens the mutation spectrum of PEO1 and is the first to report the PEO1 mutation in the Chinese population.
C1 [Liu, Zhirong; Ding, Yao; Du, Ailian; Zhang, Baorong; Zhao, Guohua; Ding, Meiping] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Neurol, Hangzhou 310009, Zhejiang, Peoples R China.
C3 Zhejiang University
RP Ding, MP (corresponding author), Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Neurol, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.
EM dingmeiping@tom.com
FU National Natural Science Foundation of China [305070643]; Youth Foundation of the College of Medicine, Zhejiang University [491020-542966]
CR Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   Houshmand M, 2006, NEUROL INDIA, V54, P182
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kiechl S, 2004, J NEUROL NEUROSUR PS, V75, P1125, DOI 10.1136/jnnp.2003.025890
   Korhonen JA, 2008, J MOL BIOL, V377, P691, DOI 10.1016/j.jmb.2008.01.035
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Li FY, 1999, NEUROLOGY, V53, P1265, DOI 10.1212/WNL.53.6.1265
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Rivera H, 2007, NEUROMUSCULAR DISORD, V17, P677, DOI 10.1016/j.nmd.2007.05.006
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Shutt TE, 2006, J MOL EVOL, V62, P588, DOI 10.1007/s00239-005-0162-8
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   VIRGILIO R, 2008, J NEUROL, V0, P0
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 22
TC 9
Z9 9
U1 0
U2 3
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E, ATLANTA, GA 30322 USA
SN 1090-0535
EI 
J9 MOL VIS
JI Mol. Vis.
PD NOV 3
PY 2008
VL 14
IS 235-36
BP 1995
EP 2000
DI 
PG 6
WC Biochemistry & Molecular Biology; Ophthalmology
SC Biochemistry & Molecular Biology; Ophthalmology
GA 406WB
UT WOS:000263324500001
PM 18989381
DA 2024-11-01
ER

PT J
AU Pang, CY
   Ma, YS
   Wei, YH
AF Pang, Cheng-Yoong
   Ma, Yi-Shing
   Wei, Yau-Huei
TI MtDNA mutations, functional decline and turnover of mitochondria in aging
SO FRONTIERS IN BIOSCIENCE-LANDMARK
LA English
DT Review
DE aging; mitochondria; mitochondrial Dna; mutation; oxidative stress; proteasome; turnover; autophagy; review
ID human skeletal-muscle; cytochrome-c-oxidase; oxidatively modified protein; respiratory-chain activity; substantia-nigra neurons; dna deletions; superoxide-dismutase; proteomic identification; drosophila-melanogaster; degenerative diseases
AB Aging is a complex biological process that involves gradual function deterioration in various tissues and organs of an individual. Mitochondrial function decline can lead to cellular overproduction of reactive oxygen species (ROS) and increase in oxidative damage to biological molecules in the aging process. We have hypothesized that increased production of ROS by the mitochondria in affected tissues in patients with mitochondrial diseases and elderly subject results in increased oxidative stress and oxidative damage. Due to the similarity of human aging process to diseases related to bioenergetic function decline and mitochondrial DNA (mtDNA) alterations, aging is sometimes viewed as a "chronic" version of such diseases. Recent studies have also established that the expression profiles of several clusters of genes are altered, oxidative modification of proteins are increased and their turnover are decreased in tissues of old human subjects and animals. Accumulating evidence has suggested that mtDNA mutations, oxidative stress, defective disposal of dysfunctional proteins and a slower turnover of mitochondria are associated with aging.
C1 [Ma, Yi-Shing; Wei, Yau-Huei] Natl Yang Ming Univ, Sch Life Sci, Dept Biochem & Mol Biol, Taipei 112, Taiwan.
   [Pang, Cheng-Yoong] Tzu Chi Univ, Inst Med Sci, Hualien 970, Taiwan.
   [Pang, Cheng-Yoong] Tzu Chi Coll Technol, Gen Educ Ctr, Hualien 970, Taiwan.
   [Pang, Cheng-Yoong] Tzu Chi Gen Hosp, Dept Res, Hualien 970, Taiwan.
C3 National Yang Ming Chiao Tung University; Tzu Chi University; Tzu Chi University of Science & Technology; Buddhist Tzu Chi General Hospital; Hualien Tzu Chi Hospital
RP Wei, YH (corresponding author), Natl Yang Ming Univ, Sch Life Sci, Dept Biochem & Mol Biol, Taipei 112, Taiwan.
EM joeman@ym.edu.tw
CR Agarwal S, 1995, MECH AGEING DEV, V85, P55, DOI 10.1016/0047-6374(95)01655-4
   Beal MF, 2005, ANN NEUROL, V58, P495, DOI 10.1002/ana.20624
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313
   Blander G, 2003, J BIOL CHEM, V278, P38966, DOI 10.1074/jbc.M307146200
   Brambilla L, 1997, FEBS LETT, V418, P247, DOI 10.1016/S0014-5793(97)01393-8
   Brandon MC, 2005, NUCLEIC ACIDS RES, V33, P0
   Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x
   Bulteau AL, 2002, ARCH BIOCHEM BIOPHYS, V397, P298, DOI 10.1006/abbi.2001.2663
   Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502
   CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633
   Carrard G, 2002, INT J BIOCHEM CELL B, V34, P1461, DOI 10.1016/S1357-2725(02)00085-7
   Cavallini G, 2007, AUTOPHAGY, V3, P26, DOI 10.4161/auto.3268
   Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200
   CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236
   Ciechanover A, 2005, NAT REV MOL CELL BIO, V6, P79, DOI 10.1038/nrm1552
   Clark IE, 2006, NATURE, V441, P1162, DOI 10.1038/nature04779
   Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738
   Cuervo AM, 2005, AUTOPHAGY, V1, P131, DOI 10.4161/auto.1.3.2017
   Dean RT, 1997, BIOCHEM J, V324, P1
   Delaval E, 2004, EUR J BIOCHEM, V271, P4559, DOI 10.1111/j.1432-1033.2004.04422.x
   Deng H, 2005, BIOCHEM BIOPH RES CO, V337, P1133, DOI 10.1016/j.bbrc.2005.09.178
   Deretic V, 2006, CURR OPIN IMMUNOL, V18, P375, DOI 10.1016/j.coi.2006.05.019
   Donati A, 2006, REJUV RES, V9, P408, DOI 10.1089/rej.2006.9.408
   Drew B, 2002, ANN NY ACAD SCI, V959, P66, DOI 10.1111/j.1749-6632.2002.tb02084.x
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   Fahn HJ, 1996, AM J RESP CRIT CARE, V154, P1141, DOI 10.1164/ajrccm.154.4.8887618
   Ferrington DA, 2005, FASEB J, V19, P664, DOI 10.1096/fj.04-2578fje
   FROMENTY B, 1995, GASTROENTEROLOGY, V108, P193, DOI 10.1016/0016-5085(95)90024-1
   Grune T, 2003, BIOCHEM BIOPH RES CO, V305, P709, DOI 10.1016/S0006-291X(03)00809-X
   Grune T, 2000, BIOGERONTOLOGY, V1, P31, DOI 10.1023/A:1010037908060
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   HAYAKAWA M, 1991, BIOCHEM BIOPH RES CO, V179, P1023, DOI 10.1016/0006-291X(91)91921-X
   HAYAKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P979, DOI 10.1016/0006-291X(92)92300-M
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   Higami Y, 1997, AM J PATHOL, V151, P659
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Holt PR, 1998, J GERONTOL A-BIOL, V53, PB168, DOI 10.1093/gerona/53A.3.B168
   Kanski J, 2005, AM J PHYSIOL-HEART C, V288, PH371, DOI 10.1152/ajpheart.01030.2003
   Kanski J, 2003, FREE RADICAL BIO MED, V35, P1229, DOI 10.1016/S0891-5849(03)00500-8
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kim RH, 2005, P NATL ACAD SCI USA, V102, P5215, DOI 10.1073/pnas.0501282102
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kissová I, 2004, J BIOL CHEM, V279, P39068, DOI 10.1074/jbc.M406960200
   Kopsidas G, 1998, MUTAT RES-FUND MOL M, V421, P27, DOI 10.1016/S0027-5107(98)00150-X
   Kovalenko SA, 1997, BIOCHEM BIOPH RES CO, V232, P147, DOI 10.1006/bbrc.1997.6251
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121
   Lee HC, 2001, MUTAT RES-GEN TOX EN, V493, P67, DOI 10.1016/S1383-5718(01)00160-7
   LEE HC, 1994, FEBS LETT, V354, P79, DOI 10.1016/0014-5793(94)01063-3
   Lee HC, 2007, EXP BIOL MED, V232, P592
   Lemasters JJ, 2005, REJUV RES, V8, P3, DOI 10.1089/rej.2005.8.3
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Lu CY, 1999, MUTAT RES-FUND MOL M, V423, P11, DOI 10.1016/S0027-5107(98)00220-6
   Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661
   Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486
   Macip S, 2003, MOL CELL BIOL, V23, P8576, DOI 10.1128/MCB.23.23.8576-8585.2003
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MENZIES RA, 1971, J BIOL CHEM, V246, P2425
   Mitra S, 2007, DNA REPAIR, V6, P461, DOI 10.1016/j.dnarep.2006.10.010
   MO JQ, 1995, MECH AGEING DEV, V81, P73, DOI 10.1016/0047-6374(95)01586-O
   MULLERHOCKER J, 1992, MUTAT RES, V275, P115, DOI 10.1016/0921-8734(92)90016-I
   MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9
   MUNSCHER C, 1993, FEBS LETT, V317, P27, DOI 10.1016/0014-5793(93)81484-H
   Musatov A, 2006, FREE RADICAL BIO MED, V41, P238, DOI 10.1016/j.freeradbiomed.2006.03.018
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Nixon RA, 2003, AGEING RES REV, V2, P407, DOI 10.1016/S1568-1637(03)00029-1
   Ojaimi J, 1999, MECH AGEING DEV, V111, P39, DOI 10.1016/S0047-6374(99)00071-8
   OLIVER CN, 1987, J BIOL CHEM, V262, P5488
   Orr WC, 2003, J BIOL CHEM, V278, P26418, DOI 10.1074/jbc.M303095200
   PANG CY, 1994, ARCH BIOCHEM BIOPHYS, V312, P534, DOI 10.1006/abbi.1994.1342
   Pansarasa O, 1999, FREE RADICAL BIO MED, V27, P617, DOI 10.1016/S0891-5849(99)00108-2
   Paradies G, 2002, GENE, V286, P135, DOI 10.1016/S0378-1119(01)00814-9
   Paradies G, 1998, FEBS LETT, V424, P155, DOI 10.1016/S0014-5793(98)00161-6
   Park J, 2006, NATURE, V441, P1157, DOI 10.1038/nature04788
   Paterna JC, 2007, MOL THER, V15, P698, DOI 10.1038/sj.mt.6300067
   Pesah Y, 2004, DEVELOPMENT, V131, P2183, DOI 10.1242/dev.01095
   Pesce V, 2001, FREE RADICAL BIO MED, V30, P1223, DOI 10.1016/S0891-5849(01)00517-2
   Petit A, 2005, J BIOL CHEM, V280, P34025, DOI 10.1074/jbc.M505143200
   Petropoulos I, 2000, J GERONTOL A-BIOL, V55, PB220, DOI 10.1093/gerona/55.5.B220
   Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9
   POULTON J, 1994, HUM MOL GENET, V3, P947, DOI 10.1093/hmg/3.6.947
   Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002
   Ruan H, 2002, P NATL ACAD SCI USA, V99, P2748, DOI 10.1073/pnas.032671199
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Saeki K, 2000, CELL DEATH DIFFER, V7, P1263, DOI 10.1038/sj.cdd.4400759
   Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653
   Sharma R, 2006, FREE RADICAL BIO MED, V40, P1179, DOI 10.1016/j.freeradbiomed.2005.11.013
   Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102
   Shoubridge EA, 2001, HUM MOL GENET, V10, P2277, DOI 10.1093/hmg/10.20.2277
   Sun JT, 2002, GENETICS, V161, P661
   Szczesny B, 2003, P NATL ACAD SCI USA, V100, P10670, DOI 10.1073/pnas.1932854100
   Terman A, 2004, INT J BIOCHEM CELL B, V36, P1400, DOI 10.1016/j.biocel.2003.08.009
   Terman A, 2003, EXP GERONTOL, V38, P863, DOI 10.1016/S0531-5565(03)00114-1
   Tolkovsky AM, 2002, BIOCHIMIE, V84, P233, DOI 10.1016/S0300-9084(02)01371-8
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   Wauthier V, 2006, LIFE SCI, V79, P1913, DOI 10.1016/j.lfs.2006.06.046
   Webster KA, 2001, ANTIOXID REDOX SIGN, V3, P535, DOI 10.1089/15230860152542916
   Wei YH, 2001, CHINESE J PHYSIOL, V44, P1
   Wei YH, 1998, CURR SCI INDIA, V74, P887
   Welle S, 2004, EXP GERONTOL, V39, P369, DOI 10.1016/j.exger.2003.11.011
   Welle S, 2003, PHYSIOL GENOMICS, V14, P149, DOI 10.1152/physiolgenomics.00049.2003
   Wood-Kaczmar A, 2006, TRENDS MOL MED, V12, P521, DOI 10.1016/j.molmed.2006.09.007
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168
   Yan LJ, 1998, P NATL ACAD SCI USA, V95, P12896, DOI 10.1073/pnas.95.22.12896
   Yang YF, 2005, P NATL ACAD SCI USA, V102, P13670, DOI 10.1073/pnas.0504610102
   Yang YF, 2006, P NATL ACAD SCI USA, V103, P10793, DOI 10.1073/pnas.0602493103
   YEN TC, 1989, BIOCHEM BIOPH RES CO, V165, P994, DOI 10.1016/0006-291X(89)92701-0
   YEN TC, 1994, FREE RADICAL BIO MED, V16, P207, DOI 10.1016/0891-5849(94)90145-7
   Zahn JM, 2006, PLOS GENET, V2, P1058, DOI 10.1371/journal.pgen.0020115
   ZHANG CF, 1993, BIOCHEM BIOPH RES CO, V195, P1104, DOI 10.1006/bbrc.1993.2158
   Zhang YP, 2007, MECH AGEING DEV, V128, P213, DOI 10.1016/j.mad.2006.11.030
   Zhang YP, 2002, EXP GERONTOL, V37, P777, DOI 10.1016/S0531-5565(02)00013-X
NR 123
TC 25
Z9 27
U1 0
U2 13
PU FRONTIERS IN BIOSCIENCE INC
PI IRVINE
PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA
SN 1093-9946
EI 1093-4715
J9 FRONT BIOSCI-LANDMRK
JI Front. Biosci.
PD MAY 15
PY 2008
VL 13
IS 
BP 3661
EP U60
DI 10.2741/2957
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 301GS
UT WOS:000255885000038
PM 18508463
DA 2024-11-01
ER

PT J
AU Lebrecht, D
   Deveaud, C
   Beauvoit, B
   Bonnet, J
   Kirschner, J
   Walker, UA
AF Lebrecht, Dirk
   Deveaud, Catherine
   Beauvoit, Bertrand
   Bonnet, Jacques
   Kirschner, Janbernd
   Walker, Ulrich A.
TI Uridine supplementation antagonizes zidovudine-induced mitochondrial myopathy and hyperlactatemia in mice
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID reverse-transcriptase inhibitors; muscle mitochondria; didanosine ddi; toxicity; nucleoside; cells; mtdna; 3'-azido-3'-deoxythymidine; azt; dna
AB Objective. Zidovudine is an antiretroviral nucleoside analog reverse transcriptase inhibitor that induces mitochondrial myopathy by interfering with the replication of mitochondrial DNA (mtDNA). Because zidovudine inhibits thymidine kinases, the mechanism of mtDNA depletion may be related to an impairment of the de novo synthesis of pyrimidine nucleotides, which are required building blocks of mtDNA. This study was undertaken to determine whether mitochondrial myopathy is a class effect of antiretroviral nucleoside analogs, and whether the muscle disease can be prevented by treatment with uridine as a pyrimidine nucleotide precursor. Methods. BALB/c mice were treated with zidovudine or zalcitabine. Some of the mice were cotreated with mitocnol, a dietary supplement with high uridine bioavailability. Mice hind limb muscles were examined after 10 weeks. Results. Zidovudine induced muscle fiber thinning, myocellular fat deposition, and abnormalities of mitochondrial ultrastructure. In mice treated with zidovudine, organelles contained low mtDNA copy numbers and reduced cytochrome c oxidase activity. The expression of the mtDNA-encoded cytochrome c oxidase I subunit, but not of nucleus-encoded mitochondrial proteins, was impaired. Zidovudine also increased the levels of myocellular reactive oxygen species and blood lactate. Uridine supplementation attenuated or normalized all pathologic abnormalities and had no intrinsic effects. Zalcitabine did not elicit muscle toxicity. Conclusion. Our findings indicate that zidovudine, but not zalcitabine, induces mitochondrial myopathy, which is substantially antagonized by uridine supplementation. These results provide proof of the importance of pyrimidine pools in the pathogenesis of zidovudine myopathy. Since uridine supplementation is tolerated well by humans, this treatment strategy should be investigated in clinical trials.
C1 [Walker, Ulrich A.] Univ Basel, Dept Rheumatol, CH-4012 Basel, Switzerland.
   [Lebrecht, Dirk; Kirschner, Janbernd; Walker, Ulrich A.] Med Univ Klin, Freiburg, Germany.
   [Deveaud, Catherine; Beauvoit, Bertrand; Bonnet, Jacques] INSERM, Unite 828, Pessac, France.
C3 University of Basel; University of Freiburg; Institut National de la Sante et de la Recherche Medicale (Inserm)
RP Walker, UA (corresponding author), Univ Basel, Dept Rheumatol, Felix Platter Spital,Burgfelderstr 101, CH-4012 Basel, Switzerland.
EM ulrich.walker@fps-basel.ch
CR ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5
   Banasch M, 2006, AIDS, V20, P1554, DOI 10.1097/01.aids.0000237373.38939.14
   Benbrik E, 1997, J NEUROL SCI, V149, P19, DOI 10.1016/S0022-510X(97)05376-8
   CHARIOT P, 1994, ARTHRITIS RHEUM, V37, P583, DOI 10.1002/art.1780370421
   Collins ML, 2004, JAIDS-J ACQ IMM DEF, V37, P1132, DOI 10.1097/01.qai.0000131585.77530.64
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   de la Asunción JG, 1998, J CLIN INVEST, V102, P4, DOI 10.1172/JCI1418
   Deveaud C, 2005, BIOCHEM PHARMACOL, V70, P90, DOI 10.1016/j.bcp.2005.04.015
   Fox RI, 1998, J RHEUMATOL, V25, P20
   FRINGS CS, 1972, CLIN CHEM, V18, P673
   Gattermann N, 2004, NUCLEOS NUCLEOT NUCL, V23, P1275, DOI 10.1081/NCN-200027545
   GIROT R, 1983, NEW ENGL J MED, V308, P700, DOI 10.1056/NEJM198303243081207
   Hosseini SH, 2007, AM J PATHOL, V170, P865, DOI 10.2353/ajpath.2007.060655
   Kakuda TN, 2000, CLIN THER, V22, P685, DOI 10.1016/S0149-2918(00)90004-3
   Koch EC, 2003, ANTIVIR THER, V8, P485
   Lebrecht D, 2003, CIRCULATION, V108, P2423, DOI 10.1161/01.CIR.0000093196.59829.DF
   Lebrecht D, 2007, HEPATOLOGY, V45, P72, DOI 10.1002/hep.21490
   LEWIS W, 1992, J CLIN INVEST, V89, P1354, DOI 10.1172/JCI115722
   Lynx MD, 2006, BIOCHEM PHARMACOL, V72, P239, DOI 10.1016/j.bcp.2006.04.004
   MCCOMSEY GA, 2007, URIDINE SUPPLEMENTAT, V0, P0
   Nohl H, 2005, BIOCHEM PHARMACOL, V69, P719, DOI 10.1016/j.bcp.2004.12.002
   Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031
   Pedrol E, 1996, J NEUROL SCI, V138, P42, DOI 10.1016/0022-510X(96)00009-3
   POULTON J, 1995, J INHERIT METAB DIS, V18, P4, DOI 10.1007/BF00711367
   Rylova SN, 2005, BIOCHEM PHARMACOL, V69, P951, DOI 10.1016/j.bcp.2004.12.010
   SILVESTRI G, 1994, HUM MUTAT, V3, P37, DOI 10.1002/humu.1380030107
   SOMMADOSSI JP, 1988, ANTIMICROB AGENTS CH, V32, P997, DOI 10.1128/AAC.32.7.997
   Susan-Resiga D, 2007, ANTIMICROB AGENTS CH, V51, P1142, DOI 10.1128/AAC.01227-06
   Sutinen J, 2007, ANTIVIR THER, V12, P97
   Tuzgen S, 1998, SPINAL CORD, V36, P654, DOI 10.1038/sj.sc.3100660
   Venhoff N, 2005, AIDS, V19, P739, DOI 10.1097/01.aids.0000166101.44262.52
   Walker UA, 2006, ANTIVIR THER, V11, P25
   Walker UA, 2005, ANTIVIR THER, V10, P0
   Walker UA, 2003, ANTIVIR THER, V8, P463
   Walker UA, 2002, AIDS, V16, P2165, DOI 10.1097/00002030-200211080-00009
NR 35
TC 21
Z9 22
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD JAN 15
PY 2008
VL 58
IS 1
BP 318
EP 326
DI 10.1002/art.23235
PG 9
WC Rheumatology
SC Rheumatology
GA 256ML
UT WOS:000252733100036
PM 18163507
DA 2024-11-01
ER

PT J
AU Yamashita, S
   Nishino, I
   Nonaka, I
   Goto, YI
AF Yamashita, Shintaro
   Nishino, Ichizo
   Nonaka, Ikuya
   Goto, Yu-ichi
TI Genotype and phenotype analyses in 136 patients with single large-scale mitochondrial DNA deletions
SO JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE mitochondrial DNA; deletion; CPEO; KSS; direct repeat
ID progressive external ophthalmoplegia; multiple deletions; mtdna; muscle; involvement; mutations; genetics; lacking
AB We examined 136 patients with mitochondrial DNA (mtDNA) deletion. Clinical diagnoses included chronic progressive external ophthalmoplegia (94 patients); Kearns-Sayre syndrome (KSS; 33 patients); Pearson's marrow-pancreas syndrome (six patients); and Leigh syndrome, Reye-like syndrome, and mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (one patient). The length and location of deletion were highly variable. Only one patient had deletion within the so-called shorter arc between the two origins of mtDNA replication. The length of deletion and the number of deleted transfer ribonucleic acid (tRNAs) showed a significant relationship with age at onset. Furthermore, KSS patients had longer and larger numbers of deleted tRNAs, which could be risk factors for the systemic involvement of single mtDNA deletion diseases. We found 81 patterns of deletion. Direct repeats of 4 bp or longer flanking the breakpoints were found in 96 patients (70.5%) and those of 10 bp or longer in 49 patients (36.0%). We found two other common deletions besides the most common deletion (34 patients: 25.0%): the 2,310-bp deletion from nt 12113 to nt 14421 (11 patients: 8.0%) and the 7,664-bp deletion from nt 6330 to nt 13993 (ten patients: 7.3%). These deletions had incomplete direct repeats longer than 13 bp with one base mismatch.
C1 [Yamashita, Shintaro; Goto, Yu-ichi] Natl Ctr Neurol & Psychiat, Dept Mental Retardat & Birth Defect Res, Natl Inst Neurosci, Kodaira, Tokyo 1878502, Japan.
   [Nishino, Ichizo; Nonaka, Ikuya] Natl Ctr Neurol & Psychiat, Dept Neuromuscular Res, Natl Inst Neurosci, Kodaira, Tokyo 1878502, Japan.
   [Yamashita, Shintaro] Juntendo Univ, Sch Med, Dept Pediat & Adolescent Med, Bunkyo Ku, Tokyo 113, Japan.
C3 National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan; Juntendo University
RP Goto, YI (corresponding author), Natl Ctr Neurol & Psychiat, Dept Mental Retardat & Birth Defect Res, Natl Inst Neurosci, 4-1-1 Ogawahigashi, Kodaira, Tokyo 1878502, Japan.
EM goto@ncnp.go.jp
CR Akman CI, 2004, J CHILD NEUROL, V19, P258, DOI 10.1177/088307380401900403
   Auré K, 2007, BRAIN, V130, P1516, DOI 10.1093/brain/awm067
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Campos Y, 2000, NEUROMUSCULAR DISORD, V10, P56, DOI 10.1016/S0960-8966(99)00072-3
   DEUGOL F, 1991, NUCLEIC ACIDS RES, V19, P403
   GOTO Y, 1990, J NEUROL SCI, V100, P63, DOI 10.1016/0022-510X(90)90014-E
   GOTO Y, 1990, J PEDIATR-US, V116, P904, DOI 10.1016/S0022-3476(05)80648-1
   Goto YI, 1996, BIOCHEM BIOPH RES CO, V222, P215, DOI 10.1006/bbrc.1996.0724
   HAMMANS SR, 1992, BRAIN, V115, P343, DOI 10.1093/brain/115.2.343
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Horton TM, 1996, GENE CHROMOSOME CANC, V15, P95, DOI 10.1002/(SICI)1098-2264(199602)15:2<95::AID-GCC3>3.0.CO;2-Z
   JOHNS DR, 1991, BIOCHEM BIOPH RES CO, V174, P244, DOI 10.1016/0006-291X(91)90512-6
   KATAYAMA M, 1991, BIOCHEM INT, V25, P47
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   Marzuki S, 1997, J NEUROL SCI, V145, P155, DOI 10.1016/S0022-510X(96)00241-9
   MCSHANE MA, 1991, AM J HUM GENET, V48, P39
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1991, MOL CELL BIOL, V11, P1631, DOI 10.1128/MCB.11.3.1631
   MORI K, 1991, AM J MED GENET, V38, P583, DOI 10.1002/ajmg.1320380417
   NAKAI A, 1994, LANCET, V343, P1397, DOI 10.1016/S0140-6736(94)92527-5
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   OZAWA T, 1988, BIOCHEM BIOPH RES CO, V154, P1240, DOI 10.1016/0006-291X(88)90272-0
   POULTON J, 1989, LANCET, V1, P236
   ROTIG A, 1989, LANCET, V1, P902
   ROWLAND LP, 1983, NEUROLOGY, V33, P1179, DOI 10.1212/WNL.33.9.1179
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   SERVIDEI S, 1991, NEUROLOGY, V41, P1053, DOI 10.1212/WNL.41.7.1053
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Vu TH, 2000, MUSCLE NERVE, V23, P80, DOI 10.1002/(SICI)1097-4598(200001)23:1<80::AID-MUS10>3.0.CO;2-V
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 39
TC 64
Z9 68
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1434-5161
EI 1435-232X
J9 J HUM GENET
JI J. Hum. Genet.
PD JUL 15
PY 2008
VL 53
IS 7
BP 598
EP 606
DI 10.1007/s10038-008-0289-8
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA 320BH
UT WOS:000257208200003
PM 18414780
DA 2024-11-01
ER

PT J
AU Bergamin, CS
   Rolim, LC
   Dib, SA
   Moisés, RS
AF Bergamin, Carla S.
   Rolim, Lua Clemente
   Dib, Sergio A.
   Moises, Regina S.
TI Unusual Occurrence of Intestinal Pseudo Obstruction in a Patient with Maternally Inherited Diabetes and Deafness (MIDD) and Favorable Outcome with Coenzyme Q10
SO ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA
LA English
DT Article
DE Pseudo intestinal obstruction; MIDD; Coenzyme Q10
ID stroke-like episodes; mitochondrial-dna; lactic-acidosis; trna(leu(uur)) mutation; clinical phenotypes; renal complications; mellitus; gene; prevalence; encephalomyopathy
AB Maternally inherited diabetes and deafness (MIDD) has been related to an A to G transition in the mitochondrial tRNA Leu (UUR) gene at the base pair 3243. This subtype of diabetes is characterized by maternal transmission, young age at onset and bilateral hearing impairment. Besides diabetes and deafness, the main diagnostic features, a wide range of multisystemic symptoms may be associated with the A3243G mutation. Organs that are most metabolically active, such as muscles, myocardium, retina, cochlea, kidney and brain are frequently affected. Gastrointestinal tract symptoms are also common in patients with mitochondrial disease and constipation and diarrhea are the most frequent manifestations. However, there are few prior reports of intestinal pseudo obstruction in MIDD patients. Here we report the case of a patient with MIDD associated with the mtDNA A3243G mutation who developed chronic intestinal pseudo obstruction, and the introduction of Coenzyme Q10 as adjunctive therapy led to a solution of the pseudo obstruction. (Arq Bras Endocrinol Metab 2008; 52/8:1345-1349)
C1 [Bergamin, Carla S.; Rolim, Lua Clemente; Dib, Sergio A.; Moises, Regina S.] Univ Fed Sao Paulo, EPM, Escola Paulista Med, Disciplina Endocrinol, BR-04034970 Sao Paulo, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP)
RP Moisés, RS (corresponding author), Univ Fed Sao Paulo, EPM, Escola Paulista Med, Disciplina Endocrinol, Rua Botucatu,740-2o Andar, BR-04034970 Sao Paulo, Brazil.
EM rmoises@unifesp.br
CR Antonucci A, 2008, WORLD J GASTROENTERO, V14, P2953, DOI 10.3748/wjg.14.2953
   Aoki Y, 2002, ANN INTERN MED, V137, P703, DOI 10.7326/0003-4819-137-8-200210150-00031
   Campos Y, 2000, NEUROMUSCULAR DISORD, V10, P56, DOI 10.1016/S0960-8966(99)00072-3
   Chinnery PF, 2001, GUT, V48, P121, DOI 10.1136/gut.48.1.121
   Crispim D, 2002, CLIN ENDOCRINOL, V57, P141, DOI 10.1046/j.1365-2265.2002.01569_1.x
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   García-Velasco A, 2003, J INTERN MED, V253, P381, DOI 10.1046/j.1365-2796.2003.01095.x
   Guillausseau PJ, 2001, ANN INTERN MED, V134, P721, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00008
   HESS J, 1995, LANCET, V346, P189, DOI 10.1016/S0140-6736(95)91251-7
   Hiel JAP, 1998, NETH J MED, V53, P27, DOI 10.1016/S0300-2977(98)00018-7
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Holmes-Walker DJ, 1998, DIABETIC MED, V15, P946, DOI 10.1002/(SICI)1096-9136(1998110)15:11<946::AID-DIA707>3.0.CO;2-L
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   KATAGIRI H, 1994, DIABETOLOGIA, V37, P504, DOI 10.1007/s001250050139
   KISHIMOTO M, 1995, LANCET, V345, P452, DOI 10.1016/S0140-6736(95)90433-6
   Maassen JA, 2004, DIABETES, V53, PS103, DOI 10.2337/diabetes.53.2007.S103
   Massin P, 2008, DIABETOLOGIA, V51, P1664, DOI 10.1007/s00125-008-1073-1
   Nakamura S, 1999, DIABETES RES CLIN PR, V44, P183, DOI 10.1016/S0168-8227(99)00051-0
   Narbonne H, 2004, DIABETES METAB, V30, P61, DOI 10.1016/S1262-3636(07)70090-3
   Ohkubo K, 2001, CLIN CHEM, V47, P1641
   Oka Y, 1996, DIABETIC MED, V13, P0
   REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3
   Saker PJ, 1997, DIABETIC MED, V14, P42, DOI 10.1002/(SICI)1096-9136(199701)14:1<42::AID-DIA295>3.0.CO;2-T
   Salles JE, 2006, DIABETES RES CLIN PR, V72, P100, DOI 10.1016/j.diabres.2005.09.005
   Salles JE, 2007, PANCREAS, V34, P133, DOI 10.1097/01.mpa.0000246659.38375.4d
   Salles JEN, 2007, ARQ BRAS ENDOCRINOL, V51, P559, DOI 10.1590/S0004-27302007000400009
   Shimotake T, 1998, J PEDIATR SURG, V33, P1837, DOI 10.1016/S0022-3468(98)90301-3
   Suzuki S, 1998, DIABETOLOGIA, V41, P584, DOI 10.1007/s001250050950
   SUZUKI Y, 1995, ENDOCR J, V42, P141, DOI 10.1507/endocrj.42.141
   Suzuki Y, 1997, MOL ASPECTS MED, V18, P0
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Velho G, 1996, DIABETES, V45, P478, DOI 10.2337/diabetes.45.4.478
   YAMAMOTO M, 1987, J NEUROL NEUROSUR PS, V50, P1475, DOI 10.1136/jnnp.50.11.1475
NR 33
TC 11
Z9 14
U1 1
U2 5
PU SBEM-SOC BRASIL ENDOCRINOLOGIA & METABOLOGIA
PI RIO DE JANEIRO, RJ
PA RUA HUMAITA, 85 CJ 501, RIO DE JANEIRO, RJ, 22261-000, BRAZIL
SN 0004-2730
EI 1677-9487
J9 ARQ BRAS ENDOCRINOL
JI Arq. Bras. Endocrinol. Metabol.
PD NOV 15
PY 2008
VL 52
IS 8
BP 1345
EP 1349
DI 10.1590/S0004-27302008000800023
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 392PB
UT WOS:000262313500023
PM 19169492
DA 2024-11-01
ER

PT J
AU Hakonen, AH
   Goffart, S
   Marjavaara, S
   Paetau, A
   Cooper, H
   Mattila, K
   Lampinen, M
   Sajantila, A
   Lönnqvist, T
   Spelbrink, JN
   Suomalainen, A
AF Hakonen, Anna H.
   Goffart, Steffi
   Marjavaara, Sanna
   Paetau, Anders
   Cooper, Helen
   Mattila, Kimmo
   Lampinen, Milla
   Sajantila, Antti
   Lonnqvist, Tuula
   Spelbrink, Johannes N.
   Suomalainen, Anu
TI Infantile-onset spinocerebellar ataxia and mitochondrial recessive ataxia syndrome are associated with neuronal complex I defect and mtDNA depletion
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID progressive external ophthalmoplegia; dna copy number; multiple deletions; polg mutations; oxidative-phosphorylation; sensory neuropathy; twinkle helicase; alpers-syndrome; polymerase; region
AB Infantile-onset spinocerebellar ataxia (IOSCA) is a severe neurodegenerative disorder caused by the recessive mutation in PEO1, leading to an Y508C change in the mitochondrial helicase Twinkle, in its helicase domain. However, no mitochondrial dysfunction has been found in this disease. We studied here the consequences of IOSCA for the central nervous system, as well as the in vitro performance of the IOSCA mutant protein. The results of the mtDNA analyses were compared to findings in a similar juvenile or adult-onset ataxia syndrome, mitochondrial recessive ataxia syndrome (MIRAS), caused by the W748S mutation in the mitochondrial DNA polymerase (POLG). We show here that IOSCA brain does not harbor mtDNA deletions or increased amount of mtDNA point mutations, whereas MIRAS brain shows multiple deletions of mtDNA. However, IOSCA, and to a lesser extent also MIRAS, show mtDNA depletion in the brain and the liver. In both diseases, especially large neurons show respiratory chain complex I (CI) deficiency, but also CIV is decreased in IOSCA. Helicase activity, hexamerization and nucleoid structure of the IOSCA mutant were, however, unaffected. The lack of in vitro helicase defect or cell culture phenotype suggest that Twinkle-Y508C dysfunction affects mtDNA maintenance in a highly context and cell-type specific manner. Our results indicate that IOSCA is a new member of the mitochondrial DNA depletion syndromes.
C1 [Suomalainen, Anu] Univ Helsinki, Biomedicum, Res Program Mol Neurol, FIN-00290 Helsinki, Finland.
   [Paetau, Anders] Univ Helsinki, Dept Pathol, FIN-00290 Helsinki, Finland.
   [Sajantila, Antti] Univ Helsinki, Dept Forens Med, FIN-00290 Helsinki, Finland.
   [Goffart, Steffi; Cooper, Helen; Spelbrink, Johannes N.] Tampere Univ Hosp, Inst Med Technol, Tampere, Finland.
   [Mattila, Kimmo] Ctr Comp Sci, Espoo, Finland.
   [Lonnqvist, Tuula] Hosp Children & Adolescents, Dept Child Neurol, Helsinki, Finland.
   [Suomalainen, Anu] Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki, Finland.
C3 University of Helsinki; University of Helsinki; University of Helsinki; Tampere University; Tampere University Hospital; University of Helsinki; Helsinki University Central Hospital
RP Suomalainen, A (corresponding author), Univ Helsinki, Biomedicum, Res Program Mol Neurol, Rc523B,POB 63, FIN-00290 Helsinki, Finland.
EM anu.wartiovaara@helsinki.fi
FU University of Helsinki; Academy of Finland; Sigrid Juselius Foundation; Finnish Foundation for Pediatric Research; EU; Tampere University Hospital Medical Research Fund [9G072, 9H079]; Biomedicum Helsinki foundationc
CR Antonicka H, 2006, HUM MOL GENET, V15, P1835, DOI 10.1093/hmg/ddl106
   BARKER PD, 1993, P NATL ACAD SCI USA, V90, P6542, DOI 10.1073/pnas.90.14.6542
   Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   Bogenhagen DF, 2008, J BIOL CHEM, V283, P3665, DOI 10.1074/jbc.M708444200
   Braun M, 2005, APPL MICROBIOL BIOT, V67, P234, DOI 10.1007/s00253-004-1804-2
   BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Durham SE, 2005, NEUROLOGY, V65, P453, DOI 10.1212/01.wnl.0000171861.30277.88
   Farge G, 2008, NUCLEIC ACIDS RES, V36, P393, DOI 10.1093/nar/gkm1025
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Friedman KL, 1995, METHOD ENZYMOL, V262, P613
   Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Korhonen JA, 2008, J MOL BIOL, V377, P691, DOI 10.1016/j.jmb.2008.01.035
   KOSKINEN T, 1994, J NEUROL SCI, V121, P50, DOI 10.1016/0022-510X(94)90156-2
   Kruse SE, 2008, CELL METAB, V7, P312, DOI 10.1016/j.cmet.2008.02.004
   Kulkarni A, 2008, AM J HUM GENET, V82, P539, DOI 10.1016/j.ajhg.2008.01.009
   Lin YW, 2005, CHEMBIOCHEM, V6, P1356, DOI 10.1002/cbic.200500030
   Lönnqvist T, 1998, J NEUROL SCI, V161, P57, DOI 10.1016/S0022-510X(98)00249-4
   Lonnqvist T, 2000, HDB ATAXIA DISORDERS, V0, P293
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Lyly A, 2008, HUM MOL GENET, V17, P1406, DOI 10.1093/hmg/ddn028
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   VARGAS C, 1993, ANAL BIOCHEM, V209, P323, DOI 10.1006/abio.1993.1127
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   Wanrooij S, 2007, NUCLEIC ACIDS RES, V35, P3238, DOI 10.1093/nar/gkm215
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Yasukawa T, 2005, MOL CELL, V18, P651, DOI 10.1016/j.molcel.2005.05.002
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 46
TC 95
Z9 102
U1 1
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD DEC 1
PY 2008
VL 17
IS 23
BP 3822
EP 3835
DI 10.1093/hmg/ddn280
PG 14
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 373OG
UT WOS:000260980800020
PM 18775955
DA 2024-11-01
ER

PT J
AU Rossmanith, W
   Freilinger, M
   Roka, J
   Raffelsberger, T
   Moser-Thier, K
   Prayer, D
   Bernert, G
   Bittner, RE
AF Rossmanith, W.
   Freilinger, M.
   Roka, J.
   Raffelsberger, T.
   Moser-Thier, K.
   Prayer, D.
   Bernert, G.
   Bittner, R. E.
TI Isolated cytochrome c oxidase deficiency as a cause of MELAS
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID mitochondrial myopathy; lactic-acidosis; episodes melas; encephalopathy; diagnosis; gene
AB Background: MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) is one of the more common mitochondrial encephalomyopathies. About 80% of MELAS cases are caused by transition 3243A -> G in the mitochondrial tRNA(Leu(UUR)) gene (MT-TL1). Other mutations in MT-TL1, other mitochondrial tRNA genes and mitochondrial-encoded subunits of respiratory complex I account for the remainder of cases. Objective: To characterise the molecular basis of a MELAS case without a mutation in any recognised MELAS target gene. Results and methods: Deletion of a single nucleotide (7630delT) within MT-CO2, the gene of subunit II of cytochrome c oxidase (COX), was identified by mitochondrial DNA (mtDNA) sequencing. The deletion-induced frameshift results in a stop codon close to the 59 end of the reading frame. The lack of subunit II (COII) precludes the assembly of COX and leads to the degradation of unassembled subunits, even those not directly affected by the mutation. Despite mitochondrial proliferation and transcriptional upregulation of nuclear and mtDNA-encoded COX genes (including MT-CO2), a severe COX deficiency was found with all investigations of the muscle biopsy (histochemistry, biochemistry, immunoblotting). Conclusions: The 7630delT mutation in MT-CO2 leads to a lack of COII with subsequent misassembly and degradation of respiratory complex IV despite transcriptional upregulation of its subunits. The causal association of the resulting isolated COX deficiency with MELAS is at odds with current concepts of the biochemical deficits underlying this common mitochondrial disease, and indicates that the genetic and pathobiochemical heterogeneity of MELAS is greater than previously appreciated.
C1 [Rossmanith, W.; Roka, J.; Raffelsberger, T.; Moser-Thier, K.; Bittner, R. E.] Med Univ Vienna, Ctr Anat & Cell Biol, A-1090 Vienna, Austria.
   [Freilinger, M.; Bernert, G.] Med Univ Vienna, Dept Pediat, Vienna, Austria.
   [Prayer, D.] Med Univ Vienna, Dept Radiol, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna; Medical University of Vienna
RP Rossmanith, W (corresponding author), Med Univ Vienna, Ctr Anat & Cell Biol, Wahringer Str 13, A-1090 Vienna, Austria.
EM walter.rossmanith@meduniwien.ac.at
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Barisic N, 2002, NEUROPEDIATRICS, V33, P157, DOI 10.1055/s-2002-33679
   Conti E, 2005, CURR OPIN CELL BIOL, V17, P316, DOI 10.1016/j.ceb.2005.04.005
   GOTO Y, 1995, MUSCLE NERVE S, V3, P107
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   Jacobs HT, 2003, HUM MOL GENET, V12, PR293, DOI 10.1093/hmg/ddg285
   Khalimonchuk E, 2005, MITOCHONDRION, V5, P363, DOI 10.1016/j.mito.2005.08.002
   Kirby DM, 2004, J MED GENET, V41, P784, DOI 10.1136/jmg.2004.020537
   KOEHLER CM, 2003, GENETICS MITOCHONDRI, V0, P47
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   McFarland R, 2007, CURR TOP DEV BIOL, V77, P113, DOI 10.1016/S0070-2153(06)77005-3
   Naini A, 2005, J NEUROL SCI, V229, P187, DOI 10.1016/j.jns.2004.11.026
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, P0, DOI 10.1093/nar/29.9.e45
   Rahman S, 1999, AM J HUM GENET, V65, P1030, DOI 10.1086/302590
   Rossmanith W, 2003, ANN NEUROL, V54, P820, DOI 10.1002/ana.10753
   Sambrook J, 1990, COLD SPRING HARBOR LABORATORIES, V186, P182
   Scaglia F, 2006, CNS DRUGS, V20, P443, DOI 10.2165/00023210-200620060-00002
   Shoubridge EA, 2001, AM J MED GENET, V106, P46, DOI 10.1002/ajmg.1378
   Taanman JW, 2001, BIOCHEM SOC T, V29, P446, DOI 10.1042/BST0290446
   Taanman JW, 2003, GENETICS MITOCHONDRI, V1, P27
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Thambisetty M, 2004, EXPERT REV MOL DIAGN, V4, P631, DOI 10.1586/14737159.4.5.631
   Vandesompele J, 2002, ANAL BIOCHEM, V303, P95, DOI 10.1006/abio.2001.5564
   Yoneda M, 1996, METHODS ENZYMOL, V264, P432, DOI 10.1016/S0076-6879(96)64039-7
NR 28
TC 23
Z9 27
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD FEB 15
PY 2008
VL 45
IS 2
BP 117
EP 121
DI 10.1136/jmg.2007.052076
PG 5
WC Genetics & Heredity
SC Genetics & Heredity
GA 258MF
UT WOS:000252871300009
PM 18245391
DA 2024-11-01
ER

PT J
AU Markaryan, A
   Nelson, EG
   Hinojosa, R
AF Markaryan, Adam
   Nelson, Erik G.
   Hinojosa, Raul
TI Detection of mitochondrial DNA deletions in the cochlea and its structural elements from archival human temporal bone tissue
SO MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
LA English
DT Article
DE MtDNA deletions; nested PCR; cochlea
ID polymerase-chain-reaction; common deletion; human brain; mutations; rearrangements; presbycusis; pathology; patterns; increase; pcr
AB Large-scale deletions of mitochondrial DNA (mtDNA) have been associated with aging and disease in post-mitotic tissues. These post-mitotic tissues, including skeletal muscle, heart and brain, are heavily dependent on intact functional mitochondria. The cochlear tissues are known to contain an abundance of mitochondria. This observation stimulated a search for mtDNA deletions in the cochlea and its elements using a sensitive nested PCR methodology and long range PCR to explain the functional deficits observed in age-related hearing loss. The presence of the so-called "common" deletion (CD) was detected in cochlear tissue from two individuals with age-related hearing loss, 73 and 78 years of age. Three additional deletions, that to our knowledge have not been previously reported, were also identified in these two individuals, including a 5354 bp deletion flanked with a 3 bp repeat, a 9682 bp deletion flanked by a 10 bp repeat and a 5142 bp deletion without a flanking repeat. The 9682 and 5142 bp deletions were also detected in an individual 39 years of age with normal hearing, however, these two deletions were not detected in a normal hearing individual 9 years of age. In contrast, the 5354 bp deletion was detected in all four of the individuals studied. To localize the deletions within the cochlea, the cochlear elements were removed by laser capture microdissection (LCM) and the mtDNA from these tissues was studied. The 5142 and 5354 bp deletions were detected in the organ of corti, spiral ligament, and ganglion cells, but not in the stria vascularis. These findings correlate with the reduction in the number of spiral ganglion cells and outer hair cells, and the normal stria vascularis volume observed in this individual. All four of these deletions involve the cytochrome c oxidase (COX) subunit III gene, encoded by mtDNA. These observations suggest that multiple mtDNA deletions may contribute to a deficit in mitochondrial function in the cochlea and result in hearing loss if a level of physiological significance is reached. (C) 2007 Elsevier B.V. All rights reserved.
C1 [Markaryan, Adam; Nelson, Erik G.; Hinojosa, Raul] Univ Chicago, Dept Surg, Sect Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA.
C3 University of Chicago
RP Markaryan, A (corresponding author), Univ Chicago, Dept Surg, Sect Otolaryngol Head & Neck Surg, 5841 S Maryland Ave,MC 1035, Chicago, IL 60637 USA.
EM amarkary@surgery.bsd.uchicago.edu
CR Bai U, 1997, AM J OTOL, V18, P449
   Bai UM, 2001, HEARING RES, V154, P73, DOI 10.1016/S0378-5955(01)00221-0
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Chomyn A, 2003, BIOCHEM BIOPH RES CO, V304, P519, DOI 10.1016/S0006-291X(03)00625-9
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927
   Dai P, 2004, ACTA OTO-LARYNGOL, V124, P130, DOI 10.1080/00016480410016586
   FRIEDMANN I, 1984, ULTRASTRUCTURAL ATAL, V0, P99
   Gates GA, 2005, LANCET, V366, P1111, DOI 10.1016/S0140-6736(05)67423-5
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   IURATO S, 1967, SUBMICROSCOPIC STRUC, V0, P59
   Kimura Y, 2005, ACTA OTO-LARYNGOL, V125, P697, DOI 10.1080/00016480510027510
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Liu VWS, 1998, NUCLEIC ACIDS RES, V26, P1268, DOI 10.1093/nar/26.5.1268
   MARTON A, 1991, NUCLEIC ACIDS RES, V19, P2423, DOI 10.1093/nar/19.9.2423
   Meissner C, 2006, EXP GERONTOL, V41, P518, DOI 10.1016/j.exger.2006.03.010
   MELOV S, 1995, NUCLEIC ACIDS RES, V23, P4122, DOI 10.1093/nar/23.20.4122
   Melov S, 1999, NEUROBIOL AGING, V20, P565, DOI 10.1016/S0197-4580(99)00092-5
   Nelson EG, 2006, LARYNGOSCOPE, V116, P1, DOI 10.1097/01.mlg.0000236089.44566.62
   PAABO S, 1990, J BIOL CHEM, V265, P4718
   Pogozelski WK, 2003, MITOCHONDRION, V2, P415, DOI 10.1016/S1567-7249(03)00033-3
   Samuels DC, 2004, TRENDS GENET, V20, P393, DOI 10.1016/j.tig.2004.07.003
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   Seidman MD, 2004, ACTA OTO-LARYNGOL, V124, P16, DOI 10.1080/03655230410017823
   Seidman MD, 1996, LARYNGOSCOPE, V106, P777, DOI 10.1097/00005537-199606000-00021
   SIMPSON TA, 1995, LARYNGOSCOPE, V105, P28, DOI 10.1288/00005537-199501000-00009
   SOONG NW, 1992, NAT GENET, V2, P318
   Srivastava S, 2005, HUM MOL GENET, V14, P893, DOI 10.1093/hmg/ddi082
   Thayer RE, 2003, EXP GERONTOL, V38, P567, DOI 10.1016/S0531-5565(03)00033-0
   Wackym PA, 1998, LARYNGOSCOPE, V108, P4, DOI 10.1097/00005537-199808001-00002
   ZHANG C, 1992, FEBS LETT, V297, P34, DOI 10.1016/0014-5793(92)80321-7
NR 33
TC 32
Z9 39
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-1964
EI 1873-135X
J9 MUTAT RES-FUND MOL M
JI Mutat. Res.-Fundam. Mol. Mech. Mutagen.
PD APR 2
PY 2008
VL 640
IS 1-2
BP 38
EP 45
DI 10.1016/j.mrfmmm.2007.12.007
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
GA 289UZ
UT WOS:000255080700005
PM 18242646
DA 2024-11-01
ER

PT J
AU Dufour, E
   Terzioglu, M
   Sterky, FH
   Sörensen, L
   Galter, D
   Olson, L
   Wilbertz, J
   Larsson, NG
AF Dufour, Eric
   Terzioglu, Muegen
   Sterky, Fredrik Hansson
   Sorensen, Lene
   Galter, Dagmar
   Olson, Lars
   Wilbertz, Johannes
   Larsson, Nils-Goeran
TI Age-associated mosaic respiratory chain deficiency causes <i>trans</i>-neuronal degeneration
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID mitochondrial-dna deletions; oxidative-phosphorylation; transcription factor; skeletal-muscle; point mutations; nervous-system; fluoro-jade; human brain; stem-cells; mice
AB Heteroplasmic mitochondrial DNA (mtDNA) mutations (mutations present only in a subset of cellular mtDNA copies) arise de novo during the normal ageing process or may be maternally inherited in pedigrees with mitochondrial disease syndromes. A pathogenic mtDNA mutation causes respiratory chain deficiency only if the fraction of mutated mtDNA exceeds a certain threshold level. These mutations often undergo apparently random mitotic segregation and the levels of normal and mutated mtDNA can vary considerably between cells of the same tissue. In human ageing, segregation of somatic mtDNA mutations leads to mosaic respiratory chain deficiency in a variety of tissues, such as brain, heart and skeletal muscle. A similar pattern of mutation segregation with mosaic respiratory chain deficiency is seen in patients with mitochondrial disease syndromes caused by inherited pathogenic mtDNA mutations. We have experimentally addressed the role of mosaic respiratory chain deficiency in ageing and mitochondrial disease by creating mouse chimeras with a mixture of normal and respiratory chain-deficient neurons in cerebral cortex. We report here that a low proportion (> 20%) of respiratory chain-deficient neurons in the forebrain are sufficient to cause symptoms, whereas premature death of the animal occurs only if the proportion is high (> 60-80%). The presence of neurons with normal respiratory chain function does not only prevent mortality but also delays the age at which onset of disease symptoms occur. Unexpectedly, respiratory chain-deficient neurons have adverse effect on normal adjacent neurons and induce trans-neuronal degeneration. In summary, our study defines the minimal threshold level of respiratory chain-deficient neurons needed to cause symptoms and also demonstrate that neurons with normal respiratory chain function ameliorate disease progression. Finally, we show that respiratory chain-deficient neurons induce death of normal neurons by a trans-neuronal degeneration mechanism. These findings provide novel insights into the pathogenesis of mosaic respiratory chain deficiency in ageing and mitochondrial disease.
C1 [Larsson, Nils-Goeran] Karolinska Inst, Dept Lab Med, Div Metab Dis, S-14186 Stockholm, Sweden.
   [Galter, Dagmar; Olson, Lars] Karolinska Inst, Dept Neurosci, S-14186 Stockholm, Sweden.
   [Wilbertz, Johannes] Karolinska Inst, Dept Cell & Mol Biol, S-14186 Stockholm, Sweden.
C3 Karolinska Institutet; Karolinska Institutet; Karolinska Institutet
RP Larsson, NG (corresponding author), Karolinska Inst, Dept Lab Med, Div Metab Dis, S-14186 Stockholm, Sweden.
EM nils-goran.larsson@ki.se
CR AGNATI LF, 1995, PROG NEUROBIOL, V46, P561, DOI 10.1016/0301-0082(95)00017-P
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Bredesen DE, 2006, NATURE, V443, P796, DOI 10.1038/nature05293
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   Cottrell D A, 2000, CURR OPIN CLIN NUTR METAB CARE, V3, P473, DOI 10.1097/00075197-200011000-00009
   Cottrell DA, 2002, NEUROPATH APPL NEURO, V28, P390, DOI 10.1046/j.1365-2990.2002.00414.x
   Cottrell DA, 2001, NEUROBIOL AGING, V22, P265, DOI 10.1016/S0197-4580(00)00234-7
   Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109
   Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513
   Khaidakov M, 2003, MUTAT RES-FUND MOL M, V526, P1, DOI 10.1016/S0027-5107(03)00010-1
   Kirkwood TBL, 2005, CELL, V120, P437, DOI 10.1016/j.cell.2005.01.027
   Krishnan KJ, 2007, NUCLEIC ACIDS RES, V35, P7399, DOI 10.1093/nar/gkm635
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055
   Low-Zeddies SS, 2001, CELL, V105, P25, DOI 10.1016/S0092-8674(01)00294-X
   MUELLER-HOECKER J, 1989, AMERICAN JOURNAL OF PATHOLOGY, V134, P1167
   MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9
   PIKO L, 1988, MECH AGEING DEV, V43, P279, DOI 10.1016/0047-6374(88)90037-1
   SATO W, 1989, BIOCHEM BIOPH RES CO, V162, P664, DOI 10.1016/0006-291X(89)92362-0
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X
   Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0
   SCHWARZE SR, 1995, MECH AGEING DEV, V83, P91, DOI 10.1016/0047-6374(95)01611-3
   Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   SOONG NW, 1992, NAT GENET, V2, P318
   Sörensen L, 2001, J NEUROSCI, V21, P8082, DOI 10.1523/JNEUROSCI.21-20-08082.2001
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Trifunovic A, 2008, J INTERN MED, V263, P167, DOI 10.1111/j.1365-2796.2007.01905.x
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0
   Wallace D C, 2001, NOVARTIS FOUND SYMP, V235, P247
   Wang JM, 2001, P NATL ACAD SCI USA, V98, P4038, DOI 10.1073/pnas.061038798
   Wredenberg A, 2002, P NATL ACAD SCI USA, V99, P15066, DOI 10.1073/pnas.232591499
   YEN TC, 1989, BIOCHEM BIOPH RES CO, V165, P994, DOI 10.1016/0006-291X(89)92701-0
   Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789
NR 38
TC 31
Z9 36
U1 0
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAY 15
PY 2008
VL 17
IS 10
BP 1418
EP 1426
DI 10.1093/hmg/ddn030
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 296DJ
UT WOS:000255523400007
PM 18245781
DA 2024-11-01
ER

PT J
AU Bayrakci, US
   Baskin, E
   Ozcay, F
   Ozdemir, BH
   Karakayali, H
   Haberal, M
AF Bayrakci, Umut Selda
   Baskin, Esra
   Ozcay, Figen
   Ozdemir, Binnaz Handan
   Karakayali, Hamdi
   Haberal, Mehmet
TI Renal Fanconi syndrome and myopathy after liver transplantation: Drug-related mitochondrial cytopathy?
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE renal Fanconi syndrome; mitochondrial cytopathy; liver transplantation; tacrolimus; lamivudine; children
ID reverse-transcriptase inhibitors; tubular-acidosis secondary; wilsons-disease; dna; nephrotoxicity; nephropathy; tacrolimus; depletion; therapy; failure
AB Advances in the field of transplantation provide a better quality of life and allow more favorable conditions for growth and development in children. However, combinations of different therapeutic regimens require consideration of potential adverse reactions. We describe a 15-yr-old girl who had orthotopic liver transplantation because of Wilson's disease. Tacrolimus, MMF, and steroids were given as immunosuppressant. Lamivudine was added because of de nova hepatitis B infection during her follow-up. Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria. Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse. Proximal muscle weakness has developed during her follow-up. Fanconi syndrome, as well as myopathy, is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA. We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.
C1 [Bayrakci, Umut Selda; Baskin, Esra] Baskent Univ, Tip Fak, Dept Pediat Nephrol, Pediat Nephrol Unitesi 6, TR-06490 Ankara, Turkey.
   [Ozcay, Figen] Baskent Univ, Dept Pediat Gastroenterol, TR-06490 Ankara, Turkey.
   [Ozcay, Figen] Baskent Univ, Dept Pathol, TR-06490 Ankara, Turkey.
   [Karakayali, Hamdi; Haberal, Mehmet] Baskent Univ, Dept Gen Surg, TR-06490 Ankara, Turkey.
C3 Baskent University; Baskent University; Baskent University; Baskent University
RP Bayrakci, US (corresponding author), Baskent Univ, Tip Fak, Dept Pediat Nephrol, Pediat Nephrol Unitesi 6, Cad 72-3, TR-06490 Ankara, Turkey.
EM ukavak@yahoo.com
CR Allen KJ, 2004, J GASTROEN HEPATOL, V19, P1283, DOI 10.1111/j.1440-1746.2004.03451.x
   ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5
   BELLARY S, 1995, J HEPATOL, V23, P373, DOI 10.1016/0168-8278(95)80194-4
   Bennett WM, 1996, KIDNEY INT, V50, P1089, DOI 10.1038/ki.1996.415
   Bhandari S, 2002, NEPHROL DIAL TRANSPL, V17, P1914, DOI 10.1093/ndt/17.11.1914
   Brinkman K, 1998, AIDS, V12, P1735, DOI 10.1097/00002030-199814000-00004
   Chariot Patrick, 1995, CURRENT OPINION IN RHEUMATOLOGY, V7, P497, DOI 10.1097/00002281-199511000-00006
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   Daugas E, 2005, KIDNEY INT, V67, P393, DOI 10.1111/j.1523-1755.2005.67096.x
   de Mattos AM, 2000, AM J KIDNEY DIS, V35, P333, DOI 10.1016/S0272-6386(00)70348-9
   Haydon GRH, 2003, CURR OPIN INFECT DIS, V16, P473, DOI 10.1097/00001432-200310000-00015
   Johns DR, 1996, NAT MED, V2, P1065, DOI 10.1038/nm1096-1065
   Kitaura K, 1999, JPN J CANCER RES, V90, P385, DOI 10.1111/j.1349-7006.1999.tb00759.x
   Morris AAM, 2001, AIDS, V15, P140, DOI 10.1097/00002030-200101050-00027
   Murphy MD, 2003, CLIN INFECT DIS, V36, P1082, DOI 10.1086/368313
   OGORMAN MA, 1995, CLIN TRANSPLANT, V9, P312
   Oishi M, 2000, TRANSPLANT P, V32, P2225, DOI 10.1016/S0041-1345(00)01645-6
   Olyaei A J, 2001, CURR OPIN CRIT CARE, V7, P384, DOI 10.1097/00075198-200112000-00003
   Rollins S, 2001, AM J CLIN PATHOL, V116, P326
   Schapira AHV, 2002, J INHERIT METAB DIS, V25, P207, DOI 10.1023/A:1015629912477
   Schwarz C, 2006, NEPHROL DIAL TRANSPL, V21, P2615, DOI 10.1093/ndt/gfl211
   Simon N, 2003, BRIT J PHARMACOL, V138, P369, DOI 10.1038/sj.bjp.0705038
   Tanji N, 2001, HUM PATHOL, V32, P734, DOI 10.1053/hupa.2001.25586
   UZMANN LL, 1948, AM J MED SCI, V260, P381
   WOLFF SM, 1964, LANCET, V1, P843
NR 25
TC 15
Z9 20
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB 15
PY 2008
VL 12
IS 1
BP 109
EP 112
DI 10.1111/j.1399-3046.2007.00839.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 247ZX
UT WOS:000252122200020
PM 18186898
DA 2024-11-01
ER

PT J
AU Jones, CN
   Jones, CI
   Graham, WD
   Agris, PF
   Spremulli, LL
AF Jones, Christie N.
   Jones, Christopher I.
   Graham, William D.
   Agris, Paul F.
   Spremulli, Linda L.
TI A Disease-causing Point Mutation in Human Mitochondrial tRNA<SUP>Met</SUP> Results in tRNA Misfolding Leading to Defects in Translational Initiation and Elongation
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID selective 2'-hydroxyl acylation; aminoacyl-transfer-rnas; higher-order structure; steady-state levels; factor tu; protein-synthesis; escherichia-coli; dna; trna(phe); shape
AB The mitochondrial tRNA genes are hot spots for mutations that lead to human disease. A single point mutation (T4409C) in the gene for human mitochondrial tRNAMet (hmtRNA(Met)) has been found to cause mitochondrial myopathy. This mutation results in the replacement of U8 in hmtRNA(Met) with a C8. The hmtRNAMet serves both in translational initiation and elongation in human mitochondria making this tRNA of particular interest in mitochondrial protein synthesis. Here we show that the single 8U -> C mutation leads to a failure of the tRNA to respond conformationally to Mg2+. This mutation results in a drastic disruption of the structure of the hmtRNAMet, which significantly reduces its aminoacylation. The small fraction of hmtRNAMet that can be aminoacylated is not formylated by the mitochondrial Met-tRNA transformylase preventing its function in initiation, and it is unable to form a stable ternary complex with elongation factor EF-Tu preventing any participation in chain elongation. We have used structural probing and molecular reconstitution experiments to examine the structures formed by the normal and mutated tRNAs. In the presence of Mg2+, the normal tRNA displays the structural features expected of a tRNA. However, even in the presence of Mg2+, the mutated tRNA does not form the cloverleaf structure typical of tRNAs. Thus, we believe that this mutation has disrupted a critical Mg2+-binding site on the tRNA required for formation of the biologically active structure. This work establishes a foundation for understanding the physiological consequences of the numerous mitochondrial tRNA mutations that result in disease in humans.
C1 [Jones, Christopher I.; Graham, William D.; Agris, Paul F.] N Carolina State Univ, Dept Struct & Mol Biol, Raleigh, NC 27695 USA.
   [Jones, Christie N.; Spremulli, Linda L.] Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA.
C3 North Carolina State University; University of North Carolina; University of North Carolina Chapel Hill
RP Agris, PF (corresponding author), N Carolina State Univ, Dept Struct & Mol Biol, Campus Box 7622, Raleigh, NC 27695 USA.
EM Paul_Agris@ncsu.edu; Linda_Spremulli@unc.edu
FU National Institutes of Health [GM32734, GM23037]; United Mitochondrial Disease Foundation; National Science Foundation [MCB 548602]
CR ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1
   Ashraf SS, 2000, CELL BIOCHEM BIOPHYS, V33, P241, DOI 10.1385/CBB:33:3:241
   ATTARDI G, 1985, INT REV CYTOL, V93, P93, DOI 10.1016/S0074-7696(08)61373-X
   Bacman SR, 2003, BIOCHEM J, V374, P131, DOI 10.1042/BJ20030222
   Badorrek CS, 2006, BIOCHEMISTRY-US, V45, P12664, DOI 10.1021/bi060521k
   BAEYENS KJ, 1995, NAT STRUCT BIOL, V2, P56, DOI 10.1038/nsb0195-56
   Bonnefond L, 2008, RNA, V14, P641, DOI 10.1261/rna.938108
   Bullard JM, 1999, BBA-GENE STRUCT EXPR, V1446, P102, DOI 10.1016/S0167-4781(99)00077-9
   Cai YC, 2000, J BIOL CHEM, V275, P20308, DOI 10.1074/jbc.M001899200
   CENATIEMPO Y, 1987, BIOCHEMISTRY-US, V26, P5070, DOI 10.1021/bi00390a028
   Das R, 2005, RNA, V11, P344, DOI 10.1261/rna.7214405
   Dirheimer G, 1995, P93, V0, P0
   ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47
   Florentz C, 2003, CELL MOL LIFE SCI, V60, P1356, DOI 10.1007/s00018-003-2343-1
   Hao HL, 1997, MOL CELL BIOL, V17, P6831, DOI 10.1128/MCB.17.12.6831
   Helm M, 1999, BIOCHEMISTRY-US, V38, P13338, DOI 10.1021/bi991061g
   Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047
   Hunter SE, 2004, MITOCHONDRION, V4, P21, DOI 10.1016/j.mito.2004.04.003
   Jones CI, 2006, J MOL BIOL, V362, P771, DOI 10.1016/j.jmb.2006.07.036
   Jovine L, 2000, J MOL BIOL, V301, P401, DOI 10.1006/jmbi.2000.3950
   Kelley SO, 2000, NAT STRUCT BIOL, V7, P862, DOI 10.1038/79612
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kirino Y, 2004, P NATL ACAD SCI USA, V101, P15070, DOI 10.1073/pnas.0405173101
   LaRiviere FJ, 2001, SCIENCE, V294, P165, DOI 10.1126/science.1064242
   Levinger L, 2001, NUCLEIC ACIDS RES, V29, P4334, DOI 10.1093/nar/29.21.4334
   Ling JQ, 2007, P NATL ACAD SCI USA, V104, P15299, DOI 10.1073/pnas.0704441104
   Lombes A, 1998, HUM MUTAT, V0, PS175
   LOUIE A, 1984, J BIOL CHEM, V259, P5010
   Merino EJ, 2005, J AM CHEM SOC, V127, P4223, DOI 10.1021/ja043822v
   Mortimer SA, 2007, J AM CHEM SOC, V129, P4144, DOI 10.1021/ja0704028
   Pavlov MY, 2008, EMBO J, V27, P1706, DOI 10.1038/emboj.2008.99
   Qu J, 2006, INVEST OPHTH VIS SCI, V47, P475, DOI 10.1167/iovs.05-0665
   SCHULMAN LH, 1988, SCIENCE, V242, P765, DOI 10.1126/science.3055296
   Schwartzbach C J, 1996, METHODS ENZYMOL, V264, P248, DOI 10.1016/S0076-6879(96)64025-7
   Sharma MR, 2003, CELL, V115, P97, DOI 10.1016/S0092-8674(03)00762-1
   Spencer AC, 2004, NUCLEIC ACIDS RES, V32, P5464, DOI 10.1093/nar/gkh886
   Spencer AC, 2004, BIOCHEMISTRY-US, V43, P9743, DOI 10.1021/bi049639w
   SPRINZL M, 1980, NUCLEIC ACIDS RES, V8, P4737, DOI 10.1093/nar/8.20.4737
   Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148
   STEIN A, 1976, BIOCHEMISTRY-US, V15, P160, DOI 10.1021/bi00646a025
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   Takeuchi N, 1998, J BIOL CHEM, V273, P15085, DOI 10.1074/jbc.273.24.15085
   Vissing J, 1998, NEUROLOGY, V50, P1875, DOI 10.1212/WNL.50.6.1875
   WAKITA K, 1994, NUCLEIC ACIDS RES, V22, P347, DOI 10.1093/nar/22.3.347
   WATANABE Y, 1994, NUCLEIC ACIDS RES, V22, P5378, DOI 10.1093/nar/22.24.5378
   Wilkinson KA, 2005, J AM CHEM SOC, V127, P4659, DOI 10.1021/ja0436749
   Wilkinson KA, 2006, NAT PROTOC, V1, P1610, DOI 10.1038/nprot.2006.249
   Wittenhagen LM, 2003, TRENDS BIOCHEM SCI, V28, P605, DOI 10.1016/j.tibs.2003.09.006
   Wittenhagen LM, 2003, NUCLEIC ACIDS RES, V31, P596, DOI 10.1093/nar/gkg131
   Yarian CS, 1999, NUCLEIC ACIDS RES, V27, P3543, DOI 10.1093/nar/27.17.3543
   Yokogawa T, 1991, NUCLEIC ACIDS RES, V19, P6101, DOI 10.1093/nar/19.22.6101
   Zifa E, 2007, RNA BIOL, V4, P38, DOI 10.4161/rna.4.1.4548
NR 53
TC 25
Z9 33
U1 1
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 5
PY 2008
VL 283
IS 49
BP 34445
EP 34456
DI 10.1074/jbc.M806992200
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 377UY
UT WOS:000261277700072
PM 18835817
DA 2024-11-01
ER

PT J
AU Matsushima, Y
   Farr, CL
   Fan, L
   Kaguni, LS
AF Matsushima, Yuichi
   Farr, Carol L.
   Fan, Li
   Kaguni, Laurie S.
TI Physiological and biochemical defects in carboxyl-terminal mutants of mitochondrial DNA helicase
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID progressive external ophthalmoplegia; replicative helicase; crystal-structure; multiple deletions; bacteriophage t7; gene-4 helicase; binding protein; copy number; twinkle; domain
AB Mitochondrial DNA helicase, also called Twinkle, is essential for mtDNA maintenance. Its helicase domain shares high homology with helicases from superfamily 4. Structural analyses of helicases from this family indicate that carboxyl-terminal residues contribute to NTP hydrolysis required for translocation and DNA unwinding, yet genetic and biochemical information is very limited. Here, we evaluate the effects of overexpression in Drosophila cell culture of variants carrying a series of deletion and alanine substitution mutations in the carboxyl terminus and identify critical residues between amino acids 572 and 596 of the 613 amino acid polypeptide that are essential for mitochondrial DNA helicase function in vivo. Likewise, amino acid substitution mutants K574A, R576A, Y577A, F588A, and F595A show dose-dependent dominant-negative phenotypes. Arg-576 and Phe-588 are analogous to the arginine finger and base stack of other helicases, including the bacteriophage T7 gene 4 protein and bacterial DnaB helicase, respectively. We show here that representative human recombinant proteins that are analogous to the alanine substitution mutants exhibit defects in nucleotide hydrolysis. Our findings may be applicable to understand the role of the carboxyl-terminal region in superfamily 4 DNA helicases in general.
C1 [Matsushima, Yuichi; Farr, Carol L.; Kaguni, Laurie S.] Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.
   [Fan, Li] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.
C3 Michigan State University; Scripps Research Institute
RP Kaguni, LS (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.
EM lskaguni@msu.edu
FU National Institutes of Health [GM45295, RO1 CA112093, PO1 CA92584]
CR Bailey S, 2007, SCIENCE, V318, P459, DOI 10.1126/science.1147353
   Bailey S, 2007, NUCLEIC ACIDS RES, V35, P4728, DOI 10.1093/nar/gkm507
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Crampton DJ, 2006, MOL CELL, V21, P165, DOI 10.1016/j.molcel.2005.11.027
   Crampton DJ, 2004, P NATL ACAD SCI USA, V101, P4373, DOI 10.1073/pnas.0400968101
   Donmez I, 2006, NUCLEIC ACIDS RES, V34, P4216, DOI 10.1093/nar/gkl508
   Farge G, 2008, NUCLEIC ACIDS RES, V36, P393, DOI 10.1093/nar/gkm1025
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hamdan SM, 2007, MOL CELL, V27, P539, DOI 10.1016/j.molcel.2007.06.020
   Hamdan SM, 2005, P NATL ACAD SCI USA, V102, P5096, DOI 10.1073/pnas.0501637102
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Kong DC, 1998, J BIOL CHEM, V273, P6556, DOI 10.1074/jbc.273.11.6556
   Korhonen JA, 2008, J MOL BIOL, V377, P691, DOI 10.1016/j.jmb.2008.01.035
   Lee SJ, 2006, J BIOL CHEM, V281, P25841, DOI 10.1074/jbc.M604602200
   Leipe DD, 2000, GENOME RES, V10, P5
   Matsushima Y, 2005, J BIOL CHEM, V280, P16815, DOI 10.1074/jbc.M500569200
   Matsushima Y, 2004, J BIOL CHEM, V279, P26900, DOI 10.1074/jbc.M401643200
   Matsushima Y, 2007, J BIOL CHEM, V282, P9436, DOI 10.1074/jbc.M610550200
   McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094
   Niedenzu T, 2001, J MOL BIOL, V306, P479, DOI 10.1006/jmbi.2000.4398
   Notarnicola SM, 1997, J BIOL CHEM, V272, P18425, DOI 10.1074/jbc.272.29.18425
   Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7
   Singleton MR, 2007, ANNU REV BIOCHEM, V76, P23, DOI 10.1146/annurev.biochem.76.052305.115300
   Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Wang G, 2008, NAT STRUCT MOL BIOL, V15, P94, DOI 10.1038/nsmb1356
   Wanrooij S, 2007, NUCLEIC ACIDS RES, V35, P3238, DOI 10.1093/nar/gkm215
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Ziebarth TD, 2007, J MOL BIOL, V367, P1382, DOI 10.1016/j.jmb.2007.01.079
   Ziegelin G, 2003, NUCLEIC ACIDS RES, V31, P5917, DOI 10.1093/nar/gkg790
NR 35
TC 19
Z9 21
U1 0
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 29
PY 2008
VL 283
IS 35
BP 23964
EP 23971
DI 10.1074/jbc.M803674200
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 340II
UT WOS:000258638900052
PM 18593709
DA 2024-11-01
ER

PT J
AU Scruggs, ER
   Naylor, AJD
AF Scruggs, Erin R.
   Naylor, Amie J. Dirks
TI Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy
SO PHARMACOLOGY
LA English
DT Review
DE azidothymidine; zidovudine; skeletal muscle; apoptosis; oxidative stress
ID skeletal-muscle; oxidative stress; dna depletion; l-carnitine; apoptosis; azt; cells; expression; inhibitor; susceptibility
AB Zidovudine (3-azido-3 '-deoxythymidine), also referred to as azidothymidine (AZT), has become an integral component in highly active antiretroviral therapy, and has also been used in the treatment of cancer. The clinical effectiveness of AZT is constrained due to its association with increased adverse effects, such as myopathy. There are numerous potential mechanisms that may contribute to AZT-induced myopathy. The first hypothesized mechanism to explain AZT-induced toxicity was mtDNA depletion due to inhibition of DNA polymerase gamma. Although mtDNA depletion is present in patients with myopathy, current data suggests that alternative mechanisms may play a more direct role in the myotoxicity. These mechanisms include AZT-induced oxidative stress, direct inhibition of mitochondrial bioenergetic machinery, and mitochondrial depletion of L-carnitine. Furthermore, we hypothesize that apoptosis may play a role in AZT-induced myopathy. Copyright (C) 2008 S. Karger AG, Basel.
C1 [Scruggs, Erin R.; Naylor, Amie J. Dirks] Wingate Univ, Sch Pharm, Wingate, NC 28174 USA.
C3 Wingate University
RP Naylor, AJD (corresponding author), Wingate Univ, Sch Pharm, 316 N Main St, Wingate, NC 28174 USA.
EM adirks@wingate.edu
CR Adams V, 1999, J AM COLL CARDIOL, V33, P959, DOI 10.1016/S0735-1097(98)00626-3
   Allen DL, 1997, AM J PHYSIOL-CELL PH, V273, PC579, DOI 10.1152/ajpcell.1997.273.2.C579
   Alway SE, 2003, J GERONTOL A-BIOL, V58, P687
   Alway SE, 2002, AM J PHYSIOL-CELL PH, V283, PC66, DOI 10.1152/ajpcell.00598.2001
   ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5
   Belizário JE, 2001, BRIT J CANCER, V84, P1135, DOI 10.1054/bjoc.2001.1700
   Cazzalini O, 2001, BIOCHEM PHARMACOL, V62, P893, DOI 10.1016/S0006-2952(01)00713-4
   Collier AC, 2003, TOXICOL APPL PHARM, V192, P164, DOI 10.1016/S0041-008X(03)00274-6
   Coté HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035
   DALAKAS MC, 1994, ANN NEUROL, V35, P482, DOI 10.1002/ana.410350418
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   de la Asunción JG, 1998, J CLIN INVEST, V102, P4, DOI 10.1172/JCI1418
   Dirks A, 2002, AM J PHYSIOL-REG I, V282, PR519, DOI 10.1152/ajpregu.00458.2001
   Dirks AJ, 2004, FREE RADICAL BIO MED, V36, P27, DOI 10.1016/j.freeradbiomed.2003.10.003
   Dirks AJ, 2006, AM J PHYSIOL-CELL PH, V291, PC1208, DOI 10.1152/ajpcell.00226.2006
   Falchetti A, 2005, J BONE MINER RES, V20, P410, DOI 10.1359/JBMR.041123
   Formichi P, 2003, JOURNAL OF SUBMICROSCOPIC CYTOLOGY AND PATHOLOGY, V35, P29
   Georges B, 2003, BIOCHEM PHARMACOL, V65, P1483, DOI 10.1016/S0006-2952(03)00110-2
   Ikezoe K, 2002, ACTA NEUROPATHOL, V103, P531, DOI 10.1007/s00401-001-0502-8
   Ji HJ, 2005, BREAST CANCER RES TR, V93, P227, DOI 10.1007/s10549-005-5156-0
   Kokoszka JE, 2001, P NATL ACAD SCI USA, V98, P2278, DOI 10.1073/pnas.051627098
   Lebrecht D, 2008, ARTHRITIS RHEUM-US, V58, P318, DOI 10.1002/art.23235
   Lee MC, 2005, J NUTR, V135, P1806S, DOI 10.1093/jn/135.7.1806S
   Lewis W, 2001, LAB INVEST, V81, P777, DOI 10.1038/labinvest.3780288
   LINNANE AW, 1995, BBA-MOL BASIS DIS, V1271, P191, DOI 10.1016/0925-4439(95)00027-2
   Liu CY, 2004, ANN NY ACAD SCI, V1011, P133, DOI 10.1196/annals.1293.014
   Lynx MD, 2006, BIOCHEM PHARMACOL, V72, P239, DOI 10.1016/j.bcp.2006.04.004
   MARTIN JL, 1994, ANTIMICROB AGENTS CH, V38, P2743, DOI 10.1128/AAC.38.12.2743
   Masanés F, 1998, J NEUROL SCI, V159, P226, DOI 10.1016/S0022-510X(98)00151-8
   Mirabella M, 2000, BRAIN, V123, P93, DOI 10.1093/brain/123.1.93
   MODICANAPOLITANO JS, 1993, BIOCHEM BIOPH RES CO, V194, P170, DOI 10.1006/bbrc.1993.1800
   Owczarek J, 2005, PHARMACOL REP, V57, P23
   Purevjav E, 2007, CARDIOVASC TOXICOL, V7, P255, DOI 10.1007/s12012-007-9004-9
   RATAN RR, 1994, J NEUROCHEM, V62, P376
   Rosenfeldt FL, 2005, INT J STD AIDS, V16, P827, DOI 10.1258/095646205774988127
   Rylova SN, 2005, BIOCHEM PHARMACOL, V69, P951, DOI 10.1016/j.bcp.2004.12.010
   SANDRI M, 1995, FEBS LETT, V373, P291, DOI 10.1016/0014-5793(95)00908-R
   SEMINOMORA MC, 1994, LAB INVEST, V71, P102
   Sun YQ, 2007, WORLD J GASTROENTERO, V13, P4185, DOI 10.3748/wjg.v13.i31.4185
   Tolomeo M, 2003, J CLIN PATHOL, V56, P147, DOI 10.1136/jcp.56.2.147
   Umaki Y, 2002, ACTA NEUROPATHOL, V103, P163
   Unger RH, 2002, BBA-MOL CELL BIOL L, V1585, P202, DOI 10.1016/S1388-1981(02)00342-6
   Wheeler S, 2005, RESPIROLOGY, V10, P171, DOI 10.1111/j.1440-1843.2005.00646.x
   Yamaguchi T, 2002, EUR J BIOCHEM, V269, P2782, DOI 10.1046/j.1432-1033.2002.02954.x
   Zhou FX, 2007, BIOCHEM BIOPH RES CO, V354, P351, DOI 10.1016/j.bbrc.2006.12.180
NR 45
TC 102
Z9 121
U1 0
U2 7
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0031-7012
EI 1423-0313
J9 PHARMACOLOGY
JI Pharmacology
PD JUN 15
PY 2008
VL 82
IS 2
BP 83
EP 88
DI 10.1159/000134943
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 341EL
UT WOS:000258696900001
PM 18504416
DA 2024-11-01
ER

PT J
AU Krishnan, KJ
   Reeve, AK
   Samuels, DC
   Chinnery, PF
   Blackwood, JK
   Taylor, RW
   Wanrooij, S
   Spelbrink, JN
   Lightowlers, RN
   Turnbull, DM
AF Krishnan, Kim J.
   Reeve, Amy K.
   Samuels, David C.
   Chinnery, Patrick F.
   Blackwood, John K.
   Taylor, Robert W.
   Wanrooij, Sjoerd
   Spelbrink, Johannes N.
   Lightowlers, Robert N.
   Turnbull, Doug M.
TI What causes mitochondrial DNA deletions in human cells?
SO NATURE GENETICS
LA English
DT Article
ID aicardi-goutieres-syndrome; substantia-nigra neurons; double-strand breaks; external ophthalmoplegia; escherichia-coli; common deletion; mtdna deletions; lagging-strand; muscle-fibers; human-disease
AB Mitochondrial DNA (mtDNA) deletions are a primary cause of mitochondrial disease and are likely to have a central role in the aging of postmitotic tissues. Understanding the mechanism of the formation and subsequent clonal expansion of these mtDNA deletions is an essential first step in trying to prevent their occurrence. We review the previous literature and recent results from our own laboratories, and conclude that mtDNA deletions are most likely to occur during repair of damaged mtDNA rather than during replication. This conclusion has important implications for prevention of mtDNA disease and, potentially, for our understanding of the aging process.
C1 [Krishnan, Kim J.; Reeve, Amy K.; Chinnery, Patrick F.; Blackwood, John K.; Taylor, Robert W.; Lightowlers, Robert N.; Turnbull, Doug M.] Univ Newcastle Upon Tyne, Mitochondrial Res Grp, Sch Med, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.
   [Krishnan, Kim J.; Turnbull, Doug M.] Univ Newcastle Upon Tyne, Inst Ageing & Hlth, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.
   [Samuels, David C.] Virginia Polytech Inst & State Univ, Virginia Bioinformat Inst, Blacksburg, VA 24061 USA.
   [Wanrooij, Sjoerd; Spelbrink, Johannes N.] Inst Med Technol, Tampere 33014, Finland.
   [Wanrooij, Sjoerd; Spelbrink, Johannes N.] Tampere Univ Hosp, Tampere 33014, Finland.
   [Wanrooij, Sjoerd] Karolinska Inst, Dept Metab Dis, SE-14186 Huddinge, Sweden.
C3 Newcastle University - UK; Newcastle University - UK; Virginia Polytechnic Institute & State University; Tampere University; Tampere University Hospital; Karolinska Institutet
RP Krishnan, KJ (corresponding author), Univ Newcastle Upon Tyne, Mitochondrial Res Grp, Sch Med, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.
EM d.m.turnbull@ncl.ac.uk
FU MRC [G0700718] Funding Source: UKRI; Medical Research Council [G0700718] Funding Source: Medline; Wellcome Trust [074454] Funding Source: Medline
CR Arai T, 2006, ACTA NEUROPATHOL, V112, P139, DOI 10.1007/s00401-006-0081-9
   Barnérias C, 2006, DEV MED CHILD NEUROL, V48, P227, DOI 10.1017/S001216220600048X
   Barritt JA, 1999, MOL HUM REPROD, V5, P927, DOI 10.1093/molehr/5.10.927
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Berneburg M, 1999, J BIOL CHEM, V274, P15345, DOI 10.1074/jbc.274.22.15345
   Blakely EL, 2004, J MED GENET, V41, P0, DOI 10.1136/jmg.2003.011296
   Bowmaker M, 2003, J BIOL CHEM, V278, P50961, DOI 10.1074/jbc.M308028200
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Chan CCW, 2005, MOL HUM REPROD, V11, P843, DOI 10.1093/molehr/gah243
   CHEN X, 1995, AM J HUM GENET, V57, P239
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   Crow YJ, 2006, NAT GENET, V38, P917, DOI 10.1038/ng1845
   deGrey ADNJ, 1997, BIOESSAYS, V19, P161, DOI 10.1002/bies.950190211
   Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9
   HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x
   Hanekamp T, 1999, CURR GENET, V34, P438, DOI 10.1007/s002940050418
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   Horiguchi M, 2001, CANCER RES, V61, P3913
   Hudson G, 2006, HUM MOL GENET, V15, PR244, DOI 10.1093/hmg/ddl233
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Krishnan KJ, 2004, J INVEST DERMATOL, V123, P1020, DOI 10.1111/j.0022-202X.2004.23457.x
   Murphy JEJ, 2005, MUTAT RES-GEN TOX EN, V585, P127, DOI 10.1016/j.mrgentox.2005.04.011
   Nguyen LH, 2000, J BIOL CHEM, V275, P25900, DOI 10.1074/jbc.M002672200
   Prithivirajsingh S, 2004, FEBS LETT, V571, P227, DOI 10.1016/j.febslet.2004.06.078
   Reeve AK, 2008, AM J HUM GENET, V82, P228, DOI 10.1016/j.ajhg.2007.09.018
   ROBBERSODL, 1972, P NATL ACAD SCI USA, V69, P3810, DOI 10.1073/pnas.69.12.3810
   Samuels DC, 2004, TRENDS GENET, V20, P393, DOI 10.1016/j.tig.2004.07.003
   SARGENTINI NJ, 1992, MUTAT RES, V265, P83, DOI 10.1016/0027-5107(92)90041-Y
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   Srivastava S, 2005, HUM MOL GENET, V14, P893, DOI 10.1093/hmg/ddi082
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   THACKER J, 1992, NUCLEIC ACIDS RES, V20, P6183, DOI 10.1093/nar/20.23.6183
   VanGoethem G, 1997, EUR J NEUROL, V4, P476
   WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   Wang GJ, 1997, BIOCHEM PHARMACOL, V54, P181, DOI 10.1016/S0006-2952(97)00158-5
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   Wanrooij S, 2007, NUCLEIC ACIDS RES, V35, P3238, DOI 10.1093/nar/gkm215
   Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9
   Yasukawa T, 2006, EMBO J, V25, P5358, DOI 10.1038/sj.emboj.7601392
   YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164
NR 48
TC 295
Z9 331
U1 0
U2 35
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 
J9 NAT GENET
JI Nature Genet.
PD MAR 15
PY 2008
VL 40
IS 3
BP 275
EP 279
DI 10.1038/ng.f.94
PG 5
WC Genetics & Heredity
SC Genetics & Heredity
GA 267ZT
UT WOS:000253548400015
PM 18305478
DA 2024-11-01
ER

PT J
AU Wani, AA
   Rangrez, AY
   Kumar, H
   Bapat, SA
   Suresh, CG
   Barnabas, S
   Patole, MS
   Shouche, Y
AF Wani, Aijaz A.
   Rangrez, Ashraf Y.
   Kumar, Himanshu
   Bapat, Sharmila A.
   Suresh, C. G.
   Barnabas, Shama
   Patole, Milind S.
   Shouche, Yogesh
TI Analysis of reactive oxygen species and antioxidant defenses in complex I deficient patients revealed a specific increase in superoxide dismutase activity
SO FREE RADICAL RESEARCH
LA English
DT Article
DE mitochondrial myopathies; reactive oxygen species (ROS); antioxidant enzymes; mitochondrial complex I
ID gamma-glutamylcysteine synthetase; oxidative stress; mitochondrial-dna; glutathione-peroxidase; lipid-peroxidation; hydrogen-peroxide; mutations; damage; impairment; expression
AB The mechanism of free radical production by complex I deficiency is ill-defined, although it is of significant contemporary interest. This study studied the ROS production and antioxidant defenses in children with mitochondrial NADH dehydrogenase deficiency. ROS production has remained significantly elevated in patients compared to controls. The expression of all antioxidant enzymes significantly increased at mRNA level. However, the enzyme activities did not correlate with high mRNA or protein expression. Only the activity of superoxide dismutase (SOD) was found to correlate with higher mRNA expression in patient derived cell lines. The activities of the enzymes such as glutathione peroxidase (GPx), Catalase (CAT) and glutathione-S-transferase (GST) were significantly reduced in patients (p < 0.05 or p < 0.01). Glutathione reductase (GR) activity and intracellular glutathione (GSH) levels were not changed. Decreased enzyme activities could be due to post-translational or oxidative modification of ROS scavenging enzymes. The information on the status of ROS and marking the alteration of ROS scavenging enzymes in peripheral lymphocytes or lymphoblast cell lines will provide a better way to design antioxidant therapies for such disorders.
C1 [Wani, Aijaz A.; Rangrez, Ashraf Y.; Kumar, Himanshu; Bapat, Sharmila A.; Patole, Milind S.; Shouche, Yogesh] Natl Ctr Cell Sci, Mol Biol Unit, Pune 411007, Maharashtra, India.
   [Suresh, C. G.; Barnabas, Shama] Natl Chem Lab, Div Biochem Sci, Pune 411004, Maharashtra, India.
C3 Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS); Council of Scientific & Industrial Research (CSIR) - India; CSIR - National Chemical Laboratory (NCL)
RP Shouche, Y (corresponding author), Natl Ctr Cell Sci, Mol Biol Unit, Pune Univ Campus, Pune 411007, Maharashtra, India.
EM yogesh@nccs.res.in
CR Acín-Pérez R, 2004, MOL CELL, V13, P805, DOI 10.1016/S1097-2765(04)00124-8
   Beretta S, 2004, BRAIN, V127, P2183, DOI 10.1093/brain/awh258
   BOLTER CJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P65, DOI 10.1016/0003-9861(90)90232-N
   Chan TS, 2002, FREE RADICAL RES, V36, P421, DOI 10.1080/10715760290021270
   Chowdhury SKR, 2007, FREE RADICAL RES, V41, P1116, DOI 10.1080/10715760701579314
   Cyrne L, 2003, FREE RADICAL BIO MED, V34, P385, DOI 10.1016/S0891-5849(02)01300-X
   deHaan JB, 1996, HUM MOL GENET, V5, P283, DOI 10.1093/hmg/5.2.283
   Del Maestro R, 1989, CRC HANDBOOK OF METHODS FOR OXYGEN RADICAL RESEARCH, V4th, P291
   DeLaAsuncion JG, 1996, FASEB J, V10, P333, DOI 10.1096/fasebj.10.2.8641567
   DiMauro S, 2005, NEUROMUSCULAR DISORD, V15, P276, DOI 10.1016/j.nmd.2004.12.008
   Du G, 1998, FREE RADICAL BIO MED, V25, P1066, DOI 10.1016/S0891-5849(98)00148-8
   El Mouatassim S, 1999, MOL HUM REPROD, V5, P720, DOI 10.1093/molehr/5.8.720
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   FLOHE L, 1984, METHOD ENZYMOL, V105, P114
   Floreani M, 2005, FEBS J, V272, P1124, DOI 10.1111/j.1742-4658.2004.04542.x
   HABIG WH, 1974, J BIOL CHEM, V249, P7130
   Halliwell B, 2004, BRIT J PHARMACOL, V142, P231, DOI 10.1038/sj.bjp.0705776
   HALLIWELL B, 1995, FREE RADICAL BIO MED, V18, P125, DOI 10.1016/0891-5849(95)91457-3
   HAYAKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P979, DOI 10.1016/0006-291X(92)92300-M
   Jazin EE, 1996, P NATL ACAD SCI USA, V93, P12382, DOI 10.1073/pnas.93.22.12382
   Li N, 1998, J CELL PHYSIOL, V175, P359, DOI 10.1002/(SICI)1097-4652(199806)175:3<359::AID-JCP14>3.0.CO;2-0
   Luo XP, 1997, J CLIN INVEST, V99, P2877, DOI 10.1172/JCI119481
   Mattiazzi M, 2004, HUM MOL GENET, V13, P869, DOI 10.1093/hmg/ddh103
   Nijtmans LGJ, 2002, METHODS, V26, P327, DOI 10.1016/S1046-2023(02)00038-5
   OBERLEY LW, 1984, METHOD ENZYMOL, V105, P457
   Pang CY, 2001, DIABETES RES CLIN PR, V54, PS45, DOI 10.1016/S0168-8227(01)00335-7
   PICCOLO G, 1991, J NEUROL SCI, V105, P57, DOI 10.1016/0022-510X(91)90118-Q
   PIGEOLET E, 1991, FREE RADICAL BIO MED, V11, P191, DOI 10.1016/0891-5849(91)90171-X
   PIGEOLET E, 1990, MECH AGEING DEV, V51, P283, DOI 10.1016/0047-6374(90)90078-T
   Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798
   RUSH GF, 1985, TOXICOL APPL PHARM, V78, P473, DOI 10.1016/0041-008X(85)90255-8
   SHI MM, 1994, J BIOL CHEM, V269, P26512
   Suzuki H, 1998, BIOCHEM BIOPH RES CO, V249, P542, DOI 10.1006/bbrc.1998.9181
   Tian L, 1997, ARCH BIOCHEM BIOPHYS, V342, P126, DOI 10.1006/abbi.1997.9997
   TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421
   TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0
   Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887
   Vergani L, 2004, EUR J BIOCHEM, V271, P3646, DOI 10.1111/j.1432-1033.2004.04298.x
   Vives-Bauza C, 2006, NEUROSCI LETT, V391, P136, DOI 10.1016/j.neulet.2005.08.049
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wani AA, 2007, PLOS ONE, V2, P0, DOI 10.1371/journal.pone.0000942
   Wei YH, 2001, CHINESE J PHYSIOL, V44, P1
   Wong A, 2002, HUM MOL GENET, V11, P431, DOI 10.1093/hmg/11.4.431
NR 43
TC 6
Z9 7
U1 0
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1071-5762
EI 1029-2470
J9 FREE RADICAL RES
JI Free Radic. Res.
PD MAY 15
PY 2008
VL 42
IS 5
BP 415
EP 427
DI 10.1080/10715760802068571
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 311EI
UT WOS:000256583100002
PM 18551809
DA 2024-11-01
ER

PT J
AU Chou, HF
   Liang, WC
   Zhang, Q
   Goto, Y
   Jong, YJ
AF Chou, Hsiao-Feng
   Liang, Wen-Chen
   Zhang, Qing
   Goto, Yu-ichi
   Jong, Yuh-Jyh
TI Clinical and genetic features in a MELAS child with a 3271T&gt;C mutation
SO PEDIATRIC NEUROLOGY
LA English
DT Article
ID stroke-like episodes; mitochondrial-dna; lactic-acidosis; encephalopathy; myopathy; merrf
AB A mitochondrial DNA 3271T > C point mutation was reported to be the second most common mutation (following the mutation 3243A > G) in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) in Japan. This mutation has rarely been reported in other countries. We present an 11-year-old Taiwanese girl with MELAS, who harbored the 3271T > C mutation and had manifested short stature, epilepsia partialis continua, and recurrent basal ganglia infarctions since age 6 years, and rapid intellectual regression, dysarthria, and unsteady gait since age 10 years. The proportion of 3271T > C mutant genomes in various tissues, including urinary sediments, hair follicles, blood leukocytes, and buccal mucosa cells from the patient and her mother, was analyzed by polymerase chain reaction-restriction fragment length polymorphism analysis and quantitative real-time polymerase chain reaction. The proportion of mutant load in the patient's muscles was near 100%. Except for muscle, the highest mutation load was detected in urinary sediments of the patient by both methods. This is the first report involving mutant load analysis with quantitative real-time polymerase chain reaction in the 3271T > C mutation. The results suggest that urinary sediments may be an alternative tissue of choice which can be obtained noninvasively in the diagnosis of mitochondrial DNA 3271T > C mutations. (c) 2008 by Elsevier Inc. All rights reserved.
C1 [Chou, Hsiao-Feng; Liang, Wen-Chen; Jong, Yuh-Jyh] Kaohsiung Med Univ Hosp, Dept Pediat, Kaohsiung 807, Taiwan.
   [Zhang, Qing] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Goto, Yu-ichi] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Tokyo, Japan.
   [Jong, Yuh-Jyh] Kaohsiung Med Univ Hosp, Dept Lab Med, Kaohsiung 807, Taiwan.
   [Jong, Yuh-Jyh] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University Hospital; Baylor College of Medicine; National Center for Neurology & Psychiatry - Japan; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University
RP Jong, YJ (corresponding author), Kaohsiung Med Univ Hosp, Dept Pediat, 100 Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.
EM yjjong@kmu.edu.tw
CR Barisic N, 2002, CROAT MED J, V43, P37
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   KOO B, 1993, ANN NEUROL, V34, P25, DOI 10.1002/ana.410340107
   MARIE SKN, 1994, BIOCHEM MED METAB B, V52, P136, DOI 10.1006/bmmb.1994.1045
   Nishigaki Y, 2003, NEUROMUSCULAR DISORD, V13, P334, DOI 10.1016/S0960-8966(02)00283-3
   SAKUTA R, 1993, J NEUROL SCI, V115, P158, DOI 10.1016/0022-510X(93)90219-O
   Shanske S, 2004, AM J MED GENET A, V130A, P134, DOI 10.1002/ajmg.a.30220
   Stenqvist L, 2005, PEDIATR RES, V58, P258, DOI 10.1203/01.PDR.0000169966.82325.1A
   Tarnopolsky MA, 1998, MUSCLE NERVE, V21, P25, DOI 10.1002/(SICI)1097-4598(199801)21:1<25::AID-MUS4>3.0.CO;2-I
   Tay SKH, 2005, J CHILD NEUROL, V20, P142, DOI 10.1177/08830738050200022301
   Wong LJC, 2005, CLIN CHIM ACTA, V354, P1, DOI 10.1016/j.cccn.2004.11.003
NR 12
TC 13
Z9 15
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0887-8994
EI 
J9 PEDIATR NEUROL
JI Pediatr. Neurol.
PD FEB 15
PY 2008
VL 38
IS 2
BP 143
EP 146
DI 10.1016/j.pediatrneurol.2007.09.015
PG 4
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 257IQ
UT WOS:000252792800013
PM 18206799
DA 2024-11-01
ER

PT J
AU Rath, PP
   Jenkins, S
   Michaelides, M
   Smith, A
   Sweeney, MG
   Davis, MB
   Fitzke, FW
   Bird, AC
AF Rath, P. P.
   Jenkins, S.
   Michaelides, M.
   Smith, A.
   Sweeney, M. G.
   Davis, M. B.
   Fitzke, F. W.
   Bird, A. C.
TI Characterisation of the macular dystrophy in patients with the A3243G mitochondrial DNA point mutation with fundus autofluorescence
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID transfer rnaleu(uur) gene; diabetes-mellitus; geographic atrophy; pattern dystrophy; retinal manifestations; transfer rna(leu(uur)); prevalence; deafness; melas; myopathy
AB Introduction: The mitochondrial DNA A3243G point mutation is associated with a wide variety of systemic manifestations including a macular dystrophy. The characteristics of fundus autofluorescence (AF) in these patients are distinctive and have not been previously described. Methods: A complete history and ophthalmic examination, including fundus photography and autofluorescence imaging, was performed on twelve probands harbouring the A3243G point mutation. Results: Four patients had diabetes, 10/12 hearing loss, and 7/12 were visually symptomatic. A positive family history was present in 5/12. Fundus findings consisted of two primary phenotypes: discontinuous circumferentially oriented perifoveal atrophy (9/12) or an appearance consistent with pattern dystrophy (3/12). In both phenotypes pale deposits and pigment clumping were seen at the level of the retinal pigment epithelium, with occasional changes also noted outside the arcades and nasal to the optic nerve. Fundus AF imaging revealed decreased autofluorescence in areas of atrophy and increased AF of the pale subretinal deposits. In areas of the retina that appeared normal clinically, variable sized flecks of increased and decreased AF were present. Conclusions: The mitochondrial DNA A3243G point mutation can result in disease with a variable presentation. Fundus autofluorescence reveals a recognisable phenotype in most cases that is different from other macular dystrophies.
C1 [Rath, P. P.] Retina Vitreous Consultants, Pittsburgh, PA 15213 USA.
   [Rath, P. P.; Jenkins, S.; Michaelides, M.; Smith, A.; Bird, A. C.] Moorfields Eye Hosp, London, England.
   [Jenkins, S.; Michaelides, M.; Fitzke, F. W.; Bird, A. C.] Inst Ophthalmol, London, England.
   [Smith, A.] Cty Hosp, Hereford HR1 2ER, England.
   [Sweeney, M. G.; Davis, M. B.] Inst Neurol, Dept Mol Neurosci, London WC1N 3BG, England.
C3 University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; University of London; University College London; University of London; University College London
RP Rath, PP (corresponding author), Retina Vitreous Consultants, 3501 Forbes Ave,Suite 500, Pittsburgh, PA 15213 USA.
EM prprath@yahoo.com
CR Andrews RM, 1999, EYE, V13, P595, DOI 10.1038/eye.1999.151
   Bellmann C, 2002, ARCH OPHTHALMOL-CHIC, V120, P579, DOI 10.1001/archopht.120.5.579
   Bonte CA, 1997, RETINA-J RET VIT DIS, V17, P216, DOI 10.1097/00006982-199705000-00008
   Chinnery PF, 1999, J MED GENET, V36, P505, DOI 10.1136/jmg.36.7.505
   Chinnery PF, 1999, J MED GENET, V36, P425
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Deschauer M, 1999, NEUROMUSCULAR DISORD, V9, P305, DOI 10.1016/S0960-8966(99)00019-X
   Downes SM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1373, DOI 10.1001/archopht.117.10.1373
   Downes SM, 2001, ARCH OPHTHALMOL-CHIC, V119, P96
   Gavin JR, 1999, DIABETES CARE, V22, P0
   Goodship JA, 2002, J MED GENET, V39, P221, DOI 10.1136/jmg.39.3.221
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Guillausseau PJ, 2001, ANN INTERN MED, V134, P721, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00008
   HAMMANS SR, 1991, LANCET, V337, P1311, DOI 10.1016/0140-6736(91)92981-7
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   Harrison TJ, 1997, AM J OPHTHALMOL, V124, P217, DOI 10.1016/S0002-9394(14)70787-1
   Holmes-Walker DJ, 1999, DIABETOLOGIA, V42, P1028
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Isashiki Y, 1998, ACTA OPHTHALMOL SCAN, V76, P6, DOI 10.1034/j.1600-0420.1998.760103.x
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   KISHIMOTO M, 1995, DIABETOLOGIA, V38, P193, DOI 10.1007/s001250050270
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   Kurz-Levin MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P567, DOI 10.1001/archopht.120.5.567
   Latkany P, 1999, AM J OPHTHALMOL, V128, P112, DOI 10.1016/S0002-9394(99)00057-4
   Lehto M, 1999, DIABETOLOGIA, V42, P1131, DOI 10.1007/s001250051281
   Lois N, 2001, ARCH OPHTHALMOL-CHIC, V119, P359, DOI 10.1001/archopht.119.3.359
   MANOUVRIER S, 1995, J MED GENET, V32, P654, DOI 10.1136/jmg.32.8.654
   MASSIN P, 1995, AM J OPHTHALMOL, V120, P247, DOI 10.1016/S0002-9394(14)72615-7
   Massin P, 1999, OPHTHALMOLOGY, V106, P1821, DOI 10.1016/S0161-6420(99)90356-1
   MORGANHUGHES JA, 1995, BBA-MOL BASIS DIS, V1271, P135, DOI 10.1016/0925-4439(95)00020-5
   MULLIE MA, 1985, ARCH OPHTHALMOL-CHIC, V103, P1825, DOI 10.1001/archopht.1985.01050120059020
   Newkirk JE, 1997, DIABETIC MED, V14, P457, DOI 10.1002/(SICI)1096-9136(199706)14:6<457::AID-DIA372>3.3.CO;2-N
   OTABE S, 1994, J CLIN ENDOCR METAB, V79, P768, DOI 10.1210/jc.79.3.768
   REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3
   Saker PJ, 1997, DIABETIC MED, V14, P42, DOI 10.1002/(SICI)1096-9136(199701)14:1<42::AID-DIA295>3.0.CO;2-T
   Smith PR, 1999, OPHTHALMOLOGY, V106, P1101, DOI 10.1016/S0161-6420(99)90244-0
   THART LM, 1994, DIABETOLOGIA, V37, P1169
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   VIONNET N, 1993, LANCET, V342, P1429, DOI 10.1016/0140-6736(93)92792-R
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, ARCH OPHTHALMOL-CHIC, V115, P609, DOI 10.1001/archopht.1997.01100150611006
NR 41
TC 39
Z9 42
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY 15
PY 2008
VL 92
IS 5
BP 623
EP 629
DI 10.1136/bjo.2007.131177
PG 7
WC Ophthalmology
SC Ophthalmology
GA 293MC
UT WOS:000255338400010
PM 18441172
DA 2024-11-01
ER

PT J
AU Kohler, JJ
   Hosseini, SH
   Green, E
   Hoying-Brandt, A
   Cucoranu, I
   Haase, CP
   Russ, R
   Srivastava, J
   Ivey, K
   Ludaway, T
   Kapoor, V
   Abuin, A
   Shapoval, A
   Santoianni, R
   Saada, A
   Elpeleg, O
   Lewis, W
AF Kohler, James J.
   Hosseini, Seyed H.
   Green, Elgin
   Hoying-Brandt, Amy
   Cucoranu, Ioan
   Haase, Chad P.
   Russ, Rodney
   Srivastava, Jaya
   Ivey, Kristopher
   Ludaway, Tomika
   Kapoor, Victor
   Abuin, Allison
   Shapoval, Alexsey
   Santoianni, Robert
   Saada, Ann
   Elpeleg, Orly
   Lewis, William
TI Cardiac-targeted transgenic mutant mitochondrial enzymes: MtDNA defects, antiretroviral toxicity and cardiomyopathy
SO CARDIOVASCULAR TOXICOLOGY
LA English
DT Article
DE cardiomyopathy; murine model; mtDNA; NRTI; toxicity
ID dna-polymerase-gamma; thymidine kinase; deoxynucleotide carrier; depletion myopathy; antiviral drugs; heart-failure; long-term; zidovudine; mechanism; therapy
AB Mitochondrial (mt) DNA biogenesis is critical to cardiac contractility. DNA polymerase gamma (Pol gamma) replicates mtDNA, whereas thymidine kinase 2 (TK2) monophosphorylates pyrimidines intramitochondrially. Point mutations in POLG and TK2 result in clinical diseases associated with mtDNA depletion and organ dysfunction. Pyrimidine analogs (NRTIs) inhibit Pol gamma and mtDNA replication. Cardiac "dominant negative" murine transgenes (TGs; Pol gamma Y955C, and TK2 H121N or I212N) defined the role of each in the heart. mtDNA abundance, histopathological features, histochemistry, mitochondrial protein abundance, morphometry, and echocardiography were determined for TGs in "2 x 2" studies with or without pyrimidine analogs. Cardiac mtDNA abundance decreased in Y955C TGs (similar to 50%) but increased in H121N and I212N TGs (20-70%). Succinate dehydrogenase (SDH) increased in hearts of all mutants. Ultrastructural changes occurred in Y955C and H121N TGs. Histopathology demonstrated hypertrophy in H121N, LV dilation in I212N, and both hypertrophy and dilation in Y955C TGs. Antiretrovirals increased LV mass (approximate to 50%) for all three TGs which combined with dilation indicates cardiomyopathy. Taken together, these studies demonstrate three manifestations of cardiac dysfunction that depend on the nature of the specific mutation and antiretroviral treatment. Mutations in genes for mtDNA biogenesis increase risk for defective mtDNA replication, leading to LV hypertrophy.
C1 [Kohler, James J.; Hosseini, Seyed H.; Green, Elgin; Hoying-Brandt, Amy; Cucoranu, Ioan; Haase, Chad P.; Russ, Rodney; Srivastava, Jaya; Ivey, Kristopher; Ludaway, Tomika; Kapoor, Victor; Abuin, Allison; Shapoval, Alexsey; Santoianni, Robert; Lewis, William] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA.
   [Saada, Ann; Elpeleg, Orly] Hadassah Univ Med Ctr, Metab Dis Unit, Jerusalem, Israel.
C3 Emory University; Hebrew University of Jerusalem
RP Kohler, JJ (corresponding author), Emory Univ, Sch Med, Dept Pathol, 7126 Woodruff Mem Bldg,101 Woodrufff Circle, Atlanta, GA 30322 USA.
EM jjkohle@emory.edu
FU NHLBI NIH HHS [R01 HL059798, R01 HL079867, R01 HL079867-02, R01 HL072707, R01 HL059798-09] Funding Source: Medline; NIDDK NIH HHS [K01 DK078513-01A1, K01 DK078513] Funding Source: Medline
CR Abu-Amero KK, 2006, BRIT J OPHTHALMOL, V90, P823, DOI 10.1136/bjo.2006.090332
   BARTH E, 1992, J MOL CELL CARDIOL, V24, P669, DOI 10.1016/0022-2828(92)93381-S
   Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   Bishop JB, 2004, ENVIRON MOL MUTAGEN, V43, P3, DOI 10.1002/em.10210
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Côté HCF, 2003, J INFECT DIS, V187, P1972, DOI 10.1086/375353
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   DAMATI G, 1994, LAB INVEST, V71, P879
   Divi RL, 2007, ENVIRON MOL MUTAGEN, V48, P179, DOI 10.1002/em.20245
   Eriksson S, 2002, CELL MOL LIFE SCI, V59, P1327, DOI 10.1007/s00018-002-8511-x
   Ferraro P, 2006, P NATL ACAD SCI USA, V103, P18586, DOI 10.1073/pnas.0609020103
   Golden KL, 2004, HORM METAB RES, V36, P197
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hosseini SH, 2007, AM J PATHOL, V170, P865, DOI 10.2353/ajpath.2007.060655
   Iacobazzi V, 2001, CYTOGENET CELL GENET, V93, P40, DOI 10.1159/000056945
   Jiang WW, 2005, CLIN CANCER RES, V11, P2486, DOI 10.1158/1078-0432.CCR-04-2147
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Katz AM, 2003, J CELL MOL MED, V7, P1, DOI 10.1111/j.1582-4934.2003.tb00197.x
   Kohler JJ, 2007, ENVIRON MOL MUTAGEN, V48, P166, DOI 10.1002/em.20223
   Lewis W, 2006, AIDS, V20, P675, DOI 10.1097/01.aids.0000216367.23325.58
   Lewis W, 2005, ANTIVIR THER, V10, P0
   Lewis W, 2005, LAB INVEST, V85, P182, DOI 10.1038/labinvest.3700222
   Lewis W, 2003, NAT REV DRUG DISCOV, V2, P812, DOI 10.1038/nrd1201
   Lewis W, 2000, LAB INVEST, V80, P187, DOI 10.1038/labinvest.3780022
   LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417
   Lewis W, 2001, LAB INVEST, V81, P1527, DOI 10.1038/labinvest.3780366
   Lewis W, 2007, LAB INVEST, V87, P326, DOI 10.1038/labinvest.3700523
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   Llamas B, 2007, PHYSIOL GENOMICS, V31, P176, DOI 10.1152/physiolgenomics.00072.2007
   McComsey G, 2004, JAIDS-J ACQ IMM DEF, V37, PS30, DOI 10.1097/01.qai.0000137004.63376.27
   Miró O, 2004, JAIDS-J ACQ IMM DEF, V37, P1550, DOI 10.1097/00126334-200412150-00002
   MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096
   RAIDEL SM, 2002, HEART CIRCULATORY PH, V282, P0
   ROSENKRANZWEISS P, 1994, J MOL CELL CARDIOL, V26, P261, DOI 10.1006/jmcc.1994.1029
   Saada A, 2004, DNA CELL BIOL, V23, P797
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Sebastiani M, 2007, J AM COLL CARDIOL, V50, P1362, DOI 10.1016/j.jacc.2007.06.035
   SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613
   Vivet-Boudou V, 2006, CELL MOL LIFE SCI, V63, P163, DOI 10.1007/s00018-005-5367-x
   Wang LY, 2000, BIOCHEM J, V351, P469, DOI 10.1042/0264-6021:3510469
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
NR 44
TC 13
Z9 15
U1 0
U2 0
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1530-7905
EI 1559-0259
J9 CARDIOVASC TOXICOL
JI Cardiovasc. Toxicol.
PD JUN 15
PY 2008
VL 8
IS 2
BP 57
EP 69
DI 10.1007/s12012-008-9015-1
PG 13
WC Cardiac & Cardiovascular Systems; Toxicology
SC Cardiovascular System & Cardiology; Toxicology
GA 322IL
UT WOS:000257368300002
PM 18446447
DA 2024-11-01
ER

PT J
AU Schapira, AHV
AF Schapira, Anthony H. V.
TI Mitochondrial Dysfunction in Neurodegenerative Diseases
SO NEUROCHEMICAL RESEARCH
LA English
DT Review
DE Mitochondria; Mitochondrial DNA; Genes Parkinson's disease; Friedreich's ataxia; Oxidative stress
ID complex-i deficiency; magnetic-resonance spectroscopy; kearns-sayre syndrome; cytochrome-c-oxidase; red fibers merrf; parkinsons-disease; leigh-syndrome; friedreichs-ataxia; skeletal-muscle; huntingtons-disease
AB Mitochondria play a pivotal role in mammalian cell metabolism, hosting a number of important biochemical pathways including oxidative phosphorylation. As might be expected from this fundamental contribution to cell function, abnormalities of mitochondrial metabolism are a common cause of human disease. Primary mutations of mitochondrial DNA result in a diverse group of disorders often collectively referred to as the mitochondrial encephalomyopathies. Perhaps more importantly in numerical terms are those neurodegenerative diseases caused by mutations of nuclear genes encoding mitochondrial proteins. Finally there are mitochondrial abnormalities induced by secondary events e. g. oxidative stress that may contribute to senescence, and environmental toxins that may cause disease either alone or in combination with a genetic predisposition.
C1 UCL, Inst Neurol, Univ Dept Clin Neurosci, London NW3 2PF, England.
C3 University of London; University College London
RP Schapira, AHV (corresponding author), UCL, Inst Neurol, Univ Dept Clin Neurosci, Rowland Hill St, London NW3 2PF, England.
EM a.schapira@medsch.ucl.ac.uk
FU MRC [G0601943] Funding Source: UKRI; Medical Research Council [G0601943] Funding Source: Medline
CR BAUMGARTNER ER, 1989, PEDIATR RES, V26, P260, DOI 10.1203/00006450-198909000-00021
   BERENBERG RA, 1977, ANN NEUROL, V1, P37, DOI 10.1002/ana.410010104
   BERKOVIC SF, 1989, BRAIN, V112, P1231, DOI 10.1093/brain/112.5.1231
   Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209
   BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144
   Bradley JL, 2000, HUM MOL GENET, V9, P275, DOI 10.1093/hmg/9.2.275
   Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423
   Chowers I, 1999, BRIT J OPHTHALMOL, V83, P190, DOI 10.1136/bjo.83.2.190
   CIAFALONI E, 1993, J PEDIATR-US, V122, P419, DOI 10.1016/S0022-3476(05)83431-6
   Clark IE, 2006, NATURE, V441, P1162, DOI 10.1038/nature04779
   Cooper JM, 2007, MITOCHONDRION, V7, PS127, DOI 10.1016/j.mito.2007.04.001
   COOPER JM, 1995, MOVEMENT DISORD, V10, P295, DOI 10.1002/mds.870100311
   COX GB, 1986, BIOCHIM BIOPHYS ACTA, V849, P62, DOI 10.1016/0005-2728(86)90096-4
   Cui LB, 2006, CELL, V127, P59, DOI 10.1016/j.cell.2006.09.015
   DEVOLDER A, 1988, J COMPUT ASSIST TOMO, V12, P854
   DEVRIES DD, 1993, ANN NEUROL, V34, P410, DOI 10.1002/ana.410340319
   DiMauro S, 1996, ANN NEUROL, V40, P5, DOI 10.1002/ana.410400104
   Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5
   FRYER A, 1994, ARCH DIS CHILD, V71, P419, DOI 10.1136/adc.71.5.419
   Gu M, 1998, ANN NEUROL, V44, P177, DOI 10.1002/ana.410440207
   Gu M, 1997, MOVEMENT DISORD, V12, P418, DOI 10.1002/mds.870120323
   Gutzmann H, 1998, J NEURAL TRANSM-SUPP, V0, P301
   HAMMANS SR, 1991, LANCET, V337, P1311, DOI 10.1016/0140-6736(91)92981-7
   HAMMANS SR, 1993, BRAIN, V116, P617, DOI 10.1093/brain/116.3.617
   Hart PE, 2005, ARCH NEUROL-CHICAGO, V62, P621, DOI 10.1001/archneur.62.4.621
   Hausse AO, 2002, HEART, V87, P346, DOI 10.1136/heart.87.4.346
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   KEMP GJ, 1993, NMR BIOMED, V6, P302, DOI 10.1002/nbm.1940060504
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   KRETZSCHMAR HA, 1987, PEDIATRICS, V79, P370
   KRIGE D, 1992, ANN NEUROL, V32, P782, DOI 10.1002/ana.410320612
   Kuroda Y, 2006, HUM MOL GENET, V15, P883, DOI 10.1093/hmg/ddl006
   Leonard JV, 2000, LANCET, V355, P389, DOI 10.1016/S0140-6736(99)05226-5
   Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3
   Lodi R, 1999, P NATL ACAD SCI USA, V96, P11492, DOI 10.1073/pnas.96.20.11492
   Lodi R, 2001, CARDIOVASC RES, V52, P111, DOI 10.1016/S0008-6363(01)00357-1
   Lodi R, 2001, ANN NEUROL, V49, P590
   Loeffen J, 1998, AM J HUM GENET, V63, P1598, DOI 10.1086/302154
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   MAKELABENGS P, 1995, PEDIATR RES, V37, P634
   MANN VM, 1990, LANCET, V336, P749, DOI 10.1016/0140-6736(90)92242-A
   MANN VM, 1994, ANN NEUROL, V36, P876, DOI 10.1002/ana.410360612
   MANN VM, 1992, FEBS LETT, V299, P218, DOI 10.1016/0014-5793(92)80118-Z
   Martins LM, 2004, MOL CELL BIOL, V24, P9848, DOI 10.1128/MCB.24.22.9848-9862.2004
   MATTHEWS PM, 1993, ANN NEUROL, V33, P652, DOI 10.1002/ana.410330616
   Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Mordente A, 1998, CHEM RES TOXICOL, V11, P54, DOI 10.1021/tx970136j
   MORGANHUGHES JA, 1995, BBA-MOL BASIS DIS, V1271, P135, DOI 10.1016/0925-4439(95)00020-5
   MORGANHUGHES JA, 1988, J BIOENERG BIOMEMBR, V20, P365, DOI 10.1007/BF00769638
   Morris AAM, 1998, J HEPATOL, V28, P556, DOI 10.1016/S0168-8278(98)80278-X
   Orth M, 2002, NEUROCHEM INT, V40, P533, DOI 10.1016/S0197-0186(01)00124-3
   ORTIZ RG, 1993, ARCH OPHTHALMOL-CHIC, V111, P1525, DOI 10.1001/archopht.1993.01090110091031
   Park J, 2006, NATURE, V441, P1157, DOI 10.1038/nature04788
   PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606
   Pook M A, 2000, J MED GENET, V37, PE38, DOI 10.1136/jmg.37.11.e38
   Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818
   PUDDU P, 1993, BRIT J OPHTHALMOL, V77, P84, DOI 10.1136/bjo.77.2.84
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Ranen NG, 1996, MOVEMENT DISORD, V11, P549, DOI 10.1002/mds.870110510
   Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215
   SANTORELLI FM, 1993, ANN NEUROL, V34, P827, DOI 10.1002/ana.410340612
   SANTORELLI FM, 1994, NEUROLOGY, V44, P972, DOI 10.1212/WNL.44.5.972
   Schapira AHV, 2007, CELL DEATH DIFFER, V14, P1261, DOI 10.1038/sj.cdd.4402160
   SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0
   SCHAPIRA AHV, 1994, MOVEMENT DISORD, V9, P125, DOI 10.1002/mds.870090202
   Schapira AHV, 2002, J NEUROL NEUROSUR PS, V72, P144, DOI 10.1136/jnnp.72.2.144
   SCHAPIRA AHV, 1990, J NEUROCHEM, V55, P2142, DOI 10.1111/j.1471-4159.1990.tb05809.x
   SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x
   SCHAPIRA AHV, 1988, LANCET, V1, P500
   Schapira AHV, 2008, LANCET NEUROL, V7, P97, DOI 10.1016/S1474-4422(07)70327-7
   Schapira AHV, 2006, NAT REV DRUG DISCOV, V5, P845, DOI 10.1038/nrd2087
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Strauss KM, 2005, HUM MOL GENET, V14, P2099, DOI 10.1093/hmg/ddi215
   Sue CM, 2000, ANN NEUROL, V47, P589, DOI 10.1002/1531-8249(200005)47:5<589::AID-ANA6>3.3.CO;2-4
   Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417
   Taanman JW, 2005, NEUROSCI LETT, V376, P56, DOI 10.1016/j.neulet.2004.11.023
   Tabrizi SJ, 2000, ANN NEUROL, V47, P80
   Tabrizi SJ, 1999, ANN NEUROL, V45, P25, DOI 10.1002/1531-8249(199901)45:1<25::AID-ART6>3.0.CO;2-E
   TAKEDA S, 1988, ACTA NEUROPATHOL, V75, P433, DOI 10.1007/BF00687129
   TAYLOR DJ, 1994, J NEUROL SCI, V125, P77, DOI 10.1016/0022-510X(94)90245-3
   THOMAS PK, 1993, J ANAT, V183, P451
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   TSAIRIS P, 1973, NEUROLOGY, V23, P408
   Unoki M, 2001, ONCOGENE, V20, P4457, DOI 10.1038/sj.onc.1204608
   Uziel G, 1997, J NEUROL NEUROSUR PS, V63, P16, DOI 10.1136/jnnp.63.1.16
   Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284
   VANCOSTER R, 1991, J NEUROL SCI, V104, P97, DOI 10.1016/0022-510X(91)90222-S
   VANERVEN PMM, 1987, ARCH NEUROL-CHICAGO, V44, P775, DOI 10.1001/archneur.1987.00520190079019
   VazquezMemije ME, 1996, J INHERIT METAB DIS, V19, P43, DOI 10.1007/BF01799347
   WILLEMS JL, 1977, PEDIATRICS, V60, P850
   Xu J, 2005, HUM MOL GENET, V14, P1231, DOI 10.1093/hmg/ddi134
   YAMADORI I, 1992, ACTA NEUROPATHOL, V84, P337
   YAMAMOTO M, 1991, NEUROLOGY, V41, P1822, DOI 10.1212/WNL.41.11.1822
   Zeviani M, 1998, NEUROLOGY, V51, P1525, DOI 10.1212/WNL.51.6.1525-a
   ZEVIANI M, 1991, AM J HUM GENET, V48, P203
   Zhang L, 2005, HUM MOL GENET, V14, P2063, DOI 10.1093/hmg/ddi211
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
NR 103
TC 59
Z9 74
U1 0
U2 4
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-3190
EI 
J9 NEUROCHEM RES
JI Neurochem. Res.
PD DEC 15
PY 2008
VL 33
IS 12
BP 2502
EP 2509
DI 10.1007/s11064-008-9855-x
PG 8
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 373HJ
UT WOS:000260961400013
PM 18998208
DA 2024-11-01
ER

PT J
AU Askanas, V
   Engel, WK
AF Askanas, Valerie
   Engel, W. King
TI Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains
SO ACTA NEUROPATHOLOGICA
LA English
DT Review
DE Inclusion-body myositis; Amyloid-beta; Multiprotein aggregates; Muscle-fiber degeneration; Inflammation; Endoplasmic-reticulum stress; Alzheimer's disease; Parkinson's disease; Lithium; Resveratrol; Aging
ID cultured human muscle; amyloid precursor protein; endoplasmic-reticulum stress; nf-kappa-b; mitochondrial-dna deletions; paired-helical filaments; beta-secretase site; a-beta; proteasome inhibition; skeletal-muscle
AB Sporadic inclusion-body myositis (s-IBM), the most common muscle disease of older persons, is of unknown cause and lacks successful treatment. Here we summarize diagnostic criteria and discuss our current understanding of the steps in the pathogenic cascade. While it is agreed that both degeneration and mononuclear-cell inflammation are components of the s-IBM pathology, how each relates to the pathogenesis remains unsettled. We suggest that the intra-muscle-fiber degenerative component plays the primary role, leading to muscle-fiber destruction and clinical weakness, since anti-inflammatory treatments are not of sustained benefit. We discuss possible treatment strategies aimed toward ameliorating a degenerative component, for example, lithium and resveratrol. Also discussed are the intriguing phenotypic similarities between s-IBM muscle fibers and the brains of Alzheimer and Parkinson's diseases, the most common neurodegenerative diseases associated with aging. Similarities include, in the respective tissues, cellular aging, mitochondrial abnormalities, oxidative and endoplasmic-reticulum stresses, proteasome inhibition and multiprotein aggregates.
C1 [Askanas, Valerie; Engel, W. King] Univ So Calif, Good Samaritan Hosp, Keck Sch Med, USC Neuromuscular Ctr,Dept Neurol, Los Angeles, CA 90017 USA.
C3 University of Southern California
RP Askanas, V (corresponding author), Univ So Calif, Good Samaritan Hosp, Keck Sch Med, USC Neuromuscular Ctr,Dept Neurol, 637 S Lucas Ave, Los Angeles, CA 90017 USA.
EM askanas@usc.edu
FU National Institutes of Health [NS31836, NS34103, AG16768]; The Myositis Association; Helen Lewis Research
CR Abou-Sleiman PM, 2006, NAT REV NEUROSCI, V7, P207, DOI 10.1038/nrn1868
   Askanas V, 1998, AM J PATHOL, V153, P1673, DOI 10.1016/S0002-9440(10)65680-5
   Askanas V, 2006, NEUROLOGY, V66, PS39, DOI 10.1212/01.wnl.0000192128.13875.1e
   Askanas V, 2000, J NEUROPATH EXP NEUR, V59, P592, DOI 10.1093/jnen/59.7.592
   ASKANAS V, 1993, NEUROLOGY, V43, P1265, DOI 10.1212/WNL.43.6.1265-a
   Askanas V, 2003, CURR OPIN RHEUMATOL, V15, P737, DOI 10.1097/00002281-200311000-00009
   ASKANAS V, 1992, AM J PATHOL, V141, P31
   Askanas V, 1996, ANN NEUROL, V39, P389, DOI 10.1002/ana.410390318
   Askanas V, 1996, P NATL ACAD SCI USA, V93, P1314, DOI 10.1073/pnas.93.3.1314
   ASKANAS V, 1992, NEUROLOGY, V42, P460, DOI 10.1212/WNL.42.2.460
   Askanas V, 2001, J NEUROPATH EXP NEUR, V60, P1
   Askanas V, 1998, AM J PATHOL, V152, P889
   ASKANAS V, 1993, ANN NEUROL, V34, P551, DOI 10.1002/ana.410340408
   Askanas V, 1997, NEUROREPORT, V8, P2155, DOI 10.1097/00001756-199707070-00012
   ASKANAS V, 1994, AM J PATHOL, V144, P177
   Askanas V, 2007, CURR OPIN RHEUMATOL, V19, P550, DOI 10.1097/BOR.0b013e3282efdc7c
   Baron P, 2001, NEUROLOGY, V57, P1561, DOI 10.1212/WNL.57.9.1561
   Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315
   Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209
   Bossy-Wetzel E, 2004, NAT MED, V10, PS2, DOI 10.1038/nm1067
   Brunn A, 2006, ACTA NEUROPATHOL, V112, P325, DOI 10.1007/s00401-006-0113-5
   Chahin N, 2008, NEUROLOGY, V70, P418, DOI 10.1212/01.wnl.0000277527.69388.fe
   Chang KA, 2006, MOL CELL BIOL, V26, P4327, DOI 10.1128/MCB.02393-05
   Chen J, 2005, J BIOL CHEM, V280, P40364, DOI 10.1074/jbc.M509329200
   Choi J, 2006, J BIOL CHEM, V281, P10816, DOI 10.1074/jbc.M509079200
   Choi YC, 2000, J BIOL CHEM, V275, P8703, DOI 10.1074/jbc.275.12.8703
   Cookson MR, 2005, ANNU REV BIOCHEM, V74, P29, DOI 10.1146/annurev.biochem.74.082803.133400
   Cucciolla V, 2007, CELL CYCLE, V6, P2495, DOI 10.4161/cc.6.20.4815
   Dalakas MC, 2008, ANN NEUROL, V64, P1, DOI 10.1002/ana.21452
   Dalakas MC, 2006, NAT CLIN PRACT NEURO, V2, P437, DOI 10.1038/ncpneuro0261
   Dalakas MC, 2006, NEUROLOGY, V66, PS33, DOI 10.1212/01.wnl.0000192129.65677.87
   Darin N, 2007, EUR J PAEDIATR NEURO, V11, P353, DOI 10.1016/j.ejpn.2007.02.018
   Derham BK, 1999, PROG RETIN EYE RES, V18, P463, DOI 10.1016/S1350-9462(98)00030-5
   Engel T, 2008, NEURODEGENER DIS, V5, P247, DOI 10.1159/000113715
   ENGEL WK, 1962, NEUROLOGY, V12, P778, DOI 10.1212/WNL.12.11.778
   Engel WK, 2006, NEUROLOGY, V66, PS20, DOI 10.1212/01.wnl.0000192260.33106.bb
   ENGEL WK, 1963, NEUROLOGY, V13, P919, DOI 10.1212/WNL.13.11.919
   ENGEL WK, 1971, EXCERPTA MED INT C S, V237, P28
   Ferreira ST, 2007, IUBMB LIFE, V59, P332, DOI 10.1080/15216540701283882
   Forloni G, 2002, NEUROBIOL AGING, V23, P957, DOI 10.1016/S0197-4580(02)00076-3
   Fratta P, 2005, AM J PATHOL, V167, P517, DOI 10.1016/S0002-9440(10)62994-X
   Fratta P, 2004, NEUROLOGY, V63, P1114, DOI 10.1212/01.WNL.0000138574.56908.5D
   Glabe C, 2001, J MOL NEUROSCI, V17, P137, DOI 10.1385/JMN:17:2:137
   Glabe CG, 2006, NEUROLOGY, V66, PS74, DOI 10.1212/01.wnl.0000192103.24796.42
   Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506
   Hashimoto M, 2003, NEUROMOL MED, V4, P21, DOI 10.1385/NMM:4:1-2:21
   Hong WK, 2007, NEUROCHEM RES, V32, P1483, DOI 10.1007/s11064-007-9336-7
   Hoozemans JJM, 2007, BIOCHEM BIOPH RES CO, V354, P707, DOI 10.1016/j.bbrc.2007.01.043
   Hussain I, 2000, MOL CELL NEUROSCI, V16, P609, DOI 10.1006/mcne.2000.0884
   Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200
   Jaworska-Wilczynska M, 2002, NEUROLOGY, V58, P438, DOI 10.1212/WNL.58.3.438
   Joulia-Ekaza D, 2006, EXP CELL RES, V312, P3458, DOI 10.1016/j.yexcr.2006.07.010
   Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x
   Kitazawa M, 2008, ANN NEUROL, V64, P15, DOI 10.1002/ana.21325
   KSIEZAKREDING H, 1987, P NATL ACAD SCI USA, V84, P3410, DOI 10.1073/pnas.84.10.3410
   Kudo T, 2002, ANN NY ACAD SCI, V977, P349, DOI 10.1111/j.1749-6632.2002.tb04837.x
   Kumamoto T, 2004, ACTA NEUROPATHOL, V107, P59, DOI 10.1007/s00401-003-0774-2
   LaFerla FM, 2007, NAT REV NEUROSCI, V8, P499, DOI 10.1038/nrn2168
   Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105
   Lee MS, 2003, J CELL BIOL, V163, P83, DOI 10.1083/jcb.200301115
   Li H, 2008, J MOL MED, V86, P1113, DOI 10.1007/s00109-008-0373-8
   Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456
   Lindersson E, 2004, J BIOL CHEM, V279, P12924, DOI 10.1074/jbc.M306390200
   Matus S, 2008, CURR MOL MED, V8, P157, DOI 10.2174/156652408784221324
   Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140
   Mirabella M, 1996, J NEUROPATH EXP NEUR, V55, P774, DOI 10.1097/00005072-199607000-00003
   Morosetti R, 2006, P NATL ACAD SCI USA, V103, P16995, DOI 10.1073/pnas.0603386103
   Moslemi AR, 1997, HUM MUTAT, V10, P381, DOI 10.1002/(SICI)1098-1004(1997)10:5<381::AID-HUMU8>3.0.CO;2-I
   Needham M, 2007, LANCET NEUROL, V6, P620, DOI 10.1016/S1474-4422(07)70171-0
   Nogalska A, 2006, J NEUROCHEM, V96, P1491, DOI 10.1111/j.1471-4159.2006.03668.x
   NOGALSKA A, 2008, NEUROBIOL AGING, V0, P0, DOI DOI 10.1016/J.NEUROBIOLAGING.2008.08.21
   Nogalska A, 2008, ANN NEUROL, V64, P0
   Nogalska A, 2007, EXP NEUROL, V204, P610, DOI 10.1016/j.expneurol.2006.12.014
   Olanow CW, 2006, MOVEMENT DISORD, V21, P1806, DOI 10.1002/mds.21013
   Oldfors A, 2006, NEUROLOGY, V66, PS49, DOI 10.1212/01.wnl.0000192127.63013.8d
   Paciello O, 2006, ACTA MYOL, V25, P13
   Prayson RA, 1997, HUM PATHOL, V28, P887, DOI 10.1016/S0046-8177(97)90002-2
   Qin WP, 2006, J BIOL CHEM, V281, P21745, DOI 10.1074/jbc.M602909200
   Santorelli FM, 1996, ANN NEUROL, V39, P789, DOI 10.1002/ana.410390615
   SARKOZI E, 1994, EXP NEUROL, V128, P27, DOI 10.1006/exnr.1994.1109
   Schlossmacher MG, 2002, AM J PATHOL, V160, P1655, DOI 10.1016/S0002-9440(10)61113-3
   Schmidt J, 2008, BRAIN, V131, P1228, DOI 10.1093/brain/awn053
   Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741
   Selkoe DJ, 2003, NEUROCHEM RES, V28, P1705, DOI 10.1023/A:1026065122854
   Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627
   Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114
   Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785
   Stege GJJ, 1999, BIOCHEM BIOPH RES CO, V262, P152, DOI 10.1006/bbrc.1999.1167
   Sun Y, 2005, FEBS J, V272, P2613, DOI 10.1111/j.1742-4658.2005.04708.x
   SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313
   Taira T, 2004, EMBO REP, V5, P213, DOI 10.1038/sj.embor.7400074
   TERRACCIANO C, 2008, NEUROLOGY, V70, PA304, DOI 10.1212/01.WNL.0000296829.66406.14
   Terracciano C, 2008, FREE RADICAL BIO MED, V45, P773, DOI 10.1016/j.freeradbiomed.2008.05.030
   Terracciano C, 2008, ANN NEUROL, V64, P0
   Todd DJ, 2008, NAT REV IMMUNOL, V8, P663, DOI 10.1038/nri2359
   Triantafilou M, 2001, HUM IMMUNOL, V62, P764, DOI 10.1016/S0198-8859(01)00269-5
   Tsai YC, 2003, J BIOL CHEM, V278, P22044, DOI 10.1074/jbc.M212235200
   Tsigelny IF, 2008, PLOS ONE, V3, P0, DOI 10.1371/journal.pone.0003135
   van Leeuwen FW, 2006, J ALZHEIMERS DIS, V9, P319
   Vaquero A, 2007, ONCOGENE, V26, P5505, DOI 10.1038/sj.onc.1210617
   Vattemi G, 2004, AM J PATHOL, V164, P1, DOI 10.1016/S0002-9440(10)63089-1
   Vattemi G, 2003, J NEUROCHEM, V85, P1539, DOI 10.1046/j.1471-4159.2003.01798.x
   Vattemi G, 2003, EXP NEUROL, V179, P150, DOI 10.1016/S0014-4886(02)00025-0
   Vattemi G, 2001, LANCET, V358, P1962, DOI 10.1016/S0140-6736(01)06969-0
   VATTEMI G, 2003, NEUROLOGY, V60, P333
   Vattemi Gaetano, 2003, NEUROLOGY, V60, P0
   Vetrivel KS, 2006, NEUROLOGY, V66, PS69, DOI 10.1212/01.wnl.0000192107.17175.39
   Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015
   Walsh DM, 2007, J NEUROCHEM, V101, P1172, DOI 10.1111/j.1471-4159.2006.04426.x
   Wang HQ, 2007, ANTIOXID REDOX SIGN, V9, P553, DOI 10.1089/ars.2006.1524
   Wojcik S, 2007, NEUROPATH APPL NEURO, V33, P238, DOI 10.1111/j.1365-2990.2006.00821.x
   Wójcik S, 2005, ACTA NEUROPATHOL, V110, P173, DOI 10.1007/s00401-005-1035-3
   Wojcik S, 2007, ACTA NEUROPATHOL, V114, P517, DOI 10.1007/s00401-007-0281-y
   Wojcik S, 2006, NEUROMUSCULAR DISORD, V16, P839, DOI 10.1016/j.nmd.2006.08.009
   Yamamoto H, 2007, MOL ENDOCRINOL, V21, P1745, DOI 10.1210/me.2007-0079
   Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244
   Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203
   Zhang KZ, 2006, NEUROLOGY, V66, PS102, DOI 10.1212/01.wnl.0000192306.98198.ec
NR 118
TC 85
Z9 93
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0001-6322
EI 1432-0533
J9 ACTA NEUROPATHOL
JI Acta Neuropathol.
PD DEC 15
PY 2008
VL 116
IS 6
BP 583
EP 595
DI 10.1007/s00401-008-0449-0
PG 13
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 374EH
UT WOS:000261025200001
PM 18974994
DA 2024-11-01
ER

PT J
AU Brunetti-Pierri, N
   Selby, K
   O'Sullivan, M
   Hendson, G
   Truong, C
   Waters, PJ
   Wong, LJ
AF Brunetti-Pierri, N.
   Selby, K.
   O'Sullivan, M.
   Hendson, G.
   Truong, C.
   Waters, P. J.
   Wong, L. -J.
TI Rapidly Progressive Neurological Deterioration in a Child with Alpers Syndrome Exhibiting a Previously Unremarkable Brain MRI
SO NEUROPEDIATRICS
LA English
DT Article
DE POLG; Alpers syndrome; mitochondrial DNA depletion; DNA polymerase gamma
ID dna-polymerase-gamma; diffuse cerebral degeneration; polg mutations; external ophthalmoplegia; disorders; disease
AB Alpers syndrome is a fatal disorder due to mutations in the POLG gene encoding the catalytic subunit of mitochondrial DNA polymerase gamma (Pol gamma) involved in mitochondrial DNA (mtDNA) replication. We describe a case of Alpers syndrome due to POLG mutations, with rapidly progressive course, a fatal outcome, and an essentially normal brain MRI in the early oligo-symptomatic phase. Our observation suggests that Alpers syndrome should be considered even in patients with an initially unremarkable brain MRI. The patient was found to harbor the p.Q497H, p.W748S and p.E1143G mutations in cis on one allele, and a fourth mutation, the p.G848S on the other allele. Although the individual mutations detected in the presented case have been previously reported, the specific genotype formed by the particular combination of these is novel.
C1 [Brunetti-Pierri, N.; Truong, C.; Wong, L. -J.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Selby, K.] Childrens & Womens Hlth Ctr British Columbia, Dept Pediat, Div Neurol, Vancouver, BC, Canada.
   [Selby, K.; O'Sullivan, M.; Hendson, G.; Waters, P. J.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
   [O'Sullivan, M.; Hendson, G.; Waters, P. J.] Childrens & Womens Hlth Ctr British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada.
C3 Baylor College of Medicine; BC Women's Hospital & Health Centre; University of British Columbia; BC Women's Hospital & Health Centre
RP Wong, LJ (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza,NAB 2015, Houston, TX 77030 USA.
EM ljwong@bcm.edu
FU Dr. Ken Poskitt, Neuroradiologist, British Columbia's Children's Hospital
CR Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   BLACKWOOD W, 1963, ARCH DIS CHILD, V38, P193, DOI 10.1136/adc.38.199.193
   Chan SSL, 2006, HUM MOL GENET, V15, P3473, DOI 10.1093/hmg/ddl424
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   de Laveaucoupet J, 2005, PRENATAL DIAG, V25, P307, DOI 10.1002/pd.1128
   de Vries MC, 2007, EUR J PEDIATR, V166, P229, DOI 10.1007/s00431-006-0234-9
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Hakonen AH, 2007, EUR J HUM GENET, V15, P779, DOI 10.1038/sj.ejhg.5201831
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   HUTTENLOCHER PR, 1976, ARCH NEUROL-CHICAGO, V33, P186, DOI 10.1001/archneur.1976.00500030042009
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   TAYLOR RW, 1997, LAB DIAGNOSIS MITOCH, V0, P0
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
NR 20
TC 9
Z9 9
U1 0
U2 3
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0174-304X
EI 
J9 NEUROPEDIATRICS
JI Neuropediatrics
PD JUN 15
PY 2008
VL 39
IS 3
BP 179
EP 183
DI 10.1055/s-0028-1093334
PG 5
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 375MJ
UT WOS:000261117700008
PM 18991199
DA 2024-11-01
ER

PT J
AU Passtoors, WM
   Beekman, M
   Gunn, D
   Boer, JM
   Heijmans, BT
   Westendorp, RGJ
   Zwaan, BJ
   Slagboom, PE
AF Passtoors, W. M.
   Beekman, M.
   Gunn, D.
   Boer, J. M.
   Heijmans, B. T.
   Westendorp, R. G. J.
   Zwaan, B. J.
   Slagboom, P. E.
TI Genomic studies in ageing research: the need to integrate genetic and gene expression approaches
SO JOURNAL OF INTERNAL MEDICINE
LA English
DT Article; Proceedings Paper
DE ageing; expression; genomics; longevity; transcriptomics
ID sex-specific regulation; transcriptional profile; caloric restriction; skeletal-muscle; microarray data; human longevity; sample-size; oldest-old; blood; disease
AB Genome-wide and hypothesis-based approaches to the study of ageing and longevity have been dominated by genetic investigations. To identify essential mechanisms of a complex trait such as ageing in higher species, a holistic understanding of interacting pathways is required. More information on such interactions is expected to be obtained from global gene expression analysis if combined with genetic studies. Genetic sequence variation often provides a functional gene marker for the trait, whereas a gene expression profile may provide a quantitative biomarker representing complex cellular pathway interactions contributing to the trait. Thus far, gene expression studies have associated multiple pathways to ageing including mitochondrial electron transport and the oxidative stress response. However, most of the studies are underpowered to detect small age-changes. A systematic survey of gene expression changes as a function of age in human individuals and animal models is lacking. Well designed gene expression studies, especially at the level of biological processes, will provide hypotheses on gene-environmental interactions determining biological ageing rate. Cross-sectional studies monitoring the profile as a chronological marker of ageing must be integrated with prospective studies indicating which profiles represent biomarkers preceding and predicting physiological decline and mortality. New study designs such as the Leiden Longevity Study, including two generations of subjects from longevity families, aim to achieve these combined approaches.
C1 [Passtoors, W. M.; Beekman, M.; Heijmans, B. T.; Slagboom, P. E.] Leiden Univ, Med Ctr, Sect Mol Epidemiol, NL-2300 RC Leiden, Netherlands.
   [Gunn, D.] Unilever Corp Res Corp Res, Colworth Lab, Bedford, England.
   [Westendorp, R. G. J.] Leiden Univ, Med Ctr, Dept Gerontol & Geriatr, Leiden, Netherlands.
   [Zwaan, B. J.] Leiden Univ, Inst Biol, Sect Evolutionary Biol, Leiden, Netherlands.
C3 Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Unilever; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC
RP Passtoors, WM (corresponding author), Leiden Univ, Med Ctr, Sect Mol Epidemiol, POB 9600,Zone S5-P, NL-2300 RC Leiden, Netherlands.
EM w.m.passtoors@lumc.nl
CR Achiron A, 2006, AUTOIMMUN REV, V5, P517, DOI 10.1016/j.autrev.2006.02.009
   Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501
   Allison DB, 2006, NAT REV GENET, V7, P55, DOI 10.1038/nrg1749
   Ambra R, 2004, EXP GERONTOL, V39, P1475, DOI 10.1016/j.exger.2004.07.009
   Baird AE, 2007, STROKE, V38, P694, DOI 10.1161/01.STR.0000250431.99687.7b
   Barzilai N, 2001, J AM GERIATR SOC, V49, P76, DOI 10.1046/j.1532-5415.2001.49013.x
   Batliwalla FM, 2005, MOL MED, V11, P21, DOI 10.2119/2006-00003.Gulko
   Borovecki F, 2005, P NATL ACAD SCI USA, V102, P11023, DOI 10.1073/pnas.0504921102
   CAL SX, 2001, P NATL ACAD SCI USA, V98, P10630
   Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8
   Chondrogianni N, 2004, BIOGERONTOLOGY, V5, P401, DOI 10.1007/s10522-004-3188-1
   Chondrogianni N, 2000, EXP GERONTOL, V35, P721, DOI 10.1016/S0531-5565(00)00137-6
   Christensen K, 2006, NAT REV GENET, V7, P436, DOI 10.1038/nrg1871
   Corder EH, 1996, ARCH NEUROL-CHICAGO, V53, P418, DOI 10.1001/archneur.1996.00550050048022
   Csoka AB, 2004, AGING CELL, V3, P235, DOI 10.1111/j.1474-9728.2004.00105.x
   DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279
   Dobbin K, 2005, BIOSTATISTICS, V6, P27, DOI 10.1093/biostatistics/kxh015
   Erraji-Benchekroun L, 2005, BIOL PSYCHIAT, V57, P549, DOI 10.1016/j.biopsych.2004.10.034
   Fjaerli HO, 2006, BMC INFECT DIS, V6, P0, DOI 10.1186/1471-2334-6-175
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Garge NR, 2005, BMC BIOINFORMATICS, V6, P0, DOI 10.1186/1471-2105-6-S2-S10
   Girardot F, 2006, BMC GENOMICS, V7, P0, DOI 10.1186/1471-2164-7-69
   Goeman JJ, 2004, BIOINFORMATICS, V20, P93, DOI 10.1093/bioinformatics/btg382
   Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531
   Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700
   Han ES, 2001, MECH AGEING DEV, V122, P999, DOI 10.1016/S0047-6374(01)00215-9
   Hauser MA, 2005, ARCH NEUROL-CHICAGO, V62, P917, DOI 10.1001/archneur.62.6.917
   Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857
   Heijmans BT, 2006, PLOS MED, V3, P2317, DOI 10.1371/journal.pmed.0030495
   Heijmans BT, 2000, EXP GERONTOL, V35, P865, DOI 10.1016/S0531-5565(00)00171-6
   Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150
   Herndon LA, 2002, NATURE, V419, P808, DOI 10.1038/nature01135
   Herskind AM, 1996, HUM GENET, V97, P319, DOI 10.1007/s004390050042
   HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007
   Huang H, 2004, FRONT BIOSCI-LANDMRK, V9, P1100, DOI 10.2741/1298
   Izuhara Kenji, 2006, ALLERGOL INT, V55, P361, DOI 10.2332/allergolint.55.361
   Kayo T, 2001, P NATL ACAD SCI USA, V98, P5093, DOI 10.1073/pnas.081061898
   Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002
   Kyng KJ, 2005, AGEING RES REV, V4, P579, DOI 10.1016/j.arr.2005.06.008
   Kyng KJ, 2003, P NATL ACAD SCI USA, V100, P12259, DOI 10.1073/pnas.2130723100
   Lacelle C, 2002, MECH AGEING DEV, V123, P1133, DOI 10.1016/S0047-6374(02)00005-2
   LAGAAY AM, 1992, ARCH GERONTOL GERIAT, V15, P115, DOI 10.1016/0167-4943(92)90012-S
   Lai CQ, 2007, MECH AGEING DEV, V128, P237, DOI 10.1016/j.mad.2006.12.003
   Laprise C, 2004, BMC GENOMICS, V5, P0, DOI 10.1186/1471-2164-5-21
   Lee CK, 2002, P NATL ACAD SCI USA, V99, P14988, DOI 10.1073/pnas.232308999
   Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390
   Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046
   López-Lluch G, 2006, P NATL ACAD SCI USA, V103, P1768, DOI 10.1073/pnas.0510452103
   Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661
   Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486
   McCarroll SA, 2004, NAT GENET, V36, P197, DOI 10.1038/ng1291
   McElwee JJ, 2007, GENOME BIOL, V8, P0, DOI 10.1186/gb-2007-8-7-r132
   Michiels S, 2007, BRIT J CANCER, V96, P1155, DOI 10.1038/sj.bjc.6603673
   Nagasaka Y, 2005, P NATL ACAD SCI USA, V102, P14854, DOI 10.1073/pnas.0504178102
   Orwoll ES, 1996, ANN INTERN MED, V124, P187, DOI 10.7326/0003-4819-124-2-199601150-00001
   Palmer C, 2006, BMC GENOMICS, V7, P0, DOI 10.1186/1471-2164-7-115
   Pawitan Y, 2005, BIOINFORMATICS, V21, P3017, DOI 10.1093/bioinformatics/bti448
   Perls TT, 1998, LANCET, V351, P1560, DOI 10.1016/S0140-6736(05)61126-9
   Perls TT, 2002, P NATL ACAD SCI USA, V99, P8442, DOI 10.1073/pnas.122587599
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Qiu HY, 2007, PHYSIOL GENOMICS, V29, P169, DOI 10.1152/physiolgenomics.00229.2006
   Rao DV, 2003, MECH AGEING DEV, V124, P55, DOI 10.1016/S0047-6374(02)00170-7
   Rodwell GEJ, 2004, PLOS BIOL, V2, P2191, DOI 10.1371/journal.pbio.0020427
   Roepman P, 2005, NAT GENET, V37, P182, DOI 10.1038/ng1502
   Schoenmaker M, 2006, EUR J HUM GENET, V14, P79, DOI 10.1038/sj.ejhg.5201508
   Sharma A, 2005, PHYSIOL GENOMICS, V21, P117, DOI 10.1152/physiolgenomics.00228.2003
   Sharp FR, 2007, STROKE, V38, P691, DOI 10.1161/01.STR.0000247940.27518.38
   Sharp FR, 2006, ARCH NEUROL-CHICAGO, V63, P1529, DOI 10.1001/archneur.63.11.1529
   Skytthe A, 2003, TWIN RES, V6, P448, DOI 10.1375/136905203770326457
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sreekumar R, 2002, AM J PHYSIOL-ENDOC M, V283, PE38, DOI 10.1152/ajpendo.00387.2001
   Sullivan PF, 2006, AM J MED GENET B, V141B, P261, DOI 10.1002/ajmg.b.30272
   Tan QH, 2005, HUM GENET, V117, P267, DOI 10.1007/s00439-005-1308-x
   Tang Y, 2005, ARCH NEUROL-CHICAGO, V62, P210, DOI 10.1001/archneur.62.2.210
   Tang Y, 2006, J CEREBR BLOOD F MET, V26, P1089, DOI 10.1038/sj.jcbfm.9600264
   Tatar Marc, 2007, V35, V0, P115
   Terry DF, 2004, J AM GERIATR SOC, V52, P2074, DOI 10.1111/j.1532-5415.2004.52561.x
   Tower J, 2006, MECH AGEING DEV, V127, P705, DOI 10.1016/j.mad.2006.05.001
   van Baarsen LGM, 2006, GENES IMMUN, V7, P522, DOI 10.1038/sj.gene.6364324
   vant Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Vijg J, 2003, MECH AGEING DEV, V124, P3, DOI 10.1016/S0047-6374(02)00163-X
   Welle S, 2004, EXP GERONTOL, V39, P369, DOI 10.1016/j.exger.2003.11.011
   Welle S, 2003, PHYSIOL GENOMICS, V14, P149, DOI 10.1152/physiolgenomics.00049.2003
   Whitney AR, 2003, P NATL ACAD SCI USA, V100, P1896, DOI 10.1073/pnas.252784499
   Yang T, 2004, MOL BRAIN RES, V132, P155, DOI 10.1016/j.molbrainres.2003.10.014
   Zahn JM, 2006, PLOS GENET, V2, P1058, DOI 10.1371/journal.pgen.0020115
NR 86
TC 15
Z9 15
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0954-6820
EI 1365-2796
J9 J INTERN MED
JI J. Intern. Med.
PD FEB 15
PY 2008
VL 263
IS 2
BP 153
EP 166
DI 10.1111/j.1365-2796.2007.01904.x
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA 254AE
UT WOS:000252557900005
PM 18226093
DA 2024-11-01
ER

PT J
AU Mancuso, M
   Ricci, G
   Choub, A
   Filosto, M
   DiMauro, S
   Davidzon, G
   Tessa, A
   Santorelli, FM
   Murri, L
   Siciliano, G
AF Mancuso, Michelangelo
   Ricci, Giulia
   Choub, Anna
   Filosto, Massimiliano
   DiMauro, Salvatore
   Davidzon, Guido
   Tessa, Alessandra
   Santorelli, Filippo M.
   Murri, Luigi
   Siciliano, Gabriele
TI Autosomal dominant psychiatric disorders and mitochondrial DNA multiple deletions: Report of a family
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Article
DE mtDNA; mitochondrial disease; psychiatric symptoms; bipolar disorder; schizophrenia
ID bipolar affective-disorder; progressive external ophthalmoplegia; mutation; schizophrenia; symptoms; disease; melas
AB Background: Psychiatric problems, including bipolar affective disorder (BD) and schizophrenia, are common in mitochondrial diseases (MD) and frequently precede the diagnosis of mitochondrial dysfunction. However, they are rarely the only persistent manifestation of a MD and they are usually associated with other neurological or non-neuro logical features. Case report: Here, we describe an Italian family with multiple deletions of mtDNA in muscle, in which BD, schizophrenia, and depression recurred over several generations in the absence of other major signs of mitochondrial dysfunction. Conclusion: In patients with positive family history of psychiatric problems, the possibility of MD should be kept in mind, even in absence of other canonical features of mitochondrial encephalomyopathies. (c) 2007 Elsevier B.V. All rights reserved.
C1 [Mancuso, Michelangelo; Ricci, Giulia; Choub, Anna; Murri, Luigi; Siciliano, Gabriele] Univ Pisa, Dept Neurosci, Neurol Clin, I-56126 Pisa, Italy.
   [Filosto, Massimiliano] Univ Brescia, Neurol Clin, I-25121 Brescia, Italy.
   [DiMauro, Salvatore; Davidzon, Guido] Columbia Univ, Med Ctr, Dept Neurol, New York, NY USA.
   [Tessa, Alessandra; Santorelli, Filippo M.] Bambino Gesu Pediat Hosp, IRCCS, Rome, Italy.
C3 University of Pisa; University of Brescia; Columbia University; IRCCS Bambino Gesu
RP Mancuso, M (corresponding author), Univ Pisa, Dept Neurosci, Neurol Clin, Via Roma 67, I-56126 Pisa, Italy.
EM mmancuso@inwind.it
CR Ben-Shachar D, 2004, INT REV NEUROBIOL, V59, P273
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Gershon ES, 1990, MANICDEPRESSIVE ILLNESS, V0, P373
   Inagaki T, 1997, BIOL PSYCHIAT, V42, P1067, DOI 10.1016/S0006-3223(97)00351-X
   Kato T, 1997, BIOL PSYCHIAT, V42, P871, DOI 10.1016/S0006-3223(97)00012-7
   Kato T, 1998, J NEUROPSYCH CLIN N, V10, P133, DOI 10.1176/jnp.10.2.133
   Kato T, 2001, J AFFECT DISORDERS, V62, P151, DOI 10.1016/S0165-0327(99)00173-1
   Kato T, 2000, BIPOLAR DISORD, V2, P180, DOI 10.1034/j.1399-5618.2000.020305.x
   Kirk R, 1999, AM J HUM GENET, V65, P508, DOI 10.1086/302507
   Köller H, 2003, J NEUROL, V250, P1501, DOI 10.1007/s00415-003-0260-8
   Lewis CM, 2003, AM J HUM GENET, V73, P34, DOI 10.1086/376549
   Mancuso M, 2004, NEUROLOGY, V62, P2119, DOI 10.1212/01.WNL.0000127608.48406.F1
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   MCMAHON FJ, 1995, AM J HUM GENET, V56, P1277
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Thomeer EC, 1998, J NEUROL NEUROSUR PS, V64, P692, DOI 10.1136/jnnp.64.5.692
NR 18
TC 26
Z9 28
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0327
EI 
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD FEB 15
PY 2008
VL 106
IS 1-2
BP 173
EP 177
DI 10.1016/j.jad.2007.05.016
PG 5
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 258YC
UT WOS:000252905300018
PM 17588675
DA 2024-11-01
ER

PT J
AU Ferraris, S
   Clark, S
   Garelli, E
   Davidzon, G
   Moore, SA
   Kardon, RH
   Bienstock, RJ
   Longley, MJ
   Mancuso, M
   Ríos, PG
   Hirano, M
   Copeland, WC
   DiMauro, S
AF Ferraris, Silvio
   Clark, Susanna
   Garelli, Emanuela
   Davidzon, Guido
   Moore, Steven A.
   Kardon, Randy H.
   Bienstock, Rachelle J.
   Longley, Matthew J.
   Mancuso, Michelangelo
   Rios, Purificacion Gutierrez
   Hirano, Michio
   Copeland, William C.
   DiMauro, Salvatore
TI Progressive external ophthalmoplegia and vision and hearing loss in a patient with mutations in <i>POLG2</i> and <i>OPA1</i>
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID accessory subunit; autosomal-dominant; dna-synthesis; polymerase; deletions; binding
AB objective: To describe the clinical features, muscle pathological characteristics, and molecular studies of a patient with a mutation in the gene encoding the accessory subunit (p55) of polymerase gamma (POLG2) and a mutation in the OPAL gene. Design: Clinical examination and morphological., biochemical, and molecular analyses. Setting: Tertiary care university hospitals and molecular genetics and scientific computing laboratory. Patient: A 42-year-old man experienced hearing loss, progressive external ophthalmoplegia (PEO), loss of central vision, macrocytic anemia, and hypogonadism. His family history was negative for neurological disease, and his serum lactate level was normal. Results: A muscle biopsy specimen showed scattered intensely succinate dehydrogenase-positive and cytochrome-c oxidase-negative fibers. Southern blot of muscle mitochondrial DNA showed multiple deletions. The results of screening for mutations in the nuclear genes associated with PEO and multiple mitochondrial DNA deletions, including those in POLG (polymerase gamma gene), ANTI (gene. encoding adenine nucleotide translocator 1), and PEO1, were negative, but sequencing of POLG2 revealed a G1247C mutation in exon 7, resulting in the substitution of a highly conserved glycine with an alanine at codon 416 (G416A). Because biochemical analysis of the mutant protein showed no alteration in chromatographic properties and normal ability to protect the catalytic subunit from N-ethylmaleimide, we also sequenced the OPAL gene and identified a novel heterozygous mutation (Y582C). Conclusion: Although we initially focused on the mutation in POLG2, the mutation in OPAL is more likely to explain the late-onset PEO and multisystem disorder in this patient.
C1 [Davidzon, Guido; Rios, Purificacion Gutierrez; Hirano, Michio; DiMauro, Salvatore] Columbia Univ, Dept Neurol, Med Ctr, New York, NY 10032 USA.
   [Ferraris, Silvio; Garelli, Emanuela] Univ Turin, Dept Pediat, I-10124 Turin, Italy.
   [Clark, Susanna; Bienstock, Rachelle J.; Longley, Matthew J.; Copeland, William C.] Natl Inst Environm Hlth Sci, Lab Mol Genet & Sci Comp Lab, NIH, Res Triangle Pk, NC USA.
   [Moore, Steven A.] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA.
   [Kardon, Randy H.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA USA.
   [Mancuso, Michelangelo] Univ Pisa, Dept Neurosci, Neurol Inst, Pisa, Italy.
C3 Columbia University; University of Turin; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Iowa; University of Iowa; University of Pisa
RP DiMauro, S (corresponding author), Columbia Univ, Dept Neurol, Med Ctr, 1150 St Nicholas Ave,Room 313, New York, NY 10032 USA.
EM sd12@columbia.edu
FU Intramural NIH HHS [Z01 ES065078-14] Funding Source: Medline; NICHD NIH HHS [HD32062, P01 HD032062] Funding Source: Medline; NINDS NIH HHS [NS11766, P01 NS011766] Funding Source: Medline
CR Carr M J, 2001, CURR OPIN PULM MED, V7, P1, DOI 10.1097/00063198-200101000-00001
   Carrodeguas JA, 2002, J BIOL CHEM, V277, P50008, DOI 10.1074/jbc.M207030200
   Di Mauro S, 2004, MYOLOGY PHILADELPHIA, V0, P1623
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Fan L, 2006, J MOL BIOL, V358, P1229, DOI 10.1016/j.jmb.2006.02.073
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Hudson G, 2006, NEUROLOGY, V66, P1439, DOI 10.1212/01.wnl.0000210486.32196.24
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Longley Matthew J, 2002, METHODS MOL BIOL, V197, P245, DOI 10.1385/1-59259-284-8:245
   Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244
   Pinz KG, 2006, DNA REPAIR, V5, P121, DOI 10.1016/j.dnarep.2005.08.014
   Rowland LP, 1994, MITOCHONDRIAL DISORDERS IN NEUROLOGY, V0, P116
   Sambrook J, 1990, COLD SPRING HARBOR LABORATORIES, V186, P182
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 23
TC 40
Z9 45
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9942
EI 1538-3687
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD JAN 15
PY 2008
VL 65
IS 1
BP 125
EP 131
DI 10.1001/archneurol.2007.9
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 250PR
UT WOS:000252313000017
PM 18195150
DA 2024-11-01
ER

PT J
AU Hirano, M
   Angelini, C
   Montagna, P
   Hays, AP
   Tanji, K
   Mitsumoto, H
   Gordon, PH
   Naini, AB
   DiMauro, S
   Rowland, LP
AF Hirano, Michio
   Angelini, Corrado
   Montagna, Pasquale
   Hays, Arthur P.
   Tanji, Kurenai
   Mitsumoto, Hiroshi
   Gordon, Paul H.
   Naini, Ali B.
   DiMauro, Salvatore
   Rowland, Lewis P.
TI Amyotrophic lateral sclerosis with ragged-red fibers
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID spinal muscular-atrophy; mitochondrial-dna depletion; c-oxidase deficiency; mutation; gene; myopathy; disease
AB Background: Motor neuron diseases (amyotrophic lateral sclerosis [ALS] and spinal muscular atrophy [SMA]) have been rarely associated with mitochondrial respiratory chain defects. Objectives: To describe a patient with typical ALS and the finding of ragged-red fibers in muscle biopsy specimens and to review the literature on respiratory chain defects in ALS and SMA. Design: Case report and review of the literature. Setting: Collaboration between tertiary care academic hospitals. Patient: A 65-year-old man with typical ALS. Main Outcome Measures: The patient had 10% ragged-red fibers and 3% cytochrome-c oxidase-negative fibers in muscle biopsy specimens but no biochemical defects of respiratory chain enzymes or alterations of mitochondrial DNA (mtDNA). Results: Amyotrophic lateral sclerosis with ragged-red fibers has been reported in 5 families and is associated with mtDNA mutations in some subjects. Spinal muscular atrophy without mutations in the survival motor neuron gene (SMN; OMIM 600354) has been associated with mtDNA depletion or with mutations in the cytochrome-c oxidase assembly gene (SCO2; OMIM 604377). Conclusion: Respiratory chain defects can mimic ALS or SMA and should be considered in the differential diagnosis.
C1 [Hirano, Michio; Hays, Arthur P.; Tanji, Kurenai; Mitsumoto, Hiroshi; Gordon, Paul H.; Naini, Ali B.; DiMauro, Salvatore; Rowland, Lewis P.] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA.
   [Hays, Arthur P.; Tanji, Kurenai] Columbia Univ, Med Ctr, Dept Pathol, New York, NY 10032 USA.
   [Angelini, Corrado] Univ Padua, Dept Neurol, Padua, Italy.
   [Montagna, Pasquale] Univ Bologna, Dept Neurol Sci, Bologna, Italy.
C3 Columbia University; Columbia University; University of Padua; University of Bologna
RP Hirano, M (corresponding author), Columbia Univ, Med Ctr, Dept Neurol, 3-317 Russ Berrie Med Sci Pavil,1150 St Nicholas, New York, NY 10032 USA.
EM mh29@columbia.edu
FU NICHD NIH HHS [HD32062] Funding Source: Medline; Telethon [GTF05003] Funding Source: Medline
CR Beal MF, 2005, ANN NEUROL, V58, P495, DOI 10.1002/ana.20624
   Borthwick Gillian M, 2006, ANN NEUROL, V59, P570, DOI 10.1002/ana.20758
   Comi GP, 1998, ANN NEUROL, V43, P110, DOI 10.1002/ana.410430119
   DiMauro S, 2004, BBA-BIOENERGETICS, V1659, P107, DOI 10.1016/j.bbabio.2004.08.003
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   DOBKIN BH, 1976, NEUROLOGY, V26, P754, DOI 10.1212/WNL.26.8.754
   Fetoni V, 2004, NEUROMUSCULAR DISORD, V14, P723, DOI 10.1016/j.nmd.2004.07.002
   Finsterer J, 2003, NEUROLOGIST, V9, P45, DOI 10.1097/01.nrl.0000038589.58012.a8
   Hays AP, 2006, MITOCHONDRIAL MEDICINE, V0, P45
   Mancuso M, 2003, ACTA NEUROPATHOL, V105, P621, DOI 10.1007/s00401-003-0699-9
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Pons R, 1996, PEDIATR NEUROL, V15, P153, DOI 10.1016/0887-8994(96)00118-X
   ROWLAND LP, 1991, REV NEUROL-FRANCE, V147, P467
   Rubio-Gozalbo ME, 1999, NEUROLOGY, V52, P383, DOI 10.1212/WNL.52.2.383
   Salviati L, 2002, ARCH NEUROL-CHICAGO, V59, P862, DOI 10.1001/archneur.59.5.862
   Tanji K, 2001, METHOD CELL BIOL, V65, P311, DOI 10.1016/S0091-679X(01)65019-2
   Tarnopolsky MA, 2004, AM J MED GENET A, V125A, P310, DOI 10.1002/ajmg.a.20466
NR 18
TC 25
Z9 28
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9942
EI 1538-3687
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD MAR 15
PY 2008
VL 65
IS 3
BP 403
EP 406
DI 10.1001/archneurol.2007.65
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 272TD
UT WOS:000253881900017
PM 18332255
DA 2024-11-01
ER

PT J
AU Giordano, C
   Sebastiani, M
   De Giorgio, R
   Travaglini, C
   Tancredi, A
   Valentino, ML
   Bellan, M
   Cossarizza, A
   Hirano, M
   d'Amati, G
   Carelli, V
AF Giordano, Carla
   Sebastiani, Mariangela
   De Giorgio, Roberto
   Travaglini, Claudia
   Tancredi, Andrea
   Valentino, Maria Lucia
   Bellan, Marzio
   Cossarizza, Andrea
   Hirano, Michio
   d'Amati, Giulia
   Carelli, Valerio
TI Gastrointestinal dysmotility in mitochondrial neurogastrointestinal encephalomyopathy is caused by mitochondrial DNA depletion
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID thymidine; deletions; expression; tissue; disease; model
AB Chronic intestinal pseudo-obstruction is a life-threatening condition of unknown pathogenic mechanisms. Chronic intestinal pseudo-obstruction can be a feature of mitochondrial disorders, such as mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), a rare autosomal-recessive syndrome, resulting from mutations in the thymidine phosphorylase gene. MNGIE patients show elevated circulating levels of thyrmidine and deoxyuridine, and accumulate somatic mitochondrial DNA (mtDNA) defects. The present study aimed to clarify the molecular basis of chronic intestinal pseudo-obstruction in MNGIE. Using laser capture microdissection, we correlated the histopathological features with mtDNA defects in different tissues from the gastrointestinal wall of five MNGIE and ten control patients. We found mtDNA depletion, mitochondrial proliferation, and smooth cell atrophy in the external layer of the muscularis propria, in the stomach and in the small intestine of MNGIE patients. in controls, the lowest amounts of mtDNA were present at the same sites, as compared with other layers of the gastrointestinal wall. We also observed mitochondrial proliferation and mtDNA depletion in small vessel endothelial and smooth muscle cells. Thus, visceral mitochondrial myopathy likely causes gastrointestinal dysmotility in MNGIE patients. The low baseline abundance of mtDNA molecules may predispose smooth muscle cells of the muscularis propria external layer to the toxic effects of thymidine and deoxyuridine, and exposure to high circulating levels of nucleosides; may account for the mtDNA depletion observed in the small vessel wall.
C1 [Giordano, Carla; Sebastiani, Mariangela; Travaglini, Claudia; d'Amati, Giulia] Univ Roma La Sapienza, Dipartimento Med Sperimentale, I-00161 Rome, Italy.
   Univ Bologna, Dept Internal Med & Gastroentrol, I-40126 Bologna, Italy.
   Univ Bologna, Dipartimento Sci Neurol, I-40126 Bologna, Italy.
   [Tancredi, Andrea] Univ Roma La Sapienza, Dipartimento Studi Geoecon, Rome, Italy.
   [Hirano, Michio] Columbia Univ, Med Ctr, New York, NY USA.
C3 Sapienza University Rome; University of Bologna; University of Bologna; Sapienza University Rome; Columbia University
RP d'Amati, G (corresponding author), Univ Roma La Sapienza, Dipartimento Med Sperimentale, Viale Regina Elena 324, I-00161 Rome, Italy.
EM giulia.damati@uniroma1.it
FU Associazione Serena Tallarico; MIUR; University of Bologna; Sapienza University of Rome; Fondazione Del Monte di Bologna e Ravenna; Fondazione Gino Galletti
CR Archer RGE, 2004, BRIT J PHARMACOL, V143, P202, DOI 10.1038/sj.bjp.0705921
   Bindoff L, 2006, MITOCHONDRIAL MEDICINE, V0, P143
   Connor FL, 2006, GASTROENTEROLOGY, V130, PS29, DOI 10.1053/j.gastro.2005.06.081
   De Giorgio R, 2004, GUT, V53, P1549, DOI 10.1136/gut.2004.043968
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Ferraro P, 2005, J BIOL CHEM, V280, P24472, DOI 10.1074/jbc.M502869200
   GERLACH E, 1985, BASIC RES CARDIOL, V80, P459, DOI 10.1007/BF01907911
   Giordano C, 2006, GASTROENTEROLOGY, V130, P893, DOI 10.1053/j.gastro.2006.01.004
   Heddi A, 1999, J BIOL CHEM, V274, P22968, DOI 10.1074/jbc.274.33.22968
   Hirano M, 2006, NEUROLOGY, V67, P1458, DOI 10.1212/01.wnl.0000240853.97716.24
   Jain D, 2003, AM J GASTROENTEROL, V98, P618, DOI 10.1016/S0002-9270(02)06017-3
   Krishnan KJ, 2007, ANAL BIOCHEM, V370, P127, DOI 10.1016/j.ab.2007.06.024
   Löffler M, 2007, ARTERIOSCL THROM VAS, V27, P1004, DOI 10.1161/ATVBAHA.106.126714
   Mussini C, 2005, AIDS, V19, P1627, DOI 10.1097/01.aids.0000186019.47297.0d
   Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 2000, ANN NEUROL, V47, P792
   Pinheiro JC, 2000, MIXED-EFFECT. MODEL. S AND S-PLUS, V0, P3
   Pontarin G, 2006, J BIOL CHEM, V281, P22720, DOI 10.1074/jbc.M604498200
   Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Stanghellini V, 2007, NEUROGASTROENT MOTIL, V19, P440, DOI 10.1111/j.1365-2982.2007.00902.x
   Szigeti K, 2004, ANN NEUROL, V56, P881, DOI 10.1002/ana.20302
   Valentino ML, 2007, FEBS LETT, V581, P3410, DOI 10.1016/j.febslet.2007.06.042
NR 24
TC 76
Z9 79
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD OCT 15
PY 2008
VL 173
IS 4
BP 1120
EP 1128
DI 10.2353/ajpath.2008.080252
PG 9
WC Pathology
SC Pathology
GA 354OD
UT WOS:000259648000020
PM 18787099
DA 2024-11-01
ER

PT J
AU Hudson, G
   Amati-Bonneau, P
   Blakely, EL
   Stewart, JD
   He, LP
   Schaefer, AM
   Griffiths, PG
   Ahlqvist, K
   Suomalainen, A
   Reynier, P
   McFarland, R
   Turnbull, DM
   Chinnery, PF
   Taylor, RW
AF Hudson, Gavin
   Amati-Bonneau, Patrizia
   Blakely, Emma L.
   Stewart, Joanna D.
   He, Langping
   Schaefer, Andrew M.
   Griffiths, Philip G.
   Ahlqvist, Kati
   Suomalainen, Anu
   Reynier, Pascal
   McFarland, Robert
   Turnbull, Douglass M.
   Chinnery, Patrick F.
   Taylor, Robert W.
TI Mutation of <i>OPA1</i> causes dominant optic atrophy with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions:: a novel disorder of mtDNA maintenance
SO BRAIN
LA English
DT Article
DE mitochondria; mitochondrial DNA; mitochondrial encephalomyopathy; autosomal dominant progressive external ophthalmoplegia; autosomal dominant optic atrophy; multiple mtDNA deletions
ID sensorineural hearing-loss; dynamin-related protein; autosomal-dominant; 3-methylglutaconic aciduria; fusion mediators; gene; depletion; dysfunction; morphology; apoptosis
AB Mutations in nuclear genes involved in mitochondrial DNA ( mtDNA) maintenance cause a wide range of clinical phenotypes associated with the secondary accumulation of multiple mtDNA deletions in affected tissues. The majority of families with autosomal dominant progressive external ophthalmoplegia ( PEO) harbour mutations in genes encoding one of three well-characterized proteins - pol gamma, Twinkle or Ant 1. Here we show that a heterozygous mis-sense mutation in OPA1 leads to multiple mtDNA deletions in skeletal muscle and a mosaic defect of cytochrome c oxidase ( COX). The disorder presented with visual failure and optic atrophy in childhood, followed by PEO, ataxia, deafness and a sensory-motor neuropathy in adult life. COX-deficient skeletal muscle fibres contained supra-threshold levels of multiple mtDNA deletions, and genetic linkage, sequencing and expression analysis excluded POLG1, PEO1 and SLC25A4, the gene encoding Ant 1, as the cause. This demonstrates the importance of OPA1 in mtDNA maintenance, and implicates OPA1 in diseases associated with secondary defects of mtDNA.
C1 [Hudson, Gavin; Blakely, Emma L.; Stewart, Joanna D.; He, Langping; Schaefer, Andrew M.; McFarland, Robert; Turnbull, Douglass M.; Chinnery, Patrick F.; Taylor, Robert W.] Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Amati-Bonneau, Patrizia; Reynier, Pascal] Ctr Hosp Univ Angers, Dept Biochim & Genet, Angers, France.
   [Amati-Bonneau, Patrizia; Reynier, Pascal] INSERM, U694, Angers, France.
   [Griffiths, Philip G.] Royal Victoria Infirm, Dept Ophthalmol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   [Ahlqvist, Kati; Suomalainen, Anu] Univ Helsinki, Ctr Hosp, Dept Neurol, Helsinki, Finland.
   [Ahlqvist, Kati; Suomalainen, Anu] Univ Helsinki, Res Program Mol Neurol, FIN-00014 Helsinki, Finland.
   [Turnbull, Douglass M.; Chinnery, Patrick F.; Taylor, Robert W.] Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne, Tyne & Wear, England.
C3 Newcastle University - UK; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Newcastle University - UK; University of Helsinki; University of Helsinki; Newcastle University - UK
RP Chinnery, PF (corresponding author), Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM p.f.chinnery@ncl.ac.uk
FU Medical Research Council [G0601943, G108/539] Funding Source: Medline; Wellcome Trust [074454] Funding Source: Medline; MRC [G0601943, G108/539] Funding Source: UKRI
CR Alavi MV, 2007, BRAIN, V130, P1029, DOI 10.1093/brain/awm005
   Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Amati-Bonneau P, 2005, ANN NEUROL, V58, P958, DOI 10.1002/ana.20681
   Andrews RM, 1999, BRIT J OPHTHALMOL, V83, P231, DOI 10.1136/bjo.83.2.231
   Anikster Y, 2001, AM J HUM GENET, V69, P1218, DOI 10.1086/324651
   Barbet F, 2005, J MED GENET, V42, P0, DOI 10.1136/jmg.2004.025502
   Barbet F, 2003, EUR J HUM GENET, V11, P966, DOI 10.1038/sj.ejhg.5201070
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   COSTEFF H, 1995, BRAIN DEV-JPN, V17, P226, DOI 10.1016/0387-7604(95)00014-3
   Davies VJ, 2007, HUM MOL GENET, V16, P1307, DOI 10.1093/hmg/ddm079
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   Duvezin-Caubet S, 2006, J BIOL CHEM, V281, P37972, DOI 10.1074/jbc.M606059200
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2006, NEUROLOGY, V66, P1439, DOI 10.1212/01.wnl.0000210486.32196.24
   Jacobs HT, 2000, BIOESSAYS, V22, P564, DOI 10.1002/(SICI)1521-1878(200006)22:6<564::AID-BIES9>3.0.CO;2-4
   Katz BJ, 2006, AM J MED GENET A, V140A, P2207, DOI 10.1002/ajmg.a.31455
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kerrison JB, 1999, ARCH OPHTHALMOL-CHIC, V117, P805
   Kim JY, 2005, NEUROLOGY, V64, P966, DOI 10.1212/01.WNL.0000157282.76715.B1
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lee S, 2007, J BIOL CHEM, V282, P22977, DOI 10.1074/jbc.M700679200
   Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294
   Li CM, 2005, AM J MED GENET A, V138A, P208, DOI 10.1002/ajmg.a.30794
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   MANDERBACKA K, 2001, SCANDINAVIAN J P S55, V29, P41
   Nakamura M, 2006, OPHTHALMOLOGY, V113, P483, DOI 10.1016/j.ophtha.2005.10.054
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200
   Olichon A, 2002, FEBS LETT, V523, P171, DOI 10.1016/S0014-5793(02)02985-X
   Olichow A, 2007, J CELL PHYSIOL, V211, P423, DOI 10.1002/jcp.20950
   Payne M, 2004, AM J OPHTHALMOL, V138, P749, DOI 10.1016/j.ajo.2004.06.011
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Sörensen L, 2001, J NEUROSCI, V21, P8082, DOI 10.1523/JNEUROSCI.21-20-08082.2001
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Taylor RW, 1997, ORGANELLE DISEASES : CLINICAL FEATURES, V0, Pathogenesis
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Verhoeven K, 2006, BRAIN, V129, P2093, DOI 10.1093/brain/awl126
   Waterham HR, 2007, NEW ENGL J MED, V356, P1736, DOI 10.1056/NEJMoa064436
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
   Züchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
   Züchner S, 2006, ANN NEUROL, V59, P276, DOI 10.1002/ana.20797
NR 52
TC 326
Z9 342
U1 0
U2 25
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD FEB 15
PY 2008
VL 131
IS 
BP 329
EP 337
DI 10.1093/brain/awm272
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 258XO
UT WOS:000252903900006
PM 18065439
DA 2024-11-01
ER

PT J
AU Murphy, JL
   Blakely, EL
   Schaefer, AM
   He, L
   Wyrick, P
   Haller, RG
   Taylor, RW
   Turnbull, DM
   Taivassalo, T
AF Murphy, Julie L.
   Blakely, Emma L.
   Schaefer, Andrew M.
   He, Langping
   Wyrick, Phil
   Haller, Ronald G.
   Taylor, Robert W.
   Turnbull, Douglass M.
   Taivassalo, Tanja
TI Resistance training in patients with single, large-scale deletions of mitochondrial DNA
SO BRAIN
LA English
DT Article
ID human skeletal-muscle; real-time pcr; satellite cells; physiological adaptations; individual cells; trapezius muscle; point mutation; older men; myopathy; encephalomyopathy
AB Dramatic tissue variation in mitochondrial heteroplasmy has been found to exist in patients with sporadic mitochondrial DNA (mtDNA) mutations. Despite high abundance in mature skeletal muscle, levels of the causative mutation are low or undetectable in satellite cells. The activation of these typically quiescent mitotic cells and subsequent shifting of wild-type mtDNA templates to mature muscle have been proposed as a means of restoring a more normal mitochondrial genotype and function in these patients. Because resistance exercise is known to serve as a stimulus for satellite cell induction within active skeletal muscle, this study sought to assess the therapeutic potential of resistance training in eight patients with single, large-scale mtDNA deletions by assessing: physiological determinants of peak muscle strength and oxidative capacity and muscle biopsy-derived measures of damage, mtDNA mutation load, level of oxidative impairment and satellite cell numbers. Our results show that 12 weeks of progressive overload leg resistance training led to: (i) increased muscle strength; (ii) myofibre damage and regeneration; (iii) increased proportion of neural cell adhesion molecule (NCAM)-positive satellite cells; (iv) improved muscle oxidative capacity. Taken together, we believe these findings support the hypothesis of resistance exercise-induced mitochondrial gene-shifting in muscle containing satellite cells which have low or absent levels of deleted mtDNA. Further investigation is warranted to refine parameters of the exercise training protocol in order to maximize the training effect on mitochondrial genotype and treatment potential for patients with selected, sporadic mutations of mtDNA in skeletal muscle.
C1 [Murphy, Julie L.; Blakely, Emma L.; Schaefer, Andrew M.; He, Langping; Taylor, Robert W.; Turnbull, Douglass M.] Univ Newcastle, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Wyrick, Phil; Haller, Ronald G.] Inst Exercise & Environm Med, Dallas, TX USA.
   [Taivassalo, Tanja] McGill Univ, Dept Kinesiol, Montreal, PQ H3A 2T5, Canada.
   [Taivassalo, Tanja] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada.
C3 Newcastle University - UK; McGill University; McGill University
RP Murphy, JL (corresponding author), Univ Newcastle, Mitochondrial Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM d.m.turnbull@ncl.ac.uk
FU uscular Dystrophy Campaign UK; Welcome Trust; United Mitochondrial Disease Foundation; Canadian Institutes of Health Research; VA Merit Review; Muscular Dystrophy Association USA; Fonds de Recherche en Sante du Quebec (FRSQ); MRC [G0601943] Funding Source: UKRI
CR Andrews H, 2006, J NEUROSCI RES, V83, P1533, DOI 10.1002/jnr.20842
   Barron MJ, 2005, NEUROMUSCULAR DISORD, V15, P768, DOI 10.1016/j.nmd.2005.06.018
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Blakely EL, 2004, J MED GENET, V41, P0, DOI 10.1136/jmg.2003.011296
   BROOKE MH, 1970, ARCH NEUROL-CHICAGO, V23, P369, DOI 10.1001/archneur.1970.00480280083010
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   Crameri RM, 2007, J PHYSIOL-LONDON, V583, P365, DOI 10.1113/jphysiol.2007.128827
   DARR KC, 1987, J APPL PHYSIOL, V63, P1816, DOI 10.1152/jappl.1987.63.5.1816
   Deschenes MR, 2002, AM J PHYS MED REHAB, V81, PS3, DOI 10.1097/01.PHM.0000029722.06777.E9
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Hikida RS, 2000, J GERONTOL A-BIOL, V55, PB347, DOI 10.1093/gerona/55.7.B347
   Jeppesen TD, 2006, BRAIN, V129, P3402, DOI 10.1093/brain/awl149
   Kadi F, 2000, HISTOCHEM CELL BIOL, V113, P99, DOI 10.1007/s004180050012
   Kadi F, 1999, HISTOCHEM CELL BIOL, V111, P189, DOI 10.1007/s004180050348
   Kirby DM, 2007, METHOD CELL BIOL, V80, P93, DOI 10.1016/S0091-679X(06)80004-X
   KRAEMER WJ, 1988, SPORTS MED, V6, P246, DOI 10.2165/00007256-198806040-00006
   Krishnan KJ, 2007, ANAL BIOCHEM, V370, P127, DOI 10.1016/j.ab.2007.06.024
   McFarland R, 2004, NEUROMUSCULAR DISORD, V14, P162, DOI 10.1016/j.nmd.2003.10.011
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Roth SM, 2001, J GERONTOL A-BIOL, V56, PB240, DOI 10.1093/gerona/56.6.B240
   SCHULTZ E, 1985, MUSCLE NERVE, V8, P217, DOI 10.1002/mus.880080307
   SCHULTZ E, 1994, REV PHYSIOL BIOCH P, V123, P213, DOI 10.1007/BFb0030904
   Shoubridge EA, 1997, HUM MOL GENET, V6, P2239, DOI 10.1093/hmg/6.13.2239
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 1998, NEUROLOGY, V50, P1055, DOI 10.1212/WNL.50.4.1055
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   Taivassalo T, 2004, BBA-BIOENERGETICS, V1659, P221, DOI 10.1016/j.bbabio.2004.09.007
   Taivassalo T, 2006, BRAIN, V129, P3391, DOI 10.1093/brain/awl282
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   Weber K, 1997, AM J HUM GENET, V60, P373
NR 34
TC 121
Z9 127
U1 1
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 
J9 BRAIN
JI Brain
PD NOV 15
PY 2008
VL 131
IS 
BP 2832
EP 2840
DI 10.1093/brain/awn252
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 373MQ
UT WOS:000260976400005
PM 18984605
DA 2024-11-01
ER

PT J
AU Amati-Bonneau, P
   Valentino, ML
   Reynier, P
   Gallardo, ME
   Bornstein, B
   Boissière, A
   Campos, Y
   Rivera, H
   de la Aleja, JG
   Carroccia, R
   Iommarini, L
   Labauge, P
   Figarella-Branger, D
   Marcorelles, P
   Furby, A
   Beauvais, K
   Letournel, F
   Liguori, R
   La Morgia, C
   Montagna, P
   Liguori, M
   Zanna, C
   Rugolo, M
   Cossarizza, A
   Wissinger, B
   Verny, C
   Schwarzenbacher, R
   Martín, MA
   Arenas, J
   Ayuso, C
   Garesse, R
   Lenaers, G
   Bonneau, D
   Carelli, V
AF Amati-Bonneau, Patrizia
   Valentino, Maria Lucia
   Reynier, Pascal
   Gallardo, Maria Esther
   Bornstein, Belen
   Boissiere, Anne
   Campos, Yolanda
   Rivera, Henry
   de la Aleja, Jesus Gonzalez
   Carroccia, Rosanna
   Iommarini, Luisa
   Labauge, Pierre
   Figarella-Branger, Dominique
   Marcorelles, Pascale
   Furby, Alain
   Beauvais, Katell
   Letournel, Franck
   Liguori, Rocco
   La Morgia, Chiara
   Montagna, Pasquale
   Liguori, Maria
   Zanna, Claudia
   Rugolo, Michela
   Cossarizza, Andrea
   Wissinger, Bernd
   Verny, Christophe
   Schwarzenbacher, Robert
   Martin, Miguel Angel
   Arenas, Joaquin
   Ayuso, Carmen
   Garesse, Rafael
   Lenaers, Guy
   Bonneau, Dominique
   Carelli, Valerio
TI <i>OPA1</i> mutations induce mitochondrial DNA instability and optic atrophy plus phenotypes
SO BRAIN
LA English
DT Article
DE mitochondria; mtDNA multiple deletions; dominant optic atrophy; mitochondrial encephalomyopathy; chronic progressive external ophthalmoplegia
ID progressive external ophthalmoplegia; r445h mutation; hearing-loss; deletions; gene; disease; association; dynamics; deafness; protein
AB Mutations in OPA1, a dynamin-related GTPase involved in mitochondrial fusion, cristae organization and control of apoptosis, have been linked to non-syndromic optic neuropathy transmitted as an autosomal-dominant trait (DOA). We here report on eight patients from six independent families showing that mutations in the OPA1 gene can also be responsible for a syndromic form of DOA associated with sensorineural deafness, ataxia, axonal sensory-motor polyneuropathy, chronic progressive external ophthalmoplegia and mitochondrial myopathy with cytochrome c oxidase negative and Ragged Red Fibres. Most remarkably, we demonstrate that these patients all harboured multiple deletions of mitochondrial DNA (mtDNA) in their skeletal muscle, thus revealing an unrecognized role of the OPA1 protein in mtDNA stability. The five OPA1 mutations associated with these DOA plus phenotypes were all mis-sense point mutations affecting highly conserved amino acid positions and the nuclear genes previously known to induce mtDNA multiple deletions such as POLG1, PEO1 (Twinkle) and SLC25A4 (ANT1) were ruled out. Our results show that certain OPA1 mutations exert a dominant negative effect responsible for multi-systemic disease, closely related to classical mitochondrial cytopathies, by a mechanism involving mtDNA instability.
C1 [Valentino, Maria Lucia; Carroccia, Rosanna; Iommarini, Luisa; Liguori, Rocco; La Morgia, Chiara; Montagna, Pasquale; Carelli, Valerio] Univ Bologna, Dipartimento Sci Neurol, Neurogenet Lab, Via Ugo Foscolo 7, I-40123 Bologna, Italy.
   [Amati-Bonneau, Patrizia; Reynier, Pascal] Ctr Hosp Univ Angers, Dept Biochim & Genet, Angers, France.
   [Amati-Bonneau, Patrizia; Reynier, Pascal] INSERM, U694, Angers, France.
   [Gallardo, Maria Esther; Bornstein, Belen] Univ Autonoma Madrid, Fac Med, Inst Investigac Biomed Alberto Sols CSIC UAM, Dept Bioquim,CIBERERISCIII, Madrid, Spain.
   [Boissiere, Anne; Lenaers, Guy] Univ Montpellier I, Inst Neurosci, INSERM, U583, Montpellier, France.
   [Boissiere, Anne; Lenaers, Guy] Univ Montpellier 2, Inst Neurosci, INSERM, U583, Montpellier, France.
   [Campos, Yolanda; Rivera, Henry; de la Aleja, Jesus Gonzalez; Martin, Miguel Angel; Arenas, Joaquin] Hosp Univ 12 Octubre, CIBERER, ISCIII, Ctr Invest, Madrid, Spain.
   [Campos, Yolanda; Rivera, Henry; de la Aleja, Jesus Gonzalez; Martin, Miguel Angel; Arenas, Joaquin] Hosp Univ 12 Octubre, CIBERER, ISCIII, Serv Neurol, Madrid, Spain.
   [Labauge, Pierre] Ctr Hosp Univ Nimes, Serv Neurol, Nimes, France.
   [Figarella-Branger, Dominique] Ctr Hosp Univ, Hop Timone, Serv Anat Pathol & Neuropathol, Marseille, France.
   [Marcorelles, Pascale] Ctr Hosp Univ Brest, Serv Anat Pathol, Brest, France.
   [Furby, Alain; Beauvais, Katell] Ctr Hosp Univ St Brieuc, Serv Neurol, St Brieuc, France.
   [Letournel, Franck] Ctr Hosp Univ Angers, Lab Neurobiol & Neuropathol, Angers, France.
   [Liguori, Maria] Natl Res Ctr Mangone, Inst Neurol Sci, Cosenza, Italy.
   [Zanna, Claudia; Rugolo, Michela] Univ Bologna, Dipartimento Biol Evoluz Sperimentale, Bologna, Italy.
   [Cossarizza, Andrea] Univ Modena, Sezione Patol Gen, Dipartimento Sci Biomed, I-41100 Modena, Italy.
   [Cossarizza, Andrea] Univ Reggio Emilia, Sezione Patol Gen, Dipartimento Sci Biomed, Reggio Emilia, Italy.
   [Wissinger, Bernd] Univ Eye Hosp Tuebingen, Mol Genet Lab, Tubingen, Germany.
   [Verny, Christophe] Ctr Hosp Univ Angers, Dept Neurol, Angers, France.
   [Schwarzenbacher, Robert] Salzburg Univ, A-5020 Salzburg, Austria.
   [Ayuso, Carmen] Fdn Jimenez Diaz, CIBERER, ISCIII, Madrid, Spain.
C3 University of Bologna; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Instituto de Salud Carlos III; Hospital Universitario 12 de Octubre; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Hospital Universitario 12 de Octubre; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Instituto de Salud Carlos III; Universite de Montpellier; CHU de Nimes; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CHU Brest; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; University of Bologna; Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Salzburg University; Instituto de Salud Carlos III; CIBER - Centro de Investigacion Biomedica en Red; CIBERER
RP Carelli, V (corresponding author), Univ Bologna, Dipartimento Sci Neurol, Neurogenet Lab, Via Ugo Foscolo 7, I-40123 Bologna, Italy.
EM valerio.carelli@unibo.it
FU Telethon [GGP06233] Funding Source: Medline
CR Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Amati-Bonneau P, 2005, ANN NEUROL, V58, P958, DOI 10.1002/ana.20681
   Amati-Bonneau P, 2003, AM J OPHTHALMOL, V136, P1170, DOI 10.1016/S0002-9394(03)00665-2
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Chen HC, 2005, HUM MOL GENET, V14, PR283, DOI 10.1093/hmg/ddi270
   Chen HC, 2007, CELL, V130, P548, DOI 10.1016/j.cell.2007.06.026
   Cohn AC, 2007, AM J OPHTHALMOL, V143, P656, DOI 10.1016/j.ajo.2006.12.038
   Cossarizza A, 2003, ANTIVIR THER, V8, P315
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   Delettre C, 2002, MOL GENET METAB, V75, P97, DOI 10.1006/mgme.2001.3278
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Ferré M, 2005, HUM MUTAT, V25, P423, DOI 10.1002/humu.20161
   Frezza C, 2006, CELL, V126, P177, DOI 10.1016/j.cell.2006.06.025
   Ghelli A, 2003, J BIOL CHEM, V278, P4145, DOI 10.1074/jbc.M210285200
   González-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107
   Herlan M, 2003, J BIOL CHEM, V278, P27781, DOI 10.1074/jbc.M211311200
   Hirano M, 2004, NEUROLOGIST, V10, P8, DOI 10.1097/01.nrl.0000106919.06469.04
   HOPPINS S, 2007, ANN REV BIOCH, V776, P0
   HUDSON G, 2007, BRAIN, V0, P0
   Hudson G, 2006, HUM MOL GENET, V15, PR244, DOI 10.1093/hmg/ddl233
   Jaroszewski L, 2002, PROTEIN SCI, V11, P1702, DOI 10.1110/ps.4820102
   JOHNSTON W, 1995, ANN NEUROL, V37, P16, DOI 10.1002/ana.410370106
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kim JY, 2005, NEUROLOGY, V64, P966, DOI 10.1212/01.WNL.0000157282.76715.B1
   KJER P, 1959, ACTA OPHTHALMOL S54, V37, P1
   Lodi R, 2004, ANN NEUROL, V56, P719, DOI 10.1002/ana.20278
   Low HH, 2006, NATURE, V444, P766, DOI 10.1038/nature05312
   Malka F, 2006, BBA-MOL CELL RES, V1763, P463, DOI 10.1016/j.bbamcr.2006.04.001
   MEIRE F, 1985, OPHTHALMIC PAED GEN, V5, P91, DOI 10.3109/13816818509007861
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Nakamura M, 2006, OPHTHALMOLOGY, V113, P483, DOI 10.1016/j.ophtha.2005.10.054
   Niemann A, 2005, J CELL BIOL, V170, P1067, DOI 10.1083/jcb.200507087
   Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200
   Olichon A, 2006, BBA-MOL CELL RES, V1763, P500, DOI 10.1016/j.bbamcr.2006.04.003
   Payne M, 2004, AM J OPHTHALMOL, V138, P749, DOI 10.1016/j.ajo.2004.06.011
   Pesch UEA, 2001, HUM MOL GENET, V10, P1359, DOI 10.1093/hmg/10.13.1359
   Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313
   Shimizu S, 2003, AM J OPHTHALMOL, V135, P256, DOI 10.1016/S0002-9394(02)01929-3
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Staden R, 2000, METHODS MOL BIOL, V132, P115
   TREFT RL, 1984, OPHTHALMOLOGY, V91, P908
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Waterham HR, 2007, NEW ENGL J MED, V356, P1736, DOI 10.1056/NEJMoa064436
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Züchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
NR 50
TC 399
Z9 430
U1 1
U2 33
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD FEB 15
PY 2008
VL 131
IS 
BP 338
EP 351
DI 10.1093/brain/awm298
PG 14
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 258XO
UT WOS:000252903900007
PM 18158317
DA 2024-11-01
ER

PT J
AU Deschauer, M
   Zierz, S
AF Deschauer, Marcus
   Zierz, Stephan
TI Chronic Progressive External Ophthalmoplegia - A Common Ocular Manifestation of Mitochondrial Disorders
SO PEDIATRIC OPHTHALMOLOGY, NEURO-OPHTHALMOLOGY, GENETICS
LA English
DT Article; Book Chapter
ID probable germline mosaicism; kearns-sayre-syndrome; dna deletions; gene mutation; retinal manifestations; muscular-dystrophy; myasthenia-gravis; a3243g mutation; mtdna deletions; hearing-loss
C1 [Deschauer, Marcus] Univ Halle Wittenberg, Neurol Klin, D-06097 Halle, Germany.
   [Zierz, Stephan] Neurol Univ Klin, D-06120 Halle, Saale, Germany.
C3 Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg
RP Deschauer, M (corresponding author), Univ Halle Wittenberg, Neurol Klin, Ernst Grube Str 40, D-06097 Halle, Germany.
CR Andrews RM, 1999, EYE, V13, P769, DOI 10.1038/eye.1999.225
   Baker SK, 2003, EXPERT OPIN INV DRUG, V12, P1655, DOI 10.1517/eoid.12.10.1655.21840
   Bau V, 2005, STRABISMUS, V13, P133, DOI 10.1080/09273970500216432
   BEYENBURG S, 1993, ACTA NEUROL SCAND, V87, P397
   Brown DT, 2006, LANCET, V368, P87, DOI 10.1016/S0140-6736(06)68972-1
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   Deschauer M, 2007, NEUROLOGY, V68, P1741, DOI 10.1212/01.wnl.0000261929.92478.3e
   Deschauer M, 2005, NEUROMUSCULAR DISORD, V15, P311, DOI 10.1016/j.nmd.2004.12.004
   Deschauer M, 2004, GENET TEST, V8, P395, DOI 10.1089/gte.2004.8.395
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   Deschauer M, 2001, ARCH NEUROL-CHICAGO, V58, P1885, DOI 10.1001/archneur.58.11.1885
   Deschauer M, 2000, MOL GENET METAB, V70, P235, DOI 10.1006/mgme.2000.3002
   DiMauro S, 2007, J CLIN INVEST, V117, P587, DOI 10.1172/JCI31423
   Gamez J, 2002, NEUROLOGY, V59, P455, DOI 10.1212/WNL.59.3.455
   Gellerich FN, 2002, BBA-BIOENERGETICS, V1556, P41, DOI 10.1016/S0005-2728(02)00305-5
   GOETHEM GV, 2001, NAT GENET, V28, P211
   Hanisch E, 2005, EUR J MED RES, V10, P366
   Hanisch F, 2006, J NEUROL, V253, P417, DOI 10.1007/s00415-006-0987-0
   Hanisch F, 2006, J NEUROL, V253, P659, DOI 10.1007/s00415-005-0032-8
   Hirano M, 2006, NEUROLOGY, V67, P1458, DOI 10.1212/01.wnl.0000240853.97716.24
   Hoch W, 2001, NAT MED, V7, P365, DOI 10.1038/85520
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2006, NEUROLOGY, V66, P1439, DOI 10.1212/01.wnl.0000210486.32196.24
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Isashiki Y, 1998, ACTA OPHTHALMOL SCAN, V76, P6, DOI 10.1034/j.1600-0420.1998.760103.x
   Jeppesen TD, 2006, BRAIN, V129, P3402, DOI 10.1093/brain/awl149
   Jones KJ, 1997, NEUROMUSCULAR DISORD, V7, P143, DOI 10.1016/S0960-8966(97)00447-1
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KAWAI H, 1995, MUSCLE NERVEL, V8, P753
   Kornblum C, 2001, NEUROLOGY, V56, P1409, DOI 10.1212/WNL.56.10.1409
   Krasnianski M, 2004, NEUROMUSCULAR DISORD, V14, P438, DOI 10.1016/j.nmd.2004.03.007
   Krasnianski M, 2003, ARCH NEUROL-CHICAGO, V60, P1421, DOI 10.1001/archneur.60.10.1421
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Müller JS, 2007, BRAIN, V130, P1497, DOI 10.1093/brain/awm068
   Müller T, 2006, J NEUROL, V253, P892, DOI 10.1007/s00415-006-0126-y
   Müller T, 2005, ACTA NEUROPATHOL, V110, P426, DOI 10.1007/s00401-005-1063-z
   MULLIE MA, 1985, ARCH OPHTHALMOL-CHIC, V103, P1825, DOI 10.1001/archopht.1985.01050120059020
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   NITSCH J, 1990, Z KARDIOL, V79, P60
   Pineda M, 2006, ANN NEUROL, V59, P394, DOI 10.1002/ana.20746
   Remes AM, 2005, NEUROLOGY, V64, P976, DOI 10.1212/01.WNL.0000154518.31302.ED
   Richardson C, 2005, EYE, V19, P258, DOI 10.1038/sj.eye.6701488
   Sato A, 2005, P NATL ACAD SCI USA, V102, P16765, DOI 10.1073/pnas.0506197102
   SATOYOSHI E, 1977, ARCH NEUROL-CHICAGO, V34, P89, DOI 10.1001/archneur.1977.00500140043007
   Shipton EA, 2004, EUR J ANAESTH, V21, P173, DOI 10.1017/S0265021504003023
   Sinnathuray AR, 2003, OTOL NEUROTOL, V24, P418, DOI 10.1097/00129492-200305000-00012
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Swalwell H, 2006, NEUROLOGY, V66, P447, DOI 10.1212/01.wnl.0000196490.36349.83
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 2006, BRAIN, V129, P3391, DOI 10.1093/brain/awl282
   Walker M, 2005, DIABETIC MED, V22, P18, DOI 10.1111/j.1464-5491.2005.1761f.x
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wallace DK, 1997, OPHTHALMOLOGY, V104, P695, DOI 10.1016/S0161-6420(97)30250-4
   Wong VA, 2002, OPHTHALMOLOGY, V109, P1023, DOI 10.1016/S0161-6420(02)01009-6
   Yamashita T, 2004, NEUROLOGY, V63, P759, DOI 10.1212/01.WNL.0000134678.45047.F4
   YU WMC, 2005, NEUROMUSCULAR DISORD, V15, P17
   YU WMC, 2005, EYE, V20, P564
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   ZEVIANI M, 1989, J NEUROL, V236, P97
   ZIERZ S, 1990, NERVENARZT, V61, P322
NR 63
TC 4
Z9 4
U1 0
U2 0
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 1612-3212
EI 
J9 ESSENT OPHTHALMOL
PD JUN 15
PY 2008
VL 0
IS 
BP 267
EP 282
DI 10.1007/978-3-540-33679-2_15
PG 16
WC Neurosciences; Ophthalmology; Pediatrics
SC Neurosciences & Neurology; Ophthalmology; Pediatrics
GA BMM20
UT WOS:000272789100015
DA 2024-11-01
ER

PT J
AU Harihara, S
   Nakamura, K
   Fujiwara, M
   Arai, T
   Sawabe, M
   Takeuchi, F
   Takubo, K
AF Harihara, Shinji
   Nakamura, Kenichi
   Fujiwara, Mutsunori
   Arai, Tomio
   Sawabe, Motoji
   Takeuchi, Fujio
   Takubo, Kaiyo
TI Markedly different clinical features in 2 diabetes mellitus patients with extremely high tissue levels of the mitochondrial DNA A3243G mutation
SO GERONTOLOGY
LA English
DT Article
DE mitochondrial DNA; mtDNA A3243G mutation; diabetes mellitus
ID stroke-like episodes; lactic-acidosis; gene mutation; encephalopathy; heteroplasmy; deletions; myopathy; deafness; family
AB Background: Mitochondrial DNA (mtDNA) A3243G mutation is one of the major causative factors of mitochondrial diabetes mellitus. We found that tissues from 2 of 142 diabetes mellitus patients showed extremely high levels of the mutation. Objective: To investigate the level of the mutation in each tissue and to find the relationship between the mutation level and clinical features of the patients. Methods: Patient 1 was a 51-year-old woman, diagnosed as having diabetes mellitus at the age of 17, and was admitted to hospital because of cerebral infarction. Patient 2 was an 82-yearold woman who was admitted because of respiratory failure. mtDNA A3243G levels were measured in tissues collected at autopsy. Results: In patient 1, mtDNA A3243G levels were found to vary among the tissues. The patient's highest mtDNA A3243G value was 42% and the lowest value was 9%, whereas the level in most individuals is usually less than 1%. Although patient 2 did not exhibit serious clinical symptoms of diabetes mellitus, the mtDNA A3243G level was extremely high in all of the tissues surveyed (range 32-47%). Conclusion: Although both patients showed high levels of the mtDNA A3243G mutation, their clinical conditions differed greatly. Thus, mitochondrial diabetes mellitus patients may show a wide variety of clinical features and large variations in life span. Copyright (c) 2008 S. Karger AG, Basel.
C1 [Takeuchi, Fujio] Univ Tokyo, Grad Sch Sci, Fac Med, Dept Internal Med, Tokyo 1130033, Japan.
   [Harihara, Shinji] Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Fac Med,Bunkyo Ku, Tokyo 1130033, Japan.
   [Nakamura, Kenichi; Takubo, Kaiyo] Tokyo Metropolitan Inst Gerontol, Res Team Geriatr Dis, Tokyo, Japan.
   [Fujiwara, Mutsunori] Tokyo Red Cross Med Ctr, Dept Lab Med, Tokyo, Japan.
   [Arai, Tomio; Sawabe, Motoji] Tokyo Metropolitan Geriatr Med Ctr, Dept Anat, Tokyo, Japan.
   [Arai, Tomio; Sawabe, Motoji] Tokyo Metropolitan Geriatr Med Ctr, Dept Clin Pathol, Tokyo, Japan.
C3 University of Tokyo; University of Tokyo; Tokyo Metropolitan Institute of Gerontology; Tokyo Metropolitan Institute of Gerontology; Tokyo Metropolitan Institute of Gerontology
RP Harihara, S (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Fac Med,Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.
EM harihara@biol.s.u-tokyo.ac.jp
CR Asano T, 1999, DIABETOLOGIA, V42, P1439
   Chinnery PF, 1999, AM J MED GENET, V85, P498
   DEVRIES D, 1994, J NEUROL SCI, V124, P77, DOI 10.1016/0022-510X(94)90014-0
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   Harihara S, 2002, EXP GERONTOL, V37, P917, DOI 10.1016/S0531-5565(02)00020-7
   Harrison TJ, 1997, AM J OPHTHALMOL, V124, P217, DOI 10.1016/S0002-9394(14)70787-1
   HOLME E, 1995, BBA-MOL BASIS DIS, V1271, P249, DOI 10.1016/0925-4439(95)00035-3
   KATAGIRI H, 1994, DIABETOLOGIA, V37, P504, DOI 10.1007/s001250050139
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   LARSSON NG, 1995, ANNU REV GENET, V29, P51
   Maassen JA, 2004, DIABETES, V53, PS103, DOI 10.2337/diabetes.53.2007.S103
   MARIOTTI C, 1995, J NEUROL, V242, P304, DOI 10.1007/BF00878873
   Mawrin C, 2004, NEUROSCI LETT, V357, P111, DOI 10.1016/j.neulet.2003.11.073
   MORAES CT, 1992, NAT GENET, V1, P359, DOI 10.1038/ng0892-359
   OKA Y, 1993, LANCET, V342, P527, DOI 10.1016/0140-6736(93)91649-7
   REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3
   Takeuchi F, 2003, EXP GERONTOL, V38, P339, DOI 10.1016/S0531-5565(02)002090-7
   Takubo K, 2000, J GERONTOL A-BIOL, V55, PB533, DOI 10.1093/gerona/55.11.B533
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Vilarinho L, 1997, J INHERIT METAB DIS, V20, P704, DOI 10.1023/A:1005330611147
   Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251
NR 21
TC 1
Z9 1
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0304-324X
EI 
J9 GERONTOLOGY
JI Gerontology
PD JUN 15
PY 2008
VL 54
IS 3
BP 168
EP 172
DI 10.1159/000127415
PG 5
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 314GV
UT WOS:000256798800008
PM 18417955
DA 2024-11-01
ER

PT J
AU Vladutiu, GD
AF Vladutiu, Georgirene D.
TI Genetic predisposition to statin myopathy
SO CURRENT OPINION IN RHEUMATOLOGY
LA English
DT Review
DE carnitine palmitoyltransferase II deficiency; coenzyme Q10; cytochrome P-450; genetic predisposition; McArdle disease; muscle disease; pharmacogenetics; pharmacogenomics; rhabdomyolysis; statin myopathy
ID adverse drug-reactions; slco1b1 polymorphism; skeletal-muscle; risk-factors; pharmacogenomics; coenzyme-q10; mutations; atorvastatin; deficiency; therapy
AB Purpose of review Genetic predisposition to statin myopathy is a rapidly expanding area of investigation. This review summarizes the latest information on genetic risk factors associated with statin-induced myopathy. Genetic determinants involved in both pharmacokinetics of statins and metabolic muscle diseases are discussed. Data are provided on the prevalence of statin use in the United States; incidence of associated myopathy; terminology relating to statin myopathy and genetic susceptibility; and common myths surrounding this disorder. Recent findings Technological advances now make it possible to identify genetic variation in the human genome that reveals disease-causing mutations and single nucleotide polymorphisms associated with disease. More than 30 000 individuals in the United States suffer from severe life-threatening symptoms of statin-induced myopathy that may, in some cases, persist long after the cessation of therapy. Genes of interest include those involved in the pharmacokinetics of the statin response, muscle atrophy, exercise intolerance, pain perception, and mitochondrial energy metabolism. Summary Genetic analysis for variants and disease-causing mutations relevant to statin myopathy will provide predisposition testing for this and other drug-induced disorders. This testing will become an integral part of personalized medicine that will contribute to the safe and informed use of selected drugs and improved compliance.
C1 [Vladutiu, Georgirene D.] SUNY Buffalo, Sch Med & Biomed Sci, Dept Pediat Neurol & Pathol, Buffalo, NY 14260 USA.
   [Vladutiu, Georgirene D.] SUNY Buffalo, Sch Med & Biomed Sci, Dept Anat Sci, Buffalo, NY 14260 USA.
C3 State University of New York (SUNY) System; University at Buffalo, SUNY; State University of New York (SUNY) System; University at Buffalo, SUNY
RP Vladutiu, GD (corresponding author), Buffalo Gen Hosp, 100 High St, Buffalo, NY 14203 USA.
EM gdv@buffalo.edu
CR Ansell BJ, 2006, AM HEART J, V152, P976, DOI 10.1016/j.ahj.2006.05.013
   Baer AN, 2007, CURR OPIN RHEUMATOL, V19, P67
   Baker SK, 2008, CAN J NEUROL SCI, V35, P8, DOI 10.1017/S0317167100007514
   Bays H, 2006, AM J CARDIOL, V97, P6C, DOI 10.1016/j.amjcard.2005.12.006
   Capasso M, 2006, MUSCLE NERVE, V33, P760, DOI 10.1002/mus.20525
   Casarin A, 2008, BIOCHEM BIOPH RES CO, V372, P35, DOI 10.1016/j.bbrc.2008.04.172
   Caso G, 2007, AM J CARDIOL, V99, P1409, DOI 10.1016/j.amjcard.2006.12.063
   Chan J, 2005, ANN PHARMACOTHER, V39, P1611, DOI 10.1345/aph.1G035
   Christopher-Stine L, 2006, CURR OPIN RHEUMATOL, V18, P647
   Date H, 2001, NAT GENET, V29, P184, DOI 10.1038/ng1001-184
   DiMauro S, 2007, J CLIN INVEST, V117, P587, DOI 10.1172/JCI31423
   Draeger A, 2006, J PATHOL, V210, P94, DOI 10.1002/path.2018
   Frudakis TN, 2007, PHARMACOGENET GENOM, V17, P695, DOI 10.1097/FPC.0b013e328012d0a9
   Gempel K, 2007, BRAIN, V130, P2037, DOI 10.1093/brain/awm054
   Graham DJ, 2004, JAMA-J AM MED ASSOC, V292, P2585, DOI 10.1001/jama.292.21.2585
   Guis S, 2006, ARTHRIT RHEUM-ARTHR, V55, P551, DOI 10.1002/art.22100
   Haller RG, 2000, ARCH NEUROL-CHICAGO, V57, P923, DOI 10.1001/archneur.57.7.923
   Hanai JI, 2007, J CLIN INVEST, V117, P3940, DOI 10.1172/JCI32741
   Harper CR, 2007, CURR OPIN LIPIDOL, V18, P401, DOI 10.1097/MOL.0b013e32825a6773
   Kawashiri MA, 2008, CLIN PHARMACOL THER, V83, P731, DOI 10.1038/sj.clpt.6100396
   Kollek R, 2006, COMMUNITY GENET, V9, P50, DOI 10.1159/000090693
   König J, 2006, N-S ARCH PHARMACOL, V372, P432, DOI 10.1007/s00210-006-0040-y
   Lagier-Tourenne C, 2008, AM J HUM GENET, V82, P661, DOI 10.1016/j.ajhg.2007.12.024
   Law M, 2006, AM J CARDIOL, V97, P52C, DOI 10.1016/j.amjcard.2005.12.010
   Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936
   López LC, 2006, AM J HUM GENET, V79, P1125, DOI 10.1086/510023
   Mangravite LM, 2007, CURR OPIN LIPIDOL, V18, P409
   Marcoff L, 2007, J AM COLL CARDIOL, V49, P2231, DOI 10.1016/j.jacc.2007.02.049
   McKenney JM, 2006, AM J CARDIOL, V97, P89C, DOI 10.1016/j.amjcard.2006.02.030
   *MED EXP PAN SURV, 2005, AG HEALTHC RES QUAL, V0, P0
   Mollet J, 2007, J CLIN INVEST, V117, P765, DOI 10.1172/JCI29089
   Needham M, 2007, NEUROMUSCULAR DISORD, V17, P194, DOI 10.1016/j.nmd.2006.10.007
   Niemi M, 2006, CLIN PHARMACOL THER, V80, P356, DOI 10.1016/j.clpt.2006.06.010
   Oh J, 2007, LIPIDS HEALTH DIS, V6, P0, DOI 10.1186/1476-511X-6-7
   Pasanen MK, 2007, CLIN PHARMACOL THER, V82, P726, DOI 10.1038/sj.clpt.6100220
   Pasternak RC, 2002, J AM COLL CARDIOL, V40, P567, DOI 10.1016/S0735-1097(02)02030-2
   Phillips PS, 2002, ANN INTERN MED, V137, P581, DOI 10.7326/0003-4819-137-7-200210010-00009
   Quinzii C, 2006, AM J HUM GENET, V78, P345, DOI 10.1086/500092
   Rodrigues AC, 2007, CURR OPIN MOL THER, V9, P545
   Ross CJD, 2007, ANN NY ACAD SCI, V1110, P177, DOI 10.1196/annals.1423.020
   Ruaño G, 2005, PHARMACOGENOMICS, V6, P865, DOI 10.2217/14622416.6.8.865
   Ruaño G, 2007, MUSCLE NERVE, V36, P329, DOI 10.1002/mus.20871
   Sailler L, 2008, ANN RHEUM DIS, V67, P614, DOI 10.1136/ard.2007.075523
   Schmitz G, 2007, CURR OPIN LIPIDOL, V18, P164, DOI 10.1097/MOL.0b013e3280555083
   Schwarz UI, 2008, NEW ENGL J MED, V358, P999, DOI 10.1056/NEJMoa0708078
   Shek A, 2001, ANN PHARMACOTHER, V35, P908, DOI 10.1345/aph.10315
   Shurin SB, 2008, NEW ENGL J MED, V358, P1061, DOI 10.1056/NEJMe0800801
   Thompson PD, 2006, AM J CARDIOL, V97, P69C, DOI 10.1016/j.amjcard.2005.12.013
   Vladutiu G, 2007, ARTHRIT RHEUM-ARTHR, V57, P186, DOI 10.1002/art.22487
   Vladutiu GD, 2006, MUSCLE NERVE, V34, P153, DOI 10.1002/mus.20567
   Wilke RA, 2007, NAT REV DRUG DISCOV, V6, P904, DOI 10.1038/nrd2423
NR 51
TC 58
Z9 63
U1 1
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8711
EI 1531-6963
J9 CURR OPIN RHEUMATOL
JI Curr. Opin. Rheumatol.
PD NOV 15
PY 2008
VL 20
IS 6
BP 648
EP 655
DI 10.1097/BOR.0b013e328314b7b4
PG 8
WC Rheumatology
SC Rheumatology
GA 374LW
UT WOS:000261045900002
PM 18946323
DA 2024-11-01
ER

PT J
AU Swalwell, H
   Blakely, EL
   Sutton, R
   Tonska, K
   Elstner, M
   He, L
   Taivassalo, T
   Burns, DK
   Turnbull, DM
   Haller, RG
   Davidson, MM
   Taylor, RW
AF Swalwell, Helen
   Blakely, Emma L.
   Sutton, Ruth
   Tonska, Kasia
   Elstner, Matthias
   He, Langping
   Taivassalo, Tanja
   Burns, Dennis K.
   Turnbull, Douglass M.
   Haller, Ronald G.
   Davidson, Mercy M.
   Taylor, Robert W.
TI A homoplasmic mtDNA variant can influence the phenotype of the pathogenic m.7472Cins <i>MTTS1</i> mutation:: are two mutations better than one?
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE mitochondrial DNA; tRNA mutation; heteroplasmy; cybrid analysis; homoplasmic variant
ID mitochondrial genome database; inherited hearing-loss; 7472insc mutation; point mutation; dna mutations; trna(ser(ucn)); gene; dehydrogenase; cells
AB Mutations in mitochondrial tRNA (mt-tRNA) genes are well recognized as a common cause of human disease, exhibiting a significant degree of clinical heterogeneity. While these differences are explicable, in part, by differences in the innate pathogenicity of the mutation, its distribution and abundance, other factors, including nuclear genetic background, mitochondrial DNA (mtDNA) haplotype and additional mtDNA mutations may influence the expression of mt-tRNA mutations. We describe the clinical, biochemical and molecular findings in a family with progressive myopathy, deafness and diabetes and striking respiratory chain abnormalities due to a well-characterized heteroplasmic mt-tRNA mutation in the mt-tRNA(Ser(UCN)) (MTTS1) gene. In addition to the m.7472Cins mutation, all individuals were homoplasmic for another variant, m.7472>C, affecting the adjacent nucleotide in the mt-tRNA(Ser(UCN)) structure. In addition to available patient tissues, we have analysed transmitochondrial cybrid clones harbouring homoplasmic levels of m.7472>C and varying levels of the m.7472Cins mutation in an attempt to clarify the precise role of the m.7472A>C transversion in the underlying respiratory chain abnormality. Evidence from both in vivo and in vitro studies demonstrate that the m.7472A>C is able to modify the expression of the m.7472Cins mutation and would suggest that it is not a neutral variant but appears to cause a biochemical defect by itself, confirming that homoplasmic mtDNA variants can modulate the phenotypic expression of pathogenic, heteroplasmic mtDNA mutations.
C1 [Swalwell, Helen; Blakely, Emma L.; Tonska, Kasia; Elstner, Matthias; He, Langping; Turnbull, Douglass M.; Taylor, Robert W.] Newcastle Univ, Sch Med, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Sutton, Ruth; Turnbull, Douglass M.; Taylor, Robert W.] Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Tonska, Kasia] Univ Warsaw, Dept Genet & Biotechnol, Warsaw, Poland.
   [Elstner, Matthias] Univ Munich, Dept Neurol, D-8000 Munich, Germany.
   [Taivassalo, Tanja] McGill Univ, Dept Kinesiol & Phys Educ, Montreal, PQ, Canada.
   [Burns, Dennis K.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA.
   [Haller, Ronald G.] Presbyterian Med Ctr, Inst Exercise & Environm Med, Neuromuscular Ctr, Dallas, TX USA.
   [Haller, Ronald G.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA.
   [Haller, Ronald G.] VA Med Ctr, Dallas, TX USA.
   [Davidson, Mercy M.] Columbia Univ, Dept Neurol, Coll Phys & Surg, New York, NY USA.
C3 Newcastle University - UK; Newcastle University - UK; University of Warsaw; University of Munich; McGill University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Columbia University
RP Taylor, RW (corresponding author), Newcastle Univ, Sch Med, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM r.w.taylor@ncl.ac.uk
FU Muscular Dystrophy Association; United Mitochondrial Disease Foundation; US National Institutes of Health; Wellcome Trust, Muscular Dystrophy Campaign and Newcastle upon Tyne Hospitals NHS Foundation Trust
CR Brandon MC, 2005, NUCLEIC ACIDS RES, V33, P0
   Brown MD, 2002, HUM GENET, V110, P130, DOI 10.1007/s00439-001-0660-8
   Cardaioli E, 2006, NEUROMUSCULAR DISORD, V16, P26, DOI 10.1016/j.nmd.2005.11.001
   Chomyn A, 1996, METHODS ENZYMOL, V264, P197, DOI 10.1016/S0076-6879(96)64020-8
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   El Meziane A, 1998, NAT GENET, V18, P350
   Fetoni V, 2004, NEUROMUSCULAR DISORD, V14, P723, DOI 10.1016/j.nmd.2004.07.002
   Guan MX, 1998, MOL CELL BIOL, V18, P5868, DOI 10.1128/MCB.18.10.5868
   Hutchin TP, 2000, J MED GENET, V37, P692, DOI 10.1136/jmg.37.9.692
   Ingman M, 2006, NUCLEIC ACIDS RES, V34, PD749, DOI 10.1093/nar/gkj010
   Jaksch M, 1998, ANN NEUROL, V44, P635, DOI 10.1002/ana.410440409
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Kirby DM, 2007, METHOD CELL BIOL, V80, P93, DOI 10.1016/S0091-679X(06)80004-X
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   Pulkes T, 2005, NEUROMUSCULAR DISORD, V15, P364, DOI 10.1016/j.nmd.2005.01.006
   Pye D, 2006, NUCLEIC ACIDS RES, V34, P0, DOI 10.1093/nar/gkl516
   Qu J, 2006, INVEST OPHTH VIS SCI, V47, P475, DOI 10.1167/iovs.05-0665
   REID FM, 1994, HUM MUTAT, V3, P243, DOI 10.1002/humu.1380030311
   Schuelke M, 1998, ANN NEUROL, V44, P700, DOI 10.1002/ana.410440420
   Sue CM, 1999, NEUROLOGY, V52, P1905, DOI 10.1212/WNL.52.9.1905
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   TIRANTI V, 1995, HUM MOL GENET, V4, P1421, DOI 10.1093/hmg/4.8.1421
   Toompuu M, 1999, HUM MOL GENET, V8, P2275, DOI 10.1093/hmg/8.12.2275
   Toompuu M, 2004, BIOCHEM BIOPH RES CO, V322, P803, DOI 10.1016/j.bbrc.2004.07.181
   Toompuu M, 2002, J BIOL CHEM, V277, P22240, DOI 10.1074/jbc.M200338200
   Verhoeven K, 1999, EUR J HUM GENET, V7, P45, DOI 10.1038/sj.ejhg.5200247
NR 29
TC 25
Z9 27
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD OCT 15
PY 2008
VL 16
IS 10
BP 1265
EP 1274
DI 10.1038/ejhg.2008.65
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 352MV
UT WOS:000259502200018
PM 18398437
DA 2024-11-01
ER

PT J
AU Uusimaa, J
   Hinttala, R
   Rantala, H
   Päivärinta, M
   Herva, R
   Röyttä, M
   Soini, H
   Moilanen, JS
   Remes, AM
   Hassinen, IE
   Majamaa, K
AF Uusimaa, Johanna
   Hinttala, Reetta
   Rantala, Heikki
   Paivarinta, Markku
   Herva, Riitta
   Roytta, Matias
   Soini, Heidi
   Moilanen, Jukka S.
   Remes, Anne M.
   Hassinen, Ilmo E.
   Majamaa, Kari
TI Homozygous W748S mutation in the <i>POLG1</i> gene in patients with juvenile-onset Alpers syndrome and status epilepticus
SO EPILEPSIA
LA English
DT Article
DE status epilepticus; metabolic diseases; mitochondrial diseases; genetic diseases
ID dna-polymerase-gamma; progressive neuronal degeneration; autosomal recessive ataxia; liver-disease; external ophthalmoplegia; huttenlocher-syndrome; childhood; depletion; deletions; parkinsonism
AB Purpose: Polymerase gamma (POLG) is the sole enzyme in the replication of mitochondrial DNA (mtDNA). Numerous mutations in the POLG1 gene have been detected recently in patients with various phenotypes including a classic infantile-onset Alpers-Huttenlocher syndrome (AHS). Here we studied the molecular etiology of juvenile-onset AHS manifesting with status epilepticus and liver disease in three teenagers. Patients and Methods: We examined 14- and 17-year-old female siblings (patients 1 and 2) and an unrelated 15-year-old girl (patient 3) with juvenile-onset AHS, sequenced POLG1, and the entire mtDNA, examined mtDNA deletions by amplification of the full-length mtDNA with the long PCR method and used real-time PCR to quantify mtDNA in the tissue samples. Results: The initial manifestations were migraine-like headache and epilepsy, and the terminal manifestations status epilepticus and hepatic failure. A homozygous W748S mutation in POLG1 was detected in the three patients. No deletions or pathogenic point mutations were found in mtDNA, but all three patients had mtDNA depletion. Conclusions: POLG mutations should be considered in cases of teenagers and young adults with a sudden onset of intractable seizures or status epilepticus, and acute liver failure. The W748S POLG1 mutation seems to lead to tissue-specific, partial mtDNA depletion in patients with juvenile-onset Alpers syndrome. Valproic acid should be avoided in the treatment of epileptic seizures in these patients.
C1 [Paivarinta, Markku; Majamaa, Kari] Univ Turku, Dept Neurol, FIN-20014 Turku, Finland.
   [Uusimaa, Johanna; Rantala, Heikki] Univ Oulu, Dept Pediat, SF-90100 Oulu, Finland.
   [Uusimaa, Johanna; Hinttala, Reetta; Soini, Heidi; Moilanen, Jukka S.; Remes, Anne M.; Majamaa, Kari] Oulu Univ Hosp, Clin Res Ctr, Oulu, Finland.
   [Hinttala, Reetta; Soini, Heidi; Remes, Anne M.; Majamaa, Kari] Univ Oulu, Dept Neurol, Oulu, Finland.
   [Herva, Riitta] Univ Oulu, Dept Pathol, Oulu, Finland.
   [Roytta, Matias] Univ Turku, Dept Pathol, FIN-20014 Turku, Finland.
   [Moilanen, Jukka S.] Univ Oulu, Dept Clin Genet, Oulu, Finland.
   [Hassinen, Ilmo E.] Univ Oulu, Dept Med Biochem & Mol Biol, Oulu, Finland.
C3 University of Turku; University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Turku; University of Oulu; University of Oulu
RP Majamaa, K (corresponding author), Univ Turku, Dept Neurol, FIN-20014 Turku, Finland.
EM kari.majamaa@utu.fi
CR Alpers BJ, 1931, ARCH NEURO PSYCHIATR, V25, P469, DOI 10.1001/archneurpsyc.1931.02230030027002
   BOHNERT B, 1974, ARCH PSYCHIAT NERVEN, V218, P353, DOI 10.1007/BF00342578
   Braasch DA, 2001, CHEM BIOL, V8, P1, DOI 10.1016/S1074-5521(00)00058-2
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Gordon N, 2006, DEV MED CHILD NEUROL, V48, P1001, DOI 10.1017/S0012162206002209
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   HARDING BN, 1995, J NEUROL NEUROSUR PS, V58, P320, DOI 10.1136/jnnp.58.3.320
   HARDING BN, 1990, J CHILD NEUROL, V5, P273, DOI 10.1177/088307389000500402
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Hinttala R, 2005, J MOL MED, V83, P786, DOI 10.1007/s00109-005-0712-y
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   KLEIN H, 1969, ARCHIV FUER PSYCHIATRIE UND NERVENKRANKHEITEN, V212, P400, DOI 10.1007/BF00341587
   Kollberg G, 2005, EUR J HUM GENET, V13, P463, DOI 10.1038/sj.ejhg.5201341
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   MONTINE TJ, 1995, CLIN NEUROPATHOL, V14, P322
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Rantamäki M, 2001, NEUROLOGY, V57, P1043, DOI 10.1212/WNL.57.6.1043
   Remes AM, 2005, NEUROLOGY, V64, P976, DOI 10.1212/01.WNL.0000154518.31302.ED
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Schwabe MJ, 1997, PEDIATR NEUROL, V16, P337, DOI 10.1016/S0887-8994(97)00030-1
   Simonati A, 2003, J NEUROL, V250, P702, DOI 10.1007/s00415-003-1065-5
   Tesarova M, 2004, NEUROPEDIATRICS, V35, P217, DOI 10.1055/s-2004-821081
   Ulmer S, 2002, J COMPUT ASSIST TOMO, V26, P641, DOI 10.1097/00004728-200207000-00030
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Worle H, 1998, CLIN NEUROPATHOL, V17, P63
NR 39
TC 58
Z9 62
U1 0
U2 7
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0013-9580
EI 
J9 EPILEPSIA
JI Epilepsia
PD JUN 15
PY 2008
VL 49
IS 6
BP 1038
EP 1045
DI 10.1111/j.1528-1167.2008.01544.x
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 309XE
UT WOS:000256492700012
PM 18294203
DA 2024-11-01
ER

PT J
AU Choi, BO
   Hwang, JH
   Kim, J
   Cho, EM
   Cho, SY
   Hwang, SJ
   Lee, HW
   Kim, SJ
   Chung, KW
AF Choi, Byung-Ok
   Hwang, Jung Hee
   Kim, Joonki
   Cho, Eun Min
   Cho, Sun Young
   Hwang, Su Jin
   Lee, Hyang Woon
   Kim, Song Ja
   Chung, Ki Wha
TI A MELAS syndrome family harboring two mutations in mitochondrial genome
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
DE Asian continental ancestry group; cataract; cytochrome-c oxidase deficiency; DNA, mitochondrial; Korea; MELAS syndrome; mutation, missense; ND5 protein, human
ID hereditary optic neuropathy; lactic-acidosis; episodes melas; mtdna; gene; dna; encephalopathy; myopathy; sequence; identification
AB Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome is a genetically heterogeneous mitochondrial disorder with variable clinical symptoms. Here, from the sequencing of the entire mitochondrial genome, we report a Korean MELAS family harboring two homoplasmic missense mutations, which were reported 9957T > C (Phe251Leu) transition mutation in the cytochrome c oxidase subunit 3 (COX3) gene and a novel 13849A > C (Asn505His) transversion mutation in the NADH dehydrogenase subunit 5 (ND5) gene. Neither of these mutations was found in 205 normal controls. Both mutations were identified from the proband and his mother, but not his father. The patients showed cataract symptom in addition to MELAS phenotype. We believe that the 9957T > C mutation is pathogenic, however, the 13849A > C mutation is of unclear significance. It is likely that the 13849A > C mutation might function as the secondary mutation which increase the expressivity of overlapping phenotypes of MELAS and cataract. This study also demonstrates the importance of full sequencing of mtDNA for the molecular genetic understanding of mitochondrial disorders.
C1 [Hwang, Jung Hee; Kim, Joonki; Cho, Eun Min; Kim, Song Ja; Chung, Ki Wha] Kongju Natl Univ, Dept Biol Sci, Kong Ju 314701, South Korea.
   [Choi, Byung-Ok; Cho, Sun Young; Hwang, Su Jin; Lee, Hyang Woon] Ewha Womans Univ, Sch Med, Dept Neurol, Seoul 110783, South Korea.
   [Choi, Byung-Ok; Cho, Sun Young; Hwang, Su Jin; Lee, Hyang Woon] Ewha Womans Univ, Sch Med, Ewha Med Res Ctr, Seoul 110783, South Korea.
C3 Kongju National University; Ewha Womans University; Ewha Womans University
RP Chung, KW (corresponding author), Kongju Natl Univ, Dept Biol Sci, Kong Ju 314701, South Korea.
EM kwchung@kongju.ac.kr
CR Abu-Amero Khaled K, 2005, OPHTHALMIC GENET, V26, P31, DOI 10.1080/13816810590918235
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Brown MD, 1997, AM J HUM GENET, V60, P381
   Carelli V, 2006, AM J HUM GENET, V78, P564, DOI 10.1086/501236
   Crimi M, 2003, NEUROLOGY, V60, P1857, DOI 10.1212/01.WNL.0000066048.72780.69
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Hofmann S, 1997, HUM MOL GENET, V6, P1835, DOI 10.1093/hmg/6.11.1835
   Isashiki Y, 1998, ACTA OPHTHALMOL SCAN, V76, P6, DOI 10.1034/j.1600-0420.1998.760103.x
   Kivisild T, 2002, MOL BIOL EVOL, V19, P1737, DOI 10.1093/oxfordjournals.molbev.a003996
   Kong QP, 2006, HUM MOL GENET, V15, P2076, DOI 10.1093/hmg/ddl130
   Kong QP, 2003, HUM GENET, V113, P391, DOI 10.1007/s00439-003-1004-7
   LERTRIT P, 1992, AM J HUM GENET, V51, P457
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   MANFREDI G, 1995, NEUROMUSCULAR DISORD, V5, P391, DOI 10.1016/0960-8966(94)00079-O
   MONTAGNA P, 1988, NEUROLOGY, V38, P751, DOI 10.1212/WNL.38.5.751
   MORTEN KJ, 1993, HUM MOL GENET, V2, P2081, DOI 10.1093/hmg/2.12.2081
   Naini AB, 2005, ARCH NEUROL-CHICAGO, V62, P473, DOI 10.1001/archneur.62.3.473
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Qu J, 2006, INVEST OPHTH VIS SCI, V47, P475, DOI 10.1167/iovs.05-0665
   Ronghua L, 2006, GENE, V376, P79, DOI 10.1016/j.gene.2006.02.014
   SAKUTA R, 1993, AM J HUM GENET, V53, P964
   Salas A, 2005, PLOS MED, V2, P1158, DOI 10.1371/journal.pmed.0020296
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   SWEENEY MG, 1993, Q J MED, V86, P709
   Torroni A, 1997, AM J HUM GENET, V60, P1107
   Tzen CY, 2003, MUSCLE NERVE, V28, P575, DOI 10.1002/mus.10473
   Valentino ML, 2006, J MED GENET, V43, P0, DOI 10.1136/jmg.2005.037507
NR 29
TC 14
Z9 17
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1226-3613
EI 2092-6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD JUN 30
PY 2008
VL 40
IS 3
BP 354
EP 360
DI 10.3858/emm.2008.40.3.354
PG 7
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA 322FO
UT WOS:000257360800012
PM 18587274
DA 2024-11-01
ER

PT J
AU Reeve, AK
   Krishnan, KJ
   Turnbull, D
AF Reeve, Amy K.
   Krishnan, Kim J.
   Turnbull, Doug
TI Mitochondrial DNA Mutations in Disease, Aging, and Neurodegeneration
SO MITOCHONDRIA AND OXIDATIVE STRESS IN NEURODEGENERATIVE DISORDERS
LA English
DT Article; Proceedings Paper
DE mitochondrial; DNA; mutations
ID human substantia-nigra; mtdna point mutations; parkinsons-disease; control region; deletion mutations; neurons; muscle; accumulation; neuropathology; apoptosis
AB Patients with disorders from mutations in the mitochondrial genome have variable phenotypes, but common to many of these disorders are underlying changes in postmitotic cells, particularly neurons and muscle fibers. The mitochondrial dysfunction caused by these mutations has been shown to be associated with signs of apoptosis and to cause cell loss. Mutations of the mitochondrial genome have also been shown to accumulate with age and in common neurodegenerative diseases, such as Parkinson's disease. This review presents recent data to show that the information gained from studying patients with mitochondrial disorders can help our understanding of the role of mitochondrial DNA mutations in brain aging and neurodegeneration.
C1 [Reeve, Amy K.; Krishnan, Kim J.; Turnbull, Doug] Newcastle Univ, Sch Med, Mitochondrial Res Grp, Inst Neurosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Krishnan, Kim J.; Turnbull, Doug] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK
RP Turnbull, D (corresponding author), Newcastle Univ, Sch Med, Mitochondrial Res Grp, Inst Neurosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM d.m.turnbull@ncl.ac.uk
CR Aomi Y, 2001, BIOCHEM BIOPH RES CO, V280, P265, DOI 10.1006/bbrc.2000.4113
   Auré K, 2006, BRAIN, V129, P1249, DOI 10.1093/brain/awl061
   BAUS J, 2004, NEUROCHEM RES, V29, P505
   Beal MF, 2005, ANN NEUROL, V58, P495, DOI 10.1002/ana.20624
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Betts J, 2006, NEUROPATH APPL NEURO, V32, P359, DOI 10.1111/j.1365-2990.2006.00731.x
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Cantuti-Castelvetria I, 2005, NEUROBIOL AGING, V26, P1343, DOI 10.1016/j.neurobiolaging.2004.11.008
   CARON F, 1979, P NATL ACAD SCI USA, V76, P4265, DOI 10.1073/pnas.76.9.4265
   Chen HC, 2005, HUM MOL GENET, V14, PR283, DOI 10.1093/hmg/ddi270
   Chinnery PF, 2002, LANCET, V360, P1323, DOI 10.1016/S0140-6736(02)11310-9
   Chinnery PF, 2001, AM J HUM GENET, V68, P529, DOI 10.1086/318204
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   Cottrell DA, 2001, NEUROLOGY, V57, P260, DOI 10.1212/WNL.57.2.260
   Diaz F, 2002, NUCLEIC ACIDS RES, V30, P4626, DOI 10.1093/nar/gkf602
   Ekstrand MI, 2007, P NATL ACAD SCI USA, V104, P1325, DOI 10.1073/pnas.0605208103
   Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801
   FEARNLEY JM, 1991, BRAIN, V114, P2283, DOI 10.1093/brain/114.5.2283
   Filosto M, 2007, BIOSCIENCE REP, V27, P23, DOI 10.1007/s10540-007-9034-3
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   HORTON TM, 1995, NEUROLOGY, V45, P1879, DOI 10.1212/WNL.45.10.1879
   Itoh K, 1996, NEUROBIOL AGING, V17, P843, DOI 10.1016/S0197-4580(96)00168-6
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Kraytsberg Y, 2005, EXPERT REV MOL DIAGN, V5, P809, DOI 10.1586/14737159.5.5.809
   Krishnan KJ, 2007, ANN NY ACAD SCI, V1100, P227, DOI 10.1196/annals.1395.024
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Lin MT, 2002, HUM MOL GENET, V11, P133, DOI 10.1093/hmg/11.2.133
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Malka F, 2006, BBA-MOL CELL RES, V1763, P463, DOI 10.1016/j.bbamcr.2006.04.001
   Man PYW, 2002, J MED GENET, V39, P162, DOI 10.1136/jmg.39.3.162
   MARGULIS L, 1971, SCI AM, V225, P49
   McFarland R, 2007, CURR TOP DEV BIOL, V77, P113, DOI 10.1016/S0070-2153(06)77005-3
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   Murdock DG, 2000, NUCLEIC ACIDS RES, V28, P4350, DOI 10.1093/nar/28.21.4350
   Nakabeppu Y, 2001, PROG NUCLEIC ACID RE, V68, P75
   Pak JW, 2005, EXP GERONTOL, V40, P209, DOI 10.1016/j.exger.2004.12.005
   Pyle A, 2005, ANN NEUROL, V57, P564, DOI 10.1002/ana.20417
   Reeve AK, 2008, AM J HUM GENET, V82, P228, DOI 10.1016/j.ajhg.2007.09.018
   Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x
   Schaefer AM, 2006, NEUROLOGY, V66, P1932, DOI 10.1212/01.wnl.0000219759.72195.41
   SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   Simon DK, 2004, NEUROBIOL AGING, V25, P71, DOI 10.1016/S0197-4580(03)00037-X
   Simon DK, 2001, GENOMICS, V73, P113, DOI 10.1006/geno.2001.6515
   Smigrodzki R, 2004, NEUROBIOL AGING, V25, P1273, DOI 10.1016/j.neurobiolaging.2004.02.020
   Someya S, 2008, NEUROBIOL AGING, V29, P1080, DOI 10.1016/j.neurobiolaging.2007.01.014
   Sörensen L, 2001, J NEUROSCI, V21, P8082, DOI 10.1523/JNEUROSCI.21-20-08082.2001
   Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Vermulst M, 2007, NAT GENET, V39, P540, DOI 10.1038/ng1988
   Vives-Bauza C, 2002, BIOCHEM BIOPH RES CO, V290, P1593, DOI 10.1006/bbrc.2002.6388
   WALLACE DC, 1995, BBA-MOL BASIS DIS, V1271, P141, DOI 10.1016/0925-4439(95)00021-U
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598
   YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164
NR 58
TC 121
Z9 133
U1 2
U2 18
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA
SN 0077-8923
EI 
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PD JUN 15
PY 2008
VL 1147
IS 
BP 21
EP 29
DI 10.1196/annals.1427.016
PG 9
WC Cell Biology; Multidisciplinary Sciences; Neurosciences; Physiology
SC Cell Biology; Science & Technology - Other Topics; Neurosciences & Neurology; Physiology
GA BIR99
UT WOS:000262397800003
PM 19076427
DA 2024-11-01
ER

PT J
AU Wong, LJC
   Naviaux, RK
   Brunetti-Pierri, N
   Zhang, Q
   Schmitt, ES
   Truong, C
   Milone, M
   Cohen, BH
   Wical, B
   Ganesh, J
   Basinger, AA
   Burton, BK
   Swoboda, K
   Gilbert, DL
   Vanderver, A
   Saneto, RP
   Maranda, B
   Arnold, G
   Abdenur, JE
   Waters, PJ
   Copeland, WC
AF Wong, Lee-Jun C.
   Naviaux, Robert K.
   Brunetti-Pierri, Nicola
   Zhang, Qing
   Schmitt, Eric S.
   Truong, Cavatina
   Milone, Margherita
   Cohen, Bruce H.
   Wical, Beverly
   Ganesh, Jaya
   Basinger, Alice A.
   Burton, Barbara K.
   Swoboda, Kathryn
   Gilbert, Donald L.
   Vanderver, Adeline
   Saneto, Russell P.
   Maranda, Bruno
   Arnold, Georgianne
   Abdenur, Jose E.
   Waters, Paula J.
   Copeland, William C.
TI Molecular and Clinical Genetics of Mitochondrial Diseases Due to <i>POLG</i> Mutations
SO HUMAN MUTATION
LA English
DT Article
DE POLG; POLG1; Alpers syndrome; PEO; adPEO; arPEO; SANDO; SCAE; ANS; MEMSA; MCHS; mtDNA depletion; liver failure
ID dna-polymerase-gamma; progressive external ophthalmoplegia; autosomal-dominant; ataxic neuropathy; alpers-syndrome; w748s mutation; defects; patient; family; parkinsonism
AB Mutations in the POLG gene have emerged as one of the most common causes of inherited mitochondrial disease in children and adults. They are responsible for a heterogeneous group of at least 6 major phenotypes of neurodegenerative disease that include: 1) childhood Myocerebrohepatopathy Spectrum disorders (MCHS), 2) Alpers syndrome, 3) Ataxia Neuropathy Spectrum (ANS) disorders, 4) Myoclonus Epilepsy Myopathy Sensory Ataxia (MEMSA), 5) autosomal recessive Progressive External Ophthalmoplegia (arPEO), and 6) autosomal dominant Progressive External Ophthalmoplegia (adPEO). Due to the clinical heterogeneity, time-dependent evolution of symptoms, overlapping phenotypes, and inconsistencies in muscle pathology findings, definitive diagnosis relies on the molecular finding of deleterious mutations. We sequenced the exons and flanking intron region from approximately 350 patients displaying a phenotype consistent with POLG related mitochondrial disease and found informative mutations in 61 (17%). Two mutant alleles were identified in 31 unrelated index patients with autosomal recessive POLG-related disorders. Among them, 20 (67%) had Alpers syndrome, 4 (13%) had arPEO, and 3 (10%) had ANS. In addition, 30 patients carrying one altered POLG allele were found. A total of 25 novel alterations were identified, including 6 null mutations. We describe the predicted structural/functional and clinical importance of the previously unreported missense variants and discuss their likelihood of being pathogenic. In conclusion, sequence analysis allows the identification of mutations responsible for POLG-related disorders and, in most of the autosomal recessive cases where two mutant alleles are found in trans, finding deleterious mutations can provide an unequivocal diagnosis of the disease. Published 2008 Wiley-Liss, Inc.
C1 [Wong, Lee-Jun C.; Brunetti-Pierri, Nicola; Zhang, Qing; Schmitt, Eric S.; Truong, Cavatina] Baylor Coll Med, Dept Mol & Human Genet, One Baylor Plaza,NAB 2015, Houston, TX 77030 USA.
   [Naviaux, Robert K.] Univ Calif San Diego, Mitochondrial & Metab Dis Ctr, Dept Med, San Diego, CA 92103 USA.
   [Naviaux, Robert K.] Univ Calif San Diego, Mitochondrial & Metab Dis Ctr, Dept Pediat, San Diego, CA 92103 USA.
   [Milone, Margherita] Mayo Clin, Dept Neurol, Rochester, MN USA.
   [Cohen, Bruce H.] Cleveland Clin, Neurol Inst, Cleveland, OH 44106 USA.
   [Wical, Beverly] Gillette Childrens Specialty Healthcare, St Paul, MN USA.
   [Ganesh, Jaya] Childrens Hosp Philadelphia, Sect Biochem Genet, Philadelphia, PA 19104 USA.
   [Ganesh, Jaya] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
   [Basinger, Alice A.] Cook Childrens Phys Network, Div Genet, Ft Worth, TX USA.
   [Burton, Barbara K.] Childrens Mem Hosp, Birth Defects & Metab, Div Genet, Chicago, IL 60614 USA.
   [Swoboda, Kathryn] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT USA.
   [Gilbert, Donald L.] Cincinnati Childrens Hosp Med Ctr, Dept Neurol, Cincinnati, OH 45229 USA.
   [Vanderver, Adeline] Childrens Natl Med Ctr, Dept Neurol, Washington, DC 20010 USA.
   [Saneto, Russell P.] Univ Washington, Childrens Hosp, Div Pediat Neurol, Seattle, WA 98195 USA.
   [Saneto, Russell P.] Univ Washington, Reg Med Ctr, Seattle, WA 98195 USA.
   [Maranda, Bruno] Univ Laval, CHUL CHUQ, Dept Pediat, Serv Genet Med, Quebec City, PQ, Canada.
   [Arnold, Georgianne] Univ Rochester, Sch Med & Dent, Div Pediat & Genet, Rochester, NY USA.
   [Abdenur, Jose E.] Childrens Hosp Orange Cty, Orange, CA 92668 USA.
   [Waters, Paula J.] Childrens & Womens Hlth Ctr British Columbia, Lab Genet Div, Dept Pathol, Vancouver, BC, Canada.
   [Waters, Paula J.] Univ British Columbia, Vancouver, BC, Canada.
   [Copeland, William C.] NIEHS, Lab Mol Genet, NIH, Res Triangle Pk, NC 27709 USA.
C3 Baylor College of Medicine; University of California System; University of California San Diego; University of California System; University of California San Diego; Mayo Clinic; Cleveland Clinic Foundation; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Cook Children's Medical Center; Ann & Robert H. Lurie Children's Hospital of Chicago; Utah System of Higher Education; University of Utah; Cincinnati Children's Hospital Medical Center; Children's National Health System; University of Washington; University of Washington Seattle; Seattle Children's Hospital; University of Washington; University of Washington Seattle; Laval University; University of Rochester; Childrens Hospital of Orange County; BC Women's Hospital & Health Centre; University of British Columbia; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)
RP Wong, LJC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, One Baylor Plaza,NAB 2015, Houston, TX 77030 USA.
EM ljwong@bcm.edu
FU DHHS, NIH [5R01 CA100023]; NIH intramural research funds; NIH [5R21-NS051815]; Lennox Foundation; Hailey's Wish Foundation; UCSD Christini Fund
CR Bao XH, 2008, BRAIN DEV-JPN, V30, P295, DOI 10.1016/j.braindev.2007.08.009
   Barthélémy C, 2002, HUM GENET, V110, P479, DOI 10.1007/s00439-002-0708-4
   Baruffini E, 2007, BBA-MOL BASIS DIS, V1772, P1225, DOI 10.1016/j.bbadis.2007.10.002
   Chan SSL, 2006, HUM MOL GENET, V15, P3473, DOI 10.1093/hmg/ddl424
   Chan SSL, 2005, DNA REPAIR, V4, P1381, DOI 10.1016/j.dnarep.2005.08.010
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   de Vries MC, 2007, EUR J PEDIATR, V166, P229, DOI 10.1007/s00431-006-0234-9
   DeLano WL, 2002, THE PYMOL MOLECULAR GRAPHICS SYSTEM, V0, P0
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   DiMauro S, 2006, BRAIN, V129, P1637, DOI 10.1093/brain/awl169
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   González-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2007, ARCH NEUROL-CHICAGO, V64, P553, DOI 10.1001/archneur.64.4.553
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lecrenier N, 1997, GENE, V185, P147, DOI 10.1016/S0378-1119(96)00663-4
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Milone M, 2008, NEUROMUSCULAR DISORD, V18, P626, DOI 10.1016/j.nmd.2008.05.009
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Selby K, 2008, NEUROMUSCUL DISORD, V0, P0
   Stopinska K, 2006, ACTA BIOCHIM POL, V53, P591
   Tiangyou W, 2006, NEUROLOGY, V67, P1698, DOI 10.1212/01.wnl.0000238963.07425.d5
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Yamanaka H, 2007, J INFECT DIS, V195, P1419, DOI 10.1086/513872
NR 45
TC 203
Z9 215
U1 0
U2 12
PU WILEY-HINDAWI
PI LONDON
PA ADAM HOUSE, 3RD FL, 1 FITZROY SQ, LONDON, WIT 5HE, ENGLAND
SN 1059-7794
EI 1098-1004
J9 HUM MUTAT
JI Hum. Mutat.
PD SEP 15
PY 2008
VL 29
IS 9
BP E150
EP E172
DI 10.1002/humu.20824
PG 23
WC Genetics & Heredity
SC Genetics & Heredity
GA VJ8AP
UT WOS:000629246800002
PM 18546365
DA 2024-11-01
ER

PT J
AU Cardaioli, E
   Da Pozzo, P
   Malfatti, E
   Gallus, GN
   Rubegni, A
   Malandrini, A
   Gaudiano, C
   Guidi, L
   Serni, G
   Berti, G
   Dotti, MT
   Federico, A
AF Cardaioli, E.
   Da Pozzo, P.
   Malfatti, E.
   Gallus, G. N.
   Rubegni, A.
   Malandrini, A.
   Gaudiano, C.
   Guidi, L.
   Serni, G.
   Berti, G.
   Dotti, M. T.
   Federico, A.
TI Chronic progressive external ophthalmoplegia:: A new heteroplasmic tRNA <SUP>Leu(CUN)</SUP> mutation of mitochondrial DNA
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE chronic progressive external opthalmoplegia; mitochondrial DNA; tRNA (Leu(CUN))
ID mtdna point mutation; a3243g mutation; dilated cardiomyopathy; sporadic patient; skeletal-muscle; trna(leu(cun)); phenotypes; nucleotide; myopathy; sequence
AB We sequenced all genes of mitochondrial tRNAs of a patient with chronic progressive external ophthalmoplegia with 5% ragged red fibres and 15% COX-negative fibres but without macrorearrangements of mitochondrial DNA (mtDNA). Direct sequencing showed a novel heteroplasmic G > A substitution in position 12316 of tRNA(Leu(CUN)) gene. This change destroys a highly conserved G-C base coupling in tRNA T psi C branch. By RFLP analysis we could demonstrate different degrees of heteroplasiny in different patient's tissues. This alteration, absent in a population of 110 patients with different encephalomyopathies, can be considered pathogenic: it is the tenth tRNA (Leu(CUN)) pathogenic Mutation described up to date. (C) 2008 Elsevier B.V All rights reserved.
C1 [Cardaioli, E.; Da Pozzo, P.; Malfatti, E.; Gallus, G. N.; Rubegni, A.; Malandrini, A.; Gaudiano, C.; Serni, G.; Berti, G.; Dotti, M. T.; Federico, A.] Univ Siena, Dept Neurol & Behav Sci, I-53100 Siena, Italy.
   [Guidi, L.] S Giuseppe Hosp, Neurol Unit, Florence, Italy.
C3 University of Siena
RP Federico, A (corresponding author), Univ Siena, Dipartimento Sci Neurol & Comportamento, Viale Bracci 2, I-53100 Siena, Italy.
EM federico@unisi.it
FU University of Siena and Regione Toscana
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Cardaioli E, 2005, BIOCHEM BIOPH RES CO, V327, P675, DOI 10.1016/j.bbrc.2004.11.170
   Cardaioli E, 2007, NEUROMUSCULAR DISORD, V17, P681, DOI 10.1016/j.nmd.2007.05.001
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Chinnery PF, 2000, ANN NEUROL, V47, P381, DOI 10.1002/1531-8249(200003)47:3<381::AID-ANA17>3.0.CO;2-2
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Grasso M, 2001, EUR J HUM GENET, V9, P311, DOI 10.1038/sj.ejhg.5200622
   HATTORI Y, 1994, J NEUROL SCI, V125, P50, DOI 10.1016/0022-510X(94)90241-0
   Karadimas CL, 2002, NEUROMUSCULAR DISORD, V12, P865, DOI 10.1016/S0960-8966(02)00072-X
   Koga Y, 2000, ARCH DIS CHILD, V82, P407, DOI 10.1136/adc.82.5.407
   Laforêt P, 2000, REV NEUROL-FRANCE, V156, P1136
   Pulkes T, 2003, NEUROLOGY, V61, P1144, DOI 10.1212/01.WNL.0000090465.27024.3D
   Pulkes T, 2001, ADV DRUG DELIVER REV, V49, P27, DOI 10.1016/S0169-409X(01)00124-7
   Raffelsberger T, 2001, NEUROLOGY, V57, P2298, DOI 10.1212/WNL.57.12.2298
   Taylor RW, 2002, NEUROMUSCULAR DISORD, V12, P659, DOI 10.1016/S0960-8966(02)00026-3
   Tessa A, 1999, EUR J HUM GENET, V7, P847, DOI 10.1038/sj.ejhg.5200380
   Weber K, 1997, AM J HUM GENET, V60, P373
   Zeviani M, 1998, MEDICINE, V77, P59, DOI 10.1097/00005792-199801000-00006
NR 18
TC 15
Z9 16
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD SEP 15
PY 2008
VL 272
IS 1-2
BP 106
EP 109
DI 10.1016/j.jns.2008.05.005
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 347HM
UT WOS:000259131200014
PM 18603265
DA 2024-11-01
ER

PT J
AU Korhonen, JA
   Pande, V
   Holmlund, T
   Farge, G
   Pham, XH
   Nilsson, L
   Falkenberg, M
AF Korhonen, Jenny A.
   Pande, Vineet
   Holmlund, Teresa
   Farge, Geraldine
   Pham, Xuan Hoi
   Nilsson, Lennart
   Falkenberg, Maria
TI Structure-function defects of the TWINKLE linker region in progressive external ophthalmoplegia
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE TWINKLE; DNA replication; helicase; mitochondrion; bacteriophage T7
ID mitochondrial-dna helicase; single-stranded-dna; bacteriophage t7; gene-4 protein; multiple deletions; hexamer formation; crystal-structure; primase-helicase; polymerase; binding
AB TWINKLE is the helicase at the mitochondrial DNA (mtDNA) replication fork in mammalian cells. Mutations in the PEO1 gene, which encodes TWINKLE, cause autosomal dominant progressive external ophthalmoplegia (AdPEO), a disorder associated with deletions in mtDNA. Here, we characterized seven different AdPEO-causing mutations in the linker region of TWINKLE and we identified distinct molecular phenotypes. For some mutations, protein hexamerization and DNA helicase activity are completely abolished whereas others display more subtle effects. To better, understand these distinct phenotypes, we constructed a molecular model of TWINKLE based on the three-dimensional structure of the bacteriophage T7 gene 4 protein. The structural model explains the molecular phenotypes and also predicts the functional consequences of other AdPEO-causing mutations. Our findings provide a molecular platform for further studies in cell- and animal-based model systems and demonstrate that knowledge of the bacteriophage T7 DNA replication machinery may be key to understanding the molecular and phenotypic consequences of mutations in the mtDNA replication apparatus. (C) 2008 Published by Elsevier Ltd.
C1 [Korhonen, Jenny A.; Holmlund, Teresa; Farge, Geraldine; Pham, Xuan Hoi; Falkenberg, Maria] Karolinska Inst, Dept Lab Med, Div Metab Dis, Novum, SE-14186 Stockholm, Sweden.
   [Pande, Vineet; Nilsson, Lennart] Karolinska Inst, Dept Biosci & Nutr, Novum, SE-14186 Stockholm, Sweden.
C3 Karolinska Institutet; Karolinska Institutet
RP Falkenberg, M (corresponding author), Karolinska Inst, Dept Lab Med, Div Metab Dis, Novum, SE-14186 Stockholm, Sweden.
EM maria.falkenberg@ki.se
CR Arenas J, 2003, ANN NEUROL, V53, P278, DOI 10.1002/ana.10430
   BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066
   Chowdhury K, 2000, P NATL ACAD SCI USA, V97, P12469, DOI 10.1073/pnas.230448397
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   Crampton DJ, 2006, J MOL BIOL, V360, P667, DOI 10.1016/j.jmb.2006.05.037
   Donmez I, 2006, NUCLEIC ACIDS RES, V34, P4216, DOI 10.1093/nar/gkl508
   Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8
   Farge G, 2008, NUCLEIC ACIDS RES, V36, P393, DOI 10.1093/nar/gkm1025
   Gaspari M, 2004, EMBO J, V23, P4606, DOI 10.1038/sj.emboj.7600465
   Guo SY, 1999, J BIOL CHEM, V274, P30303, DOI 10.1074/jbc.274.42.30303
   HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0
   Jeong YJ, 2004, P NATL ACAD SCI USA, V101, P7264, DOI 10.1073/pnas.0400372101
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kiechl S, 2004, J NEUROL NEUROSUR PS, V75, P1125, DOI 10.1136/jnnp.2003.025890
   Kim DE, 2002, J MOL BIOL, V321, P807, DOI 10.1016/S0022-2836(02)00733-7
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Lee SJ, 2004, J BIOL CHEM, V279, P23384, DOI 10.1074/jbc.M400857200
   Li FY, 1999, NEUROLOGY, V53, P1265, DOI 10.1212/WNL.53.6.1265
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Matsushima Y, 2007, J BIOL CHEM, V282, P9436, DOI 10.1074/jbc.M610550200
   MENDELMAN LV, 1993, J BIOL CHEM, V268, P27208
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   NOTARNICOLA SM, 1995, J BIOL CHEM, V270, P20215, DOI 10.1074/jbc.270.34.20215
   Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651
   Picha KM, 1998, J BIOL CHEM, V273, P27315, DOI 10.1074/jbc.273.42.27315
   Pollastri G, 2005, BIOINFORMATICS, V21, P1719, DOI 10.1093/bioinformatics/bti203
   Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7
   Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520
   Shutt TE, 2006, J MOL EVOL, V62, P588, DOI 10.1007/s00239-005-0162-8
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Toth EA, 2003, MOL CELL, V12, P1113, DOI 10.1016/S1097-2765(03)00442-8
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Wanrooij S, 2007, NUCLEIC ACIDS RES, V35, P3238, DOI 10.1093/nar/gkm215
   Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Ziebarth TD, 2007, J MOL BIOL, V367, P1382, DOI 10.1016/j.jmb.2007.01.079
NR 44
TC 51
Z9 57
U1 1
U2 3
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
EI 
J9 J MOL BIOL
JI J. Mol. Biol.
PD MAR 28
PY 2008
VL 377
IS 3
BP 691
EP 705
DI 10.1016/j.jmb.2008.01.035
PG 15
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 293ZP
UT WOS:000255374200011
PM 18279890
DA 2024-11-01
ER

PT J
AU Bornstein, B
   Area, E
   Flanigan, KM
   Ganesh, J
   Jayakar, P
   Swoboda, KJ
   Coku, J
   Naini, A
   Shanske, S
   Tanji, K
   Hirano, M
   DiMauro, S
AF Bornstein, Belen
   Area, Estela
   Flanigan, Kevin M.
   Ganesh, Jaya
   Jayakar, Parul
   Swoboda, Kathryn J.
   Coku, Jorida
   Naini, Ali
   Shanske, Sara
   Tanji, Kurenal
   Hirano, Michio
   DiMauro, Salvatore
TI Mitochondrial DNA depletion syndrome due to mutations in the <i>RRM2B</i> gene
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mtDNA depletion; mitochondrial myopathy; RRM2B
ID ribonucleotide reductase; thymidine kinase; mtdna depletion; alpers-syndrome; polg mutations; deficiency
AB Mitochondrial DNA depletion syndrome (MDS) is characterized by a reduction in mtDNA copy number and has been associated with mutations in eight nuclear genes, including enzymes involved in mitochondrial nucleotide metabolism (POLG, TK2, DGUOK, SUCLA2, SUCLG1, PEO1) and MPV17. Recently, mutations in the RRM2B gene, encoding the p53-controlled ribonucleotide reductase subunit, have been described in seven infants from four families, who presented with various combinations of hypotonia, tubulopathy, seizures, respiratory distress, diarrhea, and lactic acidosis. All children died before 4 months of age. We sequenced the RRM2B gene in three unrelated cases with unexplained severe mtDNA depletion. The first patient developed intractable diarrhea, profound weakness, respiratory distress, and died at 3 months. The other two unrelated patients had a much milder phenotype and are still alive at ages 27 and 36 months. All three patients had lactic acidosis and severe depletion of mtDNA in muscle. Muscle histochemistry showed RRF and COX deficiency. Sequencing the RRM2B gene revealed three missense mutations and two single nucleotide deletions in exons 6, 8, and 9, confirming that RRM2B mutations are important causes of MDS and that the clinical phenotype is heterogeneous and not invariably fatal in infancy. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Area, Estela; Coku, Jorida; Naini, Ali; Shanske, Sara; Hirano, Michio; DiMauro, Salvatore] Columbia Univ, Med Ctr, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
   [Bornstein, Belen] UAM, CSIC, CIBERER,ISCiii,Dept Bioquim, Inst Invest Biomed,Hosp Univ Puerta Hierro, Madrid, Spain.
   [Tanji, Kurenal] Columbia Univ, Med Ctr, Dept Pathol, New York, NY 10032 USA.
   [Flanigan, Kevin M.; Swoboda, Kathryn J.] Univ Utah, Sch Med, Dept Neurol, Salt Lake City, UT USA.
   [Flanigan, Kevin M.; Swoboda, Kathryn J.] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT USA.
   [Flanigan, Kevin M.; Swoboda, Kathryn J.] Univ Utah, Sch Med, Dept Human Genet, Salt Lake City, UT 84132 USA.
   [Ganesh, Jaya] Univ Penn, Sch Med, Childrens Hosp Philadelphia, Dept Metab & Genet, Philadelphia, PA 19104 USA.
   [Jayakar, Parul] Miami Childrens Hosp, Dr John T Mcdonald Fdn Ctr Med Genet, Miami, FL USA.
C3 Columbia University; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Hospital Puerta de Hierro-Majadahonda; Autonomous University of Madrid; Instituto de Salud Carlos III; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Columbia University; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia
RP DiMauro, S (corresponding author), Columbia Univ, Med Ctr, Coll Phys & Surg, Dept Neurol, 3-313 Russ Berrie Med Sci Pavil,,1150 St Nichola, New York, NY 10032 USA.
EM sd12@columbia.edu
FU NICHD NIH HHS [P01 HD032062, HD32062] Funding Source: Medline
CR Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Chinnery PF, 2007, BRAIN, V130, P606, DOI 10.1093/brain/awm023
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Di Mauro S, 2008, MOL GENETIC BASIS NE, V0, P169
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Larsson KM, 2004, NAT STRUCT MOL BIOL, V11, P1142, DOI 10.1038/nsmb838
   Mancuso M, 2005, ARCH NEUROL-CHICAGO, V62, P745, DOI 10.1001/archneur.62.5.745
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   MANDERBACKA K, 2001, SCANDINAVIAN J P S55, V29, P41
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Tanji K, 2001, METHOD CELL BIOL, V65, P311, DOI 10.1016/S0091-679X(01)65019-2
NR 19
TC 70
Z9 77
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD JUN 15
PY 2008
VL 18
IS 6
BP 453
EP 459
DI 10.1016/j.nmd.2008.04.006
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 331PB
UT WOS:000258023000004
PM 18504129
DA 2024-11-01
ER

PT J
AU Virgilio, R
   Ronchi, D
   Hadjigeorgiou, GM
   Bordoni, A
   Saladino, F
   Moggio, M
   Adobbati, L
   Kafetsouli, D
   Tsironi, E
   Previtali, S
   Papadimitriou, A
   Bresolin, N
   Comi, GP
AF Virgilio, Roberta
   Ronchi, Dario
   Hadjigeorgiou, Georgios M.
   Bordoni, Andreina
   Saladino, Francesca
   Moggio, Maurizio
   Adobbati, Laura
   Kafetsouli, Demetra
   Tsironi, Evangelia
   Previtali, Stefano
   Papadimitriou, Alexandros
   Bresolin, Nereo
   Comi, Giacomo P.
TI Novel Twinkle (<i>PE01</i>) gene mutations in mendelian progressive external ophthalmoplegia
SO JOURNAL OF NEUROLOGY
LA English
DT Article
DE mtDNA deletions; progressive external ophthalmoplegia
ID mitochondrial-dna depletion; polymerase-gamma mutations; mtdna maintenance; optic atrophy; deletions; polg; opa1; parkinsonism; dominant; ataxia
AB Multiple deletions of mitochondrial DNA (mtDNA) are associated with different mitochondrial disorders inherited as autosomal dominant and recessive traits. Causative mutations have been found in five genes, mainly involved in mtDNA replication and stability. They include POLG1, the gene encoding the catalytic subunit of mtDNA polymerase (poly), POLG2 encoding its accessory subunit, ANT1 coding the adenine nucleotide translocator and PEO1 which codes for Twinkle, the mitochondrial helicase. Finally OPA1 missense mutations are involved in phenotypes presenting optic atrophy as a major feature. To define the relative contribution of POLG 1, POLG2, ANT1 and PEO1 genes to the mtDNA multiple deletion syndromes, we analysed them in a cohort of 67 probands showing accumulation of multiple mtDNA deletions in muscle. The patients were predominantly affected with a mitochondrial myopathy with or without progressive external ophthalmoplegia (PEO). Genetic analysis revealed that 1) PEO1 has a major role in determining familial PEO, since it accounts for 26.8 % of familial cases, followed by ANT1 (14.6 %) and POLG 1 (9.8 %); 2) no mutations in any of the known genes were found in 53.7 % of probands of this series. Six novel missense mutations contributing to the mutational load of PEO1 gene (p.R334P, p.W315S, p. S426N, p.W474S, p.F478I, p.E479K) were associated with an adult onset PEO phenotype.
C1 [Virgilio, Roberta; Ronchi, Dario; Bordoni, Andreina; Saladino, Francesca; Moggio, Maurizio; Bresolin, Nereo; Comi, Giacomo P.] Univ Milan, Ctr Dino Ferrari, Dipartimento Sci Neurol, Fdn IRCCS Osped Maggiore Policlin Mangiagolli & R, I-20122 Milan, Italy.
   [Hadjigeorgiou, Georgios M.; Papadimitriou, Alexandros] Univ Thessaly, Sch Med, Neurogenet Unit, Larisa, Greece.
   [Adobbati, Laura] Univ Milan, Ctr Dino Ferrari, Dept Neurosci, IRCCS Ist Auxol Italiano, I-20122 Milan, Italy.
   [Kafetsouli, Demetra; Tsironi, Evangelia] Univ Thessaly, Sch Med, Dept Ophthalmol, Larisa, Greece.
   [Previtali, Stefano] Ist Sci San Raffaele, Dept Neurol, Neuropathol Unit, I-20132 Milan, Italy.
   [Bresolin, Nereo] Associaz Nostra Famiglia, IRCCS E Medea, Lecce, Italy.
C3 University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Thessaly; IRCCS Istituto Auxologico Italiano; University of Milan; University of Thessaly; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; IRCCS Eugenio Medea
RP Comi, GP (corresponding author), Univ Milan, Ctr Dino Ferrari, Dipartimento Sci Neurol, Fdn IRCCS Osped Maggiore Policlin Mangiagolli & R, Via Sforza 35, I-20122 Milan, Italy.
EM giacomo.comi@unimi.it
FU Associazione Amici del Centro Dino Ferrari; Italian Ministry of University and Research [PRIN 2006]; Bank of DNA, Nerve and Muscle Tissues [GTF02008]; Eurobiobank [QLTR2001-02769]; Fondazione Telethon Funding Source: Custom
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Ferraris S, 2008, ARCH NEUROL-CHICAGO, V65, P125, DOI 10.1001/archneurol.2007.9
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
NR 22
TC 31
Z9 34
U1 0
U2 9
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 
J9 J NEUROL
JI J. Neurol.
PD SEP 15
PY 2008
VL 255
IS 9
BP 1384
EP 1391
DI 10.1007/s00415-008-0926-3
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 359IV
UT WOS:000259980900015
PM 18575922
DA 2024-11-01
ER

PT J
AU Van Hove, JLK
   Freehauf, C
   Miyamoto, S
   Vladutiu, GD
   Pancrudo, J
   Bonilla, E
   Lovell, MA
   Mierau, GW
   Thomas, JA
   Shanske, S
AF Van Hove, Johan L. K.
   Freehauf, Cynthia
   Miyamoto, Shelley
   Vladutiu, Georgirene D.
   Pancrudo, Jacklyn
   Bonilla, Eduardo
   Lovell, Mark A.
   Mierau, Gary W.
   Thomas, Janet A.
   Shanske, Sara
TI Infantile cardiomyopathy caused by the T14709C mutation in the mitochondrial tRNA glutamic acid gene
SO EUROPEAN JOURNAL OF PEDIATRICS
LA English
DT Article
DE mitochondrial respiratory chain; tRNA glutamic acid; cardiomyopathy; arrhythmias; heteroplasmy
ID diabetes-mellitus; a3243g mutation; onset myopathy; dna; deafness; disease; family; midd
AB A 6-week-old child presented with hypotonia, myopathy, and a rapidly worsening dilated cardiomyopathy with severe atrial and ventricular arrhythmias and pulmonary hypertension, which proved fatal at age 3 months. Biochemical analysis showed a combined deficiency of the enzymatic activities of complexes I and IV and molecular studies identified a T14709C mutation in the mitochondrial tRNA glutamic acid gene. A review of symptomatology in patients with this mutation shows that it mainly presents in childhood or young adults with mild myopathy and diabetes mellitus. Infants with a high, nearly homoplasmic mutant load can present with more severe symptoms including cardiomyopathy. Families with this mitochondrial DNA mutation should be aware that increased mutant load in a subsequent generation may result in severe and often fatal cardiac symptoms.
C1 [Van Hove, Johan L. K.] Univ Colorado, Hlth Sci Ctr Fitzsimmons, Dept Pediat, Aurora, CO 80045 USA.
   [Van Hove, Johan L. K.; Freehauf, Cynthia; Miyamoto, Shelley; Thomas, Janet A.] Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA.
   [Van Hove, Johan L. K.; Freehauf, Cynthia; Miyamoto, Shelley; Lovell, Mark A.; Mierau, Gary W.; Thomas, Janet A.] Childrens Hosp, Denver, CO 80218 USA.
   [Vladutiu, Georgirene D.] SUNY Buffalo, Dept Pediat, Buffalo, NY 14260 USA.
   [Pancrudo, Jacklyn; Bonilla, Eduardo; Shanske, Sara] Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
   [Lovell, Mark A.; Mierau, Gary W.] Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Denver; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; State University of New York (SUNY) System; University at Buffalo, SUNY; Columbia University; University of Colorado System; University of Colorado Denver; University of Colorado Anschutz Medical Campus
RP Van Hove, JLK (corresponding author), Univ Colorado, Hlth Sci Ctr Fitzsimmons, Dept Pediat, Mail Stop 8313,RC-1 N,12800 E 19th Ave,Room P18-4, Aurora, CO 80045 USA.
EM Johan.Vanhove@uchsc.edu
CR Antonicka H, 2003, J BIOL CHEM, V278, P43081, DOI 10.1074/jbc.M304998200
   Barclay AR, 2005, J INHERIT METAB DIS, V28, P1081, DOI 10.1007/s10545-005-4484-x
   Choo-Kang ATW, 2002, DIABETES, V51, P2317, DOI 10.2337/diabetes.51.7.2317
   Damore ME, 1999, J PEDIATR ENDOCR MET, V12, P207
   HANNA MG, 1995, AM J HUM GENET, V56, P1026
   HAO HL, 1995, AM J HUM GENET, V56, P1017
   Holmgren D, 2003, EUR HEART J, V24, P280, DOI 10.1016/S0195-668X(02)00387-1
   King TE, 1967, METHODS ENZYMOLOGY, V10, P322, DOI 10.1016/0076-6879(67)10061-X
   King T E, 1967, METHODS IN ENZYMOLOGY EDS, V10, P275, DOI 10.1016/0076-6879(67)10055-4
   Mancuso M, 2005, J NEUROL SCI, V228, P93, DOI 10.1016/j.jns.2004.10.018
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   Meulemans A, 2007, EUR J PAEDIATR NEURO, V11, P17, DOI 10.1016/j.ejpn.2006.10.004
   Narbonne H, 2004, DIABETES METAB, V30, P61, DOI 10.1016/S1262-3636(07)70090-3
   Rigoli L, 2001, DIABETIC MED, V18, P334, DOI 10.1046/j.1464-5491.2001.00429-2.x
   SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A
   SCHON EA, 2006, MITOCHONDRIAL MED, V0, P329
   Shanske S, 2004, AM J MED GENET A, V130A, P134, DOI 10.1002/ajmg.a.30220
   Srere PA, 1969, METHODS IN ENZYMOLOGY, V13, P3
   Vialettes BH, 1997, DIABETES CARE, V20, P1731, DOI 10.2337/diacare.20.11.1731
   Wharton DC, 1967, METHODS ENZYMOL, V10, P245, DOI 10.1016/0076-6879(67)10048-7
NR 20
TC 11
Z9 12
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-6199
EI 
J9 EUR J PEDIATR
JI Eur. J. Pediatr.
PD JUL 15
PY 2008
VL 167
IS 7
BP 771
EP 776
DI 10.1007/s00431-007-0587-8
PG 6
WC Pediatrics
SC Pediatrics
GA 304BL
UT WOS:000256084900010
PM 17891417
DA 2024-11-01
ER

PT J
AU Lai, CQ
   Tucker, KL
   Parnell, LD
   Adiconis, M
   García-Bailo, B
   Griffith, J
   Meydani, M
   Ordovás, JM
AF Lai, Chao-Qiang
   Tucker, Katherine L.
   Parnell, Laurence D.
   Adiconis, Man
   Garcia-Bailo, Bibiana
   Griffith, John
   Meydani, Mohsen
   Ordovas, Jose M.
TI <i>PPARGC1A</i> variation associated with DNA damage, diabetes, and cardiovascular diseases -: The Boston Puerto Rican Health Study
SO DIABETES
LA English
DT Article
ID gamma coactivator-1 pgc-1; human skeletal-muscle; pgc-1-alpha gene; physical-activity; type-2; mellitus; insulin; polymorphisms; complications; mitochondria
AB OBJECTIVE - Individuals with type 2 diabetes exhibit higher DNA damage and increased risk of cardiovascular disease (CVD). However, mechanisms underlying the association between DNA damage and development of type 2 diabetes and CVD are not understood. We sought to link peroxisome proliferator-activated receptor-gamma coactivator-1 alpha (PPARGC1A), a master transcriptional regulator of mitochondrial oxidative phosphorylation and cellular energy metabolism, with DNA damage, type 2 diabetes, and CVD. RESEARCH DESIGN AND METHODS - We measured DNA damage as urinary 8-hydroxydeoxyguanosine (8-OHdG) concentration and examined the relationship between nine PPARGC1A genetic variants, DNA damage, type 2 diabetes, and self-reported CVD in 959 participants of the Boston Puerto Rican Health Study. RESULTS - With respect to urinary 8-OHdG, PPARGC1A variants showed significant association, and PPARGC1A haplotypes exhibited significant association after correction for multiple testing. Two independent PPARGC1A variants associated significantly with type 2 diabetes (odds ratios [ORs] 1.35 and 2.46; P = 0.045 and <0.001). Carriers of minor alleles of two other PPARGC1A variants, both in strong linkage disequilibrium and associated with lower DNA damage, showed lower prevalence of CVD (ORs 0.53 and 0.65; P = 0.030 and 0.175). Moreover, we found that physical activity correlated negatively with DNA damage. CONCLUSIONS - It is plausible that low physical activity combined with risk haplotyes contribute to the high prevalence of type 2 diabetes in this population. We propose that PPARGC1A influences development of type 2 diabetes and CVD via DNA damage : Increasing physical activity, which induces PPARGC1A expression, is a potential strategy to slow DNA damage, thereby decreasing the risk of CVD for individuals with type 2 diabetes.
C1 [Lai, Chao-Qiang; Parnell, Laurence D.; Adiconis, Man; Garcia-Bailo, Bibiana; Ordovas, Jose M.] Tufts Univ, Human Nutr Res Ctr Aging, JM USDA, Nutr & Gen Lab, Boston, MA 02111 USA.
   [Tucker, Katherine L.] Tufts Univ, Human Nutr Res Ctr Aging, JM USDA, Dietary Assessment & Epidemiol Res Program, Boston, MA 02111 USA.
   [Griffith, John] Tufts Univ New England Med Ctr, Biostat Res Ctr, Boston, MA USA.
   [Meydani, Mohsen] Tufts Univ, Human Nutr Res Ctr Aging, JM USDA, Vasc Biol Lab, Boston, MA 02111 USA.
C3 Tufts University; United States Department of Agriculture (USDA); Tufts University; United States Department of Agriculture (USDA); Tufts Medical Center; Tufts University; United States Department of Agriculture (USDA)
RP Lai, CQ (corresponding author), Tufts Univ, Human Nutr Res Ctr Aging, JM USDA, Nutr & Gen Lab, Boston, MA 02111 USA.
EM chaoqiang.lai@ars.usda.gov
FU NHLBI NIH HHS [R01 HL054776, HL54776] Funding Source: Medline; NIA NIH HHS [P01 AG023394-05, P01 AG023394, 5P01-AG-023394-02] Funding Source: Medline
CR Andreassi MG, 2003, TRENDS CARDIOVAS MED, V13, P270, DOI 10.1016/S1050-1738(03)00109-9
   Andrulionyte L, 2006, DIABETES, V55, P2148, DOI 10.2337/db05-1629
   [Anonymous], 2007, DIABETES CARE, V30, P4, DOI 10.2337/DC07-S004
   Barroso I, 2006, DIABETOLOGIA, V49, P501, DOI 10.1007/s00125-005-0130-2
   Barroso I, 2003, PLOS BIOL, V1, P41, DOI 10.1371/journal.pbio.0000020
   BIENNAN EL, 1992, ARTERIOSCLER THROMB, V12, P647
   BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Choi YS, 2006, BIOCHEM BIOPH RES CO, V344, P708, DOI 10.1016/j.bbrc.2006.03.193
   Dandona P, 1996, LANCET, V347, P444, DOI 10.1016/S0140-6736(96)90013-6
   de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669
   Devaraj S, 2000, CIRCULATION, V102, P191, DOI 10.1161/01.CIR.102.2.191
   Ek J, 2001, DIABETOLOGIA, V44, P2220, DOI 10.1007/s001250100032
   EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921
   Falush D, 2003, GENETICS, V164, P1567
   Finck BN, 2006, J CLIN INVEST, V116, P615, DOI 10.1172/JCI27794
   Franks PW, 2006, EXERC SPORT SCI REV, V34, P171, DOI 10.1249/01.jes.0000240021.92254.23
   Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037
   Hara K, 2002, DIABETOLOGIA, V45, P740, DOI 10.1007/s00125-002-0803-z
   Ho GYF, 2006, REV PANAM SALUD PUBL, V19, P331, DOI 10.1590/S1020-49892006000500006
   Hoogerbrugge N, 1996, DIABETES CARE, V19, P1122, DOI 10.2337/diacare.19.10.1122
   Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9
   Kunej T, 2004, FOLIA BIOL-PRAGUE, V50, P157
   Lee IM, 1998, STROKE, V29, P2049, DOI 10.1161/01.STR.29.10.2049
   Lenaz G, 2002, ANN NY ACAD SCI, V959, P199, DOI 10.1111/j.1749-6632.2002.tb02094.x
   Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004
   Ling C, 2004, J CLIN INVEST, V114, P1518, DOI 10.1172/JCI200421889
   Livak KJ, 1999, GENET ANAL-BIOMOL E, V14, P143, DOI 10.1016/S1050-3862(98)00019-9
   Lowell BB, 2005, SCIENCE, V307, P384, DOI 10.1126/science.1104343
   Martinet W, 2002, CIRCULATION, V106, P927, DOI 10.1161/01.CIR.0000026393.47805.21
   Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108
   Miwa S, 2003, BIOCHEM SOC T, V31, P1300
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Norrbom J, 2004, J APPL PHYSIOL, V96, P189, DOI 10.1152/japplphysiol.00765.2003
   Oberkofler H, 2004, DIABETES, V53, P1385, DOI 10.2337/diabetes.53.5.1385
   Park KS, 2001, DIABETES, V50, P2837, DOI 10.2337/diabetes.50.12.2837
   Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850
   Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5
   PYORALA K, 1987, DIABETES METABOLISM REVIEWS, V3, P463
   RIM JA, 1994, DIABETES, V43, P1103
   SHIGENAGA MK, 1989, P NATL ACAD SCI USA, V86, P9697, DOI 10.1073/pnas.86.24.9697
   Sriwijitkamol A, 2007, DIABETES, V56, P836, DOI 10.2337/db06-1119
   St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200
   St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024
   Takatori A, 2004, DIABETES-METAB RES, V20, P211, DOI 10.1002/dmrr.428
   Tucker Katherine L, 2005, J MED INVEST, V52 Suppl, P252, DOI 10.2152/jmi.52.252
   Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X
   Yu ZX, 2007, GENET EPIDEMIOL, V31, P553, DOI 10.1002/gepi.20228
   Zimmet P, 2000, J INTERN MED, V247, P301, DOI 10.1046/j.1365-2796.2000.00625.x
NR 50
TC 64
Z9 72
U1 0
U2 2
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD APR 15
PY 2008
VL 57
IS 4
BP 809
EP 816
DI 10.2337/db07-1238
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 282UC
UT WOS:000254591700004
PM 18162502
DA 2024-11-01
ER

PT J
AU Finsterer, J
AF Finsterer, Josef
TI Leigh and Leigh-Like Syndrome in Children and Adults
SO PEDIATRIC NEUROLOGY
LA English
DT Review
ID cytochrome-c-oxidase; complex-i-deficiency; subacute necrotizing encephalomyelopathy; mitochondrial-dna mutation; respiratory-chain deficiency; surf1 gene-mutations; atpase 6 gene; cox deficiency; 3-methylglutaconic aciduria; oxidative-phosphorylation
AB Leigh syndrome (also termed subacute, necrotizing encephalopathy) is a devastating neurodegenerative disorder, characterized by almost identical brain changes, e.g., focal, bilaterally symmetric lesions, particularly in the basal ganglia, thalamus, and brainstem, but with considerable clinical and genetic heterogeneity. Clinically, Leigh syndrome is characterized by a wide variety of abnormalities, from severe neurologic problems to a near absence of abnormalities. Most frequently the central nervous system is affected, with psychomotor retardation, seizures, nystagmus, ophthalmoparesis, optic atrophy, ataxia, dystonia, or respiratory failure. Some patients also present with peripheral nervous system involvement, including polyneuropathy or myopathy, or non-neurologic abnormalities, e.g., diabetes, short stature, hypertrichosis, cardiomyopathy, anemia, renal failure, vomiting, or diarrhea (Leigh-like syndrome). In the majority of cases, onset is in early childhood, but in a small number of cases, adults are affected. In the majority of cases, dysfunction of the respiratory chain (particularly complexes I, II, IV, or V), of coenzyme Q, or of the pyruvate dehydrogenase complex are responsible for the disease. Associated mutations affect genes of the mitochondrial or nuclear genome. Leigh syndrome and Leigh-like syndrome are the mitochondrial disorders with the largest genetic heterogeneity. (C) 2008 by Elsevier Inc. All rights reserved.
C1 [Finsterer, Josef] Krankenanstalt Rudolfstiftung Wien, Vienna, Austria.
C3 Rudolfstiftung Hospital
RP Finsterer, J (corresponding author), Postfach 20, A-1180 Vienna, Austria.
EM fifigs1@yahoo.de
CR Araki S, 1997, PEDIATR NEUROL, V16, P329, DOI 10.1016/S0887-8994(97)00020-9
   Arii J, 2000, AM J NEURORADIOL, V21, P1502
   BAUMGARTNER ER, 1989, PEDIATR RES, V26, P260, DOI 10.1203/00006450-198909000-00021
   Bénit P, 2004, J MED GENET, V41, P14, DOI 10.1136/jmg.2003.014316
   Bénit P, 2003, HUM MUTAT, V21, P582, DOI 10.1002/humu.10225
   Bénit P, 2001, AM J HUM GENET, V68, P1344, DOI 10.1086/320603
   BERKOVIC SF, 1991, LANCET, V338, P457, DOI 10.1016/0140-6736(91)91090-H
   Blok MJ, 2007, J MED GENET, V44, P0, DOI 10.1136/jmg.2006.045716
   Böhm M, 2006, PEDIATR RES, V59, P21, DOI 10.1203/01.pdr.0000190572.68191.13
   BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144
   Bugiani M, 2005, J MED GENET, V42, P0, DOI 10.1136/jmg.2004.029926
   Campos Y, 1997, NEUROLOGY, V49, P595, DOI 10.1212/WNL.49.2.595
   Carelli V, 2002, ARCH NEUROL-CHICAGO, V59, P264, DOI 10.1001/archneur.59.2.264
   Castagna AE, 2007, AM J MED GENET A, V143A, P808, DOI 10.1002/ajmg.a.31637
   CAVANAGH JB, 1994, BRAIN, V117, P1357, DOI 10.1093/brain/117.6.1357
   CHAE JH, 2000, BRAIN DEV, V30, P387
   Chalmers RM, 1997, NEUROLOGY, V49, P589, DOI 10.1212/WNL.49.2.589
   Chol M, 2003, J MED GENET, V40, P188, DOI 10.1136/jmg.40.3.188
   Coenen MJH, 2006, J INHERIT METAB DIS, V29, P212, DOI 10.1007/s10545-006-0185-3
   Cooper MP, 2006, GENE DEV, V20, P2996, DOI 10.1101/gad.1483906
   Debray FG, 2007, AM J MED GENET A, V143A, P2046, DOI 10.1002/ajmg.a.31880
   Debray FG, 2007, PEDIATRICS, V119, P722, DOI 10.1542/peds.2006-1866
   Degoul F, 1997, J INHERIT METAB DIS, V20, P49, DOI 10.1023/A:1005357506614
   DEMEIRLEIR L, 1994, PEDIATR RES, V36, P707, DOI 10.1203/00006450-199412000-00004
   Desguerre I, 2003, NEUROPEDIATRICS, V34, P265
   DEVRIES DD, 1993, ANN NEUROL, V34, P410, DOI 10.1002/ana.410340319
   Di Rocco M, 1999, J INHERIT METAB DIS, V22, P593, DOI 10.1023/A:1005565610613
   Farina L, 2002, AM J NEURORADIOL, V23, P1095
   Formichi P, 2004, J NEUROL NEUROSUR PS, V75, P930, DOI 10.1136/jnnp.2003.016410
   Funalot B, 2002, ANN NEUROL, V52, P374, DOI 10.1002/ana.10299
   Goldenberg PC, 2003, NEUROLOGY, V60, P865, DOI 10.1212/01.WNL.0000049460.72439.7F
   GREENBERG SB, 1990, PEDIATR RADIOL, V21, P5, DOI 10.1007/BF02010803
   HAMMANS SR, 1993, BRAIN, V116, P617, DOI 10.1093/brain/116.3.617
   Horváth R, 2006, J NEUROL NEUROSUR PS, V77, P74, DOI 10.1136/jnnp.2005.067041
   Howell N, 1996, NEUROLOGY, V46, P219, DOI 10.1212/WNL.46.1.219
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   KOCH TK, 1986, ANN NEUROL, V19, P605, DOI 10.1002/ana.410190617
   Laugel V, 2007, PEDIATR NEUROL, V36, P54, DOI 10.1016/j.pediatrneurol.2006.08.007
   Lebon S, 2003, J MED GENET, V40, P896, DOI 10.1136/jmg.40.12.896
   Lebon S, 2007, MOL GENET METAB, V90, P379, DOI 10.1016/j.ymgme.2006.12.007
   LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216
   Leshinsky-Silver E, 2005, BIOCHEM BIOPH RES CO, V334, P582, DOI 10.1016/j.bbrc.2005.06.134
   Leshinsky-Silver E, 2003, PRENATAL DIAG, V23, P31, DOI 10.1002/pd.516
   Loeffen J, 2001, ANN NEUROL, V49, P195, DOI 10.1002/1531-8249(20010201)49:2<195::AID-ANA39>3.0.CO;2-M
   Loeffen J, 1998, AM J HUM GENET, V63, P1598, DOI 10.1086/302154
   López LC, 2006, AM J HUM GENET, V79, P1125, DOI 10.1086/510023
   Mak SC, 1998, J CHILD NEUROL, V13, P349, DOI 10.1177/088307389801300709
   Makino M, 1998, NEUROMUSCULAR DISORD, V8, P149, DOI 10.1016/S0960-8966(98)00017-0
   Malandrini A, 1998, J NEUROL SCI, V155, P218, DOI 10.1016/S0022-510X(98)00014-8
   Malfatti E, 2007, BRAIN, V130, P1894, DOI 10.1093/brain/awm114
   MARTIN E, 1990, PEDIATR RADIOL, V20, P349, DOI 10.1007/BF02013174
   Martín MA, 2005, ARCH NEUROL-CHICAGO, V62, P659, DOI 10.1001/archneur.62.4.659
   MATTHEWS PM, 1993, ANN NEUROL, V33, P652, DOI 10.1002/ana.410330616
   McFarland R, 2004, ANN NEUROL, V55, P58, DOI 10.1002/ana.10787
   MEDINA L, 1990, AM J ROENTGENOL, V154, P1269, DOI 10.2214/ajr.154.6.2159689
   MERANTE F, 1993, AM J HUM GENET, V53, P481
   MIRANDA AF, 1989, NEUROLOGY, V39, P697, DOI 10.1212/WNL.39.5.697
   MONTPETIT VJ, 1971, BRAIN, V94, P1, DOI 10.1093/brain/94.1.1
   MORIN C, 1993, AM J HUM GENET, V53, P488
   Munaro M, 1997, HUM MOL GENET, V6, P221, DOI 10.1093/hmg/6.2.221
   Jareño NM, 2007, J CHILD NEUROL, V22, P218, DOI 10.1177/0883073807300300
   Nagashima T, 1999, ACTA NEUROPATHOL, V97, P416, DOI 10.1007/s004010051007
   Ostergaard E, 2007, BRAIN, V130, P853, DOI 10.1093/brain/awl383
   Parfait B, 2000, HUM GENET, V106, P236, DOI 10.1007/s004390051033
   Pecina P, 2004, AM J PHYSIOL-CELL PH, V287, PC1384, DOI 10.1152/ajpcell.00286.2004
   Péquignot MO, 2001, J BIOL CHEM, V276, P15326, DOI 10.1074/jbc.M100388200
   Petruzzella V, 2001, HUM MOL GENET, V10, P529, DOI 10.1093/hmg/10.5.529
   Piao YS, 2006, NEUROPATHOLOGY, V26, P218, DOI 10.1111/j.1440-1789.2006.00686.x
   Poyau A, 2000, HUM GENET, V106, P194, DOI 10.1007/s004390051028
   Pronicki M, 2008, J CLIN PATHOL, V61, P460, DOI 10.1136/jcp.2007.051060
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Rojo A, 2006, ACTA NEUROPATHOL, V111, P610, DOI 10.1007/s00401-006-0040-5
   Rossi A, 2003, AM J NEURORADIOL, V24, P1188
   Ruiter EM, 2007, EUR J HUM GENET, V15, P155, DOI 10.1038/sj.ejhg.5201735
   Salviati L, 2004, AM J MED GENET A, V128A, P195, DOI 10.1002/ajmg.a.30073
   Santorelli FM, 1997, ANN NEUROL, V42, P256, DOI 10.1002/ana.410420220
   Sarzi E, 2007, AM J MED GENET A, V143A, P33, DOI 10.1002/ajmg.a.31565
   Scacco S, 2003, J BIOL CHEM, V278, P44161, DOI 10.1074/jbc.M307615200
   Scaglia F, 2005, AM J NEURORADIOL, V26, P1675
   Schiff M, 2006, ANN NEUROL, V59, P709, DOI 10.1002/ana.20818
   Schuelke M, 1999, NAT GENET, V21, P260, DOI 10.1038/6772
   SHOFFNER JM, 1992, NEUROLOGY, V42, P2168, DOI 10.1212/WNL.42.11.2168
   Shtilbans A, 2000, J CHILD NEUROL, V15, P759, DOI 10.1177/088307380001501109
   SPARACO M, 1993, J NEUROPATH EXP NEUR, V52, P1, DOI 10.1097/00005072-199301000-00001
   Sudo A, 2004, J HUM GENET, V49, P92, DOI 10.1007/s10038-003-0116-1
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Taylor RW, 2002, EUR J HUM GENET, V10, P141, DOI 10.1038/sj.ejhg.5200773
   Tiranti V, 2000, HUM MOL GENET, V9, P2733, DOI 10.1093/hmg/9.18.2733
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   Tiranti V, 1999, J MED GENET, V36, P927
   Triepels RH, 1999, ANN NEUROL, V45, P787, DOI 10.1002/1531-8249(199906)45:6<787::AID-ANA13>3.0.CO;2-6
   Ugalde C, 2003, ANN NEUROL, V54, P665, DOI 10.1002/ana.10734
   Ugalde C, 2007, MOL GENET METAB, V90, P10, DOI 10.1016/j.ymgme.2006.08.003
   Uziel G, 1997, J NEUROL NEUROSUR PS, V63, P16, DOI 10.1136/jnnp.63.1.16
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
   van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716
   Van Maldergem L, 2002, ANN NEUROL, V52, P750, DOI 10.1002/ana.10371
   van Riesen AKJ, 2006, NEUROPEDIATRICS, V37, P88, DOI 10.1055/s-2006-924227
   Vanniarajan A, 2006, ACTA NEUROL SCAND, V114, P350, DOI 10.1111/j.1600-0404.2006.00673.x
   Von Kleist-Retzow JC, 2001, J MED GENET, V38, P109, DOI 10.1136/jmg.38.2.109
   Wick Regula, 2007, J FORENSIC LEG MED, V14, P42, DOI 10.1016/j.jcfm.2006.01.002
   WILLEMS JL, 1977, PEDIATRICS, V60, P850
   Wilson CJ, 2000, J CHILD NEUROL, V15, P830, DOI 10.1177/088307380001501218
   Wortmann S, 2006, MOL GENET METAB, V88, P47, DOI 10.1016/j.ymgme.2006.01.013
   Yang YL, 2006, CHINESE MED J-PEKING, V119, P373, DOI 10.1097/00029330-200603010-00004
   Yoshinaga H, 2003, NEUROPEDIATRICS, V34, P81
   Yüksel A, 2006, PEDIATR NEUROL, V34, P486, DOI 10.1016/j.pediatrneurol.2005.10.020
   ZAFEIRIOU DI, 1995, BRAIN DEV-JPN, V17, P117, DOI 10.1016/0387-7604(94)00098-I
   Zhadanov SI, 2007, MITOCHONDRION, V7, P260, DOI 10.1016/j.mito.2007.01.003
   Zhang Y, 2007, J INHERIT METAB DIS, V30, P265, DOI 10.1007/s10545-006-0481-y
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
NR 111
TC 250
Z9 290
U1 0
U2 57
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0887-8994
EI 1873-5150
J9 PEDIATR NEUROL
JI Pediatr. Neurol.
PD OCT 15
PY 2008
VL 39
IS 4
BP 223
EP 235
DI 10.1016/j.pediatrneurol.2008.07.013
PG 13
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 363RU
UT WOS:000260285200001
PM 18805359
DA 2024-11-01
ER

PT J
AU Xu, F
   Ackerley, C
   Maj, MC
   Addis, JBL
   Levandovskiy, V
   Lee, J
   MacKay, N
   Cameron, JM
   Robinson, BH
AF Xu, Fenghao
   Ackerley, Cameron
   Maj, Mary C.
   Addis, Jane B. L.
   Levandovskiy, Valeriy
   Lee, Jisoo
   MacKay, Nevena
   Cameron, Jessie M.
   Robinson, Brian H.
TI Disruption of a mitochondrial RNA-binding protein gene results in decreased cytochrome <i>b</i> expression and a marked reduction in ubiquinol-cytochrome <i>c</i> reductase activity in mouse heart mitochondria
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE cytochrome b; mitochondrion; pentatricopeptide repeat (PPR) protein; pentatricopeptide repeat domain protein 2 (PTCD2); RNA processing
ID pentatricopeptide repeat proteins; blue native electrophoresis; messenger-rna; saccharomyces-cerevisiae; histiocytoid cardiomyopathy; deficiency; domain; sequence; mutation; disease
AB Mice homozygous for a defect in the PTCD2 (pentatricopeptide repeat domain protein 2) gene were generated in order to study the role of this protein in mitochondrial RNA metabolism. These mice displayed specific but variable reduction of ubiquinol-cytochronic c reductase complex activity in mitochondria of heart, liver and skeletal muscle due to a decrease in the expression of mitochondrial DNA-encoded cytochrome b, the catalytic core of the complex. This reduction in mitochondrial function has a profound effect on the myocardium, with replacement of ventricular cardiomyocytes by fibro-fatty tissue. Northern blotting showed a reduction in the mRNA for the mitochondrial DNA encoded proteins cytochrome b (cytb) and ND5 (NADH dehydrogenase subunit 5) and an elevation in a combined pre-processed ND5-CYTB transcript. This suggests that the PTCD2 protein is involved in processing RNA transcripts involving cytochrome b derived from mitochondrial DNA. This defines the site for PTCD2 action in mammalian mitochondria and suggests a possible role for dysfunction of this protein in the actiology of heart failure.
C1 [Maj, Mary C.; Addis, Jane B. L.; Levandovskiy, Valeriy; MacKay, Nevena; Cameron, Jessie M.; Robinson, Brian H.] Univ Toronto, Hosp Sick Children, Metab Res Programme, Toronto, ON MG5 1X8, Canada.
   [Xu, Fenghao; Lee, Jisoo] Univ Toronto, Hosp Sick Children, Programme Genet & Genome Biol, Toronto, ON MG5 1X8, Canada.
   [Ackerley, Cameron] Univ Toronto, Hosp Sick Children, Dept Paediat, Lab Med, Toronto, ON MG5 1X8, Canada.
C3 University of Toronto; Hospital for Sick Children (SickKids); University of Toronto; Hospital for Sick Children (SickKids); University of Toronto; Hospital for Sick Children (SickKids)
RP Robinson, BH (corresponding author), Univ Toronto, Hosp Sick Children, Metab Res Programme, 555 Univ Ave, Toronto, ON MG5 1X8, Canada.
EM bhr@sickkids.ca
FU Canadian Institutes for Health Research [MT 6573]; MitoMarch for Kirkland; Association de Addose Lactique-Saguenay-Lac-Saint-Jean (Quebec)
CR Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36
   Andreu AL, 2000, PEDIATR RES, V48, P311, DOI 10.1203/00006450-200009000-00008
   Bonawitz ND, 2006, MOL CELL BIOL, V26, P4818, DOI 10.1128/MCB.02360-05
   Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x
   Coffin JW, 1997, CURR GENET, V32, P273, DOI 10.1007/s002940050277
   Ellis TP, 2004, J BIOL CHEM, V279, P15728, DOI 10.1074/jbc.M314162200
   FERRANS VJ, 1976, CIRCULATION, V53, P708, DOI 10.1161/01.CIR.53.4.708
   Finn RD, 2006, NUCLEIC ACIDS RES, V34, PD247, DOI 10.1093/nar/gkj149
   Fisk DG, 1999, EMBO J, V18, P2621, DOI 10.1093/emboj/18.9.2621
   GOODIN JC, 1991, MODERN PATHOL, V4, P702
   Liu LY, 2002, GENOMICS, V79, P124, DOI 10.1006/geno.2001.6679
   MANTHEY GM, 1995, EMBO J, V14, P4031, DOI 10.1002/j.1460-2075.1995.tb00074.x
   Mili S, 2003, MOL CELL BIOL, V23, P4972, DOI 10.1128/MCB.23.14.4972-4982.2003
   Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699
   NARDELLI M, 1994, FEBS LETT, V344, P10, DOI 10.1016/0014-5793(94)00342-4
   Nord AS, 2006, NUCLEIC ACIDS RES, V34, PD642, DOI 10.1093/nar/gkj097
   Okuda K, 2007, P NATL ACAD SCI USA, V104, P8178, DOI 10.1073/pnas.0700865104
   PAPADIMITRIOU A, 1984, PEDIATR RES, V18, P1023, DOI 10.1203/00006450-198418100-00023
   Piruat JI, 2005, J BIOL CHEM, V280, P42676, DOI 10.1074/jbc.M507044200
   Pusnik M, 2007, MOL CELL BIOL, V27, P6876, DOI 10.1128/MCB.00708-07
   ROBINSON BH, 1990, PEDIATR RES, V28, P549, DOI 10.1203/00006450-199011000-00027
   ROBINSON BH, 1984, AM J HUM GENET, V36, P283
   SCHAGGER H, 1995, ELECTROPHORESIS, V16, P763, DOI 10.1002/elps.11501601125
   SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A
   Schmitz-Linneweber C, 2006, PLANT CELL, V18, P2650, DOI 10.1105/tpc.106.046110
   Shadel GS, 2004, TRENDS GENET, V20, P513, DOI 10.1016/j.tig.2004.08.005
   Small ID, 2000, TRENDS BIOCHEM SCI, V25, P46, DOI 10.1016/S0968-0004(99)01520-0
   STADHOUDERS AM, 1981, MITOCHONDRIA MUSCULA, V0, P113
   Tsuchiya N, 2002, EUR J BIOCHEM, V269, P2927, DOI 10.1046/j.1432-1033.2002.02966.x
   Wittig I, 2006, NAT PROTOC, V1, P418, DOI 10.1038/nprot.2006.62
   Xu FH, 2004, BIOCHEM J, V382, P331, DOI 10.1042/BJ20040469
NR 31
TC 63
Z9 77
U1 0
U2 3
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0264-6021
EI 1470-8728
J9 BIOCHEM J
JI Biochem. J.
PD NOV 15
PY 2008
VL 416
IS 
BP 15
EP 26
DI 10.1042/BJ20080847
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 374YV
UT WOS:000261080500002
PM 18729827
DA 2024-11-01
ER

PT J
AU Wang, XW
   Salinas, K
   Zuo, XM
   Kucejova, B
   Chen, XJ
AF Wang, Xiaowen
   Salinas, Kelly
   Zuo, Xiaoming
   Kucejova, Blanka
   Chen, Xin Jie
TI Dominant membrane uncoupling by mutant adenine nucleotide translocase in mitochondrial diseases
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID progressive external ophthalmoplegia; saccharomyces-cerevisiae; adp/atp carrier; proton conductance; mtdna maintenance; optic atrophy; dna deletions; fatty-acids; ant1 gene; mutation
AB Adenine nucleotide translocase (Ant) is the most abundant protein on the mitochondrial inner membrane (MIM) primarily involved in ADP/ATP exchange. Ant also possesses a discrete membrane uncoupling activity. Specific mis-sense mutations in the human Ant1 cause autosomal dominant Progressive External Ophthalmoplegia (adPEO), mitochondrial myopathy and cardiomyopathy, which are commonly manifested by fractional mitochondrial DNA (mtDNA) deletions. It is currently thought that the pathogenic mutations alter substrate preference (e.g. ATP versus ADP) thereby dominantly disturbing adenine nucleotide homeostasis in mitochondria. This may interfere with mtDNA replication, consequently affecting mtDNA stability and oxidative phosphorylation. Here, we showed that the adPEO-type A128P, A106D and M114P mutations in the yeast Aac2p share the following common dominant phenotypes: electron transport chain damage, intolerance to moderate over-expression, synthetic lethality with low Delta psi(m) conditions, hypersensitivity to the uncoupler carbonyl cyanide m-chlorophenylhydrazone (CCCP) and mtDNA instability. More interestingly, the aac2(A137D) allele mimicking ant1(A123D) in mitochondrial myopathy and cardiomyopathy exhibits similar dominant phenotypes. Because Aac2(A137D) is known to completely lack transport activity, it is strongly argued that the dominant mitochondrial damages are not caused by aberrant nucleotide transport. The four pathogenic mutations occur in a structurally dynamic gating region on the cytosolic side. We provided direct evidence that the mutant alleles uncouple mitochondrial respiration. The pathogenic mutations likely enhance the intrinsic proton-conducting activity of Ant, which excessively uncouples the MIM thereby affecting energy transduction and mitochondrial biogenesis. mtDNA disintegration is a phenotype co-lateral to mitochondrial damages. These findings provide mechanistic insights into the pathogenesis of the Ant1-induced diseases.
C1 [Wang, Xiaowen; Salinas, Kelly; Chen, Xin Jie] SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA.
   [Zuo, Xiaoming; Kucejova, Blanka] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA.
C3 State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Texas System; University of Texas Southwestern Medical Center Dallas
RP Chen, XJ (corresponding author), SUNY Upstate Med Univ, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13210 USA.
EM chenx@upstate.edu
FU National Institute of Health [AG023731]; American Heart Association [0435047N]; American Heart Association (AHA) [0435047N] Funding Source: American Heart Association (AHA)
CR Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   BETINA S, 1995, EUR J BIOCHEM, V229, P651, DOI 10.1111/j.1432-1033.1995.tb20510.x
   Brand MD, 2005, BIOCHEM J, V392, P353, DOI 10.1042/BJ20050890
   BRUSTOVETSKY N, 1994, J BIOL CHEM, V269, P27329
   Chen XJ, 1999, MOL GEN GENET, V262, P898, DOI 10.1007/s004380051156
   Chen XJ, 2005, NAT REV GENET, V6, P815, DOI 10.1038/nrg1708
   Chen XJ, 2002, HUM MOL GENET, V11, P1835, DOI 10.1093/hmg/11.16.1835
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Crompton M, 2004, AGING CELL, V3, P3, DOI 10.1046/j.1474-9728.2003.00073.x
   Deschauer M, 2005, NEUROMUSCULAR DISORD, V15, P311, DOI 10.1016/j.nmd.2004.12.004
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   Ferraris S, 2008, ARCH NEUROL-CHICAGO, V65, P125, DOI 10.1001/archneurol.2007.9
   Fontanesi F, 2004, HUM MOL GENET, V13, P923, DOI 10.1093/hmg/ddh108
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kihira Y, 2004, BIOCHEMISTRY-US, V43, P15204, DOI 10.1021/bi0494222
   Klingenberg M, 2008, BBA-BIOMEMBRANES, V1778, P1978, DOI 10.1016/j.bbamem.2008.04.011
   Komaki H, 2002, ANN NEUROL, V51, P645, DOI 10.1002/ana.10172
   Kominsky DJ, 2002, GENETICS, V162, P1595
   Leonhard K, 1996, EMBO J, V15, P4218, DOI 10.1002/j.1460-2075.1996.tb00796.x
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Nicholls DG, 2004, AGING CELL, V3, P35, DOI 10.1111/j.1474-9728.2003.00079.x
   Palmieri L, 2005, HUM MOL GENET, V14, P3079, DOI 10.1093/hmg/ddi341
   PEARCE DA, 1995, J BIOL CHEM, V270, P20879, DOI 10.1074/jbc.270.36.20879
   Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056
   Polcic P, 1997, FEBS LETT, V412, P207, DOI 10.1016/S0014-5793(97)00778-3
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Talbot DA, 2004, J PHYSIOL-LONDON, V558, P123, DOI 10.1113/jphysiol.2004.063768
   THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Wang XW, 2008, NAT CELL BIOL, V10, P1090, DOI 10.1038/ncb1769
   Weber ER, 1996, MOL BIOL CELL, V7, P307, DOI 10.1091/mbc.7.2.307
NR 35
TC 29
Z9 33
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD DEC 15
PY 2008
VL 17
IS 24
BP 4036
EP 4044
DI 10.1093/hmg/ddn306
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 377VQ
UT WOS:000261280300019
PM 18809618
DA 2024-11-01
ER

PT J
AU Saada, A
AF Saada, Ann
TI Mitochondrial deoxyribonucleotide pools in deoxyguanosine kinase deficiency
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE Deoxyguanosine kinase dGK; mtDNA depletion; Mitochondrial depletion syndrome; Hepatocerebral; Respiratory chain; Deoxyribonucleotide; dNTP; dGTP
ID dna depletion syndrome; dgk gene-mutations; thymidine kinase; replication; encephalomyopathy; fibroblasts; maintenance; myopathy; defects; assays
AB Mutated deoxyguanosine kinase (dGK), which catalyses the first step of the mitochondrial deoxypurine salvage pathway, accounts for a hepatocerebral variant of mitochondrial DNA (mtDNA) depletion syndromes. In order to elucidate the pathogenic mechanism of dGK deficiency, mitochondrial and cytoplasmic deoxyribonucleoside triphosphate (dNTP) pools in cycling and quiescent fibroblasts from a dGK deficient patient were measured. The mitochondrial dNTP pools were found to be imbalanced, mainly in quiescent cells due to decreased dGTP while mtDNA content and mitochondrial respiratory chain activities were concomitantly decreased. Supplementation of deoxyguanosine and deoxyadenosine normalized mitochondrial dNTP pools, mtDNA content and partially restored the MRC function. It is suggested that the cytoplasmic deoxycytine kinase supplemented with external substrates may compensate for the deficient dGK. (C) 2008 Elsevier Inc. All rights reserved.
C1 Hadassah Med Ctr, Metab Dis Unit, IL-91120 Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center
RP Saada, A (corresponding author), Hadassah Med Ctr, Metab Dis Unit, POB 12000, IL-91120 Jerusalem, Israel.
EM annsr@hadassah.org.il
FU Israeli Academy of Sciences and Humanities [406/02-1]; United Mitochondrial Disease Foundation (UMDF) [07-44]
CR ARNER ESJ, 1992, BIOCHEM BIOPH RES CO, V188, P712, DOI 10.1016/0006-291X(92)91114-6
   Ashley N, 2007, HUM MOL GENET, V16, P1400, DOI 10.1093/hmg/ddm090
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   DiMauro S, 2004, BBA-BIOENERGETICS, V1659, P107, DOI 10.1016/j.bbabio.2004.08.003
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Elpeleg O, 2003, PEDIATR RES, V54, P153, DOI 10.1203/01.PDR.0000072796.25097.A5
   Eriksson S, 2002, CELL MOL LIFE SCI, V59, P1327, DOI 10.1007/s00018-002-8511-x
   HURLEY MC, 1985, J BIOL CHEM, V260, P5675
   Labarthe F, 2005, J HEPATOL, V43, P333, DOI 10.1016/j.jhep.2005.03.023
   Leanza L, 2008, J BIOL CHEM, V283, P16437, DOI 10.1074/jbc.M801572200
   Mancuso M, 2005, ARCH NEUROL-CHICAGO, V62, P745, DOI 10.1001/archneur.62.5.745
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Mathews CK, 2007, FASEB J, V21, P2294, DOI 10.1096/fj.06-7977rev
   Pogozelski WK, 2003, MITOCHONDRION, V2, P415, DOI 10.1016/S1567-7249(03)00033-3
   Pontarin G, 2007, J BIOL CHEM, V282, P16820, DOI 10.1074/jbc.M701310200
   Pontarin G, 2006, J BIOL CHEM, V281, P22720, DOI 10.1074/jbc.M604498200
   Reisch AS, 2007, METHOD CELL BIOL, V80, P199, DOI 10.1016/S0091-679X(06)80010-5
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Rylova SN, 2005, BIOCHEM PHARMACOL, V69, P951, DOI 10.1016/j.bcp.2004.12.010
   Saada A, 2004, DNA CELL BIOL, V23, P797
   Saada A, 2003, BIOCHEM BIOPH RES CO, V310, P963, DOI 10.1016/j.bbrc.2003.09.104
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X
   Song SW, 2005, P NATL ACAD SCI USA, V102, P4990, DOI 10.1073/pnas.0500253102
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Taanman JW, 2003, HUM MOL GENET, V12, P1839, DOI 10.1093/hmg/ddg192
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Wang LY, 1996, FEBS LETT, V390, P39, DOI 10.1016/0014-5793(96)00623-0
NR 32
TC 31
Z9 33
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
EI 
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD NOV 15
PY 2008
VL 95
IS 3
BP 169
EP 173
DI 10.1016/j.ymgme.2008.07.007
PG 5
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine
GA 368DQ
UT WOS:000260601900007
PM 18723380
DA 2024-11-01
ER

PT J
AU Tam, EWY
   Feigenbaum, A
   Addis, JBL
   Blaser, S
   MacKay, N
   Al-Dosary, M
   Taylor, RW
   Ackerley, C
   Cameron, JM
   Robinson, BH
AF Tam, E. W. Y.
   Feigenbaum, A.
   Addis, J. B. L.
   Blaser, S.
   MacKay, N.
   Al-Dosary, M.
   Taylor, R. W.
   Ackerley, C.
   Cameron, J. M.
   Robinson, B. H.
TI A Novel Mitochondrial DNA Mutation in <i>COX1</i> Leads to Strokes, Seizures, and Lactic Acidosis
SO NEUROPEDIATRICS
LA English
DT Article
DE cytochrome c oxidase; COX; stroke; seizures; mtDNA mutation
ID cytochrome-c-oxidase; mtdna mutation; i gene; hypertrophic cardiomyopathy; recurrent myoglobinuria; nonsense mutation; missense mutation; point mutation; subunit; melas
AB Cytochrome c oxidase (COX) is the terminal enzyme of the respiratory chain, with subunits originating both from the mitochondrial and nuclear genome. An eleven-year-old female presented initially with a seizure followed two months later with tonic-clonic seizures, weakness and aphasia. MRI of the cerebral hemispheres showed multiple infarcts. Previous history suggested gross and fine motor control deficits with learning difficulties. A muscle biopsy showed a specific decrease of COX staining in all fibres and pleomorphic mitochondria. Respiratory chain studies confirmed an isolated complex IV defect in muscle, whilst fibroblasts showed an initial COX activity below normal which rapidly came up to the normal range on culture. Sequencing of mtDNA revealed an heteroplasmic m.7023G>A mutation in the COX1 gene, with levels of 96% in muscle, 70% in blood and 50% in the initial skin fibroblast culture dropping to 10% in later passages. The mutation was present in a critical region of the COX1 gene, the V374M change being close to the two histidine residues His376 and His378 co-ordinating with the heme a and a(3), and His367 which co-ordinates a magnesium ion. This case highlights that a MELAS-like syndrome can occur with isolated COX deficiency
C1 [Tam, E. W. Y.] Hosp Sick Children, Div Neurol, Toronto, ON M5G 1X8, Canada.
   [Addis, J. B. L.; MacKay, N.; Cameron, J. M.; Robinson, B. H.] Univ Toronto, Hosp Sick Children, Programme Genet & Genome Biol, Res Inst,Dept Biochem, Toronto, ON M5G 1X8, Canada.
   [Feigenbaum, A.] Hosp Sick Children, Div Clin Genet, Dept Paediat, Toronto, ON M5G 1X8, Canada.
   [Blaser, S.; Ackerley, C.] Hosp Sick Children, Dept Diagnost Imaging, Toronto, ON M5G 1X8, Canada.
   [Al-Dosary, M.; Taylor, R. W.] Hosp Sick Children, Dept Paediat Lab Med, Toronto, ON M5G 1X8, Canada.
   Newcastle Univ, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 University of Toronto; Hospital for Sick Children (SickKids); University of Toronto; Hospital for Sick Children (SickKids); University of Toronto; Hospital for Sick Children (SickKids); University of Toronto; Hospital for Sick Children (SickKids); University of Toronto; Hospital for Sick Children (SickKids); Newcastle University - UK
RP Robinson, BH (corresponding author), Hosp Sick Children, Metab Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM bhr@sickkids.ca
FU Canadian Institutes for Health Research; MitoMarch for Kirkland; Wellcome Trust; Department of Health (UK)
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Bruno C, 1999, AM J HUM GENET, V65, P611, DOI 10.1086/302546
   Campos Y, 2001, ANN NEUROL, V50, P409, DOI 10.1002/ana.1141
   Clark KM, 1999, AM J HUM GENET, V64, P1330, DOI 10.1086/302361
   Comi GP, 1998, ANN NEUROL, V43, P110, DOI 10.1002/ana.410430119
   Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T
   Gallardo ME, 2006, HUM MUTAT, V27, P575, DOI 10.1002/humu.20338
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   Hanna MG, 1998, AM J HUM GENET, V63, P29, DOI 10.1086/301910
   Horváth R, 2002, J MED GENET, V39, P812, DOI 10.1136/jmg.39.11.812
   Ingman M, 2006, NUCLEIC ACIDS RES, V34, PD749, DOI 10.1093/nar/gkj010
   Jaksch M, 1998, J MED GENET, V35, P895, DOI 10.1136/jmg.35.11.895
   Karadimas CL, 2000, NEUROLOGY, V55, P644, DOI 10.1212/WNL.55.5.644
   Keightley JA, 1996, NAT GENET, V12, P410, DOI 10.1038/ng0496-410
   Kirby DM, 2004, J MED GENET, V41, P784, DOI 10.1136/jmg.2004.020537
   Lucioli S, 2006, NEUROGENETICS, V7, P51, DOI 10.1007/s10048-005-0015-z
   MANFREDI G, 1995, NEUROMUSCULAR DISORD, V5, P391, DOI 10.1016/0960-8966(94)00079-O
   MERANTE F, 1994, AM J HUM GENET, V55, P437
   Merante F, 1996, HUM MUTAT, V8, P216, DOI 10.1002/(SICI)1098-1004(1996)8:3<216::AID-HUMU4>3.0.CO;2-7
   Pecina P, 2004, PHYSIOL RES, V53, PS213, DOI 10.33549/physiolres.930000.53.S213
   Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108
   Rahman S, 1999, AM J HUM GENET, V65, P1030, DOI 10.1086/302590
   ROBINSON BH, 1990, PEDIATR RES, V28, P549, DOI 10.1203/00006450-199011000-00027
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, PD823, DOI 10.1093/nar/gkl927
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   Seneca S, 1996, J INHERIT METAB DIS, V19, P115, DOI 10.1007/BF01799407
   Taanman JW, 1997, J BIOENERG BIOMEMBR, V29, P151, DOI 10.1023/A:1022638013825
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   Uusimaa J, 2003, PEDIATRICS, V111, P0, DOI 10.1542/peds.111.3.e262
   Varlamov DA, 2002, HUM MOL GENET, V11, P1797, DOI 10.1093/hmg/11.16.1797
NR 30
TC 34
Z9 39
U1 0
U2 3
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0174-304X
EI 1439-1899
J9 NEUROPEDIATRICS
JI Neuropediatrics
PD DEC 15
PY 2008
VL 39
IS 6
BP 328
EP 334
DI 10.1055/s-0029-1202287
PG 7
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 446MD
UT WOS:000266124800002
PM 19568996
DA 2024-11-01
ER

PT J
AU Çekmen, N
   Bedel, P
   Erdemli, O
AF Cekmen, Nedim
   Bedel, Pasa
   Erdemli, Oezcan
TI "MELAS" Syndrome with Confusion and Lactic Acidosis (Case Report)
SO NEUROLOGY PSYCHIATRY AND BRAIN RESEARCH
LA English
DT Article
DE Confusion; myopathy; lactic acidosis; MELAS syndrome
ID stroke-like episodes; mitochondrial encephalomyopathy; management; disorders; diagnosis; features
AB Introduction: MELAS characterized as mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes syndrome is a hereditary, progressive and a neurodegenerative disorder with mutations in mitochondrial DNA. Herewith, we aimed to present rarely seen a possible adult onset of MELAS syndrome with clinical demonstration of unconsciousness, myopathy and lactic acidosis. Case: A 45-year-old white man who is an army officer, with no significant past medical history represented to the emergency service with unconsciousness. First CT and MRI findings were unremarkable other than diffuse brain edema. He was accepted to intensive care unit. Response to painful stimulus were present with eye movement and extension of extremities. He did not respond to any verbal stimulus. No verbal communication was present. There was no significant finding in his history obtained from family members. Noninvasive monitoring measurements were blood pressure = 180/90 mmHg, heart rate = 100 beats/min, respiratory rate = 30/min, body temperature = 36.5 degrees C. Glascow score was 7 and immediate arterial blood gase findings were pH = 7.24, pO2 = 117 mmHg, pCO2 = 28,9 mmHg, lactate = 163 mg/dL. COHb and MetHb levels were normal. When he became unconcious, he was intubated and put on mechanical ventilation. Nasogastric decompression was applied. Drug profiles, heavy metal toxicity evaluations were performed regarding to drug toxicity. These test results related to intoxication were found negative. Chest X-ray. EKG and examination of other organ systems were unremarkable. Lactic acid level in cerebrospinal fluid was found higher (30 mg/dL), than normal values (10-22 mg/dL), as well as in serum. Along with, abnormal enzyme levels Such as aldolase and pyruvate kinase, Glukoz 6-P dehidrogenase 4.7 U/g (4.6-13.5) which can indicate the disorders in aerobic metabolism and oxidative phosphorylation did not co-exist. Besides, possible mitochondrial myopathy was considered and muscle biopsy was performed. On the second day of the admittance to intensive care unit, urine output and creatinine clearance decreased, emergent dialysis protocol was initiated. Everyday double dialyse protocol was performed. Lactate levels started to return normal ranges on the third day. On the tenth day, he was awake, responding to verbal stimulus, ventilated in CPAP mode, obeying the verbal commands and the Glascow score was 10. He was discharged from intensive care unit to another hospital in order to continue the dialysis program. Histopathological finding of previously performed muscle biopsy revealed accumulation of red painted fibres of abnormal mitochondria under sarcolemna when painted with Gomori trichrome and succinate dehidrogenase in concordance with mitochondrial myopathy. One month later, we were informed that the patient was walking with the support of a walker, his conscious level was normal and became a chronic dialiser patient. Conclusion: With these clinical findings and in concordance with mitochondrial myopathy, we diagnosed this patient as a late onset of MELAS syndrome. When unconsciousness, myopathy and lactic acidosis were present in combination, MELAS syndrome besides toxic metabolic encephalopathies should be considered as a possible diagnose even in late ages.
C1 [Cekmen, Nedim; Bedel, Pasa; Erdemli, Oezcan] Guven Hosp, Dept Anesthesiol & Intens Care, Kavaklidere, Turkey.
C3 Guven Hastanesi
RP Çekmen, N (corresponding author), Cayyolu Mah Guvengir 42 Sitesi Firuze Sok 52 Yeni, Ankara, Turkey.
EM nedimcekmen@yahoo.com
CR Chinnery PF, 1997, J NEUROL NEUROSUR PS, V63, P559, DOI 10.1136/jnnp.63.5.559
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   FERNANDEZSOLA J, 1992, POSTGRAD MED J, V68, P212, DOI 10.1136/pgmj.68.797.212
   Finsterer J, 2004, EUR J NEUROL, V11, P163, DOI 10.1046/j.1351-5101.2003.00728.x
   Finsterer J, 1999, CLIN NEUROPHYSIOL, V110, P1466, DOI 10.1016/S1388-2457(99)00090-5
   Gillis L, 2002, PEDIATR CLIN N AM, V49, P203, DOI 10.1016/S0031-3955(03)00115-9
   Honjo Kie, 2002, NIHON RONEN IGAKKAI ZASSHI, V39, P318
   Kayacan D, 2005, J ISTANB FAC MED, V68, P119
   Kubota H, 2005, J CHILD NEUROL, V20, P116, DOI 10.1177/08830738050200020601
   Leonard JV, 2000, LANCET, V355, P389, DOI 10.1016/S0140-6736(99)05226-5
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   Munnich A, 2001, AM J MED GENET, V106, P4, DOI 10.1002/ajmg.1391
   Sano M, 1998, ANN NEUROL, V44, P576
   SCHAPIRO AHV, 1994, MITOCHONDRIAL DISORD, V0, P1
   Shoffner JM, 2000, NEUROL CLIN, V18, P105, DOI 10.1016/S0733-8619(05)70180-8
   Tanji K, 2001, SEMIN CELL DEV BIOL, V12, P429, DOI 10.1006/scdb.2001.0280
   Walker HK, 1990, CLINICAL METHODS: THE HISTORY, V0, P0
   Wolf NI, 2002, NEUROLOGY, V59, P1402, DOI 10.1212/01.WNL.0000031795.91814.D8
NR 18
TC 0
Z9 0
U1 0
U2 4
PU UNIVERSITATSVERLAG ULM GMBH
PI ULM
PA BAHNHOFSTRASSE 20, D-89073 ULM, GERMANY
SN 0941-9500
EI 
J9 NEUROL PSYCHIAT BR
JI Neurol. Psychiatr. Brain Res.
PD JUN 15
PY 2008
VL 15
IS 4
BP 197
EP 202
DI 
PG 6
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 468XU
UT WOS:000267858700008
DA 2024-11-01
ER

PT J
AU Copeland, WC
AF Copeland, William C.
TI Inherited mitochondrial diseases of DNA replication
SO ANNUAL REVIEW OF MEDICINE
LA English
DT Review; Book Chapter
DE DNA polymerase gamma; nucleotide pools; mitochondrial DNA depletion syndrome; progressive external ophthalmoplegia; ataxia-neuropathy
ID progressive external ophthalmoplegia; thymidine phosphorylase-deficiency; probable germline mosaicism; polymerase-gamma mutations; alpers-syndrome; saccharomyces-cerevisiae; deoxyguanosine kinase; multiple deletions; depletion syndrome; polg mutations
AB Mitochondrial genetic diseases can result from defects in mitochondrial DNA (mtDNA) in the form of deletions, point mutations, or depletion, which ultimately cause loss of oxidative phosphorylation. These mutations may be spontaneous, maternally inherited, or a result of inherited nuclear defects in genes that maintain mtDNA. This review focuses on our current understanding of nuclear gene mutations that produce mtDNA alterations and cause mitochondrial depletion syndrome (MDS), progressive external ophthalmoplegia (PEO), ataxia-neuropathy, or mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). To date, all of these etiologic nuclear genes fall into one of two categories: genes whose products function directly at the mtDNA replication fork, such as POLG, POLG2, and TWINKLE, or genes whose products supply the mitochondria with deoxynucleotide triphosphate pools needed for DNA replication, such as TK2, DGUOK, TP, SUCLA2, ANT1, and possibly the newly identified MPV17.
C1 [Copeland, William C.] NIEHS, Mol Genet Lab, Res Triangle Pk, NC 27709 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)
RP Copeland, WC (corresponding author), NIEHS, Mol Genet Lab, POB 12233, Res Triangle Pk, NC 27709 USA.
EM copelanl@nichs.nih.gov
FU Intramural NIH HHS [Z01 ES065078-14] Funding Source: Medline
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Aknin-Seifer IE, 2005, HUM REPROD, V20, P736, DOI 10.1093/humrep/deh666
   Alberio S, 2007, MITOCHONDRION, V7, P6, DOI 10.1016/j.mito.2006.11.010
   Baruffini E, 2006, HUM MOL GENET, V15, P2846, DOI 10.1093/hmg/ddl219
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Calvo S, 2006, NAT GENET, V38, P576, DOI 10.1038/ng1776
   Carrozzo R, 2003, HUM MUTAT, V21, P0, DOI 10.1002/humu.9135
   Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389
   Chan SSL, 2006, HUM MOL GENET, V15, P3473, DOI 10.1093/hmg/ddl424
   Chan SSL, 2005, DNA REPAIR, V4, P1381, DOI 10.1016/j.dnarep.2005.08.010
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Deschauer M, 2005, NEUROMUSCULAR DISORD, V15, P311, DOI 10.1016/j.nmd.2004.12.004
   DiMauro S, 2006, BRAIN, V129, P1637, DOI 10.1093/brain/awl169
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Fontanesi F, 2004, HUM MOL GENET, V13, P923, DOI 10.1093/hmg/ddh108
   Freisinger P, 2006, ARCH NEUROL-CHICAGO, V63, P1129, DOI 10.1001/archneur.63.8.1129
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hirano M, 2006, NEUROLOGY, V67, P1458, DOI 10.1212/01.wnl.0000240853.97716.24
   Hirano M, 2005, GENE, V354, P152, DOI 10.1016/j.gene.2005.04.041
   Hirano M, 2004, NEUROLOGIST, V10, P8, DOI 10.1097/01.nrl.0000106919.06469.04
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2006, NEUROLOGY, V66, P1439, DOI 10.1212/01.wnl.0000210486.32196.24
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Hudson G, 2006, HUM MOL GENET, V15, PR244, DOI 10.1093/hmg/ddl233
   Jensen M, 2004, HUM REPROD, V19, P65, DOI 10.1093/humrep/deh038
   Karadimas CL, 2006, AM J HUM GENET, V79, P544, DOI 10.1086/506913
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kaukonen J, 1999, AM J HUM GENET, V65, P256, DOI 10.1086/302445
   Kelley RI, 2002, AM J MED GENET, V112, P318, DOI 10.1002/ajmg.10529
   Kowluru A, 2002, ARCH BIOCHEM BIOPHYS, V398, P160, DOI 10.1006/abbi.2001.2710
   Krausz C, 2004, J CLIN ENDOCR METAB, V89, P4292, DOI 10.1210/jc.2004-0008
   Lara MC, 2006, NEUROLOGY, V67, P1461, DOI 10.1212/01.wnl.0000239824.95411.52
   Lewis W, 2007, LAB INVEST, V87, P326, DOI 10.1038/labinvest.3700523
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   Lindhurst MJ, 2006, P NATL ACAD SCI USA, V103, P15927, DOI 10.1073/pnas.0607661103
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   MANDERBACKA K, 2001, SCANDINAVIAN J P S55, V29, P41
   Marobbio CMT, 2002, EMBO J, V21, P5653, DOI 10.1093/emboj/cdf583
   Martí R, 2003, BIOCHEM BIOPH RES CO, V303, P14, DOI 10.1016/S0006-291X(03)00294-8
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Ostergaard E, 2007, BRAIN, V130, P853, DOI 10.1093/brain/awl383
   Pagnamenta AT, 2006, HUM REPROD, V21, P2467, DOI 10.1093/humrep/del076
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Rosenberg MJ, 2002, NAT GENET, V32, P175, DOI 10.1038/ng948
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   SPINAZZOLA A, 2001, J BIOL CHEM, V3, P3
   Stuart GR, 2006, HUM MOL GENET, V15, P363, DOI 10.1093/hmg/ddi454
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Wang LY, 2003, FEBS LETT, V554, P319, DOI 10.1016/S0014-5793(03)01181-5
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   zumGottesberge AMM, 1996, EUR ARCH OTO-RHINO-L, V253, P470, DOI 10.1007/BF00179952
NR 84
TC 213
Z9 246
U1 3
U2 42
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA
SN 0066-4219
EI 
J9 ANNU REV MED
JI Annu. Rev. Med.
PD JUN 15
PY 2008
VL 59
IS 
BP 131
EP 146
DI 10.1146/annurev.med.59.053006.104646
PG 16
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 265YJ
UT WOS:000253397600009
PM 17892433
DA 2024-11-01
ER

PT J
AU Tarnopolsky, MA
   Safdar, A
AF Tarnopolsky, Mark A.
   Safdar, Adeel
TI The potential benefits of creatine and conjugated linoleic acid as adjuncts to resistance training in older adults
SO APPLIED PHYSIOLOGY NUTRITION AND METABOLISM
LA English
DT Article; Proceedings Paper
DE sarcopenia; aging; mitochondrial dysfunction; mitochondrial DNA deletions; oxidative stress; dietary supplement; resistance exercise training
ID human skeletal-muscle; mitochondrial-dna mutations; age-related-changes; myosin heavy-chain; body-composition; oxidative stress; oral creatine; protein-synthesis; animal-models; elderly-men
AB Human aging is associated with a significant reduction in muscle mass (sarcopenia) resulting in muscle weakness and functional limitations in the elderly. Sarcopenia has been associated with mitochondrial dysfunction and the accumulation of mtDNA deletions. Resistance training increases muscle strength and size and can increase mitochondrial capacity and decrease oxidative stress in older adults. Creatine monohydrate (CrM) and conjugated linoleic acid (CLA) have biological effects that could enhance some of the beneficial effects of resistance training in older adults (i.e., up arrow fat-free mass, down arrow total body fat). We have completed two resistance-training studies with CrM alone and CrM + CLA supplementation in older adults to evaluate the independent effects of exercise and dietary supplements, as well as their interactive effects. Our studies, and several others, have found that CrM enhanced the resistance exercise mediated gains in fat-free mass and strength. More recently, we found that the addition of CLA also lead to a significant reduction of body fat after six months of resistance training in older adults. Older adults have fewer wild-type mtDNA copies and higher amounts of mtDNA deletions as compared with younger adults in mature skeletal muscle; however, these deletions are not seen in the satellite cell-derived myoblast cultures. These findings, and the fact that mtDNA deletions are lower and wildtype mtDNA copy number is higher after resistance training in older adults, suggests that activation of satellite cells secondary to resistance exercise-induced muscle damage can dilute or "shift'' the proportion of mtDNA genotype towards that of a younger adult. Recent evidence suggests that CrM supplementation in combination with strength training can enhance satellite cell activation and total myonuclei number per muscle fiber in young men. Future studies are required to determine whether the mitochondrial adaptations to resistance exercise in older adults are further enhanced with CrM supplementation and whether this is due to increased recruitment of satellite cells. It will also be important to determine whether these changes are maintained over a longer time period.
C1 [Tarnopolsky, Mark A.; Safdar, Adeel] McMaster Univ, Dept Pediat & Med, Hamilton, ON L8N 3Z5, Canada.
C3 McMaster University
RP Tarnopolsky, MA (corresponding author), McMaster Univ, Dept Pediat & Med, HSC-2H26,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.
EM tarnopol@mcmaster.ca
CR Aiken J, 2002, ANN NY ACAD SCI, V959, P412, DOI 10.1111/j.1749-6632.2002.tb02111.x
   Antolic A, 2007, MED SCI SPORT EXER, V39, P816, DOI 10.1249/mss.0b013e318031fac4
   Balagopal P, 1997, AM J PHYSIOL-ENDOC M, V273, PE790, DOI 10.1152/ajpendo.1997.273.4.E790
   BASSEY EJ, 1992, CLIN SCI, V82, P321, DOI 10.1042/cs0820321
   Becque MD, 2000, MED SCI SPORT EXER, V32, P654, DOI 10.1097/00005768-200003000-00016
   Bermon S, 1998, ACTA PHYSIOL SCAND, V164, P147, DOI 10.1046/j.1365-201X.1998.00427.x
   Berneis K, 1999, AM J PHYSIOL-ENDOC M, V276, PE188, DOI 10.1152/ajpendo.1999.276.1.E188
   Blankson H, 2000, J NUTR, V130, P2943, DOI 10.1093/jn/130.12.2943
   Brose A, 2003, J GERONTOL A-BIOL, V58, P11
   Bua EA, 2002, J APPL PHYSIOL, V92, P2617, DOI 10.1152/japplphysiol.01102.2001
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Butterfield GE, 1997, AM J PHYSIOL-ENDOC M, V272, PE94, DOI 10.1152/ajpendo.1997.272.1.E94
   Camougrand N, 2001, RESP PHYSIOL, V128, P393, DOI 10.1016/S0034-5687(01)00314-0
   Campbell WW, 1999, J APPL PHYSIOL, V86, P29, DOI 10.1152/jappl.1999.86.1.29
   Campos GER, 2002, EUR J APPL PHYSIOL, V88, P50, DOI 10.1007/s00421-002-0681-6
   Carter Jack M, 2005, J GERIATR PHYS THER, V28, P40
   Casey A, 1996, AM J PHYSIOL-ENDOC M, V271, PE31, DOI 10.1152/ajpendo.1996.271.1.E31
   Castillo EM, 2003, AM J PREV MED, V25, P226, DOI 10.1016/S0749-3797(03)00197-1
   CHARETTE SL, 1991, J APPL PHYSIOL, V70, P1912, DOI 10.1152/jappl.1991.70.5.1912
   Chilibeck PD, 2005, J NUTR HEALTH AGING, V9, P352
   CHOI YC, 2000, ADV MATER, V10, P12
   Chrusch MJ, 2001, MED SCI SPORT EXER, V33, P2111, DOI 10.1097/00005768-200112000-00021
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   Clevenger CM, 2002, J APPL PHYSIOL, V93, P2105, DOI 10.1152/japplphysiol.00315.2002
   Cree MG, 2004, J CLIN ENDOCR METAB, V89, P3864, DOI 10.1210/jc.2003-031986
   Dangott B, 2000, INT J SPORTS MED, V21, P13, DOI 10.1055/s-2000-8848
   Dhiman TR, 2000, J DAIRY SCI, V83, P1016, DOI 10.3168/jds.S0022-0302(00)74966-6
   Doherty TJ, 1997, J APPL PHYSIOL, V82, P93, DOI 10.1152/jappl.1997.82.1.93
   EARNEST CP, 1995, ACTA PHYSIOL SCAND, V153, P207, DOI 10.1111/j.1748-1716.1995.tb09854.x
   Eijnde BO, 2003, J APPL PHYSIOL, V95, P818, DOI 10.1152/japplphysiol.00891.2002
   Evans W J, 1998, GERODONTOLOGY, V15, P15, DOI 10.1111/j.1741-2358.1998.00015.x
   EVANS WJ, 1995, J GERONTOL A-BIOL, V50, P147
   FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029
   FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501
   FORSBERG AM, 1991, CLIN SCI, V81, P249, DOI 10.1042/cs0810249
   Francaux M, 1999, EUR J APPL PHYSIOL O, V80, P165, DOI 10.1007/s004210050575
   Frontera WR, 2000, J APPL PHYSIOL, V88, P1321
   FRONTERA WR, 1988, J APPL PHYSIOL, V64, P1038, DOI 10.1152/jappl.1988.64.3.1038
   FUCHI T, 1989, EUR J APPL PHYSIOL, V58, P884, DOI 10.1007/BF02332223
   Gianni P, 2004, EXP GERONTOL, V39, P1391, DOI 10.1016/j.exger.2004.06.002
   Gillette-Goyonnet S, 2003, MECH AGEING DEV, V124, P311, DOI 10.1016/S0047-6374(02)00198-7
   Giresi PG, 2005, PHYSIOL GENOMICS, V21, P253, DOI 10.1152/physiolgenomics.00249.2004
   Golden TR, 2001, MECH AGEING DEV, V122, P1577, DOI 10.1016/S0047-6374(01)00288-3
   Greenlund LJS, 2003, MECH AGEING DEV, V124, P287, DOI 10.1016/S0047-6374(02)00196-3
   GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902
   GUTHMILLER P, 1994, J BIOL CHEM, V269, P17556
   HAGBERG JM, 1989, J APPL PHYSIOL, V66, P2589, DOI 10.1152/jappl.1989.66.6.2589
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   HARRIS RC, 1992, CLIN SCI, V83, P367, DOI 10.1042/cs0830367
   Hasten DL, 2000, AM J PHYSIOL-ENDOC M, V278, PE620, DOI 10.1152/ajpendo.2000.278.4.E620
   Hespel P, 2001, J PHYSIOL-LONDON, V536, P625, DOI 10.1111/j.1469-7793.2001.0625c.xd
   Hultman E, 1996, J APPL PHYSIOL, V81, P232
   Janssen I, 2004, J AM GERIATR SOC, V52, P80, DOI 10.1111/j.1532-5415.2004.52014.x
   Jówko E, 2001, NUTRITION, V17, P558, DOI 10.1016/S0899-9007(01)00540-8
   Juhn MS, 1999, J AM DIET ASSOC, V99, P593, DOI 10.1016/S0002-8223(99)00145-5
   Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944
   KLITGAARD H, 1990, ACTA PHYSIOL SCAND, V140, P41, DOI 10.1111/j.1748-1716.1990.tb08974.x
   Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568
   Kovalenko SA, 1997, BIOCHEM BIOPH RES CO, V232, P147, DOI 10.1006/bbrc.1997.6251
   Kreider RB, 1998, MED SCI SPORT EXER, V30, P73, DOI 10.1097/00005768-199801000-00011
   Kreider RB, 2002, J STRENGTH COND RES, V16, P325
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Lau EMC, 2005, J GERONTOL A-BIOL, V60, P213, DOI 10.1093/gerona/60.2.213
   LAUKKANEN P, 1995, AGE AGEING, V24, P468, DOI 10.1093/ageing/24.6.468
   Lawler JM, 2002, BIOCHEM BIOPH RES CO, V290, P47, DOI 10.1006/bbrc.2001.6164
   Leveille SG, 2004, CURR OPIN RHEUMATOL, V16, P114, DOI 10.1097/00002281-200403000-00007
   Li Y, 1999, J BONE MINER RES, V14, P1153, DOI 10.1359/jbmr.1999.14.7.1153
   Louis M, 2003, MUSCLE NERVE, V27, P604, DOI 10.1002/mus.10355
   Mahoney DJ, 2005, FASEB J, V19, P1498, DOI 10.1096/fj.04-3149fje
   Mahoney Douglas J, 2005, PHYS MED REHABIL CLIN N AM, V16, P859
   Matthews RT, 1998, J NEUROSCI, V18, P156
   Matthews RT, 1999, EXP NEUROL, V157, P142, DOI 10.1006/exnr.1999.7049
   McCartney N, 1996, J GERONTOL A-BIOL, V51, PB425, DOI 10.1093/gerona/51A.6.B425
   Mecocci P, 1999, FREE RADICAL BIO MED, V26, P303, DOI 10.1016/S0891-5849(98)00208-1
   Melov S, 2002, ANN NY ACAD SCI, V959, P330, DOI 10.1111/j.1749-6632.2002.tb02104.x
   Melov S, 2002, INT J BIOCHEM CELL B, V34, P1395, DOI 10.1016/S1357-2725(02)00086-9
   Melov S, 2007, PLOS ONE, V2, P0, DOI 10.1371/journal.pone.0000465
   Melton LJ, 2000, J AM GERIATR SOC, V48, P625
   Musarò A, 1999, NATURE, V400, P581, DOI 10.1038/23060
   Olsen S, 2006, J PHYSIOL-LONDON, V573, P525, DOI 10.1113/jphysiol.2006.107359
   Parise G, 2005, FREE RADICAL BIO MED, V39, P289, DOI 10.1016/j.freeradbiomed.2005.03.024
   Parise G, 2005, EXP GERONTOL, V40, P173, DOI 10.1016/j.exger.2004.09.002
   Parise G, 2001, J APPL PHYSIOL, V91, P1041, DOI 10.1152/jappl.2001.91.3.1041
   Pariza MW, 2000, P SOC EXP BIOL MED, V223, P8, DOI 10.1046/j.1525-1373.2000.22302.x
   Park Y, 1999, LIPIDS, V34, P243, DOI 10.1007/s11745-999-0359-7
   Park Y, 1997, LIPIDS, V32, P853, DOI 10.1007/s11745-997-0109-x
   Passaquin AC, 2002, NEUROMUSCULAR DISORD, V12, P174, DOI 10.1016/S0960-8966(01)00273-5
   Payne ET, 2006, MUSCLE NERVE, V33, P66, DOI 10.1002/mus.20436
   Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314
   Pinkoski C, 2006, MED SCI SPORT EXER, V38, P339, DOI 10.1249/01.mss.0000183860.42853.15
   PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.1995.03520410035023
   Rawson ES, 1999, EUR J APPL PHYSIOL O, V80, P139, DOI 10.1007/s004210050570
   Rawson ES, 2000, INT J SPORTS MED, V21, P71
   RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465
   Ritov VB, 2005, DIABETES, V54, P8, DOI 10.2337/diabetes.54.1.8
   ROGERS MA, 1990, J APPL PHYSIOL, V68, P2195, DOI 10.1152/jappl.1990.68.5.2195
   Rooyackers OE, 1996, P NATL ACAD SCI USA, V93, P15364, DOI 10.1073/pnas.93.26.15364
   Sandoval N, 1996, GENOMICS, V35, P383, DOI 10.1006/geno.1996.0373
   Sehat N, 1999, LIPIDS, V34, P407, DOI 10.1007/s11745-999-0379-3
   Short KR, 2003, DIABETES, V52, P1888, DOI 10.2337/diabetes.52.8.1888
   Smith SA, 1998, J APPL PHYSIOL, V85, P1349, DOI 10.1152/jappl.1998.85.4.1349
   Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5<723::AID-ANA5>3.0.CO;2-W
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Tarnopolsky M, 1999, NEUROLOGY, V52, P854, DOI 10.1212/WNL.52.4.854
   Tarnopolsky MA, 2004, NEUROLOGY, V62, P1771, DOI 10.1212/01.WNL.0000125178.18862.9D
   Tarnopolsky MA, 2001, MED SCI SPORT EXER, V33, P2044, DOI 10.1097/00005768-200112000-00011
   Tarnopolsky M, 2007, PLOS ONE, V2, P0, DOI 10.1371/journal.pone.0000991
   Tracy BL, 1999, J APPL PHYSIOL, V86, P195, DOI 10.1152/jappl.1999.86.1.195
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   van Leemputte M, 1999, J APPL PHYSIOL, V86, P840, DOI 10.1152/jappl.1999.86.3.840
   Vandenberghe K, 1997, J APPL PHYSIOL, V83, P2055, DOI 10.1152/jappl.1997.83.6.2055
   Vincent KR, 2002, ARCH INTERN MED, V162, P673, DOI 10.1001/archinte.162.6.673
   Visonneau S, 1997, ANTICANCER RES, V17, P969
   Volek JS, 1999, MED SCI SPORT EXER, V31, P1147, DOI 10.1097/00005768-199908000-00011
   WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021
   Watkins BA, 2000, J AM COLL NUTR, V19, P478S, DOI 10.1080/07315724.2000.10718951
   Welle S, 2004, EXP GERONTOL, V39, P369, DOI 10.1016/j.exger.2003.11.011
   WHIPPLE RH, 1987, J AM GERIATR SOC, V35, P13, DOI 10.1111/j.1532-5415.1987.tb01313.x
   Willoughby DS, 2001, MED SCI SPORT EXER, V33, P1674, DOI 10.1097/00005768-200110000-00010
   WYSS M, 1994, MOL CELL BIOCHEM, V133, P51, DOI 10.1007/BF01267947
   Yarasheski KE, 1999, AM J PHYSIOL-ENDOC M, V277, PE118, DOI 10.1152/ajpendo.1999.277.1.E118
   Yasuda N, 2005, J APPL PHYSIOL, V99, P1085, DOI 10.1152/japplphysiol.00247.2005
   Yu LK, 2002, J AGR FOOD CHEM, V50, P4135, DOI 10.1021/jf020086a
   Zahn JM, 2006, PLOS GENET, V2, P1058, DOI 10.1371/journal.pgen.0020115
NR 124
TC 32
Z9 37
U1 1
U2 22
PU CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS
PI OTTAWA
PA 65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA
SN 1715-5312
EI 1715-5320
J9 APPL PHYSIOL NUTR ME
JI Appl. Physiol. Nutr. Metab.
PD FEB 15
PY 2008
VL 33
IS 1
BP 213
EP 227
DI 10.1139/H07-142
PG 15
WC Nutrition & Dietetics; Physiology; Sport Sciences
SC Nutrition & Dietetics; Physiology; Sport Sciences
GA 318OE
UT WOS:000257100600025
PM 18347674
DA 2024-11-01
ER

PT J
AU Jeppesen, TD
   Schwartz, M
   Colding-Jorgensen, E
   Krag, T
   Hauerslev, S
   Vissing, J
AF Jeppesen, Tina D.
   Schwartz, Marianne
   Colding-Jorgensen, Eskild
   Krag, Thomas
   Hauerslev, Simon
   Vissing, John
TI Phenotype and clinical course in a family with a new <i>de novo</i> Twinkle gene mutation
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mtDNA deletion; mtDNA depletion; Twinkle gene mutation; CPEO; PEO1
ID progressive external ophthalmoplegia; mitochondrial-dna deletions
AB The Twinkle gene product is important for mtDNA replication. Only a few reports have investigated the clinically effect of mutations in this gene. We describe a new de novo mutation (1110C > A) in the PEO1 gene in a mother and her two sons. The mother had progressive ophthalmoplegia, limb weakness, sensory neuropathy, elevated resting plasma lactate, glucose intolerance and impaired VO2max while her sons only had mild ptosis. In accordance with the clinical presentation, abnormal morphological findings in muscle and multiple deletions and depletion of mtDNA in muscle were more pronounced in the proband than in her sons. (C) 2007 Elsevier B.V. All rights reserved.
C1 [Jeppesen, Tina D.; Krag, Thomas; Hauerslev, Simon; Vissing, John] Univ Copenhagen, Dept Neurol, Neuromuscular Res Unit, Rigshosp,Sect 7611, DK-2100 Copenhagen, Denmark.
   [Jeppesen, Tina D.; Krag, Thomas; Hauerslev, Simon; Vissing, John] Univ Copenhagen, Dept Neurol, Copenhagen Muscle Res Ctr, Rigshosp,Sect 7611, DK-2100 Copenhagen, Denmark.
   [Schwartz, Marianne] Univ Copenhagen, Rigshosp, Dept Clin Genet, DK-2100 Copenhagen, Denmark.
   [Colding-Jorgensen, Eskild] Univ Copenhagen, Glostrup Hosp, Dept Clin Neurophysiol, Glostrup, Denmark.
C3 Rigshospitalet; University of Copenhagen; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen
RP Jeppesen, TD (corresponding author), Univ Copenhagen, Dept Neurol, Neuromuscular Res Unit, Rigshosp,Sect 7611, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
EM Dysgaard@rh.dk
CR Carrozzo R, 1999, J NEUROL SCI, V170, P24, DOI 10.1016/S0022-510X(99)00193-8
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   Jeppesen TD, 2006, BRAIN, V129, P3402, DOI 10.1093/brain/awl149
   Kiechl S, 2004, J NEUROL NEUROSUR PS, V75, P1125, DOI 10.1136/jnnp.2003.025890
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Li FY, 1999, NEUROLOGY, V53, P1265, DOI 10.1212/WNL.53.6.1265
   SARZI E, 2007, ANN NEUROL, V0, P24
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
NR 10
TC 12
Z9 14
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD APR 15
PY 2008
VL 18
IS 4
BP 306
EP 309
DI 10.1016/j.nmd.2007.10.007
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 304PS
UT WOS:000256122000005
PM 18396044
DA 2024-11-01
ER

PT J
AU Vilá, MR
   Villarroya, J
   Garcia-Arumí, E
   Castellote, A
   Meseguer, A
   Hirano, M
   Roig, M
AF Vila, Maya R.
   Villarroya, Joan
   Garcia-Arumi, Elena
   Castellote, Amparo
   Meseguer, Anna
   Hirano, Michio
   Roig, Manuel
TI Selective muscle fiber loss and molecular compensation in mitochondrial myopathy due to TK2 deficiency
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE COX II; mitochondria DNA depletion; muscle; muscle fibers; respiratory chain; TK2
ID dna copy number; mtdna depletion; thymidine kinase; mutations; patient; gene
AB A 12-year-old patient with mitochondrial DNA (mtDNA) depletion syndrome due to TK2 gene mutations has been evaluated serially over the last 10 years. We observed progressive muscle atrophy with selective loss of type 2 muscle fibers and, despite severe depletion of mtDNA, normal activities of respiratory chain (RC) complexes and levels of COX It mitochondrial protein in the remaining muscle fibers. These results indicate that compensatory mechanisms account for the slow progression of the disease. Identification of factors that ameliorate mtDNA depletion may reveal new therapeutic targets for these devastating disorders. (C) 2007 Elsevier B.V. All rights reserved.
C1 [Roig, Manuel] Hosp Univ Vall Hebron, Seccio Neurol Pediat, Barcelona 08036, Spain.
   [Vila, Maya R.; Villarroya, Joan; Garcia-Arumi, Elena; Meseguer, Anna] Hosp Univ Vall Hebron, CIBBIM, Barcelona 08036, Spain.
   [Castellote, Amparo] Hosp Univ Vall Hebron, Dept Pediat Radiol, Barcelona 08036, Spain.
   [Roig, Manuel] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA.
C3 Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron; Columbia University
RP Roig, M (corresponding author), Hosp Univ Vall Hebron, Seccio Neurol Pediat, Pg Vall Hebron 119-129, Barcelona 08036, Spain.
EM manroig@vhebron.net
FU NICHD NIH HHS [P01 HD032062, R01 HD056103] Funding Source: Medline; NINDS NIH HHS [P01 NS011766] Funding Source: Medline
CR Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   Durham SE, 2005, NEUROLOGY, V65, P453, DOI 10.1212/01.wnl.0000171861.30277.88
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Karadimas CL, 2006, AM J HUM GENET, V79, P544, DOI 10.1086/506913
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   MANDERBACKA K, 2001, SCANDINAVIAN J P S55, V29, P41
   Miró O, 2004, JAIDS-J ACQ IMM DEF, V37, P1550, DOI 10.1097/00126334-200412150-00002
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Seidel-Rogol BL, 2002, NUCLEIC ACIDS RES, V30, P1929, DOI 10.1093/nar/30.9.1929
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Vu TH, 1998, NEUROLOGY, V51, P1190, DOI 10.1212/WNL.51.4.1190
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
NR 14
TC 17
Z9 18
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD APR 15
PY 2008
VL 267
IS 1-2
BP 137
EP 141
DI 10.1016/j.jns.2007.10.019
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 276YW
UT WOS:000254180600022
PM 18021809
DA 2024-11-01
ER

PT J
AU Yoo, YM
   Lee, CJ
   Lee, U
   Kim, YJ
AF Yoo, Young-Mi
   Lee, Chang-Joong
   Lee, Uhn
   Kim, Yong-Jung
TI Mitochondrial DNA in patients with essential tremor
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE mitochondrial DNA; essential tremor; LA-PCR
ID movement-disorders; trypanosoma-cruzi; familial tremor; blood-samples; diagnosis; deletions; disease; gene; dysfunction; myopathy
AB Essential tremor (ET) is one of the most common of the movement disorders. However, there has been little agreement in the neurological literature regarding diagnostic criteria for ET. It is not clear to what extent ET is associated with defects of mitochondrial DNA. In this study, we analyzed mitochondrial DNA (mtDNA) from the blood cells of the normal and ET patients using the long and accurate polymerase chain reaction (LA-PCR) and PCR. The large deletions were detected within several regions of mtDNA, but were not detected in the D-loop or CO I regions in ET patients. From our study, it is suggested that ET is a disorder showing a deficiency of mtDNA multicomplexes, and it also appears that mitochondrial dysfunction could be one of the causative factors of ET. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
C1 [Yoo, Young-Mi; Lee, Uhn; Kim, Yong-Jung] Gil Med Ctr, Gachon Med Sch, Dept Neurosurg, Inst Neurosci,Gachon Med Coll, Inchon 405760, South Korea.
   [Lee, Chang-Joong; Kim, Yong-Jung] Inha Univ, Coll Nat Sci, Dept Biol Sci, Inchon, South Korea.
C3 Gachon University; Inha University
RP Kim, YJ (corresponding author), Gil Med Ctr, Gachon Med Sch, Dept Neurosurg, Inst Neurosci,Gachon Med Coll, 1198 Guwol Dong, Inchon 405760, South Korea.
EM neuroaroma@gmail.com
CR BENITOLEON J, 2006, NEUROLOGY, V66, P1005
   BRITTO C, 1993, MEM I OSWALDO CRUZ, V88, P171, DOI 10.1590/S0074-02761993000100030
   Busenbark K, 1996, NEUROLOGY, V47, P264, DOI 10.1212/WNL.47.1.264
   Chouinard S, 1997, MOVEMENT DISORD, V12, P973, DOI 10.1002/mds.870120621
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   COOPER IS, 1962, ARCH NEUROL-CHICAGO, V7, P129, DOI 10.1001/archneur.1962.04210020051006
   CRITCHLEY E, 1972, J NEUROL NEUROSUR PS, V35, P365, DOI 10.1136/jnnp.35.3.365
   Dana CL, 1887, AM J MED SCI, V94, P386, DOI 10.1097/00000441-188710000-00005
   DRR A, 1996, CURR OPIN NEUROL, V9, P290
   DRR A, 1993, NEUROLOGY, V43, P2212
   Gasser T, 1997, J NEUROL, V244, P341, DOI 10.1007/s004150050100
   Gulcher JR, 1997, NAT GENET, V17, P84, DOI 10.1038/ng0997-84
   Hanna MG, 1997, CURR OPIN NEUROL, V10, P351, DOI 10.1097/00019052-199708000-00012
   Higgins JJ, 1998, MOVEMENT DISORD, V13, P972, DOI 10.1002/mds.870130621
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HOLT IJ, 1989, NUCLEIC ACIDS RES, V17, P4465, DOI 10.1093/nar/17.12.4465
   Hubble JP, 1997, MOVEMENT DISORD, V12, P969, DOI 10.1002/mds.870120620
   HUTCHIN T, 1995, P NATL ACAD SCI USA, V92, P6892, DOI 10.1073/pnas.92.15.6892
   Lindblad K, 1996, GENOME RES, V6, P965, DOI 10.1101/gr.6.10.965
   Louis ED, 1996, NEUROLOGY, V46, P1200, DOI 10.1212/WNL.46.5.1200
   Lu CY, 1999, MUTAT RES-FUND MOL M, V423, P11, DOI 10.1016/S0027-5107(98)00220-6
   MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E
   Okuma Y, 1998, CLIN NEUROL NEUROSUR, V100, P75, DOI 10.1016/S0303-8467(98)00003-1
   Rajput AH, 1997, MOVEMENT DISORD, V12, P747, DOI 10.1002/mds.870120520
   SCHALLING M, 1993, NAT GENET, V4, P135, DOI 10.1038/ng0693-135
   SCHULZ JB, 1994, CURR OPIN NEUROL, V7, P333, DOI 10.1097/00019052-199408000-00010
   Shatunov A, 2006, BRAIN, V129, P2318, DOI 10.1093/brain/awl120
   Umeda S, 2000, EUR J BIOCHEM, V267, P200, DOI 10.1046/j.1432-1327.2000.00990.x
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   Whaley NR, 2007, PARKINSONISM RELAT D, V13, P333, DOI 10.1016/j.parkreldis.2006.12.004
   WINCKER P, 1994, AM J TROP MED HYG, V51, P771, DOI 10.4269/ajtmh.1994.51.771
   WSZOLEK ZK, 1992, CURR OPIN NEUROL NEU, V5, P324
NR 32
TC 7
Z9 7
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
SN 0304-3940
EI 1872-7972
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD MAR 21
PY 2008
VL 434
IS 1
BP 29
EP 34
DI 10.1016/j.neulet.2008.01.023
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 284DS
UT WOS:000254686600006
PM 18262358
DA 2024-11-01
ER

PT J
AU Löwik, M
   Levtchenko, E
   Westra, D
   Groenen, P
   Steenbergen, E
   Weening, J
   Lilien, M
   Monnens, L
   van den Heuvel, L
AF Lowik, Marije
   Levtchenko, Elena
   Westra, Dineke
   Groenen, Patricia
   Steenbergen, Eric
   Weening, Jan
   Lilien, Marc
   Monnens, Leo
   van den Heuvel, Lambert
TI Bigenic heterozygosity and the development of steroid-resistant focal segmental glomerulosclerosis
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article
DE bigenic; CD2AP; focal segmental glomerulosclerosis en podocin
ID congenital nephrotic syndrome; nphs2 mutation analysis; clinical spectrum; finnish type; recurrence; podocin; transplantation; proteinuria; disease; cd2ap
AB Background. Focal segmental glomerulosclerosis (FSGS) is a major cause of steroid-resistant nephrotic syndrome in childhood with a central role for the podocytes in the pathogenesis. Mutated proteins expressed in podocytes cause proteinuria. The role of combined gene defects in the development of FSGS is less clear. Methods. We analysed seven podocyte genes known to cause proteinuria and FSGS in a group of 19 non-familial childhood-onset steroid-resistant FSGS patients. These genes include NPHS1, NPHS2, ACTN4, CD2AP, WT-1, TRPC6 and PLCE1. We also screened for the mitochondrial A3243G DNA transition associated with the MELAS syndrome (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes), and occasionally FSGS. Results. No mutations were found in the ACTN4 and TRPC6 genes, and no mitochondrial A3243G DNA transition was found in our group of patients. Two patients showed mutations in the CD2AP gene, one combined with an NPHS2 mutation. A tri-allelic hit was found in a patient carrying compound heterozygous NPHS2 mutations and a heterozygous NPHS1 mutation. In another patient a de novo WT-1 mutation was found combined with a heterozygous NPHS1 mutation, and finally two patients showed three heterozygous PLCE1 mutations. Conclusions. In our rather small group of 19 steroid-resistant FSGS patients, we found 11 mutations in podocyte genes in 6 patients. In four of them the found mutations could explain the pathology. Our data suggest that combined gene defects in podocyte genes may play a role in the development of FSGS.
C1 [Lowik, Marije; Levtchenko, Elena; Westra, Dineke; Monnens, Leo; van den Heuvel, Lambert] Radboud Univ Nijmegen, Med Ctr, Dept Paediat Nephrol, NL-6500 HB Nijmegen, Netherlands.
   [Groenen, Patricia; Steenbergen, Eric; Weening, Jan] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NL-6500 HB Nijmegen, Netherlands.
   [Lilien, Marc] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Paediat Nephrol, Utrecht, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis
RP van den Heuvel, L (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Paediat Nephrol, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM B.vandenheuvel@cukz.umcn.nl
FU Dutch Kidney Foundation [C.98-1764]
CR Billing H, 2004, PEDIATR NEPHROL, V19, P561, DOI 10.1007/s00467-003-1408-6
   Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166
   Caridi G, 2005, PEDIATR RES, V57, P54R, DOI 10.1203/01.PDR.0000160446.01907.B1
   Hasselbacher K, 2006, KIDNEY INT, V70, P1008, DOI 10.1038/sj.ki.5001679
   Hinkes B, 2006, NAT GENET, V38, P1397, DOI 10.1038/ng1918
   Huber TB, 2006, J CLIN INVEST, V116, P1337, DOI 10.1172/JCI27400
   Jansen JJ, 1997, J AM SOC NEPHROL, V8, P1118
   Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456
   Kim JM, 2003, SCIENCE, V300, P1298, DOI 10.1126/science.1081068
   Klamt B, 1998, HUM MOL GENET, V7, P709, DOI 10.1093/hmg/7.4.709
   Koziell A, 2002, HUM MOL GENET, V11, P379, DOI 10.1093/hmg/11.4.379
   Kurogouchi F, 1998, AM J NEPHROL, V18, P551, DOI 10.1159/000013406
   Lenkkeri U, 1999, AM J HUM GENET, V64, P51, DOI 10.1086/302182
   Liu XL, 2005, FEBS J, V272, P228, DOI 10.1111/j.1432-1033.2004.04408.x
   Löwik MM, 2007, KIDNEY INT, V72, P1198, DOI 10.1038/sj.ki.5002469
   Löwik MM, 2003, CLIN NEPHROL, V59, P143
   Piechota Janusz, 2001, JOURNAL OF APPLIED GENETICS, V42, P351
   Ruf RG, 2004, KIDNEY INT, V66, P564, DOI 10.1111/j.1523-1755.2004.00775.x
   Savin VJ, 1996, NEW ENGL J MED, V334, P878, DOI 10.1056/NEJM199604043341402
   Schwarz K, 2001, J CLIN INVEST, V108, P1621, DOI 10.1172/JCI200112849
   Srivastava T, 2006, PEDIATR NEPHROL, V21, P711, DOI 10.1007/s00467-006-0047-0
   Wang H, 2005, CIRC RES, V97, P1305, DOI 10.1161/01.RES.0000196578.15385.bb
   Weber S, 2004, KIDNEY INT, V66, P571, DOI 10.1111/j.1523-1755.2004.00776.x
   Winn MP, 2005, SCIENCE, V308, P1801, DOI 10.1126/science.1106215
   Woroniecki RP, 2007, PEDIATR NEPHROL, V22, P638, DOI 10.1007/s00467-007-0445-y
NR 25
TC 57
Z9 65
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931-0509
EI 
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD OCT 15
PY 2008
VL 23
IS 10
BP 3146
EP 3151
DI 10.1093/ndt/gfn208
PG 6
WC Transplantation; Urology & Nephrology
SC Transplantation; Urology & Nephrology
GA 350CQ
UT WOS:000259330500020
PM 18443213
DA 2024-11-01
ER

PT J
AU Schaefer, AM
   McFarland, R
   Blakely, EL
   He, L
   Whittaker, RG
   Taylor, RW
   Chinnery, PF
   Turnbull, DM
AF Schaefer, Andrew M.
   McFarland, Robert
   Blakely, Emma L.
   He, Langping
   Whittaker, Roger G.
   Taylor, Robert W.
   Chinnery, Patrick F.
   Turnbull, Douglass M.
TI Prevalence of mitochondrial DNA disease in adults
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID hereditary optic neuropathy; diabetes-mellitus; mutation; gene; encephalomyopathy; epidemiology; population; diagnosis; myopathy; stroke
AB Objective: Diverse and variable clinical features, a loose genotype-phenotype relationship, and presentation to different medical specialties have all hindered attempts to gauge the epidemiological impact of mitochondrial DNA (mtDNA) disease. Nevertheless, a clear understanding of its prevalence remains an important goal, particularly about planning appropriate clinical services. Consequently, the aim of this study was to accurately define the prevalence of mtDNA disease (primary mutation occurs in mtDNA) in the working-age population of the North East of England. Methods: Adults with suspected mitochondrial disease in the North East of England were referred to a single neurology center for investigation from 1990 to 2004. Those with pathogenic mtDNA mutations were identified and pedigree analysis performed. For the midyear period of 2001, we calculated the minimum point prevalence of mtDNA disease for adults of working age (>16 and <60/65 years for female/male patients, respectively). Results: In this population, we found that 9.2 in 100,000 people have clinically manifest mtDNA disease, making this one of the commonest inherited neuromuscular disorders. In addition, a further 16.5 in 100,000 children and adults younger than retirement age are at risk for development of mtDNA disease. Interpretation: Through detailed pedigree analysis and active family tracing, we have been able to provide revised minimum prevalence figures for mtDNA disease. These estimates confirm that mtDNA disease is a common cause of chronic morbidity and is more prevalent than has been previously appreciated.
C1 [Schaefer, Andrew M.; McFarland, Robert; Blakely, Emma L.; He, Langping; Whittaker, Roger G.; Taylor, Robert W.; Chinnery, Patrick F.; Turnbull, Douglass M.] Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK
RP McFarland, R (corresponding author), Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, 4th Floor,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM robert.mcfarland@ncl.ac.uk
FU Medical Research Council [G108/539] Funding Source: Medline; Wellcome Trust [074454] Funding Source: Medline; MRC [G108/539] Funding Source: UKRI
CR Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   BOGOUSSLAVSKY J, 1987, ARCH NEUROL-CHICAGO, V44, P479, DOI 10.1001/archneur.1987.00520170009012
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   Chinnery PF, 1999, AM J MED GENET, V85, P498
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   HANNA MG, 1995, AM J HUM GENET, V56, P1026
   HAO HL, 1995, AM J HUM GENET, V56, P1017
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   MACKEY DA, 1992, AUST NZ J OPHTHALMOL, V20, P177, DOI 10.1111/j.1442-9071.1992.tb00937.x
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Man PYW, 2002, J MED GENET, V39, P162, DOI 10.1136/jmg.39.3.162
   McDonnell MT, 2004, EUR J HUM GENET, V12, P778, DOI 10.1038/sj.ejhg.5201216
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   Newkirk JE, 1997, DIABETIC MED, V14, P457, DOI 10.1002/(SICI)1096-9136(199706)14:6<457::AID-DIA372>3.3.CO;2-N
   ODAWARA M, 1995, J CLIN ENDOCR METAB, V80, P1290, DOI 10.1210/jc.80.4.1290
   *OFF NAT STAT, 2004, 2001 CENS KEY STAT E, V0, P0
   OTABE S, 1994, J CLIN ENDOCR METAB, V79, P768, DOI 10.1210/jc.79.3.768
   REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Thelander L, 2007, NAT GENET, V39, P703, DOI 10.1038/ng0607-703
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   YANAGISAWA K, 1995, DIABETOLOGIA, V38, P809, DOI 10.1007/s001250050357
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
   ZEVIANI M, 1995, MUSCLE NERVE, V0, PS170
NR 27
TC 426
Z9 480
U1 0
U2 41
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
EI 1531-8249
J9 ANN NEUROL
JI Ann. Neurol.
PD JAN 15
PY 2008
VL 63
IS 1
BP 35
EP 39
DI 10.1002/ana.21217
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 260KH
UT WOS:000253008700006
PM 17886296
DA 2024-11-01
ER

PT J
AU Zoraster, RM
   Rison, RA
AF Zoraster, Richard M.
   Rison, Richard A.
TI Severe lactic acidosis secondary to minocycline in a teenager with infectious mononucleosis and mitochondrial myopathy
SO CLINICAL NEUROLOGY AND NEUROSURGERY
LA English
DT Article
DE mitochondrial myopathy; lactic acidosis; minocycline; infectious mononucleosis; G8363A mutation; ribosome inhibitor; respiratory chain complexes
ID antiretroviral therapy; dna; mutation; disorders; disease; melas; encephalomyopathy; epidemiology; inheritance; trna(lys)
AB Mitochondrial myopathies are heterogeneous disorders with diverse presentations including laboratory findings of lactic acidosis. Often times they are diagnosed in childhood or the early teenage years following an infectious illness. Minocycline is a common antibiotic used for the treatment of acne. It has been reported to alter mitochondrial respiratory chain complexes. We report an interesting case of a teenager in which mitochondrial myopathy with severe lactic acidosis presented following a bout of infectious mononucleosis and minocycline use. It is hypothesized that oxidative stress from the infectious illness plus the minocycline use triggered the patient's presentation. The clinical manifestations and genetics of mitochondrial myopathies and treatment are discussed along with the management of lactic acidosis. (c) 2008 Elsevier B. V. All rights reserved.
C1 [Rison, Richard A.] Univ So Calif, Keck Sch Med, Med Director Whittier Presbyterian Intercommunity, Los Angeles Cty Med Ctr,Neurol Consultants Med Gr, Whittier, CA 90606 USA.
   [Zoraster, Richard M.] Presbyterian Intercommunity Hosp Whittier, Emergency Dept, Whittier, CA 90602 USA.
C3 University of Southern California
RP Rison, RA (corresponding author), Univ So Calif, Keck Sch Med, Med Director Whittier Presbyterian Intercommunity, Los Angeles Cty Med Ctr,Neurol Consultants Med Gr, 12291 E Washington Blvd,Suite 303, Whittier, CA 90606 USA.
EM RZoraster@yahoo.com; rison@usc.edu
CR Adrogue HJ, 1999, NEW ENGL J MED, V340, P247
   Alimenti A, 2003, PEDIATR INFECT DIS J, V22, P782, DOI 10.1097/01.inf.0000086400.93257.74
   Casaletto JJ, 2005, EMERG MED CLIN N AM, V23, P771, DOI 10.1016/j.emc.2005.03.007
   Chinnery PF, 2001, AM J MED GENET, V106, P94, DOI 10.1002/ajmg.1426
   Dickerson BC, 2005, NEW ENGL J MED, V353, P2271, DOI 10.1056/NEJMcpc059032
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dimauro S, 2004, ANN NY ACAD SCI, V1011, P217, DOI 10.1196/annals.1293.022
   DiMauro S, 2000, NEUROL SCI, V21, P0
   EGGER J, 1983, NEW ENGL J MED, V309, P142, DOI 10.1056/NEJM198307213090304
   Funk MJ, 2007, DRUG SAFETY, V30, P845
   Gold DR, 2001, SEMIN NEUROL, V21, P309, DOI 10.1055/s-2001-17948
   Gropman A L, 2001, CURR NEUROL NEUROSCI REP, V1, P185
   HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Katirji B, 2002, NEUROMUSCULAR DISORD, V0, P0
   MIZOCK BA, 1992, CRIT CARE MED, V20, P80, DOI 10.1097/00003246-199201000-00020
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   Ozawa M, 1997, MUSCLE NERVE, V20, P271, DOI 10.1002/(SICI)1097-4598(199703)20:3<271::AID-MUS2>3.0.CO;2-8
   Prietsch V, 2002, J INHERIT METAB DIS, V25, P531, DOI 10.1023/A:1022040422590
   Santorelli FM, 1996, AM J HUM GENET, V58, P933
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Spellberg B, 2001, ARCH INTERN MED, V161, P2497, DOI 10.1001/archinte.161.20.2497
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taylor RW, 2003, ANN NEUROL, V54, P521, DOI 10.1002/ana.10673
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a
NR 28
TC 6
Z9 6
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0303-8467
EI 1872-6968
J9 CLIN NEUROL NEUROSUR
JI Clin. Neurol. Neurosurg.
PD JUN 15
PY 2008
VL 110
IS 6
BP 627
EP 630
DI 10.1016/j.clineuro.2008.03.006
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 324SH
UT WOS:000257538000017
PM 18440128
DA 2024-11-01
ER

PT J
AU Young, MJ
   Court, DA
AF Young, M. J.
   Court, D. A.
TI Effects of the S288c genetic background and common auxotrophic markers on mitochondrial DNA function in <i>Saccharomyces cerevisiae</i>
SO YEAST
LA English
DT Article
DE mitochondrial DNA; Saccharomyces cerevisiae; ADE2; HAP1; MIP1; MRM1
ID progressive external ophthalmoplegia; encoding mip1 gene; translation initiation; yeast mitochondria; global analysis; budding yeast; strains; protein; cardiolipin; mutations
AB Saccharomyces cerevisiae is a valuable model organism for the study of eukaryotic processes. Throughout its development as a research tool, several strain backgrounds have been utilized and different combinations of auxotrophic marker genes have been introduced into them, creating a useful but non-homogeneous set of strains. The ade2 allele was used as an auxotrophic marker, and for 'red-white' screening for respiratory competence. his3 alleles that influence the expression of MRM1 have been used as selectable markers, and the MIP1[S] allele, found in the commonly used S228c strain, is associated with mitochondrial DNA defects. The focus of the current work was to examine the effects of these alleles, singly and in combination, on the maintenance of mitochondrial function. The combination of the ade2 and MIP1[S] alleles is associated with a slight increase in point mutations in mitochondrial DNA. The deletion in the his3 Delta 200 allele, which removes the promoter for MRM1, is associated with loss of respiratory competence at 37 degrees C in the presence of either MIP1 allele. Thus, multiple factors can contribute to the maintenance of mitochondrial function, reinforcing the concept that strain background is an important consideration in both designing experiments and comparing results obtained by different research groups. Copyright (C) 2009 John Wiley & Sons, Ltd.
C1 [Young, M. J.; Court, D. A.] Univ Manitoba, Dept Microbiol, Winnipeg, MB R3T 2N2, Canada.
C3 University of Manitoba
RP Court, DA (corresponding author), Univ Manitoba, Dept Microbiol, 301 Buller Bldg, Winnipeg, MB R3T 2N2, Canada.
EM Deboroh_Court@UManitoba.ca
FU Natural Sciences and Engineering Research Council (NSERC); University of Manitoba
CR Barrientos A, 2003, IUBMB LIFE, V55, P83, DOI 10.1080/1521654031000098122
   Barrientos A, 2002, EMBO J, V21, P43, DOI 10.1093/emboj/21.1.43
   Baruffini E, 2007, GENETICS, V177, P1227, DOI 10.1534/genetics.107.079293
   Baruffini E, 2006, HUM MOL GENET, V15, P2846, DOI 10.1093/hmg/ddl219
   Becerra M, 2002, MOL MICROBIOL, V43, P545, DOI 10.1046/j.1365-2958.2002.02724.x
   Boubekeur S, 2001, EUR J BIOCHEM, V268, P5057, DOI 10.1046/j.1432-1033.2001.02418.x
   Brachmann CB, 1998, YEAST, V14, P115
   Chen OS, 2000, J BIOL CHEM, V275, P7626, DOI 10.1074/jbc.275.11.7626
   Cohen R, 2007, FEMS MICROBIOL LETT, V273, P239, DOI 10.1111/j.1574-6968.2007.00798.x
   Contamine V, 2000, MICROBIOL MOL BIOL R, V64, P281, DOI 10.1128/MMBR.64.2.281-315.2000
   Dunstan HM, 1997, GENETICS, V147, P87
   Feuermann M, 2003, EMBO REP, V4, P53, DOI 10.1038/sj.embor.embor713
   FOLLEY LS, 1991, GENETICS, V129, P659
   Foury F, 2002, CURR OPIN CHEM BIOL, V6, P106, DOI 10.1016/S1367-5931(01)00276-9
   Gelling C, 2008, MOL CELL BIOL, V28, P1851, DOI 10.1128/MCB.01963-07
   Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046
   Gietz RD, 2002, METHOD ENZYMOL, V350, P87
   GLERUM DM, 1994, P NATL ACAD SCI USA, V91, P8452, DOI 10.1073/pnas.91.18.8452
   HALDI M, 1989, J BIOL CHEM, V264, P17107
   HU JP, 1995, GENE, V160, P105, DOI 10.1016/0378-1119(95)00215-R
   Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026
   Iida M, 1998, FEBS LETT, V428, P281, DOI 10.1016/S0014-5793(98)00546-8
   Jiang F, 1997, MOL MICROBIOL, V26, P481, DOI 10.1046/j.1365-2958.1997.5841950.x
   Jin YH, 2003, NAT GENET, V34, P326, DOI 10.1038/ng1172
   Kumar C, 2003, YEAST, V20, P857, DOI 10.1002/yea.1012
   Lecrenier N, 2000, GENE, V246, P37, DOI 10.1016/S0378-1119(00)00107-4
   LECRENIER N, 1995, MOL GEN GENET, V249, P1, DOI 10.1007/BF00290229
   Luk E, 2005, J BIOL CHEM, V280, P22715, DOI 10.1074/jbc.M504257200
   Ma LN, 2004, J BIOL CHEM, V279, P44394, DOI 10.1074/jbc.M405479200
   MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x
   MATTOON JR, 1990, CURR GENET, V17, P179, DOI 10.1007/BF00312865
   MORTIMER RK, 1986, GENETICS, V113, P35
   OGUR M, 1957, SCIENCE, V125, P928, DOI 10.1126/science.125.3254.928
   Paschen SA, 2000, EMBO J, V19, P6392, DOI 10.1093/emboj/19.23.6392
   Reinders J, 2007, MOL CELL PROTEOMICS, V6, P1896, DOI 10.1074/mcp.M700098-MCP200
   Rieger KJ, 1997, YEAST, V13, P1547, DOI 10.1002/(SICI)1097-0061(199712)13:16<1547::AID-YEA230>3.3.CO;2-P
   Sato H, 2004, PROTOPLASMA, V223, P175, DOI 10.1007/s00709-004-0040-z
   SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951
   Schlossmann J, 1996, J BIOL CHEM, V271, P17890, DOI 10.1074/jbc.271.30.17890
   Schwimmer Christine, 2006, BIOTECHNOLOGY JOURNAL, V1, P270, DOI 10.1002/biot.200500053
   Shadel GS, 1999, AM J HUM GENET, V65, P1230, DOI 10.1086/302630
   SHERMAN F, 1964, GENETICS, V49, P39
   Sherman F, 2002, METHOD ENZYMOL, V350, P3, DOI 10.1016/S0076-6879(02)50954-X
   Sherman F, 1986, LAB COURSE MANUAL ME, V0, P0
   SIKORSKI RS, 1989, GENETICS, V122, P19
   SIRUMCONNOLLY K, 1993, SCIENCE, V262, P1886, DOI 10.1126/science.8266080
   STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353
   Steinmetz LM, 2002, NAT GENET, V31, P400, DOI 10.1038/ng929
   STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419
   Stuart GR, 2006, HUM MOL GENET, V15, P363, DOI 10.1093/hmg/ddi454
   Ter Linde JJM, 2002, YEAST, V19, P825, DOI 10.1002/yea.879
   Vaz FM, 2003, J BIOL CHEM, V278, P43089, DOI 10.1074/jbc.M305956200
   WernerWashburne M, 1996, MOL MICROBIOL, V19, P1159, DOI 10.1111/j.1365-2958.1996.tb02461.x
   Winzeler EA, 2003, GENETICS, V163, P79
   Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901
   Young M, 2004, B GENET SOC CAN, V35, P109
   Young MJ, 2006, YEAST, V23, P101, DOI 10.1002/yea.1344
   Zhang M, 2003, J BIOL CHEM, V278, P35204, DOI 10.1074/jbc.M306729200
   Zhong Q, 2004, J BIOL CHEM, V279, P32294, DOI 10.1074/jbc.M403275200
NR 61
TC 29
Z9 31
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0749-503X
EI 1097-0061
J9 YEAST
JI Yeast
PD DEC 15
PY 2008
VL 25
IS 12
BP 903
EP 912
DI 10.1002/yea.1644
PG 10
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Microbiology; Mycology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Microbiology; Mycology
GA 405JA
UT WOS:000263217900004
PM 19160453
DA 2024-11-01
ER

PT J
AU Khusnutdinova, E
   Gilyazova, I
   Ruiz-Pesini, E
   Derbeneva, O
   Khusainova, R
   Khidiyatova, I
   Magzhanov, R
   Wallace, DC
AF Khusnutdinova, Elza
   Gilyazova, Irina
   Ruiz-Pesini, Eduardo
   Derbeneva, Olga
   Khusainova, Rita
   Khidiyatova, Irina
   Magzhanov, Rim
   Wallace, Douglas C.
TI A Mitochondrial Etiology of Neurodegenerative Diseases: Evidence from Parkinson's Disease
SO MITOCHONDRIA AND OXIDATIVE STRESS IN NEURODEGENERATIVE DISORDERS
LA English
DT Article; Proceedings Paper
DE mitochondrial DNA; Parkinson's disease; disease risk; Tatars
ID hereditary optic neuropathy; oxidative-phosphorylation defects; electron-transport chain; skeletal-muscle; dna polymorphisms; sequence-analysis; chloramphenicol resistance; degenerative diseases; adaptive selection; alzheimers-disease
AB Evidence continues to accrue implicating mitochondrial dysfunction in the etiology of a number of neurodegenerative diseases. For example, Parkinson's disease (PD) can be induced by mitochondrial toxins, and nuclear DNA (nDNA) loci linked to PD have been associated with mitochondrial dysfunction. Although conclusions about the role of mitochondrial DNA (mtDNA) variants in PD vary, we argue here that this is attributable to the novel genetics of the mtDNA and the fact that clinically relevant: mtDNA variation encompasses ancient adaptive polymorphisms, recent deleterious mutations, and somatic mutations. An mtDNA association with PD is supported by an analysis of the Russian Tatar population which revealed that polymorphisms associated with haplogroup H mtDNAs increased PD risk (odds ratio (OR) = 2.58, P = 0.0001), whereas those associated with haplogroup UK cluster mtDNAs were protective (OR = 0.38, P = 0.003). Moreover, mtDNA sequencing revealed that PD patients with either haplogroup H or UK cluster mtDNAs can harbor additional recent variants that might further modulate PD risk. Therefore, the complexity of PD genetics may reflect the complex mitochondrial genetics.
C1 [Ruiz-Pesini, Eduardo; Derbeneva, Olga; Wallace, Douglas C.] Univ Calif Irvine, Ctr Mol & Mitochondiral Med & Genet, Irvine, CA 92697 USA.
   [Khusnutdinova, Elza; Gilyazova, Irina; Khusainova, Rita; Khidiyatova, Irina] Russian Acad Sci, Ufa Sci Ctr, Inst Biochem & Genet, Ufa 450001, Bashkortostan, Russia.
   [Khusainova, Rita; Magzhanov, Rim] Bashkir State Med Univ, Ufa, Bashkortostan, Russia.
   [Ruiz-Pesini, Eduardo] Univ Zaragoza, CIBERER ISCIII, Dept Bioquim Biol Mol & Celular, Zaragoza, Spain.
   [Ruiz-Pesini, Eduardo; Derbeneva, Olga; Wallace, Douglas C.] Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA.
   [Ruiz-Pesini, Eduardo; Derbeneva, Olga; Wallace, Douglas C.] Univ Calif Irvine, Dept Ecol & Evolut Biol, Irvine, CA 92697 USA.
   [Ruiz-Pesini, Eduardo; Derbeneva, Olga; Wallace, Douglas C.] Univ Calif Irvine, Dept Pediat, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine; Russian Academy of Sciences; Institute of Biochemistry & Genetics of Ufa Science Centre of the RAS; Bashkir State Medical University; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; University of Zaragoza; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine
RP Wallace, DC (corresponding author), Univ Calif Irvine, Ctr Mol & Mitochondiral Med & Genet, Hewit Hall,Room 2014, Irvine, CA 92697 USA.
EM dwallace@uri.edu
FU NIA NIH HHS [AG13154, AG24373, AG01751] Funding Source: Medline; ADAMHA HHS [AD16573] Funding Source: Medline
CR Achilli A, 2005, AM J HUM GENET, V76, P883, DOI 10.1086/430073
   ANDERSON JJ, 1993, J NEUROL NEUROSUR PS, V56, P477, DOI 10.1136/jnnp.56.5.477
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andreatta M, 2001, TATRA MT MATH PUBL, V23, P1
   [Anonymous], 2002, STATISTICAL METHODS IN MEDICAL RESEARCH, V0, P0
   Autere J, 2004, HUM GENET, V115, P29, DOI 10.1007/s00439-004-1123-9
   Baudouin SV, 2005, LANCET, V366, P2118, DOI 10.1016/S0140-6736(05)67890-7
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   BENECKE R, 1993, BRAIN, V116, P1451, DOI 10.1093/brain/116.6.1451
   Bermisheva MA, 2003, GENETIKA, V39, P1013
   Bermisheva MA, 2001, GENETIKA, V37, P1002
   Bermisheva MA, 2002, MOL BIOL+, V36, P802, DOI 10.1023/A:1021677708482
   Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834
   BINDOFF LA, 1991, J NEUROL SCI, V104, P203, DOI 10.1016/0022-510X(91)90311-T
   BLIN O, 1994, J NEUROL SCI, V125, P95, DOI 10.1016/0022-510X(94)90248-8
   Bonafè M, 2002, GENE, V286, P121, DOI 10.1016/S0378-1119(01)00812-5
   Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607
   Brown MD, 1996, AM J MED GENET, V61, P283, DOI 10.1002/(SICI)1096-8628(19960122)61:3<283::AID-AJMG15>3.0.CO;2-P
   Brown MD, 2002, HUM GENET, V110, P130, DOI 10.1007/s00439-001-0660-8
   Brown MD, 1997, AM J HUM GENET, V60, P381
   BUNN CL, 1974, P NATL ACAD SCI USA, V71, P1681, DOI 10.1073/pnas.71.5.1681
   CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0
   CARDELLACH F, 1993, NEUROLOGY, V43, P2258, DOI 10.1212/WNL.43.11.2258
   Carrieri G, 2001, HUM GENET, V108, P194, DOI 10.1007/s004390100463
   Cassarino DS, 1997, BBA-MOL BASIS DIS, V1362, P77, DOI 10.1016/S0925-4439(97)00070-7
   Chinnery PF, 2000, NEUROLOGY, V55, P302, DOI 10.1212/WNL.55.2.302
   Chinnery PF, 2000, TRENDS GENET, V16, P500, DOI 10.1016/S0168-9525(00)02120-X
   CORRALDEBRINSKI M, 1994, GENOMICS, V23, P471, DOI 10.1006/geno.1994.1525
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   Cortopassi GA, 1994, AMERICAN JOURNAL OF HUMAN GENETICS, V55, P0
   Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101
   Dato S, 2004, EUR J HUM GENET, V12, P1080, DOI 10.1038/sj.ejhg.5201278
   De Benedictis G, 1999, FASEB J, V13, P1532, DOI 10.1096/fasebj.13.12.1532
   Egensperger R, 1997, NEUROPATH APPL NEURO, V23, P315, DOI 10.1046/j.1365-2990.1997.4098040.x
   Ellis CE, 2005, MOL CELL BIOL, V25, P10190, DOI 10.1128/MCB.25.22.10190-10201.2005
   Finnilä S, 2001, AM J HUM GENET, V68, P1475, DOI 10.1086/320591
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Garcia-Lozano J R, 2000, HUM MUTAT, V15, P120, DOI 10.1002/(SICI)1098-1004(200001)15:1<120::AID-HUMU33>3.0.CO;2-8
   Ghezzi D, 2005, EUR J HUM GENET, V13, P748, DOI 10.1038/sj.ejhg.5201425
   GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715
   Gu M, 1998, ANN NEUROL, V44, P177, DOI 10.1002/ana.410440207
   Hsu LJ, 2000, AM J PATHOL, V157, P401, DOI 10.1016/S0002-9440(10)64553-1
   Huerta C, 2005, J NEUROL SCI, V236, P49, DOI 10.1016/j.jns.2005.04.016
   HUTCHIN T, 1995, P NATL ACAD SCI USA, V92, P6892, DOI 10.1073/pnas.92.15.6892
   Hutchin TP, 1997, BIOCHEM BIOPH RES CO, V241, P221, DOI 10.1006/bbrc.1997.7793
   IKEBE S, 1995, MOL BRAIN RES, V28, P281, DOI 10.1016/0169-328X(94)00209-W
   Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064
   Ingman M, 2007, EUR J HUM GENET, V15, P115, DOI 10.1038/sj.ejhg.5201712
   JOHNSON MJ, 1983, J MOL EVOL, V19, P255, DOI 10.1007/BF02099973
   Kalman B, 1996, J NEUROL SCI, V140, P75, DOI 10.1016/0022-510X(96)00112-8
   Kazuno AA, 2006, PLOS GENET, V2, P1167, DOI 10.1371/journal.pgen.0020128
   Khusainova RI, 2004, GENETIKA, V40, P552
   Khusnutdinova EK, 1999, GENETIKA, V35, P982
   Khusnutdinova EK, 1999, GENETIKA, V35, P509
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   KRIGE D, 1992, ANN NEUROL, V32, P782, DOI 10.1002/ana.410320612
   KRUEGER MJ, 1990, BIOCHEM BIOPH RES CO, V169, P123, DOI 10.1016/0006-291X(90)91442-U
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Kutuev I, 2006, HUM HERED, V61, P1, DOI 10.1159/000091309
   Kuzeev RG, 1992, NARODY SREDNEGO POVO, V0, P0
   Lee HJ, 2002, J BIOL CHEM, V277, P5411, DOI 10.1074/jbc.M105326200
   Macaulay V, 1999, AM J HUM GENET, V64, P232, DOI 10.1086/302204
   MACKEY D, 1992, AM J HUM GENET, V51, P1218
   MANN VM, 1992, BRAIN, V115, P333, DOI 10.1093/brain/115.2.333
   MATHEW GG, 1984, ISOLUTION HIGH MOL W, V0, P0
   Mayr-Wohlfart U, 1997, EUR J MED RES, V2, P111
   McMahon FJ, 2000, AM J PSYCHIAT, V157, P1058, DOI 10.1176/appi.ajp.157.7.1058
   MERRIWETHER DA, 1991, J MOL EVOL, V33, P543, DOI 10.1007/BF02102807
   Mishmar D, 2003, P NATL ACAD SCI USA, V100, P171, DOI 10.1073/pnas.0136972100
   *MITOMAP, 2006, HUM MIT GEN DAT WWW, V0, P0
   MIZUNO Y, 1995, BBA-MOL BASIS DIS, V1271, P265, DOI 10.1016/0925-4439(95)00038-6
   Montiel-Sosa F, 2006, GENE, V368, P21, DOI 10.1016/j.gene.2005.09.015
   NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580
   Niemi AK, 2003, HUM GENET, V112, P29, DOI 10.1007/s00439-002-0843-y
   Orth M, 2003, NEUROSCI LETT, V351, P29, DOI 10.1016/S0304-3940(03)00941-8
   OZAWA T, 1991, BIOCHEM BIOPH RES CO, V176, P938, DOI 10.1016/S0006-291X(05)80276-1
   Palacino JJ, 2004, J BIOL CHEM, V279, P18614, DOI 10.1074/jbc.M401135200
   PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606
   Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045
   Pyle A, 2005, ANN NEUROL, V57, P564, DOI 10.1002/ana.20417
   RAMSAY RR, 1986, J BIOL CHEM, V261, P7585
   REICHMANN H, 1994, EUR NEUROL, V34, P263, DOI 10.1159/000117053
   Rieder MJ, 1998, NUCLEIC ACIDS RES, V26, P967, DOI 10.1093/nar/26.4.967
   Roostalu U, 2007, MOL BIOL EVOL, V24, P436, DOI 10.1093/molbev/msl173
   Ross OA, 2003, EXP GERONTOL, V38, P397, DOI 10.1016/S0531-5565(02)00266-8
   Ross OA, 2001, EXP GERONTOL, V36, P1161, DOI 10.1016/S0531-5565(01)00094-8
   Ruiz-Pesini E, 1998, CLIN CHEM, V44, P1616
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   Ruiz-Pesini E, 2000, AM J HUM GENET, V67, P682, DOI 10.1086/303040
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, PD823, DOI 10.1093/nar/gkl927
   Ruiz-Pesini E, 2006, HUM MUTAT, V27, P1072, DOI 10.1002/humu.20378
   Sabeti PC, 2007, NATURE, V449, P913, DOI 10.1038/nature06250
   SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x
   Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653
   SHOFFNER JM, 1991, ANN NEUROL, V30, P332, DOI 10.1002/ana.410300304
   SHOFFNER JM, 1993, GENOMICS, V17, P171, DOI 10.1006/geno.1993.1299
   Shults CW, 1998, NEUROLOGY, V50, P793, DOI 10.1212/WNL.50.3.793
   Simon DK, 1999, NEUROLOGY, V53, P1787, DOI 10.1212/WNL.53.8.1787
   Simon DK, 2000, NEUROLOGY, V54, P703, DOI 10.1212/WNL.54.3.703
   SWEENEY MG, 1993, Q J MED, V86, P435
   Tan EK, 2000, NEUROLOGY, V55, P533, DOI 10.1212/WNL.55.4.533
   Tanaka M, 2004, GENOME RES, V14, P1832, DOI 10.1101/gr.2286304
   Tanno Y, 1998, NEUROBIOL AGING, V19, PS47, DOI 10.1016/S0197-4580(98)00028-1
   Tong JJY, 2007, NAT GENET, V39, P476, DOI 10.1038/ng2004
   Torroni A, 1996, GENETICS, V144, P1835
   Torroni A, 1997, AM J HUM GENET, V60, P1107
   TORRONI A, 1994, AM J HUM GENET, V55, P760
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Trimmer PA, 2004, J NEUROCHEM, V88, P800, DOI 10.1046/j.1471-4159.2003.02168.x
   Trimmer PA, 2004, NEUROBIOL DIS, V15, P29, DOI 10.1016/j.nbd.2003.09.011
   Trounce I, 2000, NUCLEIC ACIDS RES, V28, P2164, DOI 10.1093/nar/28.10.2164
   Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   Vaughan JR, 2001, ANN HUM GENET, V65, P111, DOI 10.1017/S0003480001008557
   Vives-Bauza C, 2002, BIOCHEM BIOPH RES CO, V290, P1593, DOI 10.1006/bbrc.2002.6388
   Wallace DC, 2007, EMERY AND RIMOINS PRINCIPLES AND PRACTICE OF MEDICAL GENETICS, V5th, P194
   Wallace D C, 1997, THE MOLECULAR AND GENETIC BASIS OF NEUROLOGICAL DISEASE, V0, P237
   WALLACE DC, 1992, ANN NEUROL, V32, P113, DOI 10.1002/ana.410320123
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wallace DC, 2003, COLD SPRING HARB SYM, V68, P479
   Wallace DC, 1999, GENE, V238, P211, DOI 10.1016/S0378-1119(99)00295-4
   WALLACE DC, 1987, CURR GENET, V12, P81, DOI 10.1007/BF00434661
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   WALLACE DC, 1975, J CELL BIOL, V67, P174, DOI 10.1083/jcb.67.1.174
   WALLACE DC, 2000, ORIGIN HUMANKIND, V0, P9
   Wallace DC, 2007, ANNU REV BIOCHEM, V76, P781, DOI 10.1146/annurev.biochem.76.081205.150955
   Wang ET, 2006, P NATL ACAD SCI USA, V103, P135, DOI 10.1073/pnas.0509691102
   YOSHINO H, 1992, J NEURAL TRANSM-PARK, V4, P27, DOI 10.1007/BF02257619
NR 129
TC 90
Z9 104
U1 0
U2 17
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER STREET, HOBOKEN, NJ, UNITED STATES
SN 0077-8923
EI 
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PD JUN 15
PY 2008
VL 1147
IS 
BP 1
EP 20
DI 10.1196/annals.1427.001
PG 20
WC Cell Biology; Multidisciplinary Sciences; Neurosciences; Physiology
SC Cell Biology; Science & Technology - Other Topics; Neurosciences & Neurology; Physiology
GA BIR99
UT WOS:000262397800002
PM 19076426
DA 2024-11-01
ER

PT J
AU Rodrigues, ADS
   Kiyomoto, BH
   Oliveira, ASB
   Gabbai, AA
   Schmidt, B
   Tengan, CH
AF Rodrigues, Andresa De Santi
   Kiyomoto, Beatriz H.
   Oliveira, Acary S. B.
   Gabbai, Alberto A.
   Schmidt, Beny
   Tengan, Celia H.
TI Progressive myopathy with a combined respiratory chain defect including Complex II
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE mitochondria; succinate dehydrogenase; mitochondrial myopathies; respiratory chain; lipid metabolism; muscle; myopathies
ID succinate-dehydrogenase deficiency; mitochondrial myopathy; skeletal-muscle; a dehydrogenase; mutation; patient; gene; aconitase
AB Biochemical defects in the respiratory chain are mostly associated with deficiencies in Complexes I, III and IV, caused by nuclear or mitochondrial DNA mutations. Combined defects including Complex II have been reported very rarely and have muscular symptoms as the main manifestation, including muscle weakness, exercise intolerance and myoglobinuria. We report a patient with a fatal progressive myopathy and muscle biopsy showing diffuse reduction in succinate dehydrogenase activity, ragged red fibers and intense lipid accumulation. Cytochrome c oxidase (COX) histochemistry demonstrated 30% of fibers with increased subsarcolemmal staining while 27% were COX negative. Western blotting analysis showed reduction in the expression of the 39 kDa subunit of Complex I, subunit II of Complex IV and the 70 kDa subunit of Complex II. Our findings suggest that the patient had a complex pattern of mitochondrial dysfunction affecting multiple respiratory chain complexes (I, II and IV) and fatty acid metabolism. This report adds a new histological pattern associated to combined deficiencies of respiratory chain with involvement of Complex II and shows that this disease may be fatal with a rapid progression. (c) 2007 Elsevier B.V. All rights reserved.
C1 [Rodrigues, Andresa De Santi; Kiyomoto, Beatriz H.; Oliveira, Acary S. B.; Gabbai, Alberto A.; Tengan, Celia H.] Univ Fed Sao Paulo, Escola Paulista Med, Clin Neurol Div,Lab Neurol Mol, Dept Neurol & Neurosurg, BR-04039032 Sao Paulo, SP, Brazil.
   [Schmidt, Beny] Univ Fed Sao Paulo, Escola Paulista Med, Dept Pathol, BR-04039032 Sao Paulo, SP, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP)
RP Tengan, CH (corresponding author), Univ Fed Sao Paulo, Escola Paulista Med, Clin Neurol Div,Lab Neurol Mol, Dept Neurol & Neurosurg, R Pedro Toledo 781, BR-04039032 Sao Paulo, SP, Brazil.
EM chtengan@neuro.epm.br
CR Acín-Pérez R, 2004, MOL CELL, V13, P805, DOI 10.1016/S1097-2765(04)00124-8
   ANTOZZI C, 1994, NEUROLOGY, V44, P2153, DOI 10.1212/WNL.44.11.2153
   BENNETT MJ, 1994, J INHERIT METAB DIS, V17, P283, DOI 10.1007/BF00711808
   BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144
   Brière JJ, 2005, CELL MOL LIFE SCI, V62, P2317, DOI 10.1007/s00018-005-5237-6
   Budde SMS, 2000, BIOCHEM BIOPH RES CO, V275, P63, DOI 10.1006/bbrc.2000.3257
   DESNUELLE C, 1989, BIOCHEM BIOPH RES CO, V163, P695, DOI 10.1016/0006-291X(89)92279-1
   HALL RE, 1993, J CLIN INVEST, V92, P2660, DOI 10.1172/JCI116882
   HALLER RG, 1991, J CLIN INVEST, V88, P1197, DOI 10.1172/JCI115422
   LINDERHOLM H, 1990, J INTERN MED, V228, P43, DOI 10.1111/j.1365-2796.1990.tb00191.x
   Loeffen JLCM, 2000, HUM MUTAT, V15, P123, DOI 10.1002/(SICI)1098-1004(200002)15:2<123::AID-HUMU1>3.3.CO;2-G
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   REICHMANN H, 1994, EUR NEUROL, V34, P95
   RIVNER MH, 1989, NEUROLOGY, V39, P693, DOI 10.1212/WNL.39.5.693
   RubioGozalbo ME, 1997, EUR J PEDIATR, V156, P931, DOI 10.1007/s004310050745
   Russell AP, 2003, J CLIN ENDOCR METAB, V88, P5921, DOI 10.1210/jc.2003-030885
   Rustin P, 2002, BBA-BIOENERGETICS, V1553, P117, DOI 10.1016/S0005-2728(01)00228-6
   Schägger H, 2004, J BIOL CHEM, V279, P36349, DOI 10.1074/jbc.M404033200
   SCHAPIRA AHV, 1990, NEW ENGL J MED, V323, P37, DOI 10.1056/NEJM199007053230107
   Sugimoto J, 2000, BRAIN DEV-JPN, V22, P158, DOI 10.1016/S0387-7604(00)00097-8
   Ugalde C, 2004, HUM MOL GENET, V13, P659, DOI 10.1093/hmg/ddh071
   Ugalde C, 2003, ANN NEUROL, V54, P665, DOI 10.1002/ana.10734
   VEITCH K, 1989, BIOCHIM BIOPHYS ACTA, V1006, P335, DOI 10.1016/0005-2760(89)90021-0
   Vladutiu GD, 2000, ARCH PATHOL LAB MED, V124, P1755
NR 24
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD JAN 15
PY 2008
VL 264
IS 1-2
BP 182
EP 186
DI 10.1016/j.jns.2007.08.002
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 255VO
UT WOS:000252686200033
PM 17850823
DA 2024-11-01
ER

PT J
AU Needham, M
   Mastaglia, FL
AF Needham, M.
   Mastaglia, F. L.
TI Sporadic inclusion body myositis: a continuing puzzle
SO NEUROMUSCULAR DISORDERS
LA English
DT Review
DE inclusion body myositis; pathogenesis; myodegeneration; immunopathogenesis
ID amyloid precursor protein; mhc class-i; mitochondrial-dna deletions; idiopathic inflammatory myopathy; endoplasmic-reticulum stress; ubiquitin-proteasome system; cell-adhesion molecules; infiltrating t-cells; skeletal-muscle; muscular-dystrophy
AB There is now compelling evidence that sporadic inclusion body myositis (sIBM) is a muscle-specific autoimmune disease in which both T and B-cells play a part and in which both cytotoxic muscle fibre necrosis and degeneration occur. However the factors responsible for breakdown of immune tolerance and the nature of the target antigens expressed by muscle fibres remain unknown. Genetic factors are known to contribute to susceptibility, in particular MHC haplotyes which may influence antigenic presentation, and could also operate through genetic variations in muscle fibre constituents or immune effector mechanisms. Viral infection may act as a trigger mechanism, as in cases of HIV-associated sIBM. Our understanding of the mechanisms leading to the degenerative changes in muscle fibres is still incomplete. Protein misfolding and proteasomal dysfunction rather than defective transcriptional control is likely to underlie the abnormal accumulation of multiple proteins in the muscle fibre inclusions. However, aberrant transcription is thought to be the basis for the accumulation of potentially toxic mutant protein forms (e.g. UBB+1). The origin of the multiple clonally expanded somatic mtDNA mutations in COX-negative segments of muscle fibres remains uncertain but may be linked to the effects of oxidative stress. It is proposed that the disproportionate involvement of certain muscles in sIBM may be due to the existence of muscle group-specific transcriptomes which are differentially affected by the disease process and that the male predominance of the disease may indicate the influence of genes preferentially expressed in males. There is a need to develop better animal models of sIBM in which the relationship between the inflammatory and degenerative components of the disease as well as the gender difference in susceptibility and differential vulnerability of different muscle groups can be more critically investigated. Crown copyright (C) 2007 Published by Elsevier B.V. All rights reserved.
C1 [Needham, M.; Mastaglia, F. L.] Univ Western Australia, Ctr Neuromuscular & Neurol Disorders, Australian Neuromuscular Res Inst, Queen Elizabeth II Med Ctr, Perth, WA 6009, Australia.
C3 University of Western Australia
RP Mastaglia, FL (corresponding author), Univ Western Australia, Ctr Neuromuscular & Neurol Disorders, Australian Neuromuscular Res Inst, Queen Elizabeth II Med Ctr, Level 4,A Block, Perth, WA 6009, Australia.
EM flmast@cyllene.uwa.edu.au
CR Amemiya K, 2000, BRAIN, V123, P2030, DOI 10.1093/brain/123.10.2030
   APPLEYARD ST, 1985, LANCET, V1, P361
   ARAHATA K, 1984, ANN NEUROL, V16, P193, DOI 10.1002/ana.410160206
   Argov Z, 1998, MUSCLE NERVE, V21, P1523, DOI 10.1002/(SICI)1097-4598(199811)21:11<1523::AID-MUS22>3.0.CO;2-#
   Arnardottir S, 2004, J NEUROL NEUROSUR PS, V75, P917, DOI 10.1136/jnnp.2003.018994
   ASKANAS V, 1991, NEUROSCI LETT, V130, P73, DOI 10.1016/0304-3940(91)90230-Q
   Askanas V, 2006, NEUROLOGY, V66, PS39, DOI 10.1212/01.wnl.0000192128.13875.1e
   Askanas V, 2005, MICROSC RES TECHNIQ, V67, P114, DOI 10.1002/jemt.20186
   Askanas V, 1996, P NATL ACAD SCI USA, V93, P1314, DOI 10.1073/pnas.93.3.1314
   Askanas V, 1997, NEUROREPORT, V8, P2155, DOI 10.1097/00001756-199707070-00012
   Askanas V, 1998, ARCH NEUROL-CHICAGO, V55, P915, DOI 10.1001/archneur.55.7.915
   ASKANAS V, 2002, ACTA MYOL, V21, P131
   ASKANAS V, 1996, NEUROLOGY, V46, P487
   ASKANAS V, 1998, INCLUSION BODY MYOSI, V0, P3
   Badrising UA, 2004, NEUROLOGY, V63, P2396, DOI 10.1212/01.WNL.0000148588.15052.4C
   Banwell BL, 2000, NEUROLOGY, V54, P1033, DOI 10.1212/WNL.54.5.1033
   BAO S, 1990, IMMUNOL CELL BIOL, V68, P235, DOI 10.1038/icb.1990.33
   Behrens L, 1997, BRAIN, V120, P929, DOI 10.1093/brain/120.6.929
   Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552
   Bender A, 1998, J NEUROIMMUNOL, V84, P86, DOI 10.1016/S0165-5728(97)00246-4
   Bennett EJ, 2005, MOL CELL, V17, P351, DOI 10.1016/j.molcel.2004.12.021
   Broccolini A, 2000, NEUROSCI LETT, V287, P1, DOI 10.1016/S0304-3940(00)01156-3
   Butterfield DA, 1997, CHEM RES TOXICOL, V10, P495, DOI 10.1021/tx960130e
   Calado A, 2000, HUM MOL GENET, V9, P2321, DOI 10.1093/oxfordjournals.hmg.a018924
   CANTUTICASTELVE I, 2007, NEUROBIOL DIS, V0, P0
   CARPENTER S, 1978, NEUROLOGY, V28, P8, DOI 10.1212/WNL.28.1.8
   CHOU SM, 1986, HUM PATHOL, V17, P765, DOI 10.1016/S0046-8177(86)80197-6
   CHOU SM, 1967, SCIENCE, V158, P1453, DOI 10.1126/science.158.3807.1453
   Christen U, 2004, CURR OPIN IMMUNOL, V16, P759, DOI 10.1016/j.coi.2004.09.002
   Cupler EJ, 1996, BRAIN, V119, P1887, DOI 10.1093/brain/119.6.1887
   Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200
   Dalakas MC, 2007, ANN NEUROL, V61, P466, DOI 10.1002/ana.21103
   Dalakas MC, 2006, NAT CLIN PRACT NEURO, V2, P437, DOI 10.1038/ncpneuro0261
   Dalakas MC, 1998, ARCH NEUROL-CHICAGO, V55, P1509, DOI 10.1001/archneur.55.12.1509
   Dalakas MC, 2002, RHEUM DIS CLIN N AM, V28, P779, DOI 10.1016/S0889-857X(02)00030-3
   Dalakas MC, 1997, ANN NEUROL, V41, P100, DOI 10.1002/ana.410410116
   DALAKAS MC, 2007, ANN NEUROL, V0, P0
   Dewing P, 2006, CURR BIOL, V16, P415, DOI 10.1016/j.cub.2006.01.017
   Dimitri D, 2006, BRAIN, V129, P986, DOI 10.1093/brain/awl020
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   Ferrer I, 2004, J NEUROPATH EXP NEUR, V63, P484, DOI 10.1093/jnen/63.5.484
   Fidzianska A, 2004, ACTA NEUROPATHOL, V107, P197, DOI 10.1007/s00401-003-0794-y
   Fidzianska A, 2003, J NEUROL SCI, V210, P47, DOI 10.1016/S0022-510X(03)00012-1
   Figarella-Branger D, 2003, MUSCLE NERVE, V28, P659, DOI 10.1002/mus.10462
   FIGARELLABRANGER D, 1990, ACTA NEUROPATHOL, V79, P528, DOI 10.1007/BF00296113
   Fox SA, 1996, MUSCLE NERVE, V19, P23, DOI 10.1002/(SICI)1097-4598(199601)19:1<23::AID-MUS4>3.3.CO;2-Y
   FOX SA, 1994, J NEUROL SCI, V125, P70, DOI 10.1016/0022-510X(94)90244-5
   Fratta P, 2005, AM J PATHOL, V167, P517, DOI 10.1016/S0002-9440(10)62994-X
   Fratta P, 2004, NEUROLOGY, V63, P1114, DOI 10.1212/01.WNL.0000138574.56908.5D
   Fukuchi K, 1998, AM J PATHOL, V153, P1687, DOI 10.1016/S0002-9440(10)65682-9
   Fyhr IM, 1998, ANN NEUROL, V43, P127, DOI 10.1002/ana.410430123
   Fyhr IM, 1997, J NEUROIMMUNOL, V79, P185, DOI 10.1016/S0165-5728(97)00122-7
   GARLEPP MJ, 1994, CLIN EXP IMMUNOL, V98, P40
   GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0
   GILLESPIE KM, 1920, CMAJ, V175, P165
   Giresi PG, 2005, PHYSIOL GENOMICS, V21, P253, DOI 10.1152/physiolgenomics.00249.2004
   GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606
   Goronzy JJ, 2003, ARTHRITIS RES THER, V5, P225, DOI 10.1186/ar974
   Greenberg SA, 2005, NEUROLOGY, V65, P1782, DOI 10.1212/01.wnl.0000187124.92826.20
   Greenberg SA, 2002, NEUROLOGY, V59, P1170, DOI 10.1212/WNL.59.8.1170
   Greenberg SA, 2007, MUSCLE NERVE, V35, P17, DOI 10.1002/mus.20649
   Greenberg SA, 2006, MUSCLE NERVE, V34, P406, DOI 10.1002/mus.20584
   GRIGGS RC, 1995, ANN NEUROL, V38, P705, DOI 10.1002/ana.410380504
   Horvath R, 1998, J NEUROPATH EXP NEUR, V57, P396, DOI 10.1097/00005072-199805000-00003
   Jaworska-Wilczynska M, 2002, NEUROLOGY, V58, P438, DOI 10.1212/WNL.58.3.438
   Jin LW, 1998, AM J PATHOL, V153, P1679, DOI 10.1016/S0002-9440(10)65681-7
   Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883
   JONGEN PJH, 1993, ANN RHEUM DIS, V52, P575, DOI 10.1136/ard.52.8.575
   KARPATI G, 1993, BAILLIERE CLIN NEUR, V2, P527
   KARPATI G, 1988, ANN NEUROL, V23, P64, DOI 10.1002/ana.410230111
   Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211
   Kefi M, 2002, NEUROLOGY, V58, P0
   Kitazawa M, 2006, AM J PATHOL, V168, P1986, DOI 10.2353/ajpath.2006.051232
   Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998
   Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3
   Krause S, 2005, EXP CELL RES, V304, P365, DOI 10.1016/j.yexcr.2004.11.010
   Krüger R, 2002, TRENDS MOL MED, V8, P236, DOI 10.1016/S1471-4914(02)02333-X
   Kumamoto T, 2004, ACTA NEUROPATHOL, V107, P59, DOI 10.1007/s00401-003-0774-2
   LEFF RL, 1992, LANCET, V339, P1192, DOI 10.1016/0140-6736(92)91134-T
   LEONMONZON M, 1992, ANN NEUROL, V32, P219, DOI 10.1002/ana.410320215
   Lepidi H, 1998, NEUROPATH APPL NEURO, V24, P73, DOI 10.1046/j.1365-2990.1998.00092.x
   Li J, 2006, J NEUROPATH EXP NEUR, V65, P826, DOI 10.1097/01.jnen.0000228204.19915.69
   Li M, 2000, J NEUROIMMUNOL, V106, P1, DOI 10.1016/S0165-5728(99)00162-9
   Lindsten K, 2002, J CELL BIOL, V157, P417, DOI 10.1083/jcb.200111034
   Lodi R, 1998, BRAIN, V121, P2119, DOI 10.1093/brain/121.11.2119
   Lundberg I, 1995, J NEUROIMMUNOL, V63, P9, DOI 10.1016/0165-5728(95)00122-0
   Lünemann JD, 2007, AUTOPHAGY, V3, P384
   Mayer RJ, 1998, UBIQUITIN MOL PATHOL, V0, P0
   McFerrin J, 1999, NEUROLOGY, V53, P2184, DOI 10.1212/WNL.53.9.2184
   McFerrin J, 2002, NEUROLOGY, V58, P0
   MICHAELIS D, 1993, AM J PATHOL, V143, P1142
   Müntzing K, 2003, SCAND J IMMUNOL, V58, P195, DOI 10.1046/j.1365-3083.2003.01251.x
   Murata K, 1999, AM J PATHOL, V155, P453, DOI 10.1016/S0002-9440(10)65141-3
   Nagaraju K, 2005, ARTHRITIS RHEUM, V52, P1824, DOI 10.1002/art.21103
   Nagaraju K, 2000, P NATL ACAD SCI USA, V97, P9209, DOI 10.1073/pnas.97.16.9209
   Nakano S, 2008, NEUROMUSCULAR DISORD, V18, P27, DOI 10.1016/j.nmd.2007.08.005
   NALBANTOGLU J, 1994, AM J PATHOL, V144, P874
   Needham M, 2007, MUSCLE NERVE, V35, P549, DOI 10.1002/mus.20766
   Needham M, 2007, LANCET NEUROL, V6, P620, DOI 10.1016/S1474-4422(07)70171-0
   NISHINO H, 1989, ANN NEUROL, V25, P260, DOI 10.1002/ana.410250309
   OHanlon TP, 2005, MEDICINE, V84, P338, DOI 10.1097/01.md.0000189818.63141.8c
   Oldfors A, 2006, NEUROLOGY, V66, PS49, DOI 10.1212/01.wnl.0000192127.63013.8d
   OLDFORS A, 1993, BRAIN, V116, P325, DOI 10.1093/brain/116.2.325
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   OLDFORS A, 1998, INCLUSION BODY MYOSI, V0, P306
   Ozden S, 2004, J VIROL, V78, P10320, DOI 10.1128/JVI.78.19.10320-10327.2004
   Ozden S, 2001, CLIN INFECT DIS, V32, P510, DOI 10.1086/318506
   PACIELLO W, 2006, ACTA MYOL, V25, P13
   Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239
   Pak JW, 2003, AGING CELL, V2, P1, DOI 10.1046/j.1474-9728.2003.00034.x
   Pavlath GK, 2002, J NEUROIMMUNOL, V125, P42, DOI 10.1016/S0165-5728(02)00026-7
   Price P, 2004, TISSUE ANTIGENS, V64, P575, DOI 10.1111/j.1399-0039.2004.00310.x
   Price P, 1999, IMMUNOL REV, V167, P257, DOI 10.1111/j.1600-065X.1999.tb01398.x
   Pruitt JN, 1996, ANN NEUROL, V39, P139, DOI 10.1002/ana.410390122
   Raju R, 2005, BRAIN, V128, P1887, DOI 10.1093/brain/awh518
   Raju R, 2003, J NEUROIMMUNOL, V141, P125, DOI 10.1016/S0165-5728(03)00218-2
   Santorelli FM, 1996, ANN NEUROL, V39, P789, DOI 10.1002/ana.410390615
   Schmidt J, 2004, BRAIN, V127, P1182, DOI 10.1093/brain/awh148
   Schneider C, 1996, J NEUROPATH EXP NEUR, V55, P1205, DOI 10.1097/00005072-199612000-00003
   Scott A, 2007, NEUROMUSCULAR DISORD, V17, P853, DOI 10.1016/j.nmd.2007.06.309
   SCOTT AP, 1961, NEUROMUSCULAR DISORD, V16, P311
   Semino-Mora C, 1998, NEUROLOGY, V50, P0
   Serdaroglu P, 2007, HDB CLIN NEUROLOGY M, V0, P357
   SHERRIFF FE, 1995, NEUROSCI LETT, V194, P37, DOI 10.1016/0304-3940(95)11718-C
   Sivakumar K, 1997, BRAIN, V120, P653, DOI 10.1093/brain/120.4.653
   Sugarman MC, 2006, NEUROBIOL AGING, V27, P423, DOI 10.1016/j.neurobiolaging.2005.02.011
   Sugarman MC, 2002, P NATL ACAD SCI USA, V99, P6334, DOI 10.1073/pnas.082545599
   Tateyama M, 2003, ACTA NEUROPATHOL, V105, P581, DOI 10.1007/s00401-003-0685-2
   Tiidus PM, 2003, EXERC SPORT SCI REV, V31, P40, DOI 10.1097/00003677-200301000-00008
   Tiidus PM, 2000, CAN J APPL PHYSIOL, V25, P274, DOI 10.1139/h00-022
   Toepfer M, 1995, EUR J NEUROL, V2, P31
   Tsuruta Y, 2001, ACTA NEUROPATHOL, V101, P579
   van der Vlies D, 2003, AMINO ACIDS, V25, P397, DOI 10.1007/s00726-003-0025-9
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   van der Werf N, 2007, DIABETES-METAB RES, V23, P169, DOI 10.1002/dmrr.695
   van Leeuwen FW, 2000, NEUROBIOL AGING, V21, P879, DOI 10.1016/S0197-4580(00)00151-2
   Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5
   Vattemi G, 2004, AM J PATHOL, V164, P1, DOI 10.1016/S0002-9440(10)63089-1
   Vattemi G, 2001, LANCET, V358, P1962, DOI 10.1016/S0140-6736(01)06969-0
   Vattemi Gaetano, 2003, NEUROLOGY, V60, P0
   Vetrivel KS, 2006, NEUROLOGY, V66, PS69, DOI 10.1212/01.wnl.0000192107.17175.39
   VILLANOVA M, 1993, BRAIN RES, V603, P343, DOI 10.1016/0006-8993(93)91260-Y
   von der Hagen M, 2005, NEUROMUSCULAR DISORD, V15, P863, DOI 10.1016/j.nmd.2005.09.002
   Weyand CM, 2003, EXP GERONTOL, V38, P833, DOI 10.1016/S0531-5565(03)00090-1
   Wiendl H, 2003, BRAIN, V126, P1026, DOI 10.1093/brain/awg114
   Yang CC, 1996, NEUROREPORT, V8, P153, DOI 10.1097/00001756-199612200-00031
   Yang CC, 1998, NEUROSCI LETT, V254, P77, DOI 10.1016/S0304-3940(98)00657-0
   YUNIS EJ, 1971, LAB INVEST, V25, P240
NR 149
TC 34
Z9 38
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD JAN 15
PY 2008
VL 18
IS 1
BP 6
EP 16
DI 10.1016/j.nmd.2007.11.001
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 276OH
UT WOS:000254151400002
PM 18160291
DA 2024-11-01
ER

PT J
AU Longo, N
   Schrijver, I
   Vogel, H
   Pique, LM
   Cowan, TM
   Pasquali, M
   Steinberg, GK
   Hedlund, GL
   Ernst, SL
   Gallagher, RC
   Enns, GM
AF Longo, Nicola
   Schrijver, Iris
   Vogel, Hannes
   Pique, Lynn M.
   Cowan, Tina M.
   Pasquali, Marzia
   Steinberg, Gary K.
   Hedlund, Gary L.
   Ernst, Sharon L.
   Gallagher, Renata C.
   Enns, Gregory M.
TI Progressive cerebral vascular degeneration with mitochondrial encephalopathy
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A
LA English
DT Article
DE MELAS; mitochondrial disorder; MCAD deficiency; Moyamoya; lactic acidosis; metabolic acidosis; mitochondrial encephalopathy; vascular disease
ID angiopathy; mutation; melas
AB MELAS (Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes) is a maternally inherited disorder characterized by recurrent cerebral infarctions that do not conform to discreet vascular territories. Here we report on a patient who presented at 7 years of age with loss of consciousness and severe metabolic acidosis following vomiting and dehydration. She developed progressive sensorineural hearing loss, myopathy, ptosis, short stature, and mild developmental delays after normal early development. Biochemical testing identified metabolites characteristic of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency (hexanoylglycine and suberylglycine), but also severe lactic acidemia (10-25 mM) and, in urine, excess of lactic acid, intermediates of the citric cycle, and marked ketonuria, suggesting mitochondrial dysfunction. She progressed rapidly to develop temporary cortical blindness. Brain imaging indicated generalized atrophy, more marked on the left side, in addition to white matter alterations consistent with a mitochondrial disorder. Magnetic resonance angiography indicated occlusion of the left cerebral artery with development of collateral circulation (Moyamoya syndrome). This process worsened over time to involve the other side of the brain. A muscle biopsy indicated the presence of numerous ragged red fibers. Molecular testing confirmed compound heterozygosity for the common mutation in the MCAD gene (985A>G) and a second pathogenic mutation (233T>C). MtDNA testing indicated that the muscle was almost homoplasmic for the 3243A>T mutation in tRNALeu, with a lower mutant load (about 50% heteroplasmy) in blood and skin fibroblasts. These results indicate that mitochondrial disorders may be associated with severe vascular disease resulting in Moyamoya syndrome. The contribution of the concomitant MCAD deficiency to the development of the phenotype in this case is unclear. (C) 2008 Wiley-Liss, Inc.
C1 [Longo, Nicola; Ernst, Sharon L.] Univ Utah, Dept Pediat, Div Med Genet, Ctr Hlth Sci, Salt Lake City, UT 84132 USA.
   [Longo, Nicola; Pasquali, Marzia] Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT 84132 USA.
   [Longo, Nicola; Pasquali, Marzia] Univ Utah, Hlth Sci Ctr, ARUP Labs, Salt Lake City, UT 84132 USA.
   [Schrijver, Iris; Vogel, Hannes; Pique, Lynn M.; Cowan, Tina M.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.
   [Schrijver, Iris; Vogel, Hannes; Cowan, Tina M.] Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA.
   [Steinberg, Gary K.] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA.
   [Hedlund, Gary L.] Primary Childrens Med Ctr, Dept Med Imaging, Salt Lake City, UT 84103 USA.
   [Gallagher, Renata C.; Enns, Gregory M.] Stanford Univ, Sch Med, Dept Pediat, Div Med Genet, Stanford, CA 94305 USA.
C3 Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; ARUP Laboratories; Stanford University; Stanford University; Stanford University; Stanford University
RP Longo, N (corresponding author), Univ Utah, Dept Pediat, Div Med Genet, Ctr Hlth Sci, 2C412 SOM,50 N Med Dr, Salt Lake City, UT 84132 USA.
EM nicola.longo@hsc.utah.edu
CR Andresen BS, 2001, AM J HUM GENET, V68, P1408, DOI 10.1086/320602
   Betts J, 2006, NEUROPATH APPL NEURO, V32, P359, DOI 10.1111/j.1365-2990.2006.00731.x
   FORSTER C, 1992, NEUROPEDIATRICS, V23, P165, DOI 10.1055/s-2008-1071335
   Koga Y, 2006, NEUROLOGY, V66, P1766, DOI 10.1212/01.wnl.0000220197.36849.1e
   Longo N, 2003, NEUROL CLIN, V21, P817, DOI 10.1016/S0733-8619(03)00015-X
   McKinney JT, 2004, MOL GENET METAB, V82, P112, DOI 10.1016/j.ymgme.2004.04.004
   Noguchi A, 2005, PEDIATR NEUROL, V33, P70, DOI 10.1016/j.pediatrneurol.2005.01.013
   OHAMA E, 1987, ACTA NEUROPATHOL, V74, P226, DOI 10.1007/BF00688185
   SAKUTA R, 1989, ANN NEUROL, V25, P594, DOI 10.1002/ana.410250611
   Shaag A, 1997, BIOCHEM BIOPH RES CO, V233, P637, DOI 10.1006/bbrc.1997.6496
   Shoffner JM, 2001, METABOLIC MOL BASES, V0, P2367
   Sohm B, 2003, J MOL BIOL, V328, P995, DOI 10.1016/S0022-2836(03)00373-5
   Waddell L, 2006, MOL GENET METAB, V87, P32, DOI 10.1016/j.ymgme.2005.09.020
   Wallace DC, 2001, THE METABOLIC AND MOLECULAR BASIS OF INHERITED DISEASE, V0, P2425
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
NR 15
TC 26
Z9 30
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4825
EI 1552-4833
J9 AM J MED GENET A
JI Am. J. Med. Genet. A
PD FEB 1
PY 2008
VL 146A
IS 3
BP 361
EP 367
DI 10.1002/ajmg.a.31841
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 260KD
UT WOS:000253008300014
PM 18203188
DA 2024-11-01
ER

PT J
AU Jonckheere, AI
   Hogeveen, M
   Nijtmans, LGJ
   van den Brand, MAM
   Janssen, AJM
   Diepstra, JHS
   van den Brandt, FCA
   van den Heuvel, LP
   Hol, FA
   Hofste, TGJ
   Kapusta, L
   Dillmann, U
   Shamdeen, MG
   Smeitink, JAM
   Rodenburg, RJT
AF Jonckheere, A. I.
   Hogeveen, M.
   Nijtmans, L. G. J.
   van den Brand, M. A. M.
   Janssen, A. J. M.
   Diepstra, J. H. S.
   van den Brandt, F. C. A.
   van den Heuvel, L. P.
   Hol, F. A.
   Hofste, T. G. J.
   Kapusta, L.
   Dillmann, U.
   Shamdeen, M. G.
   Smeitink, J. A. M.
   Rodenburg, R. J. T.
TI A novel mitochondrial <i>ATP8</i> gene mutation in a patient with apical hypertrophic cardiomyopathy and neuropathy
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID blue native electrophoresis; synthase subunit-8; protein complexes; proton channel; enzyme complex; deficiency; rotation; diseases; defects; genome
AB Purpose: To identify the biochemical and molecular genetic defect in a 16-year-old patient presenting with apical hypertrophic cardiomyopathy and neuropathy suspected for a mitochondrial disorder. Methods: Measurement of the mitochondrial energy-generating system (MEGS) capacity in muscle and enzyme analysis in muscle and fibroblasts were performed. Relevant parts of the mitochondrial DNA were analysed by sequencing. Transmitochondrial cybrids were obtained by fusion of 143B206 TK- rho zero cells with patient-derived enucleated fibroblasts. Immunoblotting techniques were applied to study the complex V assembly. Results: A homoplasmic nonsense mutation m. 8529G -> A ( p. Trp55X) was found in the mitochondrial ATP8 gene in the patient's fibroblasts and muscle tissue. Reduced complex V activity was measured in the patient's fibroblasts and muscle tissue, and was confirmed in cybrid clones containing patient-derived mitochondrial DNA. Immunoblotting after blue native polyacrylamide gel electrophoresis showed a lack of holocomplex V and increased amounts of mitochondrial ATP synthase subcomplexes. An in-gel activity assay of ATP hydrolysis showed activity of free F-1-ATPase in the patient's muscle tissue and in the cybrid clones. Conclusion: We describe the first pathogenic mutation in the mitochondrial ATP8 gene, resulting in an improper assembly and reduced activity of the complex V holoenzyme.
C1 [Jonckheere, A. I.; Hogeveen, M.; Nijtmans, L. G. J.; van den Brand, M. A. M.; Janssen, A. J. M.; Diepstra, J. H. S.; van den Brandt, F. C. A.; van den Heuvel, L. P.; Kapusta, L.; Smeitink, J. A. M.; Rodenburg, R. J. T.] Radboud Univ Nijmegen, Med Ctr, Dept Pediat, Nijmegen Ctr Mitochondrial Disorders, NL-6500 HB Nijmegen, Netherlands.
   [Dillmann, U.; Shamdeen, M. G.] Univ Saarland, Dept Neurol, Homburg, Germany.
   [Dillmann, U.; Shamdeen, M. G.] Univ Saarland, Dept Pediat, Homburg, Germany.
   [Dillmann, U.; Shamdeen, M. G.] Univ Saarland, Dept Juvenil Med, Homburg, Germany.
C3 Radboud University Nijmegen; Saarland University; Saarland University; Saarland University
RP Smeitink, JAM (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Pediat, Nijmegen Ctr Mitochondrial Disorders, Grootepl 10,POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM j.smeitink@cukz.umcn.nl
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Belogrudov GI, 1996, J BIOL CHEM, V271, P20340, DOI 10.1074/jbc.271.34.20340
   Bos JM, 2007, CURR OPIN CARDIOL, V22, P193, DOI 10.1097/HCO.0b013e3280e1cc7f
   Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717
   CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X
   COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665
   De Meirleir L, 2004, J MED GENET, V41, P120, DOI 10.1136/jmg.2003.012047
   Devenish RJ, 2000, BBA-BIOENERGETICS, V1458, P428, DOI 10.1016/S0005-2728(00)00092-X
   Devenish RJ, 2000, J BIOENERG BIOMEMBR, V32, P507, DOI 10.1023/A:1005621125812
   HADIKUSUMO RG, 1988, BIOCHIM BIOPHYS ACTA, V933, P212, DOI 10.1016/0005-2728(88)90072-2
   Ingman M, 2006, NUCLEIC ACIDS RES, V34, PD749, DOI 10.1093/nar/gkj010
   Janssen AJM, 2006, CLIN CHEM, V52, P860, DOI 10.1373/clinchem.2005.062414
   Janssen AJM, 2003, ANN CLIN BIOCHEM, V40, P3, DOI 10.1258/000456303321016114
   King M P, 1996, METHODS ENZYMOL, V264, P313, DOI 10.1016/S0076-6879(96)64030-0
   Löwik MM, 2005, NEPHROL DIAL TRANSPL, V20, P336, DOI 10.1093/ndt/gfh546
   MITOMAP A, 2006, HUMAN MITOCHONDRIAL, V0, P0
   Morava E, 2006, AM J MED GENET A, V140A, P863, DOI 10.1002/ajmg.a.31194
   Nijtmans LGJ, 2002, METHODS, V26, P327, DOI 10.1016/S1046-2023(02)00038-5
   Nijtmans LGJ, 2001, J BIOL CHEM, V276, P6755, DOI 10.1074/jbc.M008114200
   Nijtmans LGJ, 1995, BBA-MOL BASIS DIS, V1272, P190, DOI 10.1016/0925-4439(95)00087-9
   Nishio K, 2002, P NATL ACAD SCI USA, V99, P13448, DOI 10.1073/pnas.202149599
   Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0
   PAPAKONSTANTINOU T, 1993, BIOCHIM BIOPHYS ACTA, V1144, P22, DOI 10.1016/0005-2728(93)90026-C
   SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A
   Sgarbi G, 2006, BIOCHEM J, V395, P493, DOI 10.1042/BJ20051748
   Smeitink J, 2001, J BIOENERG BIOMEMBR, V33, P259, DOI 10.1023/A:1010743321800
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7
   Sperl W, 2006, NEUROMUSCULAR DISORD, V16, P821, DOI 10.1016/j.nmd.2006.08.008
   Srere PA, 1969, METHODS IN ENZYMOLOGY, V13, P3
   STRAFFON AFL, 1994, BIOCHEM BIOPH RES CO, V203, P1567, DOI 10.1006/bbrc.1994.2365
NR 30
TC 87
Z9 99
U1 0
U2 13
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 
J9 J MED GENET
JI J. Med. Genet.
PD MAR 15
PY 2008
VL 45
IS 3
BP 129
EP 133
DI 10.1136/jmg.2007.052084
PG 5
WC Genetics & Heredity
SC Genetics & Heredity
GA 271GL
UT WOS:000253776800001
PM 17954552
DA 2024-11-01
ER

PT J
AU Akman, HO
   Dorado, B
   López, LC
   García-Cazorla, A
   Vilà, MR
   Tanabe, LM
   Dauer, WT
   Bonilla, E
   Tanji, K
   Hirano, M
AF Akman, Hasan O.
   Dorado, Beatriz
   Lopez, Luis C.
   Garcia-Cazorla, Angeles
   Vila, Maya R.
   Tanabe, Lauren M.
   Dauer, William T.
   Bonilla, Eduardo
   Tanji, Kurenai
   Hirano, Michio
TI Thymidine kinase 2 (H126N) knockin mice show the essential role of balanced deoxynucleotide pools for mitochondrial DNA maintenance
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID mtdna depletion; tk2 deficiency; neurogastrointestinal encephalomyopathy; intergenomic communication; multiple deletions; respiratory-chain; gene-mutations; copy number; kinase gene; myopathy
AB Mitochondrial DNA (mtDNA) depletion syndrome (MDS), an autosomal recessive condition, is characterized by variable organ involvement with decreased mtDNA copy number and activities of respiratory chain enzymes in affected tissues. MtDNA depletion has been associated with mutations in nine autosomal genes, including thymidine kinase (TK2), which encodes a ubiquitous mitochondrial protein. To study the pathogenesis of TK2-deficiency, we generated mice harboring an H126N Tk2 mutation. Homozygous Tk2 mutant (Tk2(-/-)) mice developed rapidly progressive weakness after age 10 days and died between ages 2 and 3 weeks. Tk2(-/-) animals showed Tk2 deficiency, unbalanced dNTP pools, mtDNA depletion and defects of respiratory chain enzymes containing mtDNA-encoded subunits that were most prominent in the central nervous system. Histopathology revealed an encephalomyelopathy with prominent vacuolar changes in the anterior horn of the spinal cord. The H126N TK2 mouse is the first knock-in animal model of human MDS and demonstrates that the severity of TK2 deficiency in tissues may determine the organ-specific phenotype.
C1 [Akman, Hasan O.; Dorado, Beatriz; Lopez, Luis C.; Garcia-Cazorla, Angeles; Dauer, William T.; Bonilla, Eduardo; Hirano, Michio] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA.
   [Garcia-Cazorla, Angeles] Columbia Univ, Med Ctr, Dept Pharmacol, New York, NY 10032 USA.
   [Vila, Maya R.] Columbia Univ, Med Ctr, Dept Pathol, New York, NY 10032 USA.
   [Tanabe, Lauren M.; Dauer, William T.] Hosp St Joan Deu, Dept Neurol, Barcelona, Spain.
   [Tanabe, Lauren M.; Dauer, William T.] Inst Salud Carlos III, CIBER ER, Barcelona, Spain.
   [Bonilla, Eduardo; Tanji, Kurenai] Hosp Univ Vall Hebron, Ctr Invest Bioquim & Biol Mol CIBBIM, Barcelona, Spain.
C3 Columbia University; Columbia University; Columbia University; University of Barcelona; Instituto de Salud Carlos III; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Hospital Universitari Vall d'Hebron
RP Hirano, M (corresponding author), Columbia Univ, Med Ctr, Dept Neurol, 1150 St Nicholas Ave,Russ Berrie Med Pavil,Room 3, New York, NY 10032 USA.
EM mh29@columbia.edu
FU NICHD NIH HHS [R01 HD057543] Funding Source: Medline; NINDS NIH HHS [P01 NS011766] Funding Source: Medline
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   ARNER ESJ, 1992, BIOCHEM BIOPH RES CO, V188, P712, DOI 10.1016/0006-291X(92)91114-6
   Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1
   Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   BOGENHAGEN D, 1977, CELL, V11, P719, DOI 10.1016/0092-8674(77)90286-0
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferraro P, 2005, J BIOL CHEM, V280, P24472, DOI 10.1074/jbc.M502869200
   Ferraro P, 2006, P NATL ACAD SCI USA, V103, P18586, DOI 10.1073/pnas.0609020103
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hirano M, 2004, TOP CURR GENET, V8, P177
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Kirby DM, 2007, METHOD CELL BIOL, V80, P93, DOI 10.1016/S0091-679X(06)80004-X
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Manfredi G, 2002, METHODS, V26, P317, DOI 10.1016/S1046-2023(02)00037-3
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Moraes CT, 2001, TRENDS GENET, V17, P199, DOI 10.1016/S0168-9525(01)02238-7
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nevo Y, 2002, J CHILD NEUROL, V17, P499, DOI 10.1177/088307380201700705
   Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Rylova SN, 2007, BIOCHEM PHARMACOL, V74, P169, DOI 10.1016/j.bcp.2007.03.029
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2007, BIOSCIENCE REP, V27, P39, DOI 10.1007/s10540-007-9036-1
   Tanji K, 1999, ANN NEUROL, V45, P377, DOI 10.1002/1531-8249(199903)45:3<377::AID-ANA14>3.0.CO;2-M
   Vilá MR, 2008, J NEUROL SCI, V267, P137, DOI 10.1016/j.jns.2007.10.019
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
NR 38
TC 84
Z9 95
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 15
PY 2008
VL 17
IS 16
BP 2433
EP 2440
DI 10.1093/hmg/ddn143
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 330SL
UT WOS:000257963000003
PM 18467430
DA 2024-11-01
ER

PT J
AU McFarland, R
   Swalwell, H
   Blakely, EL
   He, LP
   Groen, EJ
   Turnbull, DM
   Bushby, KM
   Taylor, RW
AF McFarland, Robert
   Swalwell, Helen
   Blakely, Emma L.
   He, Langping
   Groen, Emma J.
   Turnbull, Douglass M.
   Bushby, Kate M.
   Taylor, Robert W.
TI The m.5650G &gt; A mitochondrial tRNA<SUP>A1a</SUP> mutation is pathogenic and causes a phenotype of pure myopathy
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mitochondrial myopathy; mitochondrial tRNA mutation; maternal inheritance
ID genome database; dna mutation; transfer-rna; gene; sequence
AB We report a family where a predominantly proximal myopathy has become increasingly severe with successive generations of the maternal lineage. This pure myopathy has been caused by a mutation (m.5650G > A) in the mt-tRNA(A1a) gene that has been reported only once previously in a patient with CADASIL where the phenotype was dominated by neurological complications. This report is therefore the first description of the phenotype associated solely with this mutation and confirms its pathogenicity. (C) 2007 Elsevier B.V. All rights reserved.
C1 [McFarland, Robert; Swalwell, Helen; Blakely, Emma L.; He, Langping; Turnbull, Douglass M.; Taylor, Robert W.] Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Groen, Emma J.; Turnbull, Douglass M.; Bushby, Kate M.; Taylor, Robert W.] Univ Newcastle Upon Tyne, Inst Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK
RP McFarland, R (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM robert.mcfarland@ncl.ac.uk
FU MRC [G0601943, G108/539] Funding Source: UKRI; Medical Research Council [G108/539, G0601943] Funding Source: Medline; Wellcome Trust [074454] Funding Source: Medline
CR Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Annunen-Rasila J, 2006, NEUROGENETICS, V7, P185, DOI 10.1007/s10048-006-0049-x
   Brandon MC, 2005, NUCLEIC ACIDS RES, V33, P0
   Finnilä S, 2001, J MOL MED, V79, P641, DOI 10.1007/s001090100268
   Hadjigeorgiou GM, 1999, J NEUROL SCI, V164, P153, DOI 10.1016/S0022-510X(99)00062-3
   Ingman M, 2006, NUCLEIC ACIDS RES, V34, PD749, DOI 10.1093/nar/gkj010
   Kirby DM, 2007, METHOD CELL BIOL, V80, P93, DOI 10.1016/S0091-679X(06)80004-X
   Kiyomoto BH, 2006, J NEUROL NEUROSUR PS, V77, P541, DOI 10.1136/jnnp.2005.079954
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Olsen DB, 2003, J NEUROL, V250, P1328, DOI 10.1007/s00415-003-0206-1
   PARK SJ, 1988, J BIOL CHEM, V263, P16527
   Swalwell H, 2006, NEUROLOGY, V66, P447, DOI 10.1212/01.wnl.0000196490.36349.83
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
NR 14
TC 27
Z9 28
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD JAN 15
PY 2008
VL 18
IS 1
BP 63
EP 67
DI 10.1016/j.nmd.2007.07.007
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 276OH
UT WOS:000254151400010
PM 17825557
DA 2024-11-01
ER

PT J
AU Pursell, ZF
   McDonald, JT
   Mathews, CK
   Kunkel, TA
AF Pursell, Zachary F.
   McDonald, J. Tyson
   Mathews, Christopher K.
   Kunkel, Thomas A.
TI Trace amounts of 8-oxo-dGTP in mitochondrial dNTP pools reduce DNA polymerase γ replication fidelity
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID progressive external ophthalmoplegia; point mutations; saccharomyces-cerevisiae; oxidative stress; protein; nucleotide; subunit; disease; residue; damage
AB Replication of the mitochondrial genome by DNA polymerase gamma requires dNTP precursors that are subject to oxidation by reactive oxygen species generated by the mitochondrial respiratory chain. One such oxidation product is 8-oxo-dGTP, which can compete with dTTP for incorporation opposite template adenine to yield A-T to C-G transversions. Recent reports indicate that the ratio of undamaged dGTP to dTTP in mitochondrial dNTP pools from rodent tissues varies from similar to 1:1 to >100:1. Within this wide range, we report here the proportion of 8-oxo-dGTP in the dNTP pool that would be needed to reduce the replication fidelity of human DNA polymerase gamma. When various in vivo mitochondrial dNTP pools reported previously were used here in reactions performed in vitro, 8-oxo-dGTP was readily incorporated opposite template A and the resulting 8-oxo-G-A mismatch was not proofread efficiently by the intrinsic 3' exonuclease activity of pol gamma. At the dNTP ratios reported in rodent tissues, whether highly imbalanced or relatively balanced, the amount of 8-oxo-dGTP needed to reduce fidelity was <1% of dGTP. Moreover, direct measurements reveal that 8-oxo-dGTP is present at such concentrations in the mitochondrial dNTP pools of several rat tissues. The results suggest that oxidized dNTP precursors may contribute to mitochondrial mutagenesis in vivo, which could contribute to mitochondrial dysfunction and disease.
C1 [Pursell, Zachary F.; McDonald, J. Tyson; Kunkel, Thomas A.] Natl Inst Environm Hlth Sci, Mol Genet Lab, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA.
   [Pursell, Zachary F.; McDonald, J. Tyson; Kunkel, Thomas A.] Natl Inst Environm Hlth Sci, Struct Biol Lab, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA.
   [Mathews, Christopher K.] Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Oregon State University
RP Kunkel, TA (corresponding author), Natl Inst Environm Hlth Sci, Mol Genet Lab, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA.
EM kunkel@niehs.nih.gov
FU Intramural NIH HHS Funding Source: Medline; NIGMS NIH HHS [R01GM73744, R01 GM073744] Funding Source: Medline
CR Baruffini E, 2006, HUM MOL GENET, V15, P2846, DOI 10.1093/hmg/ddl219
   Bebenek K, 1995, METHOD ENZYMOL, V262, P217
   Brieba LG, 2005, STRUCTURE, V13, P1653, DOI 10.1016/j.str.2005.07.020
   Brieba LG, 2004, EMBO J, V23, P3452, DOI 10.1038/sj.emboj.7600354
   Ferraro P, 2005, J BIOL CHEM, V280, P24472, DOI 10.1074/jbc.M502869200
   Ferraro P, 2006, P NATL ACAD SCI USA, V103, P18586, DOI 10.1073/pnas.0609020103
   FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Graziewicz MA, 2007, HUM MOL GENET, V16, P2729, DOI 10.1093/hmg/ddm227
   Hanes JW, 2006, J BIOL CHEM, V281, P36241, DOI 10.1074/jbc.M607965200
   KAGUNI LS, 1989, P NATL ACAD SCI USA, V86, P6469, DOI 10.1073/pnas.86.17.6469
   KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942
   KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659
   Krahn JM, 2003, STRUCTURE, V11, P121, DOI 10.1016/S0969-2126(02)00930-9
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   KUNKEL TA, 1988, J BIOL CHEM, V263, P4450
   KUNKEL TA, 1989, BIOCHEMISTRY-US, V28, P988, DOI 10.1021/bi00429a011
   Lewis W, 2007, LAB INVEST, V87, P326, DOI 10.1038/labinvest.3700523
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0
   Mathews CK, 2007, FASEB J, V21, P2294, DOI 10.1096/fj.06-7977rev
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021
   PAVLOV YI, 1994, BIOCHEMISTRY-US, V33, P4695, DOI 10.1021/bi00181a029
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Pursell ZF, 2007, NUCLEIC ACIDS RES, V35, P3076, DOI 10.1093/nar/gkm132
   Rampazzo C, 2004, J BIOL CHEM, V279, P17019, DOI 10.1074/jbc.M313957200
   SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0
   Shimizu M, 2003, EMBO REP, V4, P269, DOI 10.1038/sj.embor.embor765
   Song SW, 2005, P NATL ACAD SCI USA, V102, P4990, DOI 10.1073/pnas.0500253102
   Stuart GR, 2006, HUM MOL GENET, V15, P363, DOI 10.1093/hmg/ddi454
   Tassotto ML, 2002, J BIOL CHEM, V277, P15807, DOI 10.1074/jbc.M200965200
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Vermulst M, 2007, NAT GENET, V39, P540, DOI 10.1038/ng1988
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017
   Xu P, 2003, J BIOL CHEM, V278, P48422, DOI 10.1074/jbc.M307888200
   Zheng WM, 2006, MUTAT RES-FUND MOL M, V599, P11, DOI 10.1016/j.mrfmmm.2005.12.012
NR 41
TC 67
Z9 75
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD APR 15
PY 2008
VL 36
IS 7
BP 2174
EP 2181
DI 10.1093/nar/gkn062
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 290VZ
UT WOS:000255152200013
PM 18276636
DA 2024-11-01
ER

PT J
AU Oishi, M
   Miki, K
   Morita, A
   Fujioka, K
   Aoki, S
   Nishino, I
   Nonaka, I
   Goto, Y
   Mizutani, T
AF Oishi, Minoru
   Miki, Kenji
   Morita, Akihiko
   Fujioka, Kazumi
   Aoki, Shigeki
   Nishino, Ichizo
   Nonaka, Ikuya
   Goto, Yu-ichi
   Mizutani, Tomohiko
TI Mitochondrial Encephalomyopathy associated with diabetes mellitus, cataract, and corpus callosum atrophy
SO INTERNAL MEDICINE
LA English
DT Article
DE mitochondrial encephalomyopathy; diabetes mellitus; cataract; corpus callosum; diffusion tensor image
ID congenital cataract; lactic-acidosis; hypertrophic cardiomyopathy; skeletal-muscle; myopathy; mutation; melas; disorders; heart; dna
AB A 44-year-old woman with mitochondrial encephalomyopathy noticed weakness of the lower extremities at the age of 30 years. She also has type 2 diabetes mellitus, posterior subcapsular cataracts in both eyes, and corpus callosum atrophy. Family history showed that a maternal cousin had a myopathy, 3 maternal aunts had diabetes mellitus, and her mother and 2 maternal aunts had cataracts. External ophthalmoplegia, proximal myopathy, and absent deep tendon reflexes were noted. The mitochondrial DNA 3243 point mutation was negative. Muscle biopsy showed ragged-red fibers, cytochrome c oxidase (COX)-positive fibers, and COX-negative fibers.
C1 [Oishi, Minoru; Miki, Kenji; Morita, Akihiko] Nihon Univ, Nerima Hikarigaoka Hosp, Dept Neurol, Tokyo, Japan.
   [Fujioka, Kazumi] Nihon Univ, Sch Med, Dept Radiol, Tokyo, Japan.
   [Aoki, Shigeki] Univ Tokyo, Sch Med, Dept Radiol, Tokyo 113, Japan.
   [Nishino, Ichizo; Nonaka, Ikuya] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neuromuscular Res, Tokyo, Japan.
   [Goto, Yu-ichi] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Tokyo, Japan.
   [Mizutani, Tomohiko] Nihon Univ, Sch Med, Dept Med, Div Neurol, Tokyo, Japan.
C3 Nihon University; Nihon University; University of Tokyo; National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan; Nihon University
RP Oishi, M (corresponding author), Nihon Univ, Nerima Hikarigaoka Hosp, Dept Neurol, Tokyo, Japan.
EM oishimin@med.nihon-u.ac.jp
CR Brockmann K, 2004, NEURORADIOLOGY, V46, P267, DOI 10.1007/s00234-004-1181-7
   Drouet A, 2000, REVUE NEUROLOGIQUE (PARIS), V156, P780
   Ducreux D, 2005, AM J NEURORADIOL, V26, P1840
   Finsterer J, 2006, ACTA NEUROL SCAND, V114, P217, DOI 10.1111/j.1600-0404.2006.00671.x
   Hoshino S, 1997, RINSHO SHINKEIGAKU, V37, P326
   Huang CN, 1998, CLIN ENDOCRINOL, V49, P265, DOI 10.1046/j.1365-2265.1998.00455.x
   Jaksch M, 1996, HUM MUTAT, V7, P358, DOI 10.1002/(SICI)1098-1004(1996)7:4<358::AID-HUMU11>3.0.CO;2-1
   Joko T, 1997, ENDOCR J, V44, P805, DOI 10.1507/endocrj.44.805
   Komaki H, 2003, MITOCHONDRION, V2, P293, DOI 10.1016/S1567-7249(03)00003-5
   Liao Sui-Zing, 2003, ACTA PAEDIATRICA TAIWANICA, V44, P360
   Majoie CB, 2002, AM J NEURORADIOL, V23, P813
   Oexle K, 1996, EXP CLIN ENDOCR DIAB, V104, P212, DOI 10.1055/s-0029-1211445
   REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3
   Schmiedel J, 2003, J NEUROL, V250, P267, DOI 10.1007/s00415-003-0978-3
   SENGERS RCA, 1975, J PEDIATR-US, V86, P873, DOI 10.1016/S0022-3476(75)80217-4
   SENGERS RCA, 1985, BRIT HEART J, V54, P543
   SMEITINK JAM, 1989, EUR J PEDIATR, V148, P656, DOI 10.1007/BF00441527
   VANEKEREN GJ, 1993, EUR J PEDIATR, V152, P255, DOI 10.1007/BF01956157
   VANEKEREN GJ, 1987, VIRCHOWS ARCH A, V412, P47
   Wong LJC, 2007, MITOCHONDRION, V7, P45, DOI 10.1016/j.mito.2006.11.025
   Yamamoto M, 1986, RINSHO SHINKEIGAKU, V26, P1080
NR 21
TC 6
Z9 6
U1 0
U2 1
PU JAPAN SOC INTERNAL MEDICINE
PI TOKYO
PA 34-3 3-CHOME HONGO BUNKYO-KU, TOKYO, 113, JAPAN
SN 0918-2918
EI 
J9 INTERNAL MED
JI Intern. Med.
PD JUN 15
PY 2008
VL 47
IS 5
BP 441
EP 444
DI 10.2169/internalmedicine.47.0579
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 349QY
UT WOS:000259297600020
PM 18310979
DA 2024-11-01
ER

PT J
AU Rossato, LB
   Nunes, AC
   Pereira, ML
   de Souza, CFM
   Dummer, C
   Milani, V
   Porsch, DB
   de Mattos, CB
   Barros, EJ
AF Rossato, Liana Bertolin
   Fernandes Nunes, Ane Claudia
   Saraiva Pereira, Maria Luiza
   Moura de Souza, Carolina Fischinger
   Dummer, Claus
   Milani, Vagner
   Porsch, Daiana Benck
   de Mattos, Cristiane Bastos
   Guardao Barros, Elvino Jose
TI Prevalence of 4977bp deletion in mitochondrial DNA from patients with chronic kidney disease receiving conservative treatment or hemodialysis in Southern Brazil
SO RENAL FAILURE
LA English
DT Article
DE chronic kidney disease; 4977bp deletion; mitochondrial DNA
ID chronic-renal-failure; genomic damage; uremic patients; peritoneal-dialysis; oxidative stress; skeletal-muscle; blood-cells; bp deletion; mutations; lesions
AB Background. Damage to mitochondrial DNA (mtDNA) has been described in patients with chronic kidney disease (CKD). The presence of mtDNA 4977bp deletion in many different tissues can serve as a marker of this damage. However, no attempt has been made to detect the presence of mtDNA 4977bp in blood cells of patients with CKD. Methods. Polymerase chain reaction techniques (PCR) were used to detect mtDNA 4977bp deletion in blood samples of 94 CKD patients. Results. The prevalence of 4977bp deletion in mtDNA was 73.1% (38/52) in patients with CKD undergoing hemodialysis, 57.1% (27/42) in patients with CKD receiving conservative treatment, and 27.8% (15/54) in control samples (p < 0.001). Higher prevalence of this mutation was not associated with patient age (p = 0.54) or time on hemodialysis (p = 0.70). Conclusion. The higher prevalence of mtDNA 4977bp deletion in patients in this study indicates that the CKD can induce damage to mtDNA in blood cells and could be exacerbated by hemodialysis.
C1 [Rossato, Liana Bertolin; Fernandes Nunes, Ane Claudia; Dummer, Claus; Milani, Vagner; Porsch, Daiana Benck; de Mattos, Cristiane Bastos; Guardao Barros, Elvino Jose] Univ Fed Rio Grande do Sul, Hemodialysis Serv, Clin Hosp Porto Alegre, BR-90035003 Porto Alegre, RS, Brazil.
   [Rossato, Liana Bertolin; Fernandes Nunes, Ane Claudia; Dummer, Claus; Milani, Vagner; Porsch, Daiana Benck; de Mattos, Cristiane Bastos; Guardao Barros, Elvino Jose] Univ Fed Rio Grande do Sul, Grad Program Med Sci, Clin Hosp Porto Alegre, BR-90035003 Porto Alegre, RS, Brazil.
   [Saraiva Pereira, Maria Luiza; Moura de Souza, Carolina Fischinger] Univ Fed Rio Grande do Sul, Genet Serv, Clin Hosp Porto Alegre, BR-90035003 Porto Alegre, RS, Brazil.
C3 Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul
RP Rossato, LB (corresponding author), Univ Fed Rio Grande do Sul, Hemodialysis Serv, Clin Hosp Porto Alegre, Rua Ramiro Barcelos,2350-2 Andar, BR-90035003 Porto Alegre, RS, Brazil.
EM liana_rossato@yahoo.com.br
CR Bhat HK, 1999, CIRCULATION, V99, P807, DOI 10.1161/01.CIR.99.6.807
   Botto N, 2005, MUTAT RES-FUND MOL M, V570, P81, DOI 10.1016/j.mrfmmm.2004.10.003
   Buemi M, 2006, BLOOD PURIFICAT, V24, P569, DOI 10.1159/000097080
   CeballosPicot I, 1996, FREE RADICAL BIO MED, V21, P845, DOI 10.1016/0891-5849(96)00233-X
   CENGIZ K, 1988, CANCER GENET CYTOGEN, V36, P55, DOI 10.1016/0165-4608(88)90075-1
   CLAYTON DA, 1992, J INHERIT METAB DIS, V15, P439, DOI 10.1007/BF01799602
   CORRALDEBRINSKI M, 1994, GENOMICS, V23, P471, DOI 10.1006/geno.1994.1525
   Dani Maria Angela C, 2004, GENET MOL RES, V3, P395
   HAYAKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P979, DOI 10.1016/0006-291X(92)92300-M
   Ishibashi Y, 2002, PERITON DIALYSIS INT, V22, P11
   Kobras K, 2006, KIDNEY BLOOD PRESS R, V29, P10, DOI 10.1159/000092482
   KRISHNAN KJ, 2003, SOC INVESTIGATIVE DE, V0, P981
   LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444
   Lim PS, 2000, FREE RADICAL BIO MED, V29, P454, DOI 10.1016/S0891-5849(00)00334-8
   Liu CS, 2001, NEPHROL DIAL TRANSPL, V16, P561, DOI 10.1093/ndt/16.3.561
   Martin-Mateo MC, 1998, RENAL FAILURE, V20, P117, DOI 10.3109/08860229809045094
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   Mohamed SA, 2004, EXP GERONTOL, V39, P181, DOI 10.1016/j.exger.2003.10.011
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Ozawa T, 1998, ANN NY ACAD SCI, V854, P128, DOI 10.1111/j.1749-6632.1998.tb09898.x
   Prithivirajsingh S, 2004, FEBS LETT, V571, P227, DOI 10.1016/j.febslet.2004.06.078
   Schupp N, 2006, SEMIN NEPHROL, V26, P28, DOI 10.1016/j.semnephrol.2005.06.007
   SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771
   Stopper H, 2001, AM J KIDNEY DIS, V38, P296, DOI 10.1053/ajkd.2001.26094
   Stopper H, 1999, AM J KIDNEY DIS, V34, P433, DOI 10.1016/S0272-6386(99)70069-7
   Stopper H, 2005, J RENAL NUTR, V15, P81, DOI 10.1053/j.jrn.2004.09.017
   Tarng DC, 2002, J AM SOC NEPHROL, V13, P0, DOI 10.1097/01.ASN.0000013301.11876.7E
   von Wurmb N, 1998, MUTAT RES-FUND MOL M, V422, P247, DOI 10.1016/S0027-5107(98)00205-X
   Yamagata K, 2002, J AM SOC NEPHROL, V13, P0, DOI 10.1097/01.ASN.0000019772.17954.F8
   ZHANG C, 1992, FEBS LETT, V297, P34, DOI 10.1016/0014-5793(92)80321-7
   Zima T, 1996, RENAL FAILURE, V18, P113, DOI 10.3109/08860229609052781
NR 31
TC 7
Z9 8
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0886-022X
EI 
J9 RENAL FAILURE
JI Ren. Fail.
PD JUN 15
PY 2008
VL 30
IS 1
BP 9
EP 14
DI 10.1080/08860220701741650
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA 251WB
UT WOS:000252405700002
PM 18197537
DA 2024-11-01
ER

PT J
AU Ferreiro-Barros, CC
   Tengan, CH
   Barros, MH
   Palenzuela, L
   Kanki, C
   Quinzii, C
   Lou, J
   El Gharaby, N
   Shokr, A
   De Vivo, DC
   DiMauro, S
   Hirano, M
AF Ferreiro-Barros, Claudia C.
   Tengan, Celia H.
   Barros, Mario H.
   Palenzuela, Lluis
   Kanki, Chisaka
   Quinzii, Catarina
   Lou, Johanna
   El Gharaby, Nader
   Shokr, Aly
   De Vivo, Darryl C.
   DiMauro, Salvatore
   Hirano, Michio
TI Neonatal mitochondrial encephaloneuromyopathy due to a defect of mitochondrial protein synthesis
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Mitochondria; Protein synthesis; Autosomal recessive; Mitochondrial disease; Respiratory chain
ID human-cells; translation; mutation; disease; deficiency; genes; efg1
AB Mitochondrial diseases are clinically and genetically heterogeneous disorders due to primary mutations in mitochondrial DNA (mtDNA) or nuclear DNA (nDNA). We studied a male infant with severe congenital encephalopathy, peripheral neuropathy, and myopathy. The patient's lactic acidosis and biochemical defects of respiratory chain complexes I, III, and IV in muscle indicated that he had a mitochondrial disorder while parental consanguinity suggested autosomal recessive inheritance. Cultured fibroblasts from the patient showed a generalized defect of mitochondrial protein synthesis. Fusion of cells from the patient with 143B206 rho(0) cells devoid of mtDNA restored cytochrome c oxidase activity confirming the nDNA origin of the disease. Our studies indicate that the patient has a novel autosomal recessive defect of mitochondrial protein synthesis. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Hirano, Michio] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10027 USA.
   [Ferreiro-Barros, Claudia C.; Tengan, Celia H.] Univ Fed Sao Paulo, Dept Neurol, Sao Paulo, Brazil.
   [Barros, Mario H.] Univ Sao Paulo, Dept Microbiol, Sao Paulo, Brazil.
   [El Gharaby, Nader; Shokr, Aly] Bugshan Gen Hosp, Dept Pediat, Jeddah, Saudi Arabia.
C3 Columbia University; Universidade Federal de Sao Paulo (UNIFESP); Universidade de Sao Paulo
RP Hirano, M (corresponding author), Columbia Univ, Med Ctr, Dept Neurol, 1150 St Nicholas Ave Russ Berrie Room 317, New York, NY 10027 USA.
EM mh29@columbia.edu
FU National Institutes of Health [NS11766, HD32062]; FAPESP; CNPq; Marriott Mitochondrial Disorders Clinical Research Fund
CR Antonicka H, 2006, HUM MOL GENET, V15, P1835, DOI 10.1093/hmg/ddl106
   Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1
   Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   Chomyn A, 1996, METHODS ENZYMOL, V264, P197, DOI 10.1016/S0076-6879(96)64020-8
   Coenen MJH, 2004, NEW ENGL J MED, V351, P2080, DOI 10.1056/NEJMoa041878
   Davidson R L, 1977, METHODS CELL BIOL, V15, P325, DOI 10.1016/S0091-679X(08)60223-X
   DiMauro S, 2005, NEUROMUSCULAR DISORD, V15, P276, DOI 10.1016/j.nmd.2004.12.008
   Fernandez-Vizarra E, 2007, J MED GENET, V44, P173, DOI 10.1136/jmg.2006.045252
   Jacobs HT, 2005, TRENDS GENET, V21, P312, DOI 10.1016/j.tig.2005.04.003
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LOMBES A, 1991, NEUROLOGY, V41, P491, DOI 10.1212/WNL.41.4.491
   Miller C, 2004, ANN NEUROL, V56, P734, DOI 10.1002/ana.20282
   Nijtmans LGJ, 2002, METHODS, V26, P327, DOI 10.1016/S1046-2023(02)00038-5
   Rana M, 2000, ANN NEUROL, V48, P774, DOI 10.1002/1531-8249(200011)48:5<774::AID-ANA11>3.3.CO;2-9
   Rodel G, 1997, CURR GENET, V31, P375, DOI 10.1007/s002940050219
   Saada A, 2007, J MED GENET, V44, P784, DOI 10.1136/jmg.2007.053116
   Sambrook J, 1989, MOLECULAR CLONING: A LABORATORY MANUAL, V0, P0
   Smeitink JAM, 2006, AM J HUM GENET, V79, P869, DOI 10.1086/508434
   Sylvester JE, 2004, GENET MED, V6, P73, DOI 10.1097/01.GIM.0000117333.21213.17
   Taylor RW, 1997, J BIOENERG BIOMEMBR, V29, P195, DOI 10.1023/A:1022646215643
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
NR 23
TC 8
Z9 8
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD DEC 15
PY 2008
VL 275
IS 1-2
BP 128
EP 132
DI 10.1016/j.jns.2008.08.028
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 384MO
UT WOS:000261749100023
PM 18835491
DA 2024-11-01
ER

PT J
AU Hoefs, SJG
   Dieteren, CEJ
   Distelmaier, F
   Janssen, RJRJ
   Epplen, A
   Swarts, HGP
   Forkink, M
   Rodenburg, RJ
   Nijtmans, LG
   Willems, PH
   Smeitink, JAM
   van den Heuvel, LP
AF Hoefs, Saskia J. G.
   Dieteren, Cindy E. J.
   Distelmaier, Felix
   Janssen, Rolf J. R. J.
   Epplen, Andrea
   Swarts, Herman G. P.
   Forkink, Marleen
   Rodenburg, Richard J.
   Nijtmans, Leo G.
   Willems, Peter H.
   Smeitink, Jan A. M.
   van den Heuvel, Lambert P.
TI <i>NDUFA2</i> complex I mutation leads to Leigh disease
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID bovine heart-mitochondria; ubiquinone oxidoreductase; subunit composition; respiratory-chain; human nadh; deficiency; gene; pathology; encephalomyopathy; cardiomyopathy
AB Mitochondrial isolated complex I deficiency is the most frequently encountered OXPHOS defect. We report a patient with an isolated complex I deficiency expressed in skin fibroblasts as well as muscle tissue. Because the parents were consanguineous, we performed homozygosity mapping to identify homozygous regions containing candidate genes such as NDUFA2 on chromosome 5. Screening of this gene on genomic DNA revealed a mutation that interferes with correct splicing and results in the skipping of exon 2. Exon skipping was confirmed on the mRNA level. The mutation in this accessory subunit causes reduced activity and disturbed assembly of complex I. Furthermore, the mutation is associated with a mitochondrial depolarization. The expression and activity of complex I and the depolarization was (partially) rescued with a baculovirus system expressing the NDUFA2 gene.
C1 [Hoefs, Saskia J. G.; Dieteren, Cindy E. J.; Distelmaier, Felix; Janssen, Rolf J. R. J.; Forkink, Marleen; Rodenburg, Richard J.; Nijtmans, Leo G.; Smeitink, Jan A. M.; van den Heuvel, Lambert P.] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mitochondrial Disorders, Dept Pediat, NL-6500 HB Nijmegen, Netherlands.
   [Dieteren, Cindy E. J.; Distelmaier, Felix; Swarts, Herman G. P.; Willems, Peter H.] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Membrane Biochem, NL-6500 HB Nijmegen, Netherlands.
   [Distelmaier, Felix] Univ Dusseldorf, Dept Gen Pediat, D-40225 Dusseldorf, Germany.
   [Epplen, Andrea] Ruhr Univ Bochum, Dept Human Genet, D-44801 Bochum, Germany.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Heinrich Heine University Dusseldorf; Ruhr University Bochum
RP van den Heuvel, LP (corresponding author), Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mitochondrial Disorders, Dept Pediat, NL-6500 HB Nijmegen, Netherlands.
EM b.vandenheuvel@cukz.umcn.nl
CR Bénit P, 2004, J MED GENET, V41, P14, DOI 10.1136/jmg.2003.014316
   Bénit P, 2003, HUM MUTAT, V21, P582, DOI 10.1002/humu.10225
   Bénit P, 2001, AM J HUM GENET, V68, P1344, DOI 10.1086/320603
   Berger I, 2008, ANN NEUROL, V63, P405, DOI 10.1002/ana.21332
   Brockmann C, 2004, STRUCTURE, V12, P1645, DOI 10.1016/j.str.2004.06.021
   Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200
   Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775
   Distelmaier F, 2008, CYTOM PART A, V73A, P129, DOI 10.1002/cyto.a.20503
   Dunning CJR, 2007, EMBO J, V26, P3227, DOI 10.1038/sj.emboj.7601748
   El-Sheikh AAK, 2007, J PHARMACOL EXP THER, V320, P229, DOI 10.1124/jpet.106.110379
   FEARNLEY IM, 1992, BIOCHIM BIOPHYS ACTA, V1140, P105, DOI 10.1016/0005-2728(92)90001-I
   Fernandez-Moreira D, 2007, ANN NEUROL, V61, P73, DOI 10.1002/ana.21036
   Gabaldón T, 2005, J MOL BIOL, V348, P857, DOI 10.1016/j.jmb.2005.02.067
   Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8
   Janssen AJM, 2006, CLIN CHEM, V52, P860, DOI 10.1373/clinchem.2005.062414
   Janssen AJM, 2003, ANN CLIN BIOCHEM, V40, P3, DOI 10.1258/000456303321016114
   Janssen AJM, 2007, CLIN CHEM, V53, P729, DOI 10.1373/clinchem.2006.078873
   Janssen RJRJ, 2006, J INHERIT METAB DIS, V29, P499, DOI 10.1007/s10545-006-0362-4
   Kirby DM, 2004, J CLIN INVEST, V114, P837, DOI 10.1172/JCI200420683
   Komen JC, 2007, CELL MOL LIFE SCI, V64, P3271, DOI 10.1007/s00018-007-7357-7
   Koopman WJH, 2005, AM J PHYSIOL-CELL PH, V288, PC1440, DOI 10.1152/ajpcell.00607.2004
   Loeffen J, 2001, ANN NEUROL, V49, P195, DOI 10.1002/1531-8249(20010201)49:2<195::AID-ANA39>3.0.CO;2-M
   Loeffen J, 1998, AM J HUM GENET, V63, P1598, DOI 10.1086/302154
   Loeffen JLCM, 2000, HUM MUTAT, V15, P123, DOI 10.1002/(SICI)1098-1004(200002)15:2<123::AID-HUMU1>3.3.CO;2-G
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Murray J, 2003, J BIOL CHEM, V278, P13619, DOI 10.1074/jbc.C300064200
   Nijtmans LGJ, 2002, METHODS, V26, P327, DOI 10.1016/S1046-2023(02)00038-5
   Ogilvie I, 2005, J CLIN INVEST, V115, P2784, DOI 10.1172/JCI26020
   Pitkanen S, 1996, J INHERIT METAB DIS, V19, P675, DOI 10.1007/BF01799845
   Saada A, 2008, AM J HUM GENET, V82, P32, DOI 10.1016/j.ajhg.2007.08.003
   Schuelke M, 1999, NAT GENET, V21, P260, DOI 10.1038/6772
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Smeitink J, 2001, J BIOENERG BIOMEMBR, V33, P259, DOI 10.1023/A:1010743321800
   Triepels RH, 1999, ANN NEUROL, V45, P787, DOI 10.1002/1531-8249(199906)45:6<787::AID-ANA13>3.0.CO;2-6
   van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716
   Vogel RO, 2007, J BIOL CHEM, V282, P7582, DOI 10.1074/jbc.M609410200
NR 36
TC 96
Z9 103
U1 0
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD JUN 15
PY 2008
VL 82
IS 6
BP 1306
EP 1315
DI 10.1016/j.ajhg.2008.05.007
PG 10
WC Genetics & Heredity
SC Genetics & Heredity
GA 312CP
UT WOS:000256647000008
PM 18513682
DA 2024-11-01
ER

PT J
AU Riquet, A
   Auvin, S
   Cuisset, JM
   Lamblin, MD
   Sablonnière, B
   Cuvellier, JC
   Soto-Ares, G
   Maurage, CA
   Vallée, L
AF Riquet, Audrey
   Auvin, Stephane
   Cuisset, Jean-Marie
   Lamblin, Marie-Dominique
   Sablonniere, Bernard
   Cuvellier, Jean-Christophe
   Soto-Ares, Gustavo
   Maurage, Claude-Alain
   Vallee, Louis
TI Epitepsia partialis continua and defects in the mitochondrial respiratory chain
SO EPILEPSY RESEARCH
LA English
DT Article
DE epilepsy partialis continua; electroencephalography; mitochondrial disease; electron transport complex I; NADH-coenzyme Q reductase
ID epilepsia; mutation; melas; deficiency; dna; disorders; muscle
AB Epilepsia partialis continua (EPC) is characterized by continuous myoclonic or clonic jerks repeated at short intervals followed by a slowly progressive neurological disorder. We report three patients with EPC and a defect in the mitochondrial respiratory chain. Methods: Clinical, neuroradiological, and biochemical data were reported. Results: The patients presented continuous myoclonic jerks at age of 8 months, 11 months and 6 years, respectively. Two of the three patients had a previous developmental delay. Neurological examination at first admission revealed extrapyramidal symptoms in all patients. Initial biological investigations suggested mitochondrial dysfunction. Initial EEG showed a continuous discharge of periodic spikes (0.5-1 Hz). MRI studies were initially normal then progressed to cerebral hemiatrophia. EEG revealed both correlation and absence of correlation between spikes or sharp waves and myoclonic jerks. The activity of one or several complexes of the mitochondrial respiratory chain was reduced in the muscle samples of the three patients. No mutation of mtDNA was found. Conclusion: Our report suggests that EPC can be due to mitochondrial respiratory chain disorders. Some clinical findings and initial investigations were indicative of a disorder of mitochondrial metabolism. Previous developmental delay, extrapyramidal symptoms and other organ involvement should suggest a possible mitochondrial etiology of EPC. In case of infant presenting EPC, mitochondrial respiratory chain disorder should be considered first. (C) 2007 Elsevier B.V. All rights reserved.
C1 [Riquet, Audrey; Auvin, Stephane; Cuisset, Jean-Marie; Cuvellier, Jean-Christophe; Vallee, Louis] Lille Univ Hosp, Dept Pediat Neurol, Lille, France.
   [Riquet, Audrey; Auvin, Stephane; Cuisset, Jean-Marie; Lamblin, Marie-Dominique; Sablonniere, Bernard; Cuvellier, Jean-Christophe; Soto-Ares, Gustavo; Maurage, Claude-Alain; Vallee, Louis] Lille Med Sch, Lille, France.
   [Auvin, Stephane; Vallee, Louis] Lille Univ Hosp, Pharmacol Lab, EA 1046, Lille, France.
   [Lamblin, Marie-Dominique] Lille Univ Hosp, Dept Neurophysiol, Lille, France.
   [Sablonniere, Bernard] Lille Univ Hosp, Dept Biochem & Mol Biol, Lille, France.
   [Soto-Ares, Gustavo] Lille Univ Hosp, Dept Neuroradiol, Lille, France.
   [Maurage, Claude-Alain] Lille Univ Hosp, Dept Neuropathol, Lille, France.
C3 Universite de Lille; CHU Lille; Universite de Lille; CHU Lille; Universite de Lille; CHU Lille; Universite de Lille; CHU Lille; Universite de Lille; CHU Lille; Universite de Lille; CHU Lille
RP Auvin, S (corresponding author), Hop Roger Salengro, Serv Neurol Pediat, Blvd Pr J Leclercq, F-59037 Lille, France.
EM auvin@invivo.edu
CR ANTOZZI C, 1995, J NEUROL SCI, V129, P152, DOI 10.1016/0022-510X(94)00267-R
   Balestri P, 2000, J CHILD NEUROL, V15, P755, DOI 10.1177/088307380001501108
   Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006
   Cockerell OC, 1996, BRAIN, V119, P393, DOI 10.1093/brain/119.2.393
   Çokar Ö, 2004, SEIZURE-EUR J EPILEP, V13, P264, DOI 10.1016/S1059-1311(03)00155-9
   Elia M, 1996, BRAIN DEV-JPN, V18, P207, DOI 10.1016/0387-7604(95)00126-3
   Finsterer J, 2006, ACTA NEUROL SCAND, V114, P217, DOI 10.1111/j.1600-0404.2006.00671.x
   FUSCO L, 1992, BRAIN DEV-JPN, V14, P323, DOI 10.1016/S0387-7604(12)80152-5
   HOLLIDAY PL, 1983, NEUROLOGY, V33, P1619, DOI 10.1212/WNL.33.12.1619
   ISHII M, 1995, PSYCHIAT CLIN NEUROS, V49, PS302, DOI 10.1111/j.1440-1819.1995.tb02218.x
   JUULJENSEN P, 1966, ARCH NEUROL-CHICAGO, V15, P563, DOI 10.1001/archneur.1966.00470180003001
   Lin CM, 2007, METAB BRAIN DIS, V22, P105, DOI 10.1007/s11011-006-9039-9
   Pandian JD, 2002, SEIZURE-EUR J EPILEP, V11, P437, DOI 10.1053/seiz.2001.0646
   PRICK MJJ, 1981, ARCH NEUROL-CHICAGO, V38, P767, DOI 10.1001/archneur.1981.00510120067011
   Schuelke M, 1998, ANN NEUROL, V44, P700, DOI 10.1002/ana.410440420
   Shahar E, 2002, PEDIATR NEUROL, V27, P392, DOI 10.1016/S0887-8994(02)00444-7
   Sinha S, 2007, EPILEPSY RES, V74, P55, DOI 10.1016/j.eplepsyres.2006.12.003
   Stenqvist L, 2005, PEDIATR RES, V58, P258, DOI 10.1203/01.PDR.0000169966.82325.1A
   THOMAS JE, 1977, ARCH NEUROL-CHICAGO, V34, P266, DOI 10.1001/archneur.1977.00500170020003
   Varlamov DA, 2002, HUM MOL GENET, V11, P1797, DOI 10.1093/hmg/11.16.1797
   VEGGIOTTI P, 1995, NEUROPHYSIOL CLIN, V25, P158, DOI 10.1016/0987-7053(96)80168-7
   Wiedemann FR, 2000, ANAL BIOCHEM, V279, P55, DOI 10.1006/abio.1999.4434
   ZEVIANI M, 1990, ANN NEUROL, V28, P94, DOI 10.1002/ana.410280118
NR 23
TC 7
Z9 7
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-1211
EI 
J9 EPILEPSY RES
JI Epilepsy Res.
PD JAN 15
PY 2008
VL 78
IS 1
BP 1
EP 6
DI 10.1016/j.eplepsyres.2007.10.001
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 260VN
UT WOS:000253038600001
PM 18022351
DA 2024-11-01
ER

PT J
AU Karkare, K
   Sinha, S
   Ravishankar, S
   Gayathri, N
   Yasha, TC
   Goyal, MK
   Vijayan, J
   Vanniarajan, A
   Thangaraj, K
   Taly, AB
AF Karkare, Kalyani
   Sinha, Sanjib
   Ravishankar, Shivashankar
   Gayathri, Narayanappa
   Yasha, T. Chikkabasavaiah
   Goyal, Manoj K.
   Vijayan, Joy
   Vanniarajan, Ayyasamy
   Thangaraj, Kumarswamy
   Taly, Arun B.
TI Epilepsia partialis continua in mitochondrial dysfunction: Interesting phenotypic and MRI observations
SO ANNALS OF INDIAN ACADEMY OF NEUROLOGY
LA English
DT Article
DE chronic progressive external ophtalmoplegia; epilepsia partialis continua; mitochondrial dysfunction; Mitochondrial Encephalopathy with Ragged Red Fiber; MRI; periodic lateralized epileptiform discharges
ID partial status epilepticus; melas; complex
AB An 11-year-old girl manifested with photophobia, ptosis, external ophthalmoplegia, hypotonia, weakness of proximal limb muscles, hyporeflexia, and generalized seizures (six months). Her elder sister had had uncontrolled seizures and photophobia and died at seven years of age. In the patient, serum lactate was high (55 mg/dl). Muscle biopsy revealed characteristic ragged red and ragged blue fibers, diagnostic of mitochondrial cytopathy. Sequencing of the complete mitochondrial genome of the DNA obtained from the muscle biopsy of the patient did not show any characteristic mutation. Four months later, the girl was admitted with a one-week history of epilepsia partialis continua (EPC). EEG revealed Periodic Lateralized Epileptiform Discharges (PLEDs), once in 2-4 seconds, over the right temporo-occipital leads. MRI revealed signal change of right motor cortex, which had restricted diffusion. MR spectroscopy (MRS) from this region revealed lactate peak. EPC remained refractory to multiple anti-epileptic drugs, immuno-modulators, coenzyme-Q, and carnitine. This thought provoking report expands the spectrum of mitochondrial cytopathies.
C1 [Karkare, Kalyani; Sinha, Sanjib; Goyal, Manoj K.; Vijayan, Joy; Taly, Arun B.] Natl Inst Mental Hlth & Neurosci, Dept Neurol, Bangalore 560029, Karnataka, India.
   [Ravishankar, Shivashankar] Natl Inst Mental Hlth & Neurosci, Dept Neuroimaging & Intervent Radiol, Bangalore 560029, Karnataka, India.
   [Vanniarajan, Ayyasamy; Thangaraj, Kumarswamy] Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India.
   [Gayathri, Narayanappa; Yasha, T. Chikkabasavaiah] Natl Inst Mental Hlth & Neurosci, Dept Neuropathol, Bangalore 560029, Karnataka, India.
C3 National Institute of Mental Health & Neurosciences - India; National Institute of Mental Health & Neurosciences - India; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); National Institute of Mental Health & Neurosciences - India
RP Sinha, S (corresponding author), Natl Inst Mental Hlth & Neurosci, Dept Neurol, Hosur Rd, Bangalore 560029, Karnataka, India.
EM sanjib_sinha2004@yahoo.co.in
CR Cockerell OC, 1996, BRAIN, V119, P393, DOI 10.1093/brain/119.2.393
   Corda D, 2006, EPILEPSY BEHAV, V8, P655, DOI 10.1016/j.yebeh.2005.12.011
   Feddersen B, 2003, NEUROLOGY, V61, P1149, DOI 10.1212/01.WNL.0000092497.53706.1B
   Gropman AL, 2004, MITOCHONDRION, V4, P503, DOI 10.1016/j.mito.2004.07.009
   HORI A, 1989, JPN J PSYCHIAT NEUR, V43, P536
   Kim BS, 2001, YONSEI MED J, V42, P128
   Leff AP, 1998, EPILEPSIA, V39, P438, DOI 10.1111/j.1528-1157.1998.tb01397.x
   Miyamoto A, 1997, NEURORADIOLOGY, V39, P427, DOI 10.1007/s002340050438
   PohlmannEden B, 1996, J CLIN NEUROPHYSIOL, V13, P519, DOI 10.1097/00004691-199611000-00007
   Ribacoba R, 2006, NEUROLOGIA, V21, P1
   Schapira AHV, 1999, EUR J CLIN INVEST, V29, P886
   Schomer DL, 1993, EPILEPSIA S1, V34, P29
   Sinha S, 2007, EPILEPSY RES, V74, P55, DOI 10.1016/j.eplepsyres.2006.12.003
   Stenqvist L, 2005, PEDIATR RES, V58, P258, DOI 10.1203/01.PDR.0000169966.82325.1A
   VEGGIOTTI P, 1995, NEUROPHYSIOL CLIN, V25, P158, DOI 10.1016/0987-7053(96)80168-7
   Yapici Z, 2005, J CHILD NEUROL, V20, P517, DOI 10.1177/08830738050200060901
NR 16
TC 3
Z9 3
U1 0
U2 2
PU MEDKNOW PUBLICATIONS
PI MUMBAI
PA A-108-109 KANARA BUSINESS CENTRE, GHAKTOPAR, MUMBAI, 400075, INDIA
SN 0972-2327
EI 
J9 ANN INDIAN ACAD NEUR
JI Ann. Indian Acad. Neurol.
PD JUL-SEP 15
PY 2008
VL 11
IS 3
BP 193
EP 196
DI 
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 349QT
UT WOS:000259296800012
PM 19893669
DA 2024-11-01
ER

PT J
AU DiFrancesco, JC
   Cooper, JM
   Lam, A
   Hart, PE
   Tremolizzo, L
   Ferrarese, C
   Schapira, AH
AF DiFrancesco, Jacopo C.
   Cooper, J. Mark
   Lam, Amanda
   Hart, Paul E.
   Tremolizzo, Lucio
   Ferrarese, Carlo
   Schapira, Antony H.
TI MELAS mitochondrial DNA mutation A3243G reduces glutamate transport in cybrids cell lines
SO EXPERIMENTAL NEUROLOGY
LA English
DT Article
DE MELAS; A3243G; excitotoxicity; glutamate; mitochondria; cybrid
ID stroke-like episodes; lhon/melas overlap syndrome; oxidative damage; lactic-acidosis; complex-i; encephalomyopathy; defects; disease; encephalopathy; pathogenesis
AB MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) is commonly associated with the A3243G mitochondrial DNA (mtDNA) mutation encoding the transfer RNA of leucine (UUR) (tRNA (Le(UUR))). The pathogenetic mechanisms of this mutation are not completely understood. Neuronal functions are particularly vulnerable to alterations in oxidative phosphorylation, which may affect the function of the neurotransmitter glutamate, leading to excitotoxicity. In order to investigate the possible effects of A3243G upon glutamate homeostasis, we assessed glutamate uptake in osteosarcoma-derived cytoplasmic hybrids (cybrids) expressing high levels of this mutation. High-affinity Na+-dependent glutamate uptake was assessed as radioactive [H-3]-glutamate influx mediated by specific excitatory amino acid transporters (EAATs). The maximal rate (V-max) of Na+-dependent glutamate uptake was significantly reduced in all the mutant clones. Although the defect did not relate to either the mutant load or magnitude of oxidative phosphorylation defect, we found an inverse relationship between A3243G mutation load and mitochondrial ATP synthesis, without any evidence of increased cellular or mitochondrial free radical production in these A3243G clones. These data suggest that a defect of glutamate transport in MELAS neurons may be due to decreased energy production and might be involved in mediating the pathogenic effects of the A3243G mtDNA mutation. (C) 2008 Elsevier Inc. All rights reserved.
C1 [DiFrancesco, Jacopo C.; Tremolizzo, Lucio; Ferrarese, Carlo] Univ Milano Bicocca, Dept Neurosci & Biomed Technol, I-20052 Monza, MI, Italy.
   [Tremolizzo, Lucio; Ferrarese, Carlo] San Gerardo Hosp, Dept Neurol, Monza, Italy.
   [DiFrancesco, Jacopo C.; Ferrarese, Carlo] Inst Sci E Medea, Bosisio Parini, IC, Italy.
   [DiFrancesco, Jacopo C.; Cooper, J. Mark; Lam, Amanda; Hart, Paul E.; Schapira, Antony H.] Royal Free & Univ Coll Med Sch, Univ Dept Clin Neurosci, London WC1E 6BT, England.
   [Schapira, Antony H.] UCL, Inst Neurol, London, England.
C3 University of Milano-Bicocca; San Gerardo Hospital; IRCCS Eugenio Medea; University of London; University College London; University of London; University College London
RP DiFrancesco, JC (corresponding author), Univ Milano Bicocca, Dept Neurosci, Neurol Sect, Via Cadore 48, I-20052 Monza, MI, Italy.
EM jacopo.difrancesco@unimib.it
FU Medical Research Council [G0601943] Funding Source: Medline; MRC [G0601943] Funding Source: UKRI
CR ALBIN RL, 1992, NEUROLOGY, V42, P733, DOI 10.1212/WNL.42.4.733
   Beretta S, 2004, BRAIN, V127, P2183, DOI 10.1093/brain/awh258
   Beretta S, 2006, NEUROBIOL DIS, V24, P308, DOI 10.1016/j.nbd.2006.07.016
   Blakely EL, 2005, EUR J HUM GENET, V13, P623, DOI 10.1038/sj.ejhg.5201363
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   El Meziane A, 1998, NAT GENET, V18, P350
   Ferrarese C, 2004, EXCITOTOXICITY NEURO, V0, P0
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Gu M, 1998, ANN NEUROL, V44, P177, DOI 10.1002/ana.410440207
   Helm M, 1999, NUCLEIC ACIDS RES, V27, P756, DOI 10.1093/nar/27.3.756
   Hirata K, 2008, BRAIN DEV-JPN, V30, P238, DOI 10.1016/j.braindev.2007.08.007
   ICHIKI T, 1988, ANN NEUROL, V23, P287, DOI 10.1002/ana.410230312
   Iizuka T, 2005, CURR NEUROVASC RES, V2, P29, DOI 10.2174/1567202052773544
   James AM, 1999, EUR J BIOCHEM, V259, P462, DOI 10.1046/j.1432-1327.1999.00066.x
   Kariya S, 2005, NEUROPEPTIDES, V39, P97, DOI 10.1016/j.npep.2004.11.004
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Korlipara LVP, 2004, NEUROPHARMACOLOGY, V46, P562, DOI 10.1016/j.neuropharm.2003.10.015
   Liu CY, 2004, ANN NY ACAD SCI, V1011, P133, DOI 10.1196/annals.1293.014
   MOUDY AM, 1995, P NATL ACAD SCI USA, V92, P729, DOI 10.1073/pnas.92.3.729
   ONEILL CM, 1994, J NEUROCHEM, V63, P603
   Pang CY, 2001, DIABETES RES CLIN PR, V54, PS45, DOI 10.1016/S0168-8227(01)00335-7
   Pulkes T, 1999, ANN NEUROL, V46, P916, DOI 10.1002/1531-8249(199912)46:6<916::AID-ANA16>3.0.CO;2-R
   Rusanen H, 2000, BBA-MOL BASIS DIS, V1500, P10, DOI 10.1016/S0925-4439(99)00081-2
   Sandhu JK, 2005, BIOCHEM J, V391, P191, DOI 10.1042/BJ20050272
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Shepherd RK, 2006, J INHERIT METAB DIS, V29, P86, DOI 10.1007/s10545-006-0148-8
   SPARACO M, 1993, J NEUROPATH EXP NEUR, V52, P1, DOI 10.1097/00005072-199301000-00001
   Turner LF, 1998, EUR HEART J, V19, P1725, DOI 10.1053/euhj.1998.1125
   Wong A, 2002, HUM MOL GENET, V11, P431, DOI 10.1093/hmg/11.4.431
   Wong A, 1997, BIOCHEM BIOPH RES CO, V239, P139, DOI 10.1006/bbrc.1997.7443
   YONEDA M, 1989, J NEUROL SCI, V92, P143, DOI 10.1016/0022-510X(89)90132-9
NR 33
TC 12
Z9 16
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4886
EI 
J9 EXP NEUROL
JI Exp. Neurol.
PD JUL 15
PY 2008
VL 212
IS 1
BP 152
EP 156
DI 10.1016/j.expneurol.2008.03.015
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA 316NU
UT WOS:000256957700016
PM 18455161
DA 2024-11-01
ER

PT J
AU Crimi, M
   Rigolio, R
AF Crimi, Marco
   Rigolio, Roberta
TI The mitochondrial genome, a growing interest inside an organelle
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Review
DE mtDNA; heteroplasmy; molecular diagnostics; mitochondriopathies; nanogenomics
ID dna; disease; cancer; resveratrol; mice; polymorphism; myopathy; polymerase; mutation
AB Mitochondria are semi-autonomously reproductive organelles within eukaryotic cells carrying their own genetic material, called the mitochondrial genome (mtDNA). Until some years ago, mtDNA had primarily been used as a tool in population genetics. As scientists began associating mtDNA mutations with dozens of mysterious disorders, as well as the aging process and a variety of chronic degenerative diseases, it became increasingly evident that the information contained in this genome had substantial potential applications to improve human health. Today, mitochondria research covers a wide range of disciplines, including clinical medicine, biochemistry, genetics, molecular cell biology, bioinformatics, plant sciences and physiology. The present review intends to present a summary of the most exiting fields of the mitochondrial research bringing together several contributes in terms of original prospective and future applications.
C1 [Crimi, Marco] INGM, Funct Genom Unit, I-20122 Milan, Italy.
   [Rigolio, Roberta] Univ Milano Bicocca, Dept Neurosci & Biomed Technol, Monza, Italy.
C3 University of Milano-Bicocca
RP Crimi, M (corresponding author), INGM, Funct Genom Unit, Via F Sforza 28, I-20122 Milan, Italy.
EM crimi@ingm.it
CR Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354
   Bayona-Bafaluy MP, 2005, P NATL ACAD SCI USA, V102, P14392, DOI 10.1073/pnas.0502896102
   Biggin A, 2005, MOL GENET METAB, V84, P61, DOI 10.1016/j.ymgme.2004.09.011
   Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607
   Calvo S, 2006, NAT GENET, V38, P576, DOI 10.1038/ng1776
   Canter JA, 2005, CANCER RES, V65, P8028, DOI 10.1158/0008-5472.CAN-05-1428
   Capri M, 2006, ANN NY ACAD SCI, V1067, P252, DOI 10.1196/annals.1354.033
   CHUANG LY, 2006, BMC BIOINFORMATICS, V15, P7
   Crimi M, 2005, IUBMB LIFE, V57, P811, DOI 10.1080/15216540500460269
   Crimi M, 2003, EUR J HUM GENET, V11, P896, DOI 10.1038/sj.ejhg.5201056
   DiMauro S, 2007, BIOSCIENCE REP, V27, P125, DOI 10.1007/s10540-007-9041-4
   DiMauro S, 2006, CURR OPIN RHEUMATOL, V18, P636, DOI 10.1097/01.bor.0000245729.17759.f2
   DiMauro S, 2006, MUSCLE NERVE, V34, P265, DOI 10.1002/mus.20598
   DiMauro S, 2006, BRAIN, V129, P1637, DOI 10.1093/brain/awl169
   Flierl A, 2003, MOL THER, V7, P550, DOI 10.1016/S1525-0016(03)00037-6
   Hall VJ, 2006, STEM CELLS, V24, P1628, DOI 10.1634/stemcells.2005-0592
   Hirano M, 2006, NEUROLOGY, V67, P1458, DOI 10.1212/01.wnl.0000240853.97716.24
   Holt IJ, 2007, MITOCHONDRION, V7, P311, DOI 10.1016/j.mito.2007.06.004
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Jakupciak JP, 2006, CURR OPIN MOL THER, V8, P500
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Limongelli A, 2004, J MED GENET, V41, P342, DOI 10.1136/jmg.2003.016048
   Marriage B, 2003, J AM DIET ASSOC, V103, P1029, DOI 10.1016/S0002-8223(03)00476-0
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Shankar S, 2007, FRONT BIOSCI-LANDMRK, V12, P4839, DOI 10.2741/2432
   Taivassalo T, 2005, MED SCI SPORT EXER, V37, P2094, DOI 10.1249/01.mss.0000177446.97671.2a
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Wallace DC, 2005, GENE, V354, P169, DOI 10.1016/j.gene.2005.05.001
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wallace Douglas C, 2002, METHODS MOL BIOL, V197, P3, DOI 10.1385/1-59259-284-8:003
   Wong LJC, 2005, CLIN CHIM ACTA, V354, P1, DOI 10.1016/j.cccn.2004.11.003
NR 32
TC 33
Z9 45
U1 0
U2 5
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1176-9114
EI 
J9 INT J NANOMED
JI Int. J. Nanomed.
PD JUN 15
PY 2008
VL 3
IS 1
BP 51
EP 57
DI 
PG 7
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 313DY
UT WOS:000256722500005
PM 18488415
DA 2024-11-01
ER

PT J
AU Kirby, DM
   Thorburn, DR
AF Kirby, Denise M.
   Thorburn, David R.
TI Approaches to finding the molecular basis of mitochondrial oxidative phosphorylation disorders
SO TWIN RESEARCH AND HUMAN GENETICS
LA English
DT Review
DE mitochondrial disease; genes; respiratory chain; OXPHOS
ID cytochrome-c-oxidase; complex-i deficiency; dominant optic atrophy; progressive external ophthalmoplegia; respiratory-chain deficiency; coenzyme q(10) deficiency; dna-polymerase-gamma; leigh-syndrome; barth-syndrome; gene-mutations
AB Inherited disorders of mitochondrial oxidative phosphorylation are the most common group of inborn errors of metabolism and cause a wide range of clinical presentations. Mitochondrial DNA encodes 13 protein subunits required for oxidative phosphorylation plus 22 transfer RNAs and two ribosomal RNAs, and mutations in most of these genes cause human disease. Nuclear genes encode most of the protein subunits and all other proteins required for mitochondrial biogenesis and mitochondrial DNA replication and expression. Mutations in 64 nuclear genes and 34 mitochondrial genes are now known to cause mitochondrial disease and many novel mitochondrial disease genes await discovery. The genetic complexity of oxidative phosphorylation means that maternal, autosomal recessive, autosomal dominant and X-linked modes of inheritance can occur, along with de novo mutations. This complexity presents a challenge in planning efficient molecular genetic diagnosis of patients with suspected mitochondrial disease. In some situations, clinical phenotype can be strongly predictive of the underlying genotype. However, more often this is not the case and it is usually helpful, particularly with pediatric patients, to determine whether the activity of one or more of the individual oxidative phosphorylation enzymes is deficient before proceeding with mutation analysis. In this review we will summarize the genetic bases of mitochondrial disease and discuss some approaches to integrate information from clinical presentation, laboratory findings, family history, and imaging to guide molecular investigation.
C1 [Kirby, Denise M.; Thorburn, David R.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic 3052, Australia.
   [Kirby, Denise M.; Thorburn, David R.] Royal Childrens Hosp, Genet Hlth Serv Victoria, Melbourne, Vic 3052, Australia.
   [Thorburn, David R.] Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia.
C3 Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne
RP Thorburn, DR (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic 3052, Australia.
EM david.thorburn@mcri.edu.au
CR Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Allikmets R, 1999, HUM MOL GENET, V8, P743, DOI 10.1093/hmg/8.5.743
   Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489
   BAREL O, 1900, V82, V0, P1211
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Bénit P, 2004, J MED GENET, V41, P14, DOI 10.1136/jmg.2003.014316
   Bénit P, 2003, HUM MUTAT, V21, P582, DOI 10.1002/humu.10225
   Bénit P, 2001, AM J HUM GENET, V68, P1344, DOI 10.1086/320603
   Berger I, 2008, ANN NEUROL, V63, P405, DOI 10.1002/ana.21332
   Bertini I, 2008, CELL MOL LIFE SCI, V65, P89, DOI 10.1007/s00018-007-7439-6
   Bione S, 1996, NAT GENET, V12, P385, DOI 10.1038/ng0496-385
   Böhm M, 2006, PEDIATR RES, V59, P21, DOI 10.1203/01.pdr.0000190572.68191.13
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389
   Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9
   Coenen MJH, 2004, NEW ENGL J MED, V351, P2080, DOI 10.1056/NEJMoa041878
   Davey KM, 2006, J MED GENET, V43, P385, DOI 10.1136/jmg.2005.036657
   de Lonlay P, 2001, NAT GENET, V29, P57, DOI 10.1038/ng706
   De Meirleir L, 2004, J MED GENET, V41, P120, DOI 10.1136/jmg.2003.012047
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DIMAURO S, 2008, ANN REV NEUROSCIENCE, V0, P0
   Dunning CJR, 2007, EMBO J, V26, P3227, DOI 10.1038/sj.emboj.7601748
   Edvardson S, 2007, AM J HUM GENET, V81, P857, DOI 10.1086/521227
   Fernandez-Moreira D, 2007, ANN NEUROL, V61, P73, DOI 10.1002/ana.21036
   HAKONEN A, 2006, EUROPEAN J HUMAN GEN, V15, P779
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hansen JJ, 2002, AM J HUM GENET, V70, P1328, DOI 10.1086/339935
   Haut S, 2003, HUM GENET, V113, P118, DOI 10.1007/s00439-003-0946-0
   Hinson JT, 2007, NEW ENGL J MED, V356, P809, DOI 10.1056/NEJMoa055262
   Hoefs SJG, 2008, AM J HUM GENET, V82, P1306, DOI 10.1016/j.ajhg.2008.05.007
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Hudson G, 2006, HUM MOL GENET, V15, PR244, DOI 10.1093/hmg/ddl233
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kirby DM, 1999, NEUROLOGY, V52, P1255, DOI 10.1212/WNL.52.6.1255
   Kirby DM, 2000, ANN NEUROL, V48, P102, DOI 10.1002/1531-8249(200007)48:1<102::AID-ANA15>3.3.CO;2-D
   Kirby DM, 2004, J CLIN INVEST, V114, P837, DOI 10.1172/JCI200420683
   Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141
   Lagier-Tourenne C, 2008, AM J HUM GENET, V82, P661, DOI 10.1016/j.ajhg.2007.12.024
   Lebon S, 2003, J MED GENET, V40, P896, DOI 10.1136/jmg.40.12.896
   Loeffen J, 2001, ANN NEUROL, V49, P195, DOI 10.1002/1531-8249(20010201)49:2<195::AID-ANA39>3.0.CO;2-M
   Loeffen J, 1998, AM J HUM GENET, V63, P1598, DOI 10.1086/302154
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   López LC, 2006, AM J HUM GENET, V79, P1125, DOI 10.1086/510023
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Massa V, 2008, AM J HUM GENET, V82, P1281, DOI 10.1016/j.ajhg.2008.05.002
   Mayr JA, 2007, AM J HUM GENET, V80, P478, DOI 10.1086/511788
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   McKenzie M, 2006, J MOL BIOL, V361, P462, DOI 10.1016/j.jmb.2006.06.057
   Miller C, 2004, ANN NEUROL, V56, P734, DOI 10.1002/ana.20282
   Mitchell AL, 2006, J MED GENET, V43, P175, DOI 10.1136/jmg.2005.032474
   *MITOMAP, 2008, MITOMAP HUM MIT GEN, V0, P0
   Mochel F, 2008, AM J HUM GENET, V82, P652, DOI 10.1016/j.ajhg.2007.12.012
   Mollet J, 2008, AM J HUM GENET, V82, P623, DOI 10.1016/j.ajhg.2007.12.022
   Mollet J, 2007, J CLIN INVEST, V117, P765, DOI 10.1172/JCI29089
   Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699
   Morison IM, 2008, NAT GENET, V40, P387, DOI 10.1038/ng.103
   Munnich A, 2001, AM J MED GENET, V106, P4, DOI 10.1002/ajmg.1391
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Ogilvie I, 2005, J CLIN INVEST, V115, P2784, DOI 10.1172/JCI26020
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Ostergaard E, 2007, BRAIN, V130, P853, DOI 10.1093/brain/awl383
   PAGLIARINI DJ, 2008, CELL IN PRESS 0523, V0, P0
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Péquignot MO, 2001, HUM MUTAT, V17, P374, DOI 10.1002/humu.1112.abs
   Quinzii C, 2006, AM J HUM GENET, V78, P345, DOI 10.1086/500092
   Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215
   Saada A, 2007, J MED GENET, V44, P784, DOI 10.1136/jmg.2007.053116
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Saada A, 2008, AM J HUM GENET, V82, P32, DOI 10.1016/j.ajhg.2007.08.003
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Sarzi E, 2007, AM J MED GENET A, V143A, P33, DOI 10.1002/ajmg.a.31565
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Scheper GC, 2007, NAT GENET, V39, P534, DOI 10.1038/ng2013
   Shanske S, 2008, ARCH NEUROL-CHICAGO, V65, P368, DOI 10.1001/archneurol.2007.67
   Shoffner JM, 1996, LANCET, V348, P1283, DOI 10.1016/S0140-6736(96)09138-6
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Smeitink JAM, 2006, AM J HUM GENET, V79, P869, DOI 10.1086/508434
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Stenson PD, 2003, HUM MUTAT, V21, P577, DOI 10.1002/humu.10212
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Thorburn DR, 2003, MITOCHONDRIAL DNA-ASSOCIATED LEIGH SYNDROME AND NARP. SYNONYM: MTDNA-ASSOCIATED LEIGH SYNDROME AND NARP, V0, P0
   Thorburn DR, 2004, MITOCHONDRION, V4, P363, DOI 10.1016/j.mito.2004.07.003
   Thorburn DR, 2004, BBA-BIOENERGETICS, V1659, P121, DOI 10.1016/j.bbabio.2004.08.006
   Thorburn DR, 2004, J INHERIT METAB DIS, V27, P349, DOI 10.1023/B:BOLI.0000031098.41409.55
   Tiranti V, 2004, AM J HUM GENET, V74, P239, DOI 10.1086/381653
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   Triepels RH, 1999, ANN NEUROL, V45, P787, DOI 10.1002/1531-8249(199906)45:6<787::AID-ANA13>3.0.CO;2-6
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
   Valnot I, 2000, AM J HUM GENET, V67, P1104
   Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245
   van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Visapää I, 2002, AM J HUM GENET, V71, P863, DOI 10.1086/342773
   Vreken P, 2000, BIOCHEM BIOPH RES CO, V279, P378, DOI 10.1006/bbrc.2000.3952
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wimplinger I, 2006, AM J HUM GENET, V79, P878, DOI 10.1086/508474
   Xu FH, 2004, BIOCHEM J, V382, P331, DOI 10.1042/BJ20040469
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
   Zhang Y, 2007, J INHERIT METAB DIS, V30, P265, DOI 10.1007/s10545-006-0481-y
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
   Züchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
NR 107
TC 43
Z9 45
U1 0
U2 0
PU AUSTRALIAN ACAD PRESS
PI BOWEN HILLS
PA 32 JEAYS ST, BOWEN HILLS, QLD 4006, AUSTRALIA
SN 1832-4274
EI 
J9 TWIN RES HUM GENET
JI Twin Res. Hum. Genet.
PD AUG 15
PY 2008
VL 11
IS 4
BP 395
EP 411
DI 10.1375/twin.11.4.395
PG 17
WC Genetics & Heredity; Obstetrics & Gynecology
SC Genetics & Heredity; Obstetrics & Gynecology
GA 335EO
UT WOS:000258273800005
PM 18637740
DA 2024-11-01
ER

PT J
AU Blakely, E
   He, L
   Gardner, JL
   Hudson, G
   Walter, J
   Hughes, I
   Turnbull, DM
   Taylor, RW
AF Blakely, Emma
   He, Langping
   Gardner, Julie L.
   Hudson, Gavin
   Walter, John
   Hughes, Imelda
   Turnbull, Douglass M.
   Taylor, Robert W.
TI Novel mutations in the <i>TK2</i> gene associated with fatal mitochondrial DNA depletion myopathy
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mitochondrial DNA; myopathy; depletion syndrome; TK2 mutations
ID thymidine kinase; mtdna depletion
AB Mitochondrial DNA depletion syndromes are a heterogeneous group of childhood neurological disorders characterised by a quantitative abnormality of mitochondrial DNA. We describe two siblings who presented at 8 months and 14 months with myopathy, which rapidly progressed and resulted in death by respiratory failure at age 14 and 18 months, respectively. Muscle biopsy revealed marked respiratory chain defects, with real-time PCR confirming a dramatic depletion of mitochondrial DNA. Sequencing of the thymidine kinase 2 (TK2) gene revealed two, novel heterozygous mutations (p.Q87X and p.N100S) with parental DNA analysis confirming the transmission of mutated alleles. (c) 2008 Elsevier B.V. All rights reserved.
C1 [Blakely, Emma; He, Langping; Gardner, Julie L.; Hudson, Gavin; Turnbull, Douglass M.; Taylor, Robert W.] Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Walter, John] Royal Manchester Childrens Hosp, Willink Biochem Genet Unit, Manchester M27 1HA, Lancs, England.
   [Hughes, Imelda] Royal Manchester Childrens Hosp, Dept Neurol, Manchester M27 1HA, Lancs, England.
   [Turnbull, Douglass M.; Taylor, Robert W.] Univ Newcastle Upon Tyne, Inst Human Genet & Neurosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK; Royal Manchester Children's Hospital; Royal Manchester Children's Hospital; Newcastle University - UK
RP Taylor, RW (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM r.w.taylor@ncl.ac.uk
FU Wellcome Trust [074454] Funding Source: Medline
CR Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Elpeleg O, 2003, PEDIATR RES, V54, P153, DOI 10.1203/01.PDR.0000072796.25097.A5
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Johansson K, 2001, NAT STRUCT BIOL, V8, P616, DOI 10.1038/89661
   LESHINSKYSILVER E, 2007, EUR J PEDIAT NEUROL, V0, P0
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
NR 10
TC 37
Z9 41
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD JUL 15
PY 2008
VL 18
IS 7
BP 557
EP 560
DI 10.1016/j.nmd.2008.04.014
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 334AD
UT WOS:000258193800007
PM 18508266
DA 2024-11-01
ER

PT J
AU Filosto, M
   Tonin, P
   Scarpelli, M
   Savio, C
   Greco, F
   Mancuso, M
   Vattemi, G
   Govoni, V
   Rizzuto, N
   Tupler, R
   Tornelleri, G
AF Filosto, Massimiliano
   Tonin, Paola
   Scarpelli, Mauro
   Savio, Chiara
   Greco, Francesca
   Mancuso, Michelangelo
   Vattemi, Gaetano
   Govoni, Vittorio
   Rizzuto, Nicolo
   Tupler, Rossella
   Tornelleri, Giuliano
TI Novel mitochondrial tRNA<SUP>Leu(CUN)</SUP> transition and D4Z4 partial deletion in a patient with a facioscapulohumeral phenotype
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mtDNA; mitochondrial myopathy; FSHD
ID progressive external ophthalmoplegia; mtdna point mutation; transfer-rna genes; muscular-dystrophy; skeletal-muscle; sporadic patient; myopathy; dna; encephalomyopathy; deficiency
AB Point mutations in mtDNA-encoded tRNA genes frequently cause isolated myopathies but rarely cause the facioscapulohumeral phenotype. We report on a patient affected with chronic progressive weakness of facioscapulolmmeral/peroneal muscles whose muscle biopsy showed a mitochondrial myopathy. mtDNA direct sequencing and RFLP analysis revealed a heteroplasmic transition T12313C which disrupts a conserved site in the TTC stem of the tRNA(Leu(CUN)) gene and fulfills the accepted criteria of pathogenicity. A partial deletion of the nuclear DNA D4Z4 region with residual repeat sizes of 25 kb was also found in the patient and in her mother. This is the first reported case of mitochondrial myopathy/facioscapulohumeral muscular dystrophy (FSHD) "double trouble". (C) 2007 Elsevier B.V. All rights reserved.
C1 [Filosto, Massimiliano; Tonin, Paola; Scarpelli, Mauro; Savio, Chiara; Vattemi, Gaetano; Rizzuto, Nicolo; Tornelleri, Giuliano] Univ Verona, Sect Clin Neurol, Dept Neurol Sci & Vis, I-37100 Verona, Italy.
   [Filosto, Massimiliano] Univ Hosp Spedali Civili, Brescia, Italy.
   [Greco, Francesca; Tupler, Rossella] Univ Modena & Reggio Emilia, Dept Biomed Sci, Modena, Italy.
   [Mancuso, Michelangelo] Univ Pisa, Dept Neurosci, I-56100 Pisa, Italy.
   [Govoni, Vittorio] Univ Ferrara, Inst Clin Neurol, I-44100 Ferrara, Italy.
C3 University of Verona; Hospital Spedali Civili Brescia; Universita di Modena e Reggio Emilia; University of Pisa; University of Ferrara
RP Tornelleri, G (corresponding author), Univ Verona, Sect Clin Neurol, Dept Neurol Sci & Vis, I-37100 Verona, Italy.
EM giuliano.tomelleri@univr.it
CR ANDREU AL, 2002, METHODS MOL BIOL NEU, V217, P185
   BANCROFT JD, 1984, MANUAL HIST TECHNIQU, V0, P0
   Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493
   Bushby KMD, 1998, NEUROMUSCULAR DISORD, V8, P574, DOI 10.1016/S0960-8966(98)00088-1
   Cardaioli E, 2005, BIOCHEM BIOPH RES CO, V327, P675, DOI 10.1016/j.bbrc.2004.11.170
   Chuenkongkaew WL, 2005, EUR J NEUROL, V12, P388, DOI 10.1111/j.1468-1331.2004.01060.x
   DiMauro S, 2005, CURR OPIN NEUROL, V18, P538, DOI 10.1097/01.wco.0000179761.63486.1a
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Gabellini D, 2006, NATURE, V439, P973, DOI 10.1038/nature04422
   Gabellini D, 2002, CELL, V110, P339, DOI 10.1016/S0092-8674(02)00826-7
   Gattermann N, 1996, BRIT J HAEMATOL, V93, P845, DOI 10.1046/j.1365-2141.1996.d01-1724.x
   Grasso M, 2001, EUR J HUM GENET, V9, P311, DOI 10.1038/sj.ejhg.5200622
   HATTORI Y, 1994, J NEUROL SCI, V125, P50, DOI 10.1016/0022-510X(94)90241-0
   HOUSHMAND M, 1994, BBA-MOL BASIS DIS, V1226, P49, DOI 10.1016/0925-4439(94)90058-2
   HUDGSON P, 1972, J NEUROL SCI, V16, P343, DOI 10.1016/0022-510X(72)90197-9
   Karadimas CL, 2002, NEUROMUSCULAR DISORD, V12, P865, DOI 10.1016/S0960-8966(02)00072-X
   Laoudj-Chenivesse D, 2005, J MOL MED, V83, P216, DOI 10.1007/s00109-004-0583-7
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Padberg G W, 1991, NEUROMUSCUL DISORD, V1, P231, DOI 10.1016/0960-8966(91)90094-9
   PADBERG GW, 1995, MUSCLE NERVE, V0, PS73
   Pál E, 1999, EUR NEUROL, V42, P211, DOI 10.1159/000008109
   Pulkes T, 1999, ANN NEUROL, V46, P916, DOI 10.1002/1531-8249(199912)46:6<916::AID-ANA16>3.0.CO;2-R
   Pulkes T, 2003, NEUROLOGY, V61, P1144, DOI 10.1212/01.WNL.0000090465.27024.3D
   ROWLAND LP, 1991, REV NEUROL-FRANCE, V147, P467
   Sacconi S, 2006, NEUROLOGY, V67, P1464, DOI 10.1212/01.wnl.0000240071.62540.6f
   SLIPETZ DM, 1991, AM J HUM GENET, V48, P502
   Vives-Bauza C, 2001, ANN MED, V33, P493, DOI 10.3109/07853890109002099
   Weber K, 1997, AM J HUM GENET, V60, P373
   Zsurka G, 2004, J MED GENET, V41, P0, DOI 10.1136/jmg.2004.022566
NR 32
TC 12
Z9 13
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD MAR 15
PY 2008
VL 18
IS 3
BP 204
EP 209
DI 10.1016/j.nmd.2007.12.005
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 300EX
UT WOS:000255808200003
PM 18343111
DA 2024-11-01
ER

PT J
AU Scheffler, IE
AF Scheffler, Immo E.
TI MITOCHONDRIAL MUTATIONS AND DISEASE
SO MITOCHONDRIA, 2NDEDITION
LA English
DT Article; Book Chapter
ID cytoplasmic male-sterility; chinese-hamster cells; cytochrome-c-oxidase; chain complex-i; hereditary optic neuropathy; deafness dystonia syndrome; alzheimers-disease; maternal inheritance; huntingtons-disease; oxidative stress
AB When mitochondrial DNA was discovered, it could be anticipated that there could be mutations, and an explanation was provided for "cytoplasmic mutations" and non-mendelian inheritance first observed in Saccharomyces cerevisiae. Since yeast could proliferate under anaerobic conditions, mtDNA mutations affecting respiration and oxidative phosphorylation could be isolated and characterized. In humans the detection of such mutations seemed inconceivable for two reasons: (1) Respiration-deficient humans would be expected to be dead, and (2) with >1000 mtDNAs per cell it was difficult to imagine how a mutation in one of these genomes could ever be expressed as a phenotype. In the late 1980s, human pedigrees with mtDNA mutations and a phenotype were discovered, and the term "mitochondrial disease" was introduced. Soon it was recognized that such diseases were more common than expected; symptoms ranged from mild to severe, and combinations of symptoms made it a challenge to classify these diseases into distinct categories. However, neuropathies, myopathies, or a combination of these are typical. Initially, mitochondrial diseases were characterized by a partial defect in oxidative phosphorylation (an energy deficiency) due to mtDNA mutations, but it is immediately obvious that nuclear mutations could also lead to defective electron transport and ATP synthesis. Such mutations should follow mendelian genetics in a pedigree. Severe mutations are lethal (in early embryogenesis/development), and affected patients must still have partial function of the affected enzyme/complex. With >1000 proteins in mitochondria, one could in principle have thousands of "mitochondrial diseases." Here the term will be applied in a limited sense to mutations that affect oxidative phosphorylation and energy metabolism. Included in this category are diseases that are the result of problems in mtDNA replication and maintenance. Numerous other defects in mitochondrial proteins are the cause of "inborn errors of metabolism" or "metabolic diseases" that will not be discussed in this chapter. There has also been an increasing awareness over the last two decades that mitochondria and mitochondrial defects are implicated in age-dependent neurological degeneration (Alzheimer's disease, Parkinson's disease, Friedreich's ataxia, and others). The current state of knowledge will be summarized. Finally, the phenomenon of aging (senescence) has attracted attention for a long time and for obvious reasons. There are clearly multiple facets of this problem and the underlying causes. Mitochondria are thought to play a prominent role as a major source of reactive oxygen species (ROS); an accumulation of mutations in mtDNA and damage to mitochondrial proteins due to ROS provides a rationale for the diminishing capacity of mitochondria and for the accumulation of cellular debris that can overwhelm the cellular garbage disposal machinery (proteasome).
C1 Univ Calif San Diego, San Diego, CA 92103 USA.
C3 University of California System; University of California San Diego
RP Scheffler, IE (corresponding author), Univ Calif San Diego, San Diego, CA 92103 USA.
CR Abdrakhmanova A, 2004, BBA-BIOENERGETICS, V1658, P148, DOI 10.1016/j.bbabio.2004.04.019
   Abou-Sleiman PM, 2006, NAT REV NEUROSCI, V7, P207, DOI 10.1038/nrn1868
   Ackrell BAC, 2002, MOL ASPECTS MED, V23, P369, DOI 10.1016/S0098-2997(02)00012-2
   Alper G, 2003, PEDIATR NEUROL, V28, P335, DOI 10.1016/S0887-8994(03)00004-3
   AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X
   AnkelSimons F, 1996, P NATL ACAD SCI USA, V93, P13859, DOI 10.1073/pnas.93.24.13859
   [Anonymous], 2005, CELL, V120, P435
   Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370
   ASHLEY MV, 1989, NUCLEIC ACIDS RES, V17, P7325, DOI 10.1093/nar/17.18.7325
   Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282
   Au HC, 1999, P NATL ACAD SCI USA, V96, P4354, DOI 10.1073/pnas.96.8.4354
   Au HC, 1997, SOMAT CELL MOLEC GEN, V23, P27, DOI 10.1007/BF02679953
   AVISE JC, 1979, P NATL ACAD SCI USA, V76, P6694, DOI 10.1073/pnas.76.12.6694
   Bae BI, 2005, NEURON, V47, P29, DOI 10.1016/j.neuron.2005.06.005
   BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11
   Battersby BJ, 2005, HUM MOL GENET, V14, P2587, DOI 10.1093/hmg/ddi293
   Battersby BJ, 2001, HUM MOL GENET, V10, P2469, DOI 10.1093/hmg/10.22.2469
   Baur E, 1909, Z F IND ABST VEREBUN, V1, P330, DOI 10.1007/bf01990603
   Baysal BE, 2002, J MED GENET, V39, P178, DOI 10.1136/jmg.39.3.178
   Beal MF, 2005, ANN NEUROL, V58, P495, DOI 10.1002/ana.20624
   Benchoua A, 2006, MOL BIOL CELL, V17, P1652, DOI 10.1091/mbc.E05-07-0607
   Bénit P, 2003, HUM MUTAT, V21, P582, DOI 10.1002/humu.10225
   Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2
   Bertrand H, 2000, ANNU REV PHYTOPATHOL, V38, P397, DOI 10.1146/annurev.phyto.38.1.397
   BODNAR AG, 1993, AM J HUM GENET, V53, P663
   Boillée S, 2006, NEURON, V52, P39, DOI 10.1016/j.neuron.2006.09.018
   Brandt U, 2006, ANNU REV BIOCHEM, V75, P69, DOI 10.1146/annurev.biochem.75.103004.142539
   BREEN GAM, 1980, J CELL BIOL, V86, P723, DOI 10.1083/jcb.86.3.723
   BREEN GAM, 1986, J BIOL CHEM, V261, P1680
   Brière JJ, 2005, CELL MOL LIFE SCI, V62, P2317, DOI 10.1007/s00018-005-5237-6
   Brierley EJ, 1996, QJM-MON J ASSOC PHYS, V89, P251
   Brierley EJ, 1997, ANN NEUROL, V41, P114, DOI 10.1002/ana.410410120
   Brown MD, 1996, AM J MED GENET, V61, P283, DOI 10.1002/(SICI)1096-8628(19960122)61:3<283::AID-AJMG15>3.0.CO;2-P
   BROWN MD, 1994, CLIN NEUROSCI, V2, P138
   BROWN TA, 1995, J BACTERIOL, V177, P6836, DOI 10.1128/jb.177.23.6836-6843.1995
   Budar F, 2003, GENETICA, V117, P3, DOI 10.1023/A:1022381016145
   BUNN CL, 1974, P NATL ACAD SCI USA, V71, P1681, DOI 10.1073/pnas.71.5.1681
   BURNETT KG, 1981, J CELL BIOL, V90, P108, DOI 10.1083/jcb.90.1.108
   Calkins MJ, 2005, P NATL ACAD SCI USA, V102, P244, DOI 10.1073/pnas.0408487101
   Carelli V, 2004, BBA-BIOENERGETICS, V1658, P172, DOI 10.1016/j.bbabio.2004.05.009
   Chase CD, 2006, TRENDS PLANT SCI, V11, P7, DOI 10.1016/j.tplants.2005.11.003
   Chase CD, 2007, TRENDS GENET, V23, P81, DOI 10.1016/j.tig.2006.12.004
   CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337
   CHEN X, 1995, AM J HUM GENET, V57, P239
   Chew SL, 2001, CLIN ENDOCRINOL, V54, P573, DOI 10.1046/j.1365-2265.2001.01238.x
   Chinnery PF, 2002, MITOCHONDRION, V2, P149, DOI 10.1016/S1567-7249(02)00046-6
   Chinnery PF, 2000, TRENDS GENET, V16, P500, DOI 10.1016/S0168-9525(00)02120-X
   Chomyn A, 2003, BIOCHEM BIOPH RES CO, V304, P519, DOI 10.1016/S0006-291X(03)00625-9
   Chretien D, 2003, BIOCHEM BIOPH RES CO, V301, P222, DOI 10.1016/S0006-291X(02)03016-4
   Clark IE, 2006, NATURE, V441, P1162, DOI 10.1038/nature04779
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   Clayton DA, 1996, NAT GENET, V14, P123, DOI 10.1038/ng1096-123
   COLLINS MKL, 1993, TRENDS BIOCHEM SCI, V18, P307, DOI 10.1016/0968-0004(93)90042-L
   Cookson MR, 2005, ANNU REV BIOCHEM, V74, P29, DOI 10.1146/annurev.biochem.74.082803.133400
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   Correns C, 1909, ZIAV, V1, P291
   Cortopassi Gino, 1993, P125, V0, P0
   Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7
   Davis AF, 1996, J CELL BIOL, V135, P883, DOI 10.1083/jcb.135.4.883
   Davis GC, 1979, PSYCHIAT RES, V1, P649
   Davis RE, 1997, P NATL ACAD SCI USA, V94, P4526, DOI 10.1073/pnas.94.9.4526
   DAWID IB, 1972, DEV BIOL, V29, P152, DOI 10.1016/0012-1606(72)90052-8
   DAY CE, 1982, SOMAT CELL GENET, V8, P691, DOI 10.1007/BF01543012
   DEFRANCESCO L, 1976, J BIOL CHEM, V251, P4588
   DEFRANCESCO L, 1975, J CELL PHYSIOL, V85, P293, DOI 10.1002/jcp.1040850216
   Dekker PBD, 2003, J PATHOL, V201, P480, DOI 10.1002/path.1461
   Delivani P, 2006, MOL CELL, V21, P761, DOI 10.1016/j.molcel.2006.01.034
   DESJARDINS P, 1986, SOMAT CELL MOLEC GEN, V12, P133, DOI 10.1007/BF01560660
   DEWINDE JH, 1993, PROG NUCLEIC ACID RE, V46, P51, DOI 10.1016/S0079-6603(08)61018-1
   Dinopoulos A, 2005, ACTA NEUROPATHOL, V110, P199, DOI 10.1007/s00401-005-1036-2
   DITTA G, 1976, SOMAT CELL GENET, V2, P331, DOI 10.1007/BF01538838
   DITTA G, 1977, NATURE, V268, P64, DOI 10.1038/268064a0
   Dujon B, 1981, MOL BIOL YEAST SACCH, V0, P505
   Florentz C, 2002, BIOSCIENCE REP, V22, P81, DOI 10.1023/A:1016065107165
   Fridovich I, 2004, AGING CELL, V3, P13, DOI 10.1046/j.1474-9728.2003.00075.x
   Gakh O, 2006, HUM MOL GENET, V15, P467, DOI 10.1093/hmg/ddi461
   Gandhi S, 2005, HUM MOL GENET, V14, P2749, DOI 10.1093/hmg/ddi308
   GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715
   Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320
   Greenamyre JT, 2004, SCIENCE, V304, P1120, DOI 10.1126/science.1098966
   Greenamyre JT, 2003, PARKINSONISM RELAT D, V9, PS59, DOI 10.1016/S1353-8020(03)00023-3
   Greenamyre JT, 2001, IUBMB LIFE, V52, P135, DOI 10.1080/15216540152845939
   GRIFFITHS AJF, 1995, MICROBIOL REV, V59, P673, DOI 10.1128/MMBR.59.4.673-685.1995
   GRIFFITHS AJF, 1992, ANNU REV GENET, V26, P351, DOI 10.1146/annurev.ge.26.120192.002031
   GROSS NJ, 1969, J BIOL CHEM, V244, P1552
   Guan MX, 2006, AM J HUM GENET, V79, P291, DOI 10.1086/506389
   Guan MX, 2004, ANN NY ACAD SCI, V1011, P259, DOI 10.1196/annals.1293.025
   Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029
   GUPTA KP, 1990, MUTAT RES, V237, P17, DOI 10.1016/0921-8734(90)90028-P
   Gusella JF, 2006, TRENDS BIOCHEM SCI, V31, P533, DOI 10.1016/j.tibs.2006.06.009
   Guthrie C, 1991, METHOD ENZYMOL, V0, P149
   GYLLENSTEN U, 1991, NATURE, V352, P255, DOI 10.1038/352255a0
   Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064
   Halestrap AP, 2006, BIOCHEM SOC T, V34, P232, DOI 10.1042/BST0340232
   HALUSKA FG, 1989, PROG NUCLEIC ACID RE, V36, P269
   HANSON MR, 1991, ANNU REV GENET, V25, P461, DOI 10.1146/annurev.ge.25.120191.002333
   Harding AE, 1993, P53, V0, P0
   HARRIS M, 1978, P NATL ACAD SCI USA, V75, P5604, DOI 10.1073/pnas.75.11.5604
   Hauptmann S, 2006, EXP GERONTOL, V41, P668, DOI 10.1016/j.exger.2006.03.012
   Haut S, 2003, HUM GENET, V0, P0
   HAYAKAWA M, 1991, BIOCHEM BIOPH RES CO, V179, P1023, DOI 10.1016/0006-291X(91)91921-X
   HAYASHI JI, 1978, BIOCHEM BIOPH RES CO, V83, P1032, DOI 10.1016/0006-291X(78)91499-7
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   HAYASHI JI, 1983, EXP CELL RES, V147, P51, DOI 10.1016/0014-4827(83)90270-7
   HAYASHI JI, 1994, J BIOL CHEM, V269, P6878
   Hayashida K, 2005, CELL BIOL INT, V29, P472, DOI 10.1016/j.cellbi.2004.09.016
   He SC, 1996, P NATL ACAD SCI USA, V93, P11763, DOI 10.1073/pnas.93.21.11763
   Hirano M, 1997, P NATL ACAD SCI USA, V94, P14894, DOI 10.1073/pnas.94.26.14894
   HOLMANS PL, 1987, SOMAT CELL MOLEC GEN, V13, P347, DOI 10.1007/BF01534929
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HORTON TM, 1995, NEUROLOGY, V45, P1879, DOI 10.1212/WNL.45.10.1879
   Howell N, 2005, TRENDS GENET, V21, P583, DOI 10.1016/j.tig.2005.08.012
   Howell N, 2003, DEV OPHTHALMOL, V37, P94
   Howell N, 1997, VISION RES, V37, P3495, DOI 10.1016/S0042-6989(96)00167-8
   HOWELL N, 1979, SOMAT CELL GENET, V5, P833, DOI 10.1007/BF01542645
   HSIEH RH, 1994, BIOCHEM MOL BIOL INT, V32, P1009
   HUTCHIN T, 1995, P NATL ACAD SCI USA, V92, P6892, DOI 10.1073/pnas.92.15.6892
   HUTCHISOCA, 1974, NATURE, V251, P536, DOI 10.1038/251536a0
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Inoue K, 1997, J BIOL CHEM, V0, P0
   Jacobs HT, 2003, AGING CELL, V2, P11, DOI 10.1046/j.1474-9728.2003.00032.x
   JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0
   Janssen AJM, 2006, CLIN CHEM, V52, P860, DOI 10.1373/clinchem.2005.062414
   Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146
   Johnston M, 1993, REGULATION CARBON PH, V0, P193
   KADENBACH B, 1995, MUTAT RES-DNAGING G, V338, P161, DOI 10.1016/0921-8734(95)00021-W
   KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542
   Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   Keil U, 2004, J BIOL CHEM, V279, P50310, DOI 10.1074/jbc.M405600200
   Kenyon L, 1997, P NATL ACAD SCI USA, V94, P9131, DOI 10.1073/pnas.94.17.9131
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Klivenyi P, 2006, NEUROBIOL DIS, V21, P541, DOI 10.1016/j.nbd.2005.08.018
   Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132
   Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141
   Kroemer G, 2006, ONCOGENE, V25, P4630, DOI 10.1038/sj.onc.1209589
   Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X
   Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619
   KROON AM, 1978, BIOCHIM BIOPHYS ACTA, V519, P269, DOI 10.1016/0005-2787(78)90079-5
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Kwong JQ, 2006, J NEUROCHEM, V97, P1659, DOI 10.1111/j.1471-4159.2006.03990.x
   La Spada AR, 2005, NEURON, V47, P1, DOI 10.1016/j.neuron.2005.06.023
   Laderman KA, 1996, J BIOL CHEM, V271, P15891, DOI 10.1074/jbc.271.27.15891
   LAIPIS PJ, 1988, P NATL ACAD SCI USA, V85, P8107, DOI 10.1073/pnas.85.21.8107
   LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561
   LEE SLJ, 1979, AM J BOT, V66, P141, DOI 10.2307/2442516
   Lenaz G, 2006, ANTIOXID REDOX SIGN, V8, P417, DOI 10.1089/ars.2006.8.417
   Levinger L, 2004, NUCLEIC ACIDS RES, V32, P5430, DOI 10.1093/nar/gkh884
   Levings CSI, 1995, MOL BIOL PLANT MITOC, V0, P0
   LHomme Y, 1997, CURR GENET, V31, P325, DOI 10.1007/s002940050212
   Li XM, 2004, NUCLEIC ACIDS RES, V32, P867, DOI 10.1093/nar/gkh226
   LICHTOR T, 1978, P NATL ACAD SCI USA, V75, P324, DOI 10.1073/pnas.75.1.324
   Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   LIND C, 1991, PHYSIOL PLANTARUM, V83, P7, DOI 10.1111/j.1399-3054.1991.tb01274.x
   LINNANE AW, 1990, BIOCHEM INT, V22, P1067
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Liu J, 2004, NEURON, V43, P5, DOI 10.1016/j.neuron.2004.06.016
   Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9
   Liu YF, 1997, ENVIRON MOL MUTAGEN, V29, P36, DOI 10.1002/(SICI)1098-2280(1997)29:1<36::AID-EM5>3.0.CO;2-B
   Lodi R, 2006, ANTIOXID REDOX SIGN, V8, P438, DOI 10.1089/ars.2006.8.438
   Loeb LA, 2005, P NATL ACAD SCI USA, V102, P18769, DOI 10.1073/pnas.0509776102
   Loeffen JLCM, 2000, HUM MUTAT, V15, P123, DOI 10.1002/(SICI)1098-1004(200002)15:2<123::AID-HUMU1>3.3.CO;2-G
   Lorin S, 2006, BBA-BIOENERGETICS, V1757, P604, DOI 10.1016/j.bbabio.2006.03.005
   MAITI IB, 1981, SOMAT CELL GENET, V7, P567, DOI 10.1007/BF01549659
   Manczak M, 2004, NEUROMOL MED, V5, P147, DOI 10.1385/NMM:5:2:147
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Martin GM, 2003, SCIENCE, V299, P1339, DOI 10.1126/science.299.5611.1339
   Martin LJ, 2006, J NEUROSCI, V26, P41, DOI 10.1523/JNEUROSCI.4308-05.2006
   Mathupala SP, 2006, ONCOGENE, V25, P4777, DOI 10.1038/sj.onc.1209603
   McGowan E, 2006, TRENDS GENET, V22, P281, DOI 10.1016/j.tig.2006.03.007
   MELOV S, 1995, NUCLEIC ACIDS RES, V23, P4122, DOI 10.1093/nar/23.20.4122
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   Milakovic T, 2005, J BIOL CHEM, V280, P30773, DOI 10.1074/jbc.M504749200
   MITTELMEIER TM, 1995, MOL CELL BIOL, V15, P780
   MONEGER F, 1994, EMBO J, V13, P8, DOI 10.1002/j.1460-2075.1994.tb06230.x
   MONEGER F, 1992, PLANT PHYSIOL, V99, P396, DOI 10.1104/pp.99.2.396
   MORAES CT, 1991, MOL CELL BIOL, V11, P1631, DOI 10.1128/MCB.11.3.1631
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   MULLERHOCKER J, 1989, AM J PATHOL, V134, P1167
   Nagley Phillip, 1993, P137, V0, P0
   Napoli E, 2006, ANTIOXID REDOX SIGN, V8, P506, DOI 10.1089/ars.2006.8.506
   Nasir J, 1996, HUM MOL GENET, V5, P1431, DOI 10.1093/hmg/5.Supplement_1.1431
   Neuzil J, 2006, FEBS LETT, V580, P5125, DOI 10.1016/j.febslet.2006.05.072
   NEWTON KJ, 1985, P NATL ACAD SCI USA, V82, P6879, DOI 10.1073/pnas.82.20.6879
   Nishimura Y, 2006, P NATL ACAD SCI USA, V103, P1382, DOI 10.1073/pnas.0506911103
   Nishino I, 2001, NEUROMUSCULAR DISORD, V11, P7, DOI 10.1016/S0960-8966(00)00159-0
   NOWELL PC, 1990, AM J CLIN PATHOL, V94, P229, DOI 10.1093/ajcp/94.2.229
   Ogilvie I, 2005, J CLIN INVEST, V115, P2784, DOI 10.1172/JCI26020
   OOSTVEEN FG, 1995, J BIOL CHEM, V270, P26104, DOI 10.1074/jbc.270.44.26104
   PALMER JD, 1988, J MOL EVOL, V28, P87, DOI 10.1007/BF02143500
   Panov A, 2005, J BIOL CHEM, V280, P42026, DOI 10.1074/jbc.M508628200
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Partridge L, 2002, NATURE, V418, P921, DOI 10.1038/418921a
   Pasinelli P, 2004, NEURON, V43, P19, DOI 10.1016/j.neuron.2004.06.021
   Passos JF, 2006, REJUV RES, V9, P64, DOI 10.1089/rej.2006.9.64
   PEARSON HA, 1979, J PEDIATR-US, V95, P976, DOI 10.1016/S0022-3476(79)80286-3
   Petit A, 2005, J BIOL CHEM, V280, P34025, DOI 10.1074/jbc.M505143200
   PIKO L, 1987, DEV BIOL, V123, P364, DOI 10.1016/0012-1606(87)90395-2
   Piper PW, 2006, YEAST, V23, P215, DOI 10.1002/yea.1354
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Potluri P, 2004, EUR J BIOCHEM, V271, P3265, DOI 10.1111/j.1432-1033.2004.04260.x
   POULTON J, 1995, AM J HUM GENET, V57, P224
   Poyau A, 2000, HUM GENET, V106, P194, DOI 10.1007/s004390051028
   Procaccio V, 2004, NEUROLOGY, V62, P1899, DOI 10.1212/01.WNL.0000125251.56131.65
   Puranam KL, 2006, BIOCHEM BIOPH RES CO, V341, P607, DOI 10.1016/j.bbrc.2006.01.007
   Pyle A, 2005, ANN NEUROL, V57, P564, DOI 10.1002/ana.20417
   Racker E, 1976, A NEW LOOK AT MECHANISMS IN BIOENERGETICS, V0, P0
   REILLY JG, 1980, PLASMID, V3, P109, DOI 10.1016/0147-619X(80)90102-X
   Roesch K, 2002, HUM MOL GENET, V11, P477, DOI 10.1093/hmg/11.5.477
   RONNE H, 1995, TRENDS GENET, V11, P12, DOI 10.1016/S0168-9525(00)88980-5
   Rothbauer U, 2001, J BIOL CHEM, V276, P37327, DOI 10.1074/jbc.M105313200
   Rustin P, 2002, BBA-BIOENERGETICS, V1553, P117, DOI 10.1016/S0005-2728(01)00228-6
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Saada-Reisch A, 2004, NUCLEOS NUCLEOT NUCL, V23, P1205, DOI 10.1081/NCN-200027480
   Schapira AHV, 1993, P159, V0, P0
   Schapira AHV, 1997, ANN NEUROL, V41, P141, DOI 10.1002/ana.410410203
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   SCHARDL CL, 1985, CELL, V43, P361, DOI 10.1016/0092-8674(85)90041-8
   Scheffler IE, 1986, CARBOHYDRATE METABOLISM IN CULTURED CELLS, V0, P77
   Scheffler IE, 2004, REDOX GENOME INTERAC, V0, P235
   Scheffler IE, 2004, MED INTELL UNIT, V0, P1
   Scheffler IE, 2004, BBA-BIOENERGETICS, V1659, P160, DOI 10.1016/j.bbabio.2004.08.002
   SCHEFFLER IE, 1974, J CELL PHYSIOL, V83, P219, DOI 10.1002/jcp.1040830208
   Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653
   Schulz TJ, 2006, J BIOL CHEM, V281, P977, DOI 10.1074/jbc.M511064200
   Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630
   Senior K, 2000, MOL MED TODAY, V6, P183, DOI 10.1016/S1357-4310(00)01702-0
   Seong IS, 2005, HUM MOL GENET, V14, P2871, DOI 10.1093/hmg/ddi319
   Seznec H, 2005, HUM MOL GENET, V14, P463, DOI 10.1093/hmg/ddi042
   Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409
   Sherer TB, 2003, J NEUROSCI, V23, P10756, DOI 10.1523/jneurosci.23-34-10756.2003
   SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   SHOFFNER JM, 1992, NEUROLOGY, V42, P2168, DOI 10.1212/WNL.42.11.2168
   Silvestri L, 2005, HUM MOL GENET, V14, P3477, DOI 10.1093/hmg/ddi377
   SIMONETTI S, 1992, BIOCHIM BIOPHYS ACTA, V1180, P113, DOI 10.1016/0925-4439(92)90059-V
   SINGH G, 1989, NEW ENGL J MED, V320, P1300, DOI 10.1056/NEJM198905183202002
   Sligh JE, 2000, P NATL ACAD SCI USA, V97, P14461, DOI 10.1073/pnas.250491597
   SLONIMSKI PP, 1949, ANN I PASTEUR PARIS, V77, P47
   SMART CJ, 1994, PLANT CELL, V6, P811, DOI 10.1105/tpc.6.6.811
   Smeitink JA, 2006, CELL METAB, V3, P9, DOI 10.1016/j.cmet.2005.12.001
   Smeitink JAM, 2004, CURR NEUROVASC RES, V1, P29, DOI 10.2174/1567202043480224
   SODERBERG K, 1979, SOMAT CELL GENET, V5, P225, DOI 10.1007/BF01539163
   SODERBERG KL, 1977, CELL, V10, P697, DOI 10.1016/0092-8674(77)90103-9
   SPASSOVA M, 1994, PLANT MOL BIOL, V26, P1819, DOI 10.1007/BF00019495
   Spelbrink JN, 1998, HUM GENET, V102, P327, DOI 10.1007/s004390050700
   Sun JT, 2002, GENETICS, V161, P661
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Sutovsky P, 2003, MICROSC RES TECHNIQ, V61, P88, DOI 10.1002/jemt.10319
   Sutovsky P, 2004, REPROD BIOMED ONLINE, V8, P24, DOI 10.1016/S1472-6483(10)60495-6
   Sutton HE, 1988, INTRO HUMAN GENETICS, V0, P290
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Terman A, 2006, ANTIOXID REDOX SIGN, V8, P197, DOI 10.1089/ars.2006.8.197
   Thompson WE, 2003, BIOL REPROD, V69, P254, DOI 10.1095/biolreprod.102.010975
   Tiranti V, 1999, HUM MOL GENET, V8, P2533, DOI 10.1093/hmg/8.13.2533
   Touzet P, 2004, TRENDS PLANT SCI, V9, P568, DOI 10.1016/j.tplants.2004.10.001
   TRANEBJAERG L, 1995, J MED GENET, V32, P257, DOI 10.1136/jmg.32.4.257
   Triepels RH, 2001, AM J MED GENET, V106, P37, DOI 10.1002/ajmg.1397
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Trifunovic A, 2006, BBA-BIOENERGETICS, V1757, P611, DOI 10.1016/j.bbabio.2006.03.003
   Trounce IA, 2004, J BIOENERG BIOMEMBR, V36, P421, DOI 10.1023/B:JOBB.0000041778.84464.16
   TRUMBLY RJ, 1992, MOL MICROBIOL, V6, P15, DOI 10.1111/j.1365-2958.1992.tb00832.x
   TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990
   Ugalde C, 2004, HUM MOL GENET, V13, P659, DOI 10.1093/hmg/ddh071
   Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284
   van den Heuvel L, 2001, BIOESSAYS, V23, P518, DOI 10.1002/bies.1071
   van der Westhuizen FH, 2003, NEUROPEDIATRICS, V34, P14, DOI 10.1055/s-2003-38618
   Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239
   Wallace D C, 2001, NOVARTIS FOUND SYMP, V235, P247
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wallace DC, 2003, COLD SPRING HARB SYM, V68, P479
   WALLACE DC, 1995, AM J HUM GENET, V57, P201
   WALLACE DC, 1979, SOMAT CELL GENET, V5, P373, DOI 10.1007/BF01538849
   WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8
   Wallace DC, 1997, P NATL ACAD SCI USA, V94, P14900, DOI 10.1073/pnas.94.26.14900
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   Wallace Douglas C, 1993, P63, V0, P0
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   WARMKE HE, 1978, SCIENCE, V200, P561, DOI 10.1126/science.200.4341.561
   Weber K, 1997, AM J HUM GENET, V60, P373
   Whitfield CD, 1985, MOL CELL GENETICS, V0, P545
   Wickner RB, 1996, ANNU REV GENET, V30, P109, DOI 10.1146/annurev.genet.30.1.109
   Williams EH, 2003, RNA, V9, P419, DOI 10.1261/rna.2182903
   WILLIAMS GT, 1994, BIOCHEM CELL BIOL, V72, P447, DOI 10.1139/o94-059
   Wyllie AH, 1997, EUR J CELL BIOL, V73, P189
   Yan N, 2005, ANNU REV CELL DEV BI, V21, P35, DOI 10.1146/annurev.cellbio.21.012704.131040
   Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386
   YANG X, 1993, MOL GEN GENET, V237, P177, DOI 10.1007/BF00282799
   ZENKE FT, 1993, MOL CELL BIOL, V13, P7566, DOI 10.1128/MCB.13.12.7566
   Zhao H, 2005, NUCLEIC ACIDS RES, V33, P1132, DOI 10.1093/nar/gki262
   Zhu XW, 2005, MOL NEUROBIOL, V31, P205, DOI 10.1385/MN:31:1-3:205
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
NR 298
TC 0
Z9 0
U1 0
U2 3
PU BLACKWELL SCIENCE PUBL
PI OXFORD
PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND
SN 
EI 
J9 
PD JUN 15
PY 2008
VL 0
IS 
BP 345
EP 416
DI 
PG 72
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA BFS73
UT WOS:000321183700009
DA 2024-11-01
ER

PT J
AU Santos, C
   Montiel, R
   Arruda, A
   Alvarez, L
   Aluja, MP
   Lima, M
AF Santos, Cristina
   Montiel, Rafael
   Arruda, Adriana
   Alvarez, Luis
   Aluja, Maria Pilar
   Lima, Manuela
TI Mutation patterns of mtDNA: Empirical inferences for the coding region
SO BMC EVOLUTIONARY BIOLOGY
LA English
DT Article
ID mitochondrial genome variation; maternally inherited myopathy; deleterious mutations; background selection; sequence divergence; adaptive selection; substitution rates; time dependency; dna; evolution
AB Background: Human mitochondrial DNA (mtDNA) has been extensively used in population and evolutionary genetics studies. Thus, a valid estimate of human mtDNA evolutionary rate is important in many research fields. The small number of estimations performed for the coding region of the molecule, showed important differences between phylogenetic and empirical approaches. We analyzed a portion of the coding region of mtDNA (tRNA(Leu), NDI and tRNA(Ile) genes), using individuals belonging to extended families from the Azores Islands (Portugal) with the main aim of providing empirical estimations of the mutation rate of the coding region of mtDNA under different assumptions, and hence to better understand the mtDNA evolutionary process. Results: Heteroplasmy was detected in 6.5% (3/46) of the families analyzed. In all of the families the presence of mtDNA heteroplasmy resulted from three new point mutations, and no cases of insertions or deletions were identified. Major differences were found in the proportion and type of heteroplasmy found in the genes studied when compared to those obtained in a previous report for the D-loop. Our empirical estimation of mtDNA coding region mutation rate, calculated taking into account the sex of individuals carrying new mutations, the probability of intra-individual fixation of mutations present in heteroplasmy and, to the possible extent, the effect of selection, is similar to that obtained using phylogenetic approaches. Conclusion: Based on our results, the discrepancy previously reported between the human mtDNA coding region mutation rates observed along evolutionary timescales and estimations obtained using family pedigrees can be resolved when correcting for the previously cited factors.
C1 [Santos, Cristina; Montiel, Rafael; Arruda, Adriana; Lima, Manuela] Univ Azores, CIRN, Azores, Portugal.
   [Santos, Cristina; Alvarez, Luis; Aluja, Maria Pilar] Autonomous Univ Barcelona, Fac Sci, Dept BABVE, Biol Anthropol Unit, Bellaterra 08193, Spain.
C3 Universidade dos Acores; Autonomous University of Barcelona
RP Santos, C (corresponding author), Univ Azores, CIRN, 9500 Ponta Delgada, Azores, Portugal.
EM cristina.santos@uab.es; montiel@notes.uac.pt; aarruda@linus.uac.pt; Luis.Alvarez@uab.es; mariapilar.aluja@uab.es; mlima@notes.uac.pt
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Arnason U, 1996, J MOL EVOL, V43, P650, DOI 10.1007/BF02202113
   ATTARDI G, 1986, BIOESSAYS, V5, P34, DOI 10.1002/bies.950050111
   Ballard JWO, 2005, ANNU REV ECOL EVOL S, V36, P621, DOI 10.1146/annurev.ecolsys.36.091704.175513
   Bergstrom CT, 1998, GENETICS, V149, P2135
   BROWN WM, 1980, P NATL ACAD SCI-BIOL, V77, P3605, DOI 10.1073/pnas.77.6.3605
   CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0
   Cavelier L, 2000, HUM GENET, V107, P45, DOI 10.1007/s004390050009
   CHARLESWORTH B, 1994, GENET RES, V63, P213, DOI 10.1017/S0016672300032365
   CHARLESWORTH B, 1993, GENETICS, V134, P1289
   CHARLESWORTH D, 1995, GENETICS, V141, P1619
   Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101
   Denver DR, 2000, SCIENCE, V289, P2342, DOI 10.1126/science.289.5488.2342
   Emerson BC, 2007, SYST BIOL, V56, P337, DOI 10.1080/10635150701258795
   Hagelberg E, 2003, TRENDS GENET, V19, P84, DOI 10.1016/S0168-9525(02)00048-3
   Hall TA, 1999, NUCL ACIDS S SERIES, V41, P95, DOI 10.14344/IOC.ML.11.1
   HASEGAWA M, 1991, J MOL EVOL, V32, P37, DOI 10.1007/BF02099927
   HAUSWIRTH WW, 1985, NUCLEIC ACIDS RES, V13, P8093, DOI 10.1093/nar/13.22.8093
   HAUSWIRTH WW, 1984, CELL, V37, P1001, DOI 10.1016/0092-8674(84)90434-3
   Heyer E, 2001, AM J HUM GENET, V69, P1113, DOI 10.1086/324024
   Ho SYW, 2007, SYST BIOL, V56, P515, DOI 10.1080/10635150701435401
   Ho SYW, 2005, MOL BIOL EVOL, V22, P1561, DOI 10.1093/molbev/msi145
   HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532
   Howell N, 1996, AM J HUM GENET, V59, P501
   Howell N, 2003, AM J HUM GENET, V72, P659, DOI 10.1086/368264
   Ingman M, 2003, GENOME RES, V13, P1600, DOI 10.1101/gr.686603
   Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064
   Kivisild T, 2006, GENETICS, V172, P373, DOI 10.1534/genetics.105.043901
   Lee HY, 2004, ELECTROPHORESIS, V25, P28, DOI 10.1002/elps.200305681
   LUNDSTROM R, 1992, P NATL ACAD SCI USA, V89, P5961, DOI 10.1073/pnas.89.13.5961
   Macaulay VA, 1997, AM J HUM GENET, V61, P983
   MARIOTTI C, 1994, J CLIN INVEST, V93, P1102, DOI 10.1172/JCI117061
   Maynard-Smith J, 1974, GENET RES, V23, P23, DOI 10.1017/S0016672308009579
   MILLER WG, 2003, OPENSTAT2 OS2 VERSIO, V0, P0
   Mishmar D, 2003, P NATL ACAD SCI USA, V100, P171, DOI 10.1073/pnas.0136972100
   Nachman MW, 1998, GENETICA, V102-3, P61, DOI 10.1023/A:1017030708374
   OBAYASHI T, 1992, AM HEART J, V124, P1263, DOI 10.1016/0002-8703(92)90410-W
   OHTA T, 1973, NATURE, V246, P96, DOI 10.1038/246096a0
   OHTA T, 1972, J MOL EVOL, V1, P305, DOI 10.1007/BF01653959
   Paabo S, 1996, AM J HUM GENET, V59, P493
   Parsons TJ, 1997, NAT GENET, V15, P363, DOI 10.1038/ng0497-363
   PESOLE G, 1992, MOL BIOL EVOL, V9, P587
   Rand DM, 1998, GENETICA, V102-3, P393, DOI 10.1023/A:1017006118852
   Rand DM, 2001, ANNU REV ECOL SYST, V32, P415, DOI 10.1146/annurev.ecolsys.32.081501.114109
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, PD823, DOI 10.1093/nar/gkl927
   Ruiz-Pesini E, 2006, HUM MUTAT, V27, P1072, DOI 10.1002/humu.20378
   Santos C, 2005, MOL BIOL EVOL, V22, P1490, DOI 10.1093/molbev/msi141
   Siguroardóttir S, 2000, AM J HUM GENET, V66, P1599, DOI 10.1086/302902
   Soodyall H, 1997, AM J PHYS ANTHROPOL, V104, P157, DOI 10.1002/(SICI)1096-8644(199710)104:2<157::AID-AJPA2>3.0.CO;2-W
   STONEKING M, 1992, PHILOS T ROY SOC B, V337, P167, DOI 10.1098/rstb.1992.0094
   STONEKING M, 1986, COLD SPRING HARB SYM, V51, P433, DOI 10.1101/SQB.1986.051.01.052
   TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023
   Tanaka M, 2004, GENOME RES, V14, P1832, DOI 10.1101/gr.2286304
   TORRONI A, 1994, AM J HUM GENET, V54, P303
   Trejaut JA, 2005, PLOS BIOL, V3, P1362, DOI 10.1371/journal.pbio.0030247
   Pellekaan SMV, 2006, AM J PHYS ANTHROPOL, V131, P282, DOI 10.1002/ajpa.20426
   VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702
   Wallace DC, 2003, COLD SPRING HARB SYM, V68, P479
   ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D
NR 60
TC 21
Z9 22
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2148
EI 
J9 BMC EVOL BIOL
JI BMC Evol. Biol.
PD JUN 2
PY 2008
VL 8
IS 
BP 
EP 
DI 10.1186/1471-2148-8-167
PG 12
WC Evolutionary Biology; Genetics & Heredity
SC Evolutionary Biology; Genetics & Heredity
GA 323QQ
UT WOS:000257462900001
PM 18518963
DA 2024-11-01
ER

PT J
AU de Cavanagh, EMV
   Flores, I
   Ferder, M
   Inserra, F
   Ferder, L
AF de Cavanagh, Elena M. V.
   Flores, Idhaliz
   Ferder, Marcelo
   Inserra, Felipe
   Ferder, Leon
TI Renin-angiotensin system inhibitors protect against age-related changes in rat liver mitochondrial DNA content and gene expression
SO EXPERIMENTAL GERONTOLOGY
LA English
DT Article
DE Aging; Mitochondria DNA; Reactive oxygen species; Gene expression; Anti-aging; Antioxidant
ID ii receptor subtypes; nitric-oxide synthase; mtdna copy number; dietary restriction; energy-metabolism; skeletal-muscles; senescent rats; ace-inhibitors; nadph oxidase; aging process
AB Chronic renin-angiotensin system inhibition protects against liver fibrosis, ameliorates age-associated mitochondrial dysfunction and increases rodent lifespan. We hypothesized that life-long angiotensin-II-mediated stimulation of oxidant generation might participate in mitochondrial DNA "common deletion" formation, and the resulting impairment of bioenergetic capacity. Enalapril (10 mg/kg/d) or losartan (30 mg/kg/d) administered during 16.5 months were unable to prevent the age-dependent accumulation of rat liver mitochondrial DNA "common deletion", but attenuated the decrease of mitochondrial DNA content. This evidence - together with the enhancement of NRF-1 and PGC-1 mRNA contents - seems to explain why enalapril and losartan improved mitochondrial functioning and lowered oxidant production, since both the absolute number of mtDNA molecules and increased NRF-1 and PGC-1 transcription are positively related to mitochondrial respiratory capacity, and PGC-1 protects against increases in ROS production and damage. Oxidative stress evoked by abnormal respiratory function contributes to the pathophysiology of mitochondrial disease and human aging. If the present mitochondrial actions of renin-angiotensin system inhibitors are confirmed in humans they may modify the therapeutic significance of that strategy. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Ferder, Leon] Ponce Sch Med, Dept Physiol & Pharmacol, Ponce, PR 00732 USA.
   [de Cavanagh, Elena M. V.; Ferder, Marcelo; Inserra, Felipe] Univ Buenos Aires, Sch Med, Inst Cardiovasc Pathophysiol INFICA, RA-1122 Buenos Aires, DF, Argentina.
   [Flores, Idhaliz] Ponce Sch Med, Dept Microbiol, Ponce, PR 00716 USA.
C3 Instituto Cardiovascular de Buenos Aires (ICBA); University of Buenos Aires
RP Ferder, L (corresponding author), Ponce Sch Med, Dept Physiol & Pharmacol, POB 7004, Ponce, PR 00732 USA.
EM leferder@psm.edu
FU NIH/NCRR/RCMI [G12RR03050]
CR Barazzoni R, 2000, J BIOL CHEM, V275, P3343, DOI 10.1074/jbc.275.5.3343
   Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   BAUMER A, 1994, AM J HUM GENET, V54, P618
   BELMIN J, 1994, DRUG AGING, V5, P391, DOI 10.2165/00002512-199405050-00007
   Bentlage HACM, 1996, HUM MOL GENET, V5, P197, DOI 10.1093/hmg/5.2.197
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brandes RP, 2005, CARDIOVASC RES, V66, P286, DOI 10.1016/j.cardiores.2004.12.027
   Brookes PS, 2004, MITOCHONDRION, V3, P187, DOI 10.1016/j.mito.2003.10.001
   Casademont Jordi, 2002, HEART FAIL REV, V7, P131, DOI 10.1023/A:1015372407647
   Cassano P, 2004, ANN NY ACAD SCI, V1019, P269, DOI 10.1196/annals.1297.045
   Chan H, 2007, CLIN EXP PHARMACOL P, V34, P985, DOI 10.1111/j.1440-1681.2007.04669.x
   Czubryt MP, 2003, P NATL ACAD SCI USA, V100, P1711, DOI 10.1073/pnas.0337639100
   de Cavanagh EMV, 2003, FASEB J, V17, P1096, DOI 10.1096/fj.02-0063fje
   Doughan AK, 2008, CIRC RES, V102, P488, DOI 10.1161/CIRCRESAHA.107.162800
   Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109
   Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200
   ENESCO HE, 1983, EXP GERONTOL, V18, P79, DOI 10.1016/0531-5565(83)90054-2
   Ernsberger P, 2007, CURR OPIN PHARMACOL, V7, P140, DOI 10.1016/j.coph.2006.11.008
   Estabrook RW, 1974, METHODS ENZYMOLOGY, V10, P41
   FERDER L, 1993, AM J PHYSIOL, V265, PC15, DOI 10.1152/ajpcell.1993.265.1.C15
   Ferder LF, 2002, CURR OPIN PHARMACOL, V2, P189, DOI 10.1016/S1471-4892(02)00139-X
   Fernández-Alfonso MS, 1999, J HYPERTENS, V17, P1355, DOI 10.1097/00004872-199917100-00001
   Finck BN, 2006, J CLIN INVEST, V116, P615, DOI 10.1172/JCI27794
   FLOHE L, 1984, METHOD ENZYMOL, V105, P93
   GADALETA MN, 1992, MUTAT RES, V275, P181, DOI 10.1016/0921-8734(92)90022-H
   Garnier A, 2003, J PHYSIOL-LONDON, V551, P491, DOI 10.1113/jphysiol.2003.045104
   Ghafourifar P, 2005, TRENDS PHARMACOL SCI, V26, P190, DOI 10.1016/j.tips.2005.02.005
   Halle JP, 1997, EUR J CELL BIOL, V74, P281
   HEYMES C, 1994, CIRCULATION, V90, P1328, DOI 10.1161/01.CIR.90.3.1328
   Heymes C, 1998, ENDOCRINOLOGY, V139, P2579, DOI 10.1210/en.139.5.2579
   Huang SZ, 2005, WORLD J GASTROENTERO, V11, P132, DOI 10.3748/wjg.v11.i1.132
   Janke J, 2006, J HYPERTENS, V24, P1809, DOI 10.1097/01.hjh.0000242405.68461.84
   JONES OTG, 1994, METHOD ENZYMOL, V233, P222
   Kang CM, 1998, FREE RADICAL BIO MED, V24, P148, DOI 10.1016/S0891-5849(97)00204-9
   Kimura S, 2005, HYPERTENSION, V45, P438, DOI 10.1161/01.HYP.0000157169.27818.ae
   KITAMI Y, 1992, BIOCHEM BIOPH RES CO, V188, P446, DOI 10.1016/0006-291X(92)92405-M
   Knowles RG, 1998, METH MOL B, V100, P67
   Krishnan KJ, 2007, ANN NY ACAD SCI, V1100, P227, DOI 10.1196/annals.1395.024
   Lanni A, 1996, INT J BIOCHEM CELL B, V28, P337, DOI 10.1016/1357-2725(95)00137-9
   Larkin JE, 2004, PHYSIOL GENOMICS, V18, P152, DOI 10.1152/physiolgenomics.00057.2004
   LEZZA AMS, 1994, BIOCHEM BIOPH RES CO, V205, P772, DOI 10.1006/bbrc.1994.2732
   Li JM, 2003, J BIOL CHEM, V278, P12094, DOI 10.1074/jbc.M209793200
   LLORENSCORTES C, 1994, HYPERTENSION, V24, P538, DOI 10.1161/01.HYP.24.5.538
   Miquel J, 1998, EXP GERONTOL, V33, P113, DOI 10.1016/S0531-5565(97)00060-0
   Mollnau H, 2002, CIRC RES, V90, PE58, DOI 10.1161/01.RES.0000012569.55432.02
   Moraes CT, 2001, TRENDS GENET, V17, P199, DOI 10.1016/S0168-9525(01)02238-7
   Münzel T, 2001, CIRCULATION, V104, P1571, DOI 10.1161/hc3801.095585
   Nakada K, 2002, MITOCHONDRION, V2, P59, DOI 10.1016/S1567-7249(02)00007-7
   Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976
   Nakashima Hidekatsu, 2006, CURRENT VASCULAR PHARMACOLOGY, V4, P67, DOI 10.2174/157016106775203126
   Navarro A, 2007, AM J PHYSIOL-CELL PH, V292, PC670, DOI 10.1152/ajpcell.00213.2006
   Nicklas JA, 2004, ENVIRON MOL MUTAGEN, V44, P313, DOI 10.1002/em.20050
   Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368
   Nisoli E, 2004, P NATL ACAD SCI USA, V101, P16507, DOI 10.1073/pnas.0405432101
   OZAWA T, 1995, BBA-MOL BASIS DIS, V1271, P177, DOI 10.1016/0925-4439(95)00026-Z
   OZAWA T, 1999, OXIDATIVE DAMAGE FRA, V0, P0
   Phadnis N, 2005, GENETICS, V171, P1549, DOI 10.1534/genetics.105.047092
   Piotrkowski B, 2007, AM J PHYSIOL-REG I, V292, PR1494, DOI 10.1152/ajpregu.00540.2006
   Ramanujan VK, 2007, J BIOL CHEM, V282, P19217, DOI 10.1074/jbc.M700572200
   SANBE A, 1995, J MOL CELL CARDIOL, V27, P2209, DOI 10.1016/S0022-2828(95)91551-6
   Scarpulla RC, 1997, J BIOENERG BIOMEMBR, V29, P109, DOI 10.1023/A:1022681828846
   Sechi LA, 1996, HYPERTENSION, V28, P403, DOI 10.1161/01.HYP.28.3.403
   Sersté T, 2006, ACTA GASTRO-ENT BELG, V69, P296
   Sorescu Dan, 2002, CONGEST HEART FAIL, V8, P132, DOI 10.1111/j.1527-5299.2002.00717.x
   SPETH RC, 1990, BIOCHEM BIOPH RES CO, V169, P997, DOI 10.1016/0006-291X(90)91993-3
   Spiegelman BM, 2007, NOVARTIS FDN S, V286, P6
   Spiegelman BM, 2007, NOVARTIS FDN S, V286, P196
   Spiegelman BM, 2007, NOVARTIS FDN S, V286, P162
   Spiegelman Bruce M, 2007, NOVARTIS FOUND SYMP, V286, P3
   Srivastava S, 2005, HUM MOL GENET, V14, P893, DOI 10.1093/hmg/ddi082
   Strazzullo P, 2004, CURR OPIN NEPHROL HY, V13, P325, DOI 10.1097/00041552-200405000-00010
   Thompson MM, 2000, AM J PHYSIOL-REG I, V279, PR1787, DOI 10.1152/ajpregu.2000.279.5.R1787
   Toblli JE, 2002, J NEPHROL, V15, P358
   VINCENT M, 1976, CLIN SCI MOL MED, V50, P103, DOI 10.1042/cs0500103
   Wei Y H, 2001, ZHONGHUA YI XUE ZA ZHI (TAIPEI), V64, P259
   Yoshiji H, 2007, J GASTROEN HEPATOL, V22, PS93, DOI 10.1111/j.1440-1746.2006.04663.x
   Yowe DL, 1998, GENE, V209, P23, DOI 10.1016/S0378-1119(97)00628-8
   Zeviani M, 2005, J INHERIT METAB DIS, V28, P287, DOI 10.1007/s10545-005-0307-3
NR 78
TC 27
Z9 28
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0531-5565
EI 1873-6815
J9 EXP GERONTOL
JI Exp. Gerontol.
PD OCT 15
PY 2008
VL 43
IS 10
BP 919
EP 928
DI 10.1016/j.exger.2008.08.007
PG 10
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 373DN
UT WOS:000260951300006
PM 18765277
DA 2024-11-01
ER

PT J
AU Vermulst, M
   Bielas, JH
   Loeb, LA
AF Vermulst, Marc
   Bielas, Jason H.
   Loeb, Lawrence A.
TI Quantification of random mutations in the mitochondrial genome
SO METHODS
LA English
DT Article
DE Mitochondria; Mitochondrial DNA; Random mutations; Mutagenesis; qPCR; Mutation detection
ID point mutations; dna deletions
AB Mitochondrial DNA (mtDNA) mutations contribute to the pathology of a number of age-related disorders, including Parkinson disease [A. Bender et aL, Nat. Genet. 38 (2006) 515,Y. Kraytsberg et al., Nat. Genet. 38 (2006) 5181, muscle-wasting [J. Wanagat, Z. Cao, P. Pathare, J.M. Aiken, FASEB J. 15 (2001) 3221, and the metastatic potential of cancers [K. Ishikawa et al., Science 320 (2008) 661]. The impact of mitochondrial DNA mutations on a wide variety of human diseases has made it increasingly important to understand the mechanisms that drive mitochondrial mutagenesis. In order to provide new insight into the etiology and natural history of mtDNA mutations, we have developed an assay that can detect mitochondrial mutations in a variety of tissues and experimental settings [M. Vermulst et al., Nat. Genet. 40 (2008) 4. M. Vermulst et al., Nat. Genet. 39 (2007) 540). This methodology, termed the Random Mutation Capture assay, relies on single-molecule amplification to detect rare mutations among millions of wild-type bases U.H. Bielas, L.A. Loeb, Nat. Methods 2 (2005) 2851, and can be used to analyze mitochondrial mutagenesis to a single base pair level in mammals. Published by Elsevier Inc.
C1 [Vermulst, Marc] CALTECH, Dept Biol, Pasadena, CA 91125 USA.
   [Bielas, Jason H.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA.
   [Loeb, Lawrence A.] Univ Washington, Dept Pathol, UW Med Sch, Seattle, WA 98195 USA.
C3 California Institute of Technology; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle
RP Vermulst, M (corresponding author), CALTECH, Dept Biol, 1200 E Calif Blvd,MC114-96, Pasadena, CA 91125 USA.
EM vermulst@caltech.edu; laloeb@u.washington.edu
FU NCI NIH HHS [R01 CA102029-06, R01 CA102029] Funding Source: Medline; NIA NIH HHS [P01 AG001751-270007, P01 AG001751] Funding Source: Medline
CR AUSUBEL FM, 2002, CURRENT PROTOCOLS MO, V1, P0
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Bielas JH, 2005, NAT METHODS, V2, P285, DOI 10.1038/NMETH751
   Fernández-Vizarra E, 2002, METHODS, V26, P292, DOI 10.1016/S1046-2023(02)00034-8
   Garcia Ana Maria, 2007, METHODS MOL BIOL, V371, P267
   Hendricks CA, 2003, P NATL ACAD SCI USA, V100, P6325, DOI 10.1073/pnas.1232231100
   Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906
   Jacobs HT, 2003, AGING CELL, V2, P11, DOI 10.1046/j.1474-9728.2003.00032.x
   Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Kraytsberg Y, 2005, EXPERT REV MOL DIAGN, V5, P809, DOI 10.1586/14737159.5.5.809
   Lin MT, 2002, HUM MOL GENET, V11, P133, DOI 10.1093/hmg/11.2.133
   Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497
   MONNAT RJ, 1985, P NATL ACAD SCI USA, V82, P2895, DOI 10.1073/pnas.82.9.2895
   Parsons BL, 1997, MUTAT RES-REV MUTAT, V387, P97, DOI 10.1016/S1383-5742(97)00026-4
   Vermulst M, 2008, NAT GENET, V40, P392, DOI 10.1038/ng.95
   Vermulst M, 2007, NAT GENET, V39, P540, DOI 10.1038/ng1988
   Weinstock DM, 2006, DNA REPAIR, V5, P1065, DOI 10.1016/j.dnarep.2006.05.028
   Yoon YG, 2003, NUCLEIC ACIDS RES, V31, P1407, DOI 10.1093/nar/gkg228
   Zhang DK, 2000, GENOMICS, V69, P151, DOI 10.1006/geno.2000.6333
NR 20
TC 55
Z9 70
U1 0
U2 12
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1046-2023
EI 1095-9130
J9 METHODS
JI Methods
PD DEC 15
PY 2008
VL 46
IS 4
BP 263
EP 268
DI 10.1016/j.ymeth.2008.10.008
PG 6
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 383AT
UT WOS:000261647200005
PM 18948200
DA 2024-11-01
ER

PT J
AU Adjadj, E
   Mansouri, K
   Borruat, FX
AF Adjadj, E.
   Mansouri, K.
   Borruat, F. -X.
TI Mitochondrial DNA (mtDNA) A3243G mutation associated with an annular perimacular retinal atrophy
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Article; Proceedings Paper
DE MtDNA; point mutation 3243; macular atrophy
ID pigmentary retinopathy; melas; deafness; inheritance; prevalence; dystrophy
AB Background: A point mutation at the locus 3243 of the mitonchondrial DNA (mtDNA) is associated with either the MIDD syndrome (maternally inherited diabetes, deafness), the MELAS syndrome (myopathy, encephalitis, lactic acidosis, stroke) or cardiac, digestive, endocrine or exocrine dysfunctions. We report a peculiar maculopathy in two patients with an mtDNA 3243 mutation. History and Signs: Case 1: A visually asymptomatic 40-year-old woman was examined for screening of diabetic retinopathy. Visual acuity was 10/10 in both eyes. Case 2: A54-year-old woman with deafness and diabetes complained of visual loss. Visual acuity was 6/10 for the right eye and 0.5/10 for the left eye. Both patients exhibited a chorioretinal areolar atrophy. Case 1 was followed over 15 years and exhibited a slow progression of the maculopathy with moderate loss of visual acuity to 6/10 in both eyes, but marked handicap from the annular scotoma. Therapy and Outcome: None. Conclusion: Both patients presented a perimacular annular retinal atrophy. Patients harbouring mtDNA 3243 mutation should be examined for the presence of a maculopathy, even if they are asymptomatic. Conversely, the finding of such a geographic maculopathy should suggest the possibility of a point mutation at the locus 3243 of the mitochondrial DNA, especially in the presences of diabetes mellitus and/or deafness.
C1 [Borruat, F. -X.] Hop Ophtalm Jules Gonin, Unite Neuroophtalmol, CH-1004 Lausanne, Switzerland.
RP Borruat, FX (corresponding author), Hop Ophtalm Jules Gonin, Unite Neuroophtalmol, Ave France 15, CH-1004 Lausanne, Switzerland.
EM francois.borruat@ophtal.vd.ch
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   EGGER J, 1983, NEW ENGL J MED, V309, P142, DOI 10.1056/NEJM198307213090304
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Guillausseau PJ, 2001, ANN INTERN MED, V134, P721, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00008
   Latkany P, 1999, AM J OPHTHALMOL, V128, P112, DOI 10.1016/S0002-9394(99)00057-4
   Latvala T, 2002, GRAEF ARCH CLIN EXP, V240, P795, DOI 10.1007/s00417-002-0555-y
   Manwaring N, 2007, MITOCHONDRION, V7, P230, DOI 10.1016/j.mito.2006.12.004
   Massin P, 1999, OPHTHALMOLOGY, V106, P1821, DOI 10.1016/S0161-6420(99)90356-1
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   SILVESTREAILLAUD P, 1995, DIABETOLOGIA, V38, P1485
   Smith PR, 1999, OPHTHALMOLOGY, V106, P1101, DOI 10.1016/S0161-6420(99)90244-0
   Sue CM, 1997, NEUROLOGY, V49, P1013, DOI 10.1212/WNL.49.4.1013
   Suzuki S, 1998, DIABETOLOGIA, V41, P584, DOI 10.1007/s001250050950
   Takeshima T, 2005, INTERNAL MED, V44, P276, DOI 10.2169/internalmedicine.44.276
NR 14
TC 8
Z9 10
U1 0
U2 2
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD MAY 15
PY 2008
VL 225
IS 5
BP 462
EP 464
DI 10.1055/s-2008-1027257
PG 3
WC Ophthalmology
SC Ophthalmology
GA 306GZ
UT WOS:000256237600037
PM 18454399
DA 2024-11-01
ER

PT J
AU Chawla, S
   Coku, J
   Forbes, T
   Kannan, S
AF Chawla, Sanjay
   Coku, Jorida
   Forbes, Thomas
   Kannan, Sujatha
TI Kearns-Sayre syndrome presenting as complete heart block
SO PEDIATRIC CARDIOLOGY
LA English
DT Article
DE Kearns-Sayre syndrome; mitochondrial disorder; heart block
ID mitochondrial-dna deletions; progressive external ophthalmoplegia
AB Kearns-Sayre syndrome (KSS) is a rare mitochondrial disorder characterized by large-scale deletions of mitochondrial DNA. Neuromuscular and cardiac conduction systems are most commonly involved in these patients. Here, we discuss a 10-year-old patient with diabetes mellitus who presented in complete heart block leading to the diagnosis of KSS. The cardiovascular complications of this syndrome are reviewed and discussed.
C1 [Chawla, Sanjay; Forbes, Thomas; Kannan, Sujatha] Childrens Hosp Michigan, Detroit, MI 48201 USA.
   [Coku, Jorida] Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
C3 Children's Hospital of Michigan; Columbia University
RP Kannan, S (corresponding author), Childrens Hosp Michigan, 3901 Beaubien Blvd, Detroit, MI 48201 USA.
EM skannan@med.wayne.edu
CR ANAN R, 1995, CIRCULATION, V91, P955, DOI 10.1161/01.CIR.91.4.955
   BERENBERG RA, 1977, ANN NEUROL, V1, P37, DOI 10.1002/ana.410010104
   Gregoratos Gabriel, 2002, CIRCULATION, V106, P2145, DOI 10.1161/01.CIR.0000035996.46455.09
   HARVEY JN, 1992, CLIN ENDOCRINOL, V37, P97, DOI 10.1111/j.1365-2265.1992.tb02289.x
   Karanikis P, 2005, INT J CARDIOL, V101, P147, DOI 10.1016/j.ijcard.2004.01.027
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1992, NAT GENET, V1, P359, DOI 10.1038/ng0892-359
   PAVLAKIS SG, 1988, ADV CONT NEUROLOGY, V0, P95
   ROBERTS NK, 1979, AM J CARDIOL, V44, P1396, DOI 10.1016/0002-9149(79)90459-4
   SHANSKE S, 1990, NEUROLOGY, V40, P24, DOI 10.1212/WNL.40.1.24
   Young TJ, 2005, PACE, V28, P454, DOI 10.1111/j.1540-8159.2005.40049.x
NR 12
TC 16
Z9 19
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0172-0643
EI 
J9 PEDIATR CARDIOL
JI Pediatr. Cardiol.
PD MAY 15
PY 2008
VL 29
IS 3
BP 659
EP 662
DI 10.1007/s00246-007-9040-z
PG 4
WC Cardiac & Cardiovascular Systems; Pediatrics
SC Cardiovascular System & Cardiology; Pediatrics
GA 299KI
UT WOS:000255754100032
PM 17763890
DA 2024-11-01
ER

PT J
AU Hirt, L
AF Hirt, Lorenz
TI MELAS AND OTHER MITOCHONDRIAL DISORDERS
SO UNCOMMON CAUSES OF STROKE, 2ND EDITION
LA English
DT Article; Book Chapter
ID stroke-like episodes; lactic-acidosis; point mutation; diabetes-mellitus; dna 3243; myopathy; encephalopathy; gene; encephalomyopathy; features
C1 CHU Vaudois, Neurol Serv, CH-1011 Lausanne, Switzerland.
C3 University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)
RP Hirt, L (corresponding author), CHU Vaudois, Neurol Serv, CH-1011 Lausanne, Switzerland.
CR Abe K, 1999, J NEUROL SCI, V162, P65, DOI 10.1016/S0022-510X(98)00296-2
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   BOGOUSSLAVSKY J, 1982, J NEUROL SCI, V55, P351, DOI 10.1016/0022-510X(82)90132-0
   BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144
   Brandon MC, 2005, NUCLEIC ACIDS RES, V33, P0
   Campos Y, 1997, BIOCHEM BIOPH RES CO, V238, P323, DOI 10.1006/bbrc.1997.7166
   Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010
   DAMIAN MS, 1995, ACTA NEUROL SCAND, V92, P409
   DiMauro S, 1999, ANN NEUROL, V45, P693, DOI 10.1002/1531-8249(199906)45:6<693::AID-ANA2>3.0.CO;2-#
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008
   FOLGERO T, 1995, EUR NEUROL, V35, P168, DOI 10.1159/000117115
   GERBITZ KD, 1995, BBA-MOL BASIS DIS, V1271, P253, DOI 10.1016/0925-4439(95)00036-4
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Haas R, 2004, MITOCHONDRION, V4, P471, DOI 10.1016/j.mito.2004.07.008
   HESS J, 1995, LANCET, V346, P189, DOI 10.1016/S0140-6736(95)91251-7
   Hirt L, 2001, J NEUROL, V248, P332, DOI 10.1007/s004150170211
   Hirt L, 1996, J NEUROL NEUROSUR PS, V61, P422, DOI 10.1136/jnnp.61.4.422
   KURIYAMA M, 1984, NEUROLOGY, V34, P72, DOI 10.1212/WNL.34.1.72
   LERTRIT P, 1992, AM J HUM GENET, V51, P457
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Majamaa K, 1997, MOL CELL BIOCHEM, V174, P291, DOI 10.1023/A:1006833200371
   MANFREDI G, 1995, NEUROMUSCULAR DISORD, V5, P391, DOI 10.1016/0960-8966(94)00079-O
   MORGANHUGHES JA, 1995, BBA-MOL BASIS DIS, V1271, P135, DOI 10.1016/0925-4439(95)00020-5
   NAKAMURA M, 1995, BIOCHEM BIOPH RES CO, V214, P86, DOI 10.1006/bbrc.1995.2260
   Nishino I, 1996, MUSCLE NERVE, V19, P1603, DOI 10.1002/(SICI)1097-4598(199612)19:12<1603::AID-MUS10>3.0.CO;2-S
   Pavlakis SG, 1998, ARCH NEUROL-CHICAGO, V55, P849, DOI 10.1001/archneur.55.6.849
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3
   Saitoh S, 1998, NEUROLOGY, V50, P531, DOI 10.1212/WNL.50.2.531
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   SKOGLUND RR, 1979, NEUROLOGY, V29, P717, DOI 10.1212/WNL.29.5.717
   Sue CM, 1998, J NEUROL NEUROSUR PS, V65, P233, DOI 10.1136/jnnp.65.2.233
   Sue CM, 1997, NEUROLOGY, V49, P1013, DOI 10.1212/WNL.49.4.1013
   Sue CM, 1999, J PEDIATR-US, V134, P696, DOI 10.1016/S0022-3476(99)70283-0
   Tanaka J, 1997, BRAIN DEV-JPN, V19, P262, DOI 10.1016/S0387-7604(97)00573-1
   Triepels RH, 1999, ANN NEUROL, V45, P787, DOI 10.1002/1531-8249(199906)45:6<787::AID-ANA13>3.0.CO;2-6
   Uziel G, 1997, J NEUROL NEUROSUR PS, V63, P16, DOI 10.1136/jnnp.63.1.16
   Zeviani Massimo, 1993, EUROPEAN JOURNAL OF HUMAN GENETICS, V1, P80
   ZUPANC ML, 1991, ANN NEUROL, V29, P680, DOI 10.1002/ana.410290619
NR 41
TC 0
Z9 0
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND
SN 
EI 
J9 
PD JUN 15
PY 2008
VL 0
IS 
BP 149
EP 153
DI 10.1017/CBO9780511544897.025
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA BDP59
UT WOS:000314314600025
DA 2024-11-01
ER

PT J
AU Eriksson, S
   Wang, L
AF Eriksson, Staffan
   Wang, Liya
TI Molecular mechanisms of mitochondrial DNA depletion diseases caused by deficiencies in enzymes in purine and pyrimidine metabolism
SO NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
LA English
DT Article; Proceedings Paper
DE mitochondrial DNA depletion syndrome; thymidine kinase2; deoxyguanosine kinase; mtDNA synthesis
ID thymidine kinase 2; cellular deoxyribonucleoside kinases; deoxyguanosine kinase; ribonucleotide reductase; kinetic-property; mtdna depletion; alpers-syndrome; polg mutations; gene; expression
AB Mitochondrial DNA depletion syndrome (MDS), a reduction of mitochondrial DNA copy number, often affects muscle or liver. Mutations in enzymes of deoxyribonucleotide metabolism give MDS, for example, the mitochondrial thymidine kinase 2 (TK2) and deoxyguanosine kinase (dGK) genes. Sixteen TK2 and 22 dGK alterations are known. Their characteristics and symptoms are described. Levels of five key deoxynucleotide metabolizing enzymes in mouse tissues were measured. TK2 and dGK levels in muscles were 5- to 10-fold lower than other nonproliferating tissues and 100-fold lower compared to spleen. Each type of tissue apparently relies on de novo and salvage synthesis of DNA precursors to varying degrees.
C1 [Eriksson, Staffan; Wang, Liya] Swedish Univ Agr Sci, Dept Anat Phys & Biochem, SE-75123 Uppsala, Sweden.
C3 Swedish University of Agricultural Sciences
RP Eriksson, S (corresponding author), Swedish Univ Agr Sci, Dept Anat Phys & Biochem, BMC,POB 575, SE-75123 Uppsala, Sweden.
EM Staffan.Eriksson@afb.slu.se
CR Bianchi V, 2003, J BIOL CHEM, V278, P46195, DOI 10.1074/jbc.R300032200
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   De Camaret BM, 2007, BIOCHEM J, V402, P377, DOI 10.1042/BJ20060705
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Elpeleg O, 2003, PEDIATR RES, V54, P153, DOI 10.1203/01.PDR.0000072796.25097.A5
   Eriksson S, 2002, CELL MOL LIFE SCI, V59, P1327, DOI 10.1007/s00018-002-8511-x
   Freisinger P, 2006, ARCH NEUROL-CHICAGO, V63, P1129, DOI 10.1001/archneur.63.8.1129
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Johansson K, 2001, NAT STRUCT BIOL, V8, P616, DOI 10.1038/89661
   Johansson M, 1997, J BIOL CHEM, V272, P8454, DOI 10.1074/jbc.272.13.8454
   Lam W, 2005, MOL PHARMACOL, V67, P408, DOI 10.1124/mol.104.007120
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Pontarin G, 2007, J BIOL CHEM, V282, P16820, DOI 10.1074/jbc.M701310200
   Rylova SN, 2007, BIOCHEM PHARMACOL, V74, P169, DOI 10.1016/j.bcp.2007.03.029
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Thelander L, 2007, NAT GENET, V39, P703, DOI 10.1038/ng0607-703
   Wang L, 1999, FEBS LETT, V443, P170, DOI 10.1016/S0014-5793(98)01711-6
   Wang LY, 2000, BIOCHEM J, V351, P469, DOI 10.1042/0264-6021:3510469
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Wang LY, 2003, FEBS LETT, V554, P319, DOI 10.1016/S0014-5793(03)01181-5
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
NR 30
TC 16
Z9 18
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1525-7770
EI 
J9 NUCLEOS NUCLEOT NUCL
JI Nucleosides Nucleotides Nucleic Acids
PD JUN 15
PY 2008
VL 27
IS 6-7
BP 800
EP 808
DI 10.1080/15257770802146197
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 321XA
UT WOS:000257338600043
PM 18600543
DA 2024-11-01
ER

PT J
AU Leshinsky-Silver, E
   Michelson, M
   Cohen, S
   Ginsberg, M
   Sadeh, M
   Barash, V
   Lerman-Sagie, T
   Lev, D
AF Leshinsky-Silver, E.
   Michelson, M.
   Cohen, S.
   Ginsberg, M.
   Sadeh, M.
   Barash, V.
   Lerman-Sagie, T.
   Lev, D.
TI A defect in the thymidine kinase 2 gene causing isolated mitochondrial myopathy without mtDNA depletion
SO EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY
LA English
DT Article
DE mitochondrial myopathy; thymidine kinase 2; mtDNA depletion; respiratory chain
ID dna copy number; tk2 deficiency; mutations
AB Isolated mitochondrial myopathies (IMM) are either due to primary defects in mtDNA, in nuclear genes that control mtDNA abundance and structure such as thymidine kinase 2 (TK2), or due to CoQ deficiency. Defects in the TK2 gene have been found to be associated with mtDNA depletion attributed to a depleted mitochondrial dNTP pool in non-dividing cells. We report an unusual case of IMM, homozygous for the H90N mutation in the TK2 gene but unlike other cases with the same mutation, does not demonstrate mtDNA depletion. The patient's clinical course is relatively mild and a muscle biopsy showed ragged red muscle fibers with a mild decrease in complexes I and an increase in complexes IV and II activities. This report extends the phenotypic expression of TK2 defects and suggests that all patients who present with an IMM even with normal quantities of mtDNA should be screened for TK2 mutations. (C) 2007 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.
C1 [Leshinsky-Silver, E.; Cohen, S.] Wolfson Med Ctr, Mol Genet Lab, Holon, Israel.
   [Leshinsky-Silver, E.; Michelson, M.; Ginsberg, M.; Lerman-Sagie, T.; Lev, D.] Wolfson Med Ctr, Mitochondrial Dis Ctr, Holon, Israel.
   [Michelson, M.; Lev, D.] Wolfson Med Ctr, Genet Inst, Holon, Israel.
   [Ginsberg, M.; Lerman-Sagie, T.] Wolfson Med Ctr, Pediat Neurol Unit, Holon, Israel.
   [Sadeh, M.] Wolfson Med Ctr, Dept Neurol, Holon, Israel.
   [Barash, V.] Hadassah Med Ctr, Metab Unit, IL-91120 Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center
RP Leshinsky-Silver, E (corresponding author), Wolfson Med Ctr, Mol Genet Lab, Holon, Israel.
EM leshinsky@wolfson.health.gov.il
CR Brown TA, 2002, NUCLEIC ACIDS RES, V30, P2004, DOI 10.1093/nar/30.9.2004
   Carrozzo R, 2003, HUM MUTAT, V21, P0, DOI 10.1002/humu.9135
   Chiaratti MR, 2006, GENET MOL RES, V5, P55
   DiMauro S, 2005, CURR OPIN NEUROL, V18, P538, DOI 10.1097/01.wco.0000179761.63486.1a
   Durham SE, 2005, NEUROLOGY, V65, P453, DOI 10.1212/01.wnl.0000171861.30277.88
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Horváth R, 2005, NEUROMUSCULAR DISORD, V15, P851, DOI 10.1016/j.nmd.2005.09.005
   King M P, 1996, METHODS ENZYMOL, V264, P304, DOI 10.1016/S0076-6879(96)64029-4
   Lalani SR, 2005, ARCH NEUROL-CHICAGO, V62, P317, DOI 10.1001/archneur.62.2.317
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Nevo Y, 2002, J CHILD NEUROL, V17, P499, DOI 10.1177/088307380201700705
   Pyle A, 2007, J MED GENET, V44, P69, DOI 10.1136/jmg.2006.043109
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Saada A, 2003, BIOCHEM BIOPH RES CO, V310, P963, DOI 10.1016/j.bbrc.2003.09.104
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Taanman JW, 1997, HUM MOL GENET, V6, P935, DOI 10.1093/hmg/6.6.935
   Tulinius M, 2005, NEUROMUSCULAR DISORD, V15, P412, DOI 10.1016/j.nmd.2005.03.010
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
NR 21
TC 11
Z9 14
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1090-3798
EI 
J9 EUR J PAEDIATR NEURO
JI Eur. J. Paediatr. Neurol.
PD JUL 15
PY 2008
VL 12
IS 4
BP 309
EP 313
DI 10.1016/j.ejpn.2007.09.005
PG 5
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 320OQ
UT WOS:000257244800006
PM 17951082
DA 2024-11-01
ER

PT J
AU Zifa, E
   Theotokis, P
   Kaminari, A
   Maridaki, H
   Leze, H
   Petsiava, E
   Mamuris, Z
   Stathopoulos, C
AF Zifa, Emily
   Theotokis, Paschalis
   Kaminari, Archontia
   Maridaki, Helen
   Leze, Helen
   Petsiava, Efrosini
   Mamuris, Zissis
   Stathopoulos, Constantinos
TI A novel G3337A mitochondrial ND1 mutation related to cardiomyopathy co-segregates with tRNA<SUP>Leu(CUN)</SUP> A12308G and tRNA<SUP>Thr</SUP> C15946T mutations
SO MITOCHONDRION
LA English
DT Article
DE tRNA; NADH dehydrogenase 1; mitochondrial DNA; cardiomyopathies
ID ribosomal-rna c1494t; complex-i activity; hearing-loss; phenotypic manifestation; hypertrophic cardiomyopathy; chinese family; dna mutations; gene; myopathy; deafness
AB We describe a novel Mutation in human mitochondrial NADH dehydrogenase 1 gene (ND1), a G to A transition at nucleotide position 3337,which is co-segregated with two known mutations in tRNA(Leu(CUN)) A12308G and tRNA(Thr) C15946T. These mutations were detected in two unrelated patients with different clinical phenotypes, exhibiting cardiomyopathy as the common symptom. The ND1 G3337A mutation that was detected was found almost homoplasmic in the two patients and it was absent in 150 individuals that were tested as control group. Mitochondrial respiratory chain complex I activity of the patients platelets was also tested and found decreased compared to those of controls. We suggest that the co-existence of mutations in tRNA and ND1 genes may act synergistically affecting the clinical phenotype. Our study highlights the enormous phenotypic diversity that exists among pathogenic mtDNA mutations and re-emphasizes the need for a more careful clinical approach. (c) 2008 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Zifa, Emily; Theotokis, Paschalis; Kaminari, Archontia; Mamuris, Zissis; Stathopoulos, Constantinos] Univ Thessaly, Dept Biochem & Biotechnol, Larisa 41221, Greece.
   [Maridaki, Helen; Leze, Helen; Petsiava, Efrosini] Achillopoule Reg Gen Hosp Volos, Paediat Clin, Volos 38222, Greece.
   [Mamuris, Zissis; Stathopoulos, Constantinos] Inst Biomed Res & Technol BIOMED, Larisa 41221, Greece.
C3 University of Thessaly
RP Mamuris, Z (corresponding author), Univ Thessaly, Dept Biochem & Biotechnol, 26 Ploutonos St, Larisa 41221, Greece.
EM zmamur@uth.gr; cstath@bio.uth.gr
CR Akita Y, 2000, HUM MUTAT, V15, P382, DOI 10.1002/(SICI)1098-1004(200004)15:4<382::AID-HUMU15>3.0.CO;2-B
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Ballana E, 2008, HUM MUTAT, V29, P248, DOI 10.1002/humu.20639
   Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006
   Chen J, 2006, DIABETES RES CLIN PR, V74, P148, DOI 10.1016/j.diabres.2006.03.024
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   DIMAURO S, 1989, CURR OPIN CARDIOL, V13, P90
   Dror N, 2002, MOL PSYCHIATR, V7, P995, DOI 10.1038/sj.mp.4001116
   Feigenbaum A, 2006, AM J MED GENET A, V140A, P2216, DOI 10.1002/ajmg.a.31436
   Grasso M, 2001, EUR J HUM GENET, V9, P311, DOI 10.1038/sj.ejhg.5200622
   Guan MX, 2006, AM J HUM GENET, V79, P291, DOI 10.1086/506389
   Han DY, 2007, BIOCHEM BIOPH RES CO, V357, P554, DOI 10.1016/j.bbrc.2007.03.199
   Hattori Y, 2005, EXP CLIN ENDOCR DIAB, V113, P318, DOI 10.1055/s-2005-865646
   Higashikata T, 2001, INTERNAL MED, V40, P405, DOI 10.2169/internalmedicine.40.405
   Hudson G, 2007, MOL VIS, V13, P2339
   Janssen AJM, 2007, CLIN CHEM, V53, P729, DOI 10.1373/clinchem.2006.078873
   LAUBER J, 1991, NUCLEIC ACIDS RES, V19, P1393, DOI 10.1093/nar/19.7.1393
   Lev D, 2004, PEDIATR CARDIOL, V25, P443, DOI 10.1007/s00246-003-0490-7
   LEWIN HA, 1992, BIOTECHNIQUES, V13, P522
   Loeffen J, 2001, ANN NEUROL, V49, P195, DOI 10.1002/1531-8249(20010201)49:2<195::AID-ANA39>3.0.CO;2-M
   Mancuso M, 2007, BIOSCIENCE REP, V27, P31, DOI 10.1007/s10540-007-9035-2
   ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766
   Pulkes T, 2000, LANCET, V356, P2068, DOI 10.1016/S0140-6736(00)03408-5
   Qu J, 2006, INVEST OPHTH VIS SCI, V47, P475, DOI 10.1167/iovs.05-0665
   Ronghua L, 2006, GENE, V376, P79, DOI 10.1016/j.gene.2006.02.014
   Santorelli FM, 2001, AM HEART J, V141, P1
   Shin WS, 2000, AM J HUM GENET, V67, P1617, DOI 10.1086/316896
   SILVESTRI G, 1994, HUM MUTAT, V3, P37, DOI 10.1002/humu.1380030107
   SWEENEY MG, 1993, Q J MED, V86, P435
   TANIIKE M, 1992, BIOCHEM BIOPH RES CO, V186, P47, DOI 10.1016/S0006-291X(05)80773-9
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Tong Y, 2007, BIOCHEM BIOPH RES CO, V357, P524, DOI 10.1016/j.bbrc.2007.03.189
   Wong LJC, 2007, MUSCLE NERVE, V36, P279, DOI 10.1002/mus.20807
   Wu CC, 2007, EAR HEARING, V28, P332, DOI 10.1097/AUD.0b013e318047941e
   Young WY, 2006, AM J MED GENET A, V140A, P2188, DOI 10.1002/ajmg.a.31434
   Yuan H, 2007, BIOCHEM BIOPH RES CO, V362, P94, DOI 10.1016/j.bbrc.2007.07.161
   ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
   Zifa E, 2007, RNA BIOL, V4, P38, DOI 10.4161/rna.4.1.4548
NR 41
TC 22
Z9 25
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD JUN 15
PY 2008
VL 8
IS 3
BP 229
EP 236
DI 10.1016/j.mito.2008.04.001
PG 8
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 329UG
UT WOS:000257895500004
PM 18502698
DA 2024-11-01
ER

PT J
AU Pietiläinen, KH
   Naukkarinen, J
   Rissanen, A
   Saharinen, J
   Ellonen, P
   Keränen, H
   Suomalainen, A
   Götz, A
   Suortti, T
   Yki-Järvinen, H
   Oresic, M
   Kaprio, J
   Peltonen, L
AF Pietilainen, Kirsi H.
   Naukkarinen, Jussi
   Rissanen, Aila
   Saharinen, Juha
   Ellonen, Pekka
   Keranen, Heli
   Suomalainen, Anu
   Gotz, Alexandra
   Suortti, Tapani
   Yki-Jarvinen, Hannele
   Oresic, Matej
   Kaprio, Jaakko
   Peltonen, Leena
TI Global transcript profiles of fat in monozygotic twins discordant for BMI: Pathways behind acquired obesity
SO PLOS MEDICINE
LA English
DT Article
ID inflammation-related genes; nonobese pima-indians; insulin-resistance; adipose-tissue; mitochondrial biogenesis; metabolic-regulation; increased expression; motoneuron disease; skeletal-muscle; cells
AB Background The acquired component of complex traits is difficult to dissect in humans. Obesity represents such a trait, in which the metabolic and molecular consequences emerge from complex interactions of genes and environment. With the substantial morbidity associated with obesity, a deeper understanding of the concurrent metabolic changes is of considerable importance. The goal of this study was to investigate this important acquired component and expose obesity-induced changes in biological pathways in an identical genetic background. Methods and Findings We used a special study design of "clonal controls,'' rare monozygotic twins discordant for obesity identified through a national registry of 2,453 young, healthy twin pairs. A total of 14 pairs were studied ( eight male, six female; white), with a mean +/- standard deviation (SD) age 25.8 +/- 6 1.4 y and a body mass index (BMI) difference 5.2 +/- 6 1.8 kg/m(2). Sequence analyses of mitochondrial DNA ( mtDNA) in subcutaneous fat and peripheral leukocytes revealed no aberrant heteroplasmy between the co-twins. However, mtDNA copy number was reduced by 47% in the obese co-twin's fat. In addition, novel pathway analyses of the adipose tissue transcription profiles exposed significant down-regulation of mitochondrial branched-chain amino acid (BCAA) catabolism ( p < 0.0001). In line with this finding, serum levels of insulin secretion-enhancing BCAAs were increased in obese male co-twins ( 9% increase, p= 0.025). Lending clinical relevance to the findings, in both sexes the observed aberrations in mitochondrial amino acid metabolism pathways in fat correlated closely with liver fat accumulation, insulin resistance, and hyperinsulinemia, early aberrations of acquired obesity in these healthy young adults. Conclusions Our findings emphasize a substantial role of mitochondrial energy-and amino acid metabolism in obesity and development of insulin resistance.
C1 [Naukkarinen, Jussi; Saharinen, Juha; Ellonen, Pekka; Keranen, Heli; Peltonen, Leena] Natl Publ Hlth Inst, Dept Mol Med, Helsinki, Finland.
   [Pietilainen, Kirsi H.; Rissanen, Aila] Univ Helsinki, Cent Hosp, Dept Psychiat, Obes Res Unit, Helsinki, Finland.
   [Pietilainen, Kirsi H.; Yki-Jarvinen, Hannele] Univ Helsinki, Cent Hosp, Div Diabet, Dept Med, Helsinki, Finland.
   [Pietilainen, Kirsi H.; Kaprio, Jaakko] Univ Helsinki, Dept Publ Hlth, Finnish Twin Cohort Study, Helsinki, Finland.
   [Naukkarinen, Jussi; Saharinen, Juha; Ellonen, Pekka; Keranen, Heli; Peltonen, Leena] Univ Helsinki, Dept Med Genet, FIN-00014 Helsinki, Finland.
   [Naukkarinen, Jussi; Saharinen, Juha; Ellonen, Pekka; Keranen, Heli; Peltonen, Leena] Univ Helsinki, Res Program Mol Med, FIN-00014 Helsinki, Finland.
   [Suomalainen, Anu; Gotz, Alexandra] Univ Helsinki, Res Program Mol Neurol, FIN-00014 Helsinki, Finland.
   [Suomalainen, Anu; Gotz, Alexandra] Univ Helsinki, Dept Neurol, FIN-00014 Helsinki, Finland.
   [Suomalainen, Anu; Gotz, Alexandra] Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland.
   [Suortti, Tapani; Oresic, Matej] VTT Tech Res Ctr Finland, Espoo, Finland.
   [Kaprio, Jaakko] Natl Publ Hlth Inst, Dept Mental Hlth & Alcohol Res, Helsinki, Finland.
   [Peltonen, Leena] Wellcome Trust Sanger Inst, Cambridge, England.
   [Peltonen, Leena] MIT, Broad Inst, Cambridge, MA 02139 USA.
C3 Finland National Institute for Health & Welfare; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; VTT Technical Research Center Finland; Finland National Institute for Health & Welfare; Wellcome Trust Sanger Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute
RP Peltonen, L (corresponding author), Natl Publ Hlth Inst, Dept Mol Med, Helsinki, Finland.
EM leena.peltonen@ktl.fi
CR Bogacka I, 2005, DIABETES, V54, P1392, DOI 10.2337/diabetes.54.5.1392
   Boomsma D, 2002, NAT REV GENET, V3, P872, DOI 10.1038/nrg932
   Boushel R, 2007, DIABETOLOGIA, V50, P790, DOI 10.1007/s00125-007-0594-3
   Choo HJ, 2006, DIABETOLOGIA, V49, P784, DOI 10.1007/s00125-006-0170-2
   Cinti S, 2005, J LIPID RES, V46, P2347, DOI 10.1194/jlr.M500294-JLR200
   Civitarese AE, 2007, PLOS MED, V4, P485, DOI 10.1371/journal.pmed.0040076
   Clément K, 2004, FASEB J, V18, P1657, DOI 10.1096/fj.04-2204com
   DEFRONZO RA, 1979, AM J PHYSIOL, V237, P0
   FELIG P, 1969, NEW ENGL J MED, V281, P811, DOI 10.1056/NEJM196910092811503
   FLOYD JC, 1963, J CLIN INVEST, V42, P1714, DOI 10.1172/JCI104857
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Gertow K, 2004, DIABETOLOGIA, V47, P1118, DOI 10.1007/s00125-004-1417-4
   Hackl H, 2005, GENOME BIOL, V6, P0, DOI 10.1186/gb-2005-6-13-r108
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Heilbronn L, 2004, INT J OBESITY, V28, PS12, DOI 10.1038/sj.ijo.0802853
   Hinault C, 2006, J NUTR BIOCHEM, V17, P374, DOI 10.1016/j.jnutbio.2006.02.008
   Holloway GP, 2007, AM J PHYSIOL-ENDOC M, V292, PE1782, DOI 10.1152/ajpendo.00639.2006
   Hood DA, 2006, J EXP BIOL, V209, P2265, DOI 10.1242/jeb.02182
   Huang F, 2005, AM J PHYSIOL-LUNG C, V289, PL176, DOI 10.1152/ajplung.00003.2005
   Kannisto K, 2004, J CLIN ENDOCR METAB, V89, P4414, DOI 10.1210/jc.2004-0153
   Kaprio J, 2002, TWIN RES, V5, P366, DOI 10.1375/136905202320906101
   Kiialainen A, 2007, J MOL MED, V85, P971, DOI 10.1007/s00109-007-0191-4
   Lacasa D, 2007, ENDOCRINOLOGY, V148, P868, DOI 10.1210/en.2006-0687
   Lee YH, 2005, DIABETOLOGIA, V48, P1776, DOI 10.1007/s00125-005-1867-3
   Lelliott C, 2004, INT J OBESITY, V28, PS22, DOI 10.1038/sj.ijo.0802854
   Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881
   Mazzali M, 2002, QJM-INT J MED, V95, P3, DOI 10.1093/qjmed/95.1.3
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Motley ED, 2002, HYPERTENSION, V39, P508, DOI 10.1161/hy02t2.102907
   Muoio DM, 2006, ANNU REV BIOCHEM, V75, P367, DOI 10.1146/annurev.biochem.75.103004.142512
   Murugesan G, 2003, J MOL CELL CARDIOL, V35, P1375, DOI 10.1016/j.yjmcc.2003.08.004
   Nair S, 2005, DIABETOLOGIA, V48, P1784, DOI 10.1007/s00125-005-1868-2
   Nomiyama T, 2007, J CLIN INVEST, V117, P2877, DOI 10.1172/JCI31986
   Pakkasjärvi N, 2005, J NEUROBIOL, V65, P269, DOI 10.1002/neu.20185
   Pakkasjärvi N, 2007, DEV NEUROBIOL, V67, P270, DOI 10.1002/dneu.20350
   Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100
   Petersen KF, 2006, AM J MED, V119, P10S, DOI 10.1016/j.amjmed.2006.01.009
   Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314
   Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889
   Pietiläien KH, 2004, TWIN RES, V7, P421
   Pietiläinen KH, 2005, AM J PHYSIOL-ENDOC M, V288, PE768, DOI 10.1152/ajpendo.00381.2004
   Pietiläinen KH, 2007, PLOS ONE, V2, P0, DOI 10.1371/journal.pone.0000218
   Pietiläinen KH, 2006, J CLIN ENDOCR METAB, V91, P2776, DOI 10.1210/jc.2005-2848
   Pietiläinen KH, 2006, OBESITY, V14, P826, DOI 10.1038/oby.2006.96
   PIETILANIEN KH, 2007, IN PRESS OBESITY, V0, P0
   RAO JNK, 1984, ANN STAT, V12, P46, DOI 10.1214/aos/1176346391
   Schadt EE, 2005, NAT GENET, V37, P710, DOI 10.1038/ng1589
   Schadt EE, 2006, J LIPID RES, V47, P2601, DOI 10.1194/jlr.R600026-JLR200
   Valerio A, 2006, J CLIN INVEST, V116, P2791, DOI 10.1172/JCI28570
   Waki H, 2007, CELL METAB, V5, P357, DOI 10.1016/j.cmet.2007.03.010
   Wang S, 2006, PLOS GENET, V2, P148, DOI 10.1371/journal.pgen.0020015
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102
   Wick N, 2007, PHYSIOL GENOMICS, V28, P179, DOI 10.1152/physiolgenomics.00037.2006
   Wilson-Fritch L, 2004, J CLIN INVEST, V114, P1281, DOI 10.1172/JCI200421752
   Yang TL, 2006, AAPS J, V8, PE632, DOI 10.1208/aapsj080472
   Yang XL, 2004, BIOCHEM BIOPH RES CO, V317, P1045, DOI 10.1016/j.bbrc.2004.03.152
   Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001
   Yki-Järvinen H, 2005, CURR MOL MED, V5, P287, DOI 10.2174/1566524053766031
NR 59
TC 245
Z9 258
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1277
EI 1549-1676
J9 PLOS MED
JI PLos Med.
PD MAR 15
PY 2008
VL 5
IS 3
BP 
EP 
DI 10.1371/journal.pmed.0050051
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 287PL
UT WOS:000254928900020
PM 18336063
DA 2024-11-01
ER

PT J
AU Claypool, SM
   Oktay, Y
   Boontheung, P
   Loo, JA
   Koehler, CM
AF Claypool, Steven M.
   Oktay, Yavuz
   Boontheung, Pinmanee
   Loo, Joseph A.
   Koehler, Carla M.
TI Cardiolipin defines the interactome of the major ADP/ATP carrier protein of the mitochondrial inner membrane
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article
ID adenine-nucleotide translocase; site-directed mutagenesis; 6 arginine mutations; yeast mitochondria; oxidative-phosphorylation; saccharomyces-cerevisiae; respiratory-chain; barth-syndrome; positive residues; dna stability
AB Defined mutations in the mitochondrial ADP/ATP carrier (AAC) are associated with certain types of progressive external ophthalmoplegia. AAC is required for oxidative phosphorylation (OXPHOS), and dysregulation of AAC has been implicated in apoptosis. Little is known about the AAC interactome, aside from a known requirement for the phospholipid cardiolipin (CL) and that it is thought to function as a homodimer. Using a newly developed dual affinity tag, we demonstrate that yeast AAC2 physically participates in several protein complexes of distinct size and composition. The respiratory supercomplex and several smaller AAC2-containing complexes, including other members of the mitochondrial carrier family, are identified here. In the absence of CL, most of the defined interactions are destabilized or undetectable. The absence of CL and/or AAC2 results in distinct yet additive alterations in respiratory supercomplex structure and respiratory function. Thus, a single lipid can significantly alter the functional interactome of an individual protein.
C1 [Claypool, Steven M.; Oktay, Yavuz; Boontheung, Pinmanee; Loo, Joseph A.; Koehler, Carla M.] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.
   [Loo, Joseph A.] Univ Calif Los Angeles, Dept Biol Chem, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Loo, Joseph A.; Koehler, Carla M.] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles
RP Koehler, CM (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.
EM Koehler@chem.ucla.edu
FU American Heart Association [0640076N]; Muscular Dystrophy Association [4033]; National Institutes of Health [R01GM61721, R01GM07398, R01RR20004, K99HL089185-01]; W. M. Keck Foundation; American Heart Association (AHA) [0640076N] Funding Source: American Heart Association (AHA)
CR Beyer K, 1996, BIOCHEMISTRY-US, V35, P15784, DOI 10.1021/bi9610055
   Boumans H, 1998, J BIOL CHEM, V273, P4872, DOI 10.1074/jbc.273.9.4872
   Brandner K, 2005, MOL BIOL CELL, V16, P5202, DOI 10.1091/mbc.E05-03-0256
   Chicco AJ, 2007, AM J PHYSIOL-CELL PH, V292, PC33, DOI 10.1152/ajpcell.00243.2006
   Claypool SM, 2006, J CELL BIOL, V174, P379, DOI 10.1083/jcb.200605043
   Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200
   Fontanesi F, 2004, HUM MOL GENET, V13, P923, DOI 10.1093/hmg/ddh108
   HACKENBERG H, 1980, BIOCHEMISTRY-US, V19, P548, DOI 10.1021/bi00544a024
   Han XL, 2005, BIOCHEMISTRY-US, V44, P16684, DOI 10.1021/bi051908a
   Heidkamper D, 1996, BIOCHEMISTRY-US, V35, P16144, DOI 10.1021/bi960668j
   Heinemeyer J, 2007, J BIOL CHEM, V282, P12240, DOI 10.1074/jbc.M610545200
   HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2
   HOFFMANN B, 1994, J BIOL CHEM, V269, P1940
   Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199
   Koehler CM, 2000, MOL CELL BIOL, V20, P1187, DOI 10.1128/MCB.20.4.1187-1193.2000
   Koshkin V, 2000, BIOCHEM J, V347, P687, DOI 10.1042/0264-6021:3470687
   KRAMER R, 1980, BIOCHEMISTRY-US, V19, P556
   Ma LN, 2004, J BIOL CHEM, V279, P44394, DOI 10.1074/jbc.M405479200
   Muller V, 1996, BIOCHEMISTRY-US, V35, P16132, DOI 10.1021/bi960667r
   NELSON DR, 1993, J MOL BIOL, V230, P1159, DOI 10.1006/jmbi.1993.1233
   Ott M, 2007, CELL DEATH DIFFER, V14, P1243, DOI 10.1038/sj.cdd.4402135
   Palmieri L, 2005, HUM MOL GENET, V14, P3079, DOI 10.1093/hmg/ddi341
   Panneels V, 2003, BIOCHEM BIOPH RES CO, V300, P65, DOI 10.1016/S0006-291X(02)02795-X
   Pfeiffer K, 2003, J BIOL CHEM, V278, P52873, DOI 10.1074/jbc.M308366200
   Schägger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777
   SCHLAME M, 1993, J BIOL CHEM, V268, P74
   Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9
   Schlame M, 2008, J LIPID RES, V49, P1607, DOI 10.1194/jlr.R700018-JLR200
   Sedlák E, 1999, BIOCHEMISTRY-US, V38, P14966, DOI 10.1021/bi9914053
   Sharer JD, 2005, IUBMB LIFE, V57, P607, DOI 10.1080/15216540500217735
   Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h
   Vyssokikh MY, 2003, ACTA BIOCHIM POL, V50, P389
   WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310
   Xu Y, 2006, J BIOL CHEM, V281, P39217, DOI 10.1074/jbc.M606100200
   Zhang M, 2005, J BIOL CHEM, V280, P29403, DOI 10.1074/jbc.M504955200
   Zhang M, 2003, J BIOL CHEM, V278, P35204, DOI 10.1074/jbc.M306729200
   Zhang M, 2002, J BIOL CHEM, V277, P43553, DOI 10.1074/jbc.C200551200
NR 37
TC 249
Z9 289
U1 1
U2 25
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0021-9525
EI 
J9 J CELL BIOL
JI J. Cell Biol.
PD SEP 8
PY 2008
VL 182
IS 5
BP 937
EP 950
DI 10.1083/jcb.200801152
PG 14
WC Cell Biology
SC Cell Biology
GA 346EG
UT WOS:000259050700013
PM 18779372
DA 2024-11-01
ER

PT J
AU Koenig, MK
AF Koenig, Mary Kay
TI Presentation and diagnosis of mitochondrial disorders in children
SO PEDIATRIC NEUROLOGY
LA English
DT Review
ID magnetic-resonance-spectroscopy; respiratory-chain disorders; muscle biopsy; intramitochondrial fibers; oxidative-phosphorylation; ultrastructural-changes; dna characteristics; encephalomyopathy; myopathy; epidemiology
AB The first disorder of mitochondrial function was described by Luft in 1959. Over the ensuing decades, multiple cases of mitochondrial dysfunction were reported, and the term "mitochondrial disorder" arose to describe any defect in the mitochondrial electron transport chain. The sequence of the mitochondrial genome was elucidated in 1981 by Anderson et al., and during the next 20 years, >200 pathogenic point mutations, deletions, insertions, and rearrangements were described. Most of the original cases were adults, and the diagnosis of a mitochondrial disorder in an adult patient became relatively straightforward. Adults present with well-defined "mitochondrial syndromes" and generally carry mitochondrial DNA mutations that are easily identified. Children with mitochondrial disorders are much harder to define. Children are more likely to have a nuclear DNA mutation, whereas the "classic" syndromic findings tend to be absent. This review describes both the varying presentations of mitochondrial disorders and the common laboratory, imaging, and pathologic findings related to children. (C) 2008 by Elsevier Inc. All rights reserved.
C1 [Koenig, Mary Kay] Univ Texas Houston, Hlth Sci Ctr, Dept Pediat, Houston, TX 77030 USA.
   [Koenig, Mary Kay] Univ Texas Houston, Hlth Sci Ctr, Dept Neurol, Houston, TX 77030 USA.
C3 University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston
RP Koenig, MK (corresponding author), Univ Texas Houston, Hlth Sci Ctr, Dept Pediat, 6431 Fannin St, Houston, TX 77030 USA.
EM mary.k.koenig@uth.tmc.edu
FU NCRR NIH HHS [KL2 RR024149-05S1, KL2 RR024149] Funding Source: Medline
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   ARGOV Z, 1991, ANN NEUROL, V30, P90, DOI 10.1002/ana.410300116
   Bank William, 1998, BIOFACTORS, V7, P243
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Brantová O, 2006, ULTRASTRUCT PATHOL, V30, P239, DOI 10.1080/01913120600820112
   Casademont J, 2004, MED SCI MONITOR, V10, P0
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chretien D, 2003, J INHERIT METAB DIS, V26, P189, DOI 10.1023/A:1024437201166
   DiMauro S, 1999, J CHILD NEUROL, V14, PS23, DOI 10.1177/0883073899014001051
   Dimauro S, 2004, ANN NY ACAD SCI, V1011, P217, DOI 10.1196/annals.1293.022
   Dinopoulos A, 2005, NEUROPEDIATRICS, V36, P290, DOI 10.1055/s-2005-872807
   ENGEL WK, 1963, NEUROLOGY, V13, P919, DOI 10.1212/WNL.13.11.919
   Fattal O, 2006, PSYCHOSOMATICS, V47, P1, DOI 10.1176/appi.psy.47.1.1
   Finsterer J, 2006, ACTA NEUROL SCAND, V114, P217, DOI 10.1111/j.1600-0404.2006.00671.x
   Gillis LA, 2003, GASTROENTEROL CLIN N, V32, P789, DOI 10.1016/S0889-8553(03)00052-9
   Gire C, 2002, CHILD NERV SYST, V18, P621, DOI 10.1007/s00381-002-0621-0
   Hagenfeldt L, 1998, J INHERIT METAB DIS, V21, P613, DOI 10.1023/A:1005431424744
   Hancock MR, 2002, ANN CLIN BIOCHEM, V39, P456, DOI 10.1258/000456302320314467
   Hodges SD, 2004, NUCLEOS NUCLEOT NUCL, V23, P1269, DOI 10.1081/NCN-200027537
   HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603
   Hsu CH, 2005, ANN NY ACAD SCI, V1042, P36, DOI 10.1196/annals.1338.004
   Hui J, 2006, DEV MED CHILD NEUROL, V48, P132, DOI 10.1017/S0012162206000284
   Hutchesson A, 1997, CLIN CHEM, V43, P158
   JACKSON MJ, 1995, BRAIN, V118, P339, DOI 10.1093/brain/118.2.339
   Kang PB, 2001, J CHILD NEUROL, V16, P657, DOI 10.1177/088307380101600906
   Krähenbühl S, 2000, LIVER, V20, P346, DOI 10.1034/j.1600-0676.2000.020004346.x
   Kyriacou K, 1999, ULTRASTRUCT PATHOL, V23, P163
   Lamont PJ, 1998, ARCH DIS CHILD, V79, P22, DOI 10.1136/adc.79.1.22
   LINDAL S, 1992, ULTRASTRUCT PATHOL, V16, P263, DOI 10.3109/01913129209061355
   LUFT R, 1994, P NATL ACAD SCI USA, V91, P8731, DOI 10.1073/pnas.91.19.8731
   Maassen JA, 2004, DIABETES, V53, PS103, DOI 10.2337/diabetes.53.2007.S103
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Mochel F, 2005, J CLIN ENDOCR METAB, V90, P3780, DOI 10.1210/jc.2005-0009
   Munnich A, 1996, J INHERIT METAB DIS, V19, P521, DOI 10.1007/BF01799112
   NARAYANA PA, 1989, MAGN RESON IMAGING, V7, P133, DOI 10.1016/0730-725X(89)90695-4
   NASS MMK, 1963, J CELL BIOL, V19, P593, DOI 10.1083/jcb.19.3.593
   NASS S, 1963, J CELL BIOL, V19, P613, DOI 10.1083/jcb.19.3.613
   Panetta J, 2005, NEUROPEDIATRICS, V36, P256, DOI 10.1055/s-2005-865866
   Patterson K, 2004, PEDIATR DEVEL PATHOL, V7, P629, DOI 10.1007/s10024-004-5051-4
   PETTY RKH, 1986, BRAIN, V109, P915, DOI 10.1093/brain/109.5.915
   Rollins S, 2001, AM J CLIN PATHOL, V116, P326
   Rötig A, 2003, J NEPHROL, V16, P286
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   RUSTIN P, 1991, LANCET, V338, P60, DOI 10.1016/0140-6736(91)90057-V
   Shoffner JM, 2000, NEUROL CLIN, V18, P105, DOI 10.1016/S0733-8619(05)70180-8
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   SLINDE E, 1975, ANAL BIOCHEM, V66, P151, DOI 10.1016/0003-2697(75)90733-2
   STADHOUDERS AM, 1987, J INHERIT METAB DIS, V10, P62, DOI 10.1007/BF01812848
   Tarnopolsky MA, 2005, MED SCI SPORT EXER, V37, P2086, DOI 10.1249/01.mss.0000177341.89478.06
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Thorburn DR, 2004, MITOCHONDRION, V4, P363, DOI 10.1016/j.mito.2004.07.003
   Thorburn DR, 2001, J INHERIT METAB DIS, V24, P312, DOI 10.1023/A:1010347808082
   Valanne L, 1998, AM J NEURORADIOL, V19, P369
   Walker UA, 1996, EUR NEUROL, V36, P260, DOI 10.1159/000117269
   Wolf NI, 2002, NEUROLOGY, V59, P1402, DOI 10.1212/01.WNL.0000031795.91814.D8
   Zeviani M, 1998, MEDICINE, V77, P59, DOI 10.1097/00005792-199801000-00006
NR 56
TC 110
Z9 133
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0887-8994
EI 1873-5150
J9 PEDIATR NEUROL
JI Pediatr. Neurol.
PD MAY 15
PY 2008
VL 38
IS 5
BP 305
EP 313
DI 10.1016/j.pediatrneurol.2007.12.001
PG 9
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 293MU
UT WOS:000255340200001
PM 18410845
DA 2024-11-01
ER

PT J
AU Wiedemann, FR
   Bartels, C
   Kirches, E
   Mawrin, C
   Wallesch, CW
AF Wiedemann, Falk R.
   Bartels, Claudius
   Kirches, Elmar
   Mawrin, Christian
   Wallesch, Claus-W.
TI Unusual presentations of patients with the mitochondrial MERRF mutation A8344G
SO CLINICAL NEUROLOGY AND NEUROSURGERY
LA English
DT Article
DE MERRF; phenotype; respiratory failure; mutation analysis
ID ragged-red fibers; stroke-like episodes; myoclonic epilepsy; clinical-features; respiratory-chain; overlap syndrome; skeletal-muscle; dna mutation; mtdna; dysfunction
AB MERRF is typically characterized by myoclonus, generalized seizures and ragged-red fibers in Muscular biopsy. We report a family (harbouring the A8344G mutation) with a late onset of the disease and an uncommon clinical manifestation, including episodes of reversible respiratory failure, the presence of ophthalmoplegia, and the absence of seizures and myoclonus in most subjects. We conducted histochemical, biochemical and molecular genetic studies. Mutation analysis revealed that the level of Mutated mitochondrial DNA (mtDNA) was above 80% in the skeletal muscle of all siblings. Nevertheless, one severely affected individual did neither present cytochrome c oxidase-negative fibers nor ragged-red fibers in the skeletal muscle biopsy. These data extend the phenotypic range associated with the MERRF syndrome. We suggest that the analysis of mtDNA could be of importance in many cases of unclear multisystem disorders in later life. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Wiedemann, Falk R.; Bartels, Claudius; Wallesch, Claus-W.] Otto von Guericke Univ, Univ Klinikum Magdeburg, Neurol Klin, D-39120 Magdeburg, Germany.
   [Kirches, Elmar] Otto von Guericke Univ, Inst Neuropathol, D-39120 Magdeburg, Germany.
   [Mawrin, Christian] Univ Jena, Abt Neuropathol, D-07747 Jena, Germany.
C3 Otto von Guericke University; University Hospital Magdeburg; Otto von Guericke University; Friedrich Schiller University of Jena
RP Wiedemann, FR (corresponding author), Otto von Guericke Univ, Univ Klinikum Magdeburg, Neurol Klin, Leipziger Str 44, D-39120 Magdeburg, Germany.
EM falk.wiedemann@medizin.uni-magdeburg.de
FU BMBF NBL3 [01220107]
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Arpa J, 1997, ACTA NEUROL SCAND, V96, P65
   BERKOVIC SF, 1989, BRAIN, V112, P1231, DOI 10.1093/brain/112.5.1231
   Blumenthal DT, 1998, NEUROLOGY, V50, P524, DOI 10.1212/WNL.50.2.524
   DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602
   Dubowitz V, 1973, MUSCLE BIOPSY MODERN, V0, P0
   Gignoux L, 2001, REV NEUROL-FRANCE, V157, P427
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   HAMMANS SR, 1993, BRAIN, V116, P617, DOI 10.1093/brain/116.3.617
   Melone MAB, 2004, ARCH NEUROL-CHICAGO, V61, P269, DOI 10.1001/archneur.61.2.269
   Mongini T, 2002, CLIN NEUROPATHOL, V21, P72
   Moslemi AR, 1998, NEUROMUSCULAR DISORD, V8, P345, DOI 10.1016/S0960-8966(98)00029-7
   Naini AB, 2005, ARCH NEUROL-CHICAGO, V62, P473, DOI 10.1001/archneur.62.3.473
   ROSING HS, 1985, ANN NEUROL, V17, P228, DOI 10.1002/ana.410170303
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   SILVESTRI G, 1993, NEUROLOGY, V43, P1200, DOI 10.1212/WNL.43.6.1200
   SILVESTRI G, 1992, AM J HUM GENET, V51, P1213
   Sitburana Oraporn, 2001, JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND, V84, P1051
   Tanji K, 2003, ACTA NEUROPATHOL, V105, P69, DOI 10.1007/s00401-002-0604-y
   Verma A, 1996, NEUROLOGY, V46, P1334, DOI 10.1212/WNL.46.5.1334
   WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8
   Wiedemann FR, 2000, ANAL BIOCHEM, V279, P55, DOI 10.1006/abio.1999.4434
   Winkler-Stuck K, 2005, J NEURAL TRANSM, V112, P499, DOI 10.1007/s00702-004-0195-y
   ZEVIANI M, 1991, AM J HUM GENET, V48, P203
NR 25
TC 18
Z9 22
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0303-8467
EI 
J9 CLIN NEUROL NEUROSUR
JI Clin. Neurol. Neurosurg.
PD SEP 15
PY 2008
VL 110
IS 8
BP 859
EP 863
DI 10.1016/j.clineuro.2008.06.010
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 356GG
UT WOS:000259766100021
PM 18657354
DA 2024-11-01
ER

PT J
AU Scaglia, F
   Wong, LJC
AF Scaglia, Fernando
   Wong, Lee-Jun C.
TI Human mitochondrial transfer RNAs: Role of pathogenic mutation in disease
SO MUSCLE & NERVE
LA English
DT Review
DE cardiomyopathy; chronic progressive external ophthalmoplegia; diabetes mellitus; encephalomyopathy; focal segmental glomerulosclerosis; human mitochondrial tRNA genes; mitochondrial cytopathies; mitochondrial myopathy; myoclonic epilepsy; pathogenic mutations; ragged-red fibers; retinitis pigmentosa; sensorineural hearing loss; stroke-like episodes
ID progressive external ophthalmoplegia; stroke-like episodes; mtdna point mutation; ragged-red fibers; inherited hypertrophic cardiomyopathy; wobble modification deficiency; sensorineural hearing-loss; trna(val) gene mutation; kearns-sayre-syndrome; c-oxidase deficiency
AB The human mitochondrial genome encodes 13 proteins. All are subunits of the respiratory chain complexes involved in energy metabolism. These proteins are translated by a set of 22 mitochondrial transfer RNAs (tRNAs) that are required for codon reading. Human mitochondrial tRNA genes are hotspots for pathogenic mutations and have attracted interest over the last two decades with the rapid discovery of point mutations associated with a vast array of neuromuscular disorders and diverse clinical phenotypes. In this review, we use a scoring system to determine the pathogenicity of the mutations and summarize the current knowledge of structure-function relationships of these mutant tRNAs. We also provide readers with an overview of a large variety of mechanisms by which mutations may affect the mitochondrial translation machinery and cause disease.
C1 [Scaglia, Fernando; Wong, Lee-Jun C.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
C3 Baylor College of Medicine
RP Wong, LJC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.
EM ljwong@bcm.tmc.edu
CR Allen JF, 1996, J MOL EVOL, V42, P482, DOI 10.1007/BF02352278
   AMES BN, 1989, FREE RADICAL RES COM, V7, P121, DOI 10.3109/10715768909087933
   Anitori R, 2005, MOL GENET METAB, V84, P176, DOI 10.1016/j.ymgme.2004.10.003
   Ashraf SS, 1999, RNA, V5, P188, DOI 10.1017/S1355838299981529
   Bacman SR, 2003, BIOCHEM J, V374, P131, DOI 10.1042/BJ20030222
   Bataillard M, 2001, NEUROLOGY, V56, P405, DOI 10.1212/WNL.56.3.405
   BERKOVIC SF, 1991, LANCET, V338, P457, DOI 10.1016/0140-6736(91)91090-H
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Bidooki S, 2004, NEUROMUSCULAR DISORD, V14, P417, DOI 10.1016/j.nmd.2004.03.004
   Bidooki SK, 1997, AM J HUM GENET, V60, P1430, DOI 10.1086/515460
   BINDOFF LA, 1993, J BIOL CHEM, V268, P19559
   Blakely EL, 2004, J NEUROL SCI, V225, P99, DOI 10.1016/j.jns.2004.07.007
   Borthwick Gillian M, 2006, ANN NEUROL, V59, P570, DOI 10.1002/ana.20758
   BROWN MD, 1992, AM J HUM GENET, V51, P446
   Brulé H, 1998, NUCLEIC ACIDS RES, V26, P537, DOI 10.1093/nar/26.2.537
   Bruno C, 2003, J CHILD NEUROL, V18, P300, DOI 10.1177/08830738030180040401
   Campos Y, 2001, NEUROMUSCULAR DISORD, V11, P477, DOI 10.1016/S0960-8966(00)00223-6
   Cardaioli E, 2005, BIOCHEM BIOPH RES CO, V327, P675, DOI 10.1016/j.bbrc.2004.11.170
   Carnpos Y, 2003, NEUROMUSCULAR DISORD, V13, P416, DOI 10.1016/S0960-8966(03)00039-7
   CASALI C, 1995, BIOCHEM BIOPH RES CO, V213, P588, DOI 10.1006/bbrc.1995.2172
   Chalmers RM, 1997, NEUROLOGY, V49, P589, DOI 10.1212/WNL.49.2.589
   Chapiro E, 2002, EUR J HUM GENET, V10, P851, DOI 10.1038/sj.ejhg.5200894
   Chinnery PF, 1997, NEUROLOGY, V49, P1166, DOI 10.1212/WNL.49.4.1166
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   CIAFALONI E, 1991, NEUROLOGY, V41, P1663, DOI 10.1212/WNL.41.10.1663
   Corona P, 2002, ANN NEUROL, V51, P118, DOI 10.1002/ana.10059
   Coulbault L, 2005, BIOCHEM BIOPH RES CO, V329, P1152, DOI 10.1016/j.bbrc.2005.02.083
   Crimi M, 2004, MITOCHONDRION, V3, P279, DOI 10.1016/j.mito.2004.02.004
   Crimi M, 2003, NEUROLOGY, V60, P1200, DOI 10.1212/01.WNL.0000055865.30580.39
   Darin N, 2006, NEUROMUSCULAR DISORD, V16, P504, DOI 10.1016/j.nmd.2006.05.010
   de Coo IFM, 1998, NEUROLOGY, V50, P293, DOI 10.1212/WNL.50.1.293
   Degoul F, 1998, HUM MOL GENET, V7, P347, DOI 10.1093/hmg/7.3.347
   Deschauer M, 2006, ARCH NEUROL-CHICAGO, V63, P902, DOI 10.1001/archneur.63.6.902
   Dey R, 2000, NEUROMUSCULAR DISORD, V10, P488, DOI 10.1016/S0960-8966(00)00125-5
   DiMauro S, 2002, ADV NEUROL, V89, P217
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47
   Feigenbaum A, 2006, AM J MED GENET A, V140A, P2216, DOI 10.1002/ajmg.a.31436
   Finnilä S, 2001, J MED GENET, V38, P400, DOI 10.1136/jmg.38.6.400
   Finnilä S, 2001, J MOL MED, V79, P641, DOI 10.1007/s001090100268
   Florentz C, 2003, CELL MOL LIFE SCI, V60, P1356, DOI 10.1007/s00018-003-2343-1
   Florentz C, 2001, EMBO REP, V2, P481, DOI 10.1093/embo-reports/kve111
   Franceschina L, 1998, J NEUROL, V245, P755, DOI 10.1007/s004150050283
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Gabriel K, 1996, SCIENCE, V271, P195, DOI 10.1126/science.271.5246.195
   Gambello MJ, 2006, MUSCLE NERVE, V34, P437, DOI 10.1002/mus.20605
   Gattermann N, 1996, BRIT J HAEMATOL, V93, P845, DOI 10.1046/j.1365-2141.1996.d01-1724.x
   Goldstein JD, 1999, PEDIATR DEVEL PATHOL, V2, P78, DOI 10.1007/s100249900094
   GOTO Y, 1992, ANN NEUROL, V31, P672, DOI 10.1002/ana.410310617
   GOTO YI, 1994, BIOCHEM BIOPH RES CO, V202, P1624, DOI 10.1006/bbrc.1994.2119
   Grafakou O, 2003, J INHERIT METAB DIS, V26, P593, DOI 10.1023/A:1025960300710
   Grasbon-Frodl EM, 1999, NEUROGENETICS, V2, P121, DOI 10.1007/s100480050063
   Grasso M, 2001, EUR J HUM GENET, V9, P311, DOI 10.1038/sj.ejhg.5200622
   Hadjigeorgiou GM, 1999, J NEUROL SCI, V164, P153, DOI 10.1016/S0022-510X(99)00062-3
   Hamann CS, 2000, J MOL BIOL, V295, P777, DOI 10.1006/jmbi.1999.3353
   Hanna MG, 1999, CELL MOL LIFE SCI, V55, P691, DOI 10.1007/s000180050327
   Hanna MG, 1998, J NEUROL NEUROSUR PS, V65, P512, DOI 10.1136/jnnp.65.4.512
   HANNA MG, 1995, AM J HUM GENET, V56, P1026
   Hao HL, 1997, MOL CELL BIOL, V17, P6831, DOI 10.1128/MCB.17.12.6831
   HAO HL, 1995, AM J HUM GENET, V56, P1017
   Hao HL, 1996, J BIOL CHEM, V271, P2347, DOI 10.1074/jbc.271.4.2347
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   HATTORI Y, 1994, J NEUROL SCI, V125, P50, DOI 10.1016/0022-510X(94)90241-0
   HAYASHI JI, 1993, BIOCHEM BIOPH RES CO, V197, P1049, DOI 10.1006/bbrc.1993.2584
   Helm M, 1999, BIOCHEMISTRY-US, V38, P13338, DOI 10.1021/bi991061g
   Horváth R, 2003, J MED GENET, V40, P752, DOI 10.1136/jmg.40.10.752
   Houshmand M, 1999, HUM MUTAT, V13, P203, DOI 10.1002/(SICI)1098-1004(1999)13:3<203::AID-HUMU4>3.0.CO;2-3
   Hutchin TP, 2001, EUR J HUM GENET, V9, P385, DOI 10.1038/sj.ejhg.5200640
   Hutchin TP, 2000, J MED GENET, V37, P692, DOI 10.1136/jmg.37.9.692
   Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064
   IONASESCU VV, 1994, NEUROLOGY, V44, P975, DOI 10.1212/WNL.44.5.975
   Jaksch M, 1998, ANN NEUROL, V44, P635, DOI 10.1002/ana.410440409
   Jaksch M, 2001, NEUROLOGY, V57, P1930, DOI 10.1212/WNL.57.10.1930
   Janssen GMC, 1999, J BIOL CHEM, V274, P29744, DOI 10.1074/jbc.274.42.29744
   Jeppesen TD, 2003, J NEUROL SCI, V214, P17, DOI 10.1016/S0022-510X(03)00168-0
   Karadimas C, 2001, J CHILD NEUROL, V16, P531, DOI 10.1177/088307380101600715
   Karadimas CL, 2002, NEUROMUSCULAR DISORD, V12, P865, DOI 10.1016/S0960-8966(02)00072-X
   Kawarai T, 1997, NEUROLOGY, V49, P598, DOI 10.1212/WNL.49.2.598
   Kelley SO, 2001, J BIOL CHEM, V276, P10607, DOI 10.1074/jbc.M008320200
   Kelley SO, 2000, NAT STRUCT BIOL, V7, P862, DOI 10.1038/79612
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kirino Y, 2005, P NATL ACAD SCI USA, V102, P7127, DOI 10.1073/pnas.0500563102
   Kirino Y, 2004, P NATL ACAD SCI USA, V101, P15070, DOI 10.1073/pnas.0405173101
   Kleinle S, 1998, BIOCHEM BIOPH RES CO, V247, P112, DOI 10.1006/bbrc.1998.8729
   Koga A, 2003, NEUROMUSCULAR DISORD, V13, P259, DOI 10.1016/S0960-8966(02)00267-5
   Koge Y, 1998, ANN NEUROL, V43, P835, DOI 10.1002/ana.410430620
   Kogelnik AM, 1998, NUCLEIC ACIDS RES, V26, P112, DOI 10.1093/nar/26.1.112
   LAUBER J, 1991, NUCLEIC ACIDS RES, V19, P1393, DOI 10.1093/nar/19.7.1393
   Levinger L, 2004, NUCLEIC ACIDS RES, V32, P5430, DOI 10.1093/nar/gkh884
   Levinger L, 2003, NUCLEIC ACIDS RES, V31, P1904, DOI 10.1093/nar/gkg282
   Lombes A, 1998, HUM MUTAT, V0, PS175
   Lynn S, 1998, DIABETES, V47, P1800, DOI 10.2337/diabetes.47.11.1800
   Mancuso M, 2004, NEUROLOGY, V62, P2119, DOI 10.1212/01.WNL.0000127608.48406.F1
   Manfredi G, 1996, HUM MUTAT, V7, P158
   Maniura-Weber K, 2004, EUR J HUM GENET, V12, P509, DOI 10.1038/sj.ejhg.5201185
   Mansergh FC, 1999, AM J HUM GENET, V64, P971, DOI 10.1086/302344
   MARIOTTI C, 1994, J CLIN INVEST, V93, P1102, DOI 10.1172/JCI117061
   MASUCCI JP, 1995, MOL CELL BIOL, V15, P2872
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   Melone MAB, 2004, ARCH NEUROL-CHICAGO, V61, P269, DOI 10.1001/archneur.61.2.269
   MERANTE F, 1994, AM J HUM GENET, V55, P437
   Merante F, 1996, HUM MUTAT, V8, P216, DOI 10.1002/(SICI)1098-1004(1996)8:3<216::AID-HUMU4>3.0.CO;2-7
   Meulemans A, 2007, EUR J PAEDIATR NEURO, V11, P17, DOI 10.1016/j.ejpn.2006.10.004
   Meulemans A, 2006, ARCH NEUROL-CHICAGO, V63, P1194, DOI 10.1001/archneur.63.8.1194
   Mitchell AL, 2006, J MED GENET, V43, P175, DOI 10.1136/jmg.2005.032474
   MORAES CT, 1993, NAT GENET, V4, P284, DOI 10.1038/ng0793-284
   MORAES CT, 1993, J CLIN INVEST, V92, P2906, DOI 10.1172/JCI116913
   MORTEN KJ, 1993, HUM MOL GENET, V2, P2081, DOI 10.1093/hmg/2.12.2081
   Moslemi AR, 2004, NEUROMUSCULAR DISORD, V14, P46, DOI 10.1016/S0960-8966(03)00168-8
   NELSON I, 1995, ANN NEUROL, V37, P400, DOI 10.1002/ana.410370317
   Nishigaki Y, 2003, NEUROMUSCULAR DISORD, V13, P334, DOI 10.1016/S0960-8966(02)00283-3
   Nishigaki Y, 2002, NEUROLOGY, V58, P1282, DOI 10.1212/WNL.58.8.1282
   Nishino I, 1996, BIOCHEM BIOPH RES CO, V225, P180, DOI 10.1006/bbrc.1996.1150
   OHAMA E, 1987, ACTA NEUROPATHOL, V74, P226, DOI 10.1007/BF00688185
   Ozawa M, 1997, MUSCLE NERVE, V20, P271, DOI 10.1002/(SICI)1097-4598(199703)20:3<271::AID-MUS2>3.0.CO;2-8
   Pandya A, 1999, AM J HUM GENET, V65, P1803, DOI 10.1086/302658
   Park H, 2003, BIOCHEMISTRY-US, V42, P958, DOI 10.1021/bi026882r
   Perucca-Lostanlen D, 2002, BBA-MOL BASIS DIS, V1588, P210, DOI 10.1016/S0925-4439(02)00167-9
   Pesole G, 1999, J MOL EVOL, V48, P427, DOI 10.1007/PL00006487
   Pulkes T, 2000, NEUROLOGY, V55, P1210, DOI 10.1212/WNL.55.8.1210
   Pulkes T, 2005, NEUROMUSCULAR DISORD, V15, P364, DOI 10.1016/j.nmd.2005.01.006
   PUTZ J, 1994, NAT STRUCT BIOL, V1, P580, DOI 10.1038/nsb0994-580
   Raffelsberger T, 2001, NEUROLOGY, V57, P2298, DOI 10.1212/WNL.57.12.2298
   REID FM, 1994, HUM MUTAT, V3, P243, DOI 10.1002/humu.1380030311
   Rossmanith W, 2003, ANN NEUROL, V54, P820, DOI 10.1002/ana.10753
   ROSSMANITH W, 1995, J BIOL CHEM, V270, P12885, DOI 10.1074/jbc.270.21.12885
   Sacconi S, 2002, ARCH NEUROL-CHICAGO, V59, P1013, DOI 10.1001/archneur.59.6.1013
   Sahashi K, 2001, J MED GENET, V38, P703, DOI 10.1136/jmg.38.10.703
   Sakuta R, 2002, PEDIATR NEUROL, V27, P397, DOI 10.1016/S0887-8994(02)00456-3
   SAKUTA R, 1993, J NEUROL SCI, V115, P158, DOI 10.1016/0022-510X(93)90219-O
   SANTORELLI FM, 1995, BIOCHEM BIOPH RES CO, V216, P835, DOI 10.1006/bbrc.1995.2697
   Santorelli FM, 1996, PEDIATR NEUROL, V15, P145, DOI 10.1016/0887-8994(96)00163-4
   Santorelli FM, 1997, ANN NEUROL, V42, P256, DOI 10.1002/ana.410420220
   Santorelli FM, 1997, NEUROMUSCULAR DISORD, V7, P156, DOI 10.1016/S0960-8966(97)00444-6
   Scaglia F, 2003, AM J MED GENET A, V123A, P172, DOI 10.1002/ajmg.a.20315
   Scaglia F, 2006, CNS DRUGS, V20, P443, DOI 10.2165/00023210-200620060-00002
   Scheffler IE, 2001, ADV DRUG DELIVER REV, V49, P3, DOI 10.1016/S0169-409X(01)00123-5
   SCHON EA, 1992, BIOCHIM BIOPHYS ACTA, V1101, P206, DOI 10.1016/0005-2728(92)90226-R
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   SEIBEL P, 1994, BIOCHEM BIOPH RES CO, V204, P482, DOI 10.1006/bbrc.1994.2485
   Seki A, 1997, PEDIATR NEUROL, V17, P161, DOI 10.1016/S0887-8994(97)00080-5
   Seneca S, 2000, J INHERIT METAB DIS, V23, P853, DOI 10.1023/A:1026729223050
   Seneca S, 2005, AM J MED GENET A, V137A, P170, DOI 10.1002/ajmg.a.30854
   Seneca S, 2001, ARCH NEUROL-CHICAGO, V58, P1113, DOI 10.1001/archneur.58.7.1113
   Seneca S, 1998, J MED GENET, V35, P963, DOI 10.1136/jmg.35.11.963
   Sevior KB, 1998, AM J MED GENET, V75, P179, DOI 10.1002/(SICI)1096-8628(19980113)75:2<179::AID-AJMG11>3.0.CO;2-M
   Shaag A, 1997, BIOCHEM BIOPH RES CO, V233, P637, DOI 10.1006/bbrc.1997.6496
   Shin WS, 2000, AM J HUM GENET, V67, P1617, DOI 10.1086/316896
   SHOFFNER JM, 1995, NEUROLOGY, V45, P286, DOI 10.1212/WNL.45.2.286
   SHOUBRIDGE EA, 1994, J BIOENERG BIOMEMBR, V26, P301, DOI 10.1007/BF00763101
   Shtilbans A, 1999, J CHILD NEUROL, V14, P610, DOI 10.1177/088307389901400910
   SILVESTRI G, 1994, HUM MUTAT, V3, P37, DOI 10.1002/humu.1380030107
   Silvestri G, 1998, NEUROMUSCULAR DISORD, V8, P291, DOI 10.1016/S0960-8966(98)00037-6
   Silvestri G, 2000, NEUROLOGY, V54, P1693, DOI 10.1212/WNL.54.8.1693
   Silvestri G, 1996, BIOCHEM BIOPH RES CO, V220, P623, DOI 10.1006/bbrc.1996.0453
   Sohm B, 2003, J MOL BIOL, V328, P995, DOI 10.1016/S0022-2836(03)00373-5
   Spagnolo M, 2001, NEUROMUSCULAR DISORD, V11, P481, DOI 10.1016/S0960-8966(01)00195-X
   Spinazzola A, 2004, NEUROMUSCULAR DISORD, V14, P815, DOI 10.1016/j.nmd.2004.09.002
   STEINBERG S, 1994, J MOL BIOL, V236, P982, DOI 10.1016/0022-2836(94)90004-3
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   Sue CM, 1999, NEUROLOGY, V52, P1905, DOI 10.1212/WNL.52.9.1905
   Suzuki T, 2002, EMBO J, V21, P6581, DOI 10.1093/emboj/cdf656
   Suzuki Y, 1997, DIABETES CARE, V20, P1138, DOI 10.2337/diacare.20.7.1138
   Swalwell H, 2006, NEUROLOGY, V66, P447, DOI 10.1212/01.wnl.0000196490.36349.83
   SWEENEY MG, 1993, Q J MED, V86, P709
   TANAKA M, 1990, LANCET, V336, P1452, DOI 10.1016/0140-6736(90)93162-I
   TANIIKE M, 1992, BIOCHEM BIOPH RES CO, V186, P47, DOI 10.1016/S0006-291X(05)80773-9
   Taylor RW, 1998, BIOCHEM BIOPH RES CO, V243, P47, DOI 10.1006/bbrc.1997.8055
   Taylor RW, 2004, NEUROLOGY, V62, P1420, DOI 10.1212/01.WNL.0000120667.77372.46
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Taylor RW, 2002, NEUROMUSCULAR DISORD, V12, P659, DOI 10.1016/S0960-8966(02)00026-3
   Terasaki F, 2001, JPN CIRC J, V65, P691, DOI 10.1253/jcj.65.691
   Tessa A, 1999, EUR J HUM GENET, V7, P847, DOI 10.1038/sj.ejhg.5200380
   Tiranti V, 1999, NEUROMUSCULAR DISORD, V9, P66, DOI 10.1016/S0960-8966(98)00103-5
   Tiranti V, 1998, ANN NEUROL, V43, P98, DOI 10.1002/ana.410430116
   TIRANTI V, 1995, HUM MOL GENET, V4, P1421, DOI 10.1093/hmg/4.8.1421
   Tomari Y, 2003, J BIOL CHEM, V278, P16828, DOI 10.1074/jbc.M213216200
   Toompuu M, 2002, J BIOL CHEM, V277, P22240, DOI 10.1074/jbc.M200338200
   Tulinius M, 2003, NEUROPEDIATRICS, V34, P87
   TUOHY TMF, 1992, J MOL BIOL, V228, P1042, DOI 10.1016/0022-2836(92)90313-9
   Tzen CY, 2001, KIDNEY INT, V59, P846, DOI 10.1046/j.1523-1755.2001.00567.x
   Uusimaa J, 2004, PEDIATRICS, V114, P443, DOI 10.1542/peds.114.2.443
   Van Camp G, 2000, CLIN GENET, V57, P409, DOI 10.1034/j.1399-0004.2000.570601.x
   van den Bosch BJC, 2004, NEUROMUSCULAR DISORD, V14, P683, DOI 10.1016/j.nmd.2004.06.004
   Verhoeven K, 1999, EUR J HUM GENET, V7, P45, DOI 10.1038/sj.ejhg.5200247
   Verma A, 1997, PEDIATR RES, V42, P448, DOI 10.1203/00006450-199710000-00005
   Vissing J, 1998, NEUROLOGY, V50, P1875, DOI 10.1212/WNL.50.6.1875
   Vives-Bauza C, 2003, J INHERIT METAB DIS, V26, P507, DOI 10.1023/A:1025133629685
   Vives-Bauza C, 2001, ANN MED, V33, P493, DOI 10.3109/07853890109002099
   Vos MH, 2001, BIOCHEMISTRY-US, V40, P7806, DOI 10.1021/bi010060x
   Weber K, 1997, AM J HUM GENET, V60, P373
   Wilson FH, 2004, SCIENCE, V306, P1190, DOI 10.1126/science.1102521
   Wittenhagen LM, 2003, TRENDS BIOCHEM SCI, V28, P605, DOI 10.1016/j.tibs.2003.09.006
   Wittenhagen LM, 2003, NUCLEIC ACIDS RES, V31, P596, DOI 10.1093/nar/gkg131
   Wong LJC, 2007, MUSCLE NERVE, V36, P279, DOI 10.1002/mus.20807
   Wong LJC, 2002, AM J MED GENET, V113, P59, DOI 10.1002/ajmg.10767
   Yan H, 2006, J BIOL CHEM, V281, P3926, DOI 10.1074/jbc.M509822200
   Yasukawa T, 2000, NUCLEIC ACIDS RES, V28, P3779, DOI 10.1093/nar/28.19.3779
   Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251
   Yasukawa T, 2001, EMBO J, V20, P4794, DOI 10.1093/emboj/20.17.4794
   YOON KL, 1991, BIOCHEM BIOPH RES CO, V176, P1112, DOI 10.1016/0006-291X(91)90399-R
NR 204
TC 60
Z9 68
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD FEB 15
PY 2008
VL 37
IS 2
BP 150
EP 171
DI 10.1002/mus.20917
PG 22
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 258WK
UT WOS:000252900500002
PM 17999409
DA 2024-11-01
ER

PT J
AU Gianotti, TF
   Sookoian, S
   Dieuzeide, G
   García, SI
   Gemma, C
   González, CD
   Pirola, CJ
AF Gianotti, Tomas F.
   Sookoian, Silvia
   Dieuzeide, Guillermo
   Garcia, Silvia I.
   Gemma, Carolina
   Gonzalez, Claudio D.
   Pirola, Carlos J.
TI A decreased mitochondrial DNA content is related to insulin resistance in adolescents
SO OBESITY
LA English
DT Article
ID real-time pcr; metabolic syndrome; diabetes-mellitus; coactivator pgc-1; skeletal-muscle; uric-acid; disease; risk; gene; biogenesis
AB The aim of this study was to investigate whether mitochondrial DNA ( mtDNA) content is associated with insulin resistance (IR) in a sample of adolescents with features of metabolic syndrome. We further studied the link between polymorphisms in three genes involved in mitochondrial biogenesis and the presence of deleted mtDNA and mtDNA content. Data and blood samples were collected from 175 adolescents out of a cross-sectional, population-based study of 934 high school students. On the basis of the median value of homeostasis model assessment of IR (HOMA-IR) of the whole sample (2.2), the population was divided into two groups: noninsulin resistance (NIR) and IR. mtDNA quantification using nuclear DNA (nDNA) as a reference was carried out using a real-time quantitative PCR method. Genotyping for peroxisome proliferator-activated receptor gamma. (PPAR-gamma) (pro12Ala), PPAR-gamma coactivator-1 alpha (PGC-1 alpha) (Gly482Ser), and Tfam (rs1937 and rs12247015) polymorphisms was performed by PCR-based restriction fragment length polymorphism. Long-extension PCR was performed to amplify the whole mitochondrial genome. The mtDNA/nDNA ratio was significantly lower in the IR group (median: 9.08, range: 68.94) in comparison with the NIR group (12.24, 71.92) (P < 0.03). Besides, the mtDNA/nDNA ratio was inversely correlated with HOMA (R: -0.18, P < 0.02), glucose (R: -0.21, P < 0.008), and uric acid (R: -0.18, P < 0.03). Genotypes for the PPAR-gamma, PGC-1 gamma, and Tfam variants were not associated with the mtDNA/nDNA ratio. Long-extension PCR did not show significant levels of mtDNA deletions. In conclusion, our findings indicate that reduced mtDNA content in peripheral leukocytes is associated with IR. This result seems not to be related with the previously mentioned variants in genes involved in the regulation of mitochondrial biogenesis.
C1 [Gianotti, Tomas F.; Sookoian, Silvia; Garcia, Silvia I.; Gemma, Carolina; Pirola, Carlos J.] Univ Buenos Aires, CONICET, Inst Med Res A Lanari, Mol Genet & Biol Complex Dis Dept, Ciudad Autonoma De Bueno, Argentina.
   [Gonzalez, Claudio D.] Univ Buenos Aires, Sch Med, Dept Pharmacol, Buenos Aires, DF, Argentina.
   [Dieuzeide, Guillermo] CAIDEM, Chacabuco, Argentina.
C3 Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; University of Buenos Aires
RP Pirola, CJ (corresponding author), Univ Buenos Aires, CONICET, Inst Med Res A Lanari, Mol Genet & Biol Complex Dis Dept, Ciudad Autonoma De Bueno, Argentina.
EM pirola.carlos@lanari.fmed.uba.ar
CR Alberio S, 2007, MITOCHONDRION, V7, P6, DOI 10.1016/j.mito.2006.11.010
   Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216
   Bai RK, 2004, ANN NY ACAD SCI, V1011, P304, DOI 10.1196/annals.1293.029
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Cho YM, 2007, DIABETES RES CLIN PR, V77, PS172, DOI 10.1016/j.diabres.2007.01.052
   Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430
   Ek J, 2001, DIABETOLOGIA, V44, P2220, DOI 10.1007/s001250100032
   Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109
   Ford ES, 2007, CIRCULATION, V115, P2526, DOI 10.1161/CIRCULATIONAHA.106.657627
   Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356
   Garesse R, 2001, GENE, V263, P1, DOI 10.1016/S0378-1119(00)00582-5
   Gemma C, 2006, OBESITY, V14, P2193, DOI 10.1038/oby.2006.257
   Gleyzer N, 2005, MOL CELL BIOL, V25, P1354, DOI 10.1128/MCB.25.4.1354-1366.2005
   Hara K, 2002, DIABETOLOGIA, V45, P740, DOI 10.1007/s00125-002-0803-z
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   KAWASAKI ES, 1990, PCR PROTOCOLS GUIDE, V18, P146
   Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944
   Knutti D, 2001, TRENDS ENDOCRIN MET, V12, P360, DOI 10.1016/S1043-2760(01)00457-X
   Lee HK, 2005, ANN NY ACAD SCI, V1042, P1, DOI 10.1196/annals.1338.001
   Lee HK, 1998, DIABETES RES CLIN PR, V42, P161, DOI 10.1016/S0168-8227(98)00110-7
   LEE J, 1995, AM J EPIDEMIOL, V142, P288, DOI 10.1093/oxfordjournals.aje.a117634
   Lee JW, 2007, HYPERTENS RES, V30, P5, DOI 10.1291/hypres.30.5
   Liang P, 1997, DIABETES, V46, P920, DOI 10.2337/diabetes.46.5.920
   Morino K, 2006, DIABETES, V55, PS9, DOI 10.2337/db06-S002
   Nisoli E, 2007, CIRC RES, V100, P795, DOI 10.1161/01.RES.0000259591.97107.6c
   Park SY, 2005, J BIOL CHEM, V280, P9855, DOI 10.1074/jbc.M409399200
   Porto PI, 2004, PEDIATR RES, V55, P836, DOI 10.1203/01.PDR.0000119367.21770.D7
   Rutledge RG, 2004, NUCLEIC ACIDS RES, V32, P0, DOI 10.1093/nar/gnh177
   Song J, 2001, DIABETES CARE, V24, P865, DOI 10.2337/diacare.24.5.865
   Sookoian S, 2005, AM J HYPERTENS, V18, P1271, DOI 10.1016/j.amjhyper.2005.04.014
   Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000
   Weiss R, 2004, NEW ENGL J MED, V350, P2362, DOI 10.1056/NEJMoa031049
   Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X
   Yen CJ, 1997, BIOCHEM BIOPH RES CO, V241, P270, DOI 10.1006/bbrc.1997.7798
NR 34
TC 62
Z9 68
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA
SN 1930-7381
EI 
J9 OBESITY
JI Obesity
PD JUL 15
PY 2008
VL 16
IS 7
BP 1591
EP 1595
DI 10.1038/oby.2008.253
PG 5
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 321RX
UT WOS:000257325300019
PM 18451773
DA 2024-11-01
ER

PT J
AU Pijl, S
   Westerberg, BD
AF Pijl, Sipke
   Westerberg, Brian D.
TI Cochlear implantation results in patients with Kearns-Sayre syndrome
SO EAR AND HEARING
LA English
DT Article
ID progressive external ophthalmoplegia; point mutation; hearing-loss; mitochondrial-dna; features; deafness
AB Objectives: To examine the evidence for a cochlear, retrocochlear, or central site of lesion for deafness in two cochlear implant recipients with Kearns-Sayre Syndrome (KSS). Design: Speech perception data and electrically evoked Auditory Brainstem. (eABR) and Middle Latency Responses were obtained in two patients with KSS and compared with a group of non-KSS implant recipients. Results: Speech perception data and electrophysiological responses for the patients with KSS were similar to those obtained in non-KSS patients. Conclusions: Results are consistent with an initial cochlear site of lesion for deafness in KSS, and with relative sparing of the central auditory pathway early in the disease.
C1 [Pijl, Sipke] Univ British Columbia, Sch Audiol & Speech Sci, Vancouver, BC V5Z 1M9, Canada.
   [Westerberg, Brian D.] Univ British Columbia, Div Otolaryngol, Vancouver, BC V5Z 1M9, Canada.
C3 University of British Columbia; University of British Columbia
RP Pijl, S (corresponding author), St Pauls Rotary Hearing Clin, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
EM SPijl@providencehealth.bc.ca
CR Cullington HE, 1999, J LARYNGOL OTOL, V113, P353, DOI 10.1017/S0022215100143956
   DAROFF RB, 1966, NEUROLOGY, V16, P161, DOI 10.1212/WNL.16.2_Part_1.161
   Ensink RJH, 1998, CLIN OTOLARYNGOL, V23, P3
   HUIZING EH, 1987, ACTA OTO-LARYNGOL, V0, P117
   KOSMORSKY G, 1991, NEUROL CLIN, V9, P147, DOI 10.1016/S0733-8619(18)30308-6
   LINDSAY JR, 1976, ARCH OTOLARYNGOL, V102, P747
   Nishizaki K, 1999, ACTA OTO-LARYNGOL, V0, P34
   Oshima T, 1996, LARYNGOSCOPE, V106, P43, DOI 10.1097/00005537-199601000-00009
   Raut V, 2002, J LARYNGOL OTOL, V116, P373
   Rosenthal EL, 1999, AM J OTOL, V20, P187
   Sue CM, 1998, J NEUROL NEUROSUR PS, V65, P233, DOI 10.1136/jnnp.65.2.233
   Tamagawa Y, 1997, ANN OTO RHINOL LARYN, V106, P338
   Tono T, 1998, AM J OTOL, V19, P754
   Yamaguchi T, 1997, ADV OTO-RHINO-LARYNG, V52, P321
   Yamasoba T, 1999, NEUROLOGY, V52, P1705, DOI 10.1212/WNL.52.8.1705
NR 15
TC 5
Z9 8
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0196-0202
EI 
J9 EAR HEARING
JI Ear Hear.
PD JUN 15
PY 2008
VL 29
IS 3
BP 472
EP 475
DI 10.1097/01.aud.0000310791.83193.62
PG 4
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA 297OP
UT WOS:000255626300014
PM 18382375
DA 2024-11-01
ER

PT J
AU Guidi, C
   Potenza, L
   Sestill, P
   Martinelli, C
   Guescini, M
   Stocchi, L
   Zeppa, S
   Polidori, E
   Annibalini, G
   Stocchi, V
AF Guidi, Chiara
   Potenza, Lucia
   Sestill, Piero
   Martinelli, Chiara
   Guescini, Michele
   Stocchi, Laura
   Zeppa, Sabrina
   Polidori, Emanuela
   Annibalini, Giosue
   Stocchi, Vilberto
TI Differential effect of creatine on oxidatively-injured mitochondrial and nuclear DNA
SO BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
LA English
DT Article
DE creatine; oxidative DNA damage; mitochondrial DNA; nuclear DNA; antioxidant
ID single-strand breakage; hydrogen-peroxide; microsatellite instability; tert-butylhydroperoxide; colorectal carcinomas; muscle metabolism; damage; supplementation; mutations; performance
AB Creatine is a naturally occurring compound obtained in humans from endogenous production and consumption through the diet. It is used as an ergogenic aid to improve exercise performance and increase fat-free mass. Lately, creatine's positive therapeutic benefits in various oxidative stress-associated diseases have been reported in literature and, more recently, creatine has also been shown to exert direct antioxidant effects. Oxidatively-challenged DNA was analysed to show possible protective effects of creatine. Acellular and cellular studies were carried out. Acellular assays, performed using molecular approaches, showed that creatine protects circular and linear DNA from oxidative attacks. Nuclear and mitochondrial DNAs from oxidatively-injured human umbilical vein endothelial cells were analyzed. Creatine supplementation showed significant genoprotective activity on mitochondrial DNA. This evidence suggests that creatine may play an important role in mitochondrial genome stability in that it could normalize mitochondrial inutagenesis and its functional consequences. Thus, creatine supplementation could be used to prevent or ameliorate diseases related to mitochondrial DNA mutations, and possibly to delay aging. (C) 2007 Elsevier B.V. All rights reserved.
C1 [Sestill, Piero] Univ Urbino Carlo Bo, Ist Farmacol & Farmacognosia, I-61029 Urbino, Italy.
   [Potenza, Lucia; Stocchi, Vilberto] Univ Urbino Carlo Bo, Ist Chim Biol Giorgio Fornaini, Urbino, Italy.
   [Guidi, Chiara; Sestill, Piero; Martinelli, Chiara; Guescini, Michele; Stocchi, Laura; Zeppa, Sabrina; Polidori, Emanuela; Annibalini, Giosue] Univ Urbino Carlo Bo, Ist Ric Attivita Motoria, Urbino, PU, Italy.
C3 University of Urbino; University of Urbino; University of Urbino
RP Sestill, P (corresponding author), Univ Urbino Carlo Bo, Ist Farmacol & Farmacognosia, I-61029 Urbino, Italy.
EM piero.sestili@uniurb.it
CR Adam W, 2000, PHOTOCHEM PHOTOBIOL, V72, P619, DOI 10.1562/0031-8655(2000)072<0619:NHCTHT>2.0.CO;2
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   BALSOM PD, 1994, SPORTS MED, V18, P268, DOI 10.2165/00007256-199418040-00005
   Banmeyer I, 2005, FEBS LETT, V579, P2327, DOI 10.1016/j.febslet.2005.03.027
   Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633
   Bender A, 2006, NEUROLOGY, V67, P1262, DOI 10.1212/01.wnl.0000238518.34389.12
   BENDER A, 2007, NEUROBIOL AGING, V0, P0
   Benzi G, 2000, PHARMACOL RES, V41, P255, DOI 10.1006/phrs.1999.0618
   Berneburg M, 2005, J INVEST DERMATOL, V125, P213, DOI 10.1111/j.0022-202X.2005.23806.x
   Bohr VA, 2002, FREE RADICAL BIO MED, V32, P804, DOI 10.1016/S0891-5849(02)00787-6
   BURGART LJ, 1995, AM J PATHOL, V147, P1105
   Cantoni O, 1996, ARCH TOX S, V18, P223
   Cao J, 2006, TOXICOL SCI, V91, P476, DOI 10.1093/toxsci/kfj153
   Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502
   Casey A, 1996, AM J PHYSIOL-ENDOC M, V271, PE31, DOI 10.1152/ajpendo.1996.271.1.E31
   Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev
   Cortopassi GA, 2002, FREE RADICAL BIO MED, V33, P605, DOI 10.1016/S0891-5849(02)00966-8
   Demant TW, 1999, SPORTS MED, V28, P49, DOI 10.2165/00007256-199928010-00005
   Deng GM, 1999, EXP NEUROL, V159, P309, DOI 10.1006/exnr.1999.7145
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   DiMauro S, 2006, MUSCLE NERVE, V34, P265, DOI 10.1002/mus.20598
   EARNEST CP, 1995, ACTA PHYSIOL SCAND, V153, P207, DOI 10.1111/j.1748-1716.1995.tb09854.x
   Ellis AC, 2004, CNS DRUGS, V18, P967
   Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Graham A S, 1999, J AM PHARM ASSOC (WASH), V39, P803
   Guidarelli A, 1995, J PHARMACOL EXP THER, V275, P1575
   Habano W, 1998, ONCOGENE, V17, P1931, DOI 10.1038/sj.onc.1202112
   Habano W, 1999, INT J CANCER, V83, P625, DOI 10.1002/(SICI)1097-0215(19991126)83:5<625::AID-IJC10>3.0.CO;2-N
   Habano W, 2000, GASTROENTEROLOGY, V118, P835, DOI 10.1016/S0016-5085(00)70169-7
   HEERDT BG, 1994, CANCER RES, V54, P3912
   Hersch SM, 2006, NEUROLOGY, V66, P250, DOI 10.1212/01.wnl.0000194318.74946.b6
   Hillebrand U, 2006, CARDIOVASC RES, V69, P916, DOI 10.1016/j.cardiores.2005.11.025
   Hollins DL, 2006, FREE RADICAL BIO MED, V40, P1220, DOI 10.1016/j.freeradbiomed.2005.11.011
   HOLT IJ, 1988, J NEUROL NEUROSUR PS, V51, P1075, DOI 10.1136/jnnp.51.8.1075
   Ibuki Y, 2002, ENVIRON TOXICOL PHAR, V12, P37, DOI 10.1016/S1382-6689(02)00014-5
   ILIAKIS GE, 1992, RADIAT RES, V131, P192, DOI 10.2307/3578441
   Jarrett SG, 2006, REDOX REP, V11, P144, DOI 10.1179/135100006X116646
   Juhn MS, 1998, CLIN J SPORT MED, V8, P286, DOI 10.1097/00042752-199810000-00006
   Kasparová S, 2005, NEUROCHEM INT, V46, P601, DOI 10.1016/j.neuint.2005.02.006
   Kasparová S, 2000, BRAIN RES BULL, V53, P431, DOI 10.1016/S0361-9230(00)00405-6
   KIM KW, 1988, J BIOL CHEM, V263, P4704
   Kraemer WJ, 1999, CLIN SPORT MED, V18, P651, DOI 10.1016/S0278-5919(05)70174-5
   LATOUR I, 1995, FEBS LETT, V373, P299, DOI 10.1016/0014-5793(95)01065-M
   Lawler JM, 2002, BIOCHEM BIOPH RES CO, V290, P47, DOI 10.1006/bbrc.2001.6164
   MAKRIGIORGOS GM, 1995, FREE RADICAL BIO MED, V18, P669, DOI 10.1016/0891-5849(94)00184-L
   Mandavilli BS, 2000, BRAIN RES, V885, P45, DOI 10.1016/S0006-8993(00)02926-7
   Melidou M, 2005, FREE RADICAL BIO MED, V39, P1591, DOI 10.1016/j.freeradbiomed.2005.08.009
   Milano J, 2000, NUCLEIC ACIDS RES, V28, P968, DOI 10.1093/nar/28.4.968
   Mujika I, 1997, INT J SPORTS MED, V18, P491, DOI 10.1055/s-2007-972670
   Odyuo MM, 2005, FREE RADICAL RES, V39, P499, DOI 10.1080/10715760500072305
   Parrella P, 2001, CANCER RES, V61, P7623
   Pearlman JP, 2006, NUTR REV, V64, P80, DOI 10.1301/nmr.2006.feb.80-88
   Persky AM, 2001, PHARMACOL REV, V53, P161
   PIECZENIK SR, 2007, EXP MOL PATHOL, V0, P0
   Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108
   RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465
   Santos Janine H, 2002, METHODS MOL BIOL, V197, P159, DOI 10.1385/1-59259-284-8:159
   Santos JH, 2003, J BIOL CHEM, V278, P1728, DOI 10.1074/jbc.M208752200
   Sawyer DE, 1999, MUTAT RES-DNA REPAIR, V434, P161, DOI 10.1016/S0921-8777(99)00027-0
   Sestili P, 2006, FREE RADICAL BIO MED, V40, P837, DOI 10.1016/j.freeradbiomed.2005.10.035
   Sestili P, 1998, FREE RADICAL BIO MED, V25, P196, DOI 10.1016/S0891-5849(98)00040-9
   Sestili P, 2005, DNA REPAIR, V4, P271, DOI 10.1016/j.dnarep.2004.09.007
   Sestili P, 2002, BIOCHEM J, V364, P121, DOI 10.1042/bj3640121
   Sestili P, 2006, MUTAT RES-GEN TOX EN, V607, P205, DOI 10.1016/j.mrgentox.2006.04.018
   Sikorsky JA, 2004, BIOCHEM BIOPH RES CO, V323, P823, DOI 10.1016/j.bbrc.2004.08.168
   Smith SA, 1998, J APPL PHYSIOL, V85, P1349, DOI 10.1152/jappl.1998.85.4.1349
   SU YYM, 2006, FEBS LETT, V580, P4136
   Van Houten B, 2006, DNA REPAIR, V5, P145, DOI 10.1016/j.dnarep.2005.03.002
   Vandenberghe K, 1997, J APPL PHYSIOL, V83, P2055, DOI 10.1152/jappl.1997.83.6.2055
   Volek JS, 1999, MED SCI SPORT EXER, V31, P1147, DOI 10.1097/00005768-199908000-00011
   VOLEK WKJ, 1997, J STRENGTH COND RES, V10, P200
   Walker J B, 1979, ADV ENZYMOL RELAT AREAS MOL BIOL, V50, P177
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Walzel B, 2002, J BIOL CHEM, V277, P37503, DOI 10.1074/jbc.M201168200
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   Wyss M, 2002, NEUROSCIENCE, V112, P243, DOI 10.1016/S0306-4522(02)00088-X
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
NR 81
TC 64
Z9 76
U1 0
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4165
EI 1872-8006
J9 BBA-GEN SUBJECTS
JI Biochim. Biophys. Acta-Gen. Subj.
PD JAN 15
PY 2008
VL 1780
IS 1
BP 16
EP 26
DI 10.1016/j.bbagen.2007.09.018
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 249OV
UT WOS:000252239200003
PM 18022765
DA 2024-11-01
ER

PT J
AU Knott, AB
   Perkins, G
   Schwarzenbacher, R
   Bossy-Wetzel, E
AF Knott, Andrew B.
   Perkins, Guy
   Schwarzenbacher, Robert
   Bossy-Wetzel, Ella
TI Mitochondrial fragmentation in neurodegeneration
SO NATURE REVIEWS NEUROSCIENCE
LA English
DT Review
ID differentiation-associated protein-1; dynamin-related gtpase; human skeletal-muscle; marie-tooth-disease; cyclin-dependent kinases; cell-death; alzheimers-disease; optic atrophy; oxidative damage; dna mutations
AB Mitochondria are remarkably dynamic organelles that migrate, divide and fuse. Cycles of mitochondrial fission and fusion ensure metabolite and mitochondrial DNA mixing and dictate organelle shape, number and bioenergetic functionality. There is mounting evidence that mitochondrial dysfunction is an early and causal event in neurodegeneration. Mutations in the mitochondrial fusion GTPases mitofusin 2 and optic atrophy 1, neurotoxins and oxidative stress all disrupt the cable-like morphology of functional mitochondria. This results in impaired bioenergetics and mitochondrial migration, and can trigger neurodegeneration. These findings suggest potential new treatment avenues for neurodegenerative diseases.
C1 [Knott, Andrew B.; Bossy-Wetzel, Ella] Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Orlando, FL 32816 USA.
   [Perkins, Guy] Univ Calif San Diego, Sch Med, Natl Ctr Microscopy & Imaging Res, La Jolla, CA 92093 USA.
   [Schwarzenbacher, Robert] Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria.
C3 State University System of Florida; University of Central Florida; University of California System; University of California San Diego; Salzburg University
RP Bossy-Wetzel, E (corresponding author), Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, 4000 Cent Florida Blvd, Orlando, FL 32816 USA.
EM ebossywe@mail.ucf.edu
FU NCRR NIH HHS [P41 RR004050, P41 RR004050-208517] Funding Source: Medline; NEI NIH HHS [R01 EY016164, R01 EY016164-02, R01 EY016164-03, R01 EY016164-04, R01 EY016164-05, R01 EY016164-01] Funding Source: Medline; NIEHS NIH HHS [P42 ES010337-09, P42 ES010337] Funding Source: Medline; NINDS NIH HHS [R01 NS047456-04, R01 NS055193-01A2, R01 NS047456-05, R01 NS047456-01S1, R01 NS047456-02, R01 NS047456-03S1, R01 NS047456-03, R01 NS047456, R01 NS055193-02, R01 NS055193, R01 NS047456-01] Funding Source: Medline
CR Abdelwahid E, 2007, DEV CELL, V12, P793, DOI 10.1016/j.devcel.2007.04.004
   Alirol E, 2006, MOL BIOL CELL, V17, P4593, DOI 10.1091/mbc.E06-05-0377
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Bach D, 2003, J BIOL CHEM, V278, P17190, DOI 10.1074/jbc.M212754200
   Baloh RH, 2007, J NEUROSCI, V27, P422, DOI 10.1523/JNEUROSCI.4798-06.2007
   Barsoum MJ, 2006, EMBO J, V25, P3900, DOI 10.1038/sj.emboj.7601253
   Baxter RV, 2002, NAT GENET, V30, P21, DOI 10.1038/ng796
   Benard G, 2007, J CELL SCI, V120, P838, DOI 10.1242/jcs.03381
   Benchoua A, 2006, MOL BIOL CELL, V17, P1652, DOI 10.1091/mbc.E05-07-0607
   BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303
   Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834
   Bogenhagen DF, 2008, J BIOL CHEM, V283, P3665, DOI 10.1074/jbc.M708444200
   Bras M, 2007, MOL CELL BIOL, V27, P7073, DOI 10.1128/MCB.02116-06
   Bredesen DE, 2006, NATURE, V443, P796, DOI 10.1038/nature05293
   Brooks C, 2007, P NATL ACAD SCI USA, V104, P11649, DOI 10.1073/pnas.0703976104
   Busser J, 1998, J NEUROSCI, V18, P2801
   Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Cartoni R, 2005, J PHYSIOL-LONDON, V567, P349, DOI 10.1113/jphysiol.2005.092031
   Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9
   Cerveny KL, 2003, MOL BIOL CELL, V14, P4126, DOI 10.1091/mbc.E03-02-0092
   Chan DC, 2006, ANNU REV CELL DEV BI, V22, P79, DOI 10.1146/annurev.cellbio.22.010305.104638
   Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010
   Chang CR, 2007, J BIOL CHEM, V282, P21583, DOI 10.1074/jbc.C700083200
   Chang DTW, 2006, NEUROSCIENCE, V141, P727, DOI 10.1016/j.neuroscience.2006.01.034
   Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200
   Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046
   Chen HC, 2007, CELL, V130, P548, DOI 10.1016/j.cell.2007.06.026
   Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101
   Cribbs JT, 2007, EMBO REP, V8, P939, DOI 10.1038/sj.embor.7401062
   Crouch PJ, 2005, J NEUROSCI, V25, P672, DOI 10.1523/JNEUROSCI.4276-04.2005
   Cuesta A, 2002, NAT GENET, V30, P22, DOI 10.1038/ng798
   Cui LB, 2006, CELL, V127, P59, DOI 10.1016/j.cell.2006.09.015
   Damiano M, 2006, J NEUROCHEM, V96, P1349, DOI 10.1111/j.1471-4159.2006.03619.x
   Davies VJ, 2007, HUM MOL GENET, V16, P1307, DOI 10.1093/hmg/ddm079
   Detmer SA, 2007, NAT REV MOL CELL BIO, V8, P870, DOI 10.1038/nrm2275
   Detmer SA, 2007, J CELL BIOL, V176, P405, DOI 10.1083/jcb.200611080
   Diaz F, 2002, NUCLEIC ACIDS RES, V30, P4626, DOI 10.1093/nar/gkf602
   DiMauro S, 2006, MUSCLE NERVE, V34, P265, DOI 10.1002/mus.20598
   Duvezin-Caubet S, 2007, MOL BIOL CELL, V18, P3582, DOI 10.1091/mbc.E07-02-0164
   Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801
   Estaquier J, 2007, CELL DEATH DIFFER, V14, P1086, DOI 10.1038/sj.cdd.4402107
   Fornai F, 2005, P NATL ACAD SCI USA, V102, P3413, DOI 10.1073/pnas.0409713102
   Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7
   Frezza C, 2006, CELL, V126, P177, DOI 10.1016/j.cell.2006.06.025
   Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399
   Gokey NG, 2004, AGING CELL, V3, P319, DOI 10.1111/j.1474-9728.2004.00122.x
   Goyal G, 2007, DEV CELL, V12, P807, DOI 10.1016/j.devcel.2007.02.002
   Griffin EE, 2006, BBA-MOL CELL RES, V1763, P482, DOI 10.1016/j.bbamcr.2006.02.003
   Griffin EE, 2006, J BIOL CHEM, V281, P16599, DOI 10.1074/jbc.M601847200
   Griparic L, 2007, J CELL BIOL, V178, P757, DOI 10.1083/jcb.200704112
   Handschin C, 2007, GENE DEV, V21, P770, DOI 10.1101/gad.1525107
   Harder Z, 2004, CURR BIOL, V14, P340, DOI 10.1016/j.cub.2004.02.004
   Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359
   Hoppins S, 2007, ANNU REV BIOCHEM, V76, P751, DOI 10.1146/annurev.biochem.76.071905.090048
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Ingerman E, 2005, J CELL BIOL, V170, P1021, DOI 10.1083/jcb.200506078
   Irrcher I, 2003, SPORTS MED, V33, P783, DOI 10.2165/00007256-200333110-00001
   Ishihara N, 2004, J CELL SCI, V117, P6535, DOI 10.1242/jcs.01565
   Jacobs HT, 2000, BIOESSAYS, V22, P564, DOI 10.1002/(SICI)1521-1878(200006)22:6<564::AID-BIES9>3.0.CO;2-4
   Jagasia R, 2005, NATURE, V433, P754, DOI 10.1038/nature03316
   Jahani-Asl A, 2007, J BIOL CHEM, V282, P23788, DOI 10.1074/jbc.M703812200
   James DI, 2003, J BIOL CHEM, V278, P36373, DOI 10.1074/jbc.M303758200
   Johansson A, 2005, DEMENT GERIATR COGN, V20, P367, DOI 10.1159/000088634
   Johnson DT, 2007, AM J PHYSIOL-CELL PH, V292, PC698, DOI 10.1152/ajpcell.00109.2006
   Johnson DT, 2007, AM J PHYSIOL-CELL PH, V292, PC689, DOI 10.1152/ajpcell.00108.2006
   Jonas E, 2006, MOL INTERV, V6, P208, DOI 10.1124/mi.6.4.7
   Kabzinska D, 2006, ACTA MYOL, V25, P34
   Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124
   Karbowski M, 2007, J CELL BIOL, V178, P71, DOI 10.1083/jcb.200611064
   Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111
   Karren MA, 2005, J CELL BIOL, V171, P291, DOI 10.1083/jcb.200506158
   Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604
   Kijima K, 2005, HUM GENET, V116, P23, DOI 10.1007/s00439-004-1199-2
   Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793
   Kowald A, 2005, AGING CELL, V4, P273, DOI 10.1111/j.1474-9726.2005.00169.x
   Krishnan KJ, 2007, ANN NY ACAD SCI, V1100, P227, DOI 10.1196/annals.1395.024
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Kukidome D, 2006, DIABETES, V55, P120, DOI 10.2337/diabetes.55.1.120
   Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3
   Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294
   Legesse-Miller A, 2003, MOL BIOL CELL, V14, P1953, DOI 10.1091/mbc.E02-10-0657
   Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268
   Leinninger GM, 2006, NEUROBIOL DIS, V23, P11, DOI 10.1016/j.nbd.2006.01.017
   Li H, 2008, P NATL ACAD SCI USA, V105, P2169, DOI 10.1073/pnas.0711647105
   Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Liu J, 2004, NEURON, V43, P5, DOI 10.1016/j.neuron.2004.06.016
   Low HH, 2006, NATURE, V444, P766, DOI 10.1038/nature05312
   Manczak M, 2006, HUM MOL GENET, V15, P1437, DOI 10.1093/hmg/ddl066
   Mattiazzi M, 2002, J BIOL CHEM, V277, P29626, DOI 10.1074/jbc.M203065200
   McCloskey DP, 2001, BRAIN RES, V891, P168, DOI 10.1016/S0006-8993(00)03200-5
   Meeusen S, 2004, SCIENCE, V305, P1747, DOI 10.1126/science.1100612
   Meeusen S, 2006, CELL, V127, P383, DOI 10.1016/j.cell.2006.09.021
   Melov S, 2007, PLOS ONE, V2, P0, DOI 10.1371/journal.pone.0000465
   Meuer K, 2007, CELL DEATH DIFFER, V14, P651, DOI 10.1038/sj.cdd.4402087
   Milakovic T, 2005, J BIOL CHEM, V280, P30773, DOI 10.1074/jbc.M504749200
   Moraes CT, 1999, MOL BIOL CELL, V10, P3345, DOI 10.1091/mbc.10.10.3345
   Nakamura N, 2006, EMBO REP, V7, P1019, DOI 10.1038/sj.embor.7400790
   Naylor K, 2006, J BIOL CHEM, V281, P2177, DOI 10.1074/jbc.M507943200
   Nguyen MD, 2003, J NEUROSCI, V23, P2131
   Niemann A, 2005, J CELL BIOL, V170, P1067, DOI 10.1083/jcb.200507087
   Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233
   Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759
   Olichon A, 2002, FEBS LETT, V523, P171, DOI 10.1016/S0014-5793(02)02985-X
   Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197
   Panov AV, 2002, NAT NEUROSCI, V5, P731, DOI 10.1038/nn884
   Parise G, 2005, EXP GERONTOL, V40, P173, DOI 10.1016/j.exger.2004.09.002
   Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457
   Park DS, 1997, J NEUROSCI, V17, P8975
   Parone PA, 2006, MOL CELL BIOL, V26, P7397, DOI 10.1128/MCB.02282-05
   Pasinelli P, 2004, NEURON, V43, P19, DOI 10.1016/j.neuron.2004.06.021
   Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850
   Poole AC, 2008, P NATL ACAD SCI USA, V105, P1638, DOI 10.1073/pnas.0709336105
   Reddy PH, 2005, BRAIN RES REV, V49, P618, DOI 10.1016/j.brainresrev.2005.03.004
   Rikhy R, 2007, GENES BRAIN BEHAV, V6, P42, DOI 10.1111/j.1601-183X.2006.00218.x
   Santel A, 2006, BBA-MOL CELL RES, V1763, P490, DOI 10.1016/j.bbamcr.2006.02.004
   Scheckhuber CQ, 2007, NAT CELL BIOL, V9, P99, DOI 10.1038/ncb1524
   Sesaki H, 1999, J CELL BIOL, V147, P699, DOI 10.1083/jcb.147.4.699
   Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102
   Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245
   Smith PD, 2004, TRENDS MOL MED, V10, P445, DOI 10.1016/j.molmed.2004.07.003
   Smith PD, 2006, J NEUROSCI, V26, P440, DOI 10.1523/JNEUROSCI.2875-05.2006
   Song ZY, 2007, J CELL BIOL, V178, P749, DOI 10.1083/jcb.200704110
   St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200
   St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024
   Taguchi N, 2007, J BIOL CHEM, V282, P11521, DOI 10.1074/jbc.M607279200
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 2005, MED SCI SPORT EXER, V37, P2094, DOI 10.1249/01.mss.0000177446.97671.2a
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963
   Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377
   van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427
   van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368
   Verstreken P, 2005, NEURON, V47, P365, DOI 10.1016/j.neuron.2005.06.018
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wallace DC, 2007, ANNU REV BIOCHEM, V76, P781, DOI 10.1146/annurev.biochem.76.081205.150955
   Wasiak S, 2007, J CELL BIOL, V177, P439, DOI 10.1083/jcb.200610042
   Waterham HR, 2007, NEW ENGL J MED, V356, P1736, DOI 10.1056/NEJMoa064436
   Wong ED, 2003, J CELL BIOL, V160, P303, DOI 10.1083/jcb.200209015
   Yang YF, 2008, P NATL ACAD SCI USA, V105, P7070, DOI 10.1073/pnas.0711845105
   Yarosh W, 2008, PLOS GENET, V4, P0, DOI 10.1371/journal.pgen.0040006
   Yonashiro R, 2006, EMBO J, V25, P3618, DOI 10.1038/sj.emboj.7601249
   Yoon Y, 2003, MOL CELL BIOL, V23, P5409, DOI 10.1128/MCB.23.15.5409-5420.2003
   Yuan H, 2007, CELL DEATH DIFFER, V14, P462, DOI 10.1038/sj.cdd.4402046
   Zhang Y, 2007, P NATL ACAD SCI USA, V104, P18526, DOI 10.1073/pnas.0706441104
   Zhang Y, 2007, FEBS LETT, V581, P2168, DOI 10.1016/j.febslet.2007.01.095
   Züchner S, 2006, ANN NEUROL, V59, P276, DOI 10.1002/ana.20797
   ZUCHNER S, 2004, NATURE, V72, P449
NR 150
TC 793
Z9 925
U1 2
U2 94
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-003X
EI 1471-0048
J9 NAT REV NEUROSCI
JI Nat. Rev. Neurosci.
PD JUL 15
PY 2008
VL 9
IS 7
BP 505
EP 518
DI 10.1038/nrn2417
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA 316DO
UT WOS:000256929300011
PM 18568013
DA 2024-11-01
ER

PT J
AU Lee, YM
   Kang, HC
   Lee, JS
   Kim, SH
   Kim, EY
   Lee, SK
   Slama, A
   Kim, HD
AF Lee, Young Mock
   Kang, Hoon Chul
   Lee, Joon Soo
   Kim, Se Hoon
   Kim, Eung Yeop
   Lee, Seung Koo
   Slama, Abdelhamid
   Kim, Heung Dong
TI Mitochondrial respiratory chain defects: Underlying etiology in various epileptic conditions
SO EPILEPSIA
LA English
DT Article
DE mitochondrial disorder; respiratory chain; epilepsy
ID ketogenic diet; pediatric-patients; clinical-features; dna; mice; encephalomyopathy; mutations; disease; deficiency; disorders
AB Purpose: To determine if defects in mitochondrial respiratory chain enzyme complexes (MRCs) contribute to the etiology of childhood epilepsy. Methods: We reviewed the clinical and laboratory features of 48 epileptic patients (23 male, 25 female) with MRC defects that were confirmed by biochemical assays using muscle biopsies. Results: (1) Thirty-five cases (72.9%) were MRC I deficient, one case (2.1%) was MRC II deficient, 11 cases (22.9%) were MRC IV deficient, and one case (2.1%) had combined MRC I and IV deficiencies. (2) In our clinical diagnosis, there were 10 cases (20.8%) with Leigh disease and one case each with myopathy, encephalopathy, lactic acidosis, stroke-like episodes (MELAS) or Alpers' disease (2.1%). Most of the remaining cases (75.0%) had uncategorized mitochondrial cytopathy with nonspecific encephalopathy. (3) For epileptic classification, there were two cases (4.2%) of Ohtahara syndrome, 10 cases (20.8%) of West syndrome, 12 cases (25.0%) of Lennox-Gastaut syndrome, two cases (4.2%) of Landau-Kleffner syndrome, 14 cases (29.2%) of generalized epilepsy, and eight cases (16.7%) of partial epilepsy. (4) The mean age of seizure onset was 2.68 +/- 2.21 (range: 1 month - 5.5 years). (5) Magnetic resonance imaging (MRI) showed diffuse cortical atrophy in 34 cases (70.8%), basal ganglia signal changes in 18 cases (37.5%) and thalamus signal changes in 12 cases (25.0%). (6) A ketogenic diet produced clinical improvements, including seizure reduction and global functional improvement in 75% of 24 patients. Conclusions: MRC defects are one of the important causes of probably symptomatic childhood epilepsy. A ketogenic diet should be carefully considered for treatment of intractable epilepsy related to MRC defects.
C1 [Lee, Young Mock; Lee, Joon Soo; Kim, Heung Dong] Yonsei Univ, Coll Med, Dept Pediat, Severance Childrens Hosp,Inst Handicapped Childre, Seoul 120752, South Korea.
   [Kang, Hoon Chul] Inje Univ, Coll Med, Dept Pediat, Sanggye Paik Hosp, Seoul, South Korea.
   [Kang, Hoon Chul] Inje Univ, Coll Med, Epilepsy Ctr, Sanggye Paik Hosp, Seoul, South Korea.
   [Kim, Se Hoon] Yonsei Univ, Coll Med, Dept Pathol, Seoul 120752, South Korea.
   [Kim, Eung Yeop; Lee, Seung Koo] Univ Coll Med, Dept Radiol, Seoul, South Korea.
   [Slama, Abdelhamid] Hop Bicetre, APHP, Biochim Lab, Le Kremlin Bicetre, France.
C3 Yonsei University; Yonsei University Health System; Inje University; Inje University; Yonsei University; Yonsei University Health System; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Hopital Universitaire Bicetre - APHP; Hopital Universitaire Ambroise-Pare - APHP
RP Kim, HD (corresponding author), Yonsei Univ, Coll Med, Dept Pediat, Severance Childrens Hosp,Inst Handicapped Childre, 134 Shinchon Dong, Seoul 120752, South Korea.
EM hdkimmd@yumc.yonsei.ac.kr
CR Blume Warren T, 2001, EPILEPSIA, V42, P1212, DOI 10.1046/j.1528-1157.2001.22001.x
   Canafoglia L, 2001, NEUROLOGY, V56, P1340, DOI 10.1212/WNL.56.10.1340
   Chinnery PF, 1997, J NEUROL NEUROSUR PS, V63, P559, DOI 10.1136/jnnp.63.5.559
   CHRETIEN D, 1994, CLIN CHIM ACTA, V228, P53, DOI 10.1016/0009-8981(94)90056-6
   Cock H, 1999, EPILEPSIA, V40, P33, DOI 10.1111/j.1528-1157.1999.tb00897.x
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   Debray FG, 2007, PEDIATRICS, V119, P722, DOI 10.1542/peds.2006-1866
   DEVIVO DC, 1999, PEDIAT NEUROLOGY PRI, V0, P494
   Dimauro S, 2004, ANN NY ACAD SCI, V1011, P217, DOI 10.1196/annals.1293.022
   DiMauro S, 2004, ANN NY ACAD SCI, V1011, P232, DOI 10.1196/annals.1293.023
   Finsterer J, 2004, EUR J NEUROL, V11, P163, DOI 10.1046/j.1351-5101.2003.00728.x
   Jaksch M, 1998, ANN NEUROL, V44, P635, DOI 10.1002/ana.410440409
   Kang HC, 2005, EPILEPSIA, V46, P272, DOI 10.1111/j.0013-9580.2005.48504.x
   Kang HC, 2007, EPILEPSIA, V48, P82, DOI 10.1111/j.1528-1167.2006.00906.x
   Kim DW, 2004, PEDIATRICS, V114, P1627, DOI 10.1542/peds.2004-1001
   Kunz WS, 1999, J NEUROCHEM, V72, P1580, DOI 10.1046/j.1471-4159.1999.721580.x
   Kunz WS, 2002, CURR OPIN NEUROL, V15, P179, DOI 10.1097/00019052-200204000-00009
   Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3
   Liang LP, 2004, FREE RADICAL BIO MED, V36, P542, DOI 10.1016/j.freeradbiomed.2003.11.029
   Lodi R, 2001, ANN NEUROL, V49, P590
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Sadleir LG, 2004, EUR J NEUROL, V11, P103, DOI 10.1046/j.1351-5101.2003.00724.x
   Scaglia F, 2004, PEDIATRICS, V114, P925, DOI 10.1542/peds.2004-0718
   Schmiedel J, 2003, J NEUROL, V250, P267, DOI 10.1007/s00415-003-0978-3
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Tang YG, 1997, NEURON, V18, P483, DOI 10.1016/S0896-6273(00)81248-9
   Urbanska EM, 1998, EUR J PHARMACOL, V359, P55, DOI 10.1016/S0014-2999(98)00648-7
   Wexler ID, 1997, NEUROLOGY, V49, P1655, DOI 10.1212/WNL.49.6.1655
   Yamamoto HA, 1996, NEUROSCI LETT, V207, P89, DOI 10.1016/0304-3940(96)12493-9
NR 29
TC 108
Z9 115
U1 0
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0013-9580
EI 
J9 EPILEPSIA
JI Epilepsia
PD APR 15
PY 2008
VL 49
IS 4
BP 685
EP 690
DI 10.1111/j.1528-1167.2007.01522.x
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 279VF
UT WOS:000254382500018
PM 18266755
DA 2024-11-01
ER

PT J
AU Nakada, K
   Sato, A
   Hayashi, JI
AF Nakada, Kazuto
   Sato, Akitsugu
   Hayashi, Jun-Ichi
TI Reverse genetic studies of mitochondrial DNA-based diseases using a mouse model
SO PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
LA English
DT Review
DE mouse model; mitochondrial DNA; large-scale deletion mutation; mitochondrial complementation; mitochondrial diseases
ID protein-synthesis; oxidative-phosphorylation; dilated cardiomyopathy; functional integrity; respiration defects; skeletal-muscle; mutant mtdna; cell lines; mutations; mice
AB In the situation that it would not be able to produce model animals for mitochondrial diseases caused by mitochondrial DNA (mtDNA) with pathogenic mutations, we succeeded in generating mice with pathogenic deletion mutant mtDNA (Delta mtDNA), named "mito-mice", by direct introduction of mitochondria with Delta mtDNA into mouse zygotes. In the mito-mice, accumulation of Delta mtDNA induced mitochondrial respiration defects in various tissues, resulting in mitochondrial disease phenotypes, such as low body weight, lactic acidosis, ischemia, myopathy, heart block, deafness, male infertility, and renal failure. Thus, mito-mice are the first model animal for mtDNA-based diseases, and the mice could be valuable for understanding precise pathogeneses and testing therapies of mitochondrial diseases. In the present review, we summarized reverse genetic studies using the mito-mice.
C1 [Nakada, Kazuto; Sato, Akitsugu; Hayashi, Jun-Ichi] Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan.
C3 University of Tsukuba
RP Hayashi, JI (corresponding author), Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan.
EM jih45@sakura.cc.tsukuba.ac.jp
CR Anderson DE, 2002, J CELL BIOL, V156, P419, DOI 10.1083/jcb.200111002
   Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735
   CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   Cobb J, 1998, SEMIN CELL DEV BIOL, V9, P445, DOI 10.1006/scdb.1998.0202
   Cohen J, 1997, LANCET, V350, P186, DOI 10.1016/S0140-6736(05)62353-7
   Cohen J, 1998, MOL HUM REPROD, V4, P269, DOI 10.1093/molehr/4.3.269
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   Dimmer KS, 2006, PHYSIOLOGY, V21, P233, DOI 10.1152/physiol.00010.2006
   Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226
   Habu T, 1996, NUCLEIC ACIDS RES, V24, P470, DOI 10.1093/nar/24.3.470
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   HAYASHI JI, 1994, J BIOL CHEM, V269, P6878
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Inoue K, 1997, BIOCHEM BIOPH RES CO, V239, P257, DOI 10.1006/bbrc.1997.7446
   Inoue K, 1997, J BIOL CHEM, V272, P15510, DOI 10.1074/jbc.272.24.15510
   Inoue SI, 2007, FEBS LETT, V581, P1910, DOI 10.1016/j.febslet.2007.03.092
   Isobe K, 1998, J BIOL CHEM, V273, P4601, DOI 10.1074/jbc.273.8.4601
   Ito S, 1998, BIOCHEM BIOPH RES CO, V247, P432, DOI 10.1006/bbrc.1998.8800
   Ito S, 1999, P NATL ACAD SCI USA, V96, P2099, DOI 10.1073/pnas.96.5.2099
   Kasahara A, 2006, HUM MOL GENET, V15, P871, DOI 10.1093/hmg/ddl005
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Laderman KA, 1996, J BIOL CHEM, V271, P15891, DOI 10.1074/jbc.271.27.15891
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Liu VWS, 1998, NUCLEIC ACIDS RES, V26, P1268, DOI 10.1093/nar/26.5.1268
   Maechler P, 2001, NATURE, V414, P807, DOI 10.1038/414807a
   Marchington DR, 1998, AM J HUM GENET, V63, P769, DOI 10.1086/302009
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   MORITA T, 1993, P NATL ACAD SCI USA, V90, P6577, DOI 10.1073/pnas.90.14.6577
   Nagley P, 1998, TRENDS GENET, V14, P513, DOI 10.1016/S0168-9525(98)01580-7
   Nakada K, 2004, BIOCHEM BIOPH RES CO, V323, P175, DOI 10.1016/j.bbrc.2004.08.073
   Nakada K, 2001, BIOCHEM BIOPH RES CO, V288, P901, DOI 10.1006/bbrc.2001.5873
   Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976
   Nakada K, 2006, P NATL ACAD SCI USA, V103, P15148, DOI 10.1073/pnas.0604641103
   Ono T, 2001, NAT GENET, V28, P272, DOI 10.1038/90116
   Pospisilik JA, 2007, CELL, V131, P476, DOI 10.1016/j.cell.2007.08.047
   Sato A, 2005, P NATL ACAD SCI USA, V102, P16765, DOI 10.1073/pnas.0506197102
   Sato A, 2005, P NATL ACAD SCI USA, V102, P6057, DOI 10.1073/pnas.0408666102
   Sato A, 2004, GENETICS, V167, P1855, DOI 10.1534/genetics.103.021287
   Sato A, 2007, GENETICS, V177, P2031, DOI 10.1534/genetics.107.081026
   SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649
   SOONG NW, 1992, NAT GENET, V2, P318
   Sörensen L, 2001, J NEUROSCI, V21, P8082, DOI 10.1523/JNEUROSCI.21-20-08082.2001
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380
   TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089
   Wredenberg A, 2006, BIOCHEM BIOPH RES CO, V350, P202, DOI 10.1016/j.bbrc.2006.09.029
   YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699
NR 58
TC 5
Z9 7
U1 0
U2 12
PU JAPAN ACAD
PI TOKYO
PA 7-32, UENO PARK, TAITO-KU, TOKYO, 110-0007, JAPAN
SN 0386-2208
EI 
J9 P JPN ACAD B-PHYS
JI Proc. Jpn. Acad. Ser. B-Phys. Biol. Sci.
PD MAY 15
PY 2008
VL 84
IS 5
BP 155
EP 165
DI 10.2183/pjab.84.155
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 307KE
UT WOS:000256317000004
PM 18941295
DA 2024-11-01
ER

PT J
AU van Eijsden, RGE
   Eijssen, LMT
   Lindsey, PJ
   van den Burg, CMM
   de Wit, LEA
   Rubio-Gozalbo, ME
   de Die, CEM
   Ayoubi, T
   Sluiter, W
   de Coo, IFM
   Smeets, HJM
AF van Eijsden, R. G. E.
   Eijssen, L. M. T.
   Lindsey, P. J.
   van den Burg, C. M. M.
   de Wit, L. E. A.
   Rubio-Gozalbo, M. E.
   de Die, C. E. M.
   Ayoubi, T.
   Sluiter, W.
   de Coo, I. F. M.
   Smeets, H. J. M.
TI Termination of damaged protein repair defines the occurrence of symptoms in carriers of the m.3243A&gt;G tRNA<SUP>Leu</SUP> mutation
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID mitochondrial-dna; gene-expression; cell-death; a3243g mutation; apoptosis; kinase; family; encephalomyopathy; proliferation; transcription
AB Background: The m.3243A>G mutation in the mitochondrial tRNA(Leu(UUR)) gene is an example of a mutation causing a very heterogeneous phenotype. It is the most frequent cause (80%) of the MELAS syndrome ( mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes), but it can also lead in addition or separately to type 2 diabetes, deafness, renal tubulopathy and/or cardiomyopathy. Methods: To identify pathogenic processes induced by this mutation, we compared global gene expression levels of muscle biopsies from affected and unaffected mutation carriers with controls. Results and conclusions: Gene expression changes were relatively subtle. In the asymptomatic group 200 transcripts were upregulated and 12 were downregulated, whereas in the symptomatic group 15 transcripts were upregulated and 52 were downregulated. In the asymptomatic group, oxidative phosphorylation (OXPHOS) complex I and IV genes were induced. Protein turnover and apoptosis were elevated, most likely due to the formation of dysfunctional and reactive oxygen species (ROS) damaged proteins. These processes returned to normal in symptomatic patients. Components of the complement system were upregulated in both groups, but the strongest in the symptomatic group, which might indicate muscle regeneration-most likely, protein damage and OXPHOS dysfunction stimulate repair ( protein regeneration) and metabolic adaptation ( OXPHOS). In asymptomatic individuals these processes suffice to prevent the occurrence of symptoms. However, in affected individuals the repair process terminates, presumably because of excessive damage, and switches to muscle regeneration, as indicated by a stronger complement activation. This switch leaves increasingly damaged tissue in place and muscle pathology becomes manifest. Therefore, the expression of complement components might be a marker for the severity and progression of MELAS clinical course.
C1 [van Eijsden, R. G. E.; Eijssen, L. M. T.; Lindsey, P. J.; van den Burg, C. M. M.; Ayoubi, T.; Smeets, H. J. M.] Maastricht Univ, Dept Genet & Cell Biol, NL-6200 MD Maastricht, Netherlands.
   [van Eijsden, R. G. E.; Smeets, H. J. M.] Maastricht Univ, Res Inst Growth & Dev, NL-6200 MD Maastricht, Netherlands.
   [van Eijsden, R. G. E.] VIB, MicroArray Facil, Louvain, Belgium.
   [Eijssen, L. M. T.] Maastricht Univ, BiGCaT Bioinformat, NL-6200 MD Maastricht, Netherlands.
   [de Wit, L. E. A.; Sluiter, W.] Erasmus MC, Dept Biochem, Mitochondrial Res Unit, Rotterdam, Netherlands.
   [Rubio-Gozalbo, M. E.] Maastricht Univ Hosp, Dept Paediat, Maastricht, Netherlands.
   [Rubio-Gozalbo, M. E.] Maastricht Univ Hosp, Lab Genet Metab Dis, Maastricht, Netherlands.
   [de Die, C. E. M.] Maastricht Univ Hosp, Dept Clin Genet, Maastricht, Netherlands.
   [Ayoubi, T.] Maastricht Univ, Inst Cardiovasc Res Maastricht CARIM, NL-6200 MD Maastricht, Netherlands.
   [de Coo, I. F. M.] Erasmus MC, Dept Neurol, Rotterdam, Netherlands.
C3 Maastricht University; Maastricht University; Flanders Institute for Biotechnology (VIB); Maastricht University; Erasmus University Rotterdam; Erasmus MC; Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Erasmus University Rotterdam; Erasmus MC
RP Smeets, HJM (corresponding author), Maastricht Univ, Dept Genet & Cell Biol, POB 616,Post Box 16, NL-6200 MD Maastricht, Netherlands.
EM Bert.Smeets@Molcelb.Unimaas.nl
CR Akaike H, 1973, 2 INT S INFORM THEOR, V0, P267
   Alamdari DH, 2005, FREE RADICAL BIO MED, V39, P1362, DOI 10.1016/j.freeradbiomed.2005.06.023
   Andersson U, 2001, MOL CELL BIOL, V21, P3738, DOI 10.1128/MCB.21.11.3738-3749.2001
   [Anonymous], 1999, MODELS FOR REPEATED MEASUREMENTS, V0, P0
   ATKINSON AC, 1980, BIOMETRIKA, V67, P413, DOI 10.1093/biomet/67.2.413
   Auré K, 2006, BRAIN, V129, P1249, DOI 10.1093/brain/awl061
   Bilodeau PS, 2004, J BIOL CHEM, V279, P54808, DOI 10.1074/jbc.M406654200
   BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933
   CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6
   Chen RH, 2006, J BIOMED SCI, V13, P193, DOI 10.1007/s11373-005-9063-5
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Crimi M, 2005, FASEB J, V19, P866, DOI 10.1096/fj.04-3045fje
   DOrazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714
   Dai MH, 2005, NUCLEIC ACIDS RES, V33, P0, DOI 10.1093/nar/gni179
   Dennis G, 2003, GENOME BIOL, V4, P0, DOI 10.1186/gb-2003-4-9-r60
   Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Gleyzer N, 2005, MOL CELL BIOL, V25, P1354, DOI 10.1128/MCB.25.4.1354-1366.2005
   Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   Heddi A, 1999, J BIOL CHEM, V274, P22968, DOI 10.1074/jbc.274.33.22968
   Howard TL, 2001, J CELL SCI, V114, P2395
   Hsiao LL, 2001, PHYSIOL GENOMICS, V7, P97, DOI 10.1152/physiolgenomics.00040.2001
   Ishida M, 2007, MOL CELL BIOL, V27, P1348, DOI 10.1128/MCB.00658-06
   Liou ML, 1999, J BIOL CHEM, V274, P10145, DOI 10.1074/jbc.274.15.10145
   Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863
   Mork CN, 2005, CURR PHARM DESIGN, V11, P1091, DOI 10.2174/1381612053507567
   MOUDY AM, 1995, P NATL ACAD SCI USA, V92, P729, DOI 10.1073/pnas.92.3.729
   Nazarian J, 2005, PHYSIOL GENOMICS, V21, P70, DOI 10.1152/physiolgenomics.00227.2004
   Ozawa M, 1998, J NEUROL SCI, V159, P170, DOI 10.1016/S0022-510X(98)00152-X
   Park H, 2003, BIOCHEMISTRY-US, V42, P958, DOI 10.1021/bi026882r
   R Core Development Team, 1999, R LANG ENV STAT COMP, V0, P0
   Sanjo H, 1998, J BIOL CHEM, V273, P29066, DOI 10.1074/jbc.273.44.29066
   Shannan B, 2006, J MOL HISTOL, V37, P183, DOI 10.1007/s10735-006-9052-7
   Shoubridge EA, 1997, HUM MOL GENET, V6, P2239, DOI 10.1093/hmg/6.13.2239
   Silvestri G, 2000, AM J MED GENET, V94, P201, DOI 10.1002/1096-8628(20000918)94:3<201::AID-AJMG5>3.0.CO;2-2
   Stefanovic B, 2004, MOL CELL BIOL, V24, P1758, DOI 10.1128/MCB.24.4.1758-1768.2004
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Thorburn DR, 2004, J INHERIT METAB DIS, V27, P349, DOI 10.1023/B:BOLI.0000031098.41409.55
   Torroni A, 2003, AM J HUM GENET, V72, P1005, DOI 10.1086/373936
   Tsang HTH, 2006, GENOMICS, V88, P333, DOI 10.1016/j.ygeno.2006.04.003
   van Empel VPM, 2005, CIRC RES, V96, PE92, DOI 10.1161/01.RES.0000172081.30327.28
   van Essen EHR, 2000, DIABETIC MED, V17, P841, DOI 10.1046/j.1464-5491.2000.00379.x
   WANKER EE, 1995, J CELL BIOL, V130, P29, DOI 10.1083/jcb.130.1.29
   XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0
   Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4
   Zhao P, 2004, DEV DYNAM, V229, P380, DOI 10.1002/dvdy.10457
NR 48
TC 9
Z9 9
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD AUG 15
PY 2008
VL 45
IS 8
BP 525
EP 534
DI 10.1136/jmg.2008.057497
PG 10
WC Genetics & Heredity
SC Genetics & Heredity
GA 333HK
UT WOS:000258143400007
PM 18456717
DA 2024-11-01
ER

PT J
AU Harrower, T
   Stewart, JD
   Hudson, G
   Houlden, H
   Warner, G
   O'Donovan, DG
   Findlay, LJ
   Taylor, RW
   De Silva, R
   Chinnery, PF
AF Harrower, Timothy
   Stewart, Joanna D.
   Hudson, Gavin
   Houlden, Henry
   Warner, Graham
   O'Donovan, Dominic G.
   Findlay, Leslie J.
   Taylor, Robert W.
   De Silva, Rajith
   Chinnery, Patrick F.
TI <i>POLG1</i> mutations manifesting as autosomal recessive axonal Charcot-Marie-Tooth disease
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID progressive external ophthalmoplegia; polymerase-gamma; mitochondrial; spectrum; ataxia
AB Background: Although a molecular diagnosis is possible in most patients having Charcot-Marie-Tooth disease (CMT), recessively inherited and axonal neuropathies still present a diagnostic challenge. Objective: To determine the cause of axonal CMT type 2 in 3 siblings. Design: Case report. Setting: Academic research. participants: Three siblings who subsequently developed profound cerebellar ataxia. Main outcome Measures: Muscle biopsy specimen molecular genetic analysis of the POLG1 (polymerase gamma-1) gene, as well as screening of control subjects for POLG1 sequence variants. Results: Cytochrome c oxidase deficient fibers and multiple deletions of mitochondrial DNA were detected in skeletal muscle. Three compound heterozygous substitutions were detected in POLG1. Conclusion: Even in the absence of classic features of mitochondrial disease, POLG1 should be considered in patients having axonal CMT that may be associated with tremor or ataxia.
C1 [Stewart, Joanna D.; Hudson, Gavin; Taylor, Robert W.; Chinnery, Patrick F.] Univ Newcastle, Sch Med, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Harrower, Timothy; O'Donovan, Dominic G.; Findlay, Leslie J.; De Silva, Rajith] Queens Hosp, Dept Neurol, Romford, Essex, England.
   [Harrower, Timothy; O'Donovan, Dominic G.; Findlay, Leslie J.; De Silva, Rajith] Queens Hosp, Dept Neuropathol, Romford, Essex, England.
   [O'Donovan, Dominic G.] Queens Hosp, Essex Ctr Neurol Sci, Romford, Essex, England.
   [Taylor, Robert W.; Chinnery, Patrick F.] Univ Newcastle, Inst Human Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Houlden, Henry] Inst Neurol, London WC1N 3BG, England.
   [Houlden, Henry] UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England.
   [Warner, Graham] Royal Surrey Cty Hosp, Dept Neurol, Guildford, Surrey, England.
C3 Newcastle University - UK; Newcastle University - UK; University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Royal Surrey County Hospital
RP Chinnery, PF (corresponding author), Univ Newcastle, Sch Med, Mitochondrial Res Grp, Room M41014,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM p.f.chinnery@ncl.ac.uk
FU Medical Research Council [G108/638] Funding Source: Medline; MRC [G108/638] Funding Source: UKRI
CR Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hisama FM, 2005, AM J MED GENET A, V135A, P217, DOI 10.1002/ajmg.a.30672
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2006, HUM MOL GENET, V15, PR244, DOI 10.1093/hmg/ddl233
   Kollberg G, 2006, J NEUROPATH EXP NEUR, V65, P758, DOI 10.1097/01.jnen.0000229987.17548.6e
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Züchner S, 2006, NAT CLIN PRACT NEURO, V2, P45, DOI 10.1038/ncpneuro0071
NR 12
TC 30
Z9 32
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9942
EI 1538-3687
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD JAN 15
PY 2008
VL 65
IS 1
BP 133
EP 136
DI 10.1001/archneurol.2007.4
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 250PR
UT WOS:000252313000018
PM 18195151
DA 2024-11-01
ER

PT J
AU Durairaj, A
   Limbach, PA
AF Durairaj, Anita
   Limbach, Patrick A.
TI Mass spectrometry of the fifth nucleoside: A review of the identification of pseudouridine in nucleic acids
SO ANALYTICA CHIMICA ACTA
LA English
DT Review
DE N-cyclohexyl-N '-beta-(4-methylmorpholinium)ethylcarbodiimide; p-tosylate derivatization; cyanoethylation; pseudouridine-synthase; matrix-assisted laser; desorption/ionization-mass spectrometry; liquid chromatography-mass spectrometry; modified nucleosides
ID 23s ribosomal-rna; sideroblastic anemia mlasa; escherichia-coli; posttranscriptional modifications; mitochondrial myopathy; peptidyltransferase center; thermus-thermophilus; modified nucleotides; recognition region; missense mutation
AB Pseudouridine, the so-called fifth nucleoside due to its ubiquitous presence in ribonucleic acids (RNAs), remains among the most challenging modified nucleosides to characterize. As an isomer of the major nucleoside uridine, pseudouridine cannot be detected by standard reverse-transcriptase-based DNA sequencing or RNase mapping approaches. Thus, over the past 15 years, investigators have focused on the unique structural proper-ties of pseudouridine to develop selective derivatization or fragmentation strategies for its determination. While the N-cyclohexyl-N'-beta-(4-methylmorpholinium)ethylcarbodiimide p-tosylate (CMCT)-reverse transcriptase assay remains both a popular and powerful approach to screen for pseudouridine in larger RNAs, mass-spectrometry-based approaches are poised to play an increasingly important role in either confirming the findings of the CMCT-reverse transcriptase assay or in characterizing pseudouridine sequence placement and abundance in smaller RNAs. This review includes a brief discussion of pseudouridine including a summary of its biosynthesis and known importance within various RNAs. The review then focuses on chemical derivatization approaches that can be used to selectively modify pseudouridine to improve its detection, and the development of mass-spectrometry-based assays for the identification and sequencing of pseudouridine in various RNAs. (C) 2008 Published by Elsevier B.V.
C1 [Durairaj, Anita; Limbach, Patrick A.] Univ Cincinnati, Rieueschl Labs Mass Spectrometry, Dept Chem, Cincinnati, OH 45221 USA.
C3 University System of Ohio; University of Cincinnati
RP Limbach, PA (corresponding author), Univ Cincinnati, Rieueschl Labs Mass Spectrometry, Dept Chem, POB 210172, Cincinnati, OH 45221 USA.
EM Pat.Limbach@uc.edu
FU NIGMS NIH HHS [R01 GM058843-07, R01 GM058843-08, R01 GM058843, GM58843, R56 GM058843] Funding Source: Medline
CR Ansmant I, 2000, NUCLEIC ACIDS RES, V28, P1941, DOI 10.1093/nar/28.9.1941
   BAKIN A, 1994, BIOCHEMISTRY-US, V33, P13475, DOI 10.1021/bi00249a036
   BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095
   COHN WE, 1960, J BIOL CHEM, V235, P1488
   Crain PF, 2002, RNA, V8, P752, DOI 10.1017/S1355838202022045
   Davis DR, 1995, NUCLEIC ACIDS RES, V23, P5020, DOI 10.1093/nar/23.24.5020
   Del Lampo M, 2005, RNA, V11, P210, DOI 10.1261/rna.7209905
   Durairaj A, 2008, ANAL CHIM ACTA, V612, P173, DOI 10.1016/j.aca.2008.02.026
   Emmerechts G, 2005, J CHROMATOGR B, V825, P233, DOI 10.1016/j.jchromb.2005.06.041
   Emmerechts G, 2007, NUCLEIC ACIDS RES, V35, P3494, DOI 10.1093/nar/gkm248
   Felden B, 1998, EMBO J, V17, P3188, DOI 10.1093/emboj/17.11.3188
   Fernandez-Vizarra E, 2007, J MED GENET, V44, P173, DOI 10.1136/jmg.2006.045252
   GROSJEAN H, 1995, BIOCHIMIE, V77, P139, DOI 10.1016/0300-9084(96)88117-X
   Gu XR, 1999, P NATL ACAD SCI USA, V96, P14270, DOI 10.1073/pnas.96.25.14270
   GUPTA RC, 1979, NUCLEIC ACIDS RES, V6, P3443, DOI 10.1093/nar/6.11.3443
   Gutgsell N, 2000, RNA, V6, P1870, DOI 10.1017/S1355838200001588
   Guymon R, 2006, BIOCHEMISTRY-US, V45, P4888, DOI 10.1021/bi052579p
   Hammal T, 2006, CHEM BIOL, V13, P1125, DOI 10.1016/j.chembiol.2006.09.009
   Hansen MA, 2002, RNA, V8, P202, DOI 10.1017/S1355838202013365
   Helm M, 2006, NUCLEIC ACIDS RES, V34, P721, DOI 10.1093/nar/gkj471
   HO NWY, 1971, BIOCHEMISTRY-US, V10, P3651
   Hossain M, 2007, RNA, V13, P295, DOI 10.1261/rna.272507
   Kinghorn SM, 2002, MICROBIOL-SGM, V148, P3511, DOI 10.1099/00221287-148-11-3511
   Kirpekar F, 2005, J MOL BIOL, V348, P563, DOI 10.1016/j.jmb.2005.03.009
   Kirpekar F, 2000, RNA, V6, P296, DOI 10.1017/S1355838200992148
   Kowalak JA, 2000, J BIOL CHEM, V275, P24484, DOI 10.1074/jbc.M002153200
   Kowalak JA, 1996, NUCLEIC ACIDS RES, V24, P688, DOI 10.1093/nar/24.4.688
   KOWALAK JA, 1993, NUCLEIC ACIDS RES, V21, P4577, DOI 10.1093/nar/21.19.4577
   LANE BG, 1992, FEBS LETT, V302, P1, DOI 10.1016/0014-5793(92)80269-M
   LANE BG, 1995, BIOCHIMIE, V77, P7, DOI 10.1016/0300-9084(96)88098-9
   LEBOWITZ J, 1977, NUCLEIC ACIDS RES, V4, P1695, DOI 10.1093/nar/4.6.1695
   Limbach PA, 1996, MASS SPECTROM REV, V15, P297, DOI 10.1002/(SICI)1098-2787(1996)15:5<297::AID-MAS2>3.0.CO;2-D
   LIMBACH PA, 1994, NUCLEIC ACIDS RES, V22, P2183, DOI 10.1093/nar/22.12.2183
   Massenet S, 1999, MOL CELL BIOL, V19, P2142
   Mengel-Jorgensen J, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf135
   Mengel-Jorgensen J, 2006, J BIOL CHEM, V281, P22108, DOI 10.1074/jbc.M600377200
   Meroueh M, 2000, NUCLEIC ACIDS RES, V28, P2075, DOI 10.1093/nar/28.10.2075
   Ofengand J, 2001, METHODS, V25, P365, DOI 10.1006/meth.2001.1249
   Ofengand J, 2002, FEBS LETT, V514, P17, DOI 10.1016/S0014-5793(02)02305-0
   Patteson KG, 2001, NUCLEIC ACIDS RES, V29, P0, DOI 10.1093/nar/29.10.e49
   PATTON JR, 1991, MOL CELL BIOL, V11, P5998, DOI 10.1128/MCB.11.12.5998
   Patton JR, 2005, J BIOL CHEM, V280, P19823, DOI 10.1074/jbc.M500216200
   PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760
   POMERANTZ S, 1993, METHOD ENZYMOL, V193, P796
   Pomerantz SC, 2005, ANAL CHEM, V77, P4687, DOI 10.1021/ac058023p
   POWERS T, 1991, EMBO J, V10, P2203, DOI 10.1002/j.1460-2075.1991.tb07756.x
   Rozenski J, 1999, NUCLEIC ACIDS RES, V27, P196, DOI 10.1093/nar/27.1.196
   Schroeder KT, 2005, RNA, V11, P1012, DOI 10.1261/rna.2270205
   Spedaliere CJ, 2004, J AM CHEM SOC, V126, P12758, DOI 10.1021/ja046375s
   TANAKA Y, 1980, NUCLEIC ACIDS RES, V8, P1259, DOI 10.1093/nar/8.6.1259
   Urbonavicius J, 2002, J BACTERIOL, V184, P5348, DOI 10.1128/JB.184.19.5348-5357.2002
   YOSHIDA M, 1968, BIOCHIM BIOPHYS ACTA, V157, P455, DOI 10.1016/0005-2787(68)90145-7
   Zeharia A, 2005, J CHILD NEUROL, V20, P449, DOI 10.1177/08830738050200051301
   Zhao XL, 2004, RNA, V10, P681, DOI 10.1261/rna.5159504
   Zhao XL, 2002, RNA, V8, P1515, DOI 10.1017/S1355838202022537
NR 57
TC 28
Z9 36
U1 2
U2 36
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0003-2670
EI 1873-4324
J9 ANAL CHIM ACTA
JI Anal. Chim. Acta
PD AUG 15
PY 2008
VL 623
IS 2
BP 117
EP 125
DI 10.1016/j.aca.2008.06.027
PG 9
WC Chemistry, Analytical
SC Chemistry
GA 334ED
UT WOS:000258204200001
PM 18620915
DA 2024-11-01
ER

PT J
AU Shanske, S
   Coku, J
   Lu, JS
   Ganesh, J
   Krishna, S
   Tanji, K
   Bonilla, E
   Naini, AB
   Hirano, M
   DiMauro, S
AF Shanske, Sara
   Coku, Jorida
   Lu, Jiesheng
   Ganesh, Jaya
   Krishna, Sindu
   Tanji, Kurenai
   Bonilla, Eduardo
   Naini, Ali B.
   Hirano, Michio
   DiMauro, Salvatore
TI The G13513A mutation in the <i>ND</i>5 gene of mitochondrial DNA as a common cause of MELAS or Leigh syndrome -: Evidence from 12 cases
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID overlap-syndrome; frequent cause; complex-i; deficiency; subunit; disease
AB Background: The number of molecular causes of MELAS (a syndrome consisting of mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes) and Leigh syndrome (LS) has steadily increased. Among these, mutations in the ND5 gene (OMIM 516005) of mitochondrial DNA are important, and the A13513A change has emerged as a hotspot. Objective: To describe the clinical features, muscle pathological and biochemical characteristics, and molecular study findings of 12 patients harboring the G13513A mutation in the ND5 gene of mitochondrial DNA compared with 14 previously described patients with the same mutation. Design: Clinical examinations and morphological, biochemical, and molecular analyses. Setting: Tertiary care university hospital and molecular diagnostic laboratory. Patients: Three patients had the typical syndrome features of MELAS; the other 9 had typical clinical and radiological features of LS. Results: Family history suggested maternal inheritance in a few cases; morphological studies of muscle samples rarely showed typical ragged-red fibers and more often exhibited strongly succinate dehydrogenase reactive blood vessels. Biochemically, complex I deficiency was inconsistent and generally mild. The mutation load was relatively high in the muscle and blood specimens. Conclusion: The G13513A mutation is a common cause of MELAS and LS, even in the absence of obvious maternal inheritance, pathological findings in muscle, or severe complex I deficiency.
C1 [Shanske, Sara; Coku, Jorida; Lu, Jiesheng; Krishna, Sindu; Bonilla, Eduardo; Naini, Ali B.; Hirano, Michio; DiMauro, Salvatore] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA.
   [Tanji, Kurenai; Bonilla, Eduardo] Columbia Univ, Med Ctr, Dept Pathol, New York, NY 10032 USA.
   [Ganesh, Jaya] Univ Penn, Childrens Hosp Philadelphia, Sect Biochem Genet, Philadelphia, PA 19104 USA.
C3 Columbia University; Columbia University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia
RP DiMauro, S (corresponding author), Columbia Univ, Med Ctr, Dept Neurol, 3-313A Russ Berrie Med Sci Pavil,1150 St Nicholas, New York, NY 10032 USA.
EM sd12@columbia.edu
FU NICHD NIH HHS [HD32062] Funding Source: Medline
CR Chol M, 2003, J MED GENET, V40, P188, DOI 10.1136/jmg.40.3.188
   Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T
   Crimi M, 2003, NEUROLOGY, V60, P1857, DOI 10.1212/01.WNL.0000066048.72780.69
   Dickerson BC, 2005, NEW ENGL J MED, V353, P2271, DOI 10.1056/NEJMcpc059032
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Hanna MG, 1998, J NEUROL NEUROSUR PS, V65, P512, DOI 10.1136/jnnp.65.4.512
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   MALTATTI E, 2007, BRAIN, V130, P1894
   Naini AB, 2005, ARCH NEUROL-CHICAGO, V62, P473, DOI 10.1001/archneur.62.3.473
   PENLSSONBESNIER I, 2000, NEUROLOGY, V55, P317
   Petruzzella V, 2003, NEUROLOGY, V61, P1017, DOI 10.1212/01.WNL.0000080363.10902.E9
   Pulkes T, 1999, ANN NEUROL, V46, P916, DOI 10.1002/1531-8249(199912)46:6<916::AID-ANA16>3.0.CO;2-R
   Pulkes T, 2000, ANN NEUROL, V47, P841
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   Shanske S, 2004, AM J MED GENET A, V130A, P134, DOI 10.1002/ajmg.a.30220
   Tanji K, 2001, METHOD CELL BIOL, V65, P311, DOI 10.1016/S0091-679X(01)65019-2
NR 17
TC 90
Z9 101
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9942
EI 1538-3687
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD MAR 15
PY 2008
VL 65
IS 3
BP 368
EP 372
DI 10.1001/archneurol.2007.67
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA 272TD
UT WOS:000253881900011
PM 18332249
DA 2024-11-01
ER

PT J
AU Muqit, MMK
   Larner, AJ
   Sweeney, MG
   Sewry, C
   Stinton, VJ
   Davis, MB
   Healy, DG
   Payne, SJ
   Chotai, K
   Wood, NW
   Lane, RJM
AF Muqit, M. M. K.
   Larner, A. J.
   Sweeney, M. G.
   Sewry, C.
   Stinton, V. J.
   Davis, M. B.
   Healy, D. G.
   Payne, S. J.
   Chotai, K.
   Wood, N. W.
   Lane, R. J. M.
TI Multiple mitochondrial DNA deletions in monozygotic twins with OPMD
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Article
ID oculopharyngeal muscular-dystrophy; progressive external ophthalmoplegia; human skeletal-muscle; nuclear inclusions; abnormality; expansions; mutations; disease
AB Background: Oculopharyngeal muscular dystrophy (OPMD) is caused by expansions of the poly (A) binding protein 2 (PABP2) gene. Previous histological analyses have revealed mitochondrial abnormalities in the muscles of OPMD patients but their significance remains uncertain. Objective: We had the rare opportunity to study monozygotic twins with identical expansions of the PABP2 gene but with markedly different severities of OPMD. Both had histological features of mitochondrial myopathy. We determined whether mitochondrial DNA abnormalities underlay these changes. Methods: Clinical information was obtained by history and examination. Muscle biopsies were obtained from each subject and genetic analysis was performed using long-range PCR and Southern blotting. Results: We demonstrate, for the first time, the presence of mitochondrial DNA (mtDNA) deletions by Southern blotting in individuals with OPMD. This correlates with the presence of mitochondrial myopathy in both twins. Moreover, both twins had different mtDNA deletions, which might explain their phenotypic differences. Conclusion: We hypothesise that mitochondrial dysfunction may occur as a consequence of PABP2 gene mutations, and that this dysfunction may affect the phenotypic manifestations of OPMD.
C1 [Muqit, M. M. K.; Larner, A. J.; Lane, R. J. M.] Univ London Imperial Coll Sci Technol & Med, Div Clin Neurosci & Psychol Med, London SW7 2AZ, England.
   [Muqit, M. M. K.; Sweeney, M. G.; Stinton, V. J.; Davis, M. B.; Healy, D. G.; Wood, N. W.] Inst Neurol, Dept Mol Neurosci, London WC1N 3BG, England.
   [Larner, A. J.] Walton Ctr Neurol & Neurosurg, Liverpool, Merseyside, England.
   [Sewry, C.] Hammersmith Hosp, Dubowitz Neuromuscular Unit, Dept Paediat, London, England.
   [Payne, S. J.; Chotai, K.] Northwick Pk & St Marks NHS Trust, Kennedy Galton Ctr, London, England.
C3 Imperial College London; University of London; University College London; Walton Centre; Imperial College London
RP Lane, RJM (corresponding author), Charing Cross Hosp, Div Clin Neurosci & Psychol Med, Fulham Pl Rd, London W6 8RF, England.
EM r.lane@imperial.ac.uk
CR Blumen SC, 1999, ANN NEUROL, V46, P115, DOI 10.1002/1531-8249(199907)46:1<115::AID-ANA17>3.0.CO;2-O
   Brais B, 1998, NAT GENET, V18, P164, DOI 10.1038/ng0298-164
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Calado A, 2000, HUM MOL GENET, V9, P2321, DOI 10.1093/oxfordjournals.hmg.a018924
   Dreyfus M, 2002, CELL, V111, P611, DOI 10.1016/S0092-8674(02)01137-6
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   Jansson M, 2000, ACTA NEUROPATHOL, V100, P23, DOI 10.1007/s004010051188
   JULIEN J, 1974, J NEUROL SCI, V21, P165, DOI 10.1016/0022-510X(74)90067-7
   Lezza AMS, 1997, FEBS LETT, V418, P167, DOI 10.1016/S0014-5793(97)01374-4
   MITSUMOTO H, 1992, MUSCLE NERVE, V15, P1210
   OLDFORS AR, 2005, NEUROLOGY, V66, P49
   PAUZNER R, 1991, MUSCLE NERVE, V14, P947, DOI 10.1002/mus.880141004
   Pesce V, 2001, FREE RADICAL BIO MED, V30, P1223, DOI 10.1016/S0891-5849(01)00517-2
   PRATT MF, 1986, LARYNGOSCOPE, V96, P368
   Rowland LP, 1997, NEUROMUSCULAR DISORD, V7, PS15, DOI 10.1016/S0960-8966(97)00076-X
   SCHRODER JM, 1995, NEUROPATH APPL NEURO, V21, P68, DOI 10.1111/j.1365-2990.1995.tb01030.x
   TOME FMS, 1980, ACTA NEUROPATHOL, V49, P85, DOI 10.1007/BF00692226
   Van Goethem G, 2003, NEUROMOL MED, V3, P129, DOI 10.1385/NMM:3:3:129
   VICTOR M, 1962, NEW ENGL J MED, V267, P1267, DOI 10.1056/NEJM196212202672501
   Wong KT, 1996, NEUROMUSCULAR DISORD, V6, P163, DOI 10.1016/0960-8966(95)00039-9
   YUSAKI M, 1989, BIOCHEM BIOPH RES CO, V164, P1352
NR 21
TC 11
Z9 12
U1 0
U2 0
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
EI 
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD JAN 15
PY 2008
VL 79
IS 1
BP 68
EP 71
DI 10.1136/jnnp.2006.112250
PG 4
WC Clinical Neurology; Psychiatry; Surgery
SC Neurosciences & Neurology; Psychiatry; Surgery
GA 240ZD
UT WOS:000251625800019
PM 17550990
DA 2024-11-01
ER

PT J
AU Janssen, AJM
   Schuelke, M
   Smeitink, JAM
   Trijbels, FJM
   Sengers, RCA
   Lucke, B
   Wintjes, LTM
   Morava, E
   van Engelen, BGM
   Struts, BW
   Hol, FA
   Siers, MH
   ter Laak, H
   van der Knaap, MS
   van Spronsen, FJ
   Rodenburg, RJT
   van den Heuvel, LP
AF Janssen, Antoon J. M.
   Schuelke, Markus
   Smeitink, Jan A. M.
   Trijbels, Frans J. M.
   Sengers, Rob C. A.
   Lucke, Barbara
   Wintjes, Liesbeth T. M.
   Morava, Eva
   van Engelen, Baziel G. M.
   Struts, Bart W.
   Hol, Frans A.
   Siers, Marloes H.
   ter Laak, Henk
   van der Knaap, Marjo S.
   van Spronsen, Francjan J.
   Rodenburg, Richard J. T.
   van den Heuvel, Lambert P.
TI Muscle 3243A→G mutation load and capacity of the mitochondrial energy-generating system
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID transfer rnaleu(uur) gene; a3243g point mutation; stroke-like episodes; lactic-acidosis; clinical-features; complex-i; oxidative-phosphorylation; trna(leu(uur)) mutation; delayed diagnosis; skeletal-muscle
AB Objective: The mitochondrial energy-generating system (MEGS) encompasses the mitochondrial enzymatic reactions from oxidation of pyruvate to the export of adenosine triphosphate. It is investigated in intact muscle mitochondria by measuring the pyruvate oxidation and adenosine triphosphate production rates, which we refer to as the "MEGS capacity." Currently, little is known about MEGS pathology in patients with mutations in the mitochondrial DNA. Because MEGS capacity is an indicator for the overall mitochondrial function related to energy production, we searched for a correlation between MEGS capacity and 3243A -> G mutation load in muscle of patients with the MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes) syndrome. Methods: In muscle tissue of 24 patients with the 3243A -> G mutation, we investigated the MEGS capacity, the respiratory chain enzymatic activities, and the 3243A -> G mutation load. To exclude coinciding mutations, we sequenced all 22 mitochondrial transfer RNA genes in the patients, if possible. Results: We found highly significant differences between patients and control subjects with respect to the MEGS capacity and complex I, III, and IV activities. MEGS-related measurements correlated considerably better with the mutation load than respiratory chain enzyme activities. We found no additional mutations in the mitochondrial transfer RNA genes of the patients. Interpretation: The results show that MEGS capacity has a greater sensitivity than respiratory chain enzymatic activities for detection of subtle mitochondrial dysfunction. This is important in the workup of patients with rare or new mitochondrial DNA mutations, and with low mutation loads. In these cases we suggest to determine the MEGS capacity.
C1 Radboud Univ Nijmegen, Med Ctr, Lab Pediat & Neurol, Nijmegen Ctr Mitochondrial Disorders, NL-6525 GA Nijmegen, Netherlands.
   Radboud Univ Nijmegen, Med Ctr, Dept Pediat, NL-6525 GA Nijmegen, Netherlands.
   [Schuelke, Markus; Lucke, Barbara] Charite, Med Ctr, Dept Neuropediat, Berlin, Germany.
   [van Engelen, Baziel G. M.; Struts, Bart W.] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, Nijmegen, Netherlands.
   [Hol, Frans A.; Siers, Marloes H.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen, Netherlands.
   [ter Laak, Henk] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, Nijmegen, Netherlands.
   [van der Knaap, Marjo S.] Vrije Univ Amsterdam, Med Ctr, Dept Child Neurol, Amsterdam, Netherlands.
   [van Spronsen, Francjan J.] Univ Groningen, Beatrix Children Hosp, Univ Med Ctr, Groningen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Berlin Institute of Health; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Vrije Universiteit Amsterdam; University of Groningen
RP van den Heuvel, LP (corresponding author), Radboud Univ Nijmegen, Med Ctr, Lab Pediat & Neurol, Nijmegen Ctr Mitochondrial Disorders, Geert Grootepl Zuid 10, NL-6525 GA Nijmegen, Netherlands.
EM b.vandenheuvel@cukz.umcn.nl; b.vandenheuvel@cukz.umcn.nl
CR ATTARDI G, 1995, BBA-MOL BASIS DIS, V1271, P241, DOI 10.1016/0925-4439(95)00034-2
   BENTLAGE H, 1995, EUR J BIOCHEM, V227, P909, DOI 10.1111/j.1432-1033.1995.tb20218.x
   Bentlage HACM, 1996, NEUROLOGY, V47, P243, DOI 10.1212/WNL.47.1.243
   Chang TM, 2004, PEDIATR NEUROL, V31, P374, DOI 10.1016/j.pediatrneurol.2004.05.009
   Chinnery PF, 2001, NEUROLOGY, V56, P1101, DOI 10.1212/WNL.56.8.1101
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   Chomyn A, 2001, J BIOENERG BIOMEMBR, V33, P251, DOI 10.1023/A:1010791204961
   COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665
   Crimi M, 2003, EUR J HUM GENET, V11, P896, DOI 10.1038/sj.ejhg.5201056
   Deschauer M, 2004, J NEUROL NEUROSUR PS, V75, P1204, DOI 10.1136/jnnp.2003.026278
   Detjen AK, 2007, TWIN RES HUM GENET, V10, P486, DOI 10.1375/twin.10.3.486
   Durand-Dubief F, 2004, REV NEUROL-FRANCE, V160, P824, DOI 10.1016/S0035-3787(04)71038-3
   Finsterer J, 2001, EUR NEUROL, V46, P92, DOI 10.1159/000050770
   FISCHER JC, 1986, CLIN CHIM ACTA, V155, P263, DOI 10.1016/0009-8981(86)90246-9
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Ingman M, 2006, NUCLEIC ACIDS RES, V34, PD749, DOI 10.1093/nar/gkj010
   Janssen AJM, 2006, CLIN CHEM, V52, P860, DOI 10.1373/clinchem.2005.062414
   Jones M, 2004, AM J OPHTHALMOL, V138, P1051, DOI 10.1016/j.ajo.2004.06.026
   Kirino Y, 2005, P NATL ACAD SCI USA, V102, P7127, DOI 10.1073/pnas.0500563102
   KOBAYASHI M, 1987, J PEDIATR-US, V110, P223, DOI 10.1016/S0022-3476(87)80158-0
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   KOGA Y, 1995, MUSCLE NERVE, V0, PS119
   Kornblum C, 2005, J NEUROL, V252, P1101, DOI 10.1007/s00415-005-0827-7
   Lev D, 2004, PEDIATR CARDIOL, V25, P443, DOI 10.1007/s00246-003-0490-7
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   Löwik MM, 2005, NEPHROL DIAL TRANSPL, V20, P336, DOI 10.1093/ndt/gfh546
   LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637
   MARIOTTI C, 1995, J NEUROL, V242, P304, DOI 10.1007/BF00878873
   Munakata K, 2005, BIOL PSYCHIAT, V57, P525, DOI 10.1016/j.biopsych.2004.11.041
   Okhuijsen-Kroes EJ, 2001, NEUROPEDIATRICS, V32, P183, DOI 10.1055/s-2001-17372
   Park H, 2003, BIOCHEMISTRY-US, V42, P958, DOI 10.1021/bi026882r
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Pons R, 2004, J PEDIATR-US, V144, P81, DOI 10.1016/j.jpeds.2003.10.023
   Sangkhathat S, 2005, PEDIATR SURG INT, V21, P745, DOI 10.1007/s00383-005-1471-0
   Schuelke M, 2000, NAT BIOTECHNOL, V18, P233, DOI 10.1038/72708
   Srere PA, 1969, METHODS IN ENZYMOLOGY, V13, P3
   Sue CM, 1998, J NEUROL SCI, V161, P36, DOI 10.1016/S0022-510X(98)00179-8
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   Ugalde C, 2003, ANN NEUROL, V54, P665, DOI 10.1002/ana.10734
   VANDENOUWELAND JMW, 1994, DIABETES, V43, P746, DOI 10.2337/diabetes.43.6.746
   Vielhaber S, 2002, J NEUROPATH EXP NEUR, V61, P885, DOI 10.1093/jnen/61.10.885
   Wittig I, 2006, BBA-BIOENERGETICS, V1757, P1066, DOI 10.1016/j.bbabio.2006.05.006
   Wong LJC, 2002, AM J MED GENET, V113, P59, DOI 10.1002/ajmg.10767
NR 45
TC 23
Z9 25
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
EI 1531-8249
J9 ANN NEUROL
JI Ann. Neurol.
PD APR 15
PY 2008
VL 63
IS 4
BP 473
EP 481
DI 10.1002/ana.21328
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 295DE
UT WOS:000255454400010
PM 18306232
DA 2024-11-01
ER

PT J
AU Reeve, AK
   Krishnan, KJ
   Elson, JL
   Morris, CM
   Bender, A
   Lightowlers, RN
   Turnbull, DM
AF Reeve, Amy K.
   Krishnan, Kim J.
   Elson, Joanna L.
   Morris, Christopher M.
   Bender, Andreas
   Lightowlers, Robert N.
   Turnbull, Douglass M.
TI Nature of mitochondrial DNA deletions in substantial nigra neurons
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID mtdna deletions; lagging-strand; muscle-fibers; replication; mutations; defects; region
AB Mitochondrial DNA (mtDNA) deletions have been investigated in a number of neurodegenerative diseases. This study aimed to investigate the characteristics of mtDNA deletions found in single substantia nigra neurons from three patient groups: controls, Parkinson disease patients, and a patient with Parkinsonism due to multiple mtDNA deletions. We have identified 89 deletions from these neurons and examined the breakpoint characteristics of them. There was no difference in the types of mtDNA deletions detected in these neurons. These results suggest that the mechanism leading to the formation of these deletions in these three distinct groups could be the same.
C1 [Reeve, Amy K.; Krishnan, Kim J.; Elson, Joanna L.; Lightowlers, Robert N.; Turnbull, Douglass M.] Univ Newcastle, Sch Med, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Krishnan, Kim J.; Morris, Christopher M.; Turnbull, Douglass M.] Univ Newcastle, Inst Ageing & Hlth, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.
   [Bender, Andreas] Univ Munich, Dept Neurol, D-81377 Munich, Germany.
C3 Newcastle University - UK; Newcastle University - UK; University of Munich
RP Turnbull, DM (corresponding author), Univ Newcastle, Sch Med, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM d.m.turnbull@ncl.ac.uk
FU Medical Research Council [G0502157, G90/63, G0400074, G0700718] Funding Source: Medline; Wellcome Trust [074454] Funding Source: Medline; MRC [G90/63, G0400074, G0502157, G0700718] Funding Source: UKRI
CR Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   Cottrell DA, 2001, NEUROLOGY, V57, P260, DOI 10.1212/WNL.57.2.260
   HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   Itoh K, 1996, NEUROBIOL AGING, V17, P843, DOI 10.1016/S0197-4580(96)00168-6
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Samuels DC, 2004, TRENDS GENET, V20, P393, DOI 10.1016/j.tig.2004.07.003
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   Srivastava S, 2005, HUM MOL GENET, V14, P893, DOI 10.1093/hmg/ddi082
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   Yasukawa T, 2006, EMBO J, V25, P5358, DOI 10.1038/sj.emboj.7601392
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 14
TC 107
Z9 110
U1 1
U2 9
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD JAN 15
PY 2008
VL 82
IS 1
BP 228
EP 235
DI 10.1016/j.ajhg.2007.09.018
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 263NM
UT WOS:000253223800026
PM 18179904
DA 2024-11-01
ER

PT J
AU Akouchekian, M
   Houshmand, M
   Hemati, S
   Shafa, M
AF Akouchekian, Mansoureh
   Houshmand, Massoud
   Hemati, Simin
   Shafa, Mehdi
TI Occurrence of large-scale mitochondrial DNA deletions in human colorectal cancer
SO ARCHIVES OF MEDICAL SCIENCE
LA English
DT Article
DE mitochondrial DNA; colon cancer; large-scale deletion; 8.7 kb deletion
ID microsatellite instability; somatic mutations; gastric-cancer; control region; nuclear-dna; tumors; carcinomas; genome
AB Introduction: The aim of this study was to determine the mutation patterns of colon cancers through screening of different regions of mitochondrial DNA (mtDNA) in colon cancer patients. Material and methods: In order to investigate whether deletions exist in the mitochondrial DNA of colon cancer patients, we used a PCR assay to assess the presence of large-scale deletions. We screened four regions of the mitochondrial genome by PCR amplification and Southern blot analysis followed by DNA sequencing. Previously, deficiency in mitochondrial complex I has been reported; therefore we focused on the region of mtDNA that encodes the genes of this complex. Results: In 11 out of 90 patients, we found an 8.7 kb deletion. Large-scale deletions of mtDNA are common events that have been found to occur in human ageing and in patients with mitochondrial myopathies. Based on our results the mtDNA 8.7 kb deletion occurs in 12.2% of the colorectal cancer (CRC) samples. Conclusions: As reactive oxygen species (ROS) are continuously generated by the respiratory chain, they may cause significant oxidative damage to mtDNA (for example mtDNA deletions or mutations) if not efficiently eliminated. Defective respiratory enzymes containing protein subunits encoded by the deleted mtDNA may further enhance free radical production, resulting in more profound oxidative damage in CRC patients.
C1 [Akouchekian, Mansoureh; Houshmand, Massoud; Shafa, Mehdi] NIGEB, Dept Med Genet, Tehran, Iran.
   [Akouchekian, Mansoureh] Leibniz Univ Hannover, Dept Biol, Hannover, Germany.
   [Akouchekian, Mansoureh; Houshmand, Massoud; Shafa, Mehdi] Special Med Ctr, Dept Genet, Tehran, Iran.
   [Hemati, Simin] Sayedalshohada Hosp, Dept Oncol, Esfahan, Iran.
C3 Leibniz University Hannover
RP Houshmand, M (corresponding author), NIGEB, Dept Med Genet, POB 14155-6343, Tehran, Iran.
EM massoudh@nigeb.ac.ir
FU National Institute for Genetic Engineering and Biotechnology and Department of Genetics, Special Medical Center, Tehran
CR Alonso A, 1997, ELECTROPHORESIS, V18, P682, DOI 10.1002/elps.1150180504
   BURGART LJ, 1995, AM J PATHOL, V147, P1105
   Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017
   Habano W, 1998, ONCOGENE, V17, P1931, DOI 10.1038/sj.onc.1202112
   Habano W, 1999, INT J CANCER, V83, P625, DOI 10.1002/(SICI)1097-0215(19991126)83:5<625::AID-IJC10>3.0.CO;2-N
   Habano W, 2000, GASTROENTEROLOGY, V118, P835, DOI 10.1016/S0016-5085(00)70169-7
   Hibi K, 2001, INT J CANCER, V94, P429, DOI 10.1002/ijc.1480
   Jerónimo C, 2001, ONCOGENE, V20, P5195, DOI 10.1038/sj.onc.1204646
   Jones JB, 2001, CANCER RES, V61, P1299
   Kamalidehghan B, 2006, ARCH MED RES, V37, P848, DOI 10.1016/j.arcmed.2006.03.007
   Kirches E, 2001, INT J CANCER, V93, P534, DOI 10.1002/ijc.1375
   Lee HC, 1997, J FORMOS MED ASSOC, V96, P770
   Liu VWS, 2001, CANCER RES, V61, P5998
   Marcelino LA, 1999, MUTAT RES-DNA REPAIR, V434, P177, DOI 10.1016/S0921-8777(99)00028-2
   Máximo V, 2000, GASTROENTEROLOGY, V119, P1808, DOI 10.1016/S0016-5085(00)70044-8
   Máximo V, 2001, GENE CHROMOSOME CANC, V32, P136, DOI 10.1002/gcc.1175
   Miyazono F, 2002, ONCOGENE, V21, P3780, DOI 10.1038/sj.onc.1205532
   Nishikawa M, 2001, CANCER RES, V61, P1843
   Park J I, 2000, ARCH FACIAL PLAST SURG, V2, P43, DOI 10.1001/archfaci.2.1.43
   Parrella P, 2001, CANCER RES, V61, P7623
   Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108
   Sanchez-Cespedes M, 2001, CANCER RES, V61, P7015
   Shoffner JM, 1995, METABOLIC MOL BASES, V7th, P1535
   Tamura G, 1999, EUR J CANCER, V35, P316, DOI 10.1016/S0959-8049(98)00360-8
   WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739
   Wei YH, 1998, P SOC EXP BIOL MED, V217, P53
   Yeh JJ, 2000, ONCOGENE, V19, P2060, DOI 10.1038/sj.onc.1203537
NR 27
TC 5
Z9 5
U1 0
U2 0
PU TERMEDIA PUBLISHING HOUSE LTD
PI POZNAN
PA KLEEBERGA ST 2, POZNAN, 61-615, POLAND
SN 1734-1922
EI 1896-9151
J9 ARCH MED SCI
JI Arch. Med. Sci.
PD SEP 15
PY 2008
VL 4
IS 3
BP 249
EP 253
DI 
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 390YB
UT WOS:000262198500006
DA 2024-11-01
ER

PT J
AU Zsurka, G
   Baron, M
   Stewart, JD
   Kornblum, C
   Bös, M
   Sassen, R
   Taylor, RW
   Elger, CE
   Chinnery, PF
   Kunz, WS
AF Zsurka, Gabor
   Baron, Miriam
   Stewart, Joanna D.
   Kornblum, Cornelia
   Boes, Monika
   Sassen, Robert
   Taylor, Robert W.
   Elger, Christian E.
   Chinnery, Patrick F.
   Kunz, Wolfram S.
TI Clonally expanded mitochondrial DNA mutations in epileptic individuals with mutated DNA polymerase γ
SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
LA English
DT Article
DE aging; Alpers-Huttenlocher syndrome; clonal expansion; DNA polymerase gamma; mitochondrial depletion; mtDNA deletion; mtDNA point mutation; POLG
ID progressive external ophthalmoplegia; multiple deletions; polg mutations; control region; accumulation
AB The instability of the mitochondrial genome in individuals harboring pathogenic mutations in the catalytic subunit of mitochondrial DNA (mtDNA) polymerase gamma (POLG) is well recognized, but the underlying molecular mechanisms remain to be elucidated. In 5 pediatric patients with severe myoclonic epilepsy and valproic acid-induced liver failure, we identified I novel and 4 previously described pathogenic mutations in the linker region of this enzyme. Although muscle biopsies in these patients showed unremarkable histologic features, postmortem liver tissue available from I individual exhibited large cytochrome c oxidase-negative areas. These cytochrome c oxidase-negative areas contained 4-fold less mtDNA than cytochrome e oxidase-positive areas. Decreased copy numbers of mtDNA were observed not only in the liver, skeletal muscle, and brain but also in blood samples from all patients. There were also patient-specific patterns of multiple mtDNA deletions in different tissues, and in 2 patients, there were clonally expanded mtDNA point mutations. The low amount of deleted mtDNA molecules makes it unlikely that the deletions contribute significantly to the general biochemical defect. The clonal expansion of a few individual-specific deletions and point mutations indicates all accelerated segregation of early mtDNA mutations that likely are a consequence of low mtDNA copy numbers. Moreover, these results Suggest a potential diagnostic approach for identifying mtDNA depletion in patients.
C1 [Zsurka, Gabor; Baron, Miriam; Boes, Monika; Sassen, Robert; Elger, Christian E.; Kunz, Wolfram S.] Univ Bonn, Dept Epileptol, D-53105 Bonn, Germany.
   [Stewart, Joanna D.; Taylor, Robert W.; Chinnery, Patrick F.] Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne, Tyne & Wear, England.
   [Kornblum, Cornelia] Univ Bonn, Dept Neurol, D-53105 Bonn, Germany.
C3 University of Bonn; Newcastle University - UK; University of Bonn
RP Kunz, WS (corresponding author), Univ Bonn, Life & Brain Ctr, Div Neurochem, Sigmund Freud Str 25, D-53105 Bonn, Germany.
EM wolfram.kunz@ukb.uni-bonn.de
FU Deutsche Forschungsgemeinschaft [KU-911/15-1, TR3 A11]; Bundesministerium fur Bildung und Forschung [01GZ0704]
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Coller HA, 2002, ANN NY ACAD SCI, V959, P434, DOI 10.1111/j.1749-6632.2002.tb02113.x
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Del Bo R, 2003, NEUROLOGY, V61, P903, DOI 10.1212/01.WNL.0000092303.13864.BE
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Kollberg G, 2006, J NEUROPATH EXP NEUR, V65, P758, DOI 10.1097/01.jnen.0000229987.17548.6e
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Kraytsberg Y, 2005, EXPERT REV MOL DIAGN, V5, P809, DOI 10.1586/14737159.5.5.809
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Moslemi AR, 1996, ANN NEUROL, V40, P707, DOI 10.1002/ana.410400506
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   PREISS T, 1995, TRENDS GENET, V11, P211, DOI 10.1016/S0168-9525(00)89048-4
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Tanaka M, 2004, GENOME RES, V14, P1832, DOI 10.1101/gr.2286304
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   Wiedemann FR, 2000, ANAL BIOCHEM, V279, P55, DOI 10.1006/abio.1999.4434
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zsurka G, 2004, J MED GENET, V41, P0, DOI 10.1136/jmg.2004.022566
NR 27
TC 32
Z9 32
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-3069
EI 1554-6578
J9 J NEUROPATH EXP NEUR
JI J. Neuropathol. Exp. Neurol.
PD SEP 15
PY 2008
VL 67
IS 9
BP 857
EP 866
DI 10.1097/NEN.0b013e3181839b2d
PG 10
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 344PA
UT WOS:000258938600004
PM 18716558
DA 2024-11-01
ER

PT J
AU Fosslien, E
AF Fosslien, Egil
TI Cancer Morphogenesis: Role of Mitochondrial Failure
SO ANNALS OF CLINICAL AND LABORATORY SCIENCE
LA English
DT Review
DE cancer; mitochondrial failure; dual genome disease; mtDNA; nDNA; Krebs cycle; OXPHOS; morphogen gradient; morphogenesis; carcinogen; teratogen; mitochondrial toxins
ID growth-factor-beta; electron-transport chain; muscle adp/atp translocator; neural-tube defects; oxidative-phosphorylation; complex-i; phthalate-esters; molecular pathology; cell-death; tca cycle
AB Adenosine triphosphate (ATP) required for normal cell metabolism is mainly supplied by mitochondrial oxidative phosphorylation (OXPHOS), which is limited by available oxygen and modulated by cell signaling pathways. Primary or secondary OXPHOS failure shifts cell metabolism towards ATP generation by glycolysis (Warburg effect). The objective of this paper is to clarify the role of mitochondrial dysfunction in cancer morphogenesis and to elucidate how faulty morphogen gradient signaling and inflammatory mediators that regulate OXPHOS can cause cancer-induced morphogenesis. Developmental morphogenesis and cancer morphogenesis are regulated by morphogenetic fields. The importance of morphogenetic fields is illustrated by transplantation of metastatic melanoma cells into the chick-embryo; the tumor cells adapt morphologies that resemble normal cells and function normally in the host. A morphogen gradient is a simple form of morphogenetic field. Morphogens such as those of the transforming growth factor (TGF)-beta family inhibit and stimulate basic cell proliferation at high and low concentrations respectively. Along a signaling gradient of declining TGF-beta concentration, with increasing distance from the gradient source, cell proliferation is first gradually less inhibited, and then gradually stimulated, thus generating a concave curved structure. In 3D cell cultures, TGF-beta concentration determines the diameter of the tubules it induces. TGF-beta 1 can modulate mitochondrial OXPHOS via adenine nucleotide translocase (ANT) or uncoupling protein (UCP) via COX-2 and prostaglandin (PG) E-2. Thus, gradients of TGF-beta can regulate the radius of curvature of tissues by modulating mitochondrial ATP generation. Derailment of morphogen control of mitochondrial ATP synthesis can lead to abnormal spatial variation in ATP supply, abnormal spatial distribution of cell proliferation, and cancer morphogenesis. Involvement of COX-2 in morphogen signaling is a mechanism whereby inflammation can promote carcinogenesis. Restoration of OXPHOS can reverse cancer morphogenesis and restore normal tissue morphology. Avoiding exposure to environmental mitochondrial toxins and toxic food ingredients should reduce the risk of cancer.
C1 [Fosslien, Egil] Univ Illinois, Coll Med, Dept Pathol, Chicago, IL 60612 USA.
C3 University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital
RP Fosslien, E (corresponding author), 502 Fairview Ave, Glen Ellyn, IL 60137 USA.
EM efosslie@uic.edu
CR Au HC, 1999, P NATL ACAD SCI USA, V96, P4354, DOI 10.1073/pnas.96.8.4354
   Barath P, 2004, EUR J BIOCHEM, V271, P1781, DOI 10.1111/j.1432-1033.2004.04090.x
   Barker N, 2000, ADV CANCER RES, V77, P1
   BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N
   BATTINI R, 1987, J BIOL CHEM, V262, P4355
   Bayley JP, 2005, BMC MED GENET, V6, P0, DOI 10.1186/1471-2350-6-39
   Belibi FA, 2004, KIDNEY INT, V66, P964, DOI 10.1111/j.1523-1755.2004.00843.x
   BELL FP, 1982, ENVIRON HEALTH PERSP, V45, P41, DOI 10.2307/3429382
   Benn DE, 2006, J CLIN ENDOCR METAB, V91, P827, DOI 10.1210/jc.2005-1862
   Benn DE, 2003, ONCOGENE, V22, P1358, DOI 10.1038/sj.onc.1206300
   Biswas G, 2008, P NATL ACAD SCI USA, V105, P186, DOI 10.1073/pnas.0706183104
   Boca M, 2006, J AM SOC NEPHROL, V17, P637, DOI 10.1681/ASN.2005050534
   Bonod-Bidaud C, 2001, MITOCHONDRION, V1, P217, DOI 10.1016/S1567-7249(01)00017-4
   Bonora E, 2006, CANCER RES, V66, P6087, DOI 10.1158/0008-5472.CAN-06-0171
   Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607
   Braun S, 2005, ANTICANCER RES, V25, P2809
   Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5
   Brown RE, 2007, ANN CLIN LAB SCI, V37, P141
   Bui T, 2006, CANCER CELL, V9, P419, DOI 10.1016/j.ccr.2006.05.012
   Calabrese EJ, 2008, ENVIRON TOXICOL CHEM, V27, P1451, DOI 10.1897/07-541.1
   Calabrese EJ, 2005, CRIT REV TOXICOL, V35, P463, DOI 10.1080/10408440591034502
   Calabrese EJ, 2001, CRIT REV TOXICOL, V31, P471, DOI 10.1080/20014091111758
   Calabrese EJ, 2001, CRIT REV TOXICOL, V31, P489, DOI 10.1080/20014091111776
   Cha YI, 2007, ANNU REV MED, V58, P239, DOI 10.1146/annurev.med.57.121304.131253
   CHCRKASSKAIA MD, 1982, VOPR MED KHIM, V28, P110
   Chen J, 2007, J VIROL, V81, P6757, DOI 10.1128/JVI.00172-07
   Chen KH, 2003, CURR EYE RES, V26, P363, DOI 10.1076/ceyr.26.5.363.15442
   Chevillotte E, 2001, J BIOL CHEM, V276, P10853, DOI 10.1074/jbc.M008010200
   Chevrollier A, 2005, J BIOENERG BIOMEMBR, V37, P307, DOI 10.1007/s10863-005-8642-5
   Child CM, 1941, PATTERNS PROBLEMS DE, V0, P0
   Child CM, 1915, P NATL ACAD SCI USA, V1, P164, DOI 10.1073/pnas.1.3.164
   CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A
   Choksi KB, 2008, FREE RADICAL BIO MED, V44, P1795, DOI 10.1016/j.freeradbiomed.2008.01.032
   CHUNG AB, 1992, J BIOL CHEM, V267, P21154
   Clotman F, 2005, GENE DEV, V19, P1849, DOI 10.1101/gad.340305
   Cochemé HM, 2008, J BIOL CHEM, V283, P1786, DOI 10.1074/jbc.M708597200
   Dakubo GD, 2006, J CLIN PATHOL, V59, P10, DOI 10.1136/jcp.2005.027664
   Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518
   Deschauer M, 2006, MOL GENET METAB, V88, P146, DOI 10.1016/j.ymgme.2006.01.007
   Diao HL, 2007, FRONT BIOSCI, V12, P3333, DOI 10.2741/2316
   Edlund S, 2005, MOL CELL BIOL, V25, P1475, DOI 10.1128/MCB.25.4.1475-1488.2005
   Emi M, 2004, BIOCHEM PHARMACOL, V67, P1259, DOI 10.1016/j.bcp.2003.10.037
   FAJARDO LF, 1992, AM J PATHOL, V140, P539
   Fantel AG, 2002, ANN NY ACAD SCI, V959, P424, DOI 10.1111/j.1749-6632.2002.tb02112.x
   Fantini B, 2000, HIST PHIL LIFE SCI, V22, P353
   Favier J, 2005, HORM RES, V63, P171, DOI 10.1159/000084685
   Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200
   Fosslien E, 2000, ANN CLIN LAB SCI, V30, P3
   Fosslien E, 2005, ANN CLIN LAB SCI, V35, P347
   Fosslien E, 2002, MED HYPOTHESES, V59, P233, DOI 10.1016/S0306-9877(02)00206-2
   Fosslien E, 2001, ANN CLIN LAB SCI, V31, P25
   Fosslien E, 2003, ANN CLIN LAB SCI, V33, P371
   Fosslien E, 2000, CRIT REV CL LAB SCI, V37, P431, DOI 10.1080/10408360091174286
   FOSSLIEN E, 1997, ANN CLIN LAB SCI, V27, P318
   Fosslien E, 2008, ANN CLIN LAB SCI, V38, P307
   Gangloff YG, 2004, MOL CELL BIOL, V24, P9508, DOI 10.1128/MCB.24.21.9508-9516.2004
   Garber K, 2004, J NATL CANCER I, V96, P1805, DOI 10.1093/jnci/96.24.1805
   Gemin A, 2005, BIOCHEM BIOPH RES CO, V332, P1122, DOI 10.1016/j.bbrc.2005.05.061
   George RJ, 2007, PROSTAG OTH LIPID M, V83, P112, DOI 10.1016/j.prostaglandins.2006.10.005
   Giraud S, 1998, J MOL BIOL, V281, P409, DOI 10.1006/jmbi.1998.1955
   Govindarajan B, 2007, J CLIN INVEST, V117, P719, DOI 10.1172/JCI30102
   GROLIER P, 1993, BIOCHEM PHARMACOL, V45, P827, DOI 10.1016/0006-2952(93)90165-S
   HARAGUCHI Y, 1994, J BIOL CHEM, V269, P9330
   Hardell L, 2008, ACTA ONCOL, V47, P347, DOI 10.1080/02841860701753697
   Hase Y, 2008, BIOCHEM BIOPH RES CO, V366, P66, DOI 10.1016/j.bbrc.2007.11.107
   Henschler D, 2006, HUM EXP TOXICOL, V25, P347, DOI 10.1191/0960327106ht642oa
   Hervouet E, 2005, CARCINOGENESIS, V26, P531, DOI 10.1093/carcin/bgi001
   Hess AR, 2007, DEV DYNAM, V236, P3283, DOI 10.1002/dvdy.21190
   Hu XY, 2005, NEOPLASIA, V7, P356, DOI 10.1593/neo.04595
   Huang GC, 2004, MOL CELL BIOL, V24, P8447, DOI 10.1128/MCB.24.19.8447-8456.2004
   Jiang JH, 2004, ANTICANCER RES, V24, P91
   Jiang JH, 2002, ANTICANCER RES, V22, P1491
   Jones CM, 1996, CURR BIOL, V6, P1468, DOI 10.1016/S0960-9822(96)00751-8
   Ju XM, 2007, P NATL ACAD SCI USA, V104, P7438, DOI 10.1073/pnas.0605874104
   Katsumoto M, 2005, CIRC J, V69, P1547, DOI 10.1253/circj.69.1547
   KORA S, 1988, J PHARMACOBIO-DYNAM, V11, P773, DOI 10.1248/bpb1978.11.773
   Ku MC, 2005, MOL CELL BIOL, V25, P7144, DOI 10.1128/MCB.25.16.7144-7157.2005
   Kulesa PM, 2006, P NATL ACAD SCI USA, V103, P3752, DOI 10.1073/pnas.0506977103
   Langsjoen PH, 2003, BIOFACTORS, V18, P101, DOI 10.1002/biof.5520180212
   Law AKT, 2004, BMC NEUROSCI, V5, P0, DOI 10.1186/1471-2202-5-1
   Lee WJ, 2005, OCCUP ENVIRON MED, V62, P0, DOI 10.1136/oem.2005.020230
   Levy SE, 2000, GENE, V254, P57, DOI 10.1016/S0378-1119(00)00252-3
   LI K, 1990, J BIOL CHEM, V265, P20585
   Li R, 1997, MOL CELL ENDOCRINOL, V128, P69, DOI 10.1016/S0303-7207(97)04023-9
   Li RG, 1996, J BIOL CHEM, V271, P18925, DOI 10.1074/jbc.271.31.18925
   López-Ríos F, 2007, CANCER RES, V67, P9013, DOI 10.1158/0008-5472.CAN-07-1678
   Lu HS, 2002, J BIOL CHEM, V277, P23111, DOI 10.1074/jbc.M202487200
   Mamelak AJ, 2005, EXP DERMATOL, V14, P336, DOI 10.1111/j.0906-6705.2005.00278.x
   Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5
   Martinez B, 2005, J LIPID RES, V46, P736, DOI 10.1194/jlr.M400392-JLR200
   Mason KE, 2008, ARCH BIOCHEM BIOPHYS, V469, P151, DOI 10.1016/j.abb.2007.10.018
   Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863
   Maximo V, 2005, BRIT J CANCER, V92, P1892, DOI 10.1038/sj.bjc.6602547
   McAnulty RJ, 1997, BIOCHEM J, V321, P639, DOI 10.1042/bj3210639
   McDowell N, 1997, CURR BIOL, V7, P671, DOI 10.1016/S0960-9822(06)00294-6
   Meinhardt H, 2008, CURR TOP DEV BIOL, V81, P1, DOI 10.1016/S0070-2153(07)81001-5
   MELNICK RL, 1985, TOXICOLOGY, V34, P13, DOI 10.1016/0300-483X(85)90075-7
   MELNICK RL, 1982, ENVIRON HEALTH PERSP, V45, P51, DOI 10.2307/3429383
   MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585
   Miyata Y, 2006, UROLOGY, V68, P1360, DOI 10.1016/j.urology.2006.09.035
   Modugno F, 2005, CANCER EPIDEM BIOMAR, V14, P2840, DOI 10.1158/1055-9965.EPI-05-0493
   Monge P, 2007, SCAND J WORK ENV HEA, V33, P293, DOI 10.5271/sjweh.1146
   MONTENEGRO MA, 1990, J CRAN GENET DEV BIO, V10, P83
   Montesano R, 2007, BMC DEV BIOL, V7, P0, DOI 10.1186/1471-213X-7-7
   Moreland RB, 2003, INT J IMPOT RES, V15, P362, DOI 10.1038/sj.ijir.3901042
   Müller M, 2002, MOL CELL BIOL, V22, P1060, DOI 10.1128/MCB.22.4.1060-1072.2002
   Nagai Seiichiro, 2004, HUM CELL, V17, P195
   Neumann HPH, 2004, JAMA-J AM MED ASSOC, V292, P1686, DOI 10.1001/jama.292.8.943
   Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551
   NIRANJAN BG, 1982, SCIENCE, V215, P73, DOI 10.1126/science.6797067
   Norman C, 2004, PLANT PHYSIOL, V134, P492, DOI 10.1104/pp.103.031039
   OHYAMA T, 1977, J BIOCHEM, V82, P9, DOI 10.1093/oxfordjournals.jbchem.a131697
   OHYAMA T, 1976, J BIOCHEM-TOKYO, V79, P153, DOI 10.1093/oxfordjournals.jbchem.a131042
   OKABE K, 1986, TOHOKU J EXP MED, V150, P373, DOI 10.1620/tjem.150.373
   Öklü R, 2000, BIOCHEM J, V352, P601, DOI 10.1042/0264-6021:3520601
   Orellana SA, 1996, IN VITRO CELL DEV-AN, V32, P329
   Orrenius S, 2007, DRUG METAB REV, V39, P443, DOI 10.1080/03602530701468516
   Paglin S, 2005, CANCER RES, V65, P11061, DOI 10.1158/0008-5472.CAN-05-1083
   Papa S, 2002, BBA-BIOENERGETICS, V1555, P147, DOI 10.1016/S0005-2728(02)00270-0
   PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043
   Petroulakis E, 2007, BR J CANCER, V96 Suppl, P0
   Phillips KP, 2008, J TOXICOL ENV HEAL B, V11, P188, DOI 10.1080/10937400701873472
   PIGUET PF, 1990, AM J PATHOL, V136, P103
   Pocernich CB, 2003, NEUROTOX RES, V5, P515, DOI 10.1007/BF03033161
   Pollard PJ, 2003, ANN MED, V35, P632, DOI 10.1080/07853890310018458
   Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227
   Potter JD, 2001, CANCER EPIDEM BIOMAR, V10, P161
   Potter JD, 2007, NAT REV CANCER, V7, P464, DOI 10.1038/nrc2146
   Putignani L, 2008, BREAST CANCER RES TR, V110, P439, DOI 10.1007/s10549-007-9738-x
   QIU L, 1995, THESIS GRADUATE COLL, V0, P0
   Quinzii CM, 2008, FASEB J, V22, P1874, DOI 10.1096/fj.07-100149
   Rao R, 2007, J BIOL CHEM, V282, P16959, DOI 10.1074/jbc.M701214200
   Ray S, 1997, MED HYPOTHESES, V48, P473, DOI 10.1016/S0306-9877(97)90113-4
   Regoes A, 2005, J BIOL CHEM, V280, P30557, DOI 10.1074/jbc.M500787200
   RENNER R, 1979, J NUTR, V109, P378, DOI 10.1093/jn/109.3.378
   Rodriguez-Martinez H, 1998, ACTA AGR SCAND A-AN, V0, P12
   Rull RP, 2006, AM J EPIDEMIOL, V163, P743, DOI 10.1093/aje/kwj101
   Rundhaug JE, 2007, MOL CARCINOGEN, V46, P692, DOI 10.1002/mc.20329
   Sajan MP, 1996, TOXICOL LETT, V84, P125
   SAJAN MP, 1995, TOXICOL LETT, V80, P55, DOI 10.1016/0378-4274(95)03256-K
   Salvi M, 2002, BBA-BIOENERGETICS, V1556, P187, DOI 10.1016/S0005-2728(02)00361-4
   Sandal T, 2007, AM J PATHOL, V170, P1739, DOI 10.2353/ajpath.2007.060922
   Sasaki T, 2006, DEVELOPMENT, V133, P371, DOI 10.1242/dev.02200
   Sass JB, 2006, INT J OCCUP ENV HEAL, V12, P260
   Sathyanarayana S, 2008, PEDIATRICS, V121, PE260, DOI 10.1542/peds.2006-3766
   Savagner F, 2001, J CLIN ENDOCR METAB, V86, P4920, DOI 10.1210/jc.86.10.4920
   Sawaoka H, 1999, PROSTAG LEUKOTR ESS, V61, P315, DOI 10.1054/plef.1999.0106
   Schieke SM, 2006, J BIOL CHEM, V281, P27643, DOI 10.1074/jbc.M603536200
   Schulz TJ, 2006, J BIOL CHEM, V281, P977, DOI 10.1074/jbc.M511064200
   Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022
   Selak MA, 2006, BBA-BIOENERGETICS, V1757, P567, DOI 10.1016/j.bbabio.2006.05.015
   Semenza G L, 2001, NOVARTIS FOUND SYMP, V240, P251
   Senthilnathan P, 2006, LIFE SCI, V78, P1010, DOI 10.1016/j.lfs.2005.06.005
   Shertzer HG, 2006, TOXICOL APPL PHARM, V217, P363, DOI 10.1016/j.taap.2006.09.014
   Shi Y, 2006, PROSTAG LEUKOTR ESS, V74, P309, DOI 10.1016/j.plefa.2006.02.005
   Shidaifat F, 1996, CANCER LETT, V107, P37, DOI 10.1016/0304-3835(96)04340-6
   Shinde SB, 2007, CLIN CHIM ACTA, V377, P138, DOI 10.1016/j.cca.2006.09.011
   Simonnet H, 2002, CARCINOGENESIS, V23, P759, DOI 10.1093/carcin/23.5.759
   Slane BG, 2006, CANCER RES, V66, P7615, DOI 10.1158/0008-5472.CAN-06-0833
   Sonnenschein C, 2000, MOL CARCINOGEN, V29, P205, DOI 10.1002/1098-2744(200012)29:4<205::AID-MC1002>3.0.CO;2-W
   St-Germain ME, 2004, MOL CANCER, V3, P0, DOI 10.1186/1476-4598-3-7
   Stankov K, 2006, THYROID, V16, P325, DOI 10.1089/thy.2006.16.325
   Steenland K, 2004, ENVIRON HEALTH PERSP, V112, P1265, DOI 10.1289/ehp.7219
   Su H, 2008, MUTAT RES-FUND MOL M, V641, P27, DOI 10.1016/j.mrfmmm.2008.02.005
   Subbaramaiah K, 2007, CANCER RES, V67, P3976, DOI 10.1158/0008-5472.CAN-06-4273
   Tabata T, 2004, DEVELOPMENT, V131, P703, DOI 10.1242/dev.01043
   Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849
   Tretter L, 2000, J NEUROSCI, V20, P8972
   Tsay HJ, 2007, NEUROTOXICOL TERATOL, V29, P562, DOI 10.1016/j.ntt.2007.05.001
   Tsikolia N, 2006, INT J DEV BIOL, V50, P333, DOI 10.1387/ijdb.052053nt
   Tsikolia N, 2003, RIV BIOL-BIOL FORUM, V96, P293
   Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6
   Tuquet C, 2000, CELL BIOL TOXICOL, V16, P207, DOI 10.1023/A:1007695308257
   Uhrbom L, 2002, CANCER RES, V62, P5551
   van der Woude H, 2005, CRIT REV TOXICOL, V35, P603, DOI 10.1080/10408440500246876
   van Waveren C, 2006, CARCINOGENESIS, V27, P409, DOI 10.1093/carcin/bgi242
   VanderWeele DJ, 2004, MOL CANCER THER, V3, P1605
   Volcik KA, 2003, BIRTH DEFECTS RES A, V67, P158, DOI 10.1002/bdra.10019
   Wagner BK, 2008, NAT BIOTECHNOL, V26, P343, DOI 10.1038/nbt1387
   Walenta S, 2000, J HISTOCHEM CYTOCHEM, V48, P509, DOI 10.1177/002215540004800409
   Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494
   WARBURG O, 1956, SCIENCE, V124, P269
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231
   Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393
   WIMMER EA, 1993, NATURE, V366, P690, DOI 10.1038/366690a0
   WINBERG LD, 1995, TOXICOL LETT, V76, P63, DOI 10.1016/0378-4274(94)03199-1
   Wittassek M, 2008, INT J ANDROL, V31, P131, DOI 10.1111/j.1365-2605.2007.00837.x
   Woodward ER, 2006, ENDOCR-RELAT CANCER, V13, P415, DOI 10.1677/erc.1.00683
   Yamaguchi T, 2000, KIDNEY INT, V57, P1460, DOI 10.1046/j.1523-1755.2000.00991.x
   Yang ZQ, 2007, MOL BIOL CELL, V18, P4681, DOI 10.1091/mbc.E06-12-1161
   Yarian CS, 2005, J BIOENERG BIOMEMBR, V37, P91, DOI 10.1007/s10863-005-4132-z
   YE M, 1992, J AM SOC NEPHROL, V3, P984
   Yeh TC, 2007, BIOCHEM PHARMACOL, V73, P782, DOI 10.1016/j.bcp.2006.11.027
   Yu M, 2007, IUBMB LIFE, V59, P450, DOI 10.1080/15216540701509955
   Zaid A, 1999, J BIOENERG BIOMEMBR, V31, P129, DOI 10.1023/A:1005499727732
   Zaid A, 2001, EUR J BIOCHEM, V268, P5497, DOI 10.1046/j.1432-1033.2001.02453.x
   Zhu CQC, 1999, CELL MOL BIOL, V45, P617
NR 198
TC 36
Z9 38
U1 0
U2 12
PU ASSOC CLINICAL SCIENTISTS
PI MIDDLEBURY
PA PO BOX 1287, MIDDLEBURY, VT 05753 USA
SN 0091-7370
EI 1550-8080
J9 ANN CLIN LAB SCI
JI Ann. Clin. Lab. Sci.
PD FAL 15
PY 2008
VL 38
IS 4
BP 307
EP 329
DI 
PG 23
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 369VM
UT WOS:000260722000001
PM 18988924
DA 2024-11-01
ER

PT J
AU Muravchick, S
AF Muravchick, Stanley
TI Clinical implications of mitochondrial disease
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Mitochondrial myopathy; Mitochondrial cytopathy; Inherited encephalomyopathy; Oxidative stress; Aging; Ischemic preconditioning; Anesthetic toxicity; Bioenergetics; Apoptosis
ID cytochrome-c-oxidase; oxidative stress; anesthetic agents; nitrous-oxide; nitric-oxide; respiratory-chain; atp synthase; kearns-sayre; dna mutation; complex-i
AB The terms mitochondrial myopathy, mitochondrial cytopathy and inherited mitochondrial encephalomyopathy encompass a large grouping of syndromes produced either by genetically transmitted or acquired disruption of mitochondrial energy production OF biosensor function. Many of these disorders are clinically apparent during infancy, but for some the metabolic signs of oxidative stress may not appear until the young or middle adult years. Initially thought to be a rare disorder, it now appears that mitochondrial dysfunction is relatively common but often unrecognized because symptoms are extremely variable and usually insidious in onset. It has also become apparent that mitochondrial dysfunction is a component of many common Cardiovascular and neurological disease states and of physiologic aging. Recent advances in our understanding of the mechanisms of mitochondrial dysfunction may explain and link a wide variety of clinical phenomena. This review summarizes the Current knowledge regarding the clinical implications of inherited and acquired mitochondrial disease, the effects of anesthetics on mitochondrial function, and the extent to which mitochondrial bioenergetic state determines anesthetic requirement and potential anesthetic toxicity. (C) 2008 Elsevier B.V. All rights reserved.
C1 Hosp Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Muravchick, S (corresponding author), Hosp Univ Penn, Dept Anesthesiol & Crit Care, Dulles Suite 680,3400 Spruce St, Philadelphia, PA 19104 USA.
EM muravchst@uphs.upenn.edu
CR Anand KJS, 2007, ANESTHESIOLOGY, V107, P2, DOI 10.1097/01.anes.0000268484.05444.35
   Barja G, 2000, FASEB J, V14, P312, DOI 10.1096/fasebj.14.2.312
   Beal MF, 2003, ANN NY ACAD SCI, V991, P120
   BECKER GL, 1986, ANESTH ANALG, V65, P355
   Boje KMK, 2004, FRONT BIOSCI-LANDMRK, V9, P763, DOI 10.2741/1268
   BRANCA D, 1995, COMP BIOCHEM PHYS C, V110, P41, DOI 10.1016/0742-8413(94)00078-O
   Bruemmer-Smith S, 2001, INTENS CARE MED, V27, P1835, DOI 10.1007/s00134-001-1131-3
   Brunori M, 1999, CELL MOL LIFE SCI, V56, P549, DOI 10.1007/s000180050452
   Budinger GRS, 1998, J BIOL CHEM, V273, P3320, DOI 10.1074/jbc.273.6.3320
   Byrne JA, 2003, ARCH MAL COEUR VAISS, V96, P214
   Calabrese V, 2001, NEUROCHEM RES, V26, P739, DOI 10.1023/A:1010955807739
   Chen HW, 2003, SHOCK, V20, P274, DOI 10.1097/00024382-200309000-00013
   Ciccotelli KK, 1997, ANESTHESIOLOGY, V87, P1240, DOI 10.1097/00000542-199711000-00030
   Cohen BH, 2000, MITOCHONDRIAL CYTOPATHIES: A PRIMER, V0, P0
   COHEN PJ, 1973, ANESTHESIOLOGY, V39, P153, DOI 10.1097/00000542-197308000-00007
   COHEN PJ, 1983, LIFE SCI, V32, P1647, DOI 10.1016/0024-3205(83)90872-X
   CORRALDEBRINSKI M, 1991, JAMA-J AM MED ASSOC, V266, P1812, DOI 10.1001/jama.266.13.1812
   DABBENISALA F, 1990, BIOCHIM BIOPHYS ACTA, V1026, P117, DOI 10.1016/0005-2736(90)90341-K
   DAMBRA MN, 1979, ANESTHESIOLOGY, V51, P343, DOI 10.1097/00000542-197910000-00014
   Davies MG, 1997, BRIT J SURG, V84, P920, DOI 10.1002/bjs.1800840707
   Delogu G, 2004, J CLIN ANESTH, V16, P189, DOI 10.1016/j.jclinane.2003.07.007
   EINARSDOTTIR O, 1988, J BIOL CHEM, V263, P9199
   Emerit J, 2004, BIOMED PHARMACOTHER, V58, P39, DOI 10.1016/j.biopha.2003.11.004
   Eng C, 2003, NAT REV CANCER, V3, P193, DOI 10.1038/nrc1013
   FIGARELLABRANGER D, 1993, NEUROMUSCULAR DISORD, V3, P553, DOI 10.1016/0960-8966(93)90114-Y
   Fink MP, 2002, CRIT CARE, V6, P491, DOI 10.1186/cc1824
   Fredriksson A, 2007, ANESTHESIOLOGY, V107, P427, DOI 10.1097/01.anes.0000278892.62305.9c
   Gardner A, 2003, J AFFECT DISORDERS, V76, P55, DOI 10.1016/S0165-0327(02)00067-8
   GARLID KD, 1983, J BIOL CHEM, V258, P7974
   Gellerich FN, 1999, SHOCK, V11, P336, DOI 10.1097/00024382-199905000-00006
   Genova ML, 2004, ANN NY ACAD SCI, V1011, P86, DOI 10.1196/annals.1293.010
   Gidday JM, 2006, NAT REV NEUROSCI, V7, P437, DOI 10.1038/nrn1927
   Gillis LA, 2003, GASTROENTEROL CLIN N, V32, P789, DOI 10.1016/S0889-8553(03)00052-9
   Graeber MB, 1998, J NEUROL SCI, V153, P251, DOI 10.1016/S0022-510X(97)00295-5
   GRATTANSMITH PJ, 1990, J CHILD NEUROL, V5, P137, DOI 10.1177/088307389000500214
   Griggs RC, 1999, NEW ENGL J MED, V341, P1077, DOI 10.1056/NEJM199909303411411
   Hanley PJ, 2002, J PHYSIOL-LONDON, V544, P687, DOI 10.1113/jphysiol.2002.025015
   HATTORI K, 1991, AM HEART J, V121, P1735, DOI 10.1016/0002-8703(91)90020-I
   Herrero A, 1998, MECH AGEING DEV, V103, P133, DOI 10.1016/S0047-6374(98)00035-9
   Holmes DJ, 2001, EXP GERONTOL, V36, P869, DOI 10.1016/S0531-5565(00)00247-3
   Irwin W, 2002, J BIOL CHEM, V277, P12221, DOI 10.1074/jbc.M108938200
   Itaya K, 1995, MASUI, V44, P710
   Jang YG, 2008, ANESTHESIOLOGY, V108, P243, DOI 10.1097/01.anes.0000299437.93898.4a
   Jevtovic-Todorovic V, 2005, NEUROBIOL AGING, V26, P947, DOI 10.1016/j.neurobiolaging.2004.07.009
   Jia BS, 2008, ANESTHESIOLOGY, V108, P426, DOI 10.1097/ALN.0b013e318164d013
   Johnson ME, 2004, ANESTHESIOLOGY, V101, P1184, DOI 10.1097/00000542-200411000-00019
   JOHNSTON W, 1995, ANN NEUROL, V37, P16, DOI 10.1002/ana.410370106
   Jordán J, 2003, J PHYSIOL BIOCHEM, V59, P129, DOI 10.1007/BF03179878
   Kagawa Y, 1997, BIOSCIENCE REP, V17, P115, DOI 10.1023/A:1027329328504
   Kalman B, 2003, NEUROMOL MED, V3, P147, DOI 10.1385/NMM:3:3:147
   Kayser EB, 1999, ANESTHESIOLOGY, V90, P545, DOI 10.1097/00000542-199902000-00031
   Kitano H, 2007, J CEREBR BLOOD F MET, V27, P1108, DOI 10.1038/sj.jcbfm.9600410
   Knight JA, 2001, ADV CLIN CHEM, V35, P1, DOI 10.1016/S0065-2423(01)35014-X
   LAUWERS MH, 1994, ANAESTHESIA, V49, P876, DOI 10.1111/j.1365-2044.1994.tb04263.x
   LEE SL, 1979, CAN J PHYSIOL PHARM, V57, P65, DOI 10.1139/y79-010
   Lennmarken C, 2003, ANESTHESIOLOGY, V99, P0
   Levy RJ, 2004, SHOCK, V21, P110, DOI 10.1097/01.shk.0000108400.56565.ab
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   LUFT R, 1994, P NATL ACAD SCI USA, V91, P8731, DOI 10.1073/pnas.91.19.8731
   Mandavilli BS, 2002, MUTAT RES-FUND MOL M, V509, P127, DOI 10.1016/S0027-5107(02)00220-8
   MASLOW A, 1993, ANESTH ANALG, V76, P884
   Matsuno S, 1994, MASUI, V43, P1038
   Mellon RD, 2007, ANESTH ANALG, V104, P509, DOI 10.1213/01.ane.0000255729.96438.b0
   Minamoto H, 1996, INTERNAL MED, V35, P991, DOI 10.2169/internalmedicine.35.991
   Monk TG, 2008, ANESTHESIOLOGY, V108, P18, DOI 10.1097/01.anes.0000296071.19434.1e
   Monteiro Pedro, 2003, REV PORT CARDIOL, V22, P407
   Morgan PG, 2002, ANESTHESIOLOGY, V96, P1268, DOI 10.1097/00000542-200205000-00036
   Mroczek-Tonska K, 2003, J APPL GENET, V44, P529
   Muravchick S, 1998, ACTA ANAESTHESIOL BELG, V49, P79
   Naguib M, 1996, ANESTHESIOLOGY, V84, P1506, DOI 10.1097/00000542-199606000-00029
   NAHRWOLD ML, 1974, ANESTHESIOLOGY, V40, P566, DOI 10.1097/00000542-197406000-00010
   Olney JW, 2004, ANESTHESIOLOGY, V101, P273, DOI 10.1097/00000542-200408000-00004
   Orth M, 2001, AM J MED GENET, V106, P27, DOI 10.1002/ajmg.1425
   Ozawa T, 1997, PHYSIOL REV, V77, P425, DOI 10.1152/physrev.1997.77.2.425
   Patel HH, 2008, ANESTHESIOLOGY, V108, P182, DOI 10.1097/01.anes.0000299750.34472.93
   Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314
   Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889
   Pipinos IL, 2003, J VASC SURG, V38, P827, DOI 10.1016/S0741-5214(03)00602-5
   Pollock ML, 1997, J APPL PHYSIOL, V82, P1508, DOI 10.1152/jappl.1997.82.5.1508
   Raeburn CD, 2001, ARCH SURG-CHICAGO, V136, P1263, DOI 10.1001/archsurg.136.11.1263
   Rosaeg OP, 1996, CAN J ANAESTH, V43, P403, DOI 10.1007/BF03011722
   Rötig A, 2003, J NEPHROL, V16, P286
   Sabate S, 1996, REV ESP ANESTESIOL REANIM, V43, P255
   Schapira AHV, 2002, J INHERIT METAB DIS, V25, P207, DOI 10.1023/A:1015629912477
   Schmiedel J, 2003, J NEUROL, V250, P267, DOI 10.1007/s00415-003-0978-3
   SCHUBERT A, 2001, ANESTHESIOLOGY S, V95, P0
   Schwartz M, 2003, BIOCHEM BIOPH RES CO, V310, P247, DOI 10.1016/j.bbrc.2003.09.037
   Sharpe MA, 1998, J BIOL CHEM, V273, P30961, DOI 10.1074/jbc.273.47.30961
   Sheth K, 2001, J SURG RES, V99, P129, DOI 10.1006/jsre.2000.6100
   Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59
   Stadtman ER, 2001, ANN NY ACAD SCI, V928, P22
   Stolzing A, 2001, CLIN EXP DERMATOL, V26, P566, DOI 10.1046/j.1365-2230.2001.00867.x
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Taillé C, 2005, J BIOL CHEM, V280, P25350, DOI 10.1074/jbc.M503512200
   Tanaka K, 2004, ANESTHESIOLOGY, V100, P707, DOI 10.1097/00000542-200403000-00035
   TARBA C, 1990, BIOCHIM BIOPHYS ACTA, V1019, P19, DOI 10.1016/0005-2728(90)90120-S
   TATUCH Y, 1993, BIOCHEM BIOPH RES CO, V192, P124, DOI 10.1006/bbrc.1993.1390
   Treem WR, 1998, SEMIN LIVER DIS, V18, P237, DOI 10.1055/s-2007-1007160
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Walker UA, 1996, EUR NEUROL, V36, P260, DOI 10.1159/000117269
   WALLACE DC, 1992, J INHERIT METAB DIS, V15, P472, DOI 10.1007/BF01799605
   WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8
   Watts JA, 2004, J MOL CELL CARDIOL, V36, P141, DOI 10.1016/j.yjmcc.2003.10.015
   Wei Yau-Huei, 1998, PROCEEDINGS OF THE NATIONAL SCIENCE COUNCIL REPUBLIC OF CHINA PART B LIFE SCIENCES, V22, P55
   Wei YH, 2002, EXP BIOL MED, V227, P671, DOI 10.1177/153537020222700901
   Weldon BC, 2002, ANESTHESIOLOGY, V96, P0
   Wickens AP, 2001, RESP PHYSIOL, V128, P379, DOI 10.1016/S0034-5687(01)00313-9
   WIESEL S, 1991, ANESTH ANALG, V72, P696
   Yorek MA, 2003, FREE RADICAL RES, V37, P471, DOI 10.1080/1071576031000083161
   Zeviani M, 1996, J INHERIT METAB DIS, V19, P504, DOI 10.1007/BF01799111
   ZUPANC ML, 1991, ANN NEUROL, V29, P680, DOI 10.1002/ana.410290619
NR 111
TC 21
Z9 25
U1 1
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD OCT-NOV 15
PY 2008
VL 60
IS 13-14
BP 1553
EP 1560
DI 10.1016/j.addr.2008.03.019
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 363LM
UT WOS:000260268800013
PM 18647627
DA 2024-11-01
ER

PT J
AU Vempati, UD
   Torraco, A
   Moraes, CT
AF Vempati, Uma D.
   Torraco, Alessandra
   Moraes, Carlos T.
TI Mouse models of oxidative phosphorylation dysfunction and disease
SO METHODS
LA English
DT Review
DE Mitochondria; Mitochondrial disease; Knockout mouse; Knockin mouse; Conditional knockout mouse
ID cytochrome-c-oxidase; manganese superoxide-dismutase; adenine-nucleotide translocator; mitochondrial-dna polymerase; apoptosis-inducing factor; iron-sulfur protein; dilated cardiomyopathy; knockout mice; skeletal-muscle; genetic-modification
AB Oxidative phosphorylation (OXPHOS) deficiency results in a number of human diseases, affecting at least one in 5000 of the general population. Altering the function of genes by mutations are central to our understanding their function. Prior to the development of gene targeting, this approach was limited to rare spontaneous mutations that resulted in a phenotype. Since its discovery, targeted mutagenesis of the mouse germline has proved to be a powerful approach to understand the in vivo function of genes. Gene targeting has yielded remarkable understanding of the role of several gene products in the OXPHOS system. We provide a "tool box" of mouse models with OXPHOS defects that could be used to answer diverse scientific questions. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Moraes, Carlos T.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Moraes, Carlos T.] Univ Miami, Dept Cell Biol & Anat, Miami, FL 33136 USA.
C3 University of Miami; University of Miami
RP Moraes, CT (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, 1095 NW 14th Terrace, Miami, FL 33136 USA.
EM CMoraes@med.miami.edu
FU Public Health Service [NS041777, CA85700, EY10804]; Muscular Dystrophy Association
CR Abuin A, 2007, HANDB EXP PHARMACOL, V0, P129
   Agostino A, 2003, HUM MOL GENET, V12, P399, DOI 10.1093/hmg/ddg038
   Akman HO, 2008, HUM MOL GENET, V17, P2433, DOI 10.1093/hmg/ddn143
   Antonicka H, 2003, HUM MOL GENET, V12, P2693, DOI 10.1093/hmg/ddg284
   Bonawitz ND, 2006, MOL CELL, V24, P813, DOI 10.1016/j.molcel.2006.11.024
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Cheung ECC, 2006, EMBO J, V25, P4061, DOI 10.1038/sj.emboj.7601276
   DellAgnello C, 2007, HUM MOL GENET, V16, P431, DOI 10.1093/hmg/ddl477
   Diaz F, 2008, GUT, V57, P232, DOI 10.1136/gut.2006.119180
   Diaz F, 2005, HUM MOL GENET, V14, P2737, DOI 10.1093/hmg/ddi307
   Diaz F, 2006, MOL CELL BIOL, V26, P4872, DOI 10.1128/MCB.01767-05
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dufour E, 2008, HUM MOL GENET, V17, P1418, DOI 10.1093/hmg/ddn030
   Ekstrand MI, 2007, P NATL ACAD SCI USA, V104, P1325, DOI 10.1073/pnas.0605208103
   Fan WW, 2008, SCIENCE, V319, P958, DOI 10.1126/science.1147786
   Fukui H, 2007, P NATL ACAD SCI USA, V104, P14163, DOI 10.1073/pnas.0705738104
   Garcia S, 2008, J INVEST DERMATOL, V128, P2343, DOI 10.1038/jid.2008.64
   Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226
   Gurung B, 2005, J BIOL CHEM, V280, P24895, DOI 10.1074/jbc.M503319200
   Hance N, 2005, HUM MOL GENET, V14, P1775, DOI 10.1093/hmg/ddi184
   Hao ZY, 2005, CELL, V121, P579, DOI 10.1016/j.cell.2005.03.016
   Huang TT, 2001, FREE RADICAL BIO MED, V31, P1101, DOI 10.1016/S0891-5849(01)00694-3
   Ikegami T, 2002, BIOCHEM BIOPH RES CO, V296, P729, DOI 10.1016/S0006-291X(02)00933-6
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Jacobs LJAM, 2006, HUM REPROD UPDATE, V12, P119, DOI 10.1093/humupd/dmi042
   Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146
   Joza N, 2005, MOL CELL BIOL, V25, P10261, DOI 10.1128/MCB.25.23.10261-10272.2005
   Kasahara A, 2006, HUM MOL GENET, V15, P871, DOI 10.1093/hmg/ddl005
   Kasahara T, 2006, MOL PSYCHIATR, V11, P577, DOI 10.1038/sj.mp.4001824
   Kokoszka JE, 2001, P NATL ACAD SCI USA, V98, P2278, DOI 10.1073/pnas.051627098
   Kruse SE, 2008, CELL METAB, V7, P312, DOI 10.1016/j.cmet.2008.02.004
   Kubota M, 2006, J NEUROSCI, V26, P12314, DOI 10.1523/JNEUROSCI.3933-06.2006
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Larsson NG, 2001, TRENDS MOL MED, V7, P578, DOI 10.1016/S1471-4914(01)02167-0
   Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782
   Li H, 2000, P NATL ACAD SCI USA, V97, P3467, DOI 10.1073/pnas.97.7.3467
   Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1
   LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376
   Lobe CG, 1998, BIOESSAYS, V20, P200, DOI 10.1002/(SICI)1521-1878(199803)20:3<200::AID-BIES3>3.0.CO;2-V
   Marth JD, 1996, J CLIN INVEST, V97, P1999, DOI 10.1172/JCI118634
   Metzger D, 2001, METHODS, V24, P71, DOI 10.1006/meth.2001.1159
   Misawa H, 2006, NEUROBIOL DIS, V23, P169, DOI 10.1016/j.nbd.2006.02.014
   Moraes CT, 2004, BBA-BIOENERGETICS, V1659, P153, DOI 10.1016/j.bbabio.2004.09.002
   Murdock DG, 1999, J BIOL CHEM, V274, P14429, DOI 10.1074/jbc.274.20.14429
   Narisawa S, 2002, MOL CELL BIOL, V22, P5554, DOI 10.1128/MCB.22.15.5554-5562.2002
   Park CB, 2007, CELL, V130, P273, DOI 10.1016/j.cell.2007.05.046
   Piruat JI, 2004, MOL CELL BIOL, V24, P10933, DOI 10.1128/MCB.24.24.10933-10940.2004
   Pospisilik JA, 2007, CELL, V131, P476, DOI 10.1016/j.cell.2007.08.047
   Radford NB, 2002, AM J PHYSIOL-HEART C, V282, PH726, DOI 10.1152/ajpheart.00308.2001
   Rajewsky K, 1996, J CLIN INVEST, V98, P600, DOI 10.1172/JCI118828
   Shoubridge EA, 2001, HUM MOL GENET, V10, P2277, DOI 10.1093/hmg/10.20.2277
   Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649
   Sligh JE, 2000, P NATL ACAD SCI USA, V97, P14461, DOI 10.1073/pnas.250491597
   Sörensen L, 2001, J NEUROSCI, V21, P8082, DOI 10.1523/JNEUROSCI.21-20-08082.2001
   Strassburger M, 2005, FREE RADICAL BIO MED, V38, P1458, DOI 10.1016/j.freeradbiomed.2005.02.009
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Trounce I, 2000, NUCLEIC ACIDS RES, V28, P2164, DOI 10.1093/nar/28.10.2164
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461
   Vempati UD, 2007, MOL CELL BIOL, V27, P1771, DOI 10.1128/MCB.00287-06
   Wallace DC, 2001, AM J MED GENET, V106, P71, DOI 10.1002/ajmg.1393
   Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089
   Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510
   Wredenberg A, 2002, P NATL ACAD SCI USA, V99, P15066, DOI 10.1073/pnas.232591499
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
   Zeviani M, 2003, CURR OPIN GENET DEV, V13, P262, DOI 10.1016/S0959-437X(03)00052-2
   Zhou XS, 2008, HUM MOL GENET, V17, P2329, DOI 10.1093/hmg/ddn133
NR 69
TC 26
Z9 29
U1 0
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1046-2023
EI 1095-9130
J9 METHODS
JI Methods
PD DEC 15
PY 2008
VL 46
IS 4
BP 241
EP 247
DI 10.1016/j.ymeth.2008.09.008
PG 7
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 383AT
UT WOS:000261647200002
PM 18848991
DA 2024-11-01
ER

PT J
AU Tanji, K
   Kaufmann, P
   Naini, AB
   Lu, J
   Parsons, TC
   Wang, D
   Willey, JZ
   Shanske, S
   Hirano, M
   Bonilla, E
   Kharldji, A
   DiMauro, S
   Rowland, LP
AF Tanji, Kurenal
   Kaufmann, Petra
   Naini, Ali B.
   Lu, Jiesheng
   Parsons, Timothy C.
   Wang, Dong
   Willey, Joshua Z.
   Shanske, Sara
   Hirano, Michio
   Bonilla, Eduardo
   Kharldji, Alexander
   DiMauro, Salvatore
   Rowland, Lewis P.
TI A novel tRNA<SUP>Val</SUP> mitochondrial DNA mutation causing MELAS
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE tRNAVal; mitochondrial DNA; stroke; MELAS
ID stroke-like episodes; lactic-acidosis; blood-vessels; gene; myopathy; encephalopathy; serial
AB Mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS) is the most common mitochondrial disease due to mitochondrial DNA (mtDNA) mutations. At least 15 distinct mtDNA mutations have been associated with MELAS, and about 80% of the cases are caused by the A3243G tRNA (Leu(UUR)) gene mutation. We report here a novel tRNA(Val) mutation in a 37-year-old woman with manifestations of MELAS, and compare her clinicopathological phenotype with other rare cases associated tRNA(Val) mutations. (c) 2008 Elsevier B.V. All rights reserved.
C1 [Tanji, Kurenal; Bonilla, Eduardo] Columbia Univ, Dept Pathol, Div Neuropathol, Coll Phys & Surg,P&S, New York, NY 10032 USA.
   [Kaufmann, Petra; Naini, Ali B.; Lu, Jiesheng; Parsons, Timothy C.; Wang, Dong; Willey, Joshua Z.; Shanske, Sara; Hirano, Michio; Bonilla, Eduardo; DiMauro, Salvatore; Rowland, Lewis P.] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
   [Kharldji, Alexander] Columbia Univ, Coll Phys & Surg, Dept Radiol, New York, NY 10032 USA.
C3 Columbia University; Columbia University; Columbia University
RP Tanji, K (corresponding author), Columbia Univ, Dept Pathol, Div Neuropathol, Coll Phys & Surg,P&S, 630 W 168th St,PH15Stem 124, New York, NY 10032 USA.
EM kt8@columbia.edu
FU NICHD NIH HHS [P01 HD080642, R01 HD056103] Funding Source: Medline; NINDS NIH HHS [U54 NS078059] Funding Source: Medline
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Betts J, 2006, NEUROPATH APPL NEURO, V32, P359, DOI 10.1111/j.1365-2990.2006.00731.x
   Blakely EL, 2004, J NEUROL SCI, V225, P99, DOI 10.1016/j.jns.2004.07.007
   Chalmers RM, 1997, NEUROLOGY, V49, P589, DOI 10.1212/WNL.49.2.589
   de Coo IFM, 1998, NEUROLOGY, V50, P293, DOI 10.1212/WNL.50.1.293
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   Hays AP, 2006, MITOCHONDRIAL MEDICINE, V0, P45
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8
   Hirano M, 2006, MITOCHONDRIAL MEDICINE, V0, P27
   MATSUOKA T, 1992, CLIN NEUROL, V32, P645
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   MIZUKAMI K, 1992, ACTA NEUROPATHOL, V83, P449, DOI 10.1007/BF00713541
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   OHAMA E, 1987, ACTA NEUROPATHOL, V74, P226, DOI 10.1007/BF00688185
   Ohshita T, 2000, NEURORADIOLOGY, V42, P651, DOI 10.1007/s002340000335
   Sacconi S, 2002, ARCH NEUROL-CHICAGO, V59, P1013, DOI 10.1001/archneur.59.6.1013
   SPRINZI M, 1989, NUCLEIC ACIDS RES, V0, PR1
   Tanji K, 2003, ACTA NEUROPATHOL, V105, P69, DOI 10.1007/s00401-002-0604-y
   Tanji K, 2001, SEMIN CELL DEV BIOL, V12, P429, DOI 10.1006/scdb.2001.0280
   Taylor RW, 1996, ANN NEUROL, V40, P459, DOI 10.1002/ana.410400318
   Tiranti V, 1998, ANN NEUROL, V43, P98, DOI 10.1002/ana.410430116
   Yoneda M, 1999, NEUROLOGY, V53, P2182, DOI 10.1212/WNL.53.9.2182
NR 25
TC 15
Z9 17
U1 1
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD JUL 15
PY 2008
VL 270
IS 1-2
BP 23
EP 27
DI 10.1016/j.jns.2008.01.016
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 323ZE
UT WOS:000257486500004
PM 18314141
DA 2024-11-01
ER

PT J
AU Johnston, APW
   De Lisio, M
   Parise, G
AF Johnston, Adam P. W.
   De Lisio, Michael
   Parise, Gianni
TI Resistance training, sarcopenia, and the mitochondrial theory of aging
SO APPLIED PHYSIOLOGY NUTRITION AND METABOLISM
LA English
DT Article; Proceedings Paper
DE mitochondria; muscle atrophy; resistance exercise; electron transport chain; aging; reactive oxygen species
ID human skeletal-muscle; dna-deletion mutations; force production characteristics; fiber contractile function; respiratory-chain function; electron-transport chain; protein-synthesis rate; age-related-changes; older men; oxidative damage
AB Skeletal muscle aging is associated with a significant loss of muscle mass, strength, function, and quality of life. In addition, the healthcare cost of aging and age-related disease is growing, and will continue to grow as a larger proportion of our population reaches retirement age and beyond. The mitochondrial theory of aging has been identified as a leading explanation of the aging process and describes a path leading to cellular senescence that includes electron transport chain deficiency, reactive oxygen species production, and the accumulation of mitochondrial DNA deletions and mutations. It is also quite clear that regular resistance exercise is a potent and effective countermeasure for skeletal muscle aging. In this review, we discuss age-related sarcopenia, the mitochondrial theory of aging, and how resistance exercise may directly affect key components of the mitochondrial theory. It is clear from the data discussed that regular resistance training can effectively disturb processes that contribute to the progression of aging as it pertains to the mitochondrial theory.
C1 [Johnston, Adam P. W.; De Lisio, Michael; Parise, Gianni] McMaster Univ, Dept Kinesiol, Hamilton, ON L8N 3Z5, Canada.
C3 McMaster University
RP Parise, G (corresponding author), McMaster Univ, Dept Kinesiol, Hamilton, ON L8N 3Z5, Canada.
EM pariseg@mcmaster.ca
CR Al Snih S, 2006, ETHNIC DIS, V16, P640
   BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205
   Balagopal P, 2001, AM J PHYSIOL-ENDOC M, V280, PE203, DOI 10.1152/ajpendo.2001.280.2.E203
   Barrientos A, 1996, BIOCHEM BIOPH RES CO, V229, P536, DOI 10.1006/bbrc.1996.1839
   Beaton LJ, 2002, CAN J APPL PHYSIOL, V27, P516, DOI 10.1139/h02-028
   Binder EF, 2005, J GERONTOL A-BIOL, V60, P1425, DOI 10.1093/gerona/60.11.1425
   BOFFOLI D, 1994, BBA-MOL BASIS DIS, V1226, P73, DOI 10.1016/0925-4439(94)90061-2
   Brill PA, 2000, MED SCI SPORT EXER, V32, P412, DOI 10.1097/00005768-200002000-00023
   BROWN AB, 1990, J APPL PHYSIOL, V69, P1725, DOI 10.1152/jappl.1990.69.5.1725
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   CAMPBELL WW, 1994, AM J CLIN NUTR, V60, P167, DOI 10.1093/ajcn/60.2.167
   Campisi J, 1996, EXP GERONTOL, V31, P7, DOI 10.1016/0531-5565(95)02024-1
   Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502
   CHARETTE SL, 1991, J APPL PHYSIOL, V70, P1912, DOI 10.1152/jappl.1991.70.5.1912
   Chretien D, 1998, BIOCHEM J, V329, P249, DOI 10.1042/bj3290249
   COOPER JM, 1992, J NEUROL SCI, V113, P91, DOI 10.1016/0022-510X(92)90270-U
   Fanò G, 2001, J MUSCLE RES CELL M, V22, P345, DOI 10.1023/A:1013122805060
   FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501
   Flynn MG, 1999, J APPL PHYSIOL, V86, P1905, DOI 10.1152/jappl.1999.86.6.1905
   Franceschi C, 1989, AGING (MILANO), V1, P3
   Fries JF, 1996, J ROY SOC MED, V89, P64, DOI 10.1177/014107689608900202
   Frontera WR, 2000, J APPL PHYSIOL, V88, P1321
   FRONTERA WR, 1988, J APPL PHYSIOL, V64, P1038, DOI 10.1152/jappl.1988.64.3.1038
   Ganguli M, 2002, ARCH GEN PSYCHIAT, V59, P1046, DOI 10.1001/archpsyc.59.11.1046
   Gianni P, 2004, EXP GERONTOL, V39, P1391, DOI 10.1016/j.exger.2004.06.002
   Häkkinen K, 1998, J GERONTOL A-BIOL, V53, PB415, DOI 10.1093/gerona/53A.6.B415
   Häkkinen K, 2002, CAN J APPL PHYSIOL, V27, P213
   Häkkinen K, 2001, ACTA PHYSIOL SCAND, V171, P51, DOI 10.1046/j.1365-201x.2001.171001051.x
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Harridge SDR, 1999, MUSCLE NERVE, V22, P831, DOI 10.1002/(SICI)1097-4598(199907)22:7<831::AID-MUS4>3.0.CO;2-3
   Herrero A, 1998, MECH AGEING DEV, V103, P133, DOI 10.1016/S0047-6374(98)00035-9
   Hikida RS, 2000, J GERONTOL A-BIOL, V55, PB347, DOI 10.1093/gerona/55.7.B347
   HSIEH RH, 1994, BIOCHEM MOL BIOL INT, V32, P1009
   HUNTER GR, 1995, J AM GERIATR SOC, V43, P756, DOI 10.1111/j.1532-5415.1995.tb07045.x
   Ivey FM, 2000, J GERONTOL A-BIOL, V55, PM641, DOI 10.1093/gerona/55.11.M641
   Janssen I, 2000, J APPL PHYSIOL, V89, P81
   KONDO H, 1993, AM J PHYSIOL, V265, PE839, DOI 10.1152/ajpendo.1993.265.6.E839
   Korhonen MT, 2006, J APPL PHYSIOL, V101, P906, DOI 10.1152/japplphysiol.00299.2006
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Kwong LK, 2000, ARCH BIOCHEM BIOPHYS, V373, P16, DOI 10.1006/abbi.1999.1495
   LEEUWENBURGH C, 1994, AM J PHYSIOL, V267, PR439, DOI 10.1152/ajpregu.1994.267.2.R439
   Lemmer JT, 2000, MED SCI SPORT EXER, V32, P1505, DOI 10.1097/00005768-200008000-00021
   LEXELL J, 1995, J GERONTOL A-BIOL, V50, P11
   Lindle RS, 1997, J APPL PHYSIOL, V83, P1581, DOI 10.1152/jappl.1997.83.5.1581
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   LUHTALA TA, 1994, J GERONTOL, V49, PB231, DOI 10.1093/geronj/49.5.B231
   Lynch NA, 1999, J APPL PHYSIOL, V86, P188, DOI 10.1152/jappl.1999.86.1.188
   Martel GF, 2006, EXP PHYSIOL, V91, P457, DOI 10.1113/expphysiol.2005.032771
   Martinez M, 1996, BRAIN RES, V731, P246, DOI 10.1016/0006-8993(96)00708-1
   McCord J M, 1985, ADV MYOCARDIOL, V5, P183
   Muller F, 2000, J AM AGING ASSOC, V23, P227, DOI 10.1007/s11357-000-0022-9
   Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200
   Ohishi S, 1997, CLIN EXP PHARMACOL P, V24, P326, DOI 10.1111/j.1440-1681.1997.tb01196.x
   ORGEL LE, 1963, P NATL ACAD SCI USA, V49, P517, DOI 10.1073/pnas.49.4.517
   PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804
   Pansarasa O, 2000, FREE RADICAL RES, V33, P287, DOI 10.1080/10715760000301451
   Parise G, 2005, FREE RADICAL BIO MED, V39, P289, DOI 10.1016/j.freeradbiomed.2005.03.024
   Parise G, 2005, EXP GERONTOL, V40, P173, DOI 10.1016/j.exger.2004.09.002
   Parise G, 2000, CURR OPIN CLIN NUTR METAB CARE, V3, P489, DOI 10.1097/00075197-200011000-00012
   Phillips SM, 2005, J AM COLL NUTR, V24, P134S, DOI 10.1080/07315724.2005.10719454
   Rasmussen UF, 2003, EXP GERONTOL, V38, P877, DOI 10.1016/S0531-5565(03)00092-5
   Rousset S, 2004, DIABETES, V53, PS130, DOI 10.2337/diabetes.53.2007.S130
   SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803
   Schlicht J, 2001, J GERONTOL A-BIOL, V56, PM281, DOI 10.1093/gerona/56.5.M281
   Singh MAF, 1999, AM J PHYSIOL-ENDOC M, V277, P0
   *STAT CAN, 2007, AG SEX PERC DISTR BO, V0, P0
   *STAT CAN, 2007, AG SEX PERC CHANG 20, V0, P0
   Stupka N, 2000, J APPL PHYSIOL, V89, P2325, DOI 10.1152/jappl.2000.89.6.2325
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Trappe S, 2003, J PHYSIOL-LONDON, V552, P47, DOI 10.1113/jphysiol.2003.044966
   Trappe S, 2000, J APPL PHYSIOL, V89, P143, DOI 10.1152/jappl.2000.89.1.143
   Trappe S, 2001, AM J PHYSIOL-CELL PH, V281, PC398, DOI 10.1152/ajpcell.2001.281.2.C398
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0
   Vermulst M, 2007, NAT GENET, V39, P540, DOI 10.1038/ng1988
   Vincent KR, 2002, EUR J APPL PHYSIOL, V87, P416, DOI 10.1007/s00421-002-0640-2
   Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com
   Welle S, 1996, J GERONTOL A-BIOL, V51, PM270, DOI 10.1093/gerona/51A.6.M270
   Yarasheski KE, 1999, AM J PHYSIOL-ENDOC M, V277, PE118, DOI 10.1152/ajpendo.1999.277.1.E118
   YARASHESKI KE, 1995, AM J PHYSIOL-ENDOC M, V268, PE268, DOI 10.1152/ajpendo.1995.268.2.E268
   YARASHESKI KE, 1993, AM J PHYSIOL, V265, PE210, DOI 10.1152/ajpendo.1993.265.2.E210
NR 82
TC 114
Z9 151
U1 3
U2 20
PU CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS
PI OTTAWA
PA 65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA
SN 1715-5312
EI 1715-5320
J9 APPL PHYSIOL NUTR ME
JI Appl. Physiol. Nutr. Metab.
PD FEB 15
PY 2008
VL 33
IS 1
BP 191
EP 199
DI 10.1139/H07-141
PG 9
WC Nutrition & Dietetics; Physiology; Sport Sciences
SC Nutrition & Dietetics; Physiology; Sport Sciences
GA 318OE
UT WOS:000257100600023
PM 18347672
DA 2024-11-01
ER

PT J
AU Chida, J
   Amagai, A
   Tanaka, M
   Maeda, Y
AF Chida, Junji
   Amagai, Aiko
   Tanaka, Masashi
   Maeda, Yasuo
TI Establishment of a new method for precisely determining the functions of individual mitochondrial genes, using <i>Dictyostelium cells</i>
SO BMC GENETICS
LA English
DT Article
ID progressive external ophthalmoplegia; targeted restriction-endonuclease; kearns-sayre syndrome; dna heteroplasmy; differentiation; discoideum; expression; sequence; growth; shift
AB Background: Disruption of mitochondrial genes may become a powerful tool for elucidating precisely the functions of individual mitochondrial genes. However, it is generally difficult to manipulate genetically mitochondrial genes, because 1) a mitochondrion is surrounded by inner and outer membranes, and 2) there are a large number of mtDNA copies in a single cell. This is the reason why we tried to establish a novel method for disrupting a certain mitochondrial gene ( rps4), using Dictyostelium cells. Results: Here, we have developed a new method for specifically disrupting a mitochondrial gene ( rps4; ribosomal protein subunit S4), by a combination of homologous recombination and delivery of an appropriate restriction endonuclease ( Sfol) into mitochondria. First, mitochondrially targeted SfoI whose expression is under control of the tetracycline ( Tet)- regulated gene expression system was introduced into cells heteroplasmic with respect to the rps4 gene. Then, the heteroplasmic cells were produced by homologous recombination by use of the construct in which the unique SfoI site and the 5'- half of the rps4 coding region were deleted not to be digested by SfoI, and therefore their mitochondria have both the wild-type mtDNA and the mutant mtDNA with the disrupted rps4 gene. In response to removal of Tet from growth medium, SfoI was selectively delivered into mitochondria and digested only the wild-type mtDNA but not the mutated rps4. Thus one can gain rps4-null cells with only the mutated mtDNA, under the Tet-minus condition. Conclusion: The mitochondrial gene-disruption method presented here must be widely useful for precisely determining the functions of individual mitochondrial genes. This is the first report to demonstrate complete and specific mitochondrial gene disruption.
C1 [Chida, Junji; Amagai, Aiko; Maeda, Yasuo] Tohoku Univ, Grad Sch Life Sci, Dept Dev Biol & Neurosci, Aoba Ku, Sendai, Miyagi 9808578, Japan.
   [Chida, Junji] Univ Tokushima, Inst Enzyme Res, Div Enzyme Chem, Tokushima 7708503, Japan.
   [Tanaka, Masashi] Tokyo Metropolitan Inst Gerontol, Itabashi Ku, Tokyo 1730015, Japan.
C3 Tohoku University; Tokushima University; Tokyo Metropolitan Institute of Gerontology
RP Maeda, Y (corresponding author), Tohoku Univ, Grad Sch Life Sci, Dept Dev Biol & Neurosci, Aoba Ku, Sendai, Miyagi 9808578, Japan.
EM j-chida@ier.tokushima-u.ac.jp; aiamagai@mail.tains.tohoku.ac.jp; mtanaka@tmig.or.jp; ymaeda@mail.tains.tohoku.ac.jp
CR Bayona-Bafaluy MP, 2005, P NATL ACAD SCI USA, V102, P14392, DOI 10.1073/pnas.0502896102
   Blaauw M, 2000, GENE, V252, P71, DOI 10.1016/S0378-1119(00)00227-4
   Chida J, 2004, J CELL SCI, V117, P3141, DOI 10.1242/jcs.01140
   DSOUZA GG, 2004, CURR GENE THER, V4, P169
   Fischel-Ghodsian N, 1998, P SOC EXP BIOL MED, V218, P1
   Gray MW, 1998, NUCLEIC ACIDS RES, V26, P865, DOI 10.1093/nar/26.4.865
   Inazu Y, 1999, DEV GENET, V25, P339, DOI 10.1002/(SICI)1520-6408(1999)25:4<339::AID-DVG8>3.0.CO;2-3
   Maeda Y, 2005, INT REV CYTOL, V244, P287, DOI 10.1016/S0074-7696(05)44007-3
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   NELLEN W, 1987, METHOD CELL BIOL, V28, P67
   Ogawa S, 2000, MOL GEN GENET, V263, P514, DOI 10.1007/PL00008685
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   Saiwaki T, 2000, J CLIN PATHOL-MOL PA, V53, P333, DOI 10.1136/mp.53.6.333
   SCHWARTZKOPFF B, 1988, J AM COLL CARDIOL, V12, P1522, DOI 10.1016/S0735-1097(88)80020-2
   Srivastava S, 2001, HUM MOL GENET, V10, P3093, DOI 10.1093/hmg/10.26.3093
   Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980
NR 16
TC 11
Z9 12
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2156
EI 
J9 BMC GENET
JI BMC Genet.
PD MAR 21
PY 2008
VL 9
IS 
BP 
EP 
DI 10.1186/1471-2156-9-25
PG 11
WC Genetics & Heredity
SC Genetics & Heredity
GA 298TQ
UT WOS:000255710400001
PM 18366713
DA 2024-11-01
ER

PT J
AU Galassi, G
   Lamantea, E
   Invernizzi, F
   Tavani, F
   Pisano, I
   Ferrero, I
   Palmieri, L
   Zeviani, M
AF Galassi, Giuliana
   Lamantea, Eleonora
   Invernizzi, Federica
   Tavani, Federica
   Pisano, Isabella
   Ferrero, Ileana
   Palmieri, Luigi
   Zeviani, Massimo
TI Additive effects of POLG1 and ANT1 mutations in a complex encephalomyopathy
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mitochondrial DNA; mtDNA multiple deletions; progressive external ophthalmoplegia; sensory-cerebellar ataxia; ANT1; POLG1
ID dna-polymerase-gamma; progressive external ophthalmoplegia; adenine-nucleotide translocator; saccharomyces-cerevisiae; bacterial expression; mitochondrial; reconstitution; transport; spectrum; protein
AB MtDNA instability is associated with a wide spectrum of clinical presentations, from dominant or recessive progressive external ophthalmoplegia (PEO) to juvenile-onset spino-cerebellar ataxia and epilepsy (SCAE) or infantile Alpers-Huttenlocher syndrome. We present here the clinical and molecular features of a patient with a clinical presentation characterized initially by PEO with mtDNA multiple deletions lately evolving into a severe neurological syndrome, which included sensory and cerebellar ataxia, peripheral neuropathy, parkinsonism, and depression. This complex phenotype is the result of mutations in two distinct proteins, ANTI and Pol gamma A, which cause additive, deleterious effects on mtDNA maintenance and integrity. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Lamantea, Eleonora; Invernizzi, Federica; Zeviani, Massimo] IRCCS, C Besta Neurol Inst Fdn, Unit Mol Neurogenet Peirfranco, I-20126 Milan, Italy.
   [Lamantea, Eleonora; Invernizzi, Federica; Zeviani, Massimo] IRCCS, C Besta Neurol Inst Fdn, Luisa Mariani Ctr Study Childrens Mitochondrial D, I-20126 Milan, Italy.
   [Galassi, Giuliana] Univ Modena, Dept Neurosci, I-41100 Modena, Italy.
   [Tavani, Federica] Univ Modena, Serv Neuroradiol, I-41100 Modena, Italy.
   [Pisano, Isabella] Univ Bari, Biochem & Mol Biol Lab, Dept Pharmacobiol, Bari, Italy.
   [Ferrero, Ileana] Univ Parma, Dept Genet Anthropol Evolut, I-43100 Parma, Italy.
   [Palmieri, Luigi] CNR Inst Biomembranes & Bioenerget, Bari, Italy.
C3 Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia; Universita degli Studi di Bari Aldo Moro; University of Parma; Consiglio Nazionale delle Ricerche (CNR)
RP Zeviani, M (corresponding author), IRCCS, C Besta Neurol Inst Fdn, Unit Mol Neurogenet Peirfranco, Via Libero, I-20126 Milan, Italy.
EM zeviani@istituto-besta.it
FU Telethon [GGP07019] Funding Source: Medline
CR Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Dolce V, 2005, FEBS LETT, V579, P633, DOI 10.1016/j.febslet.2004.12.034
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293
   Fontanesi F, 2004, HUM MOL GENET, V13, P923, DOI 10.1093/hmg/ddh108
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Palmieri F, 1995, METHOD ENZYMOL, V260, P349, DOI 10.1016/0076-6879(95)60150-3
   Palmieri L, 2005, HUM MOL GENET, V14, P3079, DOI 10.1093/hmg/ddi341
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2007, BIOSCIENCE REP, V27, P39, DOI 10.1007/s10540-007-9036-1
   Stuart GR, 2006, HUM MOL GENET, V15, P363, DOI 10.1093/hmg/ddi454
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
NR 19
TC 28
Z9 28
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD JUN 15
PY 2008
VL 18
IS 6
BP 465
EP 470
DI 10.1016/j.nmd.2008.03.013
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 331PB
UT WOS:000258023000006
PM 18504126
DA 2024-11-01
ER

PT J
AU Finsterer, J
AF Finsterer, Josef
TI Cognitive decline as a manifestation of mitochondrial disorders (mitochondrial dementia)
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Review
DE mitochondrial disorder; encephalomyopathy; metabolic disease; respiratory chain disorder; myopathy; intellectual decline; cognitive deficits
ID stroke-like episodes; kearns-sayre-syndrome; complex-i-deficiency; c-oxidase deficiency; heteroplasmic mtdna mutation; adult-onset melas; atpase 6 gene; leigh-syndrome; lactic-acidosis; point mutation
AB Mitochondrial disorders, in particular respiratory chain diseases (RCDs), present either as single organ problem or as multi-system disease. One of the most frequently affected organs in RCDs, in addition to the skeletal muscle, is the central nervous system (CNS). CNS manifestations of RCDs include epilepsy, stroke-like episodes, migraine-like headache, ataxia, spasticity, movement disorders, psychosis, demyelination, calcification, but also dementia. Cognitive impairment may be a feature of syndromic as well as non-syndromic RCDs. Syndromic RCDs associated with cognitive impairment include MELAS, KSS, Leigh syndrome, and many others. RCDs with cognitive decline not only result from nuDNA mutations but also from mutations in nuclear genes. At onset there is often no general intellectual deterioration in these patients but specific cognitive deficits, particularly in the Visual construction, attention, abstraction, or flexibility. Diagnosis of cognitive impairment from RCDs is based on neuropsychological testing, imaging studies, including MRI, PET, SPECT, or MR-spectroscopy, CSF investigations, or electroencephalography. Therapeutic strategies for dementia in RCDs rely on symptomatic measures. Only single patients may profit from cholinesterase inhibitors or memantine, antioxidants, vitamins, or other substitutes. Overall, cognitive decline in RCDs (mitochondrial dementia) needs to be included in the differentials of dementia. (C) 2008 Elsevier B.V All rights reserved.
C1 [Finsterer, Josef] Krankenanstalt Rudolfstiftung Wien, Vienna, Austria.
C3 Rudolfstiftung Hospital
RP Finsterer, J (corresponding author), Postfach 20, A-1180 Vienna, Austria.
EM fipaps@yahoo.de
CR Abe K, 2004, NEURORADIOLOGY, V46, P113, DOI 10.1007/s00234-003-1138-2
   Amemiya S, 2000, NEUROLOGY, V55, P600, DOI 10.1212/WNL.55.4.600
   Ames BN, 2004, ANN NY ACAD SCI, V1033, P108, DOI 10.1196/annals.1320.010
   [Anonymous], 1987, DIAGNOSTIC STAT MANU, V4th, P0
   Apostolova LG, 2005, ARCH NEUROL-CHICAGO, V62, P1154, DOI 10.1001/archneur.62.7.1154
   Atwood CS, 2005, J NEUROPATH EXP NEUR, V64, P93, DOI 10.1093/jnen/64.2.93
   Bartels C, 2007, NERVENARZT, V78, P597, DOI 10.1007/s00115-006-2248-y
   Bénit P, 2004, J MED GENET, V41, P14, DOI 10.1136/jmg.2003.014316
   Bénit P, 2003, HUM MUTAT, V21, P582, DOI 10.1002/humu.10225
   Bénit P, 2001, AM J HUM GENET, V68, P1344, DOI 10.1086/320603
   Berio A, 2002, PANMINERVA MED, V44, P265
   Bidooki S, 2004, NEUROMUSCULAR DISORD, V14, P417, DOI 10.1016/j.nmd.2004.03.004
   Binder J, 2003, BRAIN, V126, P1814, DOI 10.1093/brain/awg174
   Bosbach S, 2003, BRAIN, V126, P1231, DOI 10.1093/brain/awg101
   Bruno C, 1999, AM J HUM GENET, V65, P611, DOI 10.1086/302546
   Bruno C, 2002, J CHILD NEUROL, V17, P233, DOI 10.1177/088307380201700318
   Calvo S, 2006, NAT GENET, V38, P576, DOI 10.1038/ng1776
   Campos Y, 1997, NEUROLOGY, V49, P595, DOI 10.1212/WNL.49.2.595
   Campos Y, 2001, J INHERIT METAB DIS, V24, P685, DOI 10.1023/A:1012719211505
   Cantuti-Castelvetria I, 2005, NEUROBIOL AGING, V26, P1343, DOI 10.1016/j.neurobiolaging.2004.11.008
   Carod-Artal FJ, 2007, EUR J NEUROL, V14, P581, DOI 10.1111/j.1468-1331.2007.01720.x
   Chalmers RM, 1997, NEUROLOGY, V49, P589, DOI 10.1212/WNL.49.2.589
   Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010
   Chinnery P, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004426.pub2
   Chinnery PF, 1997, J NEUROL NEUROSUR PS, V63, P559, DOI 10.1136/jnnp.63.5.559
   COREYBLOOM J, 1995, NEUROLOGY, V45, P211, DOI 10.1212/WNL.45.2.211
   Corona P, 2002, ANN NEUROL, V51, P118, DOI 10.1002/ana.10059
   Crimi M, 2004, PEDIATR RES, V55, P842, DOI 10.1203/01.PDR.0000117844.73436.68
   De Coo IFM, 1999, ANN NEUROL, V45, P130, DOI 10.1002/1531-8249(199901)45:1<130::AID-ART21>3.0.CO;2-Z
   Degoul F, 1995, J INHERIT METAB DIS, V18, P682, DOI 10.1007/BF02436757
   Deschauer M, 2007, NEUROLOGY, V68, P1741, DOI 10.1212/01.wnl.0000261929.92478.3e
   DESNUELLE C, 1989, REV NEUROL-FRANCE, V145, P842
   DEVRIES DD, 1993, ANN NEUROL, V34, P410, DOI 10.1002/ana.410340319
   Dickerson BC, 2005, NEW ENGL J MED, V353, P2271, DOI 10.1056/NEJMcpc059032
   DiMauro S, 1996, J INHERIT METAB DIS, V19, P489, DOI 10.1007/BF01799110
   Dubeau F, 2000, ANN NEUROL, V47, P179, DOI 10.1002/1531-8249(200002)47:2<179::AID-ANA7>3.0.CO;2-Z
   Durga J, 2006, NEUROBIOL AGING, V27, P334, DOI 10.1016/j.neurobiolaging.2005.01.003
   Fattal O, 2006, PSYCHOSOMATICS, V47, P1, DOI 10.1176/appi.psy.47.1.1
   Fattal O, 2007, CNS SPECTRUMS, V12, P429, DOI 10.1017/S1092852900015303
   Finsterer J, 2006, ACTA NEUROL SCAND, V114, P217, DOI 10.1111/j.1600-0404.2006.00671.x
   Finsterer J, 2006, NETH J MED, V64, P61
   Finsterer J, 2005, CLIN NEUROPHARMACOL, V28, P148, DOI 10.1097/01.wnf.0000165352.10841.21
   Finsterer J, 2001, NEURORADIOLOGY, V43, P997, DOI 10.1007/s002340100618
   Gardner A, 2003, ACTA PSYCHIAT SCAND, V107, P233, DOI 10.1034/j.1600-0447.2003.02188.x
   Gilchrist JM, 1996, STROKE, V27, P1420, DOI 10.1161/01.STR.27.8.1420
   Goto Yu-ichi, 2004, NIHON RINSHO, V62 Suppl 4, P220
   Graf WD, 2000, J CHILD NEUROL, V15, P357, DOI 10.1177/088307380001500601
   GRUNWALD F, 1990, J NUCL MED, V31, P1740
   Hanna MG, 1998, AM J HUM GENET, V63, P29, DOI 10.1086/301910
   Hattori Y, 2001, RINSHO SHINKEIGAKU, V41, P668
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Houshmand M, 1999, HUM MUTAT, V13, P203, DOI 10.1002/(SICI)1098-1004(1999)13:3<203::AID-HUMU4>3.0.CO;2-3
   Howell N, 1996, NEUROLOGY, V46, P219, DOI 10.1212/WNL.46.1.219
   Hudson S A, 2003, COCHRANE DATABASE OF SYSTEMATIC REVIEWS, V0, P0, DOI DOI 10.1002/14651858.CD003158
   Ishrat T, 2006, BEHAV BRAIN RES, V171, P9, DOI 10.1016/j.bbr.2006.03.009
   ISOZUMI K, 1994, INTERNAL MED, V33, P543, DOI 10.2169/internalmedicine.33.543
   Jaksch M, 2001, NEUROLOGY, V57, P1930, DOI 10.1212/WNL.57.10.1930
   Jin H, 1996, NAT GENET, V14, P177, DOI 10.1038/ng1096-177
   JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007
   KALIMO H, 1979, ANN NEUROL, V6, P200, DOI 10.1002/ana.410060304
   KARTSOUNIS LD, 1992, ARCH NEUROL-CHICAGO, V49, P158, DOI 10.1001/archneur.1992.00530260058020
   Kato Tadafumi, 2005, NIHON SHINKEI SEISHIN YAKURIGAKU ZASSHI, V25, P61
   Kaufmann P, 2004, NEUROLOGY, V62, P1297, DOI 10.1212/01.WNL.0000120557.83907.A8
   Köller H, 2003, J NEUROL, V250, P1501, DOI 10.1007/s00415-003-0260-8
   LANG CJG, 1995, EUR J NEUROL, V2, P171, DOI 10.1111/j.1468-1331.1995.tb00112.x
   Lemon JA, 2003, EXP BIOL MED, V228, P800, DOI 10.1177/15353702-0322807-05
   Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3
   Limongelli A, 2004, J MED GENET, V41, P342, DOI 10.1136/jmg.2003.016048
   Loeffen J, 2001, ANN NEUROL, V49, P195, DOI 10.1002/1531-8249(20010201)49:2<195::AID-ANA39>3.0.CO;2-M
   Loeffen J, 1998, AM J HUM GENET, V63, P1598, DOI 10.1086/302154
   López LC, 2006, AM J HUM GENET, V79, P1125, DOI 10.1086/510023
   López-Fraile MIP, 2006, NEUROLOGIA, V21, P327
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Majamaa K, 1997, NEUROLOGY, V49, P1331, DOI 10.1212/WNL.49.5.1331
   Malfatti E, 2007, BRAIN, V130, P1894, DOI 10.1093/brain/awm114
   Mancuso M, 2008, J AFFECT DISORDERS, V106, P173, DOI 10.1016/j.jad.2007.05.016
   Martín MA, 2005, ARCH NEUROL-CHICAGO, V62, P659, DOI 10.1001/archneur.62.4.659
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   Melone MAB, 2004, ARCH NEUROL-CHICAGO, V61, P269, DOI 10.1001/archneur.61.2.269
   Möller HE, 2005, J NEUROL SCI, V229, P131, DOI 10.1016/j.jns.2004.11.014
   Montirosso R, 2002, J NEUROL SCI, V194, P3, DOI 10.1016/S0022-510X(01)00664-5
   Morimoto N, 2004, NEUROLOGY, V63, P2451, DOI 10.1212/01.WNL.0000147321.38129.ED
   Naidu S, 2005, ANN NEUROL, V58, P929, DOI 10.1002/ana.20671
   NAKAI A, 1994, LANCET, V343, P1397, DOI 10.1016/S0140-6736(94)92527-5
   NELSON I, 1995, ANN NEUROL, V37, P400, DOI 10.1002/ana.410370317
   Nishino I, 1996, BIOCHEM BIOPH RES CO, V225, P180, DOI 10.1006/bbrc.1996.1150
   Nishioka J, 2008, BRAIN DEV-JPN, V30, P100, DOI 10.1016/j.braindev.2007.06.008
   Nomura T, 1993, RINSHO SHINKEIGAKU, V33, P1198
   Oliveira G, 2005, DEV MED CHILD NEUROL, V47, P185, DOI 10.1017/S0012162205000332
   Pachalska M, 2001, NEUROL NEUROCHIR POL, V35, P681
   Park SB, 2004, YONSEI MED J, V45, P727, DOI 10.3349/ymj.2004.45.4.727
   Patel IB, 2007, SOUTH MED J, V100, P70, DOI 10.1097/01.smj.0000223691.66759.8f
   Playán A, 2002, REV NEUROLOGIA, V34, P1124, DOI 10.33588/rn.3412.2002252
   RIGGS JE, 1984, NEUROLOGY, V34, P48, DOI 10.1212/WNL.34.1.48
   Vasconcellos LFR, 2007, ARQ NEURO-PSIQUIAT, V65, P114, DOI 10.1590/S0004-282X2007000100023
   Rojo A, 2006, ACTA NEUROPATHOL, V111, P610, DOI 10.1007/s00401-006-0040-5
   Rossi A, 2003, AM J NEURORADIOL, V24, P1188
   Salviati L, 2005, NEUROLOGY, V65, P606, DOI 10.1212/01.wnl.0000172859.55579.a7
   Sano M, 1995, ACTA NEUROL SCAND, V92, P497
   Sartor H, 2002, ACTA NEUROL SCAND, V106, P309, DOI 10.1034/j.1600-0404.2002.01089.x
   Scaglia F, 2006, CNS DRUGS, V20, P443, DOI 10.2165/00023210-200620060-00002
   Schapira AHV, 2002, J NEUROL NEUROSUR PS, V72, P144, DOI 10.1136/jnnp.72.2.144
   SCHAUB RT, 2005, DEMENZEN, V0, P59
   Schmitt-Schillig S, 2005, J PHYSIOL PHARMACOL, V56 Suppl 1, P23
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   Schuelke M, 1999, NAT GENET, V21, P260, DOI 10.1038/6772
   Scuderi C, 2007, NEUROMUSCULAR DISORD, V17, P258, DOI 10.1016/j.nmd.2006.11.006
   Shaag A, 1997, BIOCHEM BIOPH RES CO, V233, P637, DOI 10.1006/bbrc.1997.6496
   Sharfstein SR, 1999, ARCH NEUROL-CHICAGO, V56, P241, DOI 10.1001/archneur.56.2.241
   Shoffner JM, 1996, LANCET, V348, P1283, DOI 10.1016/S0140-6736(96)09138-6
   SHOFFNER JM, 1992, NEUROLOGY, V42, P2168, DOI 10.1212/WNL.42.11.2168
   SHOFFNER JM, 1995, NEUROLOGY, V45, P286, DOI 10.1212/WNL.45.2.286
   Shtilbans A, 1999, J CHILD NEUROL, V14, P610, DOI 10.1177/088307389901400910
   Silvestri G, 2000, NEUROLOGY, V54, P1693, DOI 10.1212/WNL.54.8.1693
   Siwak CT, 2005, PROG NEURO-PSYCHOPH, V29, P461, DOI 10.1016/j.pnpbp.2004.12.011
   Sperl W, 1997, WIEN KLIN WOCHENSCHR, V109, P93
   Stryer L, 1996, BIOCHEMIE, V0, P0
   Sue CM, 1999, J PEDIATR-US, V134, P696, DOI 10.1016/S0022-3476(99)70283-0
   SUZUKI T, 1989, J NEUROL NEUROSUR PS, V52, P920, DOI 10.1136/jnnp.52.7.920-a
   Suzuki Y, 1997, MOL ASPECTS MED, V18, P0
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Taylor RW, 2001, ANN NEUROL, V50, P104, DOI 10.1002/ana.1084
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   TRANEBJAERG L, 1995, J MED GENET, V32, P257, DOI 10.1136/jmg.32.4.257
   Triepels RH, 1999, ANN NEUROL, V45, P787, DOI 10.1002/1531-8249(199906)45:6<787::AID-ANA13>3.0.CO;2-6
   Tsao CY, 2007, J CHILD NEUROL, V22, P1121, DOI 10.1177/0883073807306266
   Tsao CY, 2001, J CHILD NEUROL, V16, P533, DOI 10.1177/088307380101600716
   Tsuchiya K, 1999, ACTA NEUROPATHOL, V97, P520, DOI 10.1007/s004010051023
   Tulinius M, 2003, NEUROPEDIATRICS, V34, P87
   Turconi AC, 1999, J NEUROL SCI, V170, P57, DOI 10.1016/S0022-510X(99)00199-9
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Ujike H, 2001, ARCH NEUROL-CHICAGO, V58, P1004, DOI 10.1001/archneur.58.6.1004
   Uziel G, 1997, J NEUROL NEUROSUR PS, V63, P16, DOI 10.1136/jnnp.63.1.16
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
   van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Van Maldergem L, 2002, ANN NEUROL, V52, P750, DOI 10.1002/ana.10371
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Verma A, 1997, PEDIATR RES, V42, P448, DOI 10.1203/00006450-199710000-00005
   Wang JQ, 2006, J NEUROCHEM, V96, P825, DOI 10.1111/j.1471-4159.2005.03615.x
   Wolf NI, 2003, NEUROPEDIATRICS, V34, P156
   Zeviani M, 2003, CURR OPIN NEUROL, V16, P585, DOI 10.1097/00019052-200310000-00004
   Zeviani M, 2007, CURR OPIN NEUROL, V20, P564, DOI 10.1097/WCO.0b013e3282ef58cd
NR 144
TC 43
Z9 47
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD SEP 15
PY 2008
VL 272
IS 1-2
BP 20
EP 33
DI 10.1016/j.jns.2008.05.011
PG 14
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 347HM
UT WOS:000259131200003
PM 18572195
DA 2024-11-01
ER

PT J
AU Brautbar, A
   Wang, J
   Abdenur, JE
   Chang, RC
   Thomas, JA
   Grebe, TA
   Lim, C
   Weng, SW
   Graham, BH
   Wong, LJ
AF Brautbar, Ariel
   Wang, Jing
   Abdenur, Jose E.
   Chang, Richard C.
   Thomas, Janet A.
   Grebe, Theresa A.
   Lim, Cynthia
   Weng, Shao-Wen
   Graham, Brett H.
   Wong, Lee-Jun
TI The mitochondrial 13513G&gt;A mutation is associated with Leigh disease phenotypes independent of complex I deficiency in muscle
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE mitochondrial disease; Leigh syndrome; MELAS; mtDNA; 13513G > A; 13514A > G
ID dna g13513a mutation; clinical-features; gene; abnormality; dysfunction; disorders; children; frequent; subunit; melas
AB The mitochondrial 13513G>A (D393N) mutation in the ND5 subunit of the respiratory chain complex I was initially described in association with MELAS syndrome. Recent observations have linked this mutation to Leigh disease. We screened for the 13513G>A mutation in a cohort of 265 patients with Leigh and Leigh-like disease. The mutation was found in a total of 5 patients. An additional patient who had clinical presentation consistent with a Leigh-like phenotype but with a normal brain MRI was added to the cohort. None of an additional 88 patients meeting MELAS disease criteria, nor 56 patients with respiratory chain deficiency screened for the 13513G>A were found positive for the mutation. The most frequent clinical manifestations in our patients were hypotonia, ocular and cerebellar involvement. Low mutation heteroplasmy in the range of 20-40% was observed in all 6 patients. This observation is consistent with the previously reported low heteroplasmy of this mutation in some patients with the 13513G>A mutation and complex I deficiency. However, normal complex I activity was observed in two patients in our cohort. As most patients with Leigh-like disease and the 13513G>A mutation have been described with complex I deficiency, this report adds to the previously reported subset of patients with normal respiratory complex function. We conclude that in any patient with Leigh or Leigh-like disease, testing for the 13513G>A mutation is clinically relevant and low mutant loads in blood or muscle may be considered pathogenic, in the presence of normal respiratory chain enzyme activities. (C) 2008 Published by Elsevier Inc.
C1 [Brautbar, Ariel; Wang, Jing; Wong, Lee-Jun] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Abdenur, Jose E.; Chang, Richard C.] Childrens Hosp Orange Cty, Div Metab Disorders, Orange, CA 92668 USA.
   [Thomas, Janet A.] Univ Colorado, Sch Med, Dept Pediat, Sect Clin Genet & Metab, Denver, CO USA.
   [Grebe, Theresa A.; Lim, Cynthia] St Josephs Hosp, Phoenix Genet Program, Phoenix, AZ USA.
   [Weng, Shao-Wen] Chang Gung Univ, Coll Med, Kaohsiung Med Ctr, Chang Gung Mem Hosp,Dept Internal Med, Kaohsiung, Taiwan.
C3 Baylor College of Medicine; Childrens Hospital of Orange County; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; St. Joseph's Hospital and Medical Center; Chang Gung Memorial Hospital; Chang Gung University
RP Wong, LJ (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza,NAB 2015, Houston, TX 77030 USA.
EM ljwong@bcm.edu
CR Abu-Amero KK, 2005, ARCH PATHOL LAB MED, V129, P1295
   Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006
   Chol M, 2003, J MED GENET, V40, P188, DOI 10.1136/jmg.40.3.188
   Enns GM, 2005, CLIN GENET, V68, P337, DOI 10.1111/j.1399-0004.2005.00499.x
   Fisher N, 2000, J MOL BIOL, V296, P1153, DOI 10.1006/jmbi.2000.3509
   Huntsman RJ, 2005, PEDIATR NEUROL, V32, P334, DOI 10.1016/j.pediatrneurol.2004.12.009
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   Petruzzella V, 2003, NEUROLOGY, V61, P1017, DOI 10.1212/01.WNL.0000080363.10902.E9
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Ruiter EM, 2007, EUR J HUM GENET, V15, P155, DOI 10.1038/sj.ejhg.5201735
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   SANTORELLI FM, 1993, ANN NEUROL, V34, P827, DOI 10.1002/ana.410340612
   Shanske S, 2004, MITOCHONDRION, V4, P403, DOI 10.1016/j.mito.2004.07.026
   Sudo A, 2004, J HUM GENET, V49, P92, DOI 10.1007/s10038-003-0116-1
   Tang HY, 2002, GENET MED, V4, P336, DOI 10.1097/00125817-200209000-00004
   Vu TH, 1998, NEUROLOGY, V50, P1783, DOI 10.1212/WNL.50.6.1783
   Wong LJC, 2007, HEPATOLOGY, V46, P1218, DOI 10.1002/hep.21799
   Wong LJC, 2005, CLIN CHIM ACTA, V354, P1, DOI 10.1016/j.cccn.2004.11.003
   Wong LJC, 2002, CLIN CHEM, V48, P1901
   Wong LJC, 2001, AM J MED GENET, V102, P95, DOI 10.1002/1096-8628(20010722)102:1<95::AID-AJMG1412>3.0.CO;2-U
NR 22
TC 35
Z9 38
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
EI 
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD AUG 15
PY 2008
VL 94
IS 4
BP 485
EP 490
DI 10.1016/j.ymgme.2008.04.004
PG 6
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine
GA 330IT
UT WOS:000257935000017
PM 18495510
DA 2024-11-01
ER

PT J
AU Kaya, N
   Imtiaz, F
   Colak, D
   Al-Sayed, M
   Al-Odaib, A
   Al-Zahrani, F
   Al-Mubarak, BR
   Al-Owain, M
   Al-Dhalaan, H
   Chedrawi, A
   Al-Hassnan, Z
   Coskun, S
   Sakati, N
   Ozand, P
   Meyer, BF
AF Kaya, Namik
   Imtiaz, Faiqa
   Colak, Dilek
   Al-Sayed, Moeenaldeen
   Al-Odaib, Ali
   Al-Zahrani, Fatma
   Al-Mubarak, Bashayer R.
   Al-Owain, Mohammad
   Al-Dhalaan, Hesham
   Chedrawi, Aziza
   Al-Hassnan, Zuhair
   Coskun, Serdar
   Sakati, Nadia
   Ozand, Pinar
   Meyer, Brian F.
TI Genome-wide gene expression profiling and mutation analysis of Saudi patients with <i>Canavan disease</i>
SO GENETICS IN MEDICINE
LA English
DT Article
DE Canavan disease; genome-wide gene expression; muscle weakness and hypotonia; large novel deletions; aCGH; MLPA; long-PCR; mtDNA sequencing
ID non-jewish patients; apoptosis-inhibitory protein; aspartoacylase deficiency; knockout mouse; n-acetylaspartate; identification; brain; glutamate; biology; system
AB Purpose: Canavan disease, caused by a deficiency of aspartoacylase, is one of the most common cerebral degenerative diseases of infancy. The aims of this study were to identify the mutations associated with Canavan disease in Saudi Arabia and to identify differentially expressed genes likely to contribute to the development of this disease. Methods: Polymerase chain reaction, long polymerase chain reaction, multiplex ligation-dependent probe amplification, sequencing, array comparative genomic hybridization (aCGH), and global gene expression profiling were used to determine putative mutations and likely gene signatures in cultured fibroblasts of patients from Saudi Arabia. Results: One novel and one known large deletion and two previously known mutations (IVS4 + 1G>T and G27R) were identified. Compared with controls, 1440 genes were significantly modulated in Canavan patients (absolute fold change [FC] >= 4). Genome-wide gene expression profiling results indicated that some genes, involved in apoptosis, muscle contraction and development, mitochondrial oxidation, inflammation and glutamate, and aspartate metabolism, were significantly dysregulated. Conclusions: Our findings indicate that the presence of muscle weakness and hypotonia in patients may be associated with the dysregulated gene activities of cell motility, muscle contraction and development, actin binding, and cytoskeletal-related activities. Overall, these observations are in accordance with previous studies performed in a knockout mouse model.
C1 [Kaya, Namik] King Faisal Specialist Hosp & Res Ctr, Dept Genet, NeuroGenet Res Unit, Riyadh 11211, Saudi Arabia.
   [Imtiaz, Faiqa; Al-Mubarak, Bashayer R.; Meyer, Brian F.] King Faisal Specialist Hosp & Res Ctr, Arabian Diagnost Labs, Riyadh 11211, Saudi Arabia.
   [Colak, Dilek] King Faisal Specialist Hosp & Res Ctr, Dept BESC, Riyadh 11211, Saudi Arabia.
   [Al-Sayed, Moeenaldeen; Al-Owain, Mohammad; Al-Hassnan, Zuhair; Sakati, Nadia] King Faisal Specialist Hosp & Res Ctr, Dept Med Genet, Riyadh 11211, Saudi Arabia.
   [Al-Dhalaan, Hesham; Chedrawi, Aziza] King Faisal Specialist Hosp & Res Ctr, Dept Neurosci, Riyadh 11211, Saudi Arabia.
   [Coskun, Serdar] King Faisal Specialist Hosp & Res Ctr, Dept Pathol, Riyadh 11211, Saudi Arabia.
C3 King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center
RP Kaya, N (corresponding author), King Faisal Specialist Hosp & Res Ctr, Dept Genet, NeuroGenet Res Unit, POB 3354,MBC 03, Riyadh 11211, Saudi Arabia.
EM nkaya@kfshrc.edu.sa
FU Prince Salman Center
CR BANKER BQ, 1964, NEUROLOGY, V14, P981, DOI 10.1212/WNL.14.11.981
   Barbacioru CC, 2006, BMC BIOINFORMATICS, V7, P0, DOI 10.1186/1471-2105-7-533
   Baslow MH, 2003, J MOL NEUROSCI, V21, P185, DOI 10.1385/JMN:21:3:185
   Bitto E, 2007, P NATL ACAD SCI USA, V104, P456, DOI 10.1073/pnas.0607817104
   Brandon MC, 2005, NUCLEIC ACIDS RES, V33, P0
   Cackowski FC, 2004, GENOMICS, V84, P82, DOI 10.1016/j.ygeno.2004.02.001
   Damiano JS, 2004, BIOCHEM J, V381, P213, DOI 10.1042/BJ20031506
   Danley PD, 2007, BMC GENOMICS, V8, P0, DOI 10.1186/1471-2164-8-109
   Davoodi J, 2004, J BIOL CHEM, V279, P40622, DOI 10.1074/jbc.M405963200
   Gentleman RC, 2004, GENOME BIOL, V5, P0, DOI 10.1186/gb-2004-5-10-r80
   He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6
   Herga S, 2006, FEBS LETT, V580, P5899, DOI 10.1016/j.febslet.2006.09.056
   Hershfield JR, 2007, BRAIN RES, V1148, P1, DOI 10.1016/j.brainres.2007.02.069
   Hosack DA, 2003, GENOME BIOL, V4, P0, DOI 10.1186/gb-2003-4-10-r70
   Hu B, 2007, ONCOGENE, V26, P5577, DOI 10.1038/sj.onc.1210348
   Huang DW, 2007, GENOME BIOL, V8, P0, DOI 10.1186/gb-2007-8-9-r183
   Janson CG, 2006, ANN NEUROL, V59, P428, DOI 10.1002/ana.20787
   Jeffery IB, 2006, BMC BIOINFORMATICS, V7, P0, DOI 10.1186/1471-2105-7-359
   KAUL R, 1993, NAT GENET, V5, P118, DOI 10.1038/ng1093-118
   KAUL R, 1994, AM J HUM GENET, V55, P34
   Kaul R, 1996, AM J HUM GENET, V59, P95
   MATALON R, 1988, AM J MED GENET, V29, P463, DOI 10.1002/ajmg.1320290234
   Namboodiri AMA, 2006, MOL CELL ENDOCRINOL, V252, P216, DOI 10.1016/j.mce.2006.03.016
   OZAND PT, 1990, AM J MED GENET, V35, P266, DOI 10.1002/ajmg.1320350224
   Quackenbush J, 2007, J EXP BIOL, V210, P1507, DOI 10.1242/jeb.004432
   Rady P L, 2000, EUR J PAEDIATR NEUROL, V4, P27, DOI 10.1053/ejpn.1999.0256
   Rieder MJ, 1998, NUCLEIC ACIDS RES, V26, P967, DOI 10.1093/nar/26.4.967
   ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1
   Sellner LN, 2004, HUM MUTAT, V23, P413, DOI 10.1002/humu.20035
   Song JS, 2007, BIOINFORMATICS, V23, P966, DOI 10.1093/bioinformatics/btm043
   Sorlie T, 2006, BMC GENOMICS, V7, P0, DOI 10.1186/1471-2164-7-127
   Surendran S, 2005, NEUROBIOL DIS, V18, P385, DOI 10.1016/j.nbd.2004.10.014
   Surendran S, 2004, DEV BRAIN RES, V153, P19, DOI 10.1016/j.devbrainres.2004.07.003
   Surendran S, 2004, BRAIN RES, V1016, P268, DOI 10.1016/j.brainres.2004.05.035
   Surendran S, 2004, NEUROSCI LETT, V358, P29, DOI 10.1016/j.neulet.2003.12.105
   Surendran S, 2003, J CHILD NEUROL, V18, P611, DOI 10.1177/08830738030180090701
   Surendran S, 2003, J CHILD NEUROL, V18, P604, DOI 10.1177/08830738030180090601
   Surendran S, 2003, MOL GENET METAB, V80, P74, DOI 10.1016/j.ymgme.2003.08.015
   Surendran S, 2003, BRAIN RES BULL, V61, P427, DOI 10.1016/S0361-9230(03)00158-8
   Thomas PD, 2006, NUCLEIC ACIDS RES, V34, PW645, DOI 10.1093/nar/gkl229
   Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403
   Walker SJ, 2006, J NEUROSCI METH, V152, P179, DOI 10.1016/j.jneumeth.2005.09.007
   Zeng BJ, 2006, MOL GENET METAB, V89, P156, DOI 10.1016/j.ymgme.2006.05.014
   Zeng BJ, 2006, ADV EXP MED BIOL, V576, P165
NR 44
TC 21
Z9 23
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1098-3600
EI 1530-0366
J9 GENET MED
JI Genet. Med.
PD SEP 15
PY 2008
VL 10
IS 9
BP 675
EP 684
DI 10.1097/GIM.0b013e31818337a8
PG 10
WC Genetics & Heredity
SC Genetics & Heredity
GA 353VN
UT WOS:000259596800007
PM 18978679
DA 2024-11-01
ER

PT J
AU Rocher, C
   Taanman, JW
   Pierron, D
   Faustin, B
   Benard, G
   Rossignol, R
   Malgat, M
   Pedespan, L
   Letellier, T
AF Rocher, Christophe
   Taanman, Jan-Willem
   Pierron, Denis
   Faustin, Benjamin
   Benard, Giovani
   Rossignol, Rodrigue
   Malgat, Monique
   Pedespan, Laurence
   Letellier, Thierry
TI Influence of mitochondrial DNA level on cellular energy metabolism: implications for mitochondrial diseases
SO JOURNAL OF BIOENERGETICS AND BIOMEMBRANES
LA English
DT Article
DE mitochondrial DNA depletion syndrome; oxidative phosphorylation; respiratory chain; threshold effect
ID mtdna depletion; copy number; deoxyribonucleic-acid; hela-cells; muscle; expression; myopathy; 2',3'-dideoxycytidine; transcription; replication
AB The total amount of cellular mitochondrial DNA (mtDNA) varies widely and seems to be related to the nature and metabolic state of tissues and cells in culture. It is not known, however, whether this variation has any significance in vivo, and to which extent it regulates energy production. To better understand the importance of the cellular mtDNA level, we studied the influence of a gradual reduction of mtDNA copy number on oxidative phosphorylation in two models: (a) a control human cell line treated with different concentrations of 2', 3'-dideoxycytidine, a nucleoside analogue that inhibits mtDNA replication by interfering with mitochondrial DNA polymerase gamma, and (b) a cell line derived from a patient presenting mtDNA depletion. The two models were used to construct biochemical and phenotypic threshold curves. Our results show that oxidative phosphorylation activities are under a tight control by the amount of mtDNA in the cell, and that the full complement of mtDNA molecules are necessary to maintain a normal energy production level.
C1 [Rocher, Christophe; Pierron, Denis; Faustin, Benjamin; Benard, Giovani; Rossignol, Rodrigue; Malgat, Monique; Letellier, Thierry] Univ Victor Segalen Bordeaux2, INSERM, U688, F-33076 Bordeaux, France.
   [Taanman, Jan-Willem] UCL, Inst Neurol, Univ Dept Clin Neurosci, London NW3 2PF, England.
   [Pedespan, Laurence] Hop Pellegrin Enfants, F-33076 Bordeaux, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bordeaux; University of London; University College London; CHU Bordeaux
RP Letellier, T (corresponding author), Univ Victor Segalen Bordeaux2, INSERM, U688, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
EM tletel@u-bordeaux2.fr
FU Wellcome Trust [048410] Funding Source: Medline
CR ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5
   Bakker HD, 1996, J PEDIATR-US, V128, P683, DOI 10.1016/S0022-3476(96)80135-1
   Benbrik E, 1997, J NEUROL SCI, V149, P19, DOI 10.1016/S0022-510X(97)05376-8
   Blake JC, 1999, AM J PATHOL, V155, P67, DOI 10.1016/S0002-9440(10)65100-0
   BODNAR AG, 1993, AM J HUM GENET, V53, P663
   BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991
   Brown TA, 2002, NUCLEIC ACIDS RES, V30, P2004, DOI 10.1093/nar/30.9.2004
   CHEN CH, 1989, J BIOL CHEM, V264, P11934
   Duclos M, 2004, AM J PHYSIOL-ENDOC M, V286, PE159, DOI 10.1152/ajpendo.00281.2003
   Ducluzeau PH, 1999, J HEPATOL, V30, P149, DOI 10.1016/S0168-8278(99)80019-1
   Faustin B, 2004, J BIOL CHEM, V279, P20411, DOI 10.1074/jbc.M314259200
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   King M P, 1996, METHODS ENZYMOL, V264, P304, DOI 10.1016/S0076-6879(96)64029-4
   LECHER P, 1994, BIOL CELL, V80, P25, DOI 10.1016/0248-4900(94)90013-2
   LETELLIER T, 1994, BIOCHEM J, V302, P171, DOI 10.1042/bj3020171
   LETELLIER T, 1992, PEDIATR RES, V32, P17, DOI 10.1203/00006450-199207000-00004
   MARIOTTI C, 1995, J NEUROL, V242, P547, DOI 10.1007/BF00868806
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Morris AAM, 1998, J HEPATOL, V28, P556, DOI 10.1016/S0168-8278(98)80278-X
   Nelson I, 1997, SOMAT CELL MOLEC GEN, V23, P287, DOI 10.1007/BF02674419
   Nouette-Gaulain K, 2005, CARDIOVASC RES, V66, P132, DOI 10.1016/j.cardiores.2004.12.023
   Ouhabi R, 1998, ANAL BIOCHEM, V263, P169, DOI 10.1006/abio.1998.2776
   POULTON J, 1994, HUM MOL GENET, V3, P1763, DOI 10.1093/hmg/3.10.1763
   ROBIN ED, 1988, J CELL PHYSIOL, V136, P507, DOI 10.1002/jcp.1041360316
   Rossignol R, 1999, J BIOL CHEM, V274, P33426, DOI 10.1074/jbc.274.47.33426
   Rossignol R, 2000, BIOCHEM J, V347, P45, DOI 10.1042/0264-6021:3470045
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   SHAY JW, 1990, J BIOL CHEM, V265, P14802
   SPELBRINK JN, 1994, HUM MOL GENET, V3, P1989, DOI 10.1093/hmg/3.11.1989
   Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3
   Taanman JW, 2003, HUM MOL GENET, V12, P1839, DOI 10.1093/hmg/ddg192
   Trounce I A, 1996, METHODS ENZYMOL, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   VANDENBOGERT C, 1993, BIOCHIM BIOPHYS ACTA, V1144, P177, DOI 10.1016/0005-2728(93)90170-K
   WALLACE DC, 1986, SOMAT CELL MOLEC GEN, V12, P41, DOI 10.1007/BF01560726
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WILLIAMS RS, 1986, J BIOL CHEM, V261, P376
NR 37
TC 47
Z9 51
U1 0
U2 7
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0145-479X
EI 1573-6881
J9 J BIOENERG BIOMEMBR
JI J. Bioenerg. Biomembr.
PD APR 15
PY 2008
VL 40
IS 2
BP 59
EP 67
DI 10.1007/s10863-008-9130-5
PG 9
WC Biophysics; Cell Biology
SC Biophysics; Cell Biology
GA 302GK
UT WOS:000255956600001
PM 18415670
DA 2024-11-01
ER

PT J
AU Rajasimha, HK
   Chinnery, PF
   Samuels, DC
AF Rajasimha, Harsha Karur
   Chinnery, Patrick F.
   Samuels, David C.
TI Selection against pathogenic mtDNA mutations in a stem cell population leads to the loss of the 3243A→G mutation in blood
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID mitochondrial-dna mutations; ragged-red fibers; stroke-like episodes; random genetic drift; diabetes-mellitus; a3243g mutation; tissue distribution; myoclonus epilepsy; lactic-acidosis; point mutation
AB The mutation 3243A -> G is the most common heteroplasmic pathogenic mitochondrial DNA (mtDNA) mutation in humans, but it is not understood why the proportion of this mution decreases in blood during life. Changing levels of mtDNA heteroplasmy are fundamentally related to the pathophysiology of the mitochondrial disease and correlate with clinical progression. To understand this process, we simulated the segregation of mtDNA in hematopoietic stem cells and leukocyte precursors. Our observations show that the percentage of mutant mtDNA in blood decreases exponentially over time. This is consistent with the existence of a selective process acting at the stem cell level and explains why the level of mutant mtDNA in blood is almost invariably lower than in nondividing (postmitotic) tissues such as skeletal muscle. By using this approach, we derived a formula from human data to correct for the change in heteroplasmy over time. A comparison of age-corrected blood heteroplasmy levels with skeletal muscle, an embryologically distinct postmitotic tissue, provides independent confirmation of the model. These findings indicate that selection against pathogenic mtDNA mutations occurs in a stem cell population.
C1 [Rajasimha, Harsha Karur; Samuels, David C.] Virginia Polytech Inst & State Univ, Virgina Bioinformat Inst, Blacksburg, VA 24061 USA.
   [Chinnery, Patrick F.] Univ Newcastle, Sch Med, Mitochondria Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Chinnery, Patrick F.] Univ Newcastle, Sch Med, Inst Human Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Virginia Polytechnic Institute & State University; Newcastle University - UK; Newcastle University - UK
RP Samuels, DC (corresponding author), Virginia Polytech Inst & State Univ, Virgina Bioinformat Inst, Blacksburg, VA 24061 USA.
EM dsamuels@vbi.vt.edu
FU Wellcome Trust Funding Source: Medline
CR Akala OO, 2006, CURR OPIN GENET DEV, V16, P496, DOI 10.1016/j.gde.2006.08.011
   AVISE JC, 1984, J MOL EVOL, V20, P99, DOI 10.1007/BF02257369
   Barron MJ, 2005, NEUROMUSCULAR DISORD, V15, P768, DOI 10.1016/j.nmd.2005.06.018
   Battersby BJ, 2005, HUM MOL GENET, V14, P2587, DOI 10.1093/hmg/ddi293
   Bidooki SK, 1997, AM J HUM GENET, V60, P1430, DOI 10.1086/515460
   Birky CW, 2001, ANNU REV GENET, V35, P125, DOI 10.1146/annurev.genet.35.102401.090231
   Brown DT, 2001, AM J HUM GENET, V68, P533, DOI 10.1086/318190
   Canter JA, 2005, FREE RADICAL BIO MED, V38, P678, DOI 10.1016/j.freeradbiomed.2004.11.031
   Capps GJ, 2003, J THEOR BIOL, V221, P565, DOI 10.1006/jtbi.2003.3207
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 1997, LANCET, V350, P1402, DOI 10.1016/S0140-6736(05)65183-5
   Chinnery PF, 1999, AM J HUM GENET, V64, P1158, DOI 10.1086/302311
   Chinnery PF, 1999, AM J MED GENET, V85, P498
   Chinnery PF, 2000, TRENDS GENET, V16, P500, DOI 10.1016/S0168-9525(00)02120-X
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   Colijn C, 2005, J THEOR BIOL, V237, P117, DOI 10.1016/j.jtbi.2005.03.033
   Deschauer M, 1999, NEUROMUSCULAR DISORD, V9, P305, DOI 10.1016/S0960-8966(99)00019-X
   DEVRIES D, 1994, J NEUROL SCI, V124, P77, DOI 10.1016/0022-510X(94)90014-0
   Durham SE, 2006, NEUROMUSCULAR DISORD, V16, P381, DOI 10.1016/j.nmd.2006.03.012
   El Meziane A, 1998, NAT GENET, V18, P350
   Elson JL, 2002, NEUROMUSCULAR DISORD, V12, P858, DOI 10.1016/S0960-8966(02)00047-0
   Frederiksen AL, 2006, J MED GENET, V43, P0, DOI 10.1136/jmg.2005.039339
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Greaves LC, 2006, P NATL ACAD SCI USA, V103, P714, DOI 10.1073/pnas.0505903103
   GROSS NJ, 1969, J BIOL CHEM, V244, P1552
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   HAMMANS SR, 1993, BRAIN, V116, P617, DOI 10.1093/brain/116.3.617
   Ho AD, 2005, EXP HEMATOL, V33, P1, DOI 10.1016/j.exphem.2004.09.004
   Hotta O, 2001, KIDNEY INT, V59, P1236, DOI 10.1046/j.1523-1755.2001.0590041236.x
   Howell N, 2000, J NEUROL SCI, V172, P1, DOI 10.1016/S0022-510X(99)00207-5
   HUANG CC, 1994, J NEUROL NEUROSUR PS, V57, P586, DOI 10.1136/jnnp.57.5.586
   Hudson G, 2005, AM J HUM GENET, V77, P1086, DOI 10.1086/498176
   Jacobi FK, 2001, INVEST OPHTH VIS SCI, V42, P1208
   Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146
   Kato Y, 2002, DIABETIC MED, V19, P784, DOI 10.1046/j.1464-5491.2002.00777.x
   Kerrison JB, 2000, AM J OPHTHALMOL, V130, P803, DOI 10.1016/S0002-9394(00)00603-6
   Kirches E, 2001, J MED GENET, V38, P312, DOI 10.1136/jmg.38.5.312
   LARSSON NG, 1992, AM J HUM GENET, V51, P1201
   Lien LM, 2001, ACTA NEUROL SCAND, V103, P159, DOI 10.1034/j.1600-0404.2001.103003159.x
   Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3
   Lu JX, 2006, BIOCHEM BIOPH RES CO, V348, P115, DOI 10.1016/j.bbrc.2006.07.010
   Mackey MC, 2001, CELL PROLIFERAT, V34, P71, DOI 10.1046/j.1365-2184.2001.00195.x
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Majamaa-Voltti Kirsi, 2002, BMC CARDIOVASC DISORD, V2, P12
   MARTINUZZI A, 1992, J NEUROL SCI, V113, P222, DOI 10.1016/0022-510X(92)90250-O
   MATTHEWS PM, 1995, HUM GENET, V96, P261
   McDonald SAC, 2006, CELL CYCLE, V5, P808, DOI 10.4161/cc.5.8.2641
   MOSEWICH RK, 1993, ARCH NEUROL-CHICAGO, V50, P275, DOI 10.1001/archneur.1993.00540030041012
   Ng MCY, 2000, CLIN ENDOCRINOL, V52, P557, DOI 10.1046/j.1365-2265.2000.00989.x
   OBERMAIERKUSSER B, 1991, FEBS LETT, V286, P67, DOI 10.1016/0014-5793(91)80942-V
   OGAWA M, 1993, BLOOD, V81, P2844
   Olsson C, 2001, EUR J HUM GENET, V9, P917, DOI 10.1038/sj.ejhg.5200742
   Olsson C, 1998, HUM MUTAT, V12, P52, DOI 10.1002/(SICI)1098-1004(1998)12:1<52::AID-HUMU8>3.0.CO;2-K
   PICCOLO G, 1993, ACTA NEUROL SCAND, V88, P406, DOI 10.1111/j.1600-0404.1993.tb05368.x
   Pyle A, 2007, J MED GENET, V44, P69, DOI 10.1136/jmg.2006.043109
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Rossignol R, 1999, J BIOL CHEM, V274, P33426, DOI 10.1074/jbc.274.47.33426
   Rossignol R, 2000, BIOCHEM J, V347, P45, DOI 10.1042/0264-6021:3470045
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   Sadun F, 2004, AM J OPHTHALMOL, V137, P271, DOI 10.1016/j.ajo.2003.08.010
   Saitoh S, 1999, J INHERIT METAB DIS, V22, P608, DOI 10.1023/A:1005569711521
   Sciacco M, 2001, NEUROLOGY, V56, P1070, DOI 10.1212/WNL.56.8.1070
   Shepherd BE, 2004, EXP HEMATOL, V32, P1040, DOI 10.1016/j.exphem.2004.07.023
   SHOUBRIDGE EA, 1994, J BIOENERG BIOMEMBR, V26, P301, DOI 10.1007/BF00763101
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   tHart LM, 1996, HUM MUTAT, V7, P193
   TRAFF J, 1995, ACTA NEUROL SCAND, V92, P394
   van Essen EHR, 2000, DIABETIC MED, V17, P841, DOI 10.1046/j.1464-5491.2000.00379.x
   Vilarinho L, 1997, J MED GENET, V34, P607, DOI 10.1136/jmg.34.7.607
   Wilichowski E, 1998, J NEUROL SCI, V157, P206, DOI 10.1016/S0022-510X(98)00068-9
   Zhong S, 2000, J CLIN PATHOL, V53, P466, DOI 10.1136/jcp.53.6.466
NR 73
TC 84
Z9 91
U1 2
U2 4
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD FEB 15
PY 2008
VL 82
IS 2
BP 333
EP 343
DI 10.1016/j.ajhg.2007.10.007
PG 11
WC Genetics & Heredity
SC Genetics & Heredity
GA 263NN
UT WOS:000253223900006
PM 18252214
DA 2024-11-01
ER

